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Two novel classes of aza-Heck reactions have been developed. These processes generate 2-alkenyl-
N-heterocycles through the palladium-catalysed cyclisation of substrates containing an activated N–O 
bond and a pendant olefin. The first of these, based on the cyclisation of N-acyloxysulfonamides, is 
only the second reported class of aza-Heck reaction and is effective for the synthesis of complex bicyclic 
N-heterocycles commonly found in the core structures of natural products. Subsequently, an aza-Heck 
reaction of N-acyloxycarbamates was developed that provides considerable improvements in terms of 
efficiency compared to the sulfonamide-based reaction. Through the cyclisation of 
N-acyloxycarbamates, pyrrolidines and piperidines, as well as related 5- and 6-membered 
N-heterocycles, can be prepared in good to excellent yields. Furthermore, the diastereoselectivities 
achieved in these processes are generally much greater than those observed with aza-Heck cyclisations 
of N-acyloxysulfonamides. A number of mechanistic experiments have validated the aza-Heck pathway 
proposed for these transformations. 
A highly asymmetric variant of the aza-Heck reaction was also developed, based on the cyclisation of 
N-sulfonyloxycarbamates. Through the use of SPINOL-based phosphoramidite ligands, pyrrolidines 
and piperidines can be prepared in good yields and with high enantioselectivities from substrates 
containing a diverse range of alkenes. 
Additionally, palladium(0)-catalysed cascade reactions using the previously developed N–O bond 
donors have been demonstrated. These processes initiate with N–O oxidative addition and 
aminopalladation of a pendant alkene but terminate with trapping of the resulting organopalladium(II) 
intermediate, as opposed to -hydride elimination. In collaboration with co-workers, a variety of alkene 
1,2-aminofunctionalisation cascades have been achieved using this strategy. The application of these 






First of all, my supervisor, John. Without his influence, this thesis would be incomparable. I hope that 
the quality of the results presented within are an accurate reflection of his significant intellectual input, 
and I know their quantity would be greatly reduced without his encouragement. I am confident that my 
abilities in synthetic organic chemistry, both in terms of a practical and theoretical basis, have improved 
massively over the course of my PhD, something which I also attribute significantly to him. 
Additionally, during writing up, his suggestions were invaluable at improving my confusing and 
cumbersome writing style. Finally, I thank him for his honesty. 
I’d also like to thank Thomas Langer, my industrial supervisor at AstraZeneca, who was a great help to 
me during my placement. While I was there, he was crucial in getting me acquainted with how they do 
things, and also introduced me to the many people who helped me with my work. Furthermore, his 
advice on synthesis, as well as the fact that he ordered all the chemicals I needed, was much appreciated. 
Due to the paucity of synonyms for gratitude available to my vocabulary, from here on, I have broken 
down my thanks into a list format. I can only apologise if this doesn’t accurately portray the sincerity 
of my sentiments. I am extremely grateful to the following people at Bristol: 
Jess Eastwood, Gabriele Fumagalli, Jamie Cadge, Giacomo Crisenza (despite only managing to read 
5 pages in 7 weeks), Andrew Dalling, Phillippa Cooper and Ben Jones, for proofreading drafts of 
individual chapters. Of these, a special mention goes out to the first two, who had the misfortune of 
reading my work before I had learnt even the basic rules of punctuation. Xiaofeng Ma, Rafa Carmona, 
Charly Faradji, Josh Farndon and Tim Shuttleworth, for allowing me to make use of compounds they 
prepared. Xiaofeng Ma, Rafa Carmona and Ben Jones, whose results I discuss in this thesis. Professor 
Paul Pringle, for helpful discussions with regards to trioxaphosphaadamantane ligands, as well as 
providing the precursor required to prepare a variety of these. Alex Fawcett, for advice on the 
derivatisation of boronic esters. 
Conducting my research was made considerably easier by the excellent facilities available in the 
Chemistry department. Although this is the result of the efforts of a large number of people, specific 
thanks to: 
Paul Lawrence, Tom Leman and Professor Craig Butts, for running the NMR facilities, which were 
great, as well as providing help with the more technical aspects of NMR. Dr Paul Gates and Tom Leman, 
who were incredibly accommodating towards my tendency to submit an unreasonable number of MS 




Tony Rogers, for keeping everything in the lab working (my fume hood aside). Paul Egan and everyone 
in the stores. 
I’d like to thank all the people at AstraZeneca who were so welcoming and friendly towards me; I really 
appreciated working in such a positive environment. In addition to this, many people generously gave 
their time to help me out while I was there, for which I am incredibly grateful: 
Rachel Munday, Fiona Bell and Kevin Leslie, who provided a lot of help with chiral ligand screening 
during my industrial placement. David Whittaker and Michael Nunn, for their assistance with reaction 
monitoring (not to mention allowing me to put a sealed tube of THF in a spectrometer at 130 °C in the 
first place). Alex Telford, for help with hydrogenation apparatus. Anthony Bristow, for obtaining 
HRMS data for me. Lyn Powell (and his team) for welcoming me to their meetings, during which I 
gained valuable insights into the field of process chemistry. The other CASE students undertaking 
placements at the same time as me, thanks to you guys, I always knew what time to have lunch. 
Thanks also to all the students in the Bower group, as well as anyone else who worked in N518. The 
tolerance with which my musical proclivities were accepted always surprised me, and this surpassed 
what Jenny offers me in this regard. I like to think that if I taught you guys anything, it’s that good 
music doesn’t have to be aesthetically pleasing, or that I don’t like good music. Either one is fine with 
me. Outside of the lab, I had many good times with you guys, and I was lucky to be in such a social 
group. More specifically, I need to mention the following people: 
Giacomo, while I found your lab behaviour infuriating, your proofreading non-existent and your views 
on women troubling, your company was never dull. I can honestly say, you are a friend to me unlike 
any other, and, for that, I am eternally grateful. Andrew, who had the misfortune of sharing with me 
what were potentially the two worst fume hoods in the department, and for keeping me entertained with 
jokes like, “United are going to win the league this year.” Xiaofeng, who contributed so much to the 
development of the aza-Heck reactions. Rafa, who was a pleasure to work with, and never seemed to 
be in a bad mood. Phillippa, for asking challenging questions about my lifestyle. Lauren and Jamie, 
who continued to invite me to their house, despite my lack of respect towards it. Gangwei, for showing 
me cute pictures of his baby. Eric and Zedong, for keeping a close watch over my fume hood. Finally, 
thanks (and apologies) to the unfortunate people for whom I had some kind of supervisory responsibility 
towards. 
Having covered my working life, I’m also appreciative of the following people who enriched (what was 
left of) my personal life:  
My former housemates, Ollie and Sam. Their unfailing enthusiasm for weekly sessions of solvent and 




from the unimaginable horror encountered during a privileged life in the first-world. Discussions with 
Ollie were invaluable for identifying new music to inflict upon my long-suffering colleagues. 
Additionally, I appreciate Sam’s frequent decisions to behave strangely in social situations so that I 
might look normal by comparison. His capacity for self-sacrifice is truly unparalleled. They have 
continued to demonstrate their generosity to me by letting me stay with them during my frequent visits 
to Bristol. Steve Stanton and Stephen Luckham, who organised a weekly game of football, as this was 
the closest my body got to doing the physical exercise it supposedly evolved to do. My pub quiz team, 
this event is the closest my mind gets to doing what I have carefully nurtured it to do: abusing 
quizmasters.  
I am also indebted to my parents, for taking me (and my things) to and from my industrial placement in 
Macclesfield, and also for graciously storing my things (and my hair) while I am of no fixed abode. I 
am also grateful to Jenny’s mother, Silvia, for letting me stay with her and Jenny as I complete my 
thesis. 
Finally, I’d like to thank Jenny. The last six years have been the best of my life, and although I can’t 
prove a causal link, I’m confident that this is due to her. Without her unwavering love and support, 
obtaining my first and (God willing) second degrees would have been a much harder and less rewarding 
task. I know I can count on her continued love and support in the future, particularly as I pursue my 






Abbreviations ......................................................................................................................................... ix 
 Introduction ......................................................................................................................... 1 
1.1 The importance of N-heterocycles .......................................................................................... 1 
1.2 The aza-Wacker reaction ........................................................................................................ 2 
1.2.1 Initial reports and reaction development ......................................................................... 2 
1.2.2 Distinction between syn- and anti-aminopalladation pathways ...................................... 3 
1.2.3 Enantioselective aza-Wacker cyclisations ...................................................................... 5 
1.2.4 Redox-neutral variants of the aza-Wacker reaction ........................................................ 6 
1.2.5 Overview of substrate scope in aza-Wacker processes ................................................... 7 
1.3 Nitrogen-based heterocycles via electrophilic 1,2-aminofunctionalisation of alkenes ........... 8 
1.4 Aza-Heck reactions ............................................................................................................... 11 
1.4.1 The Narasaka-Heck reaction ......................................................................................... 11 
1.4.2 Bower group work: chiral heterocycles from the Narasaka-Heck reaction .................. 12 
1.5 Project objectives .................................................................................................................. 17 
1.5.1 Aza-Heck reactions of O-phenyl hydroxamates ........................................................... 19 
 Aza-Heck reactions of N-acyloxysulfonamides ................................................................ 20 
2.1 Introduction ........................................................................................................................... 20 
2.2 Substrate synthesis ................................................................................................................ 21 
2.2.1 First-generation routes to aza-Heck substrates ............................................................. 21 
2.2.2 Second-generation route to aza-Heck substrates ........................................................... 24 
2.2.3 Third-generation route to aza-Heck substrates ............................................................. 25 
2.3 Development of the N-acyloxysulfonamide-based aza-Heck reaction ................................. 26 
2.3.1 Reaction discovery ........................................................................................................ 26 
2.3.2 Observation of side products in the aza-Heck reaction ................................................. 27 
2.3.3 Optimisation .................................................................................................................. 31 
2.4 Substrate scope for the aza-Heck cyclisation ........................................................................ 35 
2.4.1 Aza-Heck cyclisations involving 1,2-disubstituted alkenes .......................................... 35 




2.4.3 Aza-Heck cyclisations of systems with substitution  to nitrogen ............................... 38 
2.4.4 Aza-Heck cyclisations of systems with substitution  to nitrogen ................................ 38 
2.4.5 Aza-Heck cyclisations involving trisubstituted alkenes................................................ 39 
2.4.6 Aza-Heck cyclisations to generate bicyclic systems ..................................................... 41 
2.4.7 Attempted cyclisations to form 4-membered rings ....................................................... 46 
2.4.8 Aza-Heck cyclisations to form 6-membered rings ........................................................ 47 
2.5 Mechanistic investigations .................................................................................................... 51 
2.6 Conclusions ........................................................................................................................... 56 
 Aza-Heck reactions of N-acyloxycarbamates ................................................................... 58 
3.1 Introduction ........................................................................................................................... 58 
3.2 Development of N-acyloxycarbamate-based aza-Heck reactions ......................................... 58 
3.2.1 Reaction discovery ........................................................................................................ 58 
3.2.2 Optimisation .................................................................................................................. 61 
3.2.3 Properties of trioxaphosphaadamantane ligands ........................................................... 63 
3.3 Substrate scope for 5-exo aza-Heck cyclisations .................................................................. 64 
3.3.1 Scope of the carbamate protecting group in the aza-Heck reaction .............................. 64 
3.3.2 Aza-Heck cyclisations involving 1,2-disubstituted alkenes .......................................... 67 
3.3.3 Aza-Heck cyclisations of systems with substitution ,  and  to nitrogen ................. 67 
3.3.4 Aza-Heck cyclisations involving trisubstituted alkenes................................................ 70 
3.3.5 Aza-Heck cyclisations to generate bicyclic systems ..................................................... 71 
3.4 Aza-Heck cyclisations to form 6-membered rings ................................................................ 72 
3.4.1 Initial results .................................................................................................................. 72 
3.4.2 Optimisation of the 6-exo aza-Heck cyclisation ........................................................... 73 
3.4.3 Aza-Heck cyclisations of substrates lacking biasing factors ........................................ 77 
3.4.4 Aza-Heck cyclisations of systems with substitution  and  to nitrogen ..................... 78 
3.4.5 Aza-Heck cyclisations of systems with heteroatom-based tethers ................................ 80 
3.4.6 Aza-Heck cyclisations of conformationally biased systems containing 1,2-disubstituted 
alkenes ....................................................................................................................................... 82 




3.5 Mechanistic investigations .................................................................................................... 86 
3.6 Conclusions ........................................................................................................................... 91 
 An enantioselective aza-Heck reaction ............................................................................. 92 
4.1 Introduction ........................................................................................................................... 92 
4.2 Investigations into enantioselective aza-Heck cyclisations of N-acyloxysulfonamide 
substrates ........................................................................................................................................... 93 
4.3 Enantioselective aza-Heck cyclisations of N-acyl- and N-sulfonyl-oxycarbamate substrates .. 
  .............................................................................................................................................. 94 
4.3.1 Reaction discovery ........................................................................................................ 94 
4.3.2 Optimisation of the carbamate-based enantioselective aza-Heck reaction ................... 97 
4.3.3 Enantioselective aza-Heck cyclisations involving trisubstituted alkenes ..................... 99 
4.3.4 Enantioselective aza-Heck cyclisations to form 6-membered rings ........................... 100 
4.3.5 Further evaluation of the substrate scope for the enantioselective aza-Heck reaction 104 
4.4 Conclusions ......................................................................................................................... 105 
 Aza-Heck cascade reactions ............................................................................................ 106 
5.1 Introduction ......................................................................................................................... 106 
5.2 Aza-Heck/Heck cascades .................................................................................................... 108 
5.3 Intermolecular 1,2-aminocarboxylation cascades ............................................................... 111 
5.3.1 Initial results ................................................................................................................ 111 
5.3.2 Studies towards the synthesis of (+)-cylindricine C ................................................... 112 
5.4 Intermolecular 1,2-amino-arylation and -borylation cascades ............................................ 114 
5.4.1 Intermolecular 1,2-aminoarylation using boronic esters ............................................. 114 
5.4.2 Extension to intermolecular 1,2-aminoborylation using diboron reagents ................. 114 
5.5 Conclusions ......................................................................................................................... 118 
 Overall summary and conclusions .................................................................................. 119 
 Experimental ................................................................................................................... 121 
7.1 General experimental details ............................................................................................... 121 
7.2 General procedures ............................................................................................................. 122 
7.3 Experimental procedures for the studies in Chapter 2 ........................................................ 126 




7.5 Experimental procedures for the studies in Chapter 4 ........................................................ 336 
7.6 Experimental procedures for the studies in Chapter 5 ........................................................ 356 
Appendix ............................................................................................................................................. 369 
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d.r.     diastereomeric ratio 
dba     dibenzylideneacetone 
DCC      N,N’-dicyclohexylcarbodiimide 
DEAD     diethyl azodicarboxylate 
DIAD      diisopropyl azodicarboxylate 
DMAP     4-dimethylaminopyridine 
dppb      1,4-bis(diphenylphosphino)butane 
e.e.      enantiomeric excess 
e.r.     enantiomeric ratio 
Im     imidazyl 
MTBE     methyl tert-butyl ether 
NBS     N-bromosuccinimide 
NFSI      N-fluorobenzenesulfonimide 
NHC      N-heterocyclic carbene 
Pin     pinacolato 
Piv     pivaloyl 
TFAA     trifluoroacetic anhydride 
Standard abbreviations are not stated here.




  - Introduction 
1.1 The importance of N-heterocycles 
Nitrogen-based heterocycles are prevalent in bioactive molecules; a recent analysis of over a thousand 
FDA-approved drugs conducted by Njardarson and co-workers found that 59 % contained at least one 
N-heterocycle, with many of these containing more.1 Furthermore, one of the major classes of natural 
products, alkaloids, contain N-heterocycles by definition.2 It has been suggested that around 20 % of 
plant species produce alkaloids, which can display a wide variety of biological activities.3 Considering 
this, it is perhaps unsurprising that out of the top ten most commonly used recreational drugs in the UK,I 
half have N-heterocycles at their cores, with four of these being alkaloids. Examples of each of these 
classes of compound are provided in Figure 1. 
 
Figure 1 – Examples of pharmaceuticals,1 natural products9-13 and recreational drugs8,14-17 containing N-heterocycles. 
While analyses such as that by Njardarson are interesting, they only provide insight into successful drug 
candidates. Very little can be said about the compounds which might have been successful but were not 
amenable to synthesis. One of the aims of developing synthetic methodology is to limit the uncertainty 
in this area by enabling access to a greater diversity of molecules in a practical manner. The ubiquity of 
                                                     
I This list has been compiled from a variety of sources4-7 and is as follows: caffeine, alcohol, nicotine, cannabis, 
cocaine, MDMA, amphetamines, amyl nitrite, hallucinogenic mushrooms and tranquilisers. Psilocin is one of the 
active components of hallucinogenic mushrooms,8 and the structure of diazepam has been provided as an example 
of a tranquiliser. 




N-heterocycles in both pharmaceutical agents and bioactive natural products suggests that they are 
valuable targets for these efforts, and that methods which allow the preparation of previously difficult 
to access structures would be highly valuable.  
Because of the importance of N-heterocycles, a variety of methods have been devised for their 
preparation. Key amongst these are palladium-catalysed cyclisations, and a brief overview of three 
classes of this kind of reaction is presented below. The first two classes are relatively well-developed 
strategies, whereas the final one is comparatively less developed and represents the focus of this thesis. 
 
1.2 The aza-Wacker reaction 
1.2.1 Initial reports and reaction development 
The palladium(II)-catalysed oxidative cyclisation of o-allylanilines to indoles was reported by Hegedus 
in 1978 (Scheme 1),18 based on an earlier study of a stoichiometric transformation.19 The reaction is 
proposed to proceed through intramolecular nucleophilic attack by nitrogen onto the palladium(II)-
activated alkene of 1, to afford intermediate 2. From 2, -hydride elimination provides enamine 3, which 
isomerises to indole 4. The palladium hydride by-product requires oxidation to re-enter the catalytic 
cycle, as, although it is formally in the +2 oxidation state, deprotonation affords a palladium(0) species. 
 
Scheme 1 – Palladium(II)-catalysed oxidative cyclisation of o-allylaniline (1).18 
The palladium(II)-catalysed oxidative substitution of alkenes with a nitrogen nucleophile in the manner 
presented in Scheme 1 is known as the aza-Wacker reaction.20 This terminology is used because of the 
analogy to the Wacker process, which involves palladium(II)-catalysed oxidation of ethylene to 
acetaldehyde.21,22 Following the initial report from Hegedus,18 further developments were made to 
improve the utility of the process. Early work focused on the use of free anilines and amines, but these 
bind too strongly to palladium(II), inhibiting catalytic activity.23 Consequently, the use of protected 
nitrogen sources was found to be beneficial.24 Improvements were also made with respect to the terminal 




oxidant, and systems where the catalytic cycle is closed by molecular oxygen were reported.25-27 
Following this, Stahl demonstrated that palladium(II)-NHC catalyst 6 is highly effective for aza-Wacker 
cyclisations, allowing air to be used as the terminal oxidant in the conversion of 5 to indole 7 
(Scheme 2).28 
 
Scheme 2 – Palladium(II)-catalysed oxidative cyclisation of substrate 5, using air as the terminal oxidant.28 
1.2.2 Distinction between syn- and anti-aminopalladation pathways 
Early reports of aza-Wacker reactions invoked anti-aminopalladation in the key C–N bond forming 
step; here, palladium(II) activates the alkene for nucleophilic attack (Scheme 1 and Scheme 3, 
pathway A). However, syn-aminopalladation is an alternative possibility (Scheme 3, pathway B); in this 
case, ligand exchange produces aminopalladium(II) complex 10, and the pendant alkene inserts into the 
Pd–N bond. Pioneering investigations into the aminopalladation of alkenes determined that the 
stereochemistry of products was consistent with an anti-aminopalladation step, although these studies 
were carried out on intermolecular reactions.29,30 For some time, despite some indication that 
syn-aminopalladation is possible,31 there was no evidence for it being operative in aza-Wacker 
reactions.32 
 
Scheme 3 – The two distinct mechanisms possible for the aza-Wacker reaction. Pathway A: anti-aminopalladation. 
Pathway B: syn-aminopalladation. 
In the course of developing an intermolecular aza-Wacker reaction of unactivated alkenes, Stahl 
observed norbornene-derived product 16, which can only result from syn-aminopalladation 
(Scheme 4a).33 The initially proposed mechanism for the formation of 16 involves two sequential 
migratory insertions of norbornene, first into the Pd–N bond of 13 and then into the Pd–C bond of 14. 
It was suggested that palladium(II) intermediate 15 undergoes C–N bond-forming reductive elimination 




to afford 16. However, Csp3-N reductive eliminations from palladium(II) complexes are very rarely 
observed;34 hence, complexes similar to 15 can be isolated.35 Another mechanism has also been 
suggested, which involves norbornene inserting into a Pd–N bond twice, followed by C–C reductive 
elimination from 17 (Scheme 4b).36 
 
Scheme 4 – a) Observation of 16 from the aza-Wacker reaction of norbornene with p-toluenesulfonamide, and the initially 
proposed mechanism for its formation.33 b) Alternative mechanism for the formation of 16.36 
Following the observation of 16, Stahl examined the geometry of aminopalladation in intramolecular 
aza-Wacker reactions under a number of conditions.37 In the cyclisation of deuterium-labelled 
substrate 18, anti-aminopalladation affords intermediate 19a, whereas syn-aminopalladation affords 
intermediate 19b (Scheme 5). From 19a, -deuteride elimination occurs to afford 20. In contrast, only 
the hydrogen atom is available for elimination in intermediate 19b, so d-20 results. By comparing the 
ratio of 20 to d-20, the preference for anti- or syn-aminopalladation under a set of reaction conditions 
was determined. The majority of conditions examined were found to favour syn-aminopalladation, 
although conditions similar to those detailed in Scheme 2 (Section 1.2.1) resulted in a 1:1 mixture of 
syn- and anti-aminopalladation products. The selectivity for a given reaction pathway was found to be 
highly dependent on the pH of the reaction conditions, with acidic conditions favouring anti- and basic 
conditions favouring syn-aminopalladation. The nature of the substrate has an effect too: substrate 21, 
the N-nosyl analogue of 18, was found to afford syn-aminopalladation products with complete 
selectivity. This was rationalised as being due to the more acidic N–H bond facilitating formation of 
the key aminopalladium(II) intermediate (analogous to 10 in Scheme 3). However, the dependence of 
reaction pathway on substrate pKa is not completely predictable, and substrate 22, which is more acidic 
than both 18 and 21, afforded mixtures of syn- and anti-aminopalladation products, with the ratio of 
products being highly dependent on the conditions used. 





Scheme 5 – Stahl’s deuterium-labelled substrate (18) for probing the stereochemical course of aminopalladation in 
aza-Wacker cyclisations.37 
In aza-Wacker reactions, syn- and anti-aminopalladation pathways generally afford the same product. 
However, the stereochemical course of these processes has a bearing on enantioselective reactions. Due 
to the differing nature of intermediates 9 and 10 (Scheme 3), it is unlikely one chiral ligand could 
provide high levels of asymmetric induction in both a syn- and an anti-aminopalladation step. 
Consequently, reactions for which both pathways are operative are unlikely to proceed with high 
enantioselectivity. Furthermore, the fact that the aminopalladation mechanism is highly substrate 
dependent could limit the generality of any enantioselective aza-Wacker reaction. Finally, in related 
palladium(II)-catalysed cyclisations that do not terminate in -hydride elimination,38-42 the geometry of 
the aminopalladation step determines which diastereomer of product is obtained. 
1.2.3 Enantioselective aza-Wacker cyclisations 
The first highly enantioselective aza-Wacker reaction was reported by Stahl in 2011.43 Using pyrox-
based ligand 23, enantioenriched pyrrolidines were prepared in good to excellent yields and with high 
enantioselectivities (Scheme 6). For substrates with a defined stereocentre in the -position, the catalyst 
can override the inherent substrate-controlled diastereoselectivity. For example, starting from 24, either 
diastereomer of 25 can be prepared, simply by using the (S)- or the (R)-enantiomer of ligand 23. This 
strategy is not effective, however, for substrates containing either - or -substitution. An alternative 
strategy for the preparation of enantioenriched pyrrolidines makes use of an enantiopure sulfinamide 
protecting group in two successive diastereoselective reactions, organometallic addition to an imine 
followed by an aza-Wacker cyclisation.44  





Scheme 6 – Enantioselective aza-Wacker cyclisations.43 
The process in Scheme 6 was initially proposed to proceed via syn-aminopalladation, as this step had 
been confirmed under similar conditions. However, in another example of the finely balanced nature of 
the two pathways, anti-aminopalladation was found to be operative in the enantioselective reaction.45 
Just by replacing pyridine with ligand 23, the selectivity for syn- versus anti-aminopalladation was 
completely reversed. Reactions using the palladium(II)/23 catalytic system that proceeded through syn-
aminopalladation resulted in significantly lowered enantioselectivity.45 This observation presumably 
explains the fact that a nosyl-protected substrate cyclised with significantly reduced enantioselectivity 
compared to the analogous tosyl-protected substrate (see Scheme 5).43 
The significant delay between the discovery of the first aza-Wacker reaction (1978) and the 
demonstration of high enantioselectivity (2011) can be attributed, at least in part, to the need for 
oxidising conditions, which generally preclude the use of phosphine ligands. Transition metal 
complexes bearing phosphine ligands have been fundamental to the development of asymmetric 
catalysis and are responsible for the rapid growth of this field over the past 40 years or so.46-48 
1.2.4 Redox-neutral variants of the aza-Wacker reaction 
Aza-Wacker reactions can be rendered redox-neutral with the incorporation of an allylic acetate group 
(Scheme 7).49 In this case, the reaction terminates in a -acetate elimination (as opposed to -hydride 
elimination); this results in a palladium(II) complex which does not require oxidation to re-enter the 
catalytic cycle. With the use of the dimeric palladium(II) catalyst 27, the cyclisation products can be 
obtained in excellent yield and with good enantioselectivity. The overall transformation is equivalent 
to an intramolecular Tsuji-Trost amination, and such reactions have been reported.50-53 While affording 
the same products, the two are mechanistically distinct; in Tsuji-Trost reactions, palladium cycles 
between the 0 and +2 oxidation states, whereas the process outlined in Scheme 7 proceeds via an 
isohypsic mechanism. Despite the absence of external oxidants, the need to prepare substrates 




containing an acetate group reduces the attractiveness of this methodology compared to oxidative aza-
Wacker reactions. Furthermore, the tolerance of other substitution patterns on the alkene has not been 
demonstrated, and only products containing a terminal alkene have been prepared. 
 
Scheme 7 – Redox-neutral palladium(II)-catalysed cyclisation of substrate 26.49 
1.2.5 Overview of substrate scope in aza-Wacker processes 
Heterocycles available: The aza-Wacker reaction can provide access to a number of different nitrogen 
heterocycles, the majority of these containing 5-membered rings, as cyclisations to form this ring size 
tend to be most facile. The following heterocycles have been prepared in this way: pyrroles,54 
pyrrolidines,27,28,55 pyrrolidinones,49 indoles,18,55 indolines,27,28,55 isoindolinones,56 imidazolidines,25 
oxazolidines,57 cyclic carbamates49 and cyclic sulfamides.58 While 5-membered rings are the most 
common target, larger ring sizes have been prepared, often with the use of conformationally biased 
benzo-fused substrates.56,59,60 Access to morpholines and piperazines, as well as individual examples of 
piperidine and diazepane synthesis, has been demonstrated by Stahl, although these processes required 
high pressures of oxygen as the terminal oxidant.61 
Alkene scope: Good substrate scope with respect to the alkene partner is very rarely demonstrated, and 
substrates containing trisubstituted alkenes with substituents larger than methyl groups are seldom used. 
With the exception of the reaction of sulfinamide-protected substrates,44 substitution  to nitrogen 
appears to be limited to methyl groups or ,-fused rings. Furthermore, transannular cyclisations to 
afford complex bicyclic systems are uncommon.  
Protecting group scope: The majority of aza-Wacker cyclisations make use of a sulfonyl protecting 
group; aza-Wacker reactions of carbamate- and amide-protected substrates are known but are 
comparatively rare.II Under identical conditions, carbamate-based substrates have been shown to be less 
reactive than the analogous tosyl-based substrates, requiring longer reaction times to go to completion.55 
While seemingly being more suitable for cyclisations, sulfonamide-based protecting groups limit the 
further synthetic use of the products, as they are generally more difficult to remove than carbamates. 
                                                     
II Examples of aza-Wacker cyclisations of substrates containing carbamate25,55,57 and amide56,62 protecting groups. 




Issues with the oxidant: As a final point, the necessity of an external oxidant has implications on more 
than just the choice of ligand in these reactions. Aza-Wacker reactions that use reagent-based oxidants, 
typically benzoquinone or Cu(OAc)2, generate stoichiometric by-products (Scheme 8). Those that use 
aerobic oxidation present obvious safety concerns, given the combination of flammable solvents with 
oxygen atmospheres, often at elevated temperatures. One recent study of a palladium-catalysed aerobic 
oxidative amination found that the active oxidant was the peroxide of the ethereal solvent the reaction 
was conducted in;63 peroxides are notorious in synthetic chemistry for their tendency to cause 
explosions.64 Consequently, the requirement for an external oxidant limits the attractiveness of these 
processes for anything greater than laboratory-scale reactions. 
 
Scheme 8 – Summary of the major limitations of aza-Wacker reactions. 
 
1.3 Nitrogen-based heterocycles via electrophilic 1,2-aminofunctionalisation of 
alkenes 
In 2004, Wolfe reported a palladium-catalysed cyclisation, conceptually related to the aza-Wacker 
reaction, to form N-aryl pyrrolidines (Scheme 9).65 The reaction constitutes a 1,2-aminoarylation of the 
alkene in 29; the amination occurs in an intramolecular fashion and the aryl unit is provided by an 
external aryl bromide. While the initial report focused on the use of aniline-based substrates, the 
downstream flexibility of the products was improved by switching to amide- and carbamate-based 
protecting groups.66,67 





Scheme 9 – Palladium(0)-catalysed 1,2-aminoarylation of alkenes 29a-c.65 
The mechanism of the general reaction is given in Scheme 10.66 Oxidative addition of the aryl halide 
affords a palladium(II) species that promotes aminopalladation of the pendant alkene of 31. Reductive 
elimination from intermediate 32 releases heterocyclic product 33 and palladium(0), which can re-enter 
the catalytic cycle. In contrast to the aza-Wacker reaction, which is an oxidative process, the 
1,2-aminoarylation reaction couples a nucleophile with an electrophile across an alkene, making the 
overall transformation redox-neutral. 
 
Scheme 10 – Mechanism of the palladium(0)-catalysed 1,2-aminoarylation of alkenes, as well as possible competing 
pathways.66 
The ability to prepare pyrrolidines in this way is notable because the reaction conditions could 
conceivably result in either Buchwald-Hartwig amination of the N–H bond or Mizoroki-Heck 
functionalisation of the alkene (34 and 35, respectively, in Scheme 10); the latter has been observed 
under similar conditions.68 The fact that this reaction does not require an external oxidant is key to the 
success of this strategy; by varying the phosphine ligand used, selectivity for either Buchwald-Hartwig 
amination or 1,2-aminoarylation products was achieved.38 Additionally, in the reaction of 36, ligand 
choice affects the isomerisation of intermediate 37 to 38, allowing selective access to either 39 or 40 
(Scheme 11).38 The relative stereochemistry of 39 and 40 demonstrates that this transformation proceeds 




through syn-aminopalladation; the strongly basic conditions used in these reactions are likely to favour 
this pathway with respect to anti-aminopalladation.37 
 
Scheme 11 – Catalyst-controlled selectivity for products 39 and 40 in the palladium(0)-catalysed aminoarylation of 
substrate 36.38 
In a similar manner to the aza-Wacker cyclisation, this kind of aminoarylation has been extended to a 
variety of N-heterocycles, including aziridines,69 pyrazolidines,70 oxazolidines,71 isoxazolidines,72,73 
cyclic ureas,74 cyclic guanidines,75,76 piperazines,77,78 morpholines,79 tetrahydroquinolines,80 
tetrahydroisoquinolines,80 tetrahydroquinoxalines80 and benzodiazepines.81 The reaction can also be 
adapted to accommodate other classes of electrophiles that undergo oxidative addition with 
palladium(0); in this way, aminoalkenylation82 and aminoalkynylation83,84 have been achieved.  
 
Scheme 12 – Synthesis of tropane derivativesIII through palladium(0)-catalysed intramolecular 1,2-aminoarylation.85 
                                                     
III For aesthetic reasons, the structures in  Scheme 12 have been depicted as enantiomeric to the reaction contained 
in reference 85. 




Wolfe has also reported the synthesis of tropane derivatives in an intramolecular reaction (Scheme 12).85 
This process made use of enantiopure substrates, such as 41, and afforded products, such as 42, with 
complete enantioretention. In addition to this enantioretentive cyclisation, enantioselective variants 
have also been developed. Using chiral phosphoramidite ligands, moderate to high levels of asymmetric 
induction have been achieved in cyclisations to form 5-membered74,86 and 6-membered rings.80 
Despite a good number of nitrogen-based heterocycles being available through this general strategy, 
and a wide variety of aryl halides being suitable for it, the scope with respect to the alkene partner is 
somewhat limited, with the vast majority of cyclisations involving terminal alkenes. In a rare case where 
tolerance of 1,2-disubstituted alkenes was demonstrated, products were obtained in relatively low yield 
(43-62 %), although they were formed with excellent diastereoselectivity.39 Substrates containing 
1,1-disubstituted alkenes appear to be more amenable to cyclisation.39 It should be noted, however, that 
for both classes of disubstituted alkene, only sterically non-demanding examples have been 
demonstrated. Furthermore, for some processes, the complete failure of substrates containing 
trisubstituted alkenes was reported.39 
 
1.4 Aza-Heck reactions 
1.4.1 The Narasaka-Heck reaction 
In 1999, Narasaka reported the palladium(0)-catalysed cyclisation of O-pentafluorobenzoyl (FBz) 
oxime esters containing pendant alkenes (Scheme 13),87 a transformation which has subsequently been 
termed the Narasaka-Heck reaction.88 The mechanism involves insertion of palladium(0) into the N–O 
bond of 43 to afford iminopalladium(II) species 44; insertion of the pendant alkene into the Pd–N bond  
 
Scheme 13 – The Narasaka-Heck reaction: synthesis of pyrroles via the palladium(0)-catalysed cyclisation of oxime esters.87 




of 44 generates intermediate 45. -Hydride elimination from 45 provides dihydropyrrole 46 as the 
initially formed product, which then undergoes isomerisation to pyrrole 47. Interestingly, the geometry 
of the starting oxime is inconsequential, as interconversion between (Z)-44 and (E)-44 appears to occur 
readily. This is evidenced by the fact that 47 can be prepared in essentially the same yield from either 
(E)-43 or (Z)-43. As the transformation involves steps analogous to the Mizoroki-Heck reaction89 – 
insertion of palladium(0) into an C–X bond, carbopalladation of an alkene and -hydride elimination – 
but initiates with an N–X bond, it can be considered an example of an aza-Heck reaction, and the 
Narasaka-Heck cyclisation was the first reported example of this class of reaction. 
Following the initial report detailing the synthesis of pyrroles, the process has been extended to provide 
access to pyridines,90 isoquinolines,90 azaanulenes91 and imidazoles.92 A relatively uncommon 6-endo 
cyclisation is observed in the reaction to form pyridines (Scheme 14), in contrast to the 5-endo mode 
operative in the other examples. The exact mechanism of the transformation outlined in Scheme 14 is 
unclear,93 although 49 is likely formed from either 50 or 51. When independently prepared, substrate 
51 was shown to be equally capable of participating in the cyclisation to afford 49.90 
 
Scheme 14 – Synthesis of pyridine 49 through the palladium(0)-catalysed 6-endo cyclisation of substrate 48.90 
1.4.2 Bower group work: chiral heterocycles from the Narasaka-Heck reaction 
Recently, it has been noted that the average degree of chiralityIV in drug candidates increases at each 
stage of the development process.95 Assuming a causal link,V this implies that candidates with a higher 
degree of chirality have a higher chance of success. Furthermore, these considerations suggest that 
medicinal chemists are making too many “flat” molecules; indeed, by one reported measure,IV the 
degree of chirality in discovery compounds has been decreasing since 1990.97 This trend has been 
associated with the rise of compound libraries synthesised via palladium-catalysed sp2–sp2 couplings.95 
These combined observations suggest that methodologies which enable efficient synthesis of complex 
scaffolds would be highly desirable. With this in mind, research at Bristol has focused on taking 
processes that typically generate achiral products, such as the Narasaka-Heck reaction, and modifying 
them to allow access to chiral products.98  
                                                     
IV The fraction of sp3 carbon atoms in a given structure has been proposed as a measure for this.94,95 
V Suggestions as to the reason for this have been proposed.96 




One example of a chiral product was observed in Narasaka’s work: in the cyclisation of 52, as well as 
desired pyrrole 53, dihydropyrrole 54 was isolated as a minor productVI (Scheme 15a).87 The formation 
of 54 is the result of -hydride elimination of Hb, rather than Ha, from intermediate 55 (Scheme 15b); 
while under these conditions this is clearly unfavoured, by employing strategies to eliminate Hb 
selectively, the Narasaka-Heck reaction might be adapted to generate chiral products.VII  
 
Scheme 15 – a) Observation of chiral dihydropyrrole 54 in the Narasaka-Heck cyclisation of substrate 52.87 b) -Hydride 
elimination from 55 is the key step in determining product distribution between 53 and 54. 
A number of strategies to achieve selective access to dihydropyrrole products were examined; the first 
of these was the use of substrates with cyclic alkenes (Scheme 16).100 Substitution of the imine (R in 
56) and in the -position was well tolerated, and substrates with cyclic alkenes with ring sizes of 5 to 7 
participated in the reaction in good yields. The key to the success of these cyclisations was the use of 
electron-deficient phosphine ligands, and, of these, P(3,5-(CF3)2C6H3)3 was optimal. The selectivity 
achieved in the case of 57 is due to Hain 58 not being available for syn--hydride elimination. 
 
Scheme 16 – Access to bicyclic dihydropyrrole products through the use of substrates containing cyclic alkenes.100 
Other approaches to chiral products were also developed (Scheme 17); substrates containing 
trisubstituted alkenes (R2 ≠ H in 59) lack Ha, so elimination of Hb from intermediate 61 occurs. A 
number of substrates containing relatively sterically congested alkenes cyclised to afford products 60a-c 
in good yields.101 Selectivity in processes involving linear 1,2-disubstituted alkenes was also achieved 
                                                     
VI The ratio of 53 and 54 is given as 2:1 in the original publication.87 However, under what appear to be the same 
conditions, a subsequent review gives a higher yield for 53, without mentioning 54.99 
VII While the dihydropyrrole and pyrrole products possess the same fraction of sp3 carbon atoms, the presence of 
a chiral carbon atom was also found to correlate to a greater chance of success in drug discovery.95 




(60d-f);102 in this case, the incorporation of an aryl group in the R3 position of 59 leads to the activation 
of the adjacent hydrogen atoms in 61, favouring elimination of Hb. 
 
Scheme 17 – Further strategies for achieving selectivity for dihydropyrrole products.101,102 
Having demonstrated the applicability of the Narasaka-Heck reaction to the synthesis of chiral products, 
the next logical target was an asymmetric variant that would allow the preparation of enantiopure 
dihydropyrroles. Through the use of P,N-based ligand 62, products were obtained with good levels of 
enantioselectivity and in good yields (Scheme 18).103 Although 1,2-disubstituted alkenes were not 
compatible with this methodology, trisubstituted alkenes were effective partners, generating products 
containing sterically congested tetrasubstituted C–N stereocentres. 
 
Scheme 18 – Palladium(0)-catalysed enantioselective Narasaka-Heck cyclisations.103 





Scheme 19 – Application of the Narasaka-Heck initiation mode to a variety of partially intermolecular 
1,2-iminofunctionalisation reactions.104 
While distinct from aza-Heck reactions, intermolecular cascades using the initiation mode of the 
Narasaka-Heck reaction were also developed (Scheme 19).104 For substrates containing exo-methylene 
or terminal alkenes, the intermediates resulting from oxidative addition and syn-iminopalladation (64 
and 66) could, in theory, be intercepted by suitable nucleophiles. This objective was achieved under 
carbonylative conditions by using boron-based nucleophiles to deliver aryl, alkenyl and alkynyl groups 
to intermediate 64 (products 65a-d), or through trapping 64 with alcohols (products 65e-h). 
Alternatively, under non-carbonylative conditions, intermediate 66 can be intercepted directly with 
boron- or tin-based nucleophiles to provide 1,2-imino-arylation, -alkenylation and -alkynylation 
products (products 67a-d).  
Although some of the products obtained from these cascades are similar to those detailed in Section 1.3, 
the approach is distinct because the exogenous component is nucleophilic, as opposed to electrophilic. 
Organometallic nucleophiles cannot be used in palladium(II)-catalysed cyclisations of substrates 
containing free N–H bonds, as these reagents effect reduction of the palladium(II) species required for 




the initial cyclisation. Consequently, oxidative cascades coupling N–H substrates with nucleophiles are 
rare.VIII 
The work presented in this section demonstrates the success achieved in applying the Narasaka-Heck 
reaction to the synthesis of chiral products. The developed methodology exhibits good substrate scope, 
particularly with regard to the alkene partner, which comfortably outstrips what is tolerated in the 
reactions presented in Sections 1.2 and 1.3. Additionally, through adaptation of the reaction conditions, 
a wide variety of cascade processes were demonstrated. However, the use of the Narasaka-Heck 
initiation mode has a number of limitations (Scheme 20a). The first of these is that the cyclic imine 
products are arguably less useful than the saturated products obtained from the aza-Wacker reaction.IX 
Furthermore, successful cyclisations generally require a large substituent  to nitrogen. The reason for 
this is twofold. Firstly, in the equilibrium of 68a with 68b, large R groups favour 68b, from which the 
desired reaction proceeds (Scheme 20b). Without competing decomposition from 68a, the position of 
the equilibrium would only be of consequence to the rate of reaction, but decomposition of 68 evidently 
does occur, as ketones analogous to 71 are the most commonly observed side products.100 Ketone 71 
 
 
Scheme 20 – a) Summary of the advantages and limitations of the Narasaka-Heck reaction. b) Larger substituents favour the 
productive isomer of 68 in the Narasaka-Heck reaction. c) Competitive decomposition pathways available to 68.100 
                                                     
VIII Exceptions to this include a tandem aminocarbonylation/Friedel-Crafts acylation which uses a bimetallic 
catalytic system along with CuCl2105 and a reaction which uses organometallic nucleophiles but is stoichiometric 
in palladium.106 
IX In Njardarson’s analysis of FDA-approved drugs, pyrrolidines were found to be the 5th most common 
N-heterocycle, in comparison, dihydropyrroles were at least ten-times less prevalent.1 




most likely arises from hydrolysis of imine 70, the product of protodepalladation from 68 (Scheme 20c). 
While protodepalladation could conceivably proceed from either 68a or 68b, by favouring 68a, the rate 
of productive reaction decreases, and hence the ratio of 57 to 71 decreases.X Secondly, aldoxime 
substrates (R = H in 56) predominantly afford nitrile elimination products (69 in Scheme 20c).100 This 
has been proposed to result from Beckmann rearrangement from 56d.100 However, a number of 
alternative elimination mechanisms could be envisaged for the formation of 69, such as -hydride 
elimination from 68a, E2 elimination from either 68b or (E)-56d, and syn-elimination from (Z)-56d. 
 
1.5 Project objectives 
A timeline of the development of aza-Heck reactions is presented in Figure 2. Following its initial 
disclosure, the Narasaka-Heck reaction was soon applied to a variety of aromatic heterocycles 
(Section 1.4.1). Further advances were subsequently achieved by our group, and the reaction was 
adapted to the synthesis of chiral dihydropyrroles (Section 1.4.2). Despite this progress, at the outset of 
the studies contained in this thesis (2014), essentially no new classes of N–O bond donors had been 
reported in aza-Heck reactions in the 15 years since the publication of Narasaka’s seminal paper. 
Consequently, the primary objective of the project was to develop further N–O bond donors suitable 
for aza-Heck reactions (Scheme 21) in the hope of overcoming some of the limitations associated with 
the Narasaka-Heck reaction (Scheme 20a). The possibility of introducing the preactivated N–O bond in 
one step, by means of a Mitsunobu alkylation, was also considered. Secondary objectives included 
achieving highly enantioselective aza-Heck cyclisations, and the application of new initiation modes to 
aza-Heck cascade reactions, similar to those outlined in Scheme 19 (Section 1.4.2). 
Two novel classes of aza-Heck reactions were devised. The first of these was based on 
N-acyloxysulfonamides (PG = sulfonyl in 72), and the development of this reaction is described in 
Chapter 2. The key results from this study were reported in 2016.107 Following this, aza-Heck 
cyclisations of N-acyloxycarbamates (PG = carbamate in 72) were successfully achieved. This work is 
contained in Chapter 3, and these efforts were published in 2018.108 Chapter 4 details attempts to 
establish an enantioselective variant of the reactions contained in the preceding two chapters. A 
manuscript based on this work is being prepared for submission. The application of these novel N–O 
bond donors to a variety of cascade processes was also explored, and Chapter 5 contains the results of 
this. 
 
                                                     
X Assuming any changes to the relative rate of protodepalladation from 68a and 68b are less significant than the 
change in the position of equilibrium between the two. 





Figure 2 – Timeline of selected advances in the development of aza-Heck reactions.XI 
 
Scheme 21 – Proposed application of the aza-Heck concept to further classes of N–O bond donors. 
                                                     
XI References: A,87 B,90 C,91 D,92 E,100 F,101 G,102 H,107 I,109 J,103 K,108 L.110  




1.5.1 Aza-Heck reactions of O-phenyl hydroxamates 
Before presenting the work contained in this thesis, it is pertinent to highlight a report from Watson 
detailing a further class of aza-Heck reaction;109 this was published after the completion of the studies 
in Chapter 2. Watson’s process made use of O-phenyl hydroxamate substrates (74) and afforded 
5-membered lactams in generally excellent yield (Scheme 22). The reaction tolerates a good variety of 
alkene partners, including the first use of a tetrasubstituted alkene in an aza-Heck reaction (75c). One 
example of the synthesis of a benzo-fused 6-membered lactam was also disclosed (75d). However, 
further substitution on nitrogen is not tolerated, and the reason for this was not speculated upon. While 
a detailed mechanistic investigation was not carried out, the reaction is proposed to proceed through an 
aza-Heck mechanism. Compared to previous aza-Heck methodology, the substrates used in this reaction 
contained the relatively weakly activating O-phenyl group; stronger activating groups were found to 
promote Lossen rearrangement.111 Recently, this methodology was extended to the synthesis of cyclic 
ureas (L in Figure 2).110  
 
Scheme 22 – Aza-Heck cyclisations of O-phenylhydroxamate substrates.109 




  - Aza-Heck reactions of N-acyloxysulfonamides 
The contents of this chapter have been communicated: Hazelden, I. R.; Ma, X.; Langer, T.; Bower, J. F. 
Angew. Chem. Int. Ed. 2016, 55, 11198-11202. Parts of this chapter have been reproduced from the 
aforementioned publication. 
2.1 Introduction 
Before commencing our studies, aza-Heck reactions had been applied to a wide variety of products 
(Figure 2, Section 1.5). However, all known classes were based on oxime esters, leading to partially 
unsaturated N-heterocycles. Our objective was to apply the aza-Heck concept to a new class of 
substrates, containing a C–N single bond, as this would generate potentially more useful saturated 
products. The proposed reaction appeared feasible, so long as access to key intermediate 76 could be 
achieved (Scheme 23a); 76 is known to be a productive intermediate in aza-Wacker reactions 
(Scheme 23b), where it is generated under oxidative conditions.  
 
Scheme 23 – a) Access to intermediate 76 through aza-Heck and aza-Wacker pathways. b) Generation of pyrrolidine 77 
from intermediate 76.  
While the products of the reaction proposed in Scheme 21 (Section 1.5) are, in theory, available to aza-
Wacker reactions, a redox-neutral approach would have a number of advantages over oxidative 
alternatives. As mentioned previously (Section 1.2.5), the scalability of oxidative processes can be 
limited due to issues with safety in the case of aerobic oxidation, or stoichiometric waste generation 
with reagent-based oxidants. External oxidants typically possess more promiscuous reactivity in 
comparison to internal N–O bond-based oxidants, as the former could conceivably react with many of 
the species in the reaction mixture, and oxidation of palladium could occur at a number of stages of the 
catalytic cycle. Furthermore, the ability to use highly-tuneable phosphine ligands could confer benefits 
over aza-Wacker reactions with respect to substrate scope, as this is somewhat limited in certain areas 
(Section 1.2.5).  
Given the prevalence of sulfonamide-based substrates in aza-Wacker reactions, and the effectiveness 
of the pentafluorobenzoate activating group in aza-Heck reactions, a substrate combining both of these 
elements was seen as a logical starting point to initiate our studies. 




2.2 Substrate synthesis 
2.2.1 First-generation routes to aza-Heck substrates 
In order to test the feasibility of the proposed transformation, substrate 79 was targeted. The initial route 
devised to synthesise 79 relied on N-alkylation of TsNHOH to afford N-hydroxysulfonamide 78, 
followed by acylation to provide 79 (Scheme 24a). The advantage of this approach was that substrates 
activated with a variety of leaving groups could be prepared from 78, should pentafluorobenzoyl-based 
substrate 79 prove unsuitable for the reaction. Although there was no literature precedence for alkylation 
of TsNHOH, an analogous alkylation of TsNHNH2 has been reported.112 Alkylation of TsNHNH2 
proceeds with good regioselectivity, as the -NH2 unit is significantly less acidic than the sulfonamide 
N–H bond. In contrast, there is a far smaller difference in the acidity of the NH and OH units of 
TsNHOH. It was hoped that by varying the reaction conditions and, if necessary, using two equivalents 
of base it would be possible to achieve a reaction with the desired selectivity. In the event, a different 
problem was encountered; when the alkylation was conducted in DMSO, the only products isolated 
were sulfone 80 and sulfinate ester 81 (Scheme 24b). Products 80 and 81 resulted from S- and 
O-alkylation, respectively, of p-toluenesulfinate, which presumably forms by elimination from the 
O-anion of TsNHOH (Scheme 24c). This kind of elimination has been used in a similar context to 
generate oximes from O-silyl-N-oxysulfonamides; here, the O-anion is generated by fluoride-mediated 
silyl deprotection, and the resulting alkyl-nitroso species tautomerises to give an oxime.113 This reaction 
highlights an issue with the proposed synthesis of 79: strongly basic conditions must be avoided in the 
formation and subsequent reactions of 78. 
 
Scheme 24 – a) Proposed synthesis of test substrate 79. b) Observation of 80 and 81 in the attempted alkylation of TsNHOH. 
c) Proposed mechanism for the formation of 80 and 81. 





Scheme 25 – Synthesis of TsNHOTBS. 
To avoid the formation of an O-anion during the alkylation step, the silyl-protected reagent TsNHOTBS 
was prepared (Route A, Scheme 25).113 While this one-step synthesis initially provided TsNHOTBS in 
high yield, it proved poorly reproducible, and a two-step synthesis was devised which, although only 
proceeding in 55 % overall yield, offered a more practical and scalable route (Route B, Scheme 25).  
 
Scheme 26 – a) Synthesis of 82 through alkylation of TsNHOTBS. b) Synthesis of alcohol 83. c) Synthesis of 85 from 
alcohol 83. d) Synthesis of 88 through Mitsunobu alkylation. 
Alkylation of TsNHOTBS using NaH and 1-bromopent-4-ene in DMSO generated 82 in 97 % yield 
(Scheme 26a). However, this route proved unsatisfactory for the synthesis of other substrates, as 
bromination of the corresponding alcohols, such as 83 (Scheme 26b), proceeded in disappointing yield 
(Scheme 26c). Attempts were made to improve the bromination step, but these were ultimately 




unsuccessful. It was found that converting alcohol 83 to tosylate 84 was a more practical alternative, as 
it allowed the use of a procedurally simpler alkylation method and was higher yielding. In another 
example of the relative ease with which the tosyl group eliminates, O-TBS-protected oxime 86 was 
observed in significant quantities when the alkylation was conducted at elevated temperature in 
rigorously dried solvent. The final improvement in the synthesis of O-TBS-N-oxysulfonamides (such 
as 82, 85 and 88) was the use of a Mitsunobu reaction (Scheme 26d). Starting from the requisite alcohol, 
this provides the desired compounds in one step in usually excellent yield, and hence was used for all 
of the other substrates which were prepared by the first-generation route. 
 
Scheme 27 – O-TBS deprotection conditions evaluated for the synthesis of 78, and acylation of 78 to afford test substrate 79. 
With access to 82 achieved, O-TBS deprotection was examined (Scheme 27). Acid-catalysed solvolysis 
proved unsuccessful, despite some literature precedence.114 The resistance of the O-TBS group in 82 to 
acidic solvolysis is likely to be due to the electron-withdrawing sulfonamide group reducing the basicity 
of the oxygen atom; as the first step in this mechanism is protonation at oxygen, this results in a 
substantially reduced rate of reaction.115 It was also confirmed that TBAF is too basic, as this generated 
oxime 89 along with 78, even in the presence of acetic acid.116 Finally, the mildly acidic fluoride source 
HF·pyridine proved effective in removing the O-TBS group selectively to afford 78 in 93 % yield. 
Acylation of 78 was not problematic, and treatment with FBzCl and Et3N in CH2Cl2 afforded test 
substrate 79 in quantitive yield (Scheme 27). In this chapter, when a substrate is described as being 
prepared by the first-generation route, this refers to Mitsunobu alkylation using TsNHOTBS, 
deprotection with HF·pyridine and then acylation with FBzCl and Et3N (Scheme 28). 
 
Scheme 28 – First-generation route for the synthesis of aza-Heck substrates. 




2.2.2 Second-generation route to aza-Heck substrates 
The removal of the O-TBS group of 90 could be achieved for most substrates using HF·pyridine 
(Scheme 28), but in cases where the substrate contained a secondary carbon atom adjacent to the 
O-TBS-N-oxysulfonamide group, such as 91 and 92, the reaction did not go to completion (Scheme 29). 
The extra steric congestion of this kind of system likely provides further stability to the oxygen-silicon 
bond by energetically disfavouring the pentavalent ate complex intermediate formed during 
deprotection. 
 
Scheme 29 – Problematic deprotection of 91 and 92. 
To improve the deprotection step, model system 93 was prepared (Scheme 30a). However, an extensive 
screen of conditions for cleaving the O-TBS group failed to identify a suitable procedure for converting 
93 to 94 selectively. These reactions either led to no observed reaction, elimination of the tosyl group 
to form oxime 95, or mixtures of 94 and 95. Given the need to avoid basic deprotection conditions 
(Scheme 24b, Section 2.2.1), the resistance of these intermediates to acidic solvolysis, and the failure 
of HF·pyridine-mediated cleavage in sterically congested substrates, a modification to the synthesis 
was clearly required.  
 
Scheme 30 – a) Synthesis and attempted O-TBS deprotection of model system 93. b) Synthesis and O-TES deprotection of 
model system 96. 
It was reasoned that changing the nature of the silyl protecting group might lead to more success in the 
deprotection step. The triethylsilyl (TES) group is a more labile alternative to TBS, as the silicon atom 
is less sterically congested.116 The reagent TsNHOTES could be synthesised analogously to 




TsNHOTBS. Although TsNHOTES proved far more susceptible to hydrolysis in air, this problem could 
be overcome by either preparing it as required or storing it in a glovebox. Model substrate 96 was 
prepared by Mitsunobu alkylation of 1-phenylethanol and subsequently deprotected with aqueous HCl 
in MeOH to afford 94 (Scheme 30b). In this chapter, when a substrate is described as being prepared 
by the second-generation route, this refers to Mitsunobu alkylation using either TsNHOTES or 
MsNHOTES, deprotection with HCl and then acylation with FBzCl and Et3N (Scheme 31). 
 
Scheme 31 – Second-generation route for the synthesis of aza-Heck substrates. 
2.2.3 Third-generation route to aza-Heck substrates 
The results in this section were obtained by Dr Xiaofeng Ma and hence are not detailed in the 
experimental section. 
Although the problems encountered in the alkylation and deprotection steps of substrate synthesis were 
solved satisfactorily by the development of the first- and second-generation routes, respectively, there 
remained an issue in the acylation step. In the course of developing a dearomatisation reaction of indoles 
and phenols, substrate 99 was sought.117 In the case of 97, acylation can occur on either oxygen or 
nitrogen, and it was found that the major product resulted from N-acylation (98, Scheme 32). This 
problem could likely have been circumvented with the use of an orthogonal nitrogen-protecting group; 
however, this was not pursued, as it would further decrease the atom and step economy of substrate 
synthesis. Instead, a more direct synthesis was sought, and the preactivated reagent TsNHOFBz was 
prepared (Scheme 33a). TsNHOFBz participates in Mitsunobu reactions, albeit in slightly lower yields 
than TsNHOTBS and TsNHOTES, and afforded target substrate 99 in one step from alcohol 100 
(Scheme 33b). Clean stereoinversion is typically observed in Mitsunobu reactions, and this was 
confirmed to be the case in the reaction of (S)-1-phenyl-ethan-1-ol (Scheme 33c). 
 
Scheme 32 – Attempted synthesis of dearomatisation substrate 99. 





Scheme 33 – a) Synthesis of TsNHOFBz. b) Synthesis of 99 by Mitsunobu alkylation using TsNHOFBz. c) Demonstration of 
stereoinversion in the Mitsunobu reaction. 
This development was a major breakthrough, as it not only allowed the preparation of a wider variety 
of substrates but also significantly increased the atom and step economy. In this chapter, when a 
substrate is described as being prepared by the third-generation route, this refers to Mitsunobu 
alkylation using either TsNHOFBz or MsNHOFBz (Scheme 34).XII  
 
Scheme 34 – Third-generation route for the synthesis of aza-Heck substrates. 
 
2.3 Development of the N-acyloxysulfonamide-based aza-Heck reaction 
2.3.1 Reaction discovery  
With test substrate 79 in hand, the desired aza-Heck reaction was investigated. When 79 was subjected 
to conditions previously identified as effective for promoting aza-Heck cyclisation of oxime esters,101 
ketone 102 was generated in 82 % yield (Scheme 35). Ketone 102 likely forms via hydrolysis of the 
initially formed enamine 101, evidenced by the fact that 101 could be observed in the 1H NMR spectrum 
of the crude reaction mixture. This promising result suggested the feasibility of the desired 
transformation; note that the overall reaction constitutes a formal Tsuji-Wacker oxidation of the pendant 
alkene, using the N–O bond as an internal oxidant.118,119 For the continued development of the desired 
reaction, other substrates, which would generate more stable aza-Heck products, were evaluated. 
 
                                                     
XII MsNHOFBz was prepared by an analogous route to TsNHOFBz. The syntheses of both compounds are 
provided in the experimental section. 





Scheme 35 – Initial attempt at the palladium(0)-catalysed cyclisation of test substrate 79. 
For the further development of the aza-Heck cyclisation, substrate 103a was prepared from 85 
(Scheme 36a). In this case, formation of an unstable enamine is not possible, as only Hb is in the correct 
configuration for -hydride elimination in intermediate 105.100 When substrate 103a was submitted to 
the aza-Heck reaction conditions, a 15 % yield of 104 and iso-104 in a 5:1 ratio was obtained 
(Scheme 36b), with iso-104 likely formed via palladium hydride-mediated isomerisation of initially 
formed 104. 
 
Scheme 36 – a) Synthesis of substrate 103a. b) Initial attempt at the palladium(0)-catalysed cyclisation of substrate 103a. 
2.3.2 Observation of side products in the aza-Heck reaction  
The yield of 104 and iso-104 obtained from the initial cyclisation of 103a was low, and formation of 
significant quantities of two side products was also observed (Scheme 36b). These were sulfonamide 
106 and p-toluenesulfonamide. Sulfonamide 106, the product of reduction of the N–O bond of 103a, 
possibly forms by protodepalladation of intermediate 107 (Scheme 37). The mechanism of 
protodepalladation is unclear, with the most likely possibility being heterolytic cleavage of the Pd–N 
bond, followed by protonation of the resulting nitrogen anion 109. Alternatively, protonation of 
nitrogen, to afford 108, could precede heterolytic cleavage. It is also possible that 106 forms through 




homolytic Pd–N cleavage, followed by hydrogen atom abstraction of the resulting nitrogen-centred 
radical 110.XIII 
 
Scheme 37 – Proposed mechanisms for the formation of protodepalladation product 106 in the cyclisation of 103a. 
The formation of p-toluenesulfonamide is likely the result of an elimination of FBzOH from 103a, either 
through -hydride elimination or via an E2 mechanism, followed by hydrolysis of the resulting imine 
(111), possibly upon workup (Scheme 38). Aldehyde 112 was not observed, although this may have 
been removed with DMF when the reaction mixture was concentrated in vacuo. While the obvious 
explanation for the elimination would be to invoke -hydride elimination from intermediate 107, 
p-toluenesulfonamide was still observed when 103a was heated with Et3N in DMF, indicating the E2 
pathway is feasible. 
 
Scheme 38 – Proposed mechanisms for the formation of p-toluenesulfonamide in the cyclisation of 103a. 
At this stage, further substrates were prepared and evaluated, and substrate 114a was synthesised in 
four steps from aldehyde 113 (Scheme 39). The transannular cyclisation of 114a represented a good 
challenge for the aza-Heck methodology, as examples of this type of reaction were, at the time, rarely 
seen with aza-Wacker and aza-Heck chemistry. A low yield was initially obtained in the cyclisation of 
114a, so further optimisation was undertaken on this substrate. 
                                                     
XIII Under certain conditions, palladium catalysts have been shown to generate nitrogen-centred radicals.120 The 
possibility of the aza-Heck cyclisation proceeding through radical 110 is discussed later (Section 2.5). 





Scheme 39 – Synthesis and palladium(0)-catalysed cyclisation of substrate 114a. 
Lowering the equivalents of Et3N used in the cyclisation of 114a resulted in an increase in the combined 
yield of 115a and iso-115a (Table 1). The observation of side product 116 (Table 1, entry 2), as well as 
the previously noted instability of these substrates to elimination (Scheme 38), provides an explanation 
for this trend. Side product 116 possibly forms by an SNAr/elimination reaction between the 
pentafluorobenzoyl group of 114a and Et3N (Scheme 40). Not only is 116 less likely to successfully 
engage in an aza-Heck reaction but the release of proton and fluoride ions could also lead to inhibition 
of the catalytic cycle.XIV An interesting observation in the cyclisation of 114a is that the majority of the 
 
Table 1 – Optimisation of the equivalents of base in the palladium(0)-catalysed cyclisation of substrate 114a. Yields were 
determined by 1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields 
are given in parentheses. 
 
Scheme 40 – Proposed mechanism for the formation of SNAr/elimination product 116. 
                                                     
XIV A higher concentration of hydrogen ions in the reaction mixture could promote protodepalladation 
(Scheme 37). While protons are also released at the end of the catalytic cycle, these do not persist in the reaction 
mixture (Section 2.5). The reaction is proposed to proceed through a cationic palladium intermediate (Scheme 77, 
Section 2.5), which fluoride ions could inhibit access to. 




product is in the form of iso-115a as opposed to 115a. This kind of isomerisation is somewhat similar 
to that observed in the 1,2-aminoarylation reaction of 36 (Scheme 11, Section 1.3).38 
With the observation that the OFBz leaving group leads to unwanted side reactions, substrates activated 
with other groups were synthesised (vide infra). One of these, 2,4-dinitrobenzoyl-activated 103f 
(Scheme 42, Section 2.3.3), generated tetracycle 120 when subjected to the aza-Heck reaction 
conditions (Scheme 41). Tetracycle 120 appears to result from a radical cascade reaction; homolysis of 
the N–O bond, either initiated thermally or by palladium(0),120 generates nitrogen-centred radical 117, 
which engages in a 5-exo cyclisation to give alkyl radical 118. A second radical cyclisation onto the 
arene of the tosyl group leads to 119, from which loss of a hydrogen atom would afford 120. Chemler 
has reported similar copper-catalysed radical cascades.121,122 The observation of this side product 
suggests that protodepalladation to 106 is unlikely to proceed via a nitrogen-centred radical intermediate 
(Scheme 37), as the ease with which this radical cascade occurs suggests that 120 would be observed 
in significant quantities if this were the case. 
 
Scheme 41 – Observation of radical product 120 in the cyclisation of 103f. 
As side products p-toluenesulfonamide, 116 and 120 result from the decomposition of substrates 103 
and 114a (Scheme 38, Scheme 40 and Scheme 41, respectively), it is feasible that their formation could 
be supressed by optimisation of the reaction conditions, for example, by reducing base equivalents or 
by preventing radical formation. However, 106 forms from 107 (Scheme 37), which is a necessary  
 
 




intermediate in the pathway to desired product 104 (Scheme 36b). Because of this, it was considered 
much harder to prevent formation of 106; in the case of most cyclisations, analogous protodepalladation 
products were the major side products observed, and this product tends to predominate in reactions 
which proceed in poor yield. 
2.3.3 Optimisation 
At this stage, the efficacy of a number of different activating groups was investigated, and substrates 
103b-f were synthesised (Scheme 42). Substrates 103b, 103e and 103f were prepared without incident; 
however, 103c and 103d were both highly susceptible to hydrolysis and could not be stored for a 
significant length of time. 
 
Scheme 42 – Synthesis of substrates 103b-f. 
Optimisation was continued using substrates 103a-f (Table 2). It was found that reducing the 
temperature from 120 to 80 °C led to a doubling of yield to 34 % in the case of 103a (Table 2, entry 2); 
by comparison, mesyl-activated substrate 103b cyclised in only 4 % yield under the same conditions 
(Table 2, entry 3). Increasing the precatalyst loading to 5.0 mol% and decreasing the equivalents of 
Et3N from 4 to 2 resulted in a 60 % yield from 103a and a 46 % yield from 103c (Table 2, entries 4 
and 5). While these results are broadly comparable, the instability of 103c made its continued use 
impractical. Substrates 103d-f did not afford significant yields of 104 (Table 2, entries 6, 7 and 10), 
although 103f underwent radical cyclisation to form 120 (Scheme 41, Section 2.3.2). By increasing the 
temperature to 100 °C and further decreasing the equivalents of Et3N, a yield of 82 % with substrate 
103a was achieved (Table 2, entry 9). However, this result varied considerably upon subsequent repeats.  





Table 2 – Optimisation of the palladium(0)-catalysed cyclisation of substrates 103a-f. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are given in parentheses. 
Attempts to overcome this irreproducibility were unsuccessful; it was considered that the source of the 
problem might be the use of DMF,XV and a solvent screen was embarked upon (Table 3). Polar aprotic 
solvents similar to DMF, such as NMP and DMA, did not lead to high-yielding cyclisations (Table 3, 
entries 1 and 2). By contrast, medium polarity solvents such as THF, 1,2-DME and EtOAc were far 
more effective, with 104 being produced in 55-65 % yield with complete selectivity over iso-104 
(Table 3, entries 3-5). When MeCN was used, a yield of 76 % was achieved, although at the expense 
of selectivity (Table 3, entry 6). Other nitrile-based solvents were trialled (Table 3, entries 7 and 8), and 
n-BuCN proved to be optimal when taking both yield and selectivity into account. Increasing the 
reaction temperature to 110 °C led to a significant increase in yield, with 104 and iso-104 being isolated 
in 85 % combined yield and a ratio of 25:1 (Table 3, entry 10); crucially, this result did not vary 
significantly upon repeating. 
With a suitable solvent identified, the effects of varying the phosphine ligand were investigated. A 
screen of monodentate ligands revealed P(3,5-(CF3)2C6H3)3 to be optimal (Table 21, Appendix). The 
majority of ligands employed provided a poor yield of 104, and bidentate ligands proved to be especially 
ineffective, with none delivering a yield of greater than 25 % (Table 22, Appendix). 
                                                     
XV This was based on anecdotal evidence suggesting reproducibility problems are commonly observed with DMF. 





Table 3 – Solvent screen for the palladium(0)-catalysed cyclisation of substrate 103a. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. 
 
Table 4 – Optimisation of precatalyst and ligand loading for the cyclisation of substrate 103a. Yields were determined by 
1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are given in 
parentheses. 
  




Having achieved a good yield for the cyclisation of 103a following optimisation of solvent and ligand, 
the effect of lowering the catalyst loading was examined (Table 4). Significant drops in yield occurred 
with each 1.25 mol% decrease in palladium precatalyst (Table 4, entries 2, 4 and 6). However, 
increasing the palladium to ligand ratio to 1:2.5 negated this effect for all but the lowest precatalyst 
loadings (Table 4, entries 3, 5 and 7). 
 
Table 5 – Final optimisation of the palladium(0)-catalysed cyclisation of substrate 114a. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are given in parentheses. 
The optimised conditions from Table 4 were applied to the challenging substrate 114a, but the results 
were still disappointing (Table 5, entry 1). Previously, when the cyclisation was run in DMF, a ratio of 
1:4 115a to iso-115a was obtained; by switching to n-BuCN this increased to 3:5, which is in line with 
the trend observed with 103a. In contrast to substrate 103a, higher catalyst loadings resulted in increased 
yield (Table 4, entries 1, 3 and 5 vs. Table 5, entries 1-3). In an attempt to fine-tune the solvent polarity, 
mixtures of n-BuCN and DMF were used, and a 6:1 mixture was found to afford a 63 % yield and 2:5 
ratio of 115a to iso-115a (Table 5, entry 5). This solvent combination was also trialled for the cyclisation 
of 103a and provided a 91 % yield and 12:1 ratio of 104 to iso-104 (Scheme 43). In general, the mixture 
of n-BuCN and DMF was more effective as solvent than n-BuCN alone. However, this was not the case 
for all substrates, and both systems were trialled in subsequent studies. 
 
Scheme 43 – Final conditions for the palladium(0)-catalysed cyclisation applied to substrate 103a. 
 




2.4 Substrate scope for the aza-Heck cyclisation 
2.4.1 Aza-Heck cyclisations involving 1,2-disubstituted alkenes 
With optimised conditions in hand, the substrate scope of the sulfonamide-based aza-Heck reaction was 
examined, and substrates 125, 126 and 127, containing acyclic 1,2-disubstituted alkenes, were 
synthesised (Scheme 44). Alcohols 121 and 122 were prepared in one step from pent-4-en-1-ol via 
alkene cross-metathesis (Scheme 44a). In the case of 122, some optimisation was required to eliminate 
chain-shortened impurity 124, which may result from competing cross-metathesis of 123, itself likely 
formed by ruthenium hydride-mediated isomerisation of pent-4-en-1-ol.123 Benzoquinone has been used 
as an additive in order to supress this type of isomerisation,124 although in this case it was found that 
simply lowering the catalyst loading to 1 mol% completely prevented formation of 124. Alcohols 87, 
121 and 122 were converted to substrates 125, 126 and 127 using the 1st and 3rd generation routes 
(Scheme 44b).  
 
Scheme 44 – a) Synthesis of alcohols 121 and 122, and proposed explanation for the formation of 124 in the synthesis 
of 122. b) Synthesis of substrates 125, 126 and 127. – G-H (II) = Grubbs-Hoveyda 2nd generation catalyst. 
When substrates 125, 126 and 127 were subjected to the aza-Heck conditions, products 12, 128 and 129 
were isolated in good yields (Scheme 45). Although complete selectivity for 12 and 128 was observed, 
substrates 125 and 126 could have, in theory, afforded enamine products. In contrast to intermediate 
105, 130a can undergo C–C bond rotation to 130b, such that -hydride elimination is possible via Ha 
or Hb. In the case of substrate 127, there is no Hb atom in intermediate 131, so bond rotation has to occur 
before -hydride elimination is possible; this accounts for the switch in alkene geometry observed 
between 127 and 129. The successful cyclisation of a substrate containing an electron-deficient alkene, 
such as 127, is also notable, as similar substrates are unlikely to be suitable for aza-Wacker cyclisations 
due to competing conjugate addition. 





Scheme 45 – Palladium(0)-catalysed cyclisation of substrates 125, 126 and 127. 
2.4.2 Aza-Heck cyclisations of systems with substitution  to nitrogen 
Next, the effects of substitution in the -position were examined. To this end, substrates 134, 136 and 
138 were prepared (Scheme 46). Copper(I)/TEMPO-catalysed oxidation of alcohol 87 afforded 
aldehyde 132,125 which was reacted with suitable organometallic nucleophiles to afford alcohols 133, 
135 and 137. Substrates 134, 136 and 138 were then synthesised from alcohols 133, 135 and 137. As  
 
 
Scheme 46 – Synthesis of substrates 134a, 134b, 136 and 138. 




noted previously (Scheme 29, Section 2.2.2), the deprotection step in the first-generation route was 
poorly yielding, and 134a was isolated in only 33 % overall yield. 
The cyclisation of substrate 134a was disappointing, with 139a obtained in 27 % yield, albeit as a single 
diastereomer (Scheme 47). The reaction proceeded slowly, and significant substrate decomposition was 
observed along with 139a; it is possible that the N–O bond of 134a is too hindered for efficient oxidative 
addition. A short period of optimisation of reaction temperature and ligand failed to improve the result 
significantly. It was thought that a substrate with a less sterically hindered N–O bond might lead to a 
higher yielding cyclisation. In order to test this hypothesis, mesyl-protected substrate 134b was 
prepared via the second-generation route (Scheme 46). As hoped, when submitted to the aza-Heck 
cyclisation conditions, substrate 134b performed significantly better than 134a, with 139b isolated in 
58 % yield (Scheme 47).  
 
Scheme 47 – Palladium(0)-catalysed cyclisation of substrates 134a and 134b. 
Although changing to the mesyl-protecting group improved the yield for phenyl-substituted system 
134b, the yield of the cyclisation was still disappointing in the case of n-butyl-substituted substrate 136 
(Scheme 48). Further optimisation was undertaken with this substrate, and it was found that conducting 
the reaction at higher temperature in toluene was key to achieving a good yield of 140. Under these 
conditions, the cyclisation of tosyl-protected substrate 138 was also successful, and 141 was obtained 
in 75 % yield (Scheme 48). 
 
Scheme 48 – Palladium(0)-catalysed cyclisation of substrates 136 and 138. 
 




2.4.3 Aza-Heck cyclisations of systems with substitution  to nitrogen 
Attention was then turned to substrates containing -substitution (Scheme 49). Synthesis of substrates 
144 and 146 proceeded from alcohols 142 and 143, which were prepared in two steps via alkylation of 
substituted acetates, followed by reduction. Cyclisation of -phenyl-system 144 progressed with 
moderate diastereoselectivity and yield, favouring the cis-diastereomer. The N-mesyl-protected 
substrate 146 provided a higher yield of target 147, although this was formed with no 
diastereoselectivity, despite incorporating a larger cyclohexyl substituent. 
 
Scheme 49 – Synthesis and palladium(0)-catalysed cyclisation of substrates 144 and 146. 
2.4.4 Aza-Heck cyclisations of systems with substitution  to nitrogen 
 
Scheme 50 – a) Synthesis of alcohols 149 and 151. b) Synthesis of substrates 152 and 153. 




While poor diastereoselectivities were obtained in the cyclisations of substrates with -substitution 
(Scheme 49), it was hoped that moving the substituent closer to the alkene would lead to a greater steric 
influence in the cyclisation step and hence result in higher diastereoselectivity. -Substituted-
,-unsaturated alcohols 149 and 151 were prepared by a Johnson-Claisen/reduction sequence from 
easily accessible allylic alcohols 148 and 150 (Scheme 50a). Substrates 152 and 153 – bearing phenyl 
and i-propyl substituents, respectively – were synthesised from the corresponding alcohols 149 and 151 
(Scheme 50b). 
Unfortunately, although substrate 152 afforded an 81 % yield of product 154, the diastereoselectivity 
achieved was disappointing (Scheme 51). When exposed to the aza-Heck conditions, substrate 153 
provided essentially the same result as 152, despite the presence of the slightly larger i-propyl group 
(Scheme 51). 
 
Scheme 51 – Palladium(0)-catalysed cyclisation of substrates 152 and 153. 
2.4.5 Aza-Heck cyclisations involving trisubstituted alkenes 
The use of trisubstituted alkenes in the aza-Heck reaction was examined; as mentioned previously, these 
kinds of substrates are relatively rare in aza-Wacker reactions (Section 1.2.5). A relatively simple 
substrate (156) was targeted initially (Scheme 52). Substrate 156 was prepared via an alkylation/ 
decarboxylation/reduction strategy starting from diethyl malonate, followed by the second-generation 
substrate synthesis route. When employed in the aza-Heck cyclisation, 156 afforded an 80 % yield of 
157 (Scheme 52). 
 
Scheme 52 – Synthesis and palladium(0)-catalysed cyclisation of substrate 156. 




Having demonstrated the tolerance of methyl-substituted alkenes with substrate 156, substrates 
containing larger substituents were evaluated. The alcohols required for this were prepared by Johnson-
Claisen reactions of allylic alcohols 158a-c, followed by reduction to afford 159a-c (Scheme 53a). From 
these alcohols, substrates 160a-c were synthesised using the second-generation route (Scheme 53b).  
 
Scheme 53 – a) Synthesis of alcohols 159a-c. b) Synthesis of substrates 160a-c. 
Unfortunately, when substrates 160a-c were trialled in the aza-Heck reaction, products 161a-c were 
obtained in disappointing yields (Scheme 54). Phenyl-substituted system 160a afforded 161a in a poor 
yield, even compared with the 31 % yield of 161b obtained with i-propyl-substituted 160b. This 
difference is potentially due to the electronic effect of conjugation of the alkene with the phenyl group. 
Although a modest yield of 54 % was achieved with benzyl-substituted substrate 160c, it is clear that 
sterically encumbered trisubstituted alkenes constitute a limitation of this methodology. 
 
Scheme 54 – Palladium(0)-catalysed cyclisation of substrates 160a-c. 
A substrate containing both -substitution and a trisubstituted alkene (163) was prepared and evaluated 
in the aza-Heck reaction (Scheme 55). By using the conditions developed for substrates 136 and 138 
(Scheme 48, Section 2.4.2), a 64 % yield of 164 was obtained from the cyclisation of 163. As was 




typically observed with other -substituted systems (Section 2.4.2), 164 was formed with excellent 
diastereoselectivity. 
 
Scheme 55 – Synthesis and palladium(0)-catalysed cyclisation of substrate 163. 
2.4.6 Aza-Heck cyclisations to generate bicyclic systems 
As an excellent result was achieved with cyclohexenyl substrate 103a (Scheme 43, Section 2.3.3), 
further cyclisations that afford bicyclic products were targeted, and cyclopentenyl substrate 166 was 
prepared from carboxylic acid 165 (Scheme 56). The yield of the cyclisation of 166 was the same as 
that for 103a but proceeded with far better selectivity, to generate 20 as a single alkene isomer 
(Scheme 56). The fact that 20 can be prepared in just three steps from commercially available carboxylic 
acid 165 demonstrates the power of the combined Mitsunobu/aza-Heck cyclisation sequence. 
 
Scheme 56 – Synthesis and palladium(0)-catalysed cyclisation of substrate 166. 
 
Scheme 57 – Palladium(0)-catalysed cyclisation of substrate 114a. 
The transannular cyclisation of substrate 114a was investigated previously (Table 1, Section 2.3.2 and 
Table 5, Section 2.3.3), and although the yield of the transformation was improved to 63 %, a significant 
amount of isomerisation of 115a to iso-115a was observed (Scheme 57). This system was revisited with 




the N-mesyl analogue 114b (Scheme 58). As a higher yield was observed in the reaction of 
-substituted N-mesyl substrate 134b compared to its N-tosyl analogue 134a (Scheme 47, 
Section 2.4.2), it was hoped that 114b would lead to a higher yielding cyclisation, which could then be 
optimised to improve product selectivity. 
 
Scheme 58 – Synthesis of substrate 114b. 
Under identical conditions to those used for N-tosyl substrate 114a, N-mesyl substrate 114b provided a 
higher yield and greater selectivity for desired product 115 (Table 6, entry 1 vs. Scheme 57), with the 
major product being 115b rather than iso-115b. Further improvements in yield and selectivity were 
observed when n-BuCN was used as a solvent alone (Table 6, entry 2), instead of as a mixture with 
DMF (Table 6, entry 1). Using THF as the reaction solvent resulted in complete selectivity for 115b, 
although in a significantly lower yield (Table 6, entry 3). A 1:1 mixture of n-BuCN and THF was found 
to provide the optimal combination of yield and selectivity, with 115b being isolated in 76 % yield as 
a single alkene isomer (Table 6, entry 4). 
 
Table 6 – Solvent screen for the palladium(0)-catalysed cyclisation of substrate 114b. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are given in parentheses. 
Following the success achieved in the cyclisation of 114b, further transannular aza-Heck processes 
were investigated. To this end, substrates 168a and 168b were prepared (Scheme 59a). Addition of two 
equivalents of but-3-en-1-ylmagnesium bromide to methyl formate afforded alcohol 167, which was 
then converted to 168a and 168b via ring-closing metathesis. The synthesis of substrate 168a is another 
example of the limitation of the first-generation route, with the deprotection of 91 proceeding in poor 
yield. When evaluated in the aza-Heck reaction, 168b cyclised in a slightly higher yield than 168a under 
identical conditions, and 169b was isolated in 60 % yield (Scheme 59b). 





Scheme 59 – a) Synthesis of substrates 168a and 168b. b) Palladium(0)-catalysed cyclisation of substrates 168a and 168b. 
 
Scheme 60 – Synthesis of substrates 170a and 170b. 
The possibility of C–N bond-forming spirocyclisation was also investigated, and substrate 170 was 
prepared via a route similar to that for 156 (Scheme 52, Section 2.4.5). As with 168, both N-tosyl- and 
N-mesyl-protected systems 170a and 170b, respectively, were prepared (Scheme 60). When employed 
in the aza-Heck cyclisation, substrate 170b performed significantly better than 170a (Scheme 61), with 
171b isolated in 42 % yield and without the isomerisation observed for 171a/iso-171a. While the yield 
of 171b was disappointing, it is broadly in line with the results obtained using other trisubstituted 
alkenes (Section 2.4.5). 
 
Scheme 61 – Palladium(0)-catalysed cyclisation of substrates 170a and 170b. 
 




Cyclic substrates 175a and 175b were targeted in the hope that the preorganisation contained in their 
structures would lead to high-yielding and highly diastereoselective cyclisations. The synthesis of these 
substrates began with the preparation of ketone 173 by alkylation of -keto ester 172, followed by 
decarboxylation. Reduction of 173 (NaBH4) afforded a 1:1 separable mixture of diastereomeric alcohols 
174a and 174b (Scheme 62a). Both 174a and 174b were poorly tolerated in the Mitsunobu reactions, 
and attempts to synthesise 175a directly via the third-generation route, using TsNHOFBz, were 
completely unsuccessful (Scheme 62b). The second-generation route, using TsNHOTES, provided an 
overall yield of 23 %, with the Mitsunobu step proceeding in 39 % yield. The relative stereochemistry 
of 175a was determined by X-ray diffraction, and the relative stereochemistry of alcohols 174a and 
174b was assigned on the assumption that the Mitsunobu step proceeded with inversion. In the case of 
alcohol 174b, neither route resulted in the formation of 175b (Scheme 62c). The failure of the 
Mitsunobu reactions with alcohols 174a and 174b is likely due to steric hindrance, with 174b 
performing worse than 174a because the nucleophile has to approach the activated substrate on the 
same face of the cyclohexane ring as the butenyl substituent. 
 
Scheme 62 – a) Synthesis of alcohols 174a and 174b. b) Synthesis of substrate 175a. c) Attempted synthesis of 
substrate 175b. 




Aza-Heck cyclisation of 175a under the standard conditions provided a low yield of 176a. As observed 
for -substituted substrates (Section 2.4.2), slightly better results were achieved in toluene at 140 °C 
(Scheme 63). In contrast to the results obtained with -substituted substrates, 176a was formed with 
essentially no diastereoselectivity. It is possible that the trans relationship of the - and -substituents 
leads to a reduction in the diastereoselectivity, as, when considered on their own, each substituent exerts 
a preference for a different diastereomer. It was disappointing that 175b could not be prepared, as there 
is a good chance that it would have cyclised in higher yield and possibly with high diastereoselectivity; 
Szabó has reported palladium-catalysed oxidative cyclisations of sulfonamides onto allyl silanes and 
achieved a significantly higher yield of 176b compared to its trans-ring junction isomer 176a.126 
Although, as the two proceed through very different mechanisms, it may not be possible to extrapolate 
those results to the aza-Heck reaction. 
 
Scheme 63 – Palladium(0)-catalysed cyclisation of substrate 175a. 
As mentioned previously, attempts to synthesise substrate 175a directly using the third-generation route 
failed. However, purification of the reaction mixture led to the isolation of a significant amount of 
degradation product 177 (Scheme 64a); the structure of which was confirmed by X-ray diffraction. This 
product is likely formed via an intramolecular SNAr reaction (Scheme 64b). This is seemingly an 
unfavourable reaction, as 177 is not observed in significant amounts in other Mitsunobu processes; in 
those cases, the intermolecular reaction appears to outcompete the intramolecular decomposition. For 
alcohol 174a, the rate of the desired reaction is presumably so slow that TsNHOFBz simply decomposes 
and formation of 177 predominates.  
 
Scheme 64 – a) Observation of TsNHOFBz degradation product 177 in an unsuccessful Mitsunobu reaction. b) Proposed 
mechanism for the formation of 177. 




2.4.7 Attempted cyclisations to form 4-membered rings 
Having established the effectiveness of the aza-Heck reaction for preparing substituted pyrrolidines, the 
synthesis of products containing other ring sizes was attempted. The possibility of forming azetidines 
was especially attractive, as this is something which is not typically possible with aza-Wacker 
methodologies. Although cyclisation to form 4-membered rings is much slower than for 5-membered 
rings,127-129 Heck reactions and related Heck-type processes which generate cyclobutanes have been 
reported.130-132 The homoallylic alcohols 123 and 179 required for 4-ring substrates could each be 
synthesised in one step; N-mesyl substrate 178 was prepared from 123, and N-tosyl substrate 180 was 
prepared from 179 (Scheme 65). 
 
Scheme 65 – Synthesis of substrates 178 and 180. 
Vinyl azetidine 181 was not observed when 178 was subjected to the aza-Heck conditions (Scheme 66), 
nor was the product of 5-endo cyclisation (182). Despite the fact that disubstituted cyclic alkenes 
have been shown to be excellent partners in the aza-Heck reaction (Scheme 43, Section 2.3.3 and 
Scheme 56, Section 2.4.6), substrate 180 did not cyclise to afford 183 (Scheme 66). The azetidine ring 
system could simply be too strained to form in this manner, especially considering the fact that 
aminopalladation is likely to be reversible.133 It is also possible that, even if formed, the vinyl azetidine 
products decompose under the reaction conditions, as similar systems undergo ring opening under 
related conditions.134 
 
Scheme 66 – Attempted cyclisation of substrates 178 and 180. 




2.4.8 Aza-Heck cyclisations to form 6-membered rings 
Although attempts to form 4-membered rings were not successful, analogous 6-exo cyclisations were 
investigated. The prevalence of the piperidine unit in natural products135 and pharmaceuticals1 makes 
them an attractive target. Six-exo cyclisations were considered a more realistic possibility than 4-exo 
cyclisations, as there is far less ring strain in piperidines compared to azetidines.  
Substrate 185 was prepared in a similar manner to 126 (Scheme 44, Section, 2.4.1). However, as was 
initially observed with alcohol 122 (Scheme 44a, Section 2.4.1), a significant amount of chain-
shortened impurity 121 was produced in the synthesis of alcohol 184 (Scheme 67a). It was not possible 
to separate 184 from 121, nor was it possible to separate the analogous compounds at any stage of the 
substrate synthesis. Hence, 185 was isolated as a 4:1 mixture with 126 (Scheme 67b).  
 
Scheme 67 – a) Synthesis of alcohol 184 and proposed explanation for the formation of 121. b) Synthesis of substrate 185.  
– G-H (II) = Grubbs-Hoveyda 2nd generation catalyst. 
The mixture of 185 and 126 was subjected to the aza-Heck cyclisation conditions; at this stage, the two 
products could be separated, and a similar amount of piperidine 186 (arising from 185) was isolated as 
pyrrolidine 128 (arising from 126) (Scheme 68). Even taking into account the impurity of the substrate, 
the yield of 186 was disappointing, so further substrates were prepared. 
 
Scheme 68 – Palladium(0)-catalysed cyclisation of substrate 185. 
Based on the observation that N-mesyl protected substrates generally cyclise in higher yields than the 
corresponding N-tosyl variants (Section 2.4.2, Section 2.4.3 and Section 2.4.6), substrate 190 was 
targeted (Scheme 69). Alcohol 189 was prepared by methylation of alkyne 187, followed by reduction 
and deprotection. Conversion of 189 to substrate 190 was then achieved via the second-generation route. 




Subjecting 190 to the aza-Heck conditions provided 191 in only 14 % yield (Scheme 69). Although this 
is a slight improvement compared to 185, the yield is still too low to be synthetically useful.  
 
Scheme 69 – Synthesis and palladium(0)-catalysed cyclisation of substrate 190. 
Substrates containing heteroatoms in the tether were prepared (194 and 195 in Scheme 70). The 
heteroatom provides a useful synthetic handle and allows for easier preparation of alcohols 192 and 193 
compared to (Z)-189. Furthermore, in a previous report on aza-Wacker cyclisations that form 
6-membered rings, the vast majority of products are either morpholines or piperazines,61 suggesting 
these kinds of substrates might be effective in the related aza-Heck reaction. However, as found with 
previous 6-ring substrates, aza-Heck cyclisation of 194 and 195 provided products 196 and 197 in 
disappointing yields (Scheme 70). 
 
Scheme 70 – Synthesis and palladium(0)-catalysed cyclisation of substrates 194 and 195. 
In the majority of cases, the yield-determining step in the cyclisation appears to be aminopalladation of 
the alkene from intermediate 198 (Scheme 71), with protodepalladation being the major competing 
pathway to afford side product 199. This hypothesis is based on the observation that, although other 
side products have been observed in some cases (Section 2.3.2), protodepalladation product 199 is the 
most commonly observed side product. The rate of the cyclisation step (k1) from 198 will be highly 
dependent on the nature of the tethered alkene; however, the protodepalladation reaction (k2) is unlikely 
to be significantly affected by this. From the yields achieved in 5-exo cyclisations it is apparent the rates 
of these two reactions are finely balanced; moving to homologated systems lowers the rate of cyclisation 
sufficiently such that protodepalladation becomes favoured. Based on this observation, it was thought 
that introducing a conformational bias into the substrates might increase the rate of cyclisation and 




hence lead to improved yields. With this in mind, alcohol 201 was prepared via methallylation of the 
Grignard reagent formed from 200, followed by O-THP deprotection (Scheme 72). Alcohol 201 was 
then converted to substrate 202 using the second-generation route. 
 
Scheme 71 – Proposed explanation for the low yields observed in cyclisations of 6-ring substrates compared to 5-ring 
substrates. 
 
Scheme 72 – Synthesis of substrate 202. 
When substrate 202 was employed in the aza-Heck cyclisation using the standard conditions, 203 was 
obtained in 15 % yield (Scheme 73). While this result is similar to the other 6-ring substrates, the major 
side product was elimination product 204, rather than protodepalladation product. The acidification of 
the C–H bonds  to nitrogen by the adjacent aromatic ring likely makes elimination more facile than in 
other substrates. Optimisation studies revealed that using toluene as the solvent at 160 °C could provide 
203 in 35 % yield. Presumably, the rate of elimination is reduced when the reaction is conducted in an 
apolar solvent, and this would account for the increased yield. 
  
Scheme 73 – Palladium(0)-catalysed cyclisation of substrate 202. 




By removing the benzylic activation present in 202, elimination might be disfavoured. Accordingly, the 
isomeric substrate 207 was prepared and evaluated in the aza-Heck cyclisation (Scheme 74). Reaction 
of the aryl lithium species derived from 205 with ethylene oxide afforded alcohol 206, and 207 was 
then synthesised from 206 using the second-generation route. When exposed to the aza-Heck 
conditions, 207 cyclised in moderate yield. 
 
Scheme 74 – Synthesis and palladium(0)-catalysed cyclisation of substrate 207. 
While substrate 207 was relatively successful, further improvements to the yield of the 6-exo cyclisation 
were sought. It was considered that a more electron-rich alkene might result in a more efficient reaction, 
as the alkene is formally the nucleophilic component. To investigate this hypothesis, substrate 209, 
bearing electron-donating methoxy groups on the arene, was synthesised (Scheme 75). However, when 
209 was subjected to the aza-Heck reaction conditions, a negligible amount of 210 was observed in the 
1H NMR spectrum of the crude material (Scheme 75). The poor result in the case of 209 could be 
attributed to a number of factors: it is possible that the hypothesis is wrong, and electron-rich alkenes 
are actually less suitable partners in the aza-Heck reaction. Alternatively, the fact that 209 contains an 
(E)-alkene compared to the (Z)-alkene in 207 could have been responsible for the low yield observed. 
Finally, the electron-rich styrene in 209 could have been too unstable to tolerate the reaction conditions, 
and the substrate may have simply decomposed. 
 
Scheme 75 – Synthesis and attempted cyclisation of substrate 209. 




A further styrenyl substrate was prepared (211 in Scheme 76), and although it was hoped that it would 
undergo 6-endo cyclisation to afford 213, the generation of 5-exo product 214 was also considered 
likely. As long as the enamine products were sufficiently stable to hydrolysis, either 214 or 213 would 
have been good additions to the scope of cyclisations to form 5- or 6-membered rings, respectively. In 
the event, neither the endo- (213) nor the exo-product (214) was formed when 211 was exposed to the 
aza-Heck conditions, and only protodepalladation product 212 was observed in the 1H NMR spectrum 
of the crude reaction mixture (Scheme 76).  
 
Scheme 76 – Synthesis and attempted cyclisation of substrate 210. 
Despite extensive efforts to form 6-membered rings using the aza-Heck cyclisation, this remains a 
significant limitation of the sulfonamide-based methodology, even taking into account the modest 
success obtained with 202 and 207 (Scheme 73 and Scheme 74). As will be seen in Chapter 3, this 
problem was solved with the development of a carbamate-based aza-Heck reaction. 
2.5 Mechanistic investigations 
A detailed mechanism for the sulfonamide-based aza-Heck cyclisation presented in this chapter is given 
in Scheme 77. This mechanism is based partly on work carried out on the O-pentafluorobenzoyl oxime 
ester system previously reported by our group104 and partly on observations obtained during the work 
detailed in this chapter. In the first step of the catalytic cycle, substrate 125 undergoes oxidative addition 
with a palladium(0) complex, likely to be Pd0[P(3,5-(CF3)2C6H3)3]2, to afford neutral intermediate 215, 
which lies in equilibrium with cationic complex 216. syn-Aminopalladation from 216 generates 
intermediate 11, and 11 then undergoes -hydride elimination to release product 12 and palladium(II) 
hydride species 217. Base-mediated reductive elimination regenerates palladium(0) from 217 and closes 
the catalytic cycle. It is likely to be complex 216 from which syn-aminopalladation proceeds to afford 
11, based on the observation that addition of excess pentafluorobenzoate inhibits the cyclisation of 
oxime ester-based systems.104 While protodepalladation (to afford (E)-8) could conceivably occur from 
either 215 or 216, it has been suggested that, at least for the oxime ester-based system, 
protodepalladation predominantly occurs from a neutral complex analogous to 215.104 Throughout the 




examination of the scope of this reaction, substoichiometric quantities of Et3N have been used; based 
on the assumption that one equivalent of FBzOH is produced as a by-product of this reaction, this might 
seem to be insufficient. However, as previously reported,104 the triethylammonium salt of 
pentafluorobenzoate decomposes via a surprisingly facile protodecarboxylation reaction to afford 
C6F5H and CO2; the observation of C6F5H in crude reaction mixtures by 19F NMR spectroscopy 
confirms that this decomposition is operative in the case of the sulfonamide-based reaction. The 
protodecarboxylation reaction clears pentafluorobenzoate, which would otherwise inhibit subsequent 
turnovers, from the reaction mixture and regenerates Et3N, allowing catalytic quantities of the base to 
be used. 
 
Scheme 77 – Proposed catalytic cycle for the sulfonamide-based aza-Heck reaction. 
Hartwig136 and Stahl137 have confirmed the oxidative addition step in palladium-catalysed reactions of 
oxime esters by crystallising the resulting iminopalladium(II) products. Inspired by this work, attempts 
were made to isolate the products of oxidative addition by reacting substrates 218a and 218b (see the 
experimental section) with stoichiometric equivalents of palladium(0) complexes (Scheme 78a). These 
substrates cannot undergo cyclisation, as they lack a pendant alkene, and, in theory, complexes 221a 
and 221b could be isolated if stable enough. However, this was not possible, despite numerous attempts 
using the palladium(0) complexes 219 and 220; analysis of the 31P NMR spectra of these reactions 
showed that complex mixtures were forming in each case. In order to identify 221b in these reaction 
mixtures, the synthesis of an authentic sample was undertaken (Scheme 78b). Unfortunately, in spite of 




there being some literature precedence for similar transformations,133 in this case, reaction of the sodium 
salt of 222 with palladium(II) complex 223 failed to generate target complex 224.  
 
Scheme 78 – a) Attempted isolation of oxidative addition products 221a and 221b. b) Attempted synthesis of an authentic 
sample of 221b. 
Despite there being good evidence for many elements of the catalytic cycle presented in Scheme 77, 
there are a number of possibilities for the route taken in going from 125 to 11. One possibility is that 
11 is formed via aza-Wacker cyclisation of protodepalladation product (E)-8 (Scheme 79a); in this case, 
rather than being an aza-Heck reaction, it would be more accurate to describe it as an aza-Wacker 
reaction using an N–O bond as the terminal oxidant. A simple experiment to determine whether or not 
the cyclisation proceeds, even in part, through an aza-Wacker mechanism is to conduct a cross-over 
experiment in the presence of an NH sufonamide. To this end, (E)-8 was prepared (see the experimental 
section) and subjected to the aza-Heck conditions in the presence of 126 (Scheme 79b). Cyclisation to 
afford 128 was observed in a similar yield to the reaction without (E)-8 (Scheme 45, Section 2.4.1), and 
 
Scheme 79 – a) Comparison of aza-Heck and aza-Wacker mechanisms for the formation of 11. b) Palladium(0)-catalysed 
cyclisation of substrate 126 in the presence of (E)-8. 




12 was not observed. This result rules out an aza-Wacker mechanism and also implies that the reverse 
of protodepalladation does not occur readily, at least in reactions which proceed in good yield. 
The formation of 11 through a radical pathway is also possible (Scheme 80a). In this scenario, 
palladium(0)-mediated N–O bond homolysis of 125 generates intermediate 225, which undergoes 
radical cyclisation to afford 226. Carbon radical 226 then recombines with a palladium(I) species to 
produce key intermediate 11.XVI Previous work from within the group has demonstrated that 
palladium(0) systems can lead to the generation of nitrogen radicals from oxime esters,120 although this 
required electron-donating ligands, as opposed to the electron-withdrawing ligands used for aza-Heck 
cyclisations. A radical-based mechanism is also considered unlikely as carbon radicals similar to 226 
undergo cyclisation onto the arene of the tosyl group fairly readily (Scheme 41, Section 2.3.2). 
Furthermore, when the cyclisation of 125 was conducted in the presence of TEMPO, trapping product 
227 was not observed (Scheme 80b). However, in order to completely rule out a radical pathway, an 
experiment was carried out using a substrate bearing a radical probe (228).139,140 
 
Scheme 80 – a) Comparison of aza-Heck and radical mechanisms for the formation of 11. b) Palladium(0)-catalysed 
cyclisation of substrate 125 in the presence of TEMPO. 
Substrate 228 was prepared by the route detailed in Scheme 81.XVII The trisubstituted cyclopropane of 
228 enables differentiation of cyclopropane ring opening proceeding via radical or -carbon elimination 
mechanisms (Scheme 82).120 In the case of a radical mechanism, intermediate 230 would be unstable  
aaaaa  
                                                     
XVI An analogous mechanism has been shown to be operative in a copper-catalysed aza-Heck-like cyclisation of 
oxime esters.138 
XVII Substrate 228 was prepared by Dr Xiaofeng Ma (University of Bristol). 





Scheme 81 – Retrosynthesis of substrate 228. 
due to the presence of the carbon radical adjacent to the cyclopropane ring. Cleavage of bond A in 230 
would be expected to afford 231 selectively, where the radical is stabilised by the phenyl group 
(Scheme 82b). Previous work has shown that in radical cyclisations, intermediates analogous to 231 
can abstract a hydrogen atom from another species in the reaction mixture.120 However, in order for the  
 
Scheme 82 – a) Formation of intermediates 229 and 230 in aza-Heck and radical cyclisations, respectively. b) Expected 
products from a radical cyclisation of substrate 228. c) Expected products from an aza-Heck cyclisation of substrate 228. 




mechanism to be consistent with the observed generation of aza-Heck products, 231 would have to 
recombine with palladium(I) and undergo -hydride elimination to afford 232. Similar to intermediate 
230, organopalladium(II) intermediate 229 is also unstable to cyclopropane opening, although the 
-carbon elimination step occurs with essentially no selectivity for cleavage of either bond A or bond B 
(Scheme 82c).120 
When substrate 228 was exposed to the reaction conditions, a yield of 31 % of 232 and 233 was obtained 
in an approximately 1:1 ratio (Scheme 83). The lack of selectivity observed in the cyclopropane 
cleavage indicates that the mechanism does not proceed via radical intermediate 230, and these results 
are consistent with those obtained in the aza-Heck cyclisation of oxime esters.120 
 
Scheme 83 – Palladium(0)-catalysed cyclisation of substrate 228. 
 
2.6 Conclusions 
The development of a novel aza-Heck reaction based on N-acyloxysulfonamide substrates was 
successfully achieved; at the time, this was only the second class of aza-Heck reaction reported. The 
scope of the cyclisation to form simple pyrrolidines is comparable to that available with aza-Wacker 
cyclisations. However, in addition to the previously mentioned improvements with respect to safety and 
efficiency associated with an aza-Heck approach (Section 2.1), substrate synthesis is generally more 
facile compared to aza-Wacker substrates, with substrates being available in one step, rather than two, 
from the requisite alcohol.XVIII Furthermore, successful examples of transannular cyclisations affording 
complex bicyclic ring systems were demonstrated (115 and 169, Section 2.4.6), these kinds of products 
had not been prepared using either aza-Wacker or aza-Heck processes previously. 
 
Scheme 84 – Proposed access to enantiopure 2,5-disubstituted pyrrolidines in two steps from enantiopure alcohols. 
                                                     
XVIII Aza-Wacker substrates cannot typically be prepared directly from the corresponding alcohol because 
primary sulfonamides do not participate in Mitsunobu reactions.141  




As the Mitsunobu reactions to prepare the aza-Heck substrates are enantiospecific (Scheme 33c, 
Section 2.2.3), and the aza-Heck cyclisations proceed with high levels of diastereoselectivity for 
-substituted systems (Section 2.4.2), the preparation of enantiopure 2,5-disubstituted pyrrolidines 
should be possible from the corresponding enantiopure alcohols (Scheme 84). This could prove 
beneficial for the application of this methodology to the synthesis of targets containing defined 
stereocentres. 
 
The bicyclic nitrogen heterocycles presented in Section 2.4.6 are commonly found in the core structures 
of natural products, for example aphanorphine,10,11 cocaine16 and cylindricine C9 (products 115b, 169b 
and 171b, respectively). Whereas it is unlikely that 115b and 171b could be easily elaborated into 
aphanorphine or cylindricine C, conversion of 169b to the N-Boc analogue would constitute a formal 
synthesis of cocaine.16,142 A comparatively simpler total synthesis is potentially possible for 
norruspoline13 (Scheme 85), as global deprotection of 234, analogous to 128 (Section 2.4.1), would 
afford the natural product. 
 
Scheme 85 – Proposed total synthesis of norruspoline.13 
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  - Aza-Heck reactions of N-acyloxycarbamates 
The contents of this chapter have been communicated: Hazelden, I. R.; Carmona, R. C.; Langer, T.; 
Pringle, P. G.; Bower, J. F. Angew. Chem. Int. Ed. 2018, 57, 5124-5128. Parts of this chapter have been 
reproduced from the aforementioned publication. 
3.1 Introduction 
A major drawback to the sulfonamide-based reaction described in the previous chapter is the difficulty 
associated with the deprotection of the products. It is generally possible to remove N-tosyl groups under 
reductive conditions, although removal of N-mesyl groups is harder.XIX Comparatively, carbamate 
protecting groups are a far more flexible alternative. Wolfe has reported a number of 1,2-aminoarylation 
processes that involve the cyclisation of carbamate-based substrates (Section 1.3). These reactions are 
proposed to proceed through syn-aminopalladation of intermediate 236. Consequently, aza-Heck 
cyclisation of substrate 235 ought to be possible, as long as access to 236 can be achieved  
through oxidative addition (Scheme 86). Despite this, the development of aza-Heck reactions of 
carbamate-protected substrates proved more difficult than the sulfonamide-based reaction (vide infra). 
 
Scheme 86 – Proposed aza-Heck reactions of carbamate-based substrates. 
 
3.2 Development of N-acyloxycarbamate-based aza-Heck reactions 
3.2.1 Reaction discovery  
During the early stages of the development of the sulfonamide-based aza-Heck reaction (Chapter 2), 
the use of other N-protecting groups was investigated. To this end, simple N-Cbz system 238a was 
prepared (Scheme 87). In contrast to the synthesis of N-tosyl-protected substrates, TBAF can be used 
                                                     
XIX The book Protective Groups in Organic Synthesis contains over 20 times as many references for N-tosyl 
removal than N-mesyl removal.116 
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to effect O-TBS cleavage of 237, as elimination of the carbamate protecting group is not possible from 
the resulting O-anion (cf. Scheme 24c, Section 2.2.1). When subjected to conditions previously 
identified as effective for promoting aza-Heck cyclisation of oxime esters,101 238a provided ketone 239 
in 50 % yield, most likely via hydrolysis of the initial aza-Heck cyclisation product 240. Compared to 
the attempted cyclisation of analogous N-tosyl substrate 79 (Scheme 35, Section 2.3.1), the yield of 
ketone 239 was lower, indicating that the desired reaction proceeds less efficiently.  
 
Scheme 87 – Synthesis and attempted cyclisation of substrate 238a. 
Although N-tosyl system 79 generated a more promising result than that achieved with 238a, the 
feasibility of a carbamate-based aza-Heck process was examined further. Substrate 241a, which is 
analogous to 103a, was prepared for this purpose (Scheme 88). The cyclisation of 241a was evaluated 
under conditions effective for the cyclisation of 103a; however, a negligible amount of target 242a was 
observed (Scheme 88, cf. 60 % with 103a, Table 2, entry 4, Section 2.3.3). With only limited success 
forthcoming from N-carbamate-protected substrates, the development of the sulfonamide-based 
cyclisation was therefore prioritised. 
  
Scheme 88 – Synthesis and attempted cyclisation of substrate 241a. 
Following the completion of the work detailed in Chapter 2, it was decided to re-examine other 
protecting groups due to the limitations of the sulfonamide-based reaction. As some indication of the 
feasibility of the cyclisation of N-Cbz-protected substrates had been observed (Scheme 87), this class 
of reaction was revisited. Substrate 243a was prepared by Mitsunobu alkylation of CbzNHOFBzXX and 
                                                     
XX CbzNHOFBz was prepared by Dr Xiaofeng Ma (University of Bristol) according to a reported procedure.117 
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trialled in the aza-Heck reaction (Scheme 89). Under reaction conditions found to be optimal for the 
sulfonamide-based system (Section 2.3.3), substrate 243a afforded a poor yield of the pyrrolidine 244a. 
With disappointing results obtained with substrates bearing an N-Cbz group, attention turned to other 
protecting groups. 
 
Scheme 89 – Synthesis and palladium(0)-catalysed cyclisation of substrate 243a, using conditions optimised for the 
sulfonamide-based aza-Heck reaction. 
In order to assess the viability of further N-protecting groups, common precursor 245 was prepared 
(Scheme 90a). From 245, substrates containing an N-benzoyl (243b) and an N-Boc (243c) group were 
synthesised. With these substrates in hand, aza-Heck cyclisation was attempted (Scheme 90b). When 
243b was submitted to the previously optimised conditions (Section 2.3.3), it appeared to be relatively 
unreactive, and product 244b was not obtained. In contrast, substrate 243c did generate 244c, and a 
brief solvent screen identified that THF led to a substantially improved yield (39 %). However, 244c 
could not be successfully purified, and the isolated yield did not match that determined by 1H NMR 
analysis of the crude mixture.  
 
Scheme 90 – a) Synthesis of substrates 243b and 243c. b) Attempted cyclisation of substrates 243b and 243c. 




Purification of 244c was likely complicated by its volatility;143 consequently, a substrate of higher 
molecular mass was targeted, and n-butyl system 246a was prepared (Scheme 91). Optimisation of the 
cyclisation of 246a initiated with a solvent screen (Table 7), which demonstrated that the reaction is 
viable in a wide range of solvent polarities (Table 7, entries 1-3 and 5), and identified THF as being 
optimal (Table 7, entry 2). The effects of reaction temperature were less pronounced (Table 7, 
entries 7-12), with the best result being achieved at 130 °C (Table 7, entry 10). 
 
Scheme 91 – Synthesis of substrate 246a. 
 
Table 7 – Optimisation of solvent and temperature in the palladium(0)-catalysed cyclisation of substrate 246a. Yields were 
determined by 1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard.  
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Following optimisation of solvent and temperature, a screen of palladium sources was undertaken 
(Table 8), which confirmed Pd2(dba)3 as the optimal precatalyst (Table 8, entry 1). While Pd(OAc)2 
gave a comparable yield of 247a (Table 8, entry 4), Pd[P(3,5-(CF3)2C6H3)3]2Cl2 failed to generate any 
product (Table 8, entry 3). This is potentially due to the presence of chloride ions preventing access to 
the cationic intermediate (analogous to 216) as proposed in the mechanism presented in Scheme 77 
(Section 2.5).  
 
Table 8 – Optimisation of palladium source in the cyclisation of substrate 246a. Yields were determined by 1H NMR analysis 
of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. 
 
Table 9 – Ligand screen for the palladium(0)-catalysed cyclisation of substrate 246a. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are given in parentheses. 
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Next, the effects of varying the phosphine ligand were examined (Table 9). In comparison to the 
sulfonamide-based aza-Heck reaction (Section 2.3.3), a greater number of ligands were found to be 
effective for the cyclisation of 246a. The electron-deficient and sterically hindered 
trioxaphosphaadamantane ligand L1 (cone angle: 202°,144 compared to PPh3: 145° and Pt-Bu3: 182°)145 
provided the best result (Table 9, entry 9). Although electron-deficient phosphine ligands were most 
effective in the cyclisation (Table 9, entries 4-7 and 9), a yield of 62 % of 247a could be achieved with 
PPh3 (Table 9, entry 2). Similar to what was observed in the sulfonamide-based reaction (Section 2.3.3), 
bidentate ligands, e.g. dppb, failed to provide significant yields of 247a (Table 9, entry 10). 
Having optimised the other parameters, the precatalyst loading was lowered to 2.5 mol%, and the effects 
of concentration and ligand loading were examined (Table 10). Higher concentrations led to better 
results (Table 10, entries 1-4), although the use of concentrations higher than 1.0 M was not considered 
practical due to the small scale at which the reactions were carried out on. Finally, it was found that a 
yield of 85 % of 247a could be achieved by increasing the ligand to palladium ratio from 2:1 to 3:1 
(Table 10, entry 6). 
 
Table 10 – Optimisation of concentration and palladium to ligand ratio in the cyclisation of substrate 246a. Yields were 
determined by 1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields 
are given in parentheses. 
3.2.3 Properties of trioxaphosphaadamantane ligands 
Although phosphine ligands containing alkyl substituents are typically considered to be electron-rich 
compared to those with aryl substituents, the properties of trioxaphosphaadamantane ligands, such as 
L1, are closer to those of phosphonites.144 The electron-deficient nature of these ligands is proposed to 
be due to two factors: firstly, the constrained C-P-C angle ( ≈ 90° in L1)144 increases the -acidity  
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of the phosphorous atom. By fixing the *-orbitals in an orientation where there is good overlap  
with the metal d-orbitals, backdonation from the metal centre is facilitated.146 Secondly, the 
electron-withdrawing inductive effect of the oxygen atoms is likely to reduce electron density on the 
phosphorous atom.144 
 
Scheme 92 – Synthesis of L1 and analogues from 248 through palladium(0)-catalysed coupling with aryl bromides.XXI  
Ligand L1 is commercially available but can be prepared in one step by condensation of PhPH2 with 
acetylacetone.148 Alternatively, condensation of acetylacetone with PH3 affords the unsubstituted ligand 
precursor 248 (Scheme 92).147 Derivatives of L1 can then be synthesised from 248XXI by coupling with 
aryl bromides;149 in this manner, a number of analogues were prepared.XXII When used in aza-Heck 
reactions, ligands L1, L2 and L3 were found to be the most effective (vide infra). 
 
3.3 Substrate scope for 5-exo aza-Heck cyclisations 
3.3.1 Scope of the carbamate protecting group in the aza-Heck reaction 
In order to assess the scope of the protecting group, substrates containing i-propyl (246b) and methyl 
carbamates (246c) were synthesised (Scheme 93b). The cyclisation yield of 246a-c decreased with 
decreasing steric bulk of the alkyl group (R in 246); pyrrolidines 247b and 247c were 
generated in 78 % and 70 % yield, respectively (Scheme 93b), compared to 85 % for 247a 
(Scheme 93a). Previously, cyclisations of N-Cbz systems were found to proceed in disappointing yields 
(Section 3.2.1). Despite this, the cyclisation of substrate 243a was re-examined using the improved 
conditions (Scheme 93c). While the yield of 244a was only 45 % using L1, a good result was achieved 
with L2 in place of L1. 
                                                     
XXI Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 
XXII Full details are provided in the experimental section. 




Scheme 93 – a) Optimised conditions for the palladium(0)-catalysed cyclisation applied to substrate 246a. b) Synthesis and 
palladium(0)-catalysed cyclisation of substrates 246b and 246c. c) Palladium(0)-catalysed cyclisation of substrate 243a. 
The cyclisation of N-Fmoc system 243d was also targeted, as this would provide products that could be 
deprotected under basic conditions, adding another element of orthogonality to the protecting groups 
suitable for the aza-Heck reaction. Unfortunately, 243d could not be prepared (Scheme 94), potentially 
due to the N-Fmoc group being unstable under the basic conditions of the Mitsunobu reaction.  
 
Scheme 94 – Attempted synthesis of substrate 243d. 
The possibility of using alkenyl carbamates was investigated with substrate 249 (Scheme 95). However, 
desired product 250 was not observed when 249 was subjected to the aza-Heck cyclisation conditions. 
It is conceivable that -allyl formation competes with oxidative addition into the N–O bond of 249, as 
the former process typically occurs at lower temperatures.150-152 




Scheme 95 – Synthesis and attempted cyclisation of substrate 249. 
Although N-benzoyl-protected substrate 243b did not participate in the aza-Heck cyclisation under the 
previously used conditions (Scheme 90b, Section 3.2.1), it was hoped that amide-based substrates 
would be tolerated following optimisation of the reaction. Substrate 251, similar to 249 but containing 
an all-carbon tether, was prepared by sequential N- and O-acylation of BnNHOH (Scheme 96). 
However, when 251 was exposed to the aza-Heck conditions, neither lactam 252 nor its hydrolysis 
product 253 were observed. Watson subsequently reported aza-Heck cyclisations which generate 
products similar to 252, but in those reactions, substitution on nitrogen was not tolerated and activation 
by an O-phenyl group was required (Section 1.5.1).109 
  
Scheme 96 – Synthesis and attempted cyclisation of substrate 251. 
Despite the failure with 251, the possibility of using N-acyloxyamides in the aza-Heck reaction was 
investigated further. With the observation that protecting groups with greater steric bulk result in higher 
yielding cyclisations (Scheme 93), N-pivaloyl substrate 246d was prepared and evaluated in the 
aza-Heck reaction (Scheme 97); unfortunately, target pyrrolidine 247d was not observed. 
 
Scheme 97 – Synthesis and attempted cyclisation of substrate 246d. 
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3.3.2 Aza-Heck cyclisations involving 1,2-disubstituted alkenes 
With 243a and 246a-c demonstrating the tolerance of methyl and n-butyl groups, respectively 
(Scheme 93, Section 3.3.1), further substrates containing 1,2-disubstituted alkenes were prepared from 
alcohols 121 and 122 (Scheme 98a). When employed in the aza-Heck cyclisation, 254 performed 
similarly to the analogous N-tosyl substrate 126 (Scheme 98b, cf. Scheme 45, Section 2.4.1). In contrast, 
256 performed far better, with 257 isolated in 95 % yield (Scheme 98b, cf. Scheme 45, Section 2.4.1).  
 
Scheme 98 – a) Synthesis of substrates 254 and 256. b) Palladium(0)-catalysed cyclisation of substrates 254 and 256. 
3.3.3 Aza-Heck cyclisations of systems with substitution ,  and  to nitrogen 
Next, the effects of substitution at the -, -, and -positions of substrates were investigated. The 
synthesis of carbamate-protected substrate 258a, containing an -phenyl substituent, was not 
straightforward. Initial attempts at Mitsunobu alkylation of 133 with BocNHOFBz afforded an 
inseparable mixture of 258a and another component, suspected to be 259 (Scheme 99). Side product 
259 likely arises from competing O-alkylation of the anion of BocNHOFBz. By conducting the reaction 
at -78 °C, an increased the ratio of 258a to 259 was obtained, and washing the resulting mixture with 
acetic acid removed residual 259. It is conceivable that analogous O-alkylated products are also 
produced in the synthesis of other substrates but are separable from the corresponding N-alkylation 
product; this could partially explain the modest yields typically achieved in the synthesis of substrates 
in this chapter. 
 
Scheme 99 – Synthesis of substrates 258a and 258b. 
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When substrate 258a was employed in the aza-Heck cyclisation, pyrrolidine 260a was isolated in only 
55 % yield (Scheme 100). By using modified conditions developed subsequently (Section 3.4.2), a 
slightly improved yield of 260a was achieved. Reduced yields in cyclisations involving -substitution 
were also observed in the sulfonamide-based aza-Heck reaction (Section 2.4.2). In that case, better 
results were achieved with a smaller protecting group (Scheme 47, Section 2.4.2). However, in the 
carbamate-based reaction, methyl carbamate substrate 258b provided a lower yield of 260b than N-Boc 
system 258a (Scheme 100). 
 
Scheme 100 – Palladium(0)-catalysed cyclisation of substrates 258a and 258b. 
Following this, substrate 261, which contains substitution at the -position, was prepared from alcohol 
142 (Scheme 101). A low yield was obtained in the Mitsunobu alkylation of 142, which was typical for 
alcohols containing -substitution (vide infra), and this constitutes a limitation of the Mitsunobu 
reaction with carbamate reagents. Substrate 261 cyclised in excellent yield and with acceptable 
diastereoselectivity (Scheme 101); this is a marked improvement over the results from the sulfonamide-
based reaction (Scheme 49, Section 2.4.3). 
 
Scheme 101 – Synthesis and palladium(0)-catalysed cyclisation of substrate 261. 
Substitution at the -position was then investigated with substrate 263a, prepared from alcohol 149 
(Scheme 102a). Although the use of ligand L1 led to a poor yield of 264a (Scheme 102b), 
P(4-(CF3)C6H4)3 provided a better result (68 %): this might reflect the sterically hindered alkene of 263a 
interacting better with a less bulky catalytic system. This observation led to the synthesis of ligands L4 
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and L5 (Scheme 102c); however, when used in the aza-Heck cyclisation, L4 and L5 failed to improve 
the yield of 264a. Ultimately, methyl carbamate substrate 263b provided the best result, and 264b was 
isolated in 77 % yield (Scheme 102d). 
 
Scheme 102 – a) Synthesis of substrates 263a and 263b. b) Palladium(0)-catalysed cyclisation of substrate 263a. 
c) Synthesis of ligands L4 and L5 from 248. d) Palladium(0)-catalysed cyclisation of substrate 263b. 
In order to provide a comparison between the diastereoselectivities achievable in an aza-Heck 
process versus an aza-Wacker process, aza-Wacker substrate 265 was prepared, and its 
cyclisation was studied (Scheme 103). As mentioned previously (Section 2.6), a major 
advantage of the aza-Heck reaction is that the substrates can be synthesised in one step from 
the corresponding alcohol. The difficulty in accessing aza-Wacker substrates is further 
demonstrated by the fact that is far simpler to prepare 265 from 263b, by adding formic acid 
to the aza-Heck reaction conditions, than it would be to prepare it by another route. With 265 
in hand, two sets of aza-Wacker conditions were evaluated. Using a procedure reported by 
Andersson,26 the cyclisation of 265 to 264b proceeded in 71 % yield and 4:1 d.r. (Scheme 103). 
Under conditions reported by Stahl,55 264b was formed in only 37 % yield and 4:3 d.r., based on 
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1H NMR analysis of the crude mixture. Both of these results compare unfavourably to the 77 % 
yield and greater than 20:1 d.r. achieved in the aza-Heck cyclisation (Scheme 102d).  
 
Scheme 103 – Synthesis and aza-Wacker cyclisation of substrate 265. 
3.3.4 Aza-Heck cyclisations involving trisubstituted alkenes 
Trisubstituted alkenes constituted a significant limitation of the sulfonamide-based aza-Heck reaction 
(Section 2.4.5). The highest yield achieved with a substrate bearing a substituent larger than a methyl 
group was 54 % for 160c (Scheme 54, Section 2.4.5). To assess this element of substrate scope for the 
carbamate-based reaction, substrate 266a was prepared (Scheme 104). When employed in the aza-Heck 
cyclisation, 266a afforded an 87 % yield of 267a, a considerable improvement over its N-mesyl 
analogue 160c.  
 
Scheme 104 – Synthesis and palladium(0)-catalysed cyclisation of substrate 266a. 
With the successful cyclisation of substrate 266a demonstrating the tolerance of trisubstituted alkenes, 
further examples were sought, and a substrate containing an exocyclic trisubstituted alkene (269) was 
synthesised from alcohol 268 (Scheme 105). Similarly to 266a, when submitted to the aza-Heck 
reaction conditions, 269 afforded an excellent yield of 270. 
As the alkene acts as the formal nucleophile in the aza-Heck cyclisation, one might expect electron-rich 
trisubstituted alkenes to be more effective partners than disubstituted alkenes, and this is consistent with 
the results obtained in this section. The fact that this was not observed for sulfonamide-based processes 
gives an indication that there is a greater steric influence in those cases. 




Scheme 105 – Synthesis and palladium(0)-catalysed cyclisation of substrate 269. 
3.3.5 Aza-Heck cyclisations to generate bicyclic systems 
Previously, excellent results had been achieved in cyclisations of N-acyloxysulfonamides containing 
cyclic alkenes (Section 2.4.6). This is potentially due to the fact that optimisation of the sulfonamide-
based reaction was undertaken on substrate 103a (Section 2.3.3). This class of cyclisation was also 
investigated with carbamate systems, starting with substrate 241b (Scheme 106a). When employed in 
the aza-Heck reaction, 241b provided a 78 % yield of 242b. While this is a good result, it is considerably 
lower than the yield obtained from 103a (Scheme 43, Section 2.3.3), although in the case of 241b no 
isomerisation of the alkene of 242b was observed. In contrast to 241b, 271 performed significantly 
better in the cyclisation than its N-mesyl analogue 170b (Scheme 106b, cf. Scheme 61, Section 2.4.6). 
This is in keeping with the observation from the previous section that trisubstituted alkenes are tolerated 
far better in the carbamate-based reaction. 
  
Scheme 106 – a) Synthesis and palladium(0)-catalysed cyclisation of substrate 241b. b) Synthesis and 
palladium(0)-catalysed cyclisation of substrate 271. 
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Next, a transannular cyclisation was investigated with substrate 273 (Scheme 107). Under the aza-Heck 
cyclisation conditions, 273 afforded a 64 % yield of 274. Although N-acyloxysulfonamide substrates 
containing 1,2-disubstituted cyclic alkenes provide higher yields of product than the analogous 
carbamate-based substrates (Scheme 106a vs. Scheme 43, Section 2.3.3 and Scheme 107 vs. Table 6, 
entry 3, Section 2.4.6), this is the only area of substrate scope for which this is the case. 
 
Scheme 107 – Synthesis and palladium(0)-catalysed cyclisation of substrate 273. 
 
3.4 Aza-Heck cyclisations to form 6-membered rings 
3.4.1 Initial results 
Despite considerable efforts, efficient 6-exo cyclisations of sulfonamide-based substrates could not be 
achieved (Section 2.4.8). Unbiased substrates performed particularly poorly, with 17 % being the 
highest yield achieved for a substrate lacking a benzo-fused tether. In the course of examining the scope 
of 5-exo aza-Heck cyclisations, carbamate-based substrates were found to provide better results than 
the analogous sulfonamide-based substrate in almost every area, and it was hoped that this improvement 
would extend to cyclisations to form 6-membered rings. 
Under the previously optimised conditions using L1, substrate 275a (see the experimental section) 
afforded a 43 % yield of 276a (Scheme 108), which is much higher than for any non-biased 
sulfonamide-based substrate. By using L2 as the ligand, the yield (1H NMR) increased to 52 %, although 
the isolated yield was only 30 %; as the mass of 276a is similar to 244c (Scheme 90b, Section 3.2.1),  
 
 
Scheme 108 – Palladium(0)-catalysed cyclisation of substrate 275a. 
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the lower isolated yield might be due to the volatility of 276a. For continued optimisation, a substrate 
which is both heavier and easier to prepare on scale was sought, as 275a requires five steps to synthesise. 
3.4.2 Optimisation of the 6-exo aza-Heck cyclisation 
Substrate 278 was viewed as a more practical choice for the optimisation of the 6-exo aza-Heck 
cyclisation, as alcohol 277 could be prepared in only two steps (Scheme 109). From 277, substrate 278 
was prepared as a 1:1 mixture of (E)- and (Z)-isomers. Optimisation of the cyclisation of 278 initiated 
with a brief solvent screen (Table 11), which revealed that dioxane resulted in the highest yield of 279 
(Table 11, entry 6).  
 
Scheme 109 – Synthesis of substrate 278. 
 
Table 11 – Solvent screen for the palladium(0)-catalysed cyclisation of substrate 278. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. 
A ligand screen was then embarked upon (Table 12). After identifying that triarylphosphines were 
generally ineffective at catalysing the reaction (Table 12, entries 1-4), additional derivatives of L1 were 
prepared using the route outlined in Scheme 92 (Section 3.2.3). Replacing the phenyl group of L1 with 
an electron-poor arene led to improved yields of 279 (Table 12, entries 6-10), with L9 affording the 
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highest yield (31 %) (Table 12, entry 10). The use of unsubstituted 248XXIII or phosphinite L10XXIV 
failed to provide significant yields of 279 (Table 12, entries 11 and 12). Ultimately, optimisation of the 
key parameters in the cyclisation of 278 failed to improve the yield of 279 to an acceptable value, and 
isolation of 279 suffered the same problems as 244c and 276 (Scheme 110). Consequently, further 
investigations with this substrate were not deemed worthwhile.  
 
Table 12 – Ligand screen for the palladium(0)-catalysed cyclisation of substrate 278. Yields were determined by 1H NMR 
analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard.XXIII,XXIV,XXV 
 
Scheme 110 – Palladium(0)-catalysed cyclisation of substrate 278. 
                                                     
XXIII Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 
XXIV Phosphinite L10 was prepared according to a literature procedure,153 as opposed to in the manner outlined in 
Scheme 92 (Section 3.2.3). 
XXV Ligand L7 was prepared by Timothy Shuttleworth (University of Bristol) according to a reported procedure.154 




Scheme 111 – Synthesis of substrates (Z)-282a, (E)-282a and (Z)-282b. 
For the continued examination of the 6-exo cyclisation, substrate 282 was targeted, and the effects of 
alkene geometry and protecting group were investigated. From commercially available alkynol 280, 
alcohol 281 can be synthesised as either the (Z)- or the (E)-isomer by reduction with either 
hydrogen/Lindlar catalyst or LiAlH4, respectively (Scheme 111). From 281, N-Boc ((Z)-282a and 
(E)-282a) and methyl carbamate ((Z)-282b) systems were prepared. When the three substrates were 
evaluated in the aza-Heck cyclisation (Table 13), (Z)-282a provided the highest yield of 283 (Table 13, 
entry 1) and was hence taken forward for further optimisation. 
 
Table 13 – Comparison of the cyclisation of substrates (Z)-282a, (E)-282a and (Z)-282b. Yields were determined by 1H 
NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. 
The use of L1 analogues led to substantial improvements in the cyclisation of 278 (Table 12), so more 
analogues were prepared and assayed with substrate (Z)-282a (Table 14). As before, the best results 
were obtained with ligands bearing electron-poor arenes (Table 14, entries 2, 3, 6 and 9), although 
beyond a certain point, decreasing the electron density on the arene further leads to lower yields 
(Table 14, entries 7, 12 and 13). In the case of (Z)-282a, ligand L9, which was optimal for 278, resulted 
in the same yield of 283a as L1 (Table 14, entries 1 and 6).  




Table 14 – Ligand screen for the palladium(0)-catalysed cyclisation of substrate (Z)-282a. Yields were determined by 1H 
NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard.XXVI 
Having identified L3 as the optimal ligand for the cyclisation of (Z)-282a (Table 14), the choice of 
reaction solvent was re-examined, including less commonly utilised solvents (Table 15). The majority 
of these resulted in poor yields of 283a (Table 15, entries 2-5 and 8), and none of them were more 
effective than dioxane (Table 15, entry 1). Fine-tuning of the reaction concentration led to a small 
increase in yield of 283a (Table 15, entry 10). Finally, conducting the reaction on a larger scale 
(0.250 mmol vs. 0.105 mmol) and with a slightly higher loading of L3 provided a 62 % yield of 283a 
(Scheme 112). 
                                                     
XXVI Ligand L12 was prepared by Rafaela Carmona via the route outlined in Scheme 92 (Section 3.2.3). 
Phosphine L18 was not prepared in the manner outlined in Scheme 92 (Section 3.2.3). 




Table 15 – Optimisation of solvent and concentration in the palladium(0)-catalysed cyclisation of substrate 282a. Yields 
were determined by 1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard.  
 
Scheme 112 – Final conditions applied to the palladium(0)-cyclisation of substrate (Z)-282a. 
3.4.3 Aza-Heck cyclisations of substrates lacking biasing factors 
In order to examine the scope of the 6-exo cyclisation, substrate 285a was prepared from alcohol 
(Z)-284 (Scheme 113a). When 285a was exposed the newly optimised conditions, piperidine 286a  
was generated in 63 % yield (Scheme 113b), an almost identical result to that obtained with  
(Z)-282a (Scheme 112). While cyclopropyl substituents have been shown to be tolerated in the 
sulfonamide-based reaction (Section 2.4.2 and Section 2.4.5), the achievement is more impressive in 
the case of 285a, as product 286a contains a vinyl cyclopropane moiety, and these have been shown to 
be reactive towards palladium complexes.155 




Scheme 113 – a) Synthesis of substrate 285a. b) Palladium(0)-catalysed cyclisation of substrate 285a. 
Following the excellent result achieved with 5-ring acrylate substrate 256 (Scheme 98, Section 3.3.2), 
the analogous 6-ring substrate 288 was synthesised (Scheme 114a). As observed previously 
(Section 2.4.1), methyl acrylate proved an excellent partner in the alkene cross-metathesis reaction, and 
alcohol 287 was obtained in quantitative yield. Unfortunately, substrate 288 provided only a modest 
yield of cyclised product, with 289 formed in 38 % yield (Scheme 114b). 
 
Scheme 114 – a) Synthesis of substrate 288. b) Palladium(0)-catalysed cyclisation of substrate 288. 
3.4.4 Aza-Heck cyclisations of systems with substitution  and  to nitrogen 
The influence of substitution at the -position was then investigated with substrate 290 (Scheme 115a). 
As with 258a (Section 3.3.3), the Mitsunobu reaction to form 290 was conducted at -78 °C, and the 
impure product required washing with AcOH to remove the suspected O-alkylated side product. When 
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290 was submitted to the aza-Heck conditions, target 291 was not observed, with protodepalladation 
predominating (Scheme 115b).  
 
Scheme 115 – a) Synthesis of substrate 290. b) Attempted cyclisation of substrate 290. 
In 5-exo cyclisations, better results were achieved with substrates containing -substitution than those 
with substitution in the -position (Section 3.3.3). Based on this observation, -substituted 6-ring 
substrate 294 was synthesised. In order to investigate the effect of alkene configuration, both the (E)- 
and (Z)-isomers of ester 292 were prepared, starting from either (E)- or (Z)-hex-3-en-1-yl iodide, 
respectively. Reduction (LiAlH4) of 292 afforded alcohols (E)-293 and (Z)-293, which were then 
converted into substrates (E)-294 and (Z)-294 (Scheme 116).  
 
Scheme 116 – Synthesis of substrates (Z)-294 and (E)-294. 
When employed in the aza-Heck reaction, (E)-294 afforded 295 in 31 % yield, compared to 45 % yield 
with (Z)-294 (Scheme 117). The improved performance of the substrate containing a (Z)-alkene is 
consistent with the results obtained with 282a (Table 13, Section 3.4.2). There was a more significant 
difference between the two substrates in terms of diastereoselectivity; while the (E)-isomer cyclised 
with no diastereoselectivity, (Z)-294 generated 295 with a 4:1 preference for the cis diastereomer. 




Scheme 117 – Palladium(0)-catalysed cyclisation of substrates (E)-294 and (Z)-294. 
The effects of substitution with an exo-methylene group were examined with substrate 297a, which was 
prepared from alcohol 296 (Scheme 118a). When submitted to the aza-Heck conditions, substrate 297a 
afforded 298 in only 11 % yield (Scheme 118b). The reason for this disappointing result is not clear. 
One possibility is that the exo-methylene group acidifies the -hydrogen atoms of 297a, favouring 
elimination in a similar manner to 202 (Scheme 73, Section 2.4.8). Alternatively, the presence of an sp2 
carbon atom in the tether of 297a might exert a conformational bias against cyclisation. 
 
Scheme 118 – a) Synthesis of substrate 297a. b) Palladium(0)-catalysed cyclisation of substrate 297a. 
3.4.5 Aza-Heck cyclisations of systems with heteroatom-based tethers 
The possibility of forming piperazines and morpholines was investigated with substrates 299 and 301 
(see the experimental section), respectively. While the analogous N-mesyl systems 194 and 195 
performed poorly in the aza-Heck cyclisation (Scheme 70, Section 2.4.8), it was hoped that 299 and 
301 would fare better, as the carbamate-based reaction has greater tolerance for the formation of 
6-membered rings. However, both substrates cyclised in relatively low yield (Scheme 119). Similar to 
what was observed with the analogous N-mesyl substrates, substrate 301 performed significantly better 
than substrate 299. 




Scheme 119 – Palladium(0)-catalysed cyclisation of substrates 299 and 301. 
Following this, the formation of other kinds of heterocycles was investigated. To this end, further 
substrates, containing an ester (305) and an amide (306) tether, were prepared from alcohols 303 and 
304 (Scheme 120a). Unfortunately, when exposed to the aza-Heck reaction conditions, neither 305 nor 
306 generated the corresponding target (Scheme 120b). The cyclisation of substrate 305 was potentially 
hindered by competing -allyl formation, as was proposed for substrate 249 (Section 3.3.1). 
 
Scheme 120 – a) Synthesis of substrates 305 and 306. b) Attempted cyclisation of substrates 305 and 306. 
Previous work established that aza-Heck cyclisations onto acrylates proceeded in excellent yield for 
5-exo cyclisations (Section 3.3.2) and moderate yield for 6-exo cyclisations (Section 3.4.3); both of 
these examples involve a migratory insertion in the direction of the acrylate carbonyl, to give an 
intermediate where palladium is  to the carbonyl (310). The feasibility of the inverse scenario, where 
migratory insertion affords an intermediate with palladium  to the carbonyl (311), was assessed with 
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substrate 309 (Scheme 121). This kind of cyclisation is evidently a more difficult process, and neither 
desired product 312 nor iso-312 were observed following the attempted aza-Heck reaction. 
 
Scheme 121 – a) Synthesis of substrate 309. b) Attempted cyclisation of substrate 309. 
3.4.6 Aza-Heck cyclisations of conformationally biased systems containing 1,2-disubstituted 
alkenes 
In the sulfonamide-based aza-Heck reaction, benzo-fused styrenyl substrate 207 produced the best 
result achieved with a 6-ring substrate, cyclising in 42 % yield (Scheme 74, Section 2.4.8). In order to 
provide a comparison for the carbamate-based reaction, the N-Boc and N-Cbz analogues of 207 were 
prepared (313a and 313b, respectively, Scheme 122a). Both 313a and 313b afforded 314 in 
significantly higher yield than 207 (Scheme 122b), with 313a performing slightly better than 313b. 
Substrate 202 also provided a relatively good result for the sulfonamide-based reaction (Scheme 73, 
Section 2.4.8); however, the analogous N-Boc substrate 315 produced only a 26 % yield of 316 
(Scheme 122c). 
Following the success of benzo-fused substrates 313a and 313b (Scheme 122), substrates fused with 
other heterocycles were targeted. Pyrrolidone-fused system 319 was synthesised from alcohol 318, 
which was prepared through alkylation of (S)-pyroglutaminol derivative 317, followed by deprotection 
(Scheme 123). Substrate 319 proved difficult to purify; its high polarity led to coelution with 
by-products of the Mitsunobu reaction. When 319 was employed in the aza-Heck cyclisation, a small 
amount of desired product 320 (less than 20 %) appeared to form.XXVII However, purification of the 
aza-Heck reaction mixture was problematic, and a pure sample of 320 could not be isolated. 
                                                     
XXVII By 1H NMR analysis of the crude reaction mixture. 




Scheme 122 – a) Synthesis of substrates 313a and 313b. b) Palladium(0)-catalysed cyclisation of substrates 313a and 313b. 
c) Synthesis and palladium(0)-catalysed cyclisation of substrate 315. 
 
Scheme 123 – Synthesis of substrate 319. 
Presumably, benzo-fused substrates increase rates of cyclisations by fixing four atoms of the forming 
ring into one plane. Bringing the Pd–N bond in close proximity to the alkene partner entropically 
favours the cyclisation through preorganisation. Rates of cyclisations can also be increased by the 
introduction of gem-dialkyl groups into the tether.156 In order to exploit this effect, an appropriate 
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substrate (324) was prepared (Scheme 124). The synthesis of 324 began with alkylation of malonate 
derivative 321, followed by reduction to afford triol 322. Protection of 322 proceeded selectively to 
provide the 6-ring acetal in 323. Alcohol 323 was then converted into 324, which, when exposed to the 
aza-Heck reaction conditions, afforded product 325 in 69 % yield (Scheme 124). 
 
Scheme 124 – Synthesis and palladium(0)-catalysed cyclisation of substrate 324. 
3.4.7 Aza-Heck cyclisations of conformationally biased systems containing acrylates 
As good results were achieved in the aza-Heck reaction using conformationally biased substrates 
(Section 3.4.6), the cyclisation of related substrates containing acrylates was investigated. Acrylates are 
excellent partners in the standard Mizoroki-Heck reaction; consequently, benzo-fused 6-ring substrates 
327a-c were easily prepared starting from aryl bromides 326a-c (Scheme 125a). Good yields were 
generally obtained in the cyclisation of 327a-c (Scheme 125b). Interestingly, the products obtained from 
327a and 327b contained alkenes with (Z)-geometry. Because aminopalladation and -hydride 
elimination both procced in a syn manner, this cannot be the initially formed isomer (Scheme 125c). 
syn-Aminopalladation of the trans acrylate in 327 leads to intermediate 329, where palladium and 
hydrogen are on opposite faces; therefore, bond rotation is required before the substituents are in the 
correct orientation for -hydride elimination. Isomerisation, potentially acid-mediated, of the (E)- to 
the (Z)-isomer is responsible for the observed geometry of products 328a and 328b. When the 
cyclisation of 327a was run to partial completion (3 vs. 24 hours) with a higher loading of base, the 
major product was determined to be (E)-328a by 1H NMR analysis (Scheme 125d). However, 
isomerisation to (Z)-328a occurs so readily that it was not possible to isolate (E)-328a. 
An acrylate substrate similar to 324 (Scheme 124, Section 3.4.6) was prepared by reduction of 
anhydride 330 and Wittig reaction of resulting hemiacetal 331, followed by Mitsunobu alkylation to 
afford 332 (Scheme 126a). When exposed to the aza-Heck cyclisation conditions, substrate 332 
afforded (E)-333 in 67 % yield (Scheme 126b). Slightly modified conditions (a shorter reaction time 
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and higher loading of base) were used in the cyclisation of 332 to prevent formation of tautomeric 
enamine iso-333. 
  
Scheme 125 – a) Synthesis of substrates 327a-c. b) Palladium(0)-catalysed cyclisation of substrates 327a-c. c) Rationale for 
the geometry of initially formed product (E)-328 in the cyclisation of substrate 327. d) Observation of (E)-328a as the 
initially formed product in the cyclisation of substrate 327a. 




Scheme 126 – a) Synthesis of substrate 332. b) Palladium(0)-catalysed cyclisation of substrate 332. 
 
3.5 Mechanistic investigations 
The aza-Heck reaction detailed in this chapter is presumed to proceed via a similar mechanism to the 
sulfonamide-based reaction in the previous chapter (Scheme 77, Section 2.5); however, the carbamate-
based reaction appears to be considerably more efficient. One possibility for this could be the 
occurrence of a background aza-Wacker reaction which converts NH carbamate side products, such as 
334, into desired products, such as 247a.XXVIII In order to investigate whether this is the case, a crossover 
experiment akin to the one detailed in Scheme 79b (Section 2.5) was carried out. When the cyclisation 
of 269 was conducted in the presence of 334 (see the experimental section), a good yield of aza-Heck 
product 270 was achieved, and aza-Wacker product 247a was not detected (Scheme 127), indicating 
that the latter process is not operative. 
 
Scheme 127 – Palladium(0)-catalysed cyclisation of substrate 269 in the presence of 334. 
                                                     
XXVIII Through a mechanism analogous to that proposed in Scheme 79a (Section 2.5). 
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Because the reactions are conducted in sealed tubes, it was not possible to follow them by sampling 
methods (e.g., TLC or GC). The standard use of a 24-hour reaction time was based on the observation 
that, in the majority of cases, no starting material remains after this time. Without monitoring, it is 
difficult to observe certain processes that might have implications for successful reaction development. 
There exist a number of phenomena which could lead to an unusual reaction profile. For instance, there 
could be an induction period, during which significant starting material decomposition occurs. There is 
also the possibility of product decomposition, as N-Boc groups are known to be thermally unstable.157,158 
This could mean longer reaction times are not only unnecessary but also detrimental to high yields. In 
order to gain more insight into the reaction, an attempt was made to obtain an accurate reaction profile. 
As techniques which require sampling of the reaction mixture were not appropriate, alternatives which 
rely on spectroscopy, such as monitoring by NMR, were a logical choice.  
The trifluoromethyl analogue (266b) of substrate 266a (Scheme 104, Section 3.3.4) was prepared from 
reagent 335 (Scheme 128a). The CF3 unit provides a fluorine-label for 19F NMR spectroscopy. The 
cyclisation of 266b to 267b (Scheme 128b) was carried out inside an NMR spectrometer and monitored 
for 24 hours, with spectra obtained every 20 minutes.XXIX In the event, the 19F resonances of the 
trifluoromethyl group of 266b, 267b and other species in the reaction mixture were too similar to use 
for quantification.XXX Nevertheless, through the use of solvent suppression, 1H NMR spectroscopy 
could be used to monitor the build-up of 267b. Furthermore, the formation of pentafluorobenzene and 
consumption of 266b, identified by its pentafluorobenzoyl group, could also be monitored. 
 
Scheme 128 – a) Synthesis of fluorine-labelled substrate 266b. b) Palladium(0)-catalysed cyclisation of substrate 266b. 
                                                     
XXIX Dr David Whittaker and Dr Michael Nunn (both AstraZeneca) set up the NMR spectrometer for reaction 
monitoring.  
XXX The situation was potentially complicated by the fact that, at room temperature at least, the 19F NMR spectrum 
of 267b consists of two resonances due to the presence of a pair of rotamers. 




Figure 3 – Reaction profile for the palladium(0)-catalysed cyclisation of substrate 266b.XXXI 
The reaction profile of the cyclisation of 266b is presented in Figure 3. Initially, the reaction proceeds 
rapidly; around 60 % of the final yield of 267b is formed after 2 hours, and 90 % is achieved after 
5 hours. The 24-hour reaction time is justified because the formation of 267b continues until around 
16 hours, and no significant product decomposition is observed following this. Protodecarboxylation of 
pentafluorobenzoate to pentafluorobenzene has been shown to be extremely facile.104 This was also the 
case for the carbamate-based aza-Heck reaction, as formation of pentafluorobenzene was closely 
aligned to generation of 267b, and pentafluorobenzoate was not observed in significant quantities. 
 
Figure 4 – Graph of the rate of formation of 267b vs. consumption of 266b. Units of rate: 1 h-1 = final yield of 267b formed 
in 1 hour. 
                                                     
XXXI The Y-axis of Figure 3 corresponds to 
[𝟐𝟔𝟔𝐛]𝑡
[𝟐𝟔𝟔𝐛]0
 for the starting material and to 
[𝑝𝑟𝑜𝑑𝑢𝑐𝑡]𝑡
[𝑝𝑟𝑜𝑑𝑢𝑐𝑡]∞






























































Chapter 3 - Aza-Heck reactions of N-acyloxycarbamates 
89 
 
Assuming catalyst decomposition does not occur, the reaction would be expected to follow simple 
pseudo-first-order kinetics, where at any moment the rate of the reaction is proportional to the amount 
of starting material remaining. However, as can be seen from Figure 4, this was not the case, and 
proportionally much higher rates were observed at low conversion. Deactivation of the catalyst is likely 
to be responsible for this. As the reaction proceeds, the concentration of catalyst decreases; hence, the 
rate of reaction also decreases, even accounting for the lower concentration of 266b. 
The loss of significant quantities of phosphine ligand to oxidation could be responsible for catalyst 
deactivation, and the corresponding oxide of the ligand (e.g. 336) was commonly observed at the end 
of the catalytic reactions (Scheme 129). There are a number of possible explanations for this, each with 
distinct implications. One possibility is that the oxidation occurs rapidly upon mixing the reagents and 
solvents but then halts. If this is the case, then the presence of peroxides in the ethereal solvents used in 
the reaction could be responsible. Alternatively, imperfectly sealed reaction vessels could allow 
sufficient oxygen into the reaction mixture to cause oxidation of the ligand; in this case, the P-oxide 
would build up at a fairly steady rate. Finally, oxidation may not occur under the reaction conditions 
and might simply be a result of exposing the crude reaction mixtures to air. Of these, the second scenario 
is most likely to cause the pattern of catalyst deactivation observed in the reaction monitoring. 
 
Scheme 129 – Ligand oxidation under aza-Heck reaction conditions. 
By monitoring the 31P NMR spectrum of the mixture as the reaction progressed, the oxidation of the 
ligand could be followed. As can be seen from Figure 5, the oxidation of L2 is rapid, with around 90 % 
of the final amount of 336 being formed after 20 minutes. However, the oxidation of L2 halted at around 
20 % conversion, consistent with a solvent- or reagent-mediated oxidation. This result appears to rule 
out ligand oxidation as being primarily responsible for catalyst decomposition. It is likely that relatively 
high ligand to palladium ratios are, at least in part, effective in the aza-Heck reaction as they counteract 
the effect of ligand oxidation. 
Figure 6 shows how the 31P resonance for L2 varies with time. At the start of the reaction, the peak is 
very broad and shifted downfield relative to the free ligand, likely as a result of reversible coordination 
to palladium. As the reaction progresses, the L2 peak sharpens and moves upfield. This could indicate 
loss of palladium from the reaction mixture, as lower quantities of palladium in solution would cause 
the L2 peak to more closely resemble that of the free ligand. Consistent with this, a black or metallic 
residue was typically found on the inside of the reaction vessels at the end of the reactions. From the  
 




Figure 5 – Reaction profile for the oxidation of L2 to 336 in the palladium(0)-catalysed cyclisation of 266b.XXXII 
results in Figure 5 and Figure 6, it appears catalyst deactivation occurs simply due to the instability of 
the palladium catalyst to aggregation and deposition, rather than as a result of oxidative loss of the 
phosphine ligand.  
 
Figure 6 – Variance of the 31P resonance of L2 during the cyclisation of 266b. 
                                                     



































The application of the aza-Heck reaction described in Chapter 2 to carbamate-protected substrates was 
successfully achieved. As well as providing products of greater synthetic value, the substrate scope of 
the carbamate variant was better in almost every regard compared to sulfonamide-based systems. 
Additionally, much greater levels of diastereoselectivity were generally observed in cyclisations to 
afford pyrrolidines containing substitution in the -, - and -positions (Section 3.3.3 vs. Section 2.4.2, 
Section 2.4.3 and Section 2.4.4). Excellent yields were obtained with substrates containing trisubstituted 
alkenes (Section 3.3.4), which were a limitation in the sulfonamide-based reaction (Section 2.4.5). 
Another limitation of the previous methodology, poor yields in 6-exo cyclisations, was overcome by 
switching to carbamate-protected substrates (Section 3.4). The success of unbiased 6-ring substrates 
282a and 285 (Scheme 112, Section 3.4.2 and Scheme 113b, Section 3.4.3) is particularly impressive; 
while aza-Heck cyclisations to form 6-membered rings had been reported previously,90,109 good yields 
had only been achieved with benzo-fused substrates.XXXIII  
                                                     
XXXIII Excluding one example of pyridine synthesis which proceeds through an unusual 6-endo cyclisation.90 
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  - An enantioselective aza-Heck reaction  
4.1 Introduction  
The aza-Heck reactions of N-acyloxysulfonamide (Chapter 2) and N-acyloxycarbamate substrates 
(Chapter 3) have provided powerful methods for the construction of 5- and 6-membered N-heterocycles. 
As these structures are ubiquitous in natural products135,159-162 and pharmaceutical agents,1 frequently 
with defined C–N stereocentres, an enantioselective variant of these cyclisations would be highly 
valuable.  
Although enantioselective processes involving the syn-aminopalladation of alkenes had been 
demonstrated previously, such as the 1,2-aminoarylation reactions developed by Wolfe 
(Section 1.3),80,86 the only example of an enantioselective aza-Heck reaction in the literature was 
recently reported by our group.103 This methodology used a catalytic system of palladium(0) and 
P,N-based ligand 62 to convert oxime ester substrates (59) into enantioenriched dihydropyrroles (60) 
(Scheme 18, Section 1.4.2 and Scheme 130). The reaction tolerated substrates containing sterically 
demanding alkenes, allowing the enantioselective formation of highly congested C–N bonds. However, 
in addition to the general limitations of the Narasaka-Heck reaction (Section 1.4.2), systems with 
1,2-disubstituted alkenes were not suitable for the enantioselective cyclisation. This is due to competing 
formation of pyrrole 337 limiting the yield of dihydropyrrole product 60 (Scheme 130).103 Furthermore, 
the enantioselectivies achieved were somewhat low (80-90 % e.e.). 
 
Scheme 130 – Palladium(0)-catalysed enantioselective Narasaka-Heck reaction.103 
The key challenge for the development of further enantioselective aza-Heck reactions was the 
identification of ligand systems which not only provide high levels of enantioinduction but also result 
in efficient cyclisations. In order to achieve this, the use of chiral ligands in the aza-Heck reactions 
detailed in Chapters 2 and 3 was investigated. 
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4.2 Investigations into enantioselective aza-Heck cyclisations of 
N-acyloxysulfonamide substrates 
Initial work focused on the development of an enantioselective aza-Heck reaction of sulfonamide-based 
substrates. Substrate 156 was identified as an ideal candidate to conduct a chiral ligand screen on, as 
the alkene substitution pattern contained in 156 was effective in the enantioselective cyclisation of 
oxime esters reported by our group (Scheme 130).103 Additionally, the product of the reaction is 
sufficiently volatile to allow for analysis by chiral phase GC. When the optimal commercially available 
ligand for the enantioselective cyclisation of oxime esters, (Sa,S)-Ph-Bn-SIPHOX,103 was used with 
substrate 156, a negligible yield of 157 was obtained (Scheme 131). Nine further chiral ligands (such 
as 338, 339 and (S,S)-CHIRAPHOS) were screened for the cyclisation of 156; however, formation of 
significant quantities of 157 was not observed with any of the ligands employed.  
The application of the aza-Heck reaction of N-acyloxysulfonamides to enantioselective cyclisations 
appeared to be hindered by its restrictive ligand requirements. During optimisation of that reaction 
(Section 2.3.3), few ligands were found to provide comparable yields to those obtained using 
P(3,5-(CF3)2C6H3)3 (Table 21 and Table 22, Appendix). A similar problem was encountered in the 
development of the enantioselective Narasaka-Heck reaction, although to a lesser extent.103 
 
Scheme 131 – Attempted enantioselective aza-Heck cyclisation of substrate 156. 
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4.3 Enantioselective aza-Heck cyclisations of N-acyl- and N-sulfonyl-
oxycarbamate substrates 
4.3.1 Reaction discovery 
The carbamate-based aza-Heck reaction described in the preceding chapter exhibited far better ligand 
tolerance, as well as wider substrate scope, than the sulfonamide-based reaction outlined in Chapter 2. 
Consequently, it was anticipated that the former reaction would prove more amenable to the 
development of a highly asymmetric protocol. Substrate 266a was selected for an initial ligand screen; 
the incorporation of a phenyl group makes 267a detectable by UV spectroscopy, which renders it 
suitable for analysis by chiral phase SFC. Due to the thermal instability of N-Boc groups,157,158 chiral 
phase GC was not considered suitable for the determination of enantiomeric excess.  
 
Scheme 132 – Attempted enantioselective aza-Heck cyclisation of substrate 266a. 
As observed with substrate 156 (Scheme 131), (Sa,S)-Ph-Bn-SIPHOX proved ineffective at promoting 
the cyclisation of 266a (Scheme 132). More promising results were achieved using other bidentate 
ligands, and the best of these are presented in Table 16. Some reactivity was observed using Josiphos 
ligands (Table 16, entries 2-4), albeit with no enantioselectivity. Biaryl ligands generated similar yields 
of 267a to Josiphos ligands but with measurable, although modest, enantioselectivity (Table 16, 
entries 1, 5 and 6). 
  




Table 16 – Bidentate ligand screen for the enantioselective aza-Heck cyclisation of substrate 266a. Yields were determined 
by 1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard.  
With only minor progress being made towards the enantioselective cyclisation of 266a using bidentate 
ligands (Table 16), chiral monodentate ligands were assayed (Table 17). Achiral monodentate ligands 
have previously been found to be more effective than bidentate ligands in aza-Heck reactions (Table 21 
and Table 22, Appendix and Table 9, Section 3.2.2), and higher yields were also obtained with chiral 
monodentate ligands in the enantioselective cyclisation. While a promising result (58 % yield, 
27 % e.e.) was achieved using (R)-SITCP (Table 17, entry 2), similar ligands were not evaluated due to 
a lack of availability. Chiral phosphoramidites are comparatively more accessible, and a number of 
these were employed in the reaction (Table 17, entries 3-7 and 9-11). SPINOL-based ligand 
(R)-SIPHOS-PE provided the best result accomplished thus far, both in terms of yield and 
enantioselectivity (Table 17, entry 10). Following this, it was found that (S)-SIPHOS-PE, the 
Chapter 4 - An enantioselective aza-Heck reaction 
96 
 
diastereomer of (R)-SIPHOS-PE, provided a far greater level of enantiomeric induction, with 267a 
isolated in 74 % yield and 61 % e.e. (Table 17, entry 11). 
 
Table 17 – Monodentate ligand screen for the enantioselective aza-Heck cyclisation of substrate 266a. Yields were 
determined by 1H NMR analysis of the crude material vs. 1,3,5-trimethoxybenzene as an internal standard. Isolated yields 
are given in parentheses. 
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Having identified a promising ligand for the enantioselective aza-Heck reaction, the effects of the 
protecting group and alkene substitution pattern were examined. To this end, the cyclisation of methyl 
carbamate substrate 266c (see the experimental section) was assessed. Under identical conditions to the 
cyclisation of 266a (Table 17, entry 11), a comparable yield of 267c was achieved from 266c 
(Scheme 133), but the product was formed with substantially lower e.e. than 267a (34 % vs. 61 % e.e.), 
indicating that the protecting group has an influence on product enantioselectivity.  
 
Scheme 133 – Synthesis and enantioselective aza-Heck cyclisation of substrate 266c. 
Substrates 254 and 243a, both containing a 1,2-disubstituted alkene, were also evaluated in the 
enantioselective aza-Heck reaction. Substrate 254 cyclised in good yield but with only 34 % e.e. 
(Scheme 134). The fact that 254 was prepared as a 6:1 mixture of alkene isomers might explain the low 
enantioselectivity observed in the cyclisation step. While alkene geometry has only a limited effect on 
cyclisations to afford racemic products (Table 13, Section 3.4.2), it was established later that it has a 
more pronounced effect on enantioselective cyclisations (Section 4.3.2). In contrast to 254, substrate 
243a generated 244a with 60 % e.e. (Scheme 134), thus demonstrating that substrates containing 
1,2-disubstituted alkenes are viable in the enantioselective aza-Heck reaction. This element of substrate 
scope was not tolerated in the previously reported oxime ester-based enantioselective cyclisation 
(Scheme 130, Section 4.1).103 
  
Scheme 134 – Enantioselective aza-Heck cyclisation of substrates 254 and 243a. 
4.3.2 Optimisation of the carbamate-based enantioselective aza-Heck reaction  
Following the discovery that (S)-SIPHOS-PE is an effective ligand for achieving moderate levels of 
enantioselectivity in the aza-Heck cyclisation, continued optimisation of the reaction was undertaken 
by Dr Xiaofeng Ma. The results presented in this section are not detailed in the experimental. 
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The use of tosyl-activated substrate 243e in the enantioselective aza-Heck cyclisation led to a 
significantly more efficient cyclisation, with 244a generated in quantitative yield (Table 18, entry 1), 
compared to 54 % yield from OFBz-activated 243a (Scheme 134). Although similar enantioselectivities 
were obtained with 243a and 243e under the same conditions, the increased reactivity of 243e allowed 
the cyclisation to proceed at lower temperatures, where 244a was formed with greater e.e. (Table 18, 
entries 2-5). Finally, conducting the reaction at higher dilution provided a modest increase in 
enantioselectivity (Table 18, entry 7). The enantioselective cyclisation was found to display a 
significant preference for substrates containing 1,2-disubstituted akenes with (E)-geometry, and 
(Z)-243e cyclised with significantly diminished yield and enantioselectivity relative to (E)-243e 
(Table 18, entry 8). It is interesting to note that a relatively low ligand to palladium ratio of 1.2:1 
provides comparable results to those achieved with a 2:1 ratio, potentially indicating that only one 
molecule of ligand is bound to palladium in the active catalyst. This is in contrast to the aza-Heck 
reactions of N-acyloxysulfonamides and N-acyloxycarbamates (Chapters 2 and 3, respectively), which 
both used ligand to palladium ratios of greater than 2.5:1. 
 
Table 18 – Optimisation of the enantioselective aza-Heck cyclisation of substrate 243e. XXXIV 
– Results obtained by Dr Xiaofeng Ma. 
 
                                                     
XXXIV The absolute configuration of (S)-244a was assigned by comparison of its specific rotation to a literature 
value.163 
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4.3.3 Enantioselective aza-Heck cyclisations involving trisubstituted alkenes 
With a substantial improvement achieved in the enantioselective cyclisation of a substrate containing a 
1,2-disubstituted alkene (243e), the reactions of substrates containing trisubstituted alkenes were 
re-examined. Having identified that the use of a tosyl activating group is beneficial for the 
enantioselective aza-Heck reaction (Table 18), substrate 266d was prepared. When trialled with the 
newly optimised conditions, 266d produced a considerably better result than OFBz system 266a, and 
(R)-267a was generated in quantitative yield and with 95 % e.e. (Scheme 135, cf. Table 17, entry 11, 
Section 4.3.1).XXXV 
 
Scheme 135 – Synthesis and enantioselective aza-Heck cyclisation of substrate 266d.XXXVI 
Following the excellent result obtained with substrate 266d, the effects of different alkene substitution 
patterns were investigated. Pleasingly, substrate 342, which contains a less sterically demanding methyl 
substituent at R1, cyclised to afford (S)-344 in 79 % yield and with 89 % e.e. (Scheme 136). While this 
was a good result, (S)-344 was formed in lower enantiopurity than the 95 % e.e. achieved for (R)-267a. 
As alkene substitution differs in two places between 342 and 266d, it was not possible to identify which 
change caused the lower enantioselectivity observed with 342 from those results alone. In order to 
determine this, substrate 343 was prepared and used in the enantioselective aza-Heck reaction 
(Scheme 136). Pyrrolidine (R)-345 was formed with 95 % e.e., the same as 267a (Scheme 135); this 
suggests that for trisubstituted alkenes, the substituent proximal to nitrogen is key to determining 
enantioselectivity, with larger groups resulting in higher levels of enantioselectivity.  
                                                     
XXXV The absolute configuration of (R)-267a was determined by X-ray diffraction analysis of a brosyl derivative. 
This was carried out by Dr Xiaofeng Ma (University of Bristol) and hence is not detailed in the experimental 
section. The absolute configurations of the other products contained in this section were assigned by analogy to 
(R)-267a. 
XXXVI BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 




Scheme 136 – Synthesis and enantioselective aza-Heck cyclisation of substrates 342 and 343. 
Although substrate 343 contains a highly congested alkene, all of the substituents are primary. To 
examine the tolerance of secondary substituents, a substrate (346) containing an i-propyl group was 
synthesised (Scheme 137). When 346 was exposed to the enantioselective aza-Heck conditions, (R)-347 
was formed in good yield and with 95 % e.e. (Scheme 137). The result achieved with 346 demonstrates 
the power of this methodology: sterically congested tertiary C–N bonds can be formed with excellent 
enantioselectivity, and the further derivatisation of products is trivial due to the ease of N-Boc removal. 
 
Scheme 137 – Synthesis and enantioselective aza-Heck cyclisation of substrate 346. 
4.3.4 Enantioselective aza-Heck cyclisations to form 6-membered rings 
The enantioselective aza-Heck reaction was then applied to the synthesis of piperidines. With previous 
systems, aza-Heck cyclisations to form products containing 6-membered rings were found to be 
considerably more challenging than those that form 5-membered rings, although good yields were 
achieved with carbamate-based substrates (Section 3.4). Reactions of N-tosyloxycarbamates proceeded 
with significantly greater efficiency than the analogous OFBz-activated substrates in the synthesis of 
pyrrolidines (cf. Table 18, Section 4.3.2 with Scheme 93c, Section 3.3.1, and Scheme 135, Section 4.3.3 
with Scheme 104, Section 3.3.4), and it was hoped that this increase in efficiency would also be 
observed for piperidine-forming cyclisations. Substrates 282c and 282d were prepared from (E)-281 
(Scheme 138). While the two substrates cyclised in almost identical yield (56 % vs. 55 %), the 
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N-Boc-protected substrate 282c provided (S)-283 with higher enantioselectivity (95 % vs. 89 % e.e., 
Scheme 138). 
 
Scheme 138 – Synthesis and enantioselective aza-Heck cyclisation of substrates 282c and 282d.XXXVII 
Next, the effects of the alkene substituent were investigated, and a substrate (275) containing an alkene 
with methyl, as opposed to n-butyl, substitution was targeted. Both the N-Boc- and the N-Cbz-protected 
variants (275b and 275c, respectively) were prepared from alcohol (E)-189 (Scheme 139). When 
employed in the enantioselective aza-Heck reaction using (S)-SIPHOS-PE, substrate 275c cyclised in 
low yield; however, the use of the related but less sterically demanding ligand (S)-SIPHOS-IPXXXVIII 
led to a good yield of (S)-276c,XXXIX albeit in lower enantioselectivity than observed with 
(S)-SIPHOS-PE (Scheme 139, cf. 283d in Scheme 138). As higher e.e. values are typically obtained 
with N-Boc-protected substrates, the cyclisation of 275b was also investigated. Due to the problems 
previously encountered in the isolation of 276a (Scheme 108, Section 3.4.1), (S)-276a was converted 
directly into the N-Cbz analogue (S)-276c, as this was necessary for the determination of enantiomeric 
excess. However, despite significantly higher enantioselectivity achieved in the reaction of 275b, 
(S)-276c was isolated in only 20 % overall yield (Scheme 139).  
                                                     
XXXVII CbzNHOTs was prepared by Dr Xiaofeng Ma (University of Bristol) according to a literature procedure.164 
XXXVIII (S)-SIPHOS-IP was prepared by Dr Xiaofeng Ma (University of Bristol) using an adaptation of a literature 
procedure.165 
XXXIX The absolute configuration of (S)-276c was assigned by comparison of its specific rotation to a literature 
value.166 The absolute configurations of the other products contained in this section were assigned by analogy to 
(S)-276c. 




Scheme 139 – Synthesis and enantioselective aza-Heck cyclisation of substrates 275b and 275c.XXXVIII 
In cyclisations to afford racemic products, cyclopropyl substrate 285a was found to provide a similar 
result to (Z)-282a (Scheme 112, Section 3.4.2 and Scheme 113b, Section 3.4.3). Because of this, 285 
was considered a good candidate for the enantioselective aza-Heck cyclisation, and alcohol (E)-284 
was converted into substrate 285b (Scheme 140). Substrate 285b cyclised to afford (S)-286b in 51 % 
yield and with 90 % e.e., a comparable result to that achieved with 282d (Scheme 138). 
 
Scheme 140 – Synthesis and enantioselective aza-Heck cyclisation of substrate 285b. 
Substrate 297b, which is analogous to OFBz-activated substrate 297a (Scheme 118, Section 3.4.4), was 
synthesised (Scheme 141). It was hoped that 297 would provide a better result in the enantioselective 
aza-Heck reaction than it did in the cyclisation to afford racemic products, as there is a preference for 
substrates containing (E)-alkenes in the former (Section 4.3.2), compared to a preference for (Z)-alkenes 
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in the latter (Table 13, Section 3.4.2). Unfortunately, this was not the case, and when 297b was exposed 
to the reaction conditions, 298 was not observed (Scheme 141). 
 
Scheme 141 – Synthesis and attempted enantioselective aza-Heck cyclisation of substrate 297b. 
In order to continue assessing the scope of the enantioselective cyclisation, further substrates were 
sought. While a variety of 6-ring substrates had previously been prepared (Section 3.4), many of these 
were deemed unsuitable for use in the enantioselective reaction, as they either cyclised in negligible 
yields or generated achiral products. This led to the examination of a previously untested class of 
substrate, and 348, containing a sulfur-based tether, was prepared (Scheme 142). When 348 was 
employed in the enantioselective aza-Heck cyclisation, target 350 was not observed, and side product 
349 was isolated in 19 % yield (Scheme 142).  
 
Scheme 142 – Synthesis and attempted enantioselective aza-Heck cyclisation of substrate 348. 
The proposed mechanism for the formation of 349 is outlined in Scheme 143. Intramolecular oxidation 
of the sulfur atom in 348 affords betaine 351, which undergoes ring closure to form 352 and  
expel O-tosyl sulfanol derivative 353. Nucleophilic attack of 352 on 353, followed by loss of a  
t-Bu cation, provides 349. Acid-catalysed cleavage of the t-Bu group of 352 evidently occurs as well, 
as oxazolidine-2-one was observed in the crude reaction mixture by 1H NMR spectroscopy. The 
observation that substrate 348 is unstable to the enantioselective aza-Heck conditions likely explains 
the absence of desired thiomorpholine 350.  




Scheme 143 – Proposed mechanism for the formation of side product 349 from substrate 348. 
4.3.5 Further evaluation of the substrate scope for the enantioselective aza-Heck reaction 
Continued exemplification of the enantioselective aza-Heck reaction was undertaken by Dr Xiaofeng 
Ma, and selected results are presented in Scheme 144. These results are not detailed in the experimental 
section. 
 
Scheme 144 – a) Further enantioselective aza-Heck cyclisations of N-sulfonyloxycarbamate substrates.  
b) Catalyst-controlled diastereoselectivity in the enantioselective aza-Heck cyclisation of substrate 358.  
– Results obtained by Dr Xiaofeng Ma. 
The enantioselective aza-Heck cyclisation allowed the synthesis of pyrrolidines from substrates 
containing 1,2-disubstituted alkenes ((S)-247a and (S)-354), although slightly lower enantioselectivities 
were observed in this kind of process. Additional examples of substrates containing trisubstituted 
alkenes were demonstrated ((S)-355 and (R)-356), and improvements were made to the yields obtained 
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in cyclisations to form piperidines ((S)-283a and (S)-357). Using substrate 358, containing a defined 
stereocentre in the -position, good diastereoselectivities could be achieved with catalyst control 
(Scheme 144b).  
 
4.4 Conclusions  
The carbamate-based aza-Heck reaction outlined in Chapter 3 has been successfully adapted into a 
highly asymmetric variant. The developed reaction constituted an effective method for preparing 
enantiopure pyrrolidines and piperidines, and tolerated systems containing both 1,2-disubstituted and 
trisubstituted alkenes. A manuscript based on the work presented in this chapter is currently being 
prepared for submission. 
The methodology presented in this chapter is a far more versatile alternative to previously reported aza-
Wacker cyclisations,43,167,168 as the latter are currently limited to forming 5-membered rings and often 
make use of tosyl protecting groups. Furthermore, the substrate scope of enantioselective aza-Wacker 
processes is either limited with respect to alkene partner or restricted to specific substrate classes, e.g. 
benzo-fused systems. By comparison, the combination of the ring size and alkene substitution tolerance 
of the enantioselective aza-Heck cyclisation, along with the synthetic flexibility of the products, far 
surpasses what is possible with enantioselective aza-Wacker cyclisations. 
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  - Aza-Heck cascade reactions 
5.1 Introduction 
The initiation mode of the Narasaka-Heck reaction has previously been applied to a variety of aza-Heck 
cascade processes. Shortly after publishing his seminal report on aza-Heck reactions, Narasaka 
disclosed an aza-Heck/Heck cyclisation cascade of oxime esters (Scheme 145).169 Here, oxidative 
addition of 360 and aminopalladation of the pendant alkene provides intermediate 361, which cannot 
undergo -hydride elimination. Instead, carbopalladation of the second olefin occurs to afford 362, 
which releases spirocyclic imine 363 through -hydride elimination. This strategy can also be adapted 
to form three rings, as demonstrated by the formation of tricyclic imine 363c. In this case, a further 
carbopalladation step occurs from intermediate 362.  
 
Scheme 145 – Palladium(0)-catalysed aza-Heck/Heck cyclisations using the Narasaka-Heck initiation mode.169 
Oxime esters have also been used in partially intermolecular aza-Heck cascade reactions. Nucleophilic 
trapping of organopalladium(II) intermediate 365, generated by cyclisation of alkynyl substrate 364, 
was demonstrated by Kitamura (Scheme 146a).170 A number of related processes, involving cyclisations 
on to alkenes, were then reported by our group (Scheme 19, Section 1.4.2).104 1,2-Iminohalogenation 
reactions have also been achieved using halides as the exogenous nucleophile (Scheme 146b).171 
In addition to these redox-neutral transformations, cascade processes based on aza-Wacker cyclisations 
have been developed. Scheme 147 contains an overview of 1,2-aminofunctionalisation reactions that 
proceed through intermediate 370, which is generated by aminopalladation of the alkene of 369. All of 
these transformations feature nucleophilic interception of 370, so they require an oxidant to be rendered 
catalytic. Redox-neutral 1,2-aminofunctionalisation reactions where the exogenous component is 
electrophilic have been discussed previously (Section 1.3). Insertion of CO into the Pd–C bond of 370 
affords acylpalladium(II) intermediate 371, which can be trapped with oxygen- or nitrogen-based 
 




Scheme 146 – a) Palladium(0)-catalysed 1,2-iminofunctionalisation of alkynyl substrate 364.170 b) Palladium(0)-catalysed 
1,2-iminohalogenisation of alkenyl substrate 367.171  
nucleophiles (A, Scheme 147). This can be achieved in either an intermolecular41 or an 
intramolecular172-174 manner. Alternatively, arylation of 371 is possible (B, Scheme 147), although this 
proceeds through a Friedel-Crafts reaction of an initially formed acyl chloride species.105 With 
substrates incorporating a second olefin in a suitable position, intramolecular aza-Wacker/Heck cascade 
reactions are feasible (C, Scheme 147).175-177 These are essentially oxidative variations of the process 
outlined in Scheme 145. Hegedus demonstrated an intermolecular aza-Wacker/Heck reaction (D, 
Scheme 147), although this was stoichiometric in palladium.178 Aza-Wacker/C–H activation cascades 
have also been used to achieve 1,2-aminoarylation (E, Scheme 147), and these have been applied in 
both intramolecular179,180 and intermolecular181 settings. The latter requires the strong fluorine-based 
oxidant NFSI and proceeds through a palladium(II)/palladium(IV) mechanism.181,182 Similar kinds  
 
  
Scheme 147 – Overview of oxidative 1,2-aminofunctionalisation reactions that proceed via intermediate 370. 
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of mechanisms have been proposed in other 1,2-aminofunctionalisation processes, such as 
aminohalogenation,183 aminoacetoxylation,184 aminoalkoxylation185 and diamination186,187 (F, 
Scheme 147). Access to palladium(IV) intermediates in these transformations is key, as this facilitates 
reductive elimination steps that would be difficult from a palladium(II) species. 
The aza-Heck reactions outlined in Chapters 2 and 3 proceed through intermediates analogous to 370, 
but as these are accessed from an electrophilic nitrogen source, nucleophilic interception would be an 
overall redox-neutral transformation. As discussed previously, processes that use internal oxidants 
possess several advantages over those that employ external oxidants (Section 2.1). Furthermore, good 
scope with respect to alkene partner and tolerance for the formation of both 5- and 6-membered rings 
have been demonstrated in aza-Heck reactions (Chapter 3), and these properties might be transferable 
to related cascade reactions. A number of alkene 1,2-aminofunctionalisation reactions were investigated 
to establish the feasibility of cascade processes utilising the N–O bond donors detailed in Chapters 2 
and 3, and the results of this work are described in this chapter. 
 
5.2 Aza-Heck/Heck cascades 
The examination of cascade processes from N-acyloxy-sulfonamide and -carbamate substrates initiated 
with an aza-Heck/Heck cascade that was inspired by the reactions demonstrated by Narasaka 
(Scheme 145, Section 5.1).169 N-Mesyl dienyl substrate 372 was prepared and evaluated in the 
aza-Heck/Heck cyclisation (Scheme 148). Substrate 372 afforded spirocyclic product 374 in excellent 
yield, demonstrating the possibility of intercepting 373 with a second alkene. 
 
Scheme 148 – Synthesis and palladium(0)-catalysed aza-Heck/Heck cyclisation of substrate 372. 
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As intermediate 373 does not contain any hydrogen atoms  to palladium, the likelihood of competing 
reaction pathways occurring is limited. Consequently, substrate 372 is ideal for aza-Heck/Heck cascade 
reactions. A comparatively more ambitious substrate was targeted in the form of 375. It was hoped that 
375 would cyclise to afford 377 (Scheme 149a), which could potentially be elaborated into cocaine16 
(Scheme 149b). Following the initial cyclisation of 375, intermediate 376 might either be intercepted 
by the second pendant alkene or undergo -hydride elimination. It was hoped that the former process 
would occur preferentially because-hydride elimination in the direction of the C–N bond was 
disfavoured in earlier studies (Section 2.4.1), likely due to the steric influence of the N-protecting group. 
 
Scheme 149 – a) Proposed aza-Heck/Heck cyclisation of substrate 375. b) Retrosynthetic analysis of cocaine16 to 
product 377. 
Substrate 375 was prepared in two steps from pent-5-enal (Scheme 150). However, 375 did not engage 
in the desired aza-Heck/Heck cascade reaction, and isomerised aza-Heck product 378 was produced 
instead (Scheme 150). The formation of 378 indicates that -hydride elimination at the stage of 376 
occurs more readily than carbopalladation of the second olefin. 
 
Scheme 150 – Synthesis and attempted aza-Heck/Heck cyclisation of substrate 375. 




Scheme 151 – a) Proposed aza-Heck/Heck cyclisation of substrate 379. b) Retrosynthetic analysis of cocaine to product 381. 
Although substrate 375 was unsuccessful at generating the bicyclic scaffold of cocaine, an analogous 
acrylate substrate (379) was considered (Scheme 151a). In this case, organopalladium(II) intermediate 
380 might be stabilised by the presence of the adjacent ester group. Furthermore, product 381 could be 
easier to convert into cocaine as the ester functionality would not need to be introduced (Scheme 151b). 
Substrate 379 was prepared and trialled in the cascade reaction (Scheme 152). As with substrate 375, 
this resulted in the aza-Heck product (382, 79 % yield), and 381 was not observed. 
 
Scheme 152 – Synthesis and attempted aza-Heck/Heck cyclisation of substrate 379. 
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5.3 Intermolecular 1,2-aminocarboxylation cascades 
5.3.1 Initial results 
The results in this section were obtained by Rafaela Carmona and Ben Jones and hence are not detailed 
in the experimental section. 
 
Scheme 153 – Palladium(0)-catalysed 1,2-aminocarboxylation of 79 and 238b. 
The possibility of developing 1,2-aminocarboxylation cascades was examined through the interception 
of intermediate 385 with carbon monoxide and benzyl alcohol. The desired transformation was achieved 
with sulfonamide- and carbamate-based substrates (79 and 238b, respectively, in Scheme 153). 
Interestingly, the reaction tolerated terminal alkenes, indicating that trapping of 385 is sufficiently fast 
to outcompete -hydride elimination;XL this is in contrast to previous cases where it was found that 
elimination outcompeted intramolecular carbopalladation (Scheme 150 and Scheme 152).  
 
Scheme 154 – Palladium(0)-catalysed 1,2-aminocarboxylation of 386a. 
The use of tosyl-activated substrate 386a led to an improvement in the carbamate-based 
1,2-aminocarboxylation cascade (Scheme 154), and this allowed substrates containing 1,1-disubstituted 
alkenes to participate in the reaction. Good protecting group tolerance was observed, with substrates 
386a-c all participating in the aminocarboxylative cyclisation in high yields (Scheme 155).  
 
Scheme 155 – Palladium(0)-catalysed aminocarboxylation of 386a-c. 
                                                     
XL Similar observations have been made previously in related palladium(0)-catalysed processes.104,188 
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5.3.2 Studies towards the synthesis of (+)-cylindricine C 
The application of the 1,2-aminocarboxylation cascade detailed in the previous section to enantiopure 
substrate (S)-391 was viewed as a route to (+)-cylindricine C,9 via -amino acid derivative 389 
(Scheme 156). Conversion of 389 to enone 388, followed by deprotection would, in theory, afford the 
natural product. However, the transformation of (S)-391 into 389 was considered ambitious, and the 
possibility of -hydride elimination outcompeting intermolecular trapping was recognised. 
 
Scheme 156 – Retrosynthetic analysis of (+)-cylindricine C9 to alcohol (R)-392. 
In order to assess the viability of the proposed 1,2-aminocarboxylation cascade, alcohol 392 was 
synthesised. The reaction of organometallic nucleophile 394 with epoxide 393 was envisaged as a 
strategy to achieve this. Due to the availability of enantiopure 393, the possibility of preparing 
enantioenriched 392 using this route was thought likely. Access to 394 through deprotonation of 
1-methylcyclohex-1-ene was considered the most direct approach; unfortunately, this was not 
successful, despite multiple sets of conditions being trialled (Scheme 157).  
 
Scheme 157 – Attempted synthesis of alcohol 392 from 1-methylcyclohex-1-ene. 
Following the failure of the previous reaction, potentially due to difficulties in the deprotonation step, 
formation of 394 from bromide 395 was considered as an alternative. However, attempts to react 393 
with a preformed Grignard reagent (M = MgBr in 394) were not successful (Scheme 158a). In this case, 
hydrocarbon 396 and bromide 397 were observed. This is most likely the result of a reaction between 
394 and 395 to afford 396, with the MgBr2 by-product then leading to ring-opening of epoxide 393 to 
form 397. This kind of phenomenon has been observed previously: formation of allylic Grignard 
reagents is known to be problematic due to competing homocoupling.189,190 By conducting the Grignard 
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formation in the presence of 393, a modest yield of alcohol 392 was achieved, which was then converted 
into substrate 391 (Scheme 158b). 
 
Scheme 158 – Attempted synthesis of alcohol 392. b) Synthesis of substrate 391. 
When submitted to the 1,2-aminocarboxylation reaction conditions (Section 5.3.1), 391 did not afford 
desired product 389 (Scheme 159). Competitive -hydride elimination from 390 (Scheme 156) did not 
appear to be the problem, as 398 was not observed either, and 391 simply appeared to be unreactive to 
the conditions employed. Following these disappointing results, investigations with this substrate were 
suspended.  
 
Scheme 159 – Attempted 1,2-aminocarboxylation of 391. 
The lack of reactivity observed with substrate 391 could have been a result of the sterically hindered 
nature of the N–O bond of 391 inhibiting oxidative addition; previously, this problem has been solved 
with the use of substrates containing smaller protecting groups (Section 2.4.2). Furthermore, methyl 
carbamate and N-Cbz systems 386a and 386b were found to provide better results in the 
1,2-aminocarboxylation reaction than N-Boc substrate 386c (Scheme 154 and Scheme 155, 
Section 5.3.1). Consequently, it was considered that analogous substrates containing smaller protecting 
groups might be more suitable for this transformation. However, due to time constraints, it was not 
possible to investigate the 1,2-aminocarboxylation cascade with other systems, although this is likely 
to be the focus of future studies within the group.  
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5.4 Intermolecular 1,2-amino-arylation and -borylation cascades 
5.4.1 Intermolecular 1,2-aminoarylation using boronic esters 
The previous sections detailed the development and attempted application of a carbonylative alkene 
1,2-aminofunctionalisation reaction. In addition to this, related non-carbonylative processes have also 
been examined. Of key relevance are studies conducted by Rafaela Carmona that aimed to achieve 
1,2-aminoarylation of alkenes. The results in this section are not detailed in the experimental section, 
but the experimental procedures and characterisation data can be found in the supporting information 
of reference 108.  
It was found that by trapping intermediate 400 with aryl boronic esters, 1,2-aminoarylation of the alkene 
in 386d was possible. The best results were obtained using electron-rich, heteroaromatic pinacol 
boronic esters (Scheme 160a). The reaction tolerated substitution in the - and -positions 
(Scheme 160b), and 2,2,4-trisubstituted pyrrolidine 403 was generated in good yield from 401, albeit 
with negligible diastereoselectivity, whereas -phenyl system 402 afforded 404 as a single diastereomer 
but in a lower yield of 50 %. 
  
Scheme 160 – a) Palladium(0)-catalysed 1,2-aminoarylation of 386d. b) Palladium(0)-catalysed 1,2-aminoarylation  
of 401 and 402. 
5.4.2 Extension to intermolecular 1,2-aminoborylation using diboron reagents 
Given the synthetic versatility of boronic esters191,192 and the ubiquity of nitrogen heterocycles 
(Section 1.1), a 1,2-aminoborylation cascade would likely be a desirable transformation. Moderating 
the reactivity of organopalladium(II) intermediate 400 (Scheme 160a) by conversion to a boronic ester 
(such as 405a) would potentially allow a wider range of reactions, which might otherwise be unavailable 
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to 400, to proceed from 405a. The feasibility of the 1,2-aminoborylation reaction was examined under 
conditions found to be effective for 1,2-aminoarylation (Section 5.4.1), with bis(pinacolato)diboron 
(B2Pin2) used in place of the aryl boronic ester (Scheme 161). The initial result was promising, and 
405a was isolated in 31 % yield. 
 
Scheme 161 – Palladium(0)-catalysed 1,2-aminoborylation of 386d. 
Optimisation of this reaction was undertaken, initially focusing on N-protecting group and the nature 
of the diboron compound (Table 19). Substrate 386e (see the experimental section), the N-Boc-
protected analogue of 386d, was unsuitable for the desired transformation (Table 19, entry 3). The use 
of B2Pin2 proved to be essential, with other diboron compounds not providing significant quantities of 
405 (Table 19, entries 4-6). From here, the reaction solvent was examined (Table 20), and n-Bu2O was 
found to provide the highest yield of 405a (39 %) (Table 20, entry 8). Following this, a ligand screen 
was conducted (Table 23, Appendix), and the reaction temperature and base equivalents were varied 
(Table 24, Appendix). However, optimisation of these parameters did not result in an improved yield 
of 405a. 
 
Table 19 – Optimisation of the palladium(0)-catalysed 1,2-aminoborylation of 386d and 386e. 




Table 20 – Solvent screen for the palladium(0)-catalysed 1,2-aminoborylation of 386d. 
Due to time constraints, further optimisation of the reaction was not undertaken, although the suitability 
of other systems for the 1,2-aminoborylation cascade was examined. A substrate containing an 
exocyclic methylene group (408) was prepared and submitted to the 1,2-aminoborylation conditions 
(Scheme 162). The result achieved with 408 was similar to that achieved with 386d (Table 20, entry 8), 
and 409 was isolated in 38 % yield. 
 
Scheme 162 – Synthesis and palladium(0)-catalysed 1,2-aminoborylation of 408. 
Derivatisation of the 1,2-aminoborylation products can be achieved (Scheme 163). Oxidation (H2O2) of 
409 under basic conditions led to spontaneous cyclisation onto the protecting group, delivering tricyclic 
carbamate 410 in 77 % yield. An initial attempt at coupling 405a with 2-thiophenyl lithium, following 
a procedure reported by Aggarwal,193 demonstrated the feasibility of the desired transformation. 




Scheme 163 – Derivatisation of 1,2-aminoborylation products 409 and 405a 
When substrate 402XLI was employed in the 1,2-aminoborylation reaction, desired product 412 was not 
observed (Scheme 164). Instead, intramolecular aminoarylation product 411 was isolated in 35 % yield. 
B2Pin2 was determined to be unnecessary for the formation of 411, as an improved yield was achieved 
in its absence. 
 
Scheme 164 – Observation of 1,2-aminoarylation product 411 in the attempted 1,2-aminoborylation of 408. 
Interestingly, the relative stereochemistry of 411, the product of intramolecular aminoarylation, is 
opposite to that observed in 404, the product of intermolecular aminoarylation (Scheme 160b, 
Section 5.4.1).XLII The stereochemistry of 404 mirrors that observed in the products of the aza-Heck 
reaction (Scheme 102, Section 3.3.3). Products 404 and 411 presumably arise from diastereomeric 
intermediates 413a and 413b, respectively (Scheme 165). It is conceivable that 413a and 413b lie in 
equilibrium, as aminopalladation has been shown to be reversible in similar contexts.133 However, given 
the similarity of the two sets of conditions (cf. Scheme 160b, Section 5.4.1 and Scheme 164), it is 
unlikely that 413a is favoured in one reaction and 413b in the other. Intermolecular trapping of 413 
with a boron-based nucleophile is presumably possible from either diastereomer, although this evidently 
proceeds preferentially from 413a. This may be due to there being a greater equilibrium concentration 
of 413a, or because transmetalation from 413a is more facile than from 413b, or a combination of these 
two factors. In the attempted 1,2-aminoborylation of 402, the selectivity for 411 could be a result of 
transmetalation with B2Pin2 being considerably slower than with ArBPin, leading to intramolecular 
arylation becoming the major reaction pathway. 
                                                     
XLI Substrate 402 was prepared by Rafaela Carmona (University of Bristol) according to a reported procedure.108 
XLII The stereochemistry of both products was determined by NOE analysis. For details of 404, see the supporting 
information of reference 108. For details of 411, see the experimental section. 




Scheme 165 – Proposed mechanism for the formation of products 404 and 411. 
 
5.5 Conclusions 
The aza-Heck initiation modes developed in Chapters 2 and 3 have been applied to aza-Heck/Heck 
cyclisations (Section 5.2) and 1,2-aminoborylation reactions (Section 5.4.2). Additionally, through the 
work of Rafaela Carmona and Ben Jones, partially intermolecular 1,2-amino-carboxylation 
and -arylation reactions were demonstrated (Sections 5.3.1 and 5.4.1, respectively). In the course of 
developing the 1,2-aminoborylation reaction, an interesting intramolecular aza-Heck/C–H activation 
cascade was observed (Scheme 164, Section 5.4.2), and further work in this area is being undertaken 
by Ben Jones. In an initial result, it was found that addition of sodium benzoate to the reaction conditions 
led to a significant increase in the yield of 411 (Scheme 166), suggesting that the C–H activation step 
may be proceeding via a concerted metalation-deprotonation step.194,195 Work to assess the substrate 
scope of this transformation is currently ongoing. 
 
Scheme 166 – Improved conditions for the palladium(0)-catalysed intramolecular 1,2-aminoarylation of substrate 402. 
– Results obtained by Ben Jones. 
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  - Overall summary and conclusions 
In summary, two novel classes of aza-Heck reactions have been discovered and developed into practical 
methodologies. The first of these, based on cyclisations of N-acyloxysulfonamides (Chapter 2), was 
only the second reported class of aza-Heck reaction, after the Narasaka-Heck process (Section 1.4). 
This reaction proved especially suited to the synthesis of bicyclic nitrogen heterocycles that are 
commonly found in the core structures of natural products, such as aphanorphine10,11 or cocaine16 (115b 
and 169b, respectively, in Scheme 167a). A carbamate-based aza-Heck reaction (Chapter 3) was 
subsequently found to be a substantially more efficient process than the N-acyloxysulfonamide variant 
(Chapter 2). Excellent yields of 1,1-disubstituted pyrrolidines (such as 270 in Scheme 167b) could be 
obtained from substrates containing trisubstituted alkenes. This is an element of substrate scope that 
was challenging for the sulfonamide-based reaction (Section 2.4.5) and is generally also not well 
tolerated in aza-Wacker cyclisations (Section 1.2.5). Additionally, good yields in the cyclisations of 
non-biased 6-exo aza-Heck cyclisations were demonstrated for the first time (286a in Scheme 167b). 
The timeline presented in Figure 2 (Section 1.5) indicates that this is a still-growing area of research. 
 
Scheme 167 – a) Aza-Heck cyclisations of N-acyloxysulfonamides. b) Aza-Heck cyclisations of N-acyloxycarbamates. 
The aza-Heck reaction of carbamate-based substrates (Chapter 3) was then elaborated into a highly 
asymmetric variant (Scheme 168 and Chapter 4). This process exhibited impressive generality: the 
reaction tolerated substrates containing a diverse range of alkenes, and both 5- and 6-exo cyclisations 
proceeded in good yields and with high enantioselectivities. Furthermore, this reaction used substrates 
activated with tosyl groups, which are preferable both in terms of cost and atom economy over the 
OFBz-activated alternatives used in Chapters 2 and 3. 




Scheme 168 – Enantioselective aza-Heck cyclisation of N-sulfonyloxycarbamate 266d. 
The application of these novel classes of N–O bond donor to a number of aza-Heck cascade reactions 
was also demonstrated (Scheme 169 and Chapter 5). 1,2-Amino-carboxylation and -arylation processes 
were developed by Rafaela Carmona and Ben Jones through the trapping of intermediate 414 with 
exogenous nucleophiles. This was then extended to alkene 1,2-aminoborylation processes, using 
diboron compounds as the nucleophilic component. In cases where 414 contains a suitably placed 
alkene (such as 373), a second Heck-type cyclisation can occur, as demonstrated with spirocyclic 
pyrrolidine 374. Furthermore, intermediate 413b can also be intercepted intramolecularly by an arene, 
leading to 1,2-aminoarylation product 411. 
 
Scheme 169 – 1,2-Aminofunctionalisation cascades proceeding from intermediates 414, 373 and 413b. 
 – The 1,2-amino-carboxylation and -arylation variants were developed by Rafaela Carmona and Ben Jones.  
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  - Experimental 
7.1  General experimental details 
Unless stated, all materials were purchased from commercial sources (Acros, Aldrich, Alfa Aesar, 
Fluorochem and Strem) and used without any further treatment. Catalytic reactions were carried out in 
Young-type re-sealable tubes. Anhydrous solvents were obtained by distillation using standard 
procedures or by passage through drying columns supplied by Anhydrous Engineering Ltd. 
High-boiling solvents were removed from the reaction crudes employing rotary evaporators connected 
to high-vacuum pumps. Flash column chromatography (FCC) was performed using silica gel (Aldrich 
40-63 µm, 230-400 mesh). Petrol refers to the fraction of petroleum ether boiling in the 40-60 °C range. 
Thin layer chromatography was performed using aluminium backed 60F254 silica plates. Visualisation 
was achieved by UV fluorescence or a basic KMnO4 solution and heat. Proton nuclear magnetic 
resonance (NMR) spectra were recorded at 400 MHz or 500 MHz as stated. 13C NMR spectra were 
recorded at 100 MHz or 125 MHz as stated. 19F NMR spectra were recorded at 283 MHz. Chemical 
shifts (δ) are given in parts per million (ppm). Peaks are described as singlets (s), doublets (d), 
triplets (t), quartets (q), heptets (hept), multiplets (m) and broad (br). Coupling constants (J) are quoted 
to the nearest 0.5 Hz. All assignments of NMR spectra were based on 2D NMR data (COSY, HSQC 
and HMBC). In situ yields were determined by employing 1,3,5-trimethoxybenzene as internal 
standard. Mass spectra were obtained by the University of Bristol mass spectrometry service and were 
recorded using a Brüker Daltonics FT-ICR-MS Apex 4e 7.0T FT-MS (ESI+ mode), a Shimadzu GCMS 
QP2010+ (EI+ mode) or a Bruker ultrafleXtreme II TOF/TOF (MALDI, using a colloidal graphite 
matrix). Infrared spectra were recorded on a Perkin Elmer Spectrum Two FTIR spectrometer as thin 
films or solids compressed on a diamond plate. Melting points were determined using a Stuart SMP30 
melting point apparatus and are reported uncorrected. Specific rotation values were measured using a 
Bellingham & Stanley ADP440+ polarimeter. Chiral SFC was performed on an Agilent 1260 Infinity 
SFC Control Module system equipped with a quaternary pump, diode array detector and column 
thermostat under the conditions specified. Enantiomeric excess was determined by integration of 
chromatogram peaks. The ordering of compounds generally reflects the order they appear in the main 
text; however, synthetic sequences have been grouped together for clarity. The numbering of compound 
structures does not necessarily reflect the numbering contained in the systematic names. 
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7.2 General procedures 
General procedure A: Alkylation of TsNHOTBS or CbzNHOTBS 
A solution of hydroxylamine-derived pronucleophile (1.0 eq.) and NaH (60 % in mineral oil, 1.05 eq.). 
in anhydrous DMSO (approx. 5 mL/mmol) was stirred at room temperature for 1 hour before addition 
of alkyl bromide (1.2 eq.). The reaction mixture was stirred at room temperature and monitored by TLC. 
Upon completion, the reaction mixture was poured into brine and extracted with EtOAc (approx. 3 × 
5 mL/mmol). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The 
crude mixture was purified by FCC. 
General procedure B: O-TBS deprotection using HF·pyridine 
To a solution of N-alkyl-N-((tert-butyldimethylsilyl)oxy)sulfonamide (1.0 eq.) in anhydrous THF 
(approx. 10 mL/mmol) was added HF·pyridine (70 % HF, 5.0 ml/g). The reaction mixture was stirred 
at room temperature and monitored by TLC. Upon completion, the reaction mixture was quenched with 
an aqueous solution (approx. 8 mL/mmol) of K2CO3 (3 g/mL of HF·pyridine) and extracted with 
CH2Cl2 (approx. 3 × 10 mL/mmol). The combined organic phases were washed with 1.0 M aqueous 
HCl (approx. 20 mL/mmol), dried over Na2SO4, filtered through a plug of silica and concentrated in 
vacuo to afford the product, which was used without further purification (unless otherwise noted). 
General procedure C: Acylation with pentafluorobenzoyl chloride 
To a solution of N,N-disubstituted hydroxylamine (1.0 eq.) in anhydrous CH2Cl2 (approx. 
7.5 mL/mmol) at 0°C was added FBzCl (1.5 eq.) followed by Et3N (2.0 eq.). The reaction mixture was 
stirred at room temperature and monitored by TLC. Upon completion, the excess acid chloride was 
quenched with MeOH (approx. 2 mL/mmol), followed by addition of saturated aqueous NaHCO3 
(approx. 7.5 mL/mmol). The resulting phases were separated, and the aqueous phase was extracted with 
CH2Cl2 (approx. 2 × 10 mL/mmol). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude mixture was purified by FCC. 
General procedure D: Palladium-catalysed aza-Heck cyclisation 
A flame-dried re-sealable tube, fitted with a magnetic stirrer, was charged with cyclisation substrate 
(1.0 eq.), Pd2(dba)3 and phosphine ligand. The tube was fitted with a rubber septum and purged with 
nitrogen before solvent and Et3N were added via syringe. The tube was sealed and heated at the specified 
temperature for the time noted. The reaction mixture was cooled to room temperature and concentrated 
in vacuo. The crude mixture was purified by FCC. 
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General procedure E: Mitsunobu alkylation employing silyl-protected N-hydroxysulfonamides 
To a solution of PPh3 (2.0 eq.) in anhydrous THF:PhMe (1:1, 10 mL/mmol) at 0 °C was added DIAD 
(1.5 eq.). The reaction mixture was stirred at 0 °C for 15 minutes before addition of alcohol (equivalents 
specified), and then a further 30 minutes before addition of hydroxylamine-derived pronucleophile 
(1.0 eq.) as a solution in anhydrous THF (1 mL/mmol). The reaction mixture was stirred at room 
temperature for the time noted before being concentrated in vacuo and loaded directly onto silica gel 
for purification by FCC. 
General procedure F: O-TES deprotection with HCl 
To a solution of N-alkyl-N-((triethylsilyl)oxy)sulfonamide (1.0 eq.) in MeOH (approx. 10 mL/mmol) 
was added 12 M aqueous HCl (1 mL/mmol). The reaction mixture was stirred at room temperature and 
monitored by TLC. Upon completion, the reaction mixture was quenched with saturated aqueous 
NaHCO3 (approx. 10 mL/mmol) and extracted with CH2Cl2 (approx. 3 × 10 mL/mmol). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude mixture was purified by 
FCC (unless otherwise noted). In cases where the starting material was poorly soluble in MeOH, small 
quantities of CH2Cl2 were added in order to solubilise it. 
General procedure G: Pentafluorobenzoylation of N-hydroxycarbamates or N-hydroxyamides 
To a suspension of N-hydroxycarbamate or N-hydroxyamide (1.0 eq.) and FBzOH (1.0 eq.) in CH2Cl2 
(approx. 10 mL/mmol) at 0 °C was added a solution of DCC (1.1 eq.) in CH2Cl2 (approx. 5 mL/mmol) 
dropwise. The reaction mixture was stirred at room temperature for the time noted before filtration. The 
filtrate was concentrated in vacuo, and the crude mixture was purified by FCC. 
General procedure H: Alkylation and decarboxylation of diethyl malonate  
To a suspension of NaH (60 % in mineral oil, 2.0 eq.) in anhydrous THF (approx. 3 mL/mmol) at 0 °C 
was added diethyl malonate (2.0 eq.) dropwise. The reaction mixture was stirred at 0 °C for 1 hour 
before dropwise addition of allylic bromide (1.0 eq.). The reaction mixture was warmed to room 
temperature and monitored by TLC. Upon completion, the reaction mixture was poured into a solution 
of KOH (12 eq.) in water (approx. 1.5 mL/mmol) and MeOH (approx. 1.5 mL/mmol) and stirred for 
30 minutes at room temperature. The reaction mixture was acidified with 12 M aqueous HCl (20 eq.), 
concentrated to an aqueous solution and extracted with EtOAc (approx. 3 × 5 mL/mmol). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude mixture of malonic acids 
was dissolved in DMF (approx. 2 mL/mmol) and heated at reflux for 3 hours before being concentrated 
in vacuo to afford the product, which was used without further purification. 
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General procedure I: Reduction of carboxylic acids or esters 
To a solution of carboxylic acid or ester (1.0 eq.) in anhydrous THF or Et2O (approx. 2.5 mL/mmol) at 
0 °C was added LiAlH4 (equivalents specified) dropwise. The reaction mixture was stirred at room 
temperature and monitored by TLC. Upon completion, the reaction mixture was cooled to 0 °C before 
addition of water (1 mL/g of LiAlH4), 15 % aqueous NaOH (1 mL/g of LiAlH4) and a final portion of 
water (3 mL/g of LiAlH4). The reaction mixture was stirred at room temperature for around 15 minutes 
before being dried over Na2SO4, filtered, and concentrated in vacuo to afford the product, which was 
used without further purification (unless otherwise noted). 
General procedure J: Bromination of alcohols 
To a solution of alcohol (1.0 eq.) in Et2O (approx. 5 mL/mmol) at 0 °C was added PBr3 (0.50 eq.). The 
reaction mixture was stirred at room temperature and monitored by TLC. Upon completion, the reaction 
mixture was poured into an aqueous solution of K2CO3 (1.0 eq.). The resulting phases were separated, 
and the aqueous phase was extracted with Et2O (approx. 2 × 4 mL/mmol). The Et2O phases were dried 
over Na2SO4 and concentrated in vacuo to afford the product, which was used without further 
purification (unless other noted). 
General procedure K: Mitsunobu alkylation employing DEAD to prepare N-acyloxysulfonamides 
To a solution of alcohol (1.0 eq.), hydroxylamine-derived pronucleophile (1.5 eq.) and PPh3 (2.0 eq.) in 
anhydrous PhMe:THF (3:1, 8 mL/mmol) at 0 °C was added a solution of DEAD (2.0 eq.) in anhydrous 
PhMe (2 mL/mmol) dropwise. The reaction mixture was stirred at room temperature for the time noted 
before being concentrated in vacuo and loaded directly onto silica gel for purification by FCC. 
General procedure L: Johnson-Claisen rearrangement 
A solution of propionic acid (0.20 eq.) in triethyl orthoacetate (10 eq.) was heated at 110 °C for 1 hour 
before addition of allylic alcohol (1.0 eq.). The reaction mixture heated at reflux for the time noted 
before being cooled to room temperature and concentrated in vacuo. The crude mixture was purified by 
FCC. 
General procedure M: TBAF deprotection 
To a solution of silyl ether (1.0 eq.) in THF (approx. 5 mL/mmol) was added TBAF (1.0 M in THF, 
equivalents specified). The reaction mixture was stirred at room temperature for the time noted before 
being concentrated in vacuo, dissolved in Et2O (approx. 10 mL/mmol) and washed with water (approx. 
5 mL/mmol) followed by brine (approx. 5 mL/mmol). The organic phase was dried over Na2SO4 and 
concentrated in vacuo. The crude mixture was purified by FCC (unless otherwise noted). 
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General procedure N: Mitsunobu alkylation employing DIAD to prepare N-acyloxysulfonamides 
To a solution of alcohol (1.0 eq.), hydroxylamine-derived pronucleophile (1.3 eq.) and PPh3 (2.0 eq.) 
in anhydrous THF:PhMe (2:1, 30 mL/mmol) at 0 °C was added a solution of DIAD (1.5 eq.) in 
anhydrous PhMe (10 mL/mmol) dropwise. The reaction mixture was stirred at room temperature for 
the time noted before being concentrated in vacuo and loaded directly onto silica gel for purification by 
FCC. 
General procedure O: Mitsunobu alkylation to prepare N-acyloxycarbamates 
To a solution of alcohol (1.0 eq.), hydroxylamine-derived pronucleophile (1.3 eq.) and PPh3 (1.5 eq.) 
in anhydrous THF:PhMe (3:1, 8 mL/mmol) at 0 °C was added a solution of DIAD (1.5 eq.) in anhydrous 
PhMe (2 mL/mmol) dropwise. The reaction mixture was stirred at room temperature for the time noted 
before being concentrated in vacuo and loaded directly onto silica gel for purification by FCC. 
General procedure P: Synthesis of trioxaphosphaadamantane ligands 
The following is an adaptation of a literature procedure.149 A suspension of 1,3,5,7-tetramethyl-2,4,6-
trioxa-8-phosphaadamantane (248)XLIII (1.0 eq.), Pd(PPh3)4 (3 mol%), aryl bromide (1.2 eq.) and K2CO3 
(2.0 eq.) in anhydrous xylenes (5 mL/mmol, argon sparged) was heated at 110 °C for the time noted. 
The reaction mixture was cooled to room temperature before being filtered through silica and rinsed 
with Et2O. The filtrate was concentrated in vacuo, and the crude product was purified by FCC. 
General procedure Q: N-Boc deprotection 
A solution of carbamate in TFA (2 mL) and CH2Cl2 (2 mL) was stirred at room temperature for 1 hour 
before being concentrated in vacuo to afford the product. 
General procedure R: Mitsunobu alkylation to prepare N-sulfonyloxycarbamates 
To a solution of alcohol (1.0 eq.), hydroxylamine-derived pronucleophile (1.0 eq.) and PPh3 (1.2 eq.) 
in anhydrous THF (2.5 mL/mmol) at 0 °C was added DIAD (1.1 eq.) dropwise. The reaction mixture 
was stirred at room temperature for the time noted before being concentrated in vacuo and loaded 
directly onto silica gel for purification by FCC. 
General procedure S: Palladium-catalysed aminoborylation cascade reaction 
A flame-dried re-sealable tube, fitted with a magnetic stirrer, was charged with cyclisation substrate 
(1.0 eq.), Pd2(dba)3, phosphine ligand and B2Pin2. The tube was fitted with a rubber septum and purged 
with nitrogen before solvent and Et3N were added via syringe. The tube was sealed and heated at the 
specified temperature for 48 hours. The reaction mixture was cooled to room temperature and 
concentrated in vacuo. The crude mixture was purified by FCC.  
                                                     
XLIII Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 
Chapter 7 - Experimental 
126 
 
7.3 Experimental procedures for the studies in Chapter 2 
N-Hydroxy-4-toluenesulfonamide 
 
This compound was prepared according to a literature procedure.196 To a solution of NH2OH·HCl 
(1.50 g, 21.6 mmol) in MeOH (9 mL) and water (6 mL) was added MgO (760 mg, 18.9 mmol). The 
reaction mixture was stirred at room temperature for 10 minutes before addition of a solution of TsCl 
(1.80 g, 9.44 mmol) in THF (30 mL) followed by another portion of MgO (380 mg, 9.43 mmol). The 
reaction mixture was stirred for 1 hour before being filtered and concentrated in vacuo. FCC (gradient 
elution: 4:1 – 3:1 – 1:1 hexane:EtOAc) afforded TsNHOH (1.09 g, 62 %) as a colourless crystalline 
solid. m.p. 136-137 °C (Et2O:hexane) [Lit., 129-130 °C (C6H6:Et2O)]197. νmax / cm-1: (solid) 3376 (br s), 
3220 (s), 1595 (m), 1387 (m), 1318 (s), 1303 (s), 1291 (m), 1156 (s), 1089 (s), 1005 (m). δH (500 MHz, 
CD3CN) 7.76 (2H, d, J = 8.5 Hz), 7.72 (1H, d, J = 3.5 Hz), 7.41 (2H, d, J = 8.5 Hz), 7.35 (2H, d, J = 
3.5 Hz), 2.43 (3H, s). δC (126 MHz, CD3CN) 144.9, 133.8, 129.6, 128.5, 20.6. HRMS: (ESI+) Calculated 
for C7H9NNaO3S: 210.0195. Found [M+Na]+: 210.0186. The spectroscopic properties were consistent 
with the data available in the literature.197 
p-(Pent-4-en-1-ylsulfonyl)toluene (80) and pent-4-en-1-yl p-tolylsulfinate (81) 
 
To a solution of TsNHOH (vide supra, 250 mg, 0.130 mmol) in anhydrous DMSO (4 mL) was added 
NaH (60 % in mineral oil, 52.0 mg, 1.30 mmol). The reaction mixture was stirred at room temperature 
for 1.5 hours before addition of 5-bromo-1-pentene (0.16 mL, 1.30 mmol). The reaction mixture was 
stirred at room temperature for 1 hour before being poured into an icy solution of brine (50 mL) and 
extracted with Et2O (3 × 40 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (gradient elution: 9:1 – 4:1 hexane:EtOAc) afforded sulfinyl ester 81 
(34.0 mg, 12 %) as a colourless oil and sulfone 80 (124 mg, 42 %) as a colourless oil. Spectroscopic 
data for 80: νmax / cm-1: (film) 2923 (s), 2853 (s), 1642 (m), 1598 (m), 1463 (m), 1378 (m), 1136 (s).  
δH (500 MHz, CDCl3) 7.81 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.38 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.70 
(1H, ddt, J = 16.0, 11.0, 6.5 Hz, C4-H), 5.04 – 5.03 (1H, m, C5-H), 5.02 – 4.99 (1H, m, C5-H’), 3.11 – 
3.06 (2H, m, C1-H2), 2.48 (3H, s, Ts CH3), 2.15 (2H, tddd, J = 7.0, 6.5, 1.5, 1.5 Hz, C3-H2), 1.87 – 1.80 
(2H, m, C2-H2). δC (126 MHz, CDCl3) 144.8 (ArC), 136.5 (C4), 136.4 (ArC), 130.0 (ArCH), 128.2 
(ArCH), 116.6 (C5), 55.8 (C1), 32.2 (C3), 22.0 (C2), 21.8 (Ts CH3). HRMS: (ESI+) Calculated for 
C12H17O2S: 225.0949. Found [M+H]+: 225.0944. 
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Spectroscopic data for 81: νmax / cm-1: (film) 3077 (m), 2980 (m), 2923 (m), 1641 (m), 1597 (m), 1455 
(m), 1405 (m), 1313 (s), 1287 (s). δH (500 MHz, CDCl3) 7.59 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.34 (2H, 
d, J = 8.0 Hz, 2 × ArCH), 5.74 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, C4-H), 5.00 (1H, ddt, J = 17.0, 2.0, 
1.5 Hz, C5-H’), 4.96 (1H, ddt, J = 10.0, 2.0, 1.5 Hz, C5-H), 4.04 (1H, dt, J = 10.0, 6.5 Hz, C1-H), 3.62 
(dt, J = 10.0, 6.5 Hz, C1-H’), 2.43 (3H, s, Tol CH3), 2.10 (2H, tddd, J = 8.0, 6.5, 1.5, 1.5 Hz, C3-H2), 
1.72 (2H, tdd, J = 8.0, 6.5, 6.5 Hz, C2-H2). δC (126 MHz, CDCl3) 142.8 (ArC), 141.9 (ArC), 137.4 (C4), 
129.8 (ArCH), 125.4 (ArCH), 115.5 (C5), 64.0 (C1), 29.9 (C3), 29.1 (C2), 21.7 (Tol CH3). 
HRMS: (ESI+) Calculated for C12H17O2S: 225.0949. Found [M+H]+: 225.0942. 
N-((tert-Butyldimethylsilyl)oxy)-4-toluenesulfonamide 
 
To a suspension of TsNHOH (5.00 g, 26.7 mmol) in anhydrous CH2Cl2 (200 mL) at 0 °C was added 
TBSCl (6.00 g, 40.1 mmol) followed by Et3N (5.6 mL, 40.1 mmol). The reaction mixture stirred at 
room temperature for 14 hours before addition of water (200 mL). The resulting phases were separated, 
and the aqueous phase was extracted with CH2Cl2 (2 × 150 mL). The combined organic phases were 
washed with brine (200 mL), dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 3:1 
hexane:EtOAc) afforded TsNHOTBS (7.20 g, 89 %) as a colourless crystalline solid. An alternative 
one-pot procedure113 failed to provide TsNHOTBS in reliable yield. νmax / cm-1: (solid) 3194 (m), 
2928 (m), 1598 (m), 1327 (m), 1252 (m), 1162 (m), 1014 (s). δH (400 MHz, CDCl3) 7.80 (2H, d, J = 
8.5 Hz), 7.33 (2H, d, J = 8.5 Hz), 6.50 (1H, s), 2.45 (3H, s), 0.88 (9H, s), 0.17 (6H, s). δC (101 MHz, 
CDCl3) 144.7, 133.1, 129.5, 128.9, 25.8, 21.7, 17.9, -5.4. HRMS: (ESI+) Calculated for C13H24NO3SSi: 
302.1246. Found [M+H]+: 302.1228. The spectroscopic properties were consistent with the data 
available in the literature.113 
N-((tert-Butyldimethylsilyl)oxy)-N-(pent-4-en-1-yl)-4-toluenesulfonamide (82) 
 
General procedure A: TsNHOTBS (vide supra, 2.71 g, 9.00 mmol) was employed with 
5-bromopent-1-ene. FCC (eluent: 19:1 hexane:EtOAc) afforded 82 (2.36 g, 97 %) as a colourless oil. 
νmax / cm-1: (film) 2930 (m), 2858 (m), 1598 (m), 1463 (m), 1356 (s), 1169 (s). δH (400 MHz, CDCl3) 
7.73 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.33 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.74 (1H, ddt, J = 17.0, 10.0, 
6.5 Hz, C4-H), 5.03 – 4.94 (2H, m, C5-H2), 2.91 (2H, t, J = 7.5 Hz, C1-H2), 2.45 (3H, s, Ts CH3), 2.09 
– 2.02 (2H, m, C3-H2), 1.65 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 0.92 (9H, s, SiC(CH3)3), 0.29 (6H, s, 
Si(CH3)2). δC (101 MHz, CDCl3) 144.5 (ArC), 137.4 (C4), 130.0 (ArC), 129.9 (ArCH), 129.2 (ArCH), 
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115.3 (C5), 55.4 (C1), 31.0 (C3), 26.1 (C2), 26.0 (SiC(CH3)3), 21.6 (Ts CH3), 18.3 (SiC(CH3)3), -4.2 
(Si(CH3)2). HRMS: (ESI+) Calculated for C18H32NO3SSi: 370.1867. Found [M+H]+: 370.1866. 
N-Hydroxy-N-(pent-4-en-1-yl)-4-toluenesulfonamide (78) 
 
General procedure B: Compound 82 (500 mg, 1.35 mmol) was employed. Compound 78 (340 mg, 
99 %) was isolated as a colourless crystalline solid. νmax / cm-1: (solid) 3369 (br s), 2925 (m), 2853 (m), 
1641 (m), 1597 (m), 1440 (m), 1331 (s), 1165 (s). δH (400 MHz, CDCl3) 7.78 (2H, d, J = 8.5 Hz, 2 × 
ArCH), 7.36 (2H, d, J = 8.5 Hz, 2 × ArCH), 6.27 (1H, s, OH), 5.78 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, 
C4-H), 5.03 (1H, ddt, J = 17.0, 1.5, 1.5 Hz, C5-H’), 4.98 (1H, ddt, J = 10.0, 1.5, 1.5 Hz, C5-H), 2.92 
(2H, t, J = 7.0 Hz, C1-H2), 2.46 (3H, s, Ts CH3), 2.16 – 2.09 (2H, m, C3-H2), 1.71 (2H, tt, J = 7.0, 
7.0 Hz, C2-H2). δC (101 MHz, CDCl3) 144.9 (ArC), 137.5 (C4), 129.6 (ArCH), 129.5 (ArCH), 129.4 
(ArC), 115.4 (C5), 51.9 (C1), 30.6 (C3), 25.9 (C2), 21.7 (Ts CH3). HRMS: (ESI+) Calculated for 
C12H17NNaO3S: 278.0821. Found [M+Na]+: 278.0821. 
N-(Pent-4-en-1-yl)-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (79) 
 
General procedure C: Compound 78 (330 mg, 1.29 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 79 (570 mg, 98 %) as a colourless crystalline solid. m.p. 89-90 °C 
(Et2O:hexane). νmax / cm-1: (solid) 2927 (m), 1787 (s), 1654 (m), 1595 (m), 1505 (s), 1367 (s), 1170 (s). 
δH (400 MHz, CDCl3) 7.80 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.38 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.75 
(ddt, J = 17.0, 10.0, 7.0 Hz, C4-H), 5.07 – 4.97 (2H, m, C5-H2), 3.23 (2H, br s, C1-H2), 2.47 (3H, s, 
Ts CH3), 2.20 (2H, dt, J = 7.0, 7.0 Hz, C3-H2), 1.67 (tt, J = 7.0, 7.0 Hz, C2-H2). δC (126 MHz, CDCl3) 
156.5 (FBz C=O), 146.0 (ArC), 137.0 (C4), 130.2 (ArC), 130.0 (ArCH), 129.8 (ArCH), 116.1 (C5), 
52.1 (C1), 30.5 (C3), 25.9 (C2), 21.9 (Ts CH3). The aromatic 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.9 – -136.1 (2F, m), -146.0 (1F, tt, J = 21.0, 5.5 Hz), -158.9 – -159.1 (2F, m). HRMS: (ESI+) 
Calculated for C19H17F5NO4S: 450.0793. Found [M+H]+: 450.0794. 
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N-(4-Oxopentyl)-4-toluenesulfonamide (102)  
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 15 mol% P(3,5-(CF3)2C6H3)3; 200 mol% 
Et3N; DMF (0.11 M); 120 °C; 2 hours. Substrate 79 (50.0 mg, 0.111 mmol) was employed. FCC 
(gradient elution: 19:1 – 9:1 – 4:1 – 0:1 hexane:EtOAc) afforded 102 (23.0 mg, 81 %) as a colourless 
oil. νmax / cm-1: (film) 3278 (br s), 2925 (m), 1709 (s), 1598 (m), 1423 (m), 1324 (s), 1155 (s). 
δH (400 MHz, CDCl3) 7.72 (2H, d, J = 8.5 Hz), 7.29 (2H, d, J = 8.5 Hz), 4.83 (1H, t, J = 6.5 Hz), 2.93 
(2H, dt, J = 6.5, 6.5 Hz), 2.50 (2H, t, J = 6.5 Hz), 2.41 (3H, s), 2.11 (3H, s), 1.72 (2H, tt, J = 6.5, 6.5 Hz). 
δC (101 MHz, CDCl3) 208.5, 143.6, 137.0, 129.9, 127.2, 42.7, 40.3, 30.2, 23.4, 21.6. HRMS: (ESI+) 
Calculated for C12H18NO3S: 256.1002. Found [M+H]+: 256.1003. The spectroscopic properties were 
consistent with the data available in the literature.198 
N-(1-Phenylethyl)-N-((tert-butyldimethylsilyl)oxy)-4-toluenesulfonamide (93) 
 
General procedure E: TsNHOTBS (vide supra, 1.20 g, 3.98 mmol) was employed with 
1-phenylethanol (1.5 eq.). The reaction time was 24 hours. FCC (eluent: 1:1 hexane:PhMe) afforded 93 
(1.31 g, 81 %) as a colourless crystalline solid. m.p. 133-134 °C (CH2Cl2:hexane, plates). νmax / cm-1: 
(solid) 2963 (m), 2858 (m), 1596 (m), 1349 (s), 1164 (s). δH (400 MHz, CDCl3) 7.74 (2H, d, J = 8.5 Hz, 
2 × ArCH), 7.40 – 7.34 (2H, m, 2 × ArCH), 7.31 – 7.19 (5H, m, 5 × ArCH), 4.98 (1H, q, J = 7.0 Hz, 
C1-H), 2.44 (3H, s, Ts CH3), 1.00 (3H, d, J = 7.0 Hz, C2-H3), 0.87 (9H, s, SiC(CH3)3), 0.24 (3H, s, 
SiCH3), -0.41 (3H, s, Si(CH3)’). δC (101 MHz, CDCl3) 144.2 (ArC), 140.5 (ArC), 133.1 (ArC), 129.3 
(ArCH), 129.2 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.4 (ArCH), 60.0 (C1), 26.1 (SiC(CH3)3), 21.6 
(Ts CH3), 18.5 (SiC(CH3)3), 13.0 (C2), -4.4 (SiCH3), -4.9 (Si(CH3)’). HRMS: (ESI+) Calculated for 
C21H31NNaO3SSi: 428.1686. Found [M+Na]+: 428.1673. 
N-((Triethylsilyl)oxy)-4-toluenesulfonamide 
 
To a suspension of TsNHOH (vide supra, 5.00 g, 26.7 mmol) in anhydrous CH2Cl2 (200 mL) at 0 °C 
was added TESCl (6.70 mL, 40.0 mmol) followed by Et3N (5.60 mL, 40.2 mmol). The reaction mixture 
was stirred at room temperature for 19 hours before addition of brine (150 mL). The resulting phases 
were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 100 mL). The combined organic 
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phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 3:1 hexane:EtOAc) afforded 
TsNHOTES (7.02 g, 87 %) as a colourless crystalline solid, which was stored in a glovebox to prevent 
hydrolysis. νmax / cm-1: (solid) 3196 (s), 2954 (m), 2914 (m), 2878 (m), 1597 (m). δH (400 MHz, CDCl3) 
7.81 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.34 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.45 (1H, s NH), 2.45 (3H, s, 
Ts CH3), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.71 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, 
CDCl3) 144.9 (ArC), 133.3 (ArC), 129.7 (ArCH), 129.0 (ArCH), 21.8 (Ts CH3), 6.7 (Si(CH2CH3)3), 4.1 
(Si(CH2CH3)3). HRMS: (ESI+) Calculated for C13H23NNaO3SSi: 324.1060. Found [M+Na]+: 324.1060. 
N-(1-Phenylethyl)-N-((triethylsilyl)oxy)-4-toluenesulfonamide (96) 
 
General procedure E: TsNHOTES (vide supra, 600 mg, 1.99 mmol) was employed with 
1-phenylethanol (1.5 eq.). The reaction time was 20 hours. FCC (gradient elution: 1:1 – 2:3 
hexane:PhMe) afforded 96 (724 mg, 90 %) as a colourless crystalline solid. m.p. 104-105 °C 
(CH2Cl2:hexane, plates). νmax / cm-1: (solid) 2958 (m), 2877 (m), 1597 (m), 1352 (s), 1164 (s).  
δH (400 MHz, CDCl3) 7.70 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.35 – 7.28 (2H, m, 2 × ArCH), 7.28 – 7.18 
(5H, m, 5 × ArCH), 4.87 (1H, q, J = 7.0 Hz, C1-H), 2.42 (3H, s, Ts CH3), 1.08 (3H, d, J = 7.0 Hz, 
C2-H3), 0.89 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.65 – 0.45 (6H, m, Si(CH2CH3)3). δC (101 MHz, CDCl3) 
144.2 (ArC), 140.4 (ArC), 133.2 (ArC), 129.4 (ArCH), 129.3 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 
127.7 (ArCH), 60.7 (C1), 21.8 (Ts CH3), 14.3 (C2), 7.0 (Si(CH2CH3)3), 4.9 (Si(CH2CH3)3). 
HRMS: (ESI+) Calculated for C21H31NNaO3SSi: 428.1686. Found [M+Na]+: 428.1685. 
N-(1-Phenylethyl)-N-hydroxy-4-toluenesulfonamide (94) 
 
General procedure F: Compound 96 (75.0 mg, 0.185 mmol) was employed. Compound 94 (52.1 mg, 
97 %) was isolated as a colourless crystalline solid, which required no further purification. νmax / cm-1: 
(solid) 3314 (br s), 2983 (m), 1597 (m), 1332 (s), 1154 (s). δH (400 MHz, CDCl3) 7.69 (2H, d, J = 
8.0 Hz, 2 × ArCH), 7.36 – 7.29 (2H, m, 2 × ArCH), 7.25 – 7.15 (5H, m, 5 × ArCH), 6.49 (1H, br s, 
OH), 4.95 (1H, q, J = 7.0 Hz, C1-H), 2.40 (3H, s, Ts CH3), 1.35 (3H, d, J = 7.0 Hz, C2-H3). 
δC (101 MHz, CDCl3) 144.4 (ArC), 140.1 (ArC), 132.9 (ArC), 129.4 (ArCH), 129.2 (ArCH), 128.4 
(ArCH), 127.8 (ArCH), 127.7 (ArCH), 60.1 (C1), 21.7 (Ts CH3), 17.0 (C2). HRMS: (ESI+) Calculated 
for C15H17NNaO3S: 314.0821. Found [M+Na]+: 314.0828. 





This compound was prepared according to a literature procedure.196 To a solution of NH2OH·HCl 
(13.9 g, 200 mmol) in MeOH (60 mL) and water (40 mL) was added MgO (6.93 g, 172 mmol). The 
reaction mixture was stirred at room temperature for 20 minutes before addition of a solution of MsCl 
(6.7 mL, 86.0 mmol) in THF (600 mL) followed by another portion of MgO (3.47 g, 86.0 mmol). The 
reaction mixture was stirred at room temperature for 2.5 hours before being filtered through celite and 
concentrated in vacuo to afford MsNHOH (9.38 g, 98 %) as a colourless crystalline solid, which was 
used without further purification. νmax / cm-1: (solid) 3373 (br s), 3253 (s), 3036 (m), 1302 (s), 1154 (s). 
δH (400 MHz, CD3CN) 7.45 (2H, m, NH and OH), 2.95 (3H, s, Ms CH3). δC (101 MHz, CD3CN) 36.0 
(Ms CH3). HRMS: (ESI+) Calculated for CH5NNaO3S: 133.9882. Found [M+Na]+: 133.9888. 
N-((Triethylsilyl)oxy)methanesulfonamide 
 
To a suspension of MsNHOH (vide supra, 1.33 g, 12.0 mmol) in anhydrous CH2Cl2 (30 mL) at 0 °C 
was added TESCl (2.61 mL, 15.6 mmol) followed by Et3N (2.17 mL, 15.6 mmol). The reaction mixture 
was stirred at room temperature for 19 hours before addition of water (25 mL). The resulting phases 
were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 30 mL). The combined organic 
phases were washed with brine (50 mL), dried over Na2SO4 and concentrated in vacuo. FCC (gradient 
elution: 6:1 – 5:1 – 4:1 hexane:EtOAc) afforded MsNHOTES (2.24 g, 83 %) as a colourless oil, which 
was stored in a glovebox to prevent hydrolysis. νmax / cm-1: (film) 3209 (br s), 2957 (s), 2879 (s), 
1320 (s), 1160 (s). δH (400 MHz, CDCl3) 6.67 (1H, s, NH), 3.05 (3H, s, Ms CH3), 0.99 (9H, t, J = 
8.0 Hz, Si(CH2CH3)3), 0.74 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 35.9 (Ms CH3), 
6.6 (Si(CH2CH3)3), 4.0 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for C7H19NNaO3SSi: 248.0747. 
Found [M+Na]+: 248.0746. 
N-((Pentafluorobenzoyl)oxy)-4-toluenesulfonamide 
 
General procedure G: TsNHOH (vide supra, 9.36 g, 50.0 mmol) was employed. The reaction time 
was 19 hours. FCC (gradient elution: 4:1 – 3:1 hexane:EtOAc) afforded TsNHOFBz (13.9 g, 73 %) as 
a colourless crystalline solid. m.p. 102-104 °C (CH2Cl2:hexane, needles). νmax / cm-1: (solid) 3189  
(br s), 1781 (s), 1653 (s), 1597 (m), 1500 (s), 1163 (s). δH (400 MHz, CDCl3) 9.01 (1H, s, NH), 7.85 
(2H, d, J = 8.5 Hz, 2 × ArCH), 7.36 (2H, d, J = 8.5 Hz, 2 × ArCH), 2.45 (3H, s, Ts CH3). δC (101 MHz, 
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CDCl3) 158.0 (C=O), 146.4 (ArC), 132.2 (ArC), 130.2 (ArCH), 129.1 (ArCH), 21.9 (Ts CH3). The 
aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their 
weak intensity. δF (377 MHz, CDCl3) -134.7 – -134.8 (2F, m), -144.1 (1F, tt, J = 21.0, 6.5 Hz), -158.7 
– -158.8 (2F, m). HRMS: (ESI+) Calculated for C14H8F5NNaO4: 403.9986. Found [M+Na]+: 403.9992.  
 
ORTEP view of TsNHOFBz. 
N-((Pentafluorobenzoyl)oxy)methanesulfonamide 
 
General procedure G: MsNHOH (vide supra, 2.22 g, 20.0 mmol) was employed. The reaction time 
was 20 hours. FCC (eluent: 3:1 hexane:EtOAc) afforded MsNHOFBz (1.93 g, 32 %) as a colourless 
crystalline solid. m.p. 135-136 °C (Et2O:hexane, cubes). νmax / cm-1: (solid) 3151 (s), 2940 (m), 1759 (s), 
1653 (m), 1500 (s), 1324 (s), 1165 (s). δH (400 MHz, CDCl3) 8.72 (1H, br s, NH), 3.20 (3H, d, J = 
1.0 Hz, Ms CH3). δC (101 MHz, CDCl3) 39.3 (Ms CH3). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -134.5 – -134.6 (2F, m), -143.5 (1F, tt, J = 21.0, 6.5 Hz), -158.4 – -158.6 (2F, m). HRMS: (ESI+) 
Calculated for C8H4F5NNaO4S: 327.9673. Found [M+Na]+: 327.9676. 
2-(Cyclohex-2-en-1-yl)acetic acid 
 
General procedure H: 3-Bromocyclohexene (6.90 mL, 60.0 mmol) was employed. The title  
compound (6.23 g, 74 %) was isolated as an orange oil, which was used without further purification.  
νmax / cm-1: (film) 3020 (m), 2927 (m), 1703 (s), 1289 (s). δH (400 MHz, CDCl3) 11.28 (1H, br s), 5.72 
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(1H, dtd, J = 10.0, 3.5, 2.0 Hz), 5.56 (1H, dtd, J = 10.0, 2.5, 2.0 Hz), 2.59 (1H, m), 2.36 (1H, dd, J = 
15.5, 7.0 Hz), 2.29 (1H, dd, J = 15.5, 8.0 Hz), 1.98 (2H, dddd, J = 10.5, 5.5, 3.0, 2.5 Hz), 1.90 – 1.81 
(1H, m), 1.75 – 1.66 (1H, m), 1.61 – 1.50 (1H, m), 1.30 (1H, dddd, J = 13.5, 11.0, 8.5, 3.0 Hz).  
δC (101 MHz, CDCl3) 179.6, 129.9, 128.5, 40.7, 32.1, 28.8, 25.1, 21.0. The spectroscopic properties 
were consistent with the data available in the literature.199 
2-(Cyclohex-2-en-1-yl)ethan-1-ol (83) 
 
General procedure I: The preceding carboxylic acid (6.20 g, 44.0 mmol) was employed, using 
anhydrous THF as solvent and 1.7 eq. LiAlH4 (1.0 M in THF). The crude product was filtered through 
a short plug of silica to afford 83 (4.85 g, 87 %) as a yellow oil. δH (400 MHz, CDCl3) 5.68 (1H, dtd, 
J = 10.0, 3.5, 2.5 Hz), 5.57 (1H, ddt, J = 10.0, 2.5, 2.0 Hz), 3.77 – 3.67 (2H, m), 2.28 – 2.17 (1H, m), 
1.97 (2H, dddd, J = 10.5, 5.5, 3.5, 2.0 Hz), 1.80 (1H, dtd, J = 12.0, 5.5, 2.5 Hz), 1.76 – 1.67 (1H, m), 
1.67 – 1.50 (3H, m), 1.50 (1H, s), 1.25 (1H, dddd, J = 12.5, 11.0, 8.5, 2.5 Hz). δC (101 MHz, CDCl3) 
131.6, 127.4, 60.9, 39.2, 31.9, 29.1, 25.3, 21.4. HRMS: (ESI+) Calculated for C8H14NaO: 149.0937. 




General procedure J: Alcohol 83 (6.40 g, 50.8 mmol) was employed. FCC (eluent: 
29:1 hexane:EtOAc) afforded the title compound (2.50 g, 26 %) as a colourless oil. δH (400 MHz, 
CDCl3) 5.72 (1H, ddt, J = 10.0, 3.5, 3.5 Hz), 5.54 (1H, ddt, J = 10.0, 2.5, 2.5 Hz), 3.52 – 3.41 (2H, m), 
2.35 – 2.25 (1H, m), 2.01 – 1.95 (2H, m), 1.90 (1H, ddd, J = 14.0, 7.0, 7.0 Hz), 1.86 – 1.76 (2H, m), 
1.76 – 1.66 (1H, m), 1.60 – 1.49 (1H, m), 1.22 (1H, dddd, J = 13.0, 11.0, 8.5, 3.0 Hz). δC (101 MHz, 
CDCl3) 130.2, 127.9, 39.2, 33.8, 31.7, 28.3, 25.2, 21.1. m/z (EI+) 189 and 187 ([M]+, 30 and 30 %), 
97 (100 %), 81 and 79 ([Br]+, 74 and 77 %). The spectroscopic properties were consistent with the data 
available in the literature.201  
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2-(Cyclohex-2-en-1-yl)ethan-1-yl tosylate (84) 
 
To a solution of alcohol 83 (3.95 g, 31.3 mmol) and Et3N (7.00 mL, 50.2 mmol) in anhydrous CH2Cl2 
(100 mL) at 0 °C was added TsCl (9.24 g, 48.5 mmol) in two roughly equal portions. The reaction 
mixture was stirred at room temperature for 22 hours before addition of saturated aqueous NaHCO3 
(100 mL). The resulting phases were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 
50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
9:1 petrol:EtOAc) afforded 84 (8.43 g, 96 %) as a colourless oil. νmax / cm-1: (film) 3017 (m), 2927 (m), 
1598 (m), 1448 (m), 1361 (s), 1176 (s). δH (500 MHz, CDCl3) 7.80 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.35 
(2H, d, J = 8.5 Hz, 2 × ArCH), 5.66 (1H, dtd, J = 10.0, 4.0, 3.5 Hz, C5-H), 5.42 (1H, ddt, J = 10.0, 2.5, 
2.5 Hz, C4-H), 4.10 (2H, t, J = 6.5 Hz, C1-H2), 2.45 (3H, s, Ts CH3), 2.17 (1H, m, C3-H), 1.94 (2H, 
dddd, J = 5.5, 5.5, 4.0, 2.5 Hz, C6-H2), 1.74 – 1.54 (4H, m, C2-H2 C7-H and C8-H), 1.52 – 1.42 (1H, 
m, C7-H’), 1.18 – 1.11 (1H, m, C8-H’). δC (101 MHz, CDCl3) 144.7 (ArC), 133.1 (ArC), 130.1 (C4), 
129.8 (ArCH), 128.0 (C5), 127.9 (ArCH), 68.6 (C1), 35.0 (C2), 31.4 (C3), 28.5 (C8), 25.1 (C6), 21.6 
(Ts CH3), 21.0 (C7). HRMS: (ESI+) Calculated for C15H20NaO3S: 303.1025. Found [M+Na]+: 303.1025. 
N-((tert-Butyldimethylsilyl)oxy)-N-(2-(cyclohex-2-en-1-yl)ethyl)-4-toluenesulfonamide (85) 
 
General procedure A: TsNHOTBS (vide supra, 2.71 g, 9.00 mmol) was employed with 
3-(2-bromoethyl)cyclohex-1-ene (vide supra). FCC (eluent: 14:1 hexane:EtOAc) afforded 85 (2.51 g, 
57 %) as a colourless oil that solidified upon standing. Alternative synthesis adapted from a literature 
procedure:113A solution of TsNHOTBS (2.35 g, 7.79 mmol), tosylate 84 (1.82 g, 6.49 mmol) and 
Cs2CO3 (3.81 g, 11.7 mmol) in DMF (40 mL) was stirred at room temperature for 17 hours before 
addition of saturated aqueous NH4Cl (50 mL) and water (50 mL). The reaction mixture was extracted 
with EtOAc (3 × 80 mL). The combined organic phases were dried over Na2SO4 and concentrated in 
vacuo. FCC (gradient elution: 29:1 – 19:1 hexane:EtOAc) afforded 85 (1.95 g, 75 %) as a colourless 
oil that solidified upon standing. νmax / cm-1: (solid) 3021 (m), 2928 (s), 2858 (m), 1597 (m), 1351 (s), 
1164 (s). δH (500 MHz, CDCl3) 7.73 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.34 (2H, d, J = 8.5 Hz, 2 × ArCH), 
5.67 (1H, ddt, J = 10.0, 3.5, 3.5 Hz, C5-H), 5.47 (1H, ddt, J = 10.0, 2.0, 2.0 Hz, C4-H), 3.04 – 2.89 (2H, 
m, C1-H2), 2.45 (3H, s, Ts CH3), 2.12 – 2.04 (1H, m, C3-H), 1.98 – 1.92 (2H, m, C6-H2), 1.78 – 1.71 
(1H, m, C8-H), 1.71 – 1.58 (2H, m, C2-H and C7-H), 1.54 – 1.44 (2H, m, C2-H’ and C7-H’), 1.16 (1H, 
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dddd, J = 12.5, 11.0, 8.5, 2.5 Hz, C8-H’), 0.92 (9H, s, SiC(CH3)3), 0.30 (3H, s, SiCH3), 0.29 (3H, s, 
Si(CH3)’). δC (101 MHz, CDCl3) 144.4 (ArC), 130.8 (C4), 130.0 (ArCH), 129.9 (ArCH), 129.2 (ArC), 
127.7 (C5), 53.9 (C1), 33.3 (C2), 32.9 (C3), 28.7 (C8), 26.0 (SiC(CH3)3), 25.2 (C6), 21.6 (Ts CH3), 
21.2 (C7), 18.3 (SiC(CH3)3), 2 × -4.2 (SiCH3 and Si(CH3)’). HRMS: (ESI+) Calculated for 
C21H36NO3SSi: 410.2180. Found [M+H]+: 410.2197. 
N-(2-(Cyclohex-2-en-1-yl)ethyl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure B: Compound 85 (2.10 g, 5.13 mmol) was employed. The title compound (1.31 g, 
87 %) was isolated as a colourless crystalline solid. νmax / cm-1: (solid) 3356 (br s), 2921 (m), 1597 (m), 
1437 (m), 1330 (s), 1163 (s). δH (500 MHz, CDCl3) 7.80 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.39 (2H, d, 
J = 8.5 Hz, 2 × ArCH), 6.28 (1H, s, OH), 5.73 – 5.67 (1H, m, C5-H), 5.57 – 5.52 (1H, m, C4-H), 3.07 
– 2.93 (2H, m, C1-H2), 2.48 (3H, s, Ts CH3), 2.21 (1H, dddd, J = 11.5, 5.5, 5.5, 2.5 Hz, C3-H), 1.98 
(2H, dddd, J = 6.5, 4.5, 3.0, 1.5 Hz, C6-H2), 1.86 – 1.78 (1H, m, C8-H), 1.73 – 1.64 (2H, m, C2-H and 
C7-H), 1.59 – 1.46 (2H, m, C2-H’ and C7-H’), 1.22 (1H, dddd, J = 12.5, 11.5, 8.5, 3.0 Hz, C8-H’).  
δC (126 MHz, CDCl3) 144.9 (ArC), 130.9 (C4), 129.7 (ArCH), 129.6 (ArCH), 129.4 (ArC), 127.7 (C5), 
50.3 (C1), 33.0 (C2), 32.5 (C3), 28.7 (C8), 25.2 (C6), 21.7 (Ts CH3), 21.2 (C7). HRMS: (ESI+) 
Calculated for C15H21NNaO3S: 318.1134. Found [M+Na]+: 318.1123. 
N-(2-(Cyclohex-2-en-1-yl)ethyl)-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (103a) 
 
General procedure C: N-2-(Cyclohex-2-en-1-yl)ethyl-N-hydroxy-4-toluenesulfonamide (vide supra, 
900 mg, 3.05 mmol) was employed. FCC (gradient elution: 19:1 – 12:1 hexane:EtOAc) afforded 103a 
(1.33 g, 89 %) as a colourless crystalline solid. m.p. 81-82 °C (Et2O:hexane). νmax / cm-1: (solid) 
2988 (m), 2929 (m), 1790 (s), 1654 (m), 1596 (m), 1503 (s), 1170 (s). δH (400 MHz, CDCl3) 7.78 (2H, 
d, J = 8.0 Hz, 2 × ArCH), 7.38 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.67 (1H, dtd, J = 10.0, 3.5, 2.5 Hz, 
C5-H), 5.46 (1H, ddt, J = 10.0, 2.5, 2.5 Hz, C4-H), 3.26 (2H, br s, C1-H2), 2.46 (3H, s, Ts CH3), 2.29 
(1H, ddddd, J = 13.5, 8.5, 5.5, 2.5, 2.5 Hz, C3-H), 1.94 (2H, dddd, J = 7.0, 5.0, 3.5, 2.5 Hz, C6-H2), 
1.83 – 1.73 (1H, m, C8-H), 1.72 – 1.44 (4H, m, C2-H2 and C7-H2), 1.29 – 1.13 (1H, m, C8-H’).  
δC (101 MHz, CDCl3) 156.4 (FBz C=O), 145.9 (ArC), 130.3 (C4), 2 × 129.9 (ArC and ArCH), 129.5 
(ArCH), 127.9 (C5), 50.6 (C1), 32.8 (C2), 32.2 (C3), 28.5 (C8), 25.1 (C6), 21.7 (Ts CH3), 21.1 (C7). 
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The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to 
their weak intensity. δF (377 MHz, CDCl3) -136.0 – -136.2 (2F, m), -146.2 (1F, tt, J = 21.0, 
5.5 Hz), -159.0 – -159.2 (2F, m). HRMS: (ESI+) Calculated for C22H20F5NNaO4S: 512.0925. Found 
[M+Na]+: 512.0902. 
 
ORTEP view of 103a. 
(3aR*,7aS*)-1-Tosyl-2,3,3a,4,5,7a-hexahydro-1H-indole (104) and (iso-104) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 50 mol% 
Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 17 hours. Substrate 103a (68.5 mg, 0.140 mmol) was 
employed. FCC (eluent: 9:1 hexane:EtOAc) afforded 104 and iso-104 (35.4 mg, 91 %, 12:1 mixture of 
104 and iso-104) as a pale-yellow oil. Spectroscopic data for 104: νmax / cm-1: (film) 3031 (m), 2923 (m), 
1598 (m), 1450 (m), 1338 (s), 1157 (s). δH (500 MHz, CDCl3) 7.73 (2H, d, J = 8.0 Hz), 7.30 (2H, d, J = 
8.0 Hz), 5.83 (1H, dddd, J = 10.5, 2.5, 2.5, 2.5 Hz), 5.80 – 5.72 (1H, m), 3.99 (1H, dd, J = 5.5, 2.5 Hz), 
3.47 (1H, ddd, J = 10.0, 7.5, 4.0 Hz), 3.16 (1H, ddd, J = 10.0, 7.5, 7.5 Hz), 2.42 (3H, s), 2.04 – 1.95 
(2H, m), 1.95 – 1.87 (1H, m), 1.76 (1H, dddd, J = 12.0, 8.0, 7.5, 7.5 Hz), 1.71 – 1.51 (3H, m).  
δC (126 MHz, CDCl3) 143.3, 135.1, 129.7, 128.4, 127.7, 127.6, 57.6, 47.4, 36.6, 27.8, 23.0, 21.6, 21.0. 
HRMS: (ESI+) Calculated for C15H20NO2S: 278.1209. Found [M+H]+: 278.1207. The spectroscopic 
properties were consistent with the data available in the literature.26 Characteristic signals for iso-104 
(obtained from 1D TOCSY): δH (500 MHz, CDCl3) 5.63 – 5.60 (m), 3.70 (ddd, J = 7.5, 7.5, 7.5 Hz), 
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3.50 – 3.45 (m), 3.12 (ddd, J = 10.0, 10.0, 7.5 Hz), 2.53 – 2.45 (m), 2.31 – 2.22 (m), 2.14 – 2.05 (m), 
1.97 – 1.91 (m), 1.91 – 1.84 (m), 1.84 – 1.77 (m), 1.76 – 1.69 (m).  
N-(2-(Cyclohex-2-en-1-yl)ethyl)-p-tolylsulfonamide (106) and p-toluenesulfonamide 
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 15 mol% P(3,5-(CF3)2C6H3)3; 400 mol% 
Et3N; DMF (0.12 M); 120 °C; 2 hours. Substrate 103a (59.2 mg, 0.121 mmol) was employed. FCC 
(gradient elution: 49:1 – 19:1 – 0:1 PhMe:EtOAc) afforded 104 and iso-104 (5.0 mg, 15 %, 5:1 
104:iso-104) as a pale-yellow oil, 106 (8.1 mg, 24 %) as a colourless oil and p-toluenesulfonamide 
(11.4 mg, 55 %) as a colourless crystalline solid. Spectroscopic data for 106: νmax / cm-1: (film) 3278 (s), 
2921 (s), 1599 (m), 1424 (s), 1308 (s), 1280 (s), 1147 (s). δH (500 MHz, CDCl3) 7.75 (2H, d, J = 8.0 Hz, 
2 × ArCH), 7.31 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.66 (1H, ddt, J = 10.0, 3.5, 3.5 Hz, C5-H), 5.42 (1H, 
ddt, J = 10.0, 2.5, 2.5 Hz, C4-H), 4.33 (1H, t, J = 6.5 Hz, NH), 3.00 (2H, ddd, J = 8.0, 6.5, 6.5 Hz, 
C1-H2), 2.43 (3H, s, Ts CH3), 2.12 – 2.04 (1H, m, C3-H), 1.97 – 1.90 (2H, m, C6-H2), 1.72 – 1.37 (5H, 
m, C2-H2, C7-H2 and C8-H), 1.18 – 1.09 (1H, m, C8-H’). δC (126 MHz, CDCl3) 143.5 (ArC), 137.1 
(ArC), 130.6 (C4), 129.9 (ArCH), 128.1 (C5), 127.3 (ArCH), 41.2 (C1), 36.0 (C2), 32.6 (C3), 28.7 
(C8), 25.3 (C6), 21.7 (Ts CH3), 21.3 (C7). HRMS: (ESI+) Calculated for C15H22NO2S: 280.1366. Found 
[M+H]+: 280.1359. The 1H spectrum was consistent with the data available in the literature.202 
Spectroscopic data for p-toluenesulfonamide: δH (500 MHz, CDCl3) 7.81 (2H, d, J = 8.0 Hz), 7.32 (2H, 
d, J = 8.0 Hz), 4.78 (2H, br s), 2.43 (3H, s). δC (126 MHz, CDCl3) 143.8, 139.2, 129.9, 126.6, 21.7. 
HRMS: (ESI+) Calculated for C7H9NNaO2S: 194.0246. Found [M+Na]+: 194.0245. The spectroscopic 
properties were consistent with the data available in the literature.203 
Characterisation data for 104 has been provided earlier. 
N-(Cyclohex-3-en-1-ylmethyl)hydroxylamine 
 
To a solution of 3-cyclohexene-1-carboxaldehyde (113) (2.00 g, 18.2 mmol) in MeOH (50 mL) was 
added NH2OH·HCl (1.90 g, 27.3 mmol) and NaOAc (2.20 g, 26.8 mmol). The reaction mixture was 
heated at reflux for 2 hours, then cooled to room temperature before addition of NaBH3CN (2.26 g, 
36.0 mmol) and a small amount of methyl orange. To the resulting suspension was added a pre-mixed 
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solution of MeOH:AcCl (3:1) dropwise at such a rate as to keep the solution pink. After 30 minutes the 
reaction mixture was concentrated in vacuo. The crude product was dissolved in water (100 mL), made 
basic with NaOH and extracted with CH2Cl2 (4 × 30 mL). The combined organic phases were dried 
over Na2SO4 and concentrated in vacuo. FCC (eluent: 1:1 hexane:EtOAc) afforded the title compound 
(1.52 g, 66 %) as a colourless oil. δH (400 MHz, CDCl3) 6.09 (2H, br s), 5.71 – 5.60 (2H, m), 2.86 (2H, 
dd, J = 6.5, 2.0 Hz), 2.14 (1H, dddd, J = 17.5, 5.0, 3.0, 1.5 Hz), 2.08 – 2.01 (2H, m), 1.97 – 1.84 (1H, 
m), 1.83 – 1.66 (2H, m), 1.27 (1H, ddt, J = 13.0, 11.0, 8.0 Hz). δC (101 MHz, CDCl3) 127.2, 126.0, 
59.7, 31.3, 30.0, 27.0, 24.8. HRMS: (ESI+) Calculated for C7H14NO: 128.1075. Found [M+H]+: 
128.1061. The spectroscopic properties were consistent with the data available in the literature.204 
N-(Cyclohex-3-en-1-ylmethyl)-N-hydroxy-4-toluenesulfonamide 
 
To a solution of the preceding compound (250 mg, 1.97 mmol) in MeOH (3 mL) and water (2 mL) was 
added MgO (40.0 mg, 0.993 mmol). The reaction mixture was stirred at room temperature for 
10 minutes before addition of a solution of TsCl (380 mg, 1.99 mmol) in THF (15 mL), followed by 
another portion of MgO (120 mg, 2.98 mmol). The suspension was stirred at room temperature for 
2 hours before being filtered and concentrated in vacuo. FCC (eluent: 6:1 hexane:EtOAc) afforded the 
title compound (403 mg, 71 %) as a colourless crystalline solid. νmax / cm-1: (solid) 3351 (br s), 2913 (m), 
1596 (m), 1442 (m), 1329 (s), 1163 (s). δH (500 MHz, CDCl3) 7.81 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.39 
(2H, J = 8.0 Hz, 2 × ArCH), 6.41 (1H, br s, OH), 5.75 – 5.63 (2H, m, C4-H and C5-H), 2.92 – 2.75 
(2H, m, C1-H2), 2.49 (3H, s, Ts CH3), 2.21 – 2.14 (1H, m, C3-H), 2.10 – 1.99 (3H, m, C2-H and C6-H2), 
1.87 – 1.73 (2H, m, C3-H’ and C7-H), 1.36 (1H, dtd, J = 13.0, 9.5, 6.0 Hz, C7-H’). δC (126 MHz, 
CDCl3) 144.9 (ArC), 129.6 (ArCH), 129.6 (ArCH), 129.5 (ArC), 127.1 (C5), 125.6 (C4), 57.6 (C1), 
31.0 (C2), 29.3 (C3), 26.1 (C7), 24.3 (C6), 21.7 (Ts CH3). HRMS: (ESI+) Calculated for C14H20NO3S: 
282.1158. Found [M+H]+: 282.1147. 
N-(Cyclohex-3-en-1-ylmethyl)-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (114a) 
 
General procedure C: The preceding compound (560 mg, 2.00 mmol) was employed. FCC (gradient 
elution: 19:1 – 9:1 hexane:EtOAc) afforded 114a (700 mg, 74 %) as a colourless crystalline solid. 
m.p. 101-102 °C (Et2O:hexane). νmax / cm-1: (solid) 2901 (m), 1789 (s), 1656 (m), 1595 (m), 1505 (s), 
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1168 (s). δH (400 MHz, CDCl3) 7.79 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.38 (2H, d, J = 8.0 Hz, 2 × ArCH), 
5.70 – 5.58 (2H, m, C4-H and C5-H), 3.22 – 2.93 (2H, m, C1-H2), 2.46 (3H, s, Ts CH3), 2.28 – 2.14 
(1H, m, C3-H), 2.11 – 1.86 (3H, m, C6-H2 and C7-H), 1.83 – 1.72 (2H, m, C2-H and C3-H’), 1.43 – 
1.31 (1H, m, C7-H’). δC (101 MHz, CDCl3) 156.3 (C=O), 145.8 (ArC), 130.0 (ArC), 129.9 (ArCH), 
129.5 (ArCH), 127.1 (C5), 125.2 (C4), 57.7 (C1), 31.3 (C2), 29.1 (C3), 25.8 (C7), 24.0 (C6), 21.7 
(Ts CH3). The aromatic 
13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.8 – -135.9 (2F, m), -146.0 (1F, tt, J = 
21.0, 5.5 Hz), -158.9 – -159.1 (2F, m). HRMS: (ESI+) Calculated for C21H19F5NO4S: 476.0949. Found 
[M+H]+: 476.0955. 
6-Tosyl-6-azabicyclo[3.2.1]oct-3-ene (115a) and 6-tosyl-6-azabicyclo[3.2.1]oct-2-ene (iso-115a) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 34 hours. Substrate 114a (65.0 mg, 0.137 mmol) was employed. 
FCC (eluent: 29:1 PhMe:EtOAc) afforded iso-115a (15.0 mg, 42 %) as a colourless crystalline solid 
and 115a (7.7 mg, 21 %, 4:1 mixture of 115a and iso-115a) as a colourless crystalline solid. 
Spectroscopic data for 115a: νmax / cm-1: (film) 3033 (m), 2950 (m), 2883 (m), 1597 (m), 1338 (s), 
1154 (s). δH (500 MHz, CDCl3) 7.71 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.28 (2H, d, J = 8.0 Hz, 2 × ArCH), 
5.99 – 5.91 (1H, m, C5-H), 5.54 – 5.50 (1H, m, C6-H), 4.21 (dd, J = 5.5, 5.0 Hz, C4-H), 3.54 – 3.46 
(1H, m, C1-H), 3.16 (1H, d, J = 10.0 Hz, C1-H’), 2.58 – 2.51 (1H, m, C2-H), 2.42 (3H, s, Ts CH3), 2.37 
(1H, dddd, J = 18.5, 4.5, 2.5, 2.5 Hz, C7-H), 2.00 (1H, dddd, J = 18.5, 4.0, 2.0, 2.0 Hz, C7-H’), 1.62 
(1H, d, J = 11.0 Hz, C3-H), 1.40 (1H, ddd, J = 11.0, 5.0, 5.0 Hz, C3-H’). δC (126 MHz, CDCl3) 143.2 
(ArC), 136.3 (ArC), 130.2 (C5), 129.7 (ArCH), 127.7 (C6), 127.6 (ArCH), 54.6 (C4), 54.1 (C1), 35.0 
(C7), 33.9 (C3), 33.5 (C2), 21.7 (Ts CH3). HRMS: (ESI+) Calculated for C14H17NNaO2S: 286.0872. 
Found [M+Na]+: 286.0869.  
Characterisation data for iso-115a: m.p. 114-115 °C (Et2O:hexane). νmax / cm-1: (solid) 2966 (m), 
2873 (m), 1597 (m), 1335 (s), 1053 (s). δH (400 MHz, CDCl3) 7.72 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.29 
(2H, d, J = 8.0 Hz, 2 × ArCH), 5.93 (1H, ddd, J = 8.5, 8.5, 1.5 Hz, C7-H), 5.54 – 5.48 (1H, m, C6-H), 
4.22 (1H, d, J = 5.5 Hz, C4-H), 3.52 (1H, dd, J = 8.5, 1.5 Hz, C1-H), 3.12 (1H, dd, J = 8.5, 4.5 Hz, 
C1-H’), 2.58 – 2.53 (1H, m, C2-H), 2.44 – 2.34 (4H, m, C5-H and Ts CH3), 2.27 (1H, dd, J = 18.5, 
3.0 Hz, C5-H’), 1.69 (1H, d, J = 10.5 Hz, C3-H), 1.35 (ddd, J = 10.5, 5.5, 5.0 Hz, C3-H’). δC (101 MHz, 
CDCl3) 143.2 (ArC), 136.1 (ArC), 131.4 (C7), 129.7 (ArCH), 127.3 (ArCH), 125.5 (C6), 57.3 (C4), 
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56.9 (C1), 36.2 (C5), 34.5 (C2), 33.8 (C3), 21.7 (Ts CH3). HRMS: (ESI+) Calculated for C14H17NNaO2S: 
286.0872. Found [M+Na]+: 286.0866. 
 




General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% P(3,5-(CF3)2C6H3)3; 200 mol% Et3N; 
DMF (0.08 M); 100 °C; 11 hours. Substrate 114a (40.0 mg, 841 µmol) was employed. FCC (gradient 
elution: 19:1 – 14:1 – 9:1 hexane:EtOAc) afforded 116 (10.4 mg, 23 %) as a colourless crystalline solid, 
iso-115a (3.3 mg, 15 %) as a colourless crystalline solid and 115a (1.3 mg, 6 %) as a colourless 
crystalline solid. Characterisation data for 116: m.p. 122-123 °C (Et2O:hexane). νmax / cm-1: (solid) 
2926 (m), 2854 (m), 1763 (s), 1634 (s), 1487 (s), 1360 (s), 1171 (s). δH (500 MHz, CDCl3) 7.76 (2H, d, 
J = 8.0 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.66 – 5.49 (2H, m, C4-H and C5-H), 3.28 
(4H, q, J = 7.0 Hz, N(CH2CH3)2), 3.12 – 2.86 (2H, m, C1-H2), 2.40 (3H, s, Ts CH3), 2.33 – 2.17 (1H, 
m, C3-H), 2.11 – 1.89 (3H, m, C6-H2 and C7-H), 1.84 – 1.72 (2H, m, C2-H and C3-H’), 1.42 – 1.33 
(1H, m, C7-H’) 1.09 (6H, t, J = 7.0 Hz, N(CH2CH3)2). δC (126 MHz, CDCl3) 157.4 (C=O), 145.6 (ArC), 
130.6 (ArC), 129.9 (ArCH), 129.8 (ArCH), 127.2 (C5), 125.5 (C4), 57.9 (C1), 46.9 (N(CH2CH3)2), 31.4 
(C2), 29.4 (C3), 26.1 (C7), 24.3 (C6), 21.9 (Ts CH3), 13.8 (N(CH2CH3)2). The 
13C signals 
corresponding to the fluorinated arene could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -137.9 – -138.0 (2F, m), -150.4 – -150.5 (2F, m). HRMS: (ESI+) Calculated for 
C25H28F4N2NaO4S: 551.1598. Found [M+Na]+: 551.1586. Characterisation data for 115a and iso-115a 
has been provided earlier. 




ORTEP view of 116. 
N-2-(Cyclohex-2-en-1-yl)ethyl-N-((mesyl)oxy)-4-toluenesulfonamide (103b) 
 
To a solution of N-2-(cyclohex-2-en-1-yl)ethyl-N-hydroxy-4-toluenesulfonamide (vide supra, 630 mg, 
2.13 mmol) in anhydrous CH2Cl2 (30 mL) at 0 °C was added MsCl (325 μL, 4.19 mmol) followed by 
Et3N (0.59 mL, 4.23 mmol). The reaction mixture was stirred at room temperature for 16 hours before 
addition of MeOH (15 mL), saturated aqueous NaHCO3 (30 mL) and brine (30 mL). The resulting 
phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 × 30 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 49:1 PhMe:EtOAc) 
afforded 103b (660 mg, 83 %) as a colourless crystalline solid. m.p. 101-102 °C (Et2O:hexane). 
νmax / cm-1: (solid) 2921 (m), 1598 (m), 1451 (m), 1373 (s), 1355 (s), 1175 (s). δH (400 MHz, CDCl3) 
7.78 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.41 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.68 (1H, ddt, J = 10.0, 3.5, 
3.0 Hz, C5-H), 5.51 – 5.46 (1H, m, C4-H), 3.37 (3H, s, Ms CH3), 3.23 (2H, br s, C1-H2). 2.49 (3H, s, 
Ts CH3), 2.21 – 2.13 (1H, m, C3-H), 1.94 (2H, ddd, J = 5.5, 5.5, 3.0 Hz, C6-H2), 1.82 – 1.61 (4H, m, 
C2-H2, C7-H and C8-H), 1.57 – 1.44 (1H, m, C7-H’), 1.28 – 1.13 (1H, m, C8-H’). δC (126 MHz, CDCl3) 
146.4 (ArC), 130.6 (C4), 130.2 (ArCH), 129.9 (ArCH), 129.3 (ArC), 128.0 (C5), 54.4 (C1), 37.9 
(Ms CH3), 33.2 (C2), 32.7 (C3), 28.7 (C8), 25.3 (C6), 21.9 (Ts CH3), 21.3 (C7). HRMS: (ESI+) 
Calculated for C16H23NNaO5S2: 396.0910. Found [M+Na]+: 396.0924. 





N-2-(Cyclohex-2-en-1-yl)ethyl-N-hydroxy-4-toluenesulfonamide (vide supra, 200 mg, 0.677 mmol) 
was dissolved in trifluoroacetic anhydride (1.0 mL) and stirred for one hour before being concentrated 
in vacuo and analysed by 1H NMR. These steps were repeated until complete conversion was achieved. 
Substrate 103c (263 mg, 99 %) was isolated as an amorphous orange solid. This compound was 
employed in the catalytic reactions immediately due to its instability to hydrolysis. νmax / cm-1: (solid) 
3024 (m), 2926 (m), 1820 (s), 1597 (m), 1371 (s), 1220 (s), 1165 (s). δH (400 MHz, CDCl3) 7.77 (2H, 
d, J = 8.5 Hz, 2 × ArCH), 7.42 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.70 (1H, ddt, J = 10.0, 3.5, 3.0 Hz, 
C5-H), 5.46 (1H, ddt, J = 10.0, 2.5, 2.5 Hz, C4-H), 3.23 (2H, br s, C1-H2), 2.49 (3H, s, Ts CH3), 2.30 – 
2.19 (1H, m, C3-H), 1.96 (2H, m, C6-H2), 1.81 – 1.73 (1H, m, C8-H), 1.72 – 1.64 (1H, m, C7-H), 1.60 
– 1.41 (3H, m, C2-H2 and C7-H’), 1.18 (1H, dddd, J = 13.0, 10.5, 8.0, 2.5 Hz, C8-H’). δC (101 MHz, 
CDCl3) 146.3 (ArC), 130.1 (ArCH), 130.0 (C4), 129.6 (ArCH), 129.0 (ArC), 128.2 (C5), 50.8 (C1), 
32.7 (C2), 32.2 (C3), 28.5 (C8), 25.1 (C6), 21.8 (Ts CH3), 21.0 (C7). The 
13C signals corresponding to 
the trifluoroacetyl group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -73.2 
(3F, s). HRMS: (ESI+) Calculated for C17H20F3NNaO4S: 414.0957. Found [M+Na]+: 414.0965. 
N-((1H-Imidazole-1-carbonyl)oxy)-N-(2-(cyclohex-2-en-1-yl)ethyl)-4-toluenesulfonamide (103d) 
 
To a solution of carbonyl diimidazole (82.2 mg, 0.507 mmol) in anhydrous CH2Cl2 (4 mL) at 0 °C was 
added a solution of N-2-(cyclohex-2-en-1-yl)ethyl-N-hydroxy-4-toluenesulfonamide (vide supra, 
150 mg, 0.507 mmol) in anhydrous CH2Cl2 (4 mL) dropwise. The reaction mixture was stirred at room 
temperature for 2.5 hours before being concentrated in vacuo, dissolved in Et2O (30 mL) and washed 
with water (4 × 25 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. FCC 
(eluent: 1:1 hexane:EtOAc) afforded 103d (88.0 mg, 44 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3129 (m), 3021 (m), 2922 (m), 1792 (s), 1597 (m), 1358 (s), 1163 (s). δH (400 MHz, 
CDCl3) 8.02 (1H, dd, J = 1.0, 1.0 Hz, ArCH), 7.76 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.40 (2H, d, J = 
8.5 Hz, 2 × ArCH), 7.33 (1H, dd, J = 1.5, 1.0 Hz, ArCH), 7.09 (1H, dd, J = 1.5, 1.0 Hz, ArCH), 5.70 – 
5.60 (1H, m, C5-H), 5.44 (1H, ddt, J = 10.0, 2.5, 2.5 Hz, C4-H), 3.28 (2H, br s, C1-H2), 2.46 (3H, s, 
Ts CH3), 2.27 (1H, ddddd, J = 11.0, 8.5, 6.0, 5.5, 2.5 Hz, C3-H), 1.97 – 1.86 (2H, m, C6-H2), 1.75 (1H, 
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dddd, J = 12.5, 8.5, 6.0, 3.0 Hz, C8-H), 1.70 – 1.56 (2H, m, C2-H and C7-H), 1.56 – 1.41 (2H, m, C2-H’ 
and C7-H’), 1.16 (1H, dddd, J = 12.5, 11.0, 8.5, 3.0 Hz, C8-H’). δC (101 MHz, CDCl3) 146.7 (C=O or 
ArC), 146.4 (C=O or ArC), 136.9 (ArCH), 131.3 (ArCH), 130.2 (ArCH), 130.1 (C4), 129.5 (ArCH), 
129.4 (ArC), 128.1 (C5), 117.1 (ArCH), 50.9 (C1), 32.8 (C2), 32.2 (C3), 28.5 (C8), 25.1 (C6), 21.7 
(Ts CH3), 21.0 (C7). HRMS: (ESI+) Calculated for C19H24N3O4S: 390.1482. Found [M+H]+: 390.1482. 
N-(Benzoyloxy)-N-(2-(cyclohex-2-en-1-yl)ethyl)-4-toluenesulfonamide (103e) 
 
To a solution of N-2-(cyclohex-2-en-1-yl)ethyl-N-hydroxy-4-toluenesulfonamide (vide supra, 100 mg, 
0.339 mmol) in anhydrous CH2Cl2 (7 mL) at 0 °C was added BzCl (48 µL, 0.407 mmol) followed by 
Et3N (0.10 mL, 0.717 mmol). The reaction mixture was stirred at room temperature for 22 hours before 
addition of saturated aqueous NaHCO3 (20 mL). The resulting phases were separated, and the aqueous 
phase was extracted with CH2Cl2 (3 × 15 mL). The combined organic phases were washed with brine 
(25 mL), dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 39:1 PhMe:EtOAc) afforded 103e 
(75.0 mg, 55 %) as a colourless oil. νmax / cm-1: (film) 2926 (m), 2857 (m), 1768 (s), 1598 (m), 1451 (m), 
1363 (s), 1233 (s), 1170 (s). δH (400 MHz, CDCl3) 7.99 – 7.92 (2H, m, 2 × ArCH), 7.82 (2H, d, J = 
8.5 Hz, 2 × ArCH), 7.65 – 7.59 (1H, m, ArCH), 7.51 – 7.42 (2H, m, 2 × ArCH), 7.38 (2H, d, J = 8.5 Hz, 
2 × ArCH), 5.65 (1H, dtd, J = 10.0, 3.5, 2.5 Hz, C5-H), 5.50 – 5.44 (1H, m, C4-H), 3.32 (2H, s, C1-H2), 
2.47 (3H, s, Ts CH3), 2.35 – 2.23 (1H, m, C3-H), 1.93 (2H, dddd, J = 5.5, 5.5, 3.5, 2.5 Hz, C6-H2), 1.77 
(1H, dddd, J = 12.5, 6.0, 6.0, 2.5 Hz, C8-H), 1.71 – 1.44 (4H, m, C2-H2 and C7-H2), 1.18 (1H, dddd, 
J = 12.5, 11.0, 8.5, 3.0 Hz, C8-H’). δC (101 MHz, CDCl3) 163.4 (C=O), 145.5 (ArC), 133.9 (ArCH), 
130.6 (ArC or C4), 130.4 (ArC or C4), 2 × 129.8 (2 × ArCH), 129.5 (ArCH), 128.7 (ArCH), 127.7  
(C5), 127.3 (ArC), 50.6 (C1), 32.9 (C2), 32.4 (C3), 28.6 (C8), 25.2 (C6), 21.7 (Ts CH3), 21.1 (C7).  
HRMS: (ESI+) Calculated for C22H26NO4S: 400.1577. Found [M+H]+: 400.1593. 
2,4-Dinitrobenzoyl chloride 
 
To a solution of 2,4-dinitrobenzoic acid (2.00 g, 9.43 mmol) in anhydrous PhMe (10 mL) was added 
thionyl chloride (1.03 mL, 14.1 mmol). The reaction mixture was heated at reflux for 16 hours before 
being concentrated in vacuo to afford the title compound (2.12 g, 98 %) as an amorphous orange solid, 
which was used without further purification. νmax / cm-1: (solid) 3099 (m), 2882 (m), 1781 (s), 1720 (s), 
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1600 (m), 1531 (s), 1343 (s). δH (400 MHz, CDCl3) 8.98 (1H, d, J = 2.0 Hz, ArCH), 8.65 (1H, dd, J = 
8.5, 2.0 Hz, ArCH), 7.90 (1H, d, J = 8.5 Hz, ArCH). δC (126 MHz, CDCl3) 164.5 (C=O), 149.3 (ArC), 
145.3 (ArC), 137.1 (ArC), 129.5 (ArCH), 128.9 (ArCH), 120.5 (ArCH). m/z (EI+) 195 ([M-Cl]+, 
100 %), 91 (75 %). 
N-(2-(Cyclohex-2-en-1-yl)ethyl)-N-((2,4-dinitrobenzoyl)oxy)-4-toluenesulfonamide (103f) 
 
To a reaction vessel charged with N-2-(cyclohex-2-en-1-yl)ethyl-N-hydroxy-4-toluenesulfonamide 
(vide supra, 150 mg, 0.508 mmol) and 2,4-dinitrobenzoyl chloride (141 mg, 0.612 mmol) in an ice bath 
was added anhydrous CH2Cl2 (5 mL) followed by Et3N (0.14 mL, 1.02 mmol). The reaction mixture 
was stirred at room temperature for two hours before addition of saturated aqueous NaHCO3 (10 mL). 
The resulting phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 × 15 mL). 
The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
9:1 hexane: EtOAc) afforded 103f (190 mg, 76 %) as a green crystalline solid. m.p. 118-119 °C 
(Et2O:hexane). νmax / cm-1: (solid) 3115 (m), 2926 (m), 1785 (s), 1603 (m), 1538 (s), 1347 (s).  
δH (400 MHz, CDCl3) 8.96 (1H, d, J = 2.0 Hz, ArCH), 8.64 (1H, dd, J = 8.5, 2.0 Hz, ArCH), 8.01 (1H, 
d, J = 8.5 Hz, ArCH), 7.71 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.35 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.69 
(1H, ddt, J = 10.0, 3.0, 3.0 Hz, C5-H), 5.53 (1H, ddt, J = 10.0, 2.0, 2.0 Hz, C4-H), 3.22 (2H, br s, 
C1-H2), 2.45 (3H, s, Ts CH3), 2.40 – 2.31 (1H, m, C3-H), 1.99 – 1.93 (2H, m, C6-H2), 1.84 – 1.75 (2H, 
m, C2-H and C8-H), 1.74 – 1.64 (2H, m, C2-H’ and C7-H), 1.59 – 1.48 (1H, m, C7-H’), 1.27 – 1.17 
(1H, m, C8-H’). δC (126 MHz, CDCl3) 161.9 (C=O), 149.2 (ArC), 146.5 (ArC), 146.0 (ArC), 131.7 
(ArC), 131.3 (ArCH), 130.5 (C4), 130.1 (ArCH), 130.0 (ArC), 129.4 (ArCH), 128.5 (ArCH), 127.9 
(C5), 120.0 (ArCH), 51.0 (C1), 32.6 (C2), 32.2 (C3), 28.5 (C8), 25.2 (C6), 21.8 (Ts CH3), 21.1 (C7). 
HRMS: (ESI+) Calculated for C22H23N3NaO8S: 512.1098. Found [M+Na]+: 512.1097. 
  




indole 7,7-dioxide (120) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% P(3,5-(CF3)2C6H3)3; 200 mol% Et3N; 
DMF (0.08 M); 100 °C; 2.5 hours. Substrate 103f (40.0 mg, 818 µmol) was employed. FCC (gradient 
elution: 19:1 – 14:1 – 9:1 – 4:1 hexane:EtOAc) afforded 104 (0.9 mg, 4 %) as a pale-yellow oil and 120 
(9.3 mg, 41 %) as a colourless crystalline solid. Characterisation data for 120: m.p. 202-204 °C 
(CH2Cl2:hexane). νmax / cm-1: (solid) 2934 (m), 2852 (m), 1605 (m), 1444 (m), 1283 (s), 1140 (s). 
δH (500 MHz, CDCl3) 7.78 (1H, d, J = 8.0 Hz, ArCH), 7.19 (1H, dd, J = 8.0, 1.5 Hz, ArCH), 7.06 (1H, 
d, J = 1.5 Hz, ArCH), 3.95 (1H, dd, J = 4.0, 4.0 Hz, C4-H), 3.86 (1H, ddd, J = 10.5, 10.5, 1.5 Hz, C1-H), 
3.42 (1H, ddd, J = 10.5, 10.5, 7.5 Hz, C1-H’), 2.94 (1H, ddd, J = 12.5, 4.5, 4.0 Hz, C5-H), 2.42 – 2.34 
(4H, m, C3-H and Ar CH3), 2.02 (1H, dddd, J = 13.0, 10.5, 10.5, 6.0 Hz, C2-H), 1.82 – 1.66 (4H, m, 
C2-H’, C6-H, C7-H and C8-H), 1.64 – 1.55 (1H, m, C6-H’), 1.41 (1H, ddddd, J = 13.0, 13.0, 13.0, 3.0, 
3.0 Hz, C7-H’), 1.30 – 1.21 (1H, m, C8-H’). δC (126 MHz, CDCl3) 142.7 (ArC), 140.5 (ArC), 134.0 
(ArC), 129.7 (ArCH), 128.4 (ArCH), 124.0 (ArCH), 61.1 (C4), 41.4 (C1), 40.1 (C5), 39.2 (C3), 30.0 
(C6), 29.8 (C2), 26.5 (C8), 24.5 (C7), 21.6 (Ar CH3). HRMS: (ESI+) Calculated for C15H20NO2S: 
278.1209. Found [M+H]+: 278.1209. Characterisation data for 104 has been provided earlier. 
 
ORTEP view of 120. 
  





General procedure E: TsNHOTBS (vide supra, 603 mg, 2.00 mmol) was employed with 
(E)-hex-4-en-1-ol (87) (1.5 eq.). The reaction time was 17 hours. FCC (eluent: 1:1 hexane:PhMe) 
afforded 88 (700 mg, 91 %) as a pale-yellow oil. νmax / cm-1: (film) 2930 (m), 2858 (m), 1598 (m), 
1463 (m), 1356 (s), 1169 (s). δH (400 MHz, CDCl3) 7.72 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.32 (2H, d, 
J = 8.5 Hz, 2 × ArCH), 5.45 – 5.28 (2H, m, C4-H and C5-H), 2.88 (2H, t, J = 7.5 Hz, C1-H2), 2.44 (3H, 
s, Ts CH3), 1.96 (2H, dt, J = 7.5, 7.0 Hz, C3-H2), 1.64 – 1.55 (5H, m, C2-H2 and C6-H3), 0.91 (9H, s, 
SiC(CH3)3), 0.28 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 144.6 (ArC), 130.2 (ArC), 2 × 130.0 (ArCH 
and C4), 129.3 (ArCH), 126.0 (C5), 55.6 (C1), 30.0 (C3), 26.9 (C2), 26.2 (SiC(CH3)3), 21.8 (Ts CH3), 
18.4 (SiC(CH3)3) 18.0 (C6), -4.1 (Si(CH3)2). HRMS: (ESI+) Calculated for C19H34NO3SSi: 384.2023. 
Found [M+H]+: 384.2024. 
(E)-N-(Hex-4-en-1-yl)-N-hydroxy-4-toluenesulfonamide  
 
General procedure B: Compound 88 (630 mg, 1.63 mmol) was employed. The title compound 
(400 mg, 91 %) was isolated as a colourless crystalline solid. νmax / cm-1: (solid) 3356 (br s), 2941 (m), 
2854 (m), 1596 (m), 1453 (m), 1330 (s), 1162 (s). δH (400 MHz, CDCl3) 7.77 (2H, d, J = 8.5 Hz, 2 × 
ArCH), 7.35 (2H, d, J = 8.5 Hz, 2 × ArCH), 6.17 (1H, s, OH), 5.49 – 5.32 (2H, m, C4-H and C5-H), 
2.89 (2H, t, J = 7.0 Hz, C1-H2), 2.45 (3H, s, Ts CH3), 2.03 (2H, dt, J = 7.0, 7.0 Hz, C3-H2), 1.70 – 1.57 
(5H, m, C2-H2 and C6-H3). δC (101 MHz, CDCl3) 145.0 (ArC), 130.1 (C4), 129.8 (ArCH), 129.7 
(ArCH), 129.6 (ArC), 126.1 (C5), 52.1 (C1), 29.6 (C3), 26.7 (C2), 21.8 (Ts CH3), 18.1 (C6).  
HRMS: (ESI+) Calculated for C13H20NO3S: 270.1158. Found [M+H]+: 270.1148. 
(E)-N-(Hex-4-en-1-yl)-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (125) 
 
General procedure C: The preceding compound (380 mg, 1.41 mmol) was employed. FCC (eluent: 
14:1 hexane:EtOAc) afforded 125 (560 mg, 86 %, 11:1 mixture of (E)- and (Z)-isomers) as a colourless 
crystalline solid. Spectroscopic data for the major (E)-isomer: νmax / cm-1: (solid) 2936 (m), 1787 (s), 
1652 (m), 1597 (m), 1504 (s), 1170 (s). δH (500 MHz, CDCl3) 7.79 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.37 
(2H, d, J = 8.5 Hz, 2 × ArCH), 5.44 (1H, dqt, J = 15.0, 6.0, 1.5 Hz, C5-H), 5.34 (1H, dtq, J = 15.0, 7.0, 
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1.5 Hz, C4-H), 3.21 (2H, br s, C1-H2), 2.46 (3H, s, Ts CH3), 2.11 (2H, dtd, J = 7.0, 7.0, 1.5 Hz, C3-H2), 
1.65 – 1.59 (5H, m, C2-H2 and C6-H3). δC (126 MHz, CDCl3) 156.3 (C=O), 145.8 (ArC), 130.1 (ArC), 
129.8 (ArCH), 129.6 (ArCH), 129.3 (C4), 126.5 (C5), 52.0 (C1), 29.2 (C3), 26.4 (C2), 21.7 (Ts CH3), 
17.9 (C6). The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.0 (2F, m), -146.1 (1F, tt, J = 
21.0, 5.5 Hz), -158.9 – -159.1 (2F, m). Characteristic signals for the (Z)-isomer (obtained from 
1D TOCSY): δH (500 MHz, CDCl3) 5.53 – 5.46 (m), 5.35 – 5.25 (m), 3.20 (s), 2.19 (dt, J = 7.5, 7.5 Hz), 
1.66 – 1.58 (m). HRMS: (ESI+) Calculated for C20H18F5NNaO4S: 486.0769. Found [M+Na]+: 486.0760. 
1-Tosyl-2-vinylpyrrolidine (12) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; 3:1 THF:DMF (0.1 M); 110 °C; 8 hours. Substrate 125 (65.0 mg, 0.140 mmol) was employed. 
FCC (eluent: 9:1 hexane:EtOAc) afforded 12 (28.4 mg, 81 %) as a colourless crystalline solid. 
m.p. 69-70 °C (Et2O:hexane) [Lit., 70 °C (no recrystallisation solvent quoted)]205. νmax / cm-1: (solid) 
2986 (m), 2884 (m), 1595 (m), 1460 (m), 1335 (s), 1154 (s). δH (400 MHz, CDCl3) 7.71 (2H, d, J = 
8.0 Hz), 7.30 (2H, d, J = 8.0 Hz), 5.80 (1H, ddd, J = 17.0, 10.0, 6.0 Hz), 5.27 (1H, ddd, J = 17.0, 1.5, 
1.5 Hz), 5.11 (1H, ddd, J = 10.0, 1.5, 1.5 Hz), 4.13 (1H, ddddd, J = 6.0, 6.0, 6.0, 1.5, 1.5 Hz), 3.44 (1H, 
ddd, J = 10.0, 7.0, 4.5 Hz), 3.23 (1H, ddd, J = 10.0, 7.5, 7.5 Hz), 2.42 (3H, s), 1.87 – 1.73 (1H, m), 1.73 
– 1.55 (3H, m). δC (101 MHz, CDCl3) 143.4, 138.8, 135.3, 129.7, 127.6, 115.4, 62.0, 48.9, 32.4, 23.9, 
21.6. m/z (ESI+) 274 ([M+Na]+, 100 %), 252 ([M+H]+, 20 %). The spectroscopic properties were 
consistent with the data available in the literature.205 
(E)-6-Phenylhex-4-en-1-ol (121) 
 
To a solution of Grubbs-Hoveyda 2nd generation catalyst (62.7 mg, 0.100 mmol) in anhydrous CH2Cl2 
(120 mL, sparged with argon) was added 4-penten-1-ol (1.03 mL, 10.0 mmol) and allyl benzene 
(13.2 mL, 100 mmol). The reaction mixture was heated at reflux for 14 hours before being concentrated 
in vacuo. FCC (eluent: 5:1 PhMe:EtOAc) afforded 121 (835 mg, 47 %, 6:1 mixture of (E)- and 
(Z)-isomers) as a light-brown oil (the colouration was due to the presence of trace amounts of 
Ru-impurities). Spectroscopic data for the major (E)-isomer: νmax / cm-1: (film) 3381 (br s), 3027 (m), 
2933 (m), 1693 (m), 1600 (m), 1452 (m), 1052 (s). δH (400 MHz, CDCl3) 7.36 – 7.28 (2H, m), 7.25 – 
7.18 (3H, m), 5.65 (1H, dt, J = 15.0, 6.5 Hz), 5.55 (1H, dt, J = 15.0, 7.0 Hz), 3.66 (2H, t, J = 6.5 Hz), 
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3.37 (2H, d, J = 6.5 Hz), 2.14 (2H, dt, J = 7.0, 6.5 Hz), 1.96 (1H, br s), 1.71 – 1.63 (2H, m). δC (101 MHz, 
CDCl3) 140.9, 131.1, 129.6, 128.5, 128.4, 125.6, 62.4, 39.1, 32.4, 28.8. Characteristic signals for the 
minor (Z)-isomer: δH (400 MHz, CDCl3) 3.45 (2H, d, J = 7.0 Hz), 2.28 (1H, dt, J = 7.0, 7.0 Hz). The 
spectroscopic properties were consistent with the data available in the literature.206,207 
(E)-N-(6-Phenylhex-4-en-1-yl)-N-((tert-butyldimethylsilyl)oxy)-4-toluenesulfonamide 
 
General procedure E: TsNHOTBS (vide supra, 1.00 g, 3.32 mmol) was employed with alcohol 121 
(1.3 eq.). The reaction time was 20 hours. FCC (eluent: 1:1 hexane:PhMe) afforded the title compound 
(1.28 g, 84 %, 6:1 mixture of (E)- and (Z)-isomers) as a colourless oil. νmax / cm-1: (film) 2955 (m), 
2930 (m), 2858 (m), 1598 (m), 1355 (s), 1168 (s). Spectroscopic data for the major (E)-isomer:  
δH (400 MHz, CDCl3) 7.71 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.34 – 7.25 (4H, m, 4 × ArCH), 7.23 – 7.12 
(3H, m, 3 × ArCH), 5.57 (1H, dtt, J = 14.5, 6.5, 1.5 Hz, C5-H), 5.48 – 5.39 (1H, m, C4-H), 3.32 (2H, 
d, J = 6.5 Hz, C6-H2), 2.93 – 2.87 (2H, m, C1-H2), 2.44 (3H, s, Ts CH3), 2.04 (2H, br td, J = 7.0, 6.5 Hz, 
C3-H2), 1.64 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 0.92 (9H, s, SiC(CH3)3), 0.29 (6H, s, Si(CH3)2).  
δC (101 MHz, CDCl3) 144.4 (ArC), 140.7 (ArC), 130.3 (C4), 2 × 130.0 (C5 and ArC), 129.9 (ArCH), 
129.2 (ArCH), 2 × 128.4 (2 × ArCH), 125.9 (ArCH), 55.4 (C1), 39.0 (C6), 29.8 (C3), 26.7 (C2), 26.0 
(SiC(CH3)3), 21.6 (Ts CH3), 18.3 (SiC(CH3)3), -4.2 (Si(CH3)2). HRMS: (ESI+) Calculated for 
C25H38NO3SSi: 460.2336. Found [M+H]+: 460.2335. Characteristic signals for the minor (Z)-isomer: 
δH (400 MHz, CDCl3) 3.37 (2H, d, J = 7.5 Hz), 2.16 (2H, dt, J = 7.5, 7.5 Hz). 
(E)-N-(6-Phenylhex-4-en-1-yl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure B: The preceding compound (1.28 g, 2.78 mmol) was employed. The title 
compound (685 mg, 71 %, 6:1 mixture of (E)- and (Z)-isomers) was isolated as a colourless oil. 
Spectroscopic data for the major (E)-isomer: νmax / cm-1: (film) 3385 (br s), 3026 (m), 2923 (s), 
1597 (m), 1342 (s), 1166 (s). δH (400 MHz, CDCl3) 7.76 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.34 (2H, d, 
J = 8.5 Hz, 2 × ArCH), 7.31 – 7.24 (2H, m, 2 × ArCH), 7.21 – 7.14 (3H, m, 3 × ArCH), 6.70 (1H, br s, 
OH), 5.60 (1H, dtt, J = 14.5, 6.5, 1.0 Hz, C5-H), 5.51 – 5.42 (1H, m, C4-H), 3.32 (2H, d, J = 6.5 Hz, 
C6-H2), 2.91 (2H, t, J = 7.0 Hz, C1-H2), 2.44 (3H, s, Ts CH3), 2.11 (2H, br dt, J = 6.5, 6.5 Hz, C3-H2), 
1.70 (2H, tt, J = 7.0, 6.5 Hz, C2-H2). δC (101 MHz, CDCl3) 144.8 (ArC), 140.8 (ArC), 130.4 (C5), 130.0 
(C4), 129.7 (ArCH), 129.5 (ArCH), 129.4 (ArC), 128.4 (ArCH), 128.3 (ArCH), 125.9 (ArCH), 52.0 
(C1), 39.0 (C6), 29.4 (C3), 26.4 (C2), 21.7 (Ts CH3). HRMS: (ESI+) Calculated for C19H23NNaO3S: 
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368.1291. Found [M+Na]+: 368.1284. Characteristic signals for the minor (Z)-isomer: δH (400 MHz, 
CDCl3) 3.39 (2H, d, J = 7.0 Hz), 2.24 (2H, dt, J = 7.5, 7.5 Hz). 
(E)-N-(6-Phenylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)-4-toluenesulfonamide (126) 
 
General procedure C: The preceding compound (650 mg, 1.88 mmol) was employed. FCC (eluent: 
14:1 hexane:EtOAc) afforded 126 (832 mg, 82 %, 7:1 mixture of (E)- and (Z)-isomers) as a colourless 
crystalline solid. Spectroscopic data for the major (E)-isomer: νmax / cm-1: (solid) 2970 (m), 2920 (m), 
1784 (s), 1655 (m), 1598 (m), 1494 (s), 1167 (s). δH (400 MHz, CDCl3) 7.76 (2H, d, J = 8.5 Hz, 2 × 
ArCH), 7.35 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.30 – 7.23 (2H, m, 2 × ArCH), 7.21 – 7.13 (3H, m, 3 × 
ArCH), 5.60 (1H, dt, J = 15.0, 6.5 Hz, C5-H), 5.43 (1H, dt, J = 15.0, 7.0 Hz, C4-H), 3.31 (2H, d, J = 
6.5 Hz, C6-H2), 3.20 (2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 2.17 (2H, dt, J = 7.0, 7.0 Hz, C3-H2), 1.65 
(2H, tt, J = 7.0, 7.0 Hz, C2-H2). δC (101 MHz, CDCl3) 146.0 (ArC), 140.8 (ArC), 130.8 (C5), 130.2 
(ArC), 130.0 (ArCH), 129.9 (C4), 129.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 126.1 (ArCH), 52.2 
(C1), 39.1 (C6), 29.3 (C3), 26.5 (C2), 21.9 (Ts CH3). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.9 – -136.0 (2F, m), -146.1 (1F, tt, J = 21.0, 5.5 Hz), -158.9 – -159.1 (2F, m). HRMS: (ESI+) 
Calculated for C26H22F5NNaO4S: 562.1082. Found [M+Na]+: 562.1072. Characteristic signals for the 
minor (Z)-isomer: δH (400 MHz, CDCl3) 3.40 (2H, d, J = 7.5 Hz), 2.32 (2H, dt, J = 7.0, 7.0 Hz). 
(E)-2-Styryl-1-tosylpyrrolidine (128) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; n-BuCN (0.1 M); 110 °C; 15 hours. Substrate 126 (75.5 mg, 0.140 mmol) was employed. FCC 
(eluent: 9:1 hexane:EtOAc) afforded 128 (35.4 mg, 77 %) as a pale-yellow oil. δH (400 MHz, CDCl3) 
7.72 (2H, d, J = 8.0 Hz), 7.33 – 7.18 (7H, m), 6.54 (1H, d, J = 16.0 Hz), 6.04 (1H, dd, J = 16.0, 6.5 Hz), 
4.34 (1H, ddd, J = 7.0, 6.5, 4.5 Hz), 3.48 (1H, ddd, J = 10.0, 7.0, 4.5 Hz), 3.34 (1H, ddd, J = 10.0, 7.0, 
7.0 Hz), 2.39 (3H, s), 1.94 – 1.79 (2H, m), 1.77 – 1.65 (2H, m). δC (101 MHz, CDCl3) 143.3, 136.7, 
135.7, 130.7, 130.1, 129.7, 128.6, 127.7, 127.6, 126.6, 61.8, 48.8, 32.9, 24.1, 21.6. The spectroscopic 
properties were consistent with the data available in the literature.208 
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Methyl (E)-6-hydroxyhex-2-enoate (122) 
 
To a solution of Grubbs-Hoveyda 2nd generation catalyst (15.7 mg, 25.0 μmol) in anhydrous CH2Cl2 
(40 mL, argon sparged) was added methyl acrylate (2.25 mL, 25.0 mmol) and pent-4-en-1-ol (0.26 mL, 
2.50 mmol). The reaction mixture was heated at reflux for 15 hours before being concentrated in vacuo. 
FCC (eluent: 2:1 hexane:EtOAc) afforded 122 (357 mg, 99 %) as a light-brown oil (the colouration was 
due to the presence of trace amounts of Ru-impurities). νmax / cm-1: (film) 3417 (br s), 2950 (m), 1720 (s), 
1656 (s), 1436 (s), 1272 (s). δH (400 MHz, CDCl3) 6.98 (1H, dt, J = 15.5, 7.0 Hz), 5.85 (1H, dt, J = 
15.5, 1.5 Hz), 3.72 (3H, s), 3.67 (2H, t, J = 6.5 Hz), 2.30 (2H, dtd, J = 7.0, 7.0, 1.5 Hz), 1.77 – 1.68 
(2H, m), 1.51 (1H, br s). δC (101 MHz, CDCl3) 167.2, 148.9, 121.4, 62.1, 51.6, 31.0, 28.7. The 
spectroscopic properties were consistent with the data available in the literature.209 
Methyl (E)-6-((N-(pentafluorobenzoyloxy)-4-tolyl)sulfonamido)hex-2-enoate (127) 
 
General procedure K: Alcohol 122 (115 mg, 0.800 mmol) was employed with TsNHOFBz (vide 
supra). The reaction time was 16 hours. FCC (eluent: 49:1 PhMe:EtOAc) afforded 127 (310 mg, 76 %) 
as a colourless crystalline solid. m.p. 118-119 °C (CH2Cl2:hexane, needles). νmax / cm-1: (solid) 
2953 (m), 1790 (s), 1706 (s), 1595 (m), 1501 (s), 1168 (s). δH (400 MHz, CDCl3) 7.79 (2H, d, J = 
8.0 Hz, 2 × ArCH), 7.38 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.90 (1H, dt, J = 15.5, 7.0 Hz, C4-H), 5.85 (1H, 
dt, J = 15.5, 1.5 Hz, C5-H), 3.72 (3H, s, OCH3), 3.24 (2H, br s, C1-H2), 2.47 (3H, s, Ts CH3), 2.42 (2H, 
tdd, J = 7.5, 7.0, 1.5 Hz, C3-H2), 1.72 (2H, tt, J = 7.5, 7.0 Hz, C2-H2). δC (101 MHz, CDCl3) 166.8 
(C6), 147.2 (C4), 146.0 (ArC), 2 × 129.9 (ArC and ArCH), 129.6 (ArCH), 122.1 (C5), 51.8 (C1), 51.5 
(OCH3), 28.8 (C3), 25.0 (C2), 21.7 (Ts CH3). The 
13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.8 – -136.0 (2F, m), 
-145.7 (1F, tt, J = 20.5, 5.0 Hz), -158.7 – -159.0 (2F, m). HRMS: (ESI+) Calculated for 
C21H18F5NNaO6S: 530.0667. Found [M+Na]+: 530.0662. 
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Methyl (E)-2-(1-tosylpyrrolidin-2-ylidene)acetate (129) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 15 hours. Substrate 127 (71.0 mg, 0.140 mmol) was 
employed. FCC (gradient elution: 3:1 – 2:1 hexane:EtOAc) afforded 129 (32.4 mg, 78 %) as a pale-
yellow oil. The product was assigned as the (E)-isomer based on the observed NOE correlation between 
the C5 and the aromatic protons. νmax / cm-1: (film) 2950 (m), 1707 (s), 1620 (s), 1346 (s), 1129 (s). 
δH (400 MHz, CDCl3) 7.75 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.32 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.03 
(1H, t, J = 2.0 Hz, C5-H), 3.76 (2H, t, J = 7.0 Hz, C1-H2), 3.64 (3H, s, OCH3), 3.03 (2H, td, J = 7.5, 
2.0 Hz, C3-H2), 2.42 (3H, s, Ts CH3), 1.88 (2H, tt, J = 7.5, 7.0 Hz, C2-H2). δC (101 MHz, CDCl3) 168.3 
(C6), 156.9 (C4), 145.0 (ArC), 134.3 (ArC), 130.0 (ArCH), 127.4 (ArCH), 94.9 (C5), 51.6 (C1), 51.0 
(OCH3), 32.4 (C3), 21.7 (Ts CH3), 21.3 (C2). HRMS: (ESI+) Calculated for C14H17NNaO4S: 318.0770. 
Found [M+Na]+: 318.0780.  
(E)-Hex-4-enal (132) 
 
This compound was prepared according to a literature procedure.125 A solution of (E)-hex-4-en-1-ol 
(87) (6.01 g, 60.0 mmol), (MeCN)4CuOTf (1.13 g, 3.00 mmol), 2,2’-bipyridine (469 mg, 3.00 mmol), 
TEMPO (469 mg, 3.00 mmol) and N-methylimidazole (0.48 mL, 6.00 mmol) in MeCN (250 mL) was 
stirred at room temperature under an atmosphere of O2 (balloon pressure) for 5 hours. The reaction 
mixture was poured into water (400 mL) and extracted with pentane (4 × 200 mL). The combined 
organic phases were washed with brine (300 mL), dried over Na2SO4 and concentrated in vacuo to 
afford 132 (3.78 g, 64 %) as an orange oil, which was used without further purification. δH (400 MHz, 
CDCl3) 9.77 (1H, t, J = 1.5 Hz), 5.57 – 5.36 (2H, m), 2.52 – 2.47 (2H, m), 2.33 (2H, dt, J = 7.0, 7.0 Hz), 
1.65 (3H, dd, J = 6.0, 1.0 Hz). δC (101 MHz, CDCl3) 202.3, 128.8, 126.3, 43.4, 25.1, 17.8. The 
spectroscopic properties were consistent with the data available in the literature.125 
  





To a solution of phenylmagnesium bromide (16.0 mmol) in anhydrous Et2O (26 mL) at 0 °C was added 
a solution of aldehyde 132 (vide supra, 981 mg, 10.0 mmol) in anhydrous Et2O (5 mL). The reaction 
mixture was stirred at 0 °C for 2 hours before addition of saturated aqueous NH4Cl (15 mL). The 
resulting phases were separated, and the aqueous phase was extracted with Et2O (2 × 20 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
7:1 hexane:EtOAc) afforded 133 (1.33 g, 75 %) as a pale-yellow oil. δH (400 MHz, CDCl3) 7.37 – 7.32 
(4H, m), 7.31 – 7.24 (1H, m), 5.52 – 5.39 (2H, m), 4.68 (1H, ddd, J = 7.5, 5.5, 3.5 Hz), 2.17 – 1.99 (2H, 
m), 1.98 – 1.94 (1H, m), 1.91 – 1.71 (2H, m), 1.67 – 1.63 (3H, m). δC (101 MHz, CDCl3) 144.8, 130.7, 
128.6, 127.6, 126.0, 125.7, 74.2, 38.9, 29.1, 18.1. HRMS: (ESI+) Calculated for C12H16NaO: 199.1093. 




This compound was synthesised by a route starting with alkylation of ethyl benzoylacetate with 
technical grade crotyl bromide. Because of this, the product contains a significant amount of the 
(Z)-isomer as an impurity. General procedure E: TsNHOTBS (vide supra, 800 mg, 2.65 mmol) was 
employed with alcohol 133 (1.3 eq.). The reaction time was 15 hours. FCC (eluent: 1:1 hexane:PhMe) 
afforded 92 (1.09 g, 89 %, 5:1 mixture of (E)- and (Z)-isomers) as a colourless oil. Spectroscopic data 
for the major (E)-isomer: νmax / cm-1: (film) 2930 (m), 2858 (m), 1598 (m), 1453 (m), 1360 (s), 1167 (s). 
δH (400 MHz, CDCl3) 7.60 – 7.55 (2H, m, 2 × ArCH), 7.24 – 7.19 (2H, m, 2 × ArCH), 7.16 – 7.12 (5H, 
m, 5 × ArCH), 5.30 – 5.10 (2H, m, C4-H and C5-H), 4.68 (1H, dd, J = 10.0, 4.0 Hz, C1-H), 2.38 (3H, 
s, Ts CH3), 1.93 – 1.80 (2H, m, C3-H2), 1.76 – 1.64 (1H, m, C2-H), 1.62 – 1.58 (3H, m, C6-H3), 1.49 – 
1.40 (1H, m, C2-H’), 0.93 (9H, s, SiC(CH3)3), 0.28 (3H, s, SiCH3), -0.07 (3H, s, Si(CH3)’). 
δC (101 MHz, CDCl3) 143.9 (ArC), 137.6 (ArC), 133.4 (ArC), 130.0 (C4), 129.3 (ArCH), 129.2 
(ArCH), 129.1 (ArCH), 127.9 (ArCH), 127.6 (ArCH), 125.9 (C5), 65.6 (C1), 2 × 29.8 (C2 and C3), 
26.5 (SiC(CH3)3), 21.7 (Ts CH3), 18.8 (SiC(CH3)3), 18.1 (C6), -3.9 (SiCH3), -4.3 (Si(CH3)’). 
HRMS: (ESI+) Calculated for C25H37NNaO3SSi: 482.2156. Found [M+Na]+: 482.2135. Characteristic 
signals for the minor (Z)-isomer (obtained from 1D TOCSY): δH (500 MHz, CDCl3) 5.44 – 5.39 (m), 
5.20 – 5.13 (m), 4.72 (dd, J = 10.0, 4.0 Hz), 1.93 – 1.79 (m), 1.41 (dd, J = 7.0, 1.5 Hz).  





General procedure B: Compound 92 (1.07 g, 2.33 mmol) was employed. FCC (gradient elution: 9:1 
– 4:1 hexane:EtOAc) was required to separate deprotected product from unconsumed 92 (490 mg 
recovered, 46 %) and afforded the title compound (360 mg, 45 %) as a colourless crystalline solid. This 
compound was used in the following step with minimal delay due to concerns about its stability.  
δH (400 MHz, CDCl3) 7.53 (2H, d, J = 8.0 Hz), 7.22 – 7.18 (2H, m), 7.16 – 7.04 (5H, m), 5.87 (1H, s), 
5.49 – 5.29 (2H, m), 4.83 – 4.76 (1H, m), 2.34 (3H, s), 2.01 – 1.83 (3H, m), 1.65 – 1.55 (4H, m). 
N-(1-Phenylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)-4-toluenesulfonamide (134a) 
 
General procedure C: The preceding compound (350 mg, 1.01 mmol) was employed. FCC (gradient 
elution: 24:1 – 14:1 hexane:EtOAc) afforded 134a (452 mg, 83 %, presumed mixture of (E) and 
(Z)-isomers) as a colourless crystalline solid. The determination of the ratio of (E) and (Z)-isomers for 
this compound was not possible due to the broad nature of the 1H and 13C spectra. νmax / cm-1: (solid) 
2972 (m), 1783 (s), 1651 (m), 1598 (m), 1493 (s), 1165 (s). δH (500 MHz, CDCl3) 7.85 – 7.56 (2H, m, 
2 × ArCH), 7.37 – 7.11 (7H, m, 7 × ArCH), 5.55 – 5.24 (2H, m, C4-H and C5-H), 5.03 – 4.92 (1H, m, 
C1-H), 2.42 (3H, br s, Ts CH3), 2.30 – 1.84 (4H, m, C2-H2 and C3-H2), 1.65 (3H, d, J = 5.0 Hz, C6-H3). 
δC (126 MHz, CDCl3) 156.5 (C=O), 145.2 (ArC), 136.3 (ArC), 132.6 (ArC), 129.4 (C4), 129.2 (ArCH), 
2 × 128.7 (2 × ArCH), 2 × 128.3 (2 × ArCH), 126.5 (C5), 65.9 (C1), 33.5 (C2), 28.9 (C3), 21.7 (Ts CH3), 
17.9 (C6). The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. HRMS: (ESI+) Calculated for C26H22F5NNaO4S: 562.1082. Found 
[M+Na]+: 562.1071. 




ORTEP view of 134a. 
(2R*,5S*)-2-Phenyl-1-tosyl-5-vinylpyrrolidine (139a) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 49 hours. Substrate 134a (75.5 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 14:1 – 9:1 – 4:1 hexane:EtOAc) afforded 139a (12.6 mg, 27 %) as a colourless 
crystalline solid. m.p. 76-77 °C (CH2Cl2:petrol) [Lit., 79 °C (Et2O:petrol)].211 δH (400 MHz, CDCl3) 
7.63 (2H, d, J = 8.0 Hz), 7.36 – 7.20 (7H, m), 6.00 (1H, ddd, J = 17.0, 10.5, 6.5 Hz), 5.33 (1H, d, J = 
17.0 Hz), 5.19 (1H, d, J = 10.5 Hz), 4.82 (1H, dd, J = 6.5, 6.5 Hz), 4.33 (1H, ddd, J = 6.5, 6.5, 6.5 Hz), 
2.41 (3H, s), 2.04 – 1.93 (1H, m) 1.91 – 1.83 (1H, m), 1.82 – 1.71 (2H, m). δC (101 MHz, CDCl3) 143.2, 
142.4, 139.0, 135.6, 129.4, 128.2, 127.7, 127.1, 126.5, 116.1, 65.0, 63.6, 34.5, 30.9, 21.5. The 
spectroscopic properties were consistent with the data available in the literature.212 
(E)-N-(1-Phenylhex-4-en-1-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 676 mg, 3.00 mmol) was employed with alcohol 133 
(vide supra, 1.1 eq.). The reaction time was 14 hours. FCC (gradient elution: 1:4:0 – 
0:19:1 hexane:PhMe:EtOAc) afforded the title compound (1.15 g, 100 %) as a colourless oil. 
νmax / cm-1: (film) 2956 (m), 2878 (m), 1455 (m), 1349 (s), 1162 (s). δH (400 MHz, CDCl3) 7.45 – 7.39 
(2H, m, 2 × ArCH), 7.38 – 7.32 (3H, m, 3 × ArCH), 5.41 – 5.32 (2H, m, C4-H and C5-H), 4.66 (1H, t, 
J = 7.5 Hz, C1-H), 2.10 – 2.03 (5H, m, C2-H2 and Ms CH3), 1.99 – 1.83 (2H, m, C3-H2), 1.64 (3H,  
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d, J = 4.0 Hz, C6-H3), 1.05 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.96 – 0.79 (6H, m, Si(CH2CH3)3).  
δC (101 MHz, CDCl3) 136.0 (ArC), 129.8 (ArCH), 129.6 (C4), 128.5 (ArCH), 128.4 (ArCH), 126.2 
(C5), 66.3 (C1), 33.6 (Ms CH3), 33.1 (C2), 29.2 (C3), 17.9 (C6), 6.9 (Si(CH2CH3)3), 5.1 (Si(CH2CH3)3). 
HRMS: (ESI+) Calculated for C19H33NNaO3SSi: 406.1843. Found [M+Na]+: 406.1861. 
(E)-N-(1-Phenylhex-4-en-1-yl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (953 mg, 2.48 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (652 mg, 98 %) as a colourless oil. νmax / cm-1: (solid) 
3345 (br s), 2937 (m), 1494 (m), 1316 (s), 1156 (s). δH (400 MHz, CDCl3) 7.49 – 7.43 (2H, m, 2 × 
ArCH), 7.39 – 7.32 (3H, m, 3 × ArCH), 7.27 (1H, br s, OH), 5.49 – 5.37 (2H, m, C4-H and C5-H), 4.73 
(1H, dd, J = 7.5, 7.5 Hz, C1-H), 2.24 – 2.16 (4H, m, C2-H and Ms CH3), 2.09 – 2.01 (2H, m, C3-H2), 
2.01 – 1.90 (1H, m, C2-H’), 1.65 (3H, d, J = 4.0 Hz, C6-H3). δC (101 MHz, CDCl3) 136.6 (ArC), 129.8 
(C4), 129.3 (ArCH), 2 × 128.6 (2 × ArCH), 126.2 (C5), 64.3 (C1), 34.2 (Ms CH3), 32.6 (C2), 29.1 (C3), 
17.8 (C6). HRMS: (ESI+) Calculated for C13H19NNaO3S: 292.0978. Found [M+Na]+: 292.0970. 
(E)-N-(1-Phenylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)methanesulfonamide (134b) 
 
General procedure C: The preceding compound (600 mg, 2.23 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 134b (965 mg, 93 %) as a colourless crystalline solid. νmax / cm-1: (solid) 
3030 (m), 2945 (m), 1775 (s), 1651 (m), 1502 (s), 1367 (s), 1165 (s). δH (500 MHz, CDCl3) 7.38 (5H, 
s, 5 × ArCH), 5.45 – 5.32 (2H, m, C4-H and C5-H), 5.02 (1H, dd, J = 8.5, 6.0 Hz, C1-H), 2.38 – 2.18 
(4H, m, C2-H and Ms CH3), 2.07 – 1.88 (3H, m, C2-H’ and C3-H2), 1.64 (3H, d, J = 5.0 Hz, C6-H3). 
δC (126 MHz, CDCl3) 156.6 (C=O), 135.8 (ArC), 129.4 (ArCH), 129.3 (C4), 129.2 (ArCH), 129.0 
(ArCH), 127.0 (C5), 66.0 (C1), 36.8 (Ms CH3), 32.8 (C2), 29.0 (C3), 18.1 (C6). The aromatic 
13C 
signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (283 MHz, CDCl3) -135.5 – -135.7 (2F, m), -144.9 – -145.2 (1F, m), -158.4 – -158.7 (2F, 
m). HRMS: (ESI+) Calculated for C20H18F5NNaO4S: 486.0769. Found [M+Na]+: 486.0756. 
  





General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 120 °C; 19 hours. Substrate 134b (64.9 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 10:1 – 5:1 – 2:1 hexane:EtOAc) afforded 139b (20.4 mg, 58 %) as a pale-yellow 
oil. The product was assigned as the cis diastereomer based on the observed NOE correlation between 
the C5 and the aryl protons. νmax / cm-1: (film) 3029 (m), 2934 (m), 1451 (m), 1328 (s), 1145 (s). 
δH (400 MHz, CDCl3) 7.41 – 7.32 (4H, m, 4 × ArCH), 7.31 – 7.26 (1H, m, ArCH), 6.02 (1H, ddd, J = 
17.0, 10.0, 7.0 Hz, C5-H), 5.40 (1H, ddd, J = 17.0, 1.0, 1.0 Hz, C6-H’), 5.27 (1H, ddd, J = 10.0, 1.0, 
1.0 Hz, C6-H), 5.00 (1H, dd, J = 7.0, 7.0 Hz, C1-H), 4.59 (1H, br ddd, J = 7.5, 7.0, 7.0 Hz, C4-H), 2.66 
(3H, s, Ms CH3), 2.40 – 2.30 (1H, m, C2-H), 2.17 (1H, dddd, J = 12.0, 7.5, 7.5, 6.0 Hz, C3-H), 2.01 
(1H, dddd, J = 12.5, 7.0, 6.0, 6.0 Hz, C2-H’), 1.95 – 1.86 (1H, m, C3-H’). δC (101 MHz, CDCl3) 142.2 
(ArC), 138.7 (C5), 128.7 (ArCH), 127.7 (ArCH), 126.9 (ArCH), 117.2 (C6), 64.7 (C1), 63.3 (C4), 41.3 




To a solution of n-BuLi (1.55 M in hexane, 10.0 mL, 15.5 mmol) in anhydrous THF (30 mL) at 0 °C 
was added a solution of aldehyde 132 (1.40 g, 14.3 mmol) in anhydrous THF (5 mL) dropwise. The 
reaction mixture was stirred for 1 hour before addition of saturated aqueous NH4Cl (25 mL). The 
resulting phases were separated, and the aqueous phase was extracted with Et2O (2 × 40 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 135 (1.75 g, 
78 %) as a pale-yellow oil. νmax / cm-1: (film) 3344 (br s), 2930 (s), 2858 (s), 1482 (s), 964 (s). 
δH (400 MHz, CDCl3) 5.52 – 5.40 (2H, m), 3.65 – 3.57 (1H, m), 2.21 – 2.01 (2H, m), 1.65 (3H, d, 
J = 4.5 Hz), 1.59 – 1.24 (9H, m), 0.91 (3H, t, J = 7.0 Hz). δC (101 MHz, CDCl3) 131.1, 125.3, 71.6, 
37.2, 37.1, 28.9, 27.8, 22.7, 17.9, 14.1. The spectroscopic properties were consistent with the data 
available in the literature.213 
 





General procedure E: MsNHOTES (676 mg, 3.00 mmol) was employed with alcohol 135 (1.1 eq.). 
The reaction time was 17 hours. FCC (eluent: PhMe) afforded the title compound (828 mg, 76 %) as a 
colourless oil. νmax / cm-1: (film) 2956 (m), 2877 (m), 1458 (m), 1347 (s), 1163 (s). δH (400 MHz, CDCl3) 
5.52 – 5.34 (2H, m, C8-H and C9-H), 3.49 (1H, tt, J = 6.5, 6.5 Hz, C5-H), 2.88 (3H, s, Ms CH3), 2.13 
– 2.02 (2H, m, C7-H2), 1.73 – 1.26 (11H, m, C2-H2, C3-H2, C4-H2, C6-H2 and C10-H3), 0.99 (9H, t, 
J = 7.5 Hz, Si(CH2CH3)3), 0.91 (3H, t, J = 7.0 Hz, C1-H3), 0.78 (6H, q, J = 7.5 Hz, Si(CH2CH3)3).  
δC (101 MHz, CDCl3) 130.3 (C8), 126.1 (C9), 63.4 (C5), 34.8 (Ms CH3), 31.7 (C6), 31.4 (C4),  
30.1 (C7), 29.3 (C3), 22.8 (C2), 18.1 (C10), 14.2 (C1), 6.9 (Si(CH2CH3)3), 5.1 (Si(CH2CH3)3). 
HRMS: (ESI+) Calculated for C17H37NNaO3SSi: 386.2156. Found [M+Na]+: 386.2156. 
(E)-N-(Dec-8-en-5-yl)-N-hydroxymethanesulfonamide 
  
General procedure F: The preceding compound (793 mg, 2.18 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (511 mg, 94 %) as a colourless oil. νmax / cm-1: (film) 
3367 (br s), 2956 (m), 1453 (m), 1320 (s), 1157 (s). δH (400 MHz, CDCl3) 6.47 (1H, br s, OH), 5.51 – 
5.35 (2H, m, C8-H and C9-H), 3.69 (1H, tt, J = 7.0, 7.0 Hz, C5-H), 3.00 (3H, s, Ms CH3), 2.16 – 1.98 
(2H, m, C7-H2), 1.66 – 1.54 (7H, m, C4-H2, C6-H2 and C10-H3), 1.42 – 1.24 (4H, m, C2-H2 and C3-H2), 
0.90 (3H, t, J = 7.0 Hz, C1-H3). δC (101 MHz, CDCl3) 130.3 (C8), 126.0 (C9), 60.2 (C5), 36.6 (Ms CH3), 
30.9 (C6), 30.6 (C4), 29.5 (C7), 28.7 (C3), 22.7 (C2), 18.1 (C10), 14.1 (C1). HRMS: (ESI+) Calculated 
for C11H23NNaO3S: 272.1291. Found [M+Na]+: 272.1287. 
(E)-N-Dec-8-en-5-yl-N-((pentafluorobenzoyl)oxy)methanesulfonamide (136) 
  
General procedure C:  The preceding compound (479 mg, 1.92 mmol) was employed. FCC (eluent: 
14:1 hexane:EtOAc) afforded 136 (775 mg, 91 %) as a colourless crystalline solid. m.p. 42-43 °C 
(Et2O:hexane, needles). νmax / cm-1: (solid) 2944 (m), 1784 (s), 1651 (m), 1496 (s), 1160 (s). 
δH (400 MHz, CDCl3) 5.54 – 5.44 (1H, m, C9-H), 5.43 – 5.34 (1H, m, C8-H), 3.98 (1H, tt, J = 6.5, 
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6.5 Hz, C5-H), 3.09 (3H, s, Ms CH3), 2.30 – 2.07 (2H, m, C7-H2), 1.75 – 1.23 (11H, m, C2-H2, C3-H2, 
C4-H2, C6-H2 and C10-H3), 0.91 (3H, t, J = 7.0 Hz, C1-H3). δC (101 MHz, CDCl3) 129.9 (C8), 126.4 
(C9), 62.3 (C5), 40.0 (Ms CH3), 31.8 (C6), 31.5 (C4), 29.5 (C7), 28.7 (C2 or C3), 22.6 (C2 or C3), 18.1 
(C10), 14.0 (C1). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.1 (2F, m), -145.4 (1F, tt, J = 21.0, 
5.5 Hz), -158.6 – -158.8 (2F, m). HRMS: (ESI+) Calculated for C18H22F5NNaO4S: 466.1082. Found 
[M+Na]+: 466.1070.  
(2R*,5R*)-2-Butyl-1-mesyl-5-vinylpyrrolidine (140) 
 
General procedure D:  Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
PhMe (0.1 M); 140 °C; 20 hours. Substrate 136 (62.1 mg, 0.140 mmol) was employed. FCC (eluent: 
5:1 hexane:EtOAc) afforded 140 (19.9 mg, 61 %, 14:1 ratio of cis and trans diastereomers) as a pale-
yellow oil. The major product was assigned as the cis diastereomer based on analogy to compounds 
139a, 139b and 141. No NOE was observed between the C5 and the C9 protons. Spectroscopic data for 
the major cis diastereomer: νmax / cm-1: (film) 2932 (m), 1331 (s), 1148 (s). δH (400 MHz, CDCl3) 5.79 
(1H, ddd, J = 17.0, 10.0, 6.5 Hz, C9-H), 5.30 (1H, ddd, J = 17.0, 1.5, 1.5 Hz, C10-H’), 5.14 (1H, ddd, 
J = 10.0, 1.5, 1.5 Hz, C10-H), 4.29 – 4.23 (1H, m, C8-H), 3.81 (1H, dddd, J = 9.5, 7.0, 5.0, 5.0 Hz, 
C5-H), 2.84 (3H, s, Ms CH3), 2.10 – 1.93 (2H, m, C6-H and C7-H), 1.92 – 1.76 (2H, m, C4-H and 
C7-H’), 1.72 – 1.62 (1H, m, C6-H’), 1.47 – 1.22 (5H, m, C2-H2, C3-H2 and C4-H’), 0.90 (3H, t, J = 
7.0 Hz, C1-H3). δC (101 MHz, CDCl3) 139.4 (C9), 116.1 (C10), 62.9 (C8), 61.8 (C5), 38.8 (Ms CH3), 
36.5 (C4), 31.7 (C7), 30.2 (C6), 28.7 (C2 or C3), 22.7 (C2 or C3), 14.2 (C1). HRMS: (ESI+) Calculated 
for C11H21NNaO2S: 254.1185. Found [M+Na]+: 254.1173. 
1H NMR data for the minor trans 
diastereomer: δH (500 MHz, CDCl3) 5.79 (1H, ddd, J = 17.0, 10.0, 8.5 Hz), 5.31 (1H, ddd, J = 17.0, 
1.0, 1.0 Hz), 5.18 (1H, ddd, J = 10.0, 1.0, 1.0 Hz), 4.30 (1H, br dd, J = 8.5, 8.5 Hz), 3.74 – 3.68 (1H, 
m), 2.86 (3H, s), 2.26 – 2.18 (1H, m), 2.11 – 1.95 (2H, m), 1.80 (1H, dddd, J = 12.5, 6.5, 1.5, 1.5 Hz), 
1.70 (1H, dddd, J = 12.5, 6.5, 1.5, 1.5 Hz), 1.48 – 1.39 (1H, m), 1.38 – 1.19 (5H, m), 0.90 (3H, t, J = 
7.0 Hz). 
  





To a suspension of magnesium turnings (413 mg, 17.0 mmol), activated with a few crystals of iodine, 
in anhydrous Et2O (15 mL) was added bromocyclopropane (1.28 mL, 16.0 mmol) before being diluted 
with Et2O (20 mL). The reaction mixture was heated at reflux for 2 hours, then cooled to room 
temperature before addition of a solution of aldehyde 132 (981 mg, 10.0 mmol) in anhydrous Et2O 
(10 mL). The reaction mixture was heated at reflux for 15 hours before addition of saturated aqueous 
NH4Cl (30 mL). The resulting phases were separated, and the aqueous phase was extracted with Et2O 
(2 × 30 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC 
(gradient elution: 5:1 – 3:1 pentane:Et2O) afforded 137 (993 mg, 71 %) as a pale-yellow oil. 
νmax / cm-1: (film) 3362 (m), 3080 (m), 2924 (s), 1435 (s), 1042 (s). δH (400 MHz, CDCl3) 5.51 – 5.38 
(2H, m, C6-H and C7-H), 2.91 – 2.82 (1H, m, C3-H), 2.22 – 2.04 (2H, m, C5-H2), 1.69 – 1.61 (5H, m, 
C4-H2 and C8-H3), 1.56 (1H, br s, OH), 0.89 (1H, dtt, J = 8.5, 8.5, 5.0 Hz, C2-H), 0.56 – 0.45 (2H, m, 
2 × C1-H), 0.31 – 0.16 (2H, m, 2 × C1-H’). δC (101 MHz, CDCl3) 131.2 (C6), 125.3 (C7), 76.5 (C3), 
37.1 (C4), 29.0 (C5), 2 × 18.1 (C2 and C8), 2.8 (C1), 2.6 (C1’). HRMS: (EI+) Calculated for C9H14: 
122.1096. Found [M-H2O]+: 122.1100. 
(E)-N-1-Cyclopropylhex-4-en-1-yl-N-(pentafluorobenzoyloxy)-4-toluenesulfonamide (138) 
 
General procedure K: Alcohol 137 (140 mg, 1.00 mmol) was employed with TsNHOFBz (vide supra). 
The reaction time was 18 hours. FCC (eluent: 1:1 hexane:PhMe) afforded 138 (261 mg, 52 %) as a 
colourless oil. νmax / cm-1: (film) 2929 (m), 1786 (s), 1653 (m), 1598 (m), 1498 (s), 1325 (s), 1165 (s). 
δH (500 MHz, CDCl3) 7.85 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.35 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.53 – 
5.43 (1H, m, C7-H), 5.42 – 5.32 (1H, m, C6-H), 3.53 – 3.33 (1H, m, C3-H), 2.47 (3H, s, Ts CH3), 2.38 
– 2.14 (2H, m, C5-H2), 1.80 – 1.64 (5H, m, C4-H2 and C8-H3), 1.05 (1H, br s, C2-H), 0.67 (1H, br s, 
C1-H), 0.63 – 0.54 (2H, m, C1-H’ and C1’-H’), 0.34 (1H, br s, C1’-H). δC (126 MHz, CDCl3) 156.4 
(C=O), 145.6 (ArC), 133.5 (ArC), 130.2 (C6), 129.8 (ArCH), 129.5 (ArCH), 126.1 (C7), 67.3 (C3), 
32.8 (C4), 29.4 (C5), 21.9 (Ts CH3), 18.1 (C8), 13.0 (C2), 2 × 5.8 (C1 and C1’). The aromatic 
13C 
signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
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intensity. δF (377 MHz, CDCl3) -136.3 – -136.5 (2F, m), -146.3 (1F, tt, J = 21.0, 5.0 Hz), -158.9 – -159.1 
(2F, m). HRMS: (ESI+) Calculated for C23H22F5NNaO4S: 526.1082. Found [M+Na]+: 526.1087. 
(2R*,5S*)-2-Cyclopropyl-1-tosyl-5-vinylpyrrolidine (141) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
PhMe (0.1 M); 140 °C; 15 hours. Substrate 138 (76.3 mg, 0.152 mmol, added as a solution in PhMe) 
was employed. FCC (eluent: 9:1 hexane:EtOAc) afforded 141 (33.2 mg, 75 %, 13:1 mixture of cis and 
trans diastereomers) as a colourless crystalline solid. The major product was assigned as the cis 
diastereomer based on the observed NOE correlation between the C2 and the C7 protons. 
Spectroscopic data for the major cis diastereomer: νmax / cm-1: (film) 3007 (m), 2967 (m), 1598 (m), 
1494 (m), 1344 (s), 1158 (s). δH (400 MHz, CDCl3) 7.71 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.27 (2H, d, 
J = 8.0 Hz, 2 × ArCH), 5.86 (1H, ddd, J = 17.0, 10.5, 6.0 Hz, C7-H), 5.29 (1H, ddd, J = 17.0, 1.5, 
1.5 Hz, C8-H’), 5.10 (1H, ddd, J = 10.5, 1.5, 1.5 Hz, C8-H), 4.17 – 4.10 (1H, m, C6-H), 3.26 (1H, ddd, 
J = 8.0, 8.0, 4.0 Hz, C3-H), 2.41 (3H, s, Ts CH3), 1.78 – 1.71 (2H, m, C5-H2), 1.70 – 1.61 (1H, m, 
C4-H), 1.57 – 1.46 (1H, m, C4-H’), 0.96 (1H, dddt, J = 8.0, 8.0, 8.0, 5.0 Hz, C2-H), 0.62 – 0.49 (2H, 
m, C1-H2), 0.48 – 0.39 (1H, m, C1’-H), 0.25 – 0.17 (1H, m, C1’-H’). δC (101 MHz, CDCl3) 143.1 
(ArC), 139.5 (C7), 136.2 (ArC), 129.4 (ArCH), 127.6 (ArCH), 115.4 (C8), 65.9 (C3), 63.3 (C6), 31.2 
(C5), 30.3 (C4), 21.5 (Ts CH3), 16.9 (C2), 4.7 (C1), 2.8 (C1’). HRMS: (ESI+) Calculated for 
C16H22NO2S: 292.1366. Found [M+H]+: 292.1376. Characteristic signals for the minor trans 
diastereomer: δH (400 MHz, CDCl3) 5.77 (1H, ddd, J = 17.0, 10.0, 7.5 Hz), 5.20 (1H, ddd, J = 17.0, 
1.0, 1.0 Hz), 5.06 (1H, ddd, J = 10.0, 1.0, 1.0 Hz), 4.42 (1H, dd, J = 7.5, 7.5 Hz). 
Crotyl bromide 
 
General procedure J: (E)-But-2-en-1-ol (21.6 g, 300 mmol) was employed. The title compound 
(24.2 g, 60 %) was isolated as a colourless oil. δH (400 MHz, CDCl3) 5.87 – 5.65 (2H, m), 3.94 (2H, d, 
J = 7.0 Hz), 1.74 (3H, d, J = 6.0 Hz). δC (101 MHz, CDCl3) 131.6, 127.7, 33.6, 17.8. The spectroscopic 
properties were consistent with the data available in the literature.214 
  





To a suspension of NaH (60 % in mineral oil, 852 mg, 21.3 mmol) in anhydrous THF (25 mL) and 
DMF (25 mL) was added methyl phenylacetate (3.00 mL, 21.3 mmol). The reaction mixture was stirred 
at room temperature for 1.5 hours before addition of crotyl bromide (vide supra, 1.46 mL, 14.2 mmol). 
The reaction mixture was stirred for two hours before addition of brine (50 mL). The resulting phases 
were separated, and the aqueous phase was extracted with Et2O (3 × 60 mL). The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 39:1 hexane:EtOAc) afforded 
the title compound (2.38 g, 82 %) as a colourless oil. νmax / cm-1: (film) 3029 (m), 2951 (m), 1734 (s), 
1435 (s), 1160 (s). δH (400 MHz, CDCl3) 7.35 – 7.28 (4H, m, 4 × ArCH), 7.28 – 7.23 (1H, m, ArCH), 
5.50 (1H, dqdd, J = 15.0, 6.5, 1.5, 1.0 Hz, C5-H), 5.40 – 5.28 (1H, m, C4-H), 3.65 (3H, s, OCH3), 3.59 
(1H, dd, J = 8.5, 6.5 Hz, C2-H), 2.81 – 2.71 (1H, m, C3-H), 2.48 – 2.39 (1H, m, C3-H’), 1.61 (3H, dd, 
J = 6.5, 1.5 Hz, C6-H3). δC (101 MHz, CDCl3) 174.0 (C1), 138.8 (ArC), 128.6 (ArCH), 127.9 (ArCH), 
127.7 (C4), 127.6 (C5), 127.2 (ArCH), 52.0 (C2), 51.9 (OCH3), 36.6 (C3), 17.9 (C6). HRMS: (ESI+) 
Calculated for C13H16NaO2: 227.1043. Found [M+Na]+: 227.1044. 
(E)-2-Phenylhex-4-en-1-ol (142) 
 
General procedure I: The preceding ester (2.05 g, 10.0 mmol) was employed, using anhydrous THF 
as the solvent and 0.6 eq. LiAlH4 (1.0 M in THF). Alcohol 142 (1.57 g, 89 %) was isolated as a 
colourless oil. δH (500 MHz, CDCl3) 7.35 – 7.31 (2H, m), 7.26 – 7.20 (3H, m), 5.46 (1H, dqdd, J = 
15.0, 6.5, 1.0, 1.0 Hz), 5.35 (1H, dddq, J = 15.0, 7.5, 6.0, 1.5 Hz), 3.80 (1H, dd, J = 11.0, 5.5 Hz), 3.73 
(1H, dd, J = 11.0, 7.5 Hz), 2.84 (1H, dddd, J = 7.5, 7.5, 7.5, 5.5 Hz), 2.40 (1H, ddddq, J = 14.0, 7.5, 
7.5, 1.0, 1.0 Hz), 2.37 – 2.27 (1H, m), 1.61 (3H, dddd, J = 6.5, 1.5, 1.5, 1.0 Hz), 1.36 (1H, br s). 
δC (126 MHz, CDCl3) 142.4, 128.9, 128.8, 128.2, 127.1, 126.9, 67.1, 48.7, 35.7, 18.1. The spectroscopic 
properties were consistent with the data available in the literature.215 
  





General procedure E: TsNHOTES (vide supra, 603 mg, 2.00 mmol) was employed with alcohol 142 
(1.3 eq.). The reaction time was 22 hours. FCC (gradient elution: 2:3 – 0:1 hexane:PhMe) afforded the 
title compound (831 mg, 90 %) as a colourless oil. νmax / cm-1: (film) 2957 (s), 2913 (s), 2878 (s), 
1598 (m), 1357 (s), 1167 (s). δH (400 MHz, CDCl3) 7.71 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.33 – 7.27 
(4H, m, 4 × ArCH), 7.23 – 7.17 (1H, m ArCH), 7.14 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.39 (1H, dq, J = 
15.0, 6.5 Hz, C5-H), 5.28 – 5.18 (1H, m, C4-H), 3.26 (1H, dd, J = 13.0, 8.5 Hz, C1-H), 3.05 – 2.96 (1H, 
m, C2-H), 2.80 (1H, dd, J = 13.0, 6.5 Hz, C1-H’), 2.61 – 2.52 (1H, m, C3-H), 2.42 (3H, s, Ts CH3), 
2.35 – 2.25 (1H, m, C3-H’), 1.57 (3H, d, J = 6.5 Hz, C6-H3), 0.99 (9H, t, J = 7.5 Hz, Si(CH2CH3)3), 
0.76 (6H, q, J = 7.5 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 144.6 (ArC), 142.3 (ArC), 130.1 (ArCH), 
129.7 (ArC), 129.4 (ArCH), 128.5 (ArCH), 2 × 128.2 (ArCH and C4), 127.4 (C5), 126.7 (ArCH), 61.2 
(C1), 43.2 (C2), 37.2 (C3), 21.8 (Ts CH3), 18.1 (C6), 7.0 (Si(CH2CH3)3), 5.1 (Si(CH2CH3)3). 
HRMS: (ESI+) Calculated for C25H37NNaO3SSi: 482.2156. Found [M+Na]+: 482.2155. 
(E)-N-(2-Phenylhex-4-en-1-yl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure F: The preceding compound (790 mg, 1.72 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (576 mg, 97 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3360 (br s), 2919 (m), 1598 (m), 1335 (s), 1164 (s). δH (500 MHz, CDCl3) 7.76 (2H, 
d, J = 8.0 Hz, 2 × ArCH), 7.36 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.34 – 7.29 (2H, m, 2 × ArCH), 7.26 – 
7.21 (1H, m, ArCH), 7.19 – 7.15 (2H, m, 2 × ArCH), 5.46 – 5.37 (1H, m, C5-H), 5.25 (1H, dddq, J = 
15.5, 8.0, 6.5, 1.5 Hz, C4-H), 3.25 – 3.20 (1H, m, C1-H), 3.07 – 2.98 (2H, m, C1-H’ and C2-H), 2.54 – 
2.47 (1H, m, C3-H), 2.46 (3H, s, Ts CH3), 2.38 – 2.30 (1H, m, C3-H’), 1.60 – 1.56 (3H, m, C6-H3). 
δC (126 MHz, CDCl3) 144.9 (ArC), 142.0 (ArC), 129.7 (ArC), 2 × 129.6 (2 × ArCH), 128.4 (ArCH), 
2 × 128.0 (C4 and ArCH), 127.3 (C5), 126.7 (ArCH), 57.1 (C1), 43.4 (C2), 36.8 (C3), 21.7 (Ts CH3), 
17.9 (C6). HRMS: (ESI+) Calculated for C19H24NO3S: 346.1471. Found [M+H]+: 346.1467. 
  





General procedure C: The preceding compound (554 mg, 1.60 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 144 (800 mg, 93 %) as a colourless crystalline solid. m.p. 68-70 °C 
(Et2O:hexane, cubes). νmax / cm-1: (film) 2919 (m), 1785 (s), 1652 (m), 1597 (m), 1496 (s), 1168 (s). 
δH (400 MHz, CDCl3) 7.77 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.36 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.25 – 
7.19 (2H, m, 2 × ArCH), 7.15 – 7.06 (3H, m, 3 × ArCH), 5.43 (1H, dq, J = 15.0, 6.5 Hz, C5-H), 5.25 – 
5.15 (1H, m, C4-H), 3.75 – 3.64 (1H, m, C1-H), 3.21 – 3.03 (1H, m, C1-H’), 2.87 – 2.82 (1H, m, C2-H), 
2.71 – 2.61 (1H, m, C3-H), 2.46 (3H, s, Ts CH3), 2.41 – 2.31 (1H, m, C3-H’), 1.57 (3H, dd, J = 6.5, 
1.5 Hz, C6-H3). δC (101 MHz, CDCl3) 145.8 (ArC), 141.3 (ArC), 130.1 (ArC), 129.9 (ArCH), 129.6 
(ArCH), 128.4 (ArCH), 127.9 (C5), 127.8 (ArCH), 127.4 (C4), 126.6 (ArCH), 57.1 (C1), 44.0 (C2), 
36.7 (C3), 21.7 (Ts CH3), 17.9 (C6). The 
13C signals corresponding to the pentafluorobenzoyl group 
could not be resolved due to their weak intensity. δF (283 MHz, CDCl3) -135.2 – -135.4 (2F, m), -146.0 
(1F, tt, J = 21.0, 5.5 Hz), -159.1 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C26H22F5NNaO4S: 
562.1082. Found [M+Na]+: 562.1060. 
(2R*,4S*)-4-Phenyl-1-tosyl-2-vinylpyrrolidine (145) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 120 °C; 20 hours. Substrate 144 (75.5 mg, 0.140 mmol) was employed. 
FCC (eluent: 9:1 hexane:EtOAc) afforded 145 (26.3 mg, 57 %, 2:1 mixture of cis and trans 
diastereomers) as a colourless crystalline solid. νmax / cm-1: (film) 2973 (m), 1643 (m), 1598 (m), 
1495 (m), 1345 (s), 1159 (s). 1H and 13C NMR data for the major cis diastereomer: δH (400 MHz, 
CDCl3) 7.79 – 7.74 (2H, m), 7.38 – 7.18 (5H, m), 7.15 – 7.09 (2H, m), 6.01 – 5.85 (1H, m), 5.28 (1H, 
ddd, J = 17.0, 1.0, 1.0 Hz), 5.15 (1H, ddd, J = 10.5, 1.0, 1.0 Hz), 4.15 (1H, br ddd, J = 9.5, 7.0, 7.0 Hz), 
3.95 – 3.84 (1H, m), 3.50 – 3.33 (1H, m), 2.85 (1H, dddd, J = 11.0, 11.0, 7.0, 7.0 Hz), 2.46 (3H, s), 2.44 
– 2.34 (1H, m), 1.94 – 1.78 (1H, m). δC (101 MHz, CDCl3) 143.5, 139.6, 138.9, 135.5, 129.7, 128.7, 
127.6, 127.1, 127.0, 115.7, 63.2, 55.2, 43.0, 40.9, 21.6. 1H and 13C NMR data for the minor trans 
diastereomer: δH (400 MHz, CDCl3) 7.79 – 7.75 (2H, m), 7.37 – 7.19 (5H, m), 7.06 – 7.03 (2H, m), 
5.99 – 5.86 (1H, m), 5.40 (1H, ddd, J = 17.0, 1.5, 1.5 Hz), 5.22 (1H, ddd, J = 10.0, 1.5, 1.5 Hz), 4.42 
(1H, ddddd, J = 7.0, 7.0, 1.5, 1.5, 1.5 Hz), 3.95 – 3.83 (1H, m), 3.51 – 3.33 (1H, m), 3.14 (1H, dd, J = 
Chapter 7 - Experimental 
164 
 
10.0, 10.0 Hz), 2.46 (3H, s), 2.03 (1H, ddd, J = 12.5, 6.0, 1.5 Hz), 1.95 – 1.79 (1H, m). δC (101 MHz, 
CDCl3) 143.5, 139.8, 138.5, 134.8, 129.7, 128.6, 127.6, 2 × 127.0, 115.7, 61.6, 54.7, 41.7, 38.8, 21.6. 
The spectroscopic properties were consistent with the data available in the literature.211 
Ethyl (E)-2-cyclohexylhex-4-enoate 
 
To a solution of i-Pr2NH (1.46 mL, 10.5 mmol) in anhydrous THF (40 mL) at 0 °C was added n-BuLi 
(1.51 M in hexane, 7.00 mL, 10.6 mmol). The reaction mixture was stirred at 0 °C for 30 minutes, then 
cooled to -78 °C before addition of ethyl 2-cyclohexylacetate (1.80 mL, 10.0 mmol) dropwise. The 
reaction mixture was stirred at -78 °C for 30 minutes before addition of crotyl bromide (vide supra, 
1.08 mL, 10.5 mmol). The reaction mixture was stirred at room temperature for 2 hours before addition 
of saturated aqueous NH4Cl (30 mL). The resulting phases were separated, and the aqueous phase was 
extracted with EtOAc (2 × 40 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 29:1 hexane:EtOAc) afforded the title compound (1.93 g, 86 %) 
as a colourless oil. νmax / cm-1: (film) 2925 (s), 2853 (s), 1731 (s), 1448 (s), 1157 (s). δH (400 MHz, 
CDCl3) 5.49 – 5.40 (1H, m, C5-H), 5.33 (1H, dtq, J = 15.0, 6.5, 1.5 Hz, C4-H), 4.11 (2H, q, J = 7.0 Hz, 
OCH2CH3), 2.25 – 2.12 (3H, m, C2-H and C3-H2), 1.83 – 1.57 (8H, m, C6-H3 and 5 × Cy CH), 1.56 – 
1.45 (1H, m, Cy CH), 1.23 (3H, t, J = 7.0 Hz, OCH2CH3), 1.29 – 0.86 (5H, m, 5 × Cy CH). δC (101 MHz, 
CDCl3) 175.3 (C1), 128.4 (C4), 126.8 (C5), 59.7 (OCH2CH3), 52.3 (C2), 39.8 (Cy CH), 32.6 (C3), 30.9 
(Cy CH), 30.6 (Cy CH), 26.4 (Cy CH), 26.3 (Cy CH), 26.2 (Cy CH), 17.9 (C6), 14.4 (OCH2CH3). 
HRMS: (ESI+) Calculated for C14H24NaO2: 247.1669. Found [M+Na]+: 247.1668. 
(E)-2-Cyclohexylhex-4-en-1-ol (143) 
 
General procedure I: The preceding ester (1.85 g, 8.25 mmol) was employed, using anhydrous THF 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in THF). Alcohol 143 (1.50 g, 100 %) was isolated as a 
colourless oil. νmax / cm-1: (film) 3335 (br s), 2921 (s), 2851 (s), 1448 (s), 1040 (s). δH (400 MHz, CDCl3) 
5.54 – 5.38 (2H, m, C4-H and C5-H), 3.67 – 3.55 (2H, m, C1-H2), 2.17 – 2.09 (1H, m, C3-H), 2.03 – 
1.92 (1H, m, C3-H’), 1.77 – 1.60 (8H, m, C6-H3 and 5 × Cy CH), 1.47 – 1.34 (3H, m, C2-H, Cy CH 
and OH), 1.29 – 0.96 (5H, m, 5 × Cy CH). δC (101 MHz, CDCl3) 130.4 (C4), 126.3 (C5), 63.8 (C1), 
46.3 (C2), 38.4 (Cy CH), 31.9 (C3), 30.3 (Cy CH), 30.1 (Cy CH), 2 × 26.8 (2 × Cy CH), 26.7 (Cy CH), 
18.0 (C6). HRMS: (ESI+) Calculated for C12H22NaO: 205.1563. Found [M+Na]+: 205.1568. 





General procedure E: MsNHOTES (vide supra, 902 mg, 4.00 mmol) was employed with alcohol 143 
(1.1 eq.). The reaction time was 15 hours. FCC (eluent: PhMe) afforded the title compound (1.45 g, 
93 %) as a colourless oil. νmax / cm-1: (film) 2921 (s), 2877 (s), 2845 (s), 1449 (s), 1347 (s), 1165 (s). 
δH (400 MHz, CDCl3) 5.49 – 5.40 (1H, m, C5-H), 5.34 (1H, dddq, J = 15.0, 7.0, 5.5, 1.5 Hz, C4-H), 
3.10 (1H, dd, J = 13.0, 6.5 Hz, C1-H), 3.00 (1H, dd, J = 13.0, 7.0 Hz, C1-H’), 2.84 (3H, s, Ms CH3), 
2.14 – 2.05 (1H, m, C3-H), 2.03 – 1.93 (1H, m, C3-H’), 1.80 – 1.52 (10H, m, C2-H, C6-H3 and 6 × 
Cy CH), 1.30 – 1.02 (5H, m, 5 × Cy CH), 0.99 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.77 (6H, q, J = 8.0 Hz, 
Si(CH2CH3)3). δC (101 MHz, CDCl3) 129.2 (C4), 126.9 (C5), 56.8 (C1), 41.0 (C2), 37.7 (Cy CH), 31.7 
(C3), 29.9 (Ms CH3), 29.7 (Cy CH), 28.9 (Cy CH), 26.8 (Cy CH), 2 × 26.7 (2 × Cy CH), 18.0 (C6), 6.8 




General procedure F: The preceding compound (1.39 g, 3.57 mmol) was employed. FCC (eluent: 
6:1 hexane:EtOAc) afforded the title compound (951 mg, 97 %) as a colourless oil. νmax / cm-1: (film) 
3368 (br s), 2924 (s), 2852 (s), 1449 (m), 1342 (s), 1164 (s). δH (400 MHz, CDCl3) 6.47 (1H, br s, OH), 
5.51 – 5.33 (2H, m, C4-H and C5-H), 3.12 (1H, dd, J = 12.5, 6.5 Hz, C1-H), 3.04 (1H, dd, J = 12.5, 
7.5 Hz, C1-H’), 2.91 (3H, s, Ms CH3), 2.17 – 2.08 (1H, m, C3-H), 2.01 (1H, ddd, J = 14.0, 7.0, 7.0 Hz, 
C3-H’), 1.79 – 1.57 (9H, m, C2-H, C6-H3 and 5 × Cy CH), 1.57 – 1.47 (1H, m, Cy CH), 1.29 – 0.98 
(5H, m, 5 × Cy CH). δC (101 MHz, CDCl3) 129.5 (C4), 126.9 (C5), 53.7 (C1), 41.0 (C2), 38.3 (Cy CH), 
32.0 (C3), 31.0 (Ms CH3), 29.9 (Cy CH), 29.5 (Cy CH), 3 × 26.9 (3 × Cy CH), 18.2 (C6). HRMS: (ESI+) 
Calculated for C13H25NNaO3S: 298.1447. Found [M+Na]+: 248.1441. 
(E)-N-(2-Cyclohexylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)methanesulfonamide (146) 
 
General procedure C: The preceding compound (909 mg, 3.30 mmol) was employed. FCC (gradient 
elution: 12:1 – 9:1 – 8:1 hexane:EtOAc) afforded 146 (1.33 g, 86 %) as a colourless crystalline solid. 
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m.p. 73-75 °C (Et2O:hexane). νmax / cm-1: (solid) 2926 (m), 1791 (s), 1654 (m), 1504 (s), 1360 (s), 
1162 (s). δH (500 MHz, CDCl3) 5.51 – 5.43 (1H, m, C5-H), 5.32 (1H, dddq, J = 15.0, 8.5, 7.0, 1.5 Hz, 
C4-H), 3.46 – 3.24 (2H, m, C1-H2), 3.03 (3H, s, Ms CH3), 2.25 – 2.04 (2H, m, C3-H2), 1.78 – 1.71 (2H, 
m, 2 × Cy CH), 1.70 – 1.57 (7H, m, C6-H3 and 4 × Cy CH), 1.51 – 1.44 (1H, m, C2-H), 1.32 – 1.20 
(2H, m, 2 × Cy CH), 1.16 – 1.08 (1H, m, Cy CH), 1.08 – 0.98 (2H, m, 2 × Cy CH). δC (101 MHz, 
CDCl3) 128.6 (C4), 127.5 (C5), 53.3 (C1), 41.4 (C2), 37.6 (Cy CH), 34.2 (Ms CH3), 31.4 (C3), 29.7 
(Cy CH), 26.7 (Cy CH), 3 × 26.6 (3 × Cy CH), 18.0 (C6). The 13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.8 – -136.1 (2F, m), -145.5 (1F, tt, J = 21.0, 5.0 Hz), -158.7 – -158.9 (2F, m). HRMS: (ESI+) 
Calculated for C20H24F5NNaO4S: 492.1238. Found [M+Na]+: 492.1230. 
4-Cyclohexyl-1-mesyl-2-vinylpyrrolidine (147) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
n-BuCN (0.1 M); 110 °C; 20 hours. Substrate 146 (65.7 mg, 0.140 mmol) was employed. FCC (gradient 
elution: 9:1 – 6:1 – 3:1 hexane:EtOAc) afforded 147 (28.1 mg, 78 %, 1:1 mixture of cis and trans 
diastereomers) as a colourless crystalline solid. The relative stereochemistry of the cis diastereomer was 
assigned based on the observed NOE correlation between the C2 and the C4 protons. Spectroscopic 
data for both diastereomers: νmax / cm-1: (film) 2922 (s), 2851 (m), 1449 (m), 1331 (s), 1150 (s). The 
1H 
signals were assigned as being from either the cis or the trans diastereomer based on 1D TOCSY 
analysis. The 1H and 13C signals corresponding to the cyclohexyl group could not be assigned to either 
diastereomer. δH (400 MHz, CDCl3) 5.85 – 5.70 (1H, m, cis and trans: C5-H), 5.26 (0.5H, ddd, J = 
17.0, 1.5, 1.5 Hz, trans: C6-H’), 5.25 (0.5H, ddd, J = 17.0, 1.0, 1.0 Hz, cis: C6-H’), 5.16 – 5.10 (1H, 
m, cis and trans: C6-H), 4.36 – 4.20 (0.5H, m, trans: C4-H), 4.16 (0.5H, br ddd, J = 9.5, 7.5, 7.0 Hz, 
cis: C4-H), 3.79 (0.5H, dd, J = 10.5, 7.5 Hz, cis: C1-H), 3.54 (0.5H, dd, J = 9.0, 7.5 Hz, trans: C1-H), 
3.00 (0.5H, dd, J = 9.5, 9.0 Hz, trans: C1-H’), 2.94 (0.5H, dd, J = 10.5, 10.5 Hz, cis: C1-H’), 2.83 (3H, 
s, cis and trans: Ms CH3), 2.31 (0.5H, ddd, J = 13.0, 7.0, 6.5 Hz, cis: C3-H), 2.10 – 1.97 (0.5H, m, 
trans: C2-H), 1.90 – 1.79 (1H, m, cis: C2-H and trans C3-H), 1.75 – 1.55 (5.5H, m, 5 × Cy CH and 
trans: C3-H’), 1.40 (0.5H, ddd, J = 13.0, 12.0, 9.5 Hz, cis: C3-H’), 1.29 – 1.06 (4H, m, 4 × Cy CH), 
1.04 – 0.86 (2H, m, 2 × Cy CH). δC (101 MHz, CDCl3) 138.9 (cis: C5), 138.3 (trans: C5), 116.4 (cis: 
C6), 115.8 (trans: C6), 63.0 (cis: C4), 61.6 (trans: C4), 52.8 (cis: C1), 52.4 (trans: C1), 44.7 (cis: C2), 
43.1 (trans: C2), 41.5 (Cy CH), 41.3 (Cy CH), 38.7 (cis: C3), 38.6 (cis or trans: Ms CH3), 37.3 (cis or 
trans: Ms CH3), 36.6 (trans: C3), 32.0 (Cy CH), 31.9 (Cy CH), 31.6 (Cy CH), 31.5 (Cy CH), 2 × 26.2 
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To a solution of cinnamaldehyde (10.0 g, 75.6 mmol) in anhydrous Et2O (250 mL) at 0 °C was added 
MeLi (1.6 M in Et2O, 56.7 mL, 90.7 mmol). The reaction mixture was stirred for 2 hours at room 
temperature before addition of water (10 mL) followed by saturated aqueous NH4Cl (150 mL). The 
resulting phases were separated, and the aqueous phase was extracted with Et2O (2 × 100 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
4:1 hexane:EtOAc) afforded 148 (8.87 g, 79 %) as a yellow oil. δH (400 MHz, CDCl3) 7.39 – 7.34 (2H, 
m), 7.33 – 7.28 (2H, m), 7.26 – 7.20 (1H, m), 6.55 (1H, br d, J = 16.0 Hz), 6.25 (1H, dd, J = 16.0, 
6.5 Hz), 4.47 (1H, dqd, J = 6.5, 6.5, 1.0 Hz), 2.16 (1H, br s), 1.36 (3H, d, J = 6.5 Hz). δC (101 MHz, 
CDCl3) 136.8, 133.7, 129.4, 128.6, 127.7, 126.5, 68.9, 23.5. The spectroscopic properties were 
consistent with the data available in the literature.216 
Ethyl (E)-3-phenylhex-4-enoate 
 
General procedure L: Allylic alcohol 148 (1.39 g, 9.38 mmol) was employed. The reaction time was 
15 hours. FCC (eluent: 49:1 hexane:EtOAc) afforded the title compound (1.61 g, 79 %) as a colourless 
oil. δH (500 MHz, CDCl3) 7.32 – 7.27 (2H, m), 7.22 – 7.18 (3H, m), 5.60 (1H, ddq, J = 15.0, 7.5, 
1.5 Hz), 5.50 (1H, dqd, J = 15.0, 6.5, 1.0 Hz), 4.10 – 4.04 (2H, m), 3.81 (1H, br dt, J = 7.5, 7.5 Hz), 
2.72 – 2.67 (2H, m), 1.66 (3H, ddd, J = 6.5, 1.5, 1.0 Hz), 1.17 (3H, t, J = 7.0 Hz). δC (126 MHz, CDCl3) 
172.1, 143.5, 133.3, 128.6, 127.6, 126.6, 125.8, 60.4, 45.1, 41.2, 18.1, 14.3. The spectroscopic 
properties were consistent with the data available in the literature.217 
(E)-3-Phenylhex-4-en-1-ol (149) 
 
General procedure I: The preceding ester (1.61 g, 7.34 mmol) was employed, using anhydrous THF 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in THF). FCC (eluent: 3:1 hexane:EtOAc) afforded 149 
(821 mg, 63 %) as a colourless oil. δH (400 MHz, CDCl3) 7.33 – 7.28 (2H, m), 7.23 – 7.17 (3H, m), 
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5.60 (1H, ddq, J = 15.0, 8.0, 1.5 Hz), 5.56 – 5.46 (1H, m), 3.67 – 3.57 (2H, m), 3.41 (1H, br dt, J = 8.0, 
8.0 Hz), 2.00 – 1.90 (2H, m), 1.68 (3H, ddd, J = 5.5, 1.5, 1.0 Hz), 1.42 (1H, br s). δC (101 MHz, CDCl3) 
144.8, 134.8, 128.7, 127.6, 126.3, 125.3, 61.3, 45.6, 38.8, 18.1. The spectroscopic properties were 
consistent with the data available in the literature.218 
(E)-N-(3-Phenylhex-4-en-1-yl)-N-((triethylsilyl)oxy)-4-toluenesulfonamide 
 
General procedure E: TsNHOTES (vide supra, 407 mg, 1.35 mmol) was employed with alcohol 149 
(1.1 eq.). The reaction time was 22 hours. FCC (gradient elution: 2:3 – 0:1 hexane:PhMe) afforded the 
title compound (590 mg, 95 %) as a colourless oil. νmax / cm-1: (film) 2956 (s), 2877 (s), 1598 (m), 
1357 (s), 1168 (s). δH (400 MHz, CDCl3) 7.66 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.34 – 7.27 (4H, m, 4 × 
ArCH), 7.22 – 7.17 (1H, m, ArCH), 7.16 – 7.13 (2H, m, 2 × ArCH), 5.55 – 5.41 (2H, m, C4-H and 
C5-H), 3.20 (1H, td, J = 7.5, 7.0 Hz, C3-H), 2.91 (1H, dt, J = 13.5, 7.5 Hz, C1-H), 2.80 (1H, dt, J = 
13.5, 7.5 Hz, C1-H’), 2.44 (3H, s, Ts CH3), 1.97 (2H, ddd, J = 7.5, 7.5, 7.5 Hz, C2-H2), 1.66 (3H, d, J = 
5.0 Hz, C6-H3), 1.00 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.79 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). 
δC (101 MHz, CDCl3) 144.4 (ArC), 144.0 (ArC), 134.0 (C4), 129.9 (ArCH), 129.8 (ArC), 129.2 
(ArCH), 128.5 (ArCH), 127.4 (ArCH), 126.3 (ArCH), 125.5 (C5), 54.4 (C1), 46.4 (C3), 32.9 (C2), 21.6 
(Ts CH3), 17.9 (C6), 6.8 (Si(CH2CH3)3), 4.8 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for 
C25H38NO3SSi: 460.2336. Found [M+H]+: 460.2329. 
(E)-N-(3-Phenylhex-4-en-1-yl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure F: The preceding compound (547 mg, 1.19 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (387 mg, 94 %) as a colourless gum. νmax / cm-1: (film) 
3382 (br s), 2972 (s), 2918 (s), 1597 (m), 1341 (s), 1167 (s). δH (400 MHz, CDCl3) 7.75 (2H, d, J = 
8.5 Hz, 2 × ArCH), 7.37 – 7.26 (4H, m, 4 × ArCH), 7.23 – 7.16 (3H, m, 3 × ArCH), 6.62 (1H, br s, 
OH), 5.58 – 5.46 (2H, m, C4-H and C5-H), 3.39 (1H, dt, J = 7.0, 7.0 Hz, C3-H), 2.96 – 2.85 (2H, m, 
C1-H2), 2.46 (3H, s, Ts CH3), 2.00 (2H, dt, J = 7.0, 7.0 Hz, C2-H2), 1.67 (3H, d, J = 5.0 Hz, C6-H3). 
δC (101 MHz, CDCl3) 144.9 (ArC), 144.4 (ArC), 133.9 (C4), 129.8 (ArCH), 129.6 (ArCH), 129.5 
(ArC), 128.6 (ArCH), 127.6 (ArCH), 126.4 (ArCH), 125.9 (C5), 50.9 (C1), 45.9 (C3), 32.7 (C2), 21.7 
(Ts CH3), 18.0 (C6). HRMS: (ESI+) Calculated for C19H24NO3S: 346.1471. Found [M+H]+: 346.1469. 
 





General procedure C: The preceding compound (354 mg, 1.02 mmol) was employed. FCC (eluent: 
7:1 hexane:EtOAc) afforded 152 (470 mg, 85 %) as a colourless crystalline solid. m.p. 121-122 °C 
(Et2O:hexane, cubes). νmax / cm-1: (solid) 2907 (m), 1780 (s), 1656 (m), 1596 (m), 1505 (s), 1171 (s). 
δH (400 MHz, CDCl3) 7.76 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.36 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.32 – 
7.25 (2H, m, 2 × ArCH), 7.21 – 7.15 (3H, m, 3 × ArCH), 5.59 – 5.46 (2H, m, C4-H and C5-H), 3.53 
(1H, dt, J = 7.0, 6.5 Hz, C3-H), 3.18 (2H, br s, C1-H2), 2.46 (3H, s, Ts CH3), 1.89 (2H, td, J = 7.0, 
6.5 Hz, C2-H2), 1.66 (3H, d, J = 4.5 Hz, C6-H3). δC (101 MHz, CDCl3) 146.0 (ArC), 144.0 (ArC), 133.3 
(C4), 130.2 (ArC), 130.0 (ArCH), 129.8 (ArCH), 128.8 (ArCH), 127.6 (ArCH), 2 × 126.5 (ArCH and 
C5), 50.9 (C1), 45.6 (C3), 33.0 (C2), 21.9 (Ts CH3), 18.1 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (283 MHz, 
CDCl3) -135.7 – -136.0 (2F, m), -146.0 (1F, tt, J = 21.0, 5.0 Hz), -158.8 – -159.2 (2F, m). HRMS: (ESI+) 
Calculated for C26H22F5NNaO4S: 562.1082. Found [M+Na]+: 562.1077. 
(2R*,3R*)-3-Phenyl-1-tosyl-2-vinylpyrrolidine (154) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; n-BuCN (0.1 M); 110 °C; 16 hours. Substrate 152 (75.5 mg, 0.140 mmol) was employed. FCC 
(gradient elution: 9:1 – 4:1 hexane:EtOAc) afforded 154 (37.2 mg, 81 %, 2:1 mixture of trans and cis 
diastereomers) as a colourless oil. Spectroscopic data for the major trans diastereomer: 
νmax / cm-1: (film) 3029 (m), 2979 (m), 1598 (m), 1345 (s), 1159 (s). δH (400 MHz, CDCl3) 7.74 (2H, d, 
J = 8.0 Hz), 7.38 – 7.16 (5H, m), 6.95 – 6.89 (2H, m), 5.86 (1H, ddd, J = 17.0, 10.5, 7.0 Hz), 5.08 (1H, 
d, J = 10.5 Hz), 5.06 (1H, d, J = 17.0 Hz), 3.97 (1H, dd, J = 7.0, 7.0 Hz), 3.74 – 3.63 (1H, m), 3.53 (1H, 
ddd, J = 11.0, 9.0, 6.5 Hz), 3.07 (1H, ddd, J = 9.5, 7.0, 7.0 Hz), 2.47 (3H, s), 2.18 – 2.01 (1H, m), 1.76 
– 1.59 (1H, m). δC (101 MHz, CDCl3) 143.4, 140.1, 137.6, 135.4, 129.6, 128.5, 127.6, 127.4, 127.0, 
116.2, 69.5, 52.0, 48.6, 32.3, 21.6. The spectroscopic properties were consistent with the data available 
in the literature.211 Characteristic signals for the minor cis diastereomer: δH (400 MHz, CDCl3) 7.80 
(2H, d, J = 8.0 Hz), 5.38 – 5.24 (2H, m), 4.52 (1H, dd, J = 8.0, 4.5 Hz), 3.35 (1H, ddd, J = 10.0, 10.0, 
7.0 Hz), 2.31 – 2.20 (1H, m). 
 





This compound was prepared according to a literature procedure.219 To a solution of 3-methylbut-1-yne 
(5.31 mL, 52.0 mmol) in anhydrous Et2O (30 mL) at 0 °C was added n-BuLi (1.55 M in hexane, 
28.4 mL, 44.0 mmol) dropwise. The reaction mixture was stirred at 0 °C for 30 minutes before addition 
of acetaldehyde (2.24 mL, 40.0 mmol), then stirred for a further 2 hours at 0 °C before addition of 
saturated aqueous NH4Cl (40 mL). The resulting phases were separated, and the aqueous phase was 
extracted with Et2O (2 × 50 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 3:1 hexane:Et2O) afforded the title compound (1.74 g, 39 %) as a 
colourless oil. νmax / cm-1: (film) 3334 (br s), 2971 (s), 2934 (s), 2873 (s), 1320 (s), 1046 (s). 
δH (400 MHz, CDCl3) 4.50 (1H, br q, J = 6.5 Hz), 2.55 (1H, hept d, J = 7.0, 2.0 Hz), 2.02 (1H, br s), 
1.40 (3H, d, J = 6.5 Hz), 1.14 (6H, d, J = 7.0 Hz). δC (101 MHz, CDCl3) 90.0, 81.4, 58.5, 24.7, 22.9, 
20.4. The spectroscopic properties were consistent with the data available in the literature.220 
(E)-5-Methylhex-3-en-2-ol (150) 
 
This compound was prepared according to a literature procedure.221 A solution of the preceding 
compound (1.50 g, 13.4 mmol), NaOMe (1.16 g, 21.4 mmol) and LiAlH4 (1.0 M in THF, 16.0 mL, 
16.0 mmol) in anhydrous THF (9 mL) was heated at reflux for 4 hours. The reaction mixture was cooled 
to 0 °C before addition of water (1 mL), 4.0 M aqueous NaOH (1 mL) and water (3 mL). The reaction 
mixture was stirred at room temperature for 15 minutes before filtration through celite and elution with 
CH2Cl2. The filtrate was dried over Na2SO4 and concentrated in vacuo to afford 150 (1.23 g, 80 %) as 
a colourless oil. νmax / cm-1: (film) 3338 (br s), 2961 (s), 2870 (s), 1464 (s), 1365 (m), 1056 (s). 
δH (400 MHz, CDCl3) 5.58 (1H, ddd, J = 15.5, 6.5, 1.0 Hz), 5.44 (1H, ddd, J = 15.5, 6.5, 1.0 Hz), 4.23 
(1H, dqd, J = 6.5, 6.5, 1.0 Hz), 2.25 (1H, hept dd, J = 6.5, 6.5, 1.0 Hz), 1.69 (1H, br s), 1.23 (3H, d, 
J = 6.5 Hz), 0.97 (6H, d, J = 6.5 Hz). δC (101 MHz, CDCl3) 137.9, 131.1, 68.9, 30.5, 23.4, 2 × 22.2. 
The spectroscopic properties were consistent with the data available in the literature.222 
  





General procedure L: Allylic alcohol 150 (1.14 g, 10.0 mmol) was employed. The reaction time was 
15 hours. FCC (eluent: 39:1 hexane:EtOAc) afforded the title compound (1.11 g, 60 %) as a colourless 
oil. νmax / cm-1: (film) 2960 (s), 2874 (m), 1735 (s), 1465 (m), 1369 (s), 1173 (s), 1036 (s). δH (400 MHz, 
CDCl3) 5.41 (1H, dq, J = 15.5, 6.5 Hz, C5-H), 5.23 (1H, ddq, J = 15.5, 8.5, 1.5 Hz, C4-H), 4.08 (2H, q, 
J = 7.0 Hz, OCH2CH3), 2.37 (1H, dd, J = 13.0, 5.0 Hz, C2-H), 2.34 – 2.26 (1H, m, C3-H), 2.19 (1H, 
dd, J = 13.0, 9.0 Hz, C2-H’), 1.63 (3H, dd, J = 6.5, 1.5 Hz, C6-H3), 1.61 – 1.53 (1H, m, CH(CH3)2), 
1.21 (3H, t, J = 7.0 Hz, OCH2CH3), 0.86 (3H, d, J = 7.0 Hz, CH(CH3)(CH3)’), 0.82 (3H, d, J = 7.0 Hz, 
CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 173.3 (C1), 131.4 (C4), 126.7 (C5), 60.2 (OCH2CH3), 45.9 
(C3), 38.3 (C2), 31.8 (CH(CH3)2), 20.5 (CH(CH3)(CH3)’), 19.0 (CH(CH3)(CH3)’), 18.1 (C6), 14.4 
(OCH2CH3). HRMS: (ESI+) Calculated for C11H20NaO2: 207.1356. Found [M+Na]+: 207.1347. 
(E)-3-Isopropylhex-4-en-1-ol (151) 
 
General procedure I: The preceding ester (1.04 g, 5.64 mmol) was employed, using anhydrous Et2O 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in Et2O). FCC (gradient elution: 5:1 – 2:1 hexane:Et2O) 
afforded 151 (675 mg, 84 %) as a colourless oil. δH (400 MHz, CDCl3) 5.41 (1H, dq, J = 15.5, 6.5 Hz), 
5.21 (1H, ddq, J = 15.5, 9.5, 1.5 Hz), 3.68 – 3.53 (2H, m), 1.92 – 1.81 (1H, m), 1.72 – 1.61 (1H, m), 
1.67 (3H, dd, J = 6.5, 1.5 Hz), 1.58 – 1.39 (3H, m), 0.86 (3H, d, J = 7.0 Hz), 0.82 (3H, d, J = 7.0 Hz). 
δC (101 MHz, CDCl3) 133.0, 126.3, 61.9, 46.3, 35.3, 32.2, 20.5, 18.9, 17.9. The spectroscopic properties 
were consistent with the data available in the literature.218  
(E)-N-(3-Isopropylhex-4-en-1-yl)-N-((tert-butyldimethylsilyl)oxy)-4-toluenesulfonamide 
 
General procedure E: TsNHOTBS (vide supra, 905 mg, 3.00 mmol) was employed with alcohol 151 
(1.1 eq.). The reaction time was 15 hours. FCC (eluent: 1:4 hexane:PhMe) afforded the title compound 
(1.25 g, 98 %) as a colourless oil. νmax / cm-1: (film) 2957 (s), 2930 (s), 2859 (s), 1598 (m), 1472 (m), 
1358 (s), 1170 (s). δH (400 MHz, CDCl3) 7.71 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.33 (2H, d, J = 8.0 Hz, 
2 × ArCH), 5.30 (1H, dq, J = 15.5, 6.5 Hz, C5-H), 5.08 (1H, ddq, J = 15.5, 8.5, 1.5 Hz, C4-H), 2.94 
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(1H, ddd, J = 13.0, 11.0, 4.5 Hz, C1-H), 2.79 (1H, ddd, J = 13.0, 10.5, 5.0 Hz, C1-H’), 2.45 (3H, s, 
Ts CH3), 1.72 – 1.59 (5H, m, C2-H, C3-H and C6-H3), 1.54 – 1.34 (2H, m, C2-H’ and CH(CH3)2), 0.92 
(9H, s, SiC(CH3)3), 0.80 (3H, d, J = 6.5 Hz, CH(CH3)(CH3)’), 0.77 (3H, d, J = 7.0 Hz, CH(CH3)(CH3)’), 
0.28 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 144.5 (ArC), 132.2 (C4), 130.4 (ArC), 130.0 (ArCH), 
129.3 (ArCH), 126.9 (C5), 55.2 (C1), 47.4 (C3), 32.2 (CH(CH3)2), 29.6 (C2), 26.2 (SiC(CH3)3), 21.8 
(Ts CH3), 20.6 (CH(CH3)(CH3)’), 19.1 (CH(CH3)(CH3)’), 18.3 (SiC(CH3)3), 18.1 (C6), -4.1 (Si(CH3)2). 
HRMS: (ESI+) Calculated for C22H40NO3SSi: 426.2493. Found [M+H]+: 426.2477. 
(E)-N-(3-Isopropylhex-4-en-1-yl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure B: The preceding compound (1.16 g, 2.72 mmol) was employed. FCC (eluent: 
5:1 hexane:EtOAc) afforded the title compound (791 mg, 93 %) as a colourless oil. νmax / cm-1: (film) 
3380 (br s), 2959 (s), 2872 (s), 1598 (m), 1439 (m), 1341 (s), 1167 (s). δH (400 MHz, CDCl3) 7.77 (2H, 
d, J = 8.0 Hz, 2 × ArCH), 7.36 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.38 (1H, s, OH), 5.38 (1H, dq, J = 15.5, 
6.5 Hz, C5-H), 5.12 (1H, ddq, J = 15.5, 9.5, 1.5 Hz, C4-H), 2.92 (1H, ddd, J = 12.5, 8.5, 7.0 Hz, C1-H), 
2.82 (1H, ddd, J = 12.5, 8.5, 5.0 Hz, C1-H’), 2.45 (3H, s, Ts CH3), 1.87 – 1.71 (2H, m, C2-H and C3-H), 
1.65 (3H, dd, J = 6.5, 1.5 Hz, C6-H3), 1.60 – 1.38 (2H, m, C2-H’ and CH(CH3)2), 0.84 (3H, d, J = 
6.5 Hz, CH(CH3)(CH3)’), 0.80 (3H, d, J = 7.0 Hz, CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 144.9 (ArC), 
132.1 (C4), 129.8 (ArCH), 129.7 (ArC), 129.6 (ArCH), 127.1 (C5), 51.5 (C1), 46.6 (C3), 32.1 
(CH(CH3)2), 29.3 (C2), 21.8 (Ts CH3), 20.7 (CH(CH3)(CH3)’), 19.1 (CH(CH3)(CH3)’), 18.2 (C6). 
HRMS: (ESI+) Calculated for C16H25NNaO3S: 334.1447. Found [M+Na]+: 334.1445.  
(E)-N-(3-Isopropylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)-4-toluenesulfonamide (153) 
 
General procedure C: The preceding compound (722 mg, 2.32 mmol) was employed. FCC (eluent: 
12:1 hexane:EtOAc) afforded 153 (869 mg, 74 %) as a colourless oil. νmax / cm-1: (film) 2961 (m), 
1786 (s), 1652 (m), 1597 (m), 1498 (s), 1169 (s). δH (400 MHz, CDCl3) 7.79 (2H, d, J = 8.0 Hz, 2 × 
ArCH), 7.37 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.40 (1H, dq, J = 15.5, 6.5 Hz, C5-H), 5.14 – 5.04 (1H, m, 
C4-H), 3.38 – 3.02 (2H, m, C1-H2), 2.47 (3H, s, Ts CH3), 1.99 – 1.86 (1H, m, C3-H), 1.72 – 1.61 (1H, 
m, C2-H), 1.66 (3H, dd, J = 6.5, 1.5 Hz, C6-H3), 1.54 – 1.36 (2H, m, C2-H’ and CH(CH3)2), 0.83 (3H, 
d, J = 7.0 Hz, CH(CH3)(CH3)’), 0.80 (3H, d, J = 7.0 Hz, CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 145.7 
(ArC), 131.5 (C4), 130.2 (ArC), 129.8 (ArCH), 129.6 (ArCH), 127.6 (C5), 51.4 (C1), 46.3 (C3), 32.0 
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(CH(CH3)2), 28.9 (C2), 21.7 (Ts CH3), 20.4 (CH(CH3)(CH3)’), 19.0 (CH(CH3)(CH3)’), 18.0 (C6). The 
13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.1 – -136.3 (2F, m), -146.3 (1F, tt, J = 21.0, 5.0 Hz), -158.9 – -159.1 
(2F, m). HRMS: (ESI+) Calculated for C23H24F5NNaO4S: 528.1238. Found [M+Na]+: 528.1229. 
(2R*,3R*)-3-Isopropyl-1-tosyl-2-vinylpyrrolidine (155) 
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 18.8 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; n-BuCN (0.1 M); 110 °C; 16 hours. Substrate 153 (70.2 mg, 0.139 mmol) was employed. FCC 
(eluent: 9:1 hexane:EtOAc) afforded 155 (32.6 mg, 80 %, 2:1 mixture of trans and cis diastereomers) 
as a pale-yellow oil. The major diastereomer was assigned as trans based on the observed NOE 
correlation between the C3 and the C5 protons. The minor diastereomer was assigned as cis based on 
the observed NOE correlation between the C6-H’ and isopropyl CH3 protons. νmax / cm-1: (film) 
2960 (m), 1598 (m), 1451 (m), 1344 (s), 1161 (s). 1H and 13C NMR data for the major trans 
diastereomer: δH (400 MHz, CDCl3) 7.70 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.28 (2H, d, J = 8.0 Hz, 2 × 
ArCH), 5.75 (1H, ddd, J = 17.0, 10.5, 7.0 Hz, C5-H), 5.24 (1H, dd, J = 17.0, 1.0 Hz, C6-H’), 5.10 (1H, 
dd, J = 10.5, 1.0 Hz, C6-H), 3.81 (1H, dd, J = 7.0, 6.5 Hz, C4-H), 3.47 – 3.39 (1H, m, C1-H), 3.31 (1H, 
ddd, J = 10.5, 8.0, 6.5 Hz, C1-H’), 2.41 (3H, s, Ts CH3), 1.73 (1H, ddd, J = 11.5, 6.5, 6.0 Hz, C2-H), 
1.68 – 1.60 (1H, m, C3-H), 1.33 – 1.17 (2H, m, C2-H’ and CH(CH3)2), 0.81 (3H, d, J = 6.5 Hz, 
CH(CH3)(CH3)’), 0.67 (3H, d, J = 6.5 Hz, CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 143.2 (ArC), 139.1 
(C5), 135.7 (ArC), 129.4 (ArCH), 127.4 (ArCH), 115.5 (C6), 65.5 (C4), 52.5 (C3), 48.0 (C1), 28.5 
(CH(CH3)2), 26.7 (C2), 21.7 (Ts CH3), 21.5 (CH(CH3)(CH3)’), 19.0 (CH(CH3)(CH3)’). 
1H and 13C NMR 
data for the minor cis diastereomer: δH (400 MHz, CDCl3) 7.70 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.28 
(2H, d, J = 8.0 Hz, 2 × ArCH), 5.67 (1H, ddd, J = 17.0, 10.0, 7.0 Hz, C5-H), 5.36 – 5.29 (1H, m, C6-H’), 
5.19 (1H, d, J = 10.5 Hz, C6-H), 4.31 (1H, dd, J = 7.0, 7.0 Hz, C4-H), 3.46 – 3.39 (1H, m, C1-H), 3.15 
(1H, ddd, J = 11.0, 10.0, 6.5 Hz, C1-H’), 2.41 (3H, s, Ts CH3), 1.88 (1H, ddd, J = 12.0, 6.5, 6.0 Hz, 
C2-H), 1.53 (1H, ddd, J = 12.0, 11.0, 8.5 Hz, C2-H’), 1.43 – 1.32 (2H, m, C3-H and CH(CH3)2), 0.85 
(3H, d, J = 6.0 Hz, CH(CH3)(CH3)’), 0.81 (3H, d, J = 6.5 Hz, CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 
143.0 (ArC), 135.8 (ArC), 133.8 (C5), 129.4 (ArCH), 127.4 (ArCH), 117.8 (C6), 63.9 (C4), 51.3 (C3), 
47.1 (C1), 28.0 (C2), 27.9 (CH(CH3)2), 21.5 (Ts CH3), 2 × 21.4 (CH(CH3)(CH3)’ and CH(CH3)(CH3)’). 
HRMS: (ESI+) Calculated for C16H24NO2S: 294.1522. Found [M+H]+: 294.1526. 
 





General procedure I: (E)-2-Methylbut-2-enoic acid (15.0 g, 150 mmol) was employed, using 
anhydrous Et2O as the solvent and 1.1 eq. LiAlH4 (1.0 M in Et2O). The title compound (10.8 g, 84 %) 
was isolated as a colourless oil. δH (400 MHz, CDCl3) 5.48 (1H, qq, J = 6.5, 1.5 Hz), 3.98 (2H, s), 1.66 
(3H, br s), 1.61 (3H, dq, J = 6.5, 1.0 Hz), 1.52 (1H, br s). δC (101 MHz, CDCl3) 135.6, 120.7, 69.1, 
13.5, 13.2. The spectroscopic properties were consistent with the data available in the literature.223 
(E)-1-Bromo-2-methylbut-2-ene 
 
General procedure J: The preceding alcohol (10.4 g, 121 mmol) was employed. The title compound 
(11.6 g, 63 %) was isolated as a colourless oil. δH (400 MHz, CDCl3) 5.73 – 5.65 (1H, m), 3.98 (2H, 
br s), 1.75 (3H, dq, J = 1.0, 1.0 Hz), 1.63 (3H, dq, J = 7.0, 1.0 Hz). δC (101 MHz, CDCl3) 132.8, 126.0, 




General procedure H: (E)-1-Bromo-2-methylbut-2-ene (vide supra, 1.18 ml, 10.0 mmol) was 
employed. The crude product was used in the next step without further purification. δH (400 MHz, 
CDCl3) 5.29 – 5.19 (1H, m), 2.47 – 2.40 (2H, m), 2.30 (2H, t, J = 7.5 Hz), 1.61 (3H, t, J = 1.0 Hz), 1.58 
– 1.53 (3H, m). δC (101 MHz, CDCl3) 178.8, 133.9, 119.5, 34.5, 33.0, 15.7, 13.5. The spectroscopic 
properties were consistent with the data available in the literature.224  
(E)-4-Methylhex-4-en-1-ol 
 
General procedure I: The preceding crude carboxylic acid was employed, using anhydrous Et2O as 
the solvent and 2.0 eq. LiAlH4 (1.0 M in Et2O). FCC (eluent: 4:1 pentane:Et2O) afforded the title 
compound (618 mg, 54 % over two steps) as a pale-yellow oil. νmax / cm-1: (film) 3327 (br s), 2936 (s), 
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2863 (s), 1444 (s), 1381 (s), 1059 (s). δH (400 MHz, CDCl3) 5.28 – 5.22 (1H, m), 3.63 (2H, t, J = 
6.5 Hz), 2.09 – 2.03 (2H, m), 1.71 – 1.63 (2H, m), 1.61 (3H, t, J = 1.0 Hz), 1.57 (3H, br d, J = 6.5 Hz), 
1.34 (1H, br s). δC (101 MHz, CDCl3) 135.6, 119.0, 63.1, 36.1, 30.9, 15.7, 13.5. The spectroscopic 
properties were consistent with the data available in the literature.225 
(E)-N-(4-Methylhex-4-en-1-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 676 mg, 3.00 mmol) was employed with the 
preceding alcohol (1.1 eq.). The reaction time was 14 hours. FCC (eluent: 12:1 hexane:EtOAc) afforded 
the title compound (897 mg, 93 %) as a colourless oil. νmax / cm-1: (film) 2956 (s), 2913 (s), 2878 (s), 
1350 (s), 1164 (s). δH (400 MHz, CDCl3) 5.22 (1H, q, J = 6.5 Hz, C5-H), 3.18 – 3.10 (2H, m, C1-H2), 
2.85 (3H, s, Ms CH3), 2.03 (2H, t, J = 7.5 Hz, C3-H2), 1.77 (2H, tt, J = 8.0, 7.5 Hz, C2-H2), 1.60 (3H, 
br s, C7-H3), 1.58 (3H, dq, J = 6.5, 1.0 Hz, C6-H3), 1.00 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.78 (6H, q, 
J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 134.2 (C4), 119.4 (C5), 55.3 (C1), 36.7 (C3), 30.4 
(Ms CH3), 25.2 (C2), 15.5 (C7), 13.4 (C6), 6.7 (Si(CH2CH3)3), 4.8 (Si(CH2CH3)3). HRMS: (ESI+) 
Calculated for C14H31NNaO3SSi: 344.1686. Found [M+Na]+: 344.1690. 
(E)-N-(4-Methylhex-4-en-1-yl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (859 mg, 2.67 mmol) was employed. FCC (eluent: 
3:1 hexane:EtOAc) afforded the title compound (546 mg, 99 %) as a pale-yellow oil. νmax / cm-1: (solid) 
3351 (br s), 2973 (m), 2938 (m), 2863 (m), 1324 (s), 1148 (s). δH (400 MHz, CDCl3) 6.80 (1H, br s, 
OH), 5.24 (1H, qq, J = 6.5, 1.5 Hz, C5-H), 3.17 – 3.12 (2H, m, C1-H2), 2.92 (3H, s, Ms CH3), 2.10 – 
2.03 (2H, m, C3-H2), 1.80 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.60 (3H, br s, C7-H3), 1.57 (3H, dq, J = 6.5, 
1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 134.4 (C4), 119.4 (C5), 52.0 (C1), 36.3 (C3), 30.9 (Ms CH3), 
25.0 (C2), 15.4 (C7), 13.4 (C6). HRMS: (ESI+) Calculated for C8H17NNaO3S: 230.0821. Found 
[M+Na]+: 230.0811. 
  





General procedure C: The preceding compound (509 mg, 2.46 mmol) was employed. FCC (gradient 
elution: 6:1 – 3:1 hexane:EtOAc) afforded 156 (859 mg, 87 %) as a colourless crystalline solid. 
m.p. 67-68 °C (Et2O:hexane, plates). νmax / cm-1: (solid) 2936 (m), 1780 (s), 1653 (m), 1502 (s), 
1354 (s), 1163 (s). δH (400 MHz, CDCl3) 5.26 (1H, q, J = 6.5 Hz, C5-H), 3.43 (2H, br s, C1-H2), 3.04 
(3H, s, Ms CH3), 2.15 (2H, t, J = 7.5 Hz, C3-H2), 1.78 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.61 – 1.56 (6H, 
m, C6-H3 and C7-H3). δC (101 MHz, CDCl3) 133.9 (C4), 120.2 (C5), 52.2 (C1), 36.3 (C3), 34.5 
(Ms CH3), 25.1 (C2), 15.5 (C7), 13.5 (C6). The 
13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.8 – -135.9 (2F, m), 
-145.3 (1F, tt, J = 21.0, 5.5 Hz), -158.8 – -159.0 (2F, m). HRMS: (ESI+) Calculated for 
C15H16F5NNaO4S: 424.0612. Found [M+Na]+: 424.0610. 
2-Methyl-1-mesyl-2-vinylpyrrolidine (157) 
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 18.8 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 16 hours. Substrate 156 (56.7 mg, 0.140 mmol) was 
employed. FCC (eluent: 10:1 PhMe:EtOAc) afforded 157 (21.3 mg, 80 %) as a pale-yellow oil. 
νmax / cm-1: (film) 2976 (m), 2928 (m), 1330 (s), 1148 (s). δH (400 MHz, CDCl3) 5.98 (1H, dd, J = 17.5, 
10.5 Hz, C5-H), 5.24 (1H, dd, J = 17.5, 0.5 Hz, C6-H’), 5.15 (1H, dd, J = 10.5, 0.5 Hz, C6-H), 3.53 – 
3.44 (2H, m, C1-H2), 2.86 (3H, s, Ms CH3), 2.04 – 1.97 (1H, m, C3-H), 1.94 – 1.81 (3H, m, C2-H2 and 
C3-H’), 1.57 (3H, s, C7-H3). δC (101 MHz, CDCl3) 142.1 (C5), 114.0 (C6), 67.0 (C4), 49.5 (C1), 41.7 
(C3), 39.7 (Ms CH3), 25.1 (C7), 22.4 (C2). HRMS: (ESI+) Calculated for C8H15NNaO2S: 212.0716. 
Found [M+Na]+: 212.0714. 
  





This compound was prepared according to a literature procedure.226 To a suspension of magnesium 
turnings (401 mg, 16.5 mmol), activated with a crystal of iodine, in anhydrous THF (35 mL) was added 
(1-bromovinyl)benzene (1.95 mL, 15.0 mmol). The reaction mixture was heated at reflux for 1 hour, 
then cooled to 0 °C before addition of acetaldehyde (1.26 mL, 22.5 mmol) dropwise. The reaction 
mixture was stirred at room temperature for 1.5 hours before addition of saturated aqueous NH4Cl 
(100 mL). The resulting phases were separated, and the aqueous phase was extracted with Et2O (2 × 
80 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
5:1 hexane:EtOAc) afforded 158a (1.68 g, 76 %) as a pale-yellow oil. νmax / cm-1: (film) 3368 (br s), 
3057 (m), 2976 (s), 1493 (s), 1070 (s). δH (400 MHz, CDCl3) 7.43 – 7.28 (5H, m), 5.38 (1H, dd, J = 
1.0, 1.0 Hz), 5.29 (1H, dd, J = 1.0, 1.0 Hz), 4.83 (1H, qdd, J = 6.5, 1.0, 1.0 Hz), 1.91 (1H, br s), 1.33 
(3H, d, J = 6.5 Hz). δC (101 MHz, CDCl3) 153.1, 139.9, 128.4, 127.6, 126.8, 111.6, 69.5, 22.6. The 
spectroscopic properties were consistent with the data available in the literature.226 
Ethyl (Z)-4-phenylhex-4-enoate 
 
General procedure L: Allylic alcohol 158a (1.48 g, 10.0 mmol) was employed. The reaction time was 
15 hours. FCC (eluent: 29:1 hexane:EtOAc) afforded the title compound (1.85 g, 85 %, 11:1 mixture 
of (Z)- and (E)-isomers) as a colourless oil. Spectroscopic data for the major (Z)-isomer: 
νmax / cm-1: (film) 2980 (m), 2935 (m), 1732 (s), 1152 (s). δH (400 MHz, CDCl3) 7.37 – 7.29 (2H, m, 2 × 
ArCH), 7.27 – 7.22 (1H, m, ArCH), 7.17 – 7.13 (2H, m, 2 × ArCH), 5.60 (1H, qt, J = 7.0, 1.0 Hz, 
C5-H), 4.08 (2H, q, J = 7.0 Hz, OCH2CH3), 2.70 – 2.64 (2H, m, C3-H2), 2.33 – 2.28 (2H, m, C2-H2), 
1.55 (3H, dt, J = 7.0, 1.0 Hz, C6-H3), 1.22 (3H, t, J = 7.0 Hz, OCH2CH3). δC (101 MHz, CDCl3) 173.3 
(C1), 140.1 (ArC), 140.0 (C4), 128.6 (ArCH), 128.1 (ArCH), 126.6 (ArCH), 122.2 (C5), 60.2 
(OCH2CH3), 34.4 (C3), 33.4 (C2), 14.6 (C6), 14.2 (OCH2CH3). HRMS: (ESI+) Calculated for 
C14H18NaO2: 241.1199. Found [M+Na]+: 241.1198. The minor isomer was assigned as E based on the 
observed NOE correlation between the C3 and the C6 protons. Characteristic signals for the minor 
(E)-isomer: δH (400 MHz, CDCl3) 5.78 (1H, q, J = 7.0 Hz), 2.88 – 2.82 (2H, m), 1.82 (3H, d, J = 
7.0 Hz). 
 





General procedure I: The preceding ester (1.80 g, 8.25 mmol) was employed, using anhydrous THF 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in THF). Alcohol 159a (1.42 g, 98 %, 11:1 mixture of (Z)- and 
(E)-isomers) was isolated as a colourless oil. Spectroscopic data for the major (Z)-isomer:  
νmax / cm-1: (film) 3326 (br s), 2936 (s), 2859 (s), 1440 (s), 1054 (s). δH (400 MHz, CDCl3) 7.37 – 7.31 
(2H, m, 2 × ArCH), 7.27 – 7.21 (1H, m, ArCH), 7.18 – 7.13 (2H, m, 2 × ArCH), 5.59 (1H, qt, J = 7.0, 
1.5 Hz, C5-H), 3.61 (2H, t, J = 6.5 Hz, C1-H2), 2.46 – 2.40 (2H, m, C3-H2), 1.61 – 1.53 (5H, m, C2-H2 
and C6-H3), 1.33 (1H, br s, OH). δC (101 MHz, CDCl3) 141.0 (ArC), 140.7 (C4), 128.5 (ArCH), 128.1 
(ArCH), 126.5 (ArCH), 121.6 (C5), 62.5 (C1), 35.4 (C3), 31.2 (C2), 14.7 (C6). HRMS: (ESI+) 
Calculated for C12H16NaO: 199.1093. Found [M+Na]+: 199.1100. Characteristic signals for the minor 




General procedure E: MsNHOTES (vide supra, 902 mg, 4.00 mmol) was employed with alcohol 159a 
(1.1 eq.). The reaction time was 16 hours. FCC (gradient elution: 1:0 – 9:1 PhMe:EtOAc) afforded the 
title compound (1.40 g, 91 %, 11:1 mixture of (Z)- and (E)-isomers) as a pale-orange oil. Spectroscopic 
data for the major (Z)-isomer: νmax / cm-1: (film) 2955 (m), 2913 (m), 2877 (m), 1349 (s), 1164 (s).  
δH (400 MHz, CDCl3) 7.38 – 7.29 (2H, m, 2 × ArCH), 7.27 – 7.22 (1H, m, ArCH), 7.16 – 7.12 (2H, m, 
2 × ArCH), 5.58 (1H, qt, J = 6.5, 1.0 Hz, C5-H), 3.18 – 3.12 (2H, m, C1-H2), 2.81 (3H, s, Ms CH3), 
2.46 – 2.37 (2H, m, C3-H2), 1.65 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.56 (3H, d, J = 6.5 Hz, C6-H3), 0.93 
(9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.69 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 2 × 
140.3 (ArC and C4), 128.5 (ArCH), 128.1 (ArCH), 126.6 (ArCH), 122.2 (C5), 55.1 (C1), 36.4 (C3), 
30.3 (Ms CH3), 25.6 (C2), 14.6 (C6), 6.7 (Si(CH2CH3)3), 4.7 (Si(CH2CH3)3). HRMS: (ESI+) Calculated 
for C19H34NO3SSi: 384.2023. Found [M+H]+: 384.2026. Characteristic signals for the minor 
(E)-isomer: δH (400 MHz, CDCl3) 5.78 (1H, q, J = 7.0 Hz), 2.57 (2H, t, J = 7.5 Hz), 1.81 (3H, d, J = 
7.0 Hz). 
  





General procedure F: The preceding compound (1.23 g, 3.21 mmol) was employed. FCC (eluent: 
3:1 hexane:EtOAc) afforded the title compound (573 mg, 66 %, 11:1 mixture of (Z)- and (E)-isomers) 
as a pale-red oil. Spectroscopic data for the major (Z)-isomer: νmax / cm-1: (film) 3379 (br s), 3021 (m), 
2935 (m), 1337 (s), 1163 (s). δH (400 MHz, CDCl3) 7.37 – 7.30 (2H, m, 2 × ArCH), 7.28 – 7.21 (1H, 
m, ArCH), 7.18 – 7.12 (2H, m, 2 × ArCH), 6.55 (1H, br s, OH), 5.60 (1H, q, J = 7.0 Hz, C5-H), 3.15 
(2H, t, J = 7.0 Hz, C1-H2), 2.89 (3H, s, Ms CH3), 2.49 – 2.42 (2H, m, C3-H2), 1.69 (2H, tt, J = 7.0, 
7.0 Hz, C2-H2), 1.57 (3H, dt, J = 7.0, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 140.5 (ArC), 140.2 (C4), 
128.5 (ArCH), 128.1 (ArCH), 126.5 (ArCH), 122.4 (C5), 51.7 (C1), 35.8 (C3), 30.8 (Ms CH3), 25.2 
(C2), 14.7 (C6). HRMS: (ESI+) Calculated for C13H19NNaO3S: 292.0978. Found [M+Na]+: 292.0974. 
Characteristic signals for the minor (E)-isomer: δH (400 MHz, CDCl3) 6.60 (1H, br s), 5.79 (1H, q, J = 
7.0 Hz), 2.63 (2H, t, J = 7.5 Hz), 1.81 (3H, d, J = 7.0 Hz). 
(Z)-N-(4-Phenylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)methanesulfonamide (160a) 
 
General procedure C: The preceding compound (563 mg, 2.09 mmol) was employed. FCC (eluent: 
5:1 hexane:EtOAc) afforded 160a (786 mg, 81 %, 12:1 mixture of (Z)- and (E)-isomers) as a colourless 
crystalline solid. Spectroscopic data for the major (Z)-isomer: νmax / cm-1: (solid) 2979 (m), 2933 (m), 
1787 (s), 1655 (m), 1504 (s), 1324 (s), 1164 (s). δH (400 MHz, CDCl3) 7.33 – 7.27 (2H, m, 2 × ArCH), 
7.23 – 7.18 (1H, m, ArCH), 7.16 – 7.12 (2H, m, 2 × ArCH), 5.63 (1H, qt, J = 7.0, 1.0 Hz, C5-H), 3.43 
(2H, br s, C1-H2), 3.01 (3H, s, Ms CH3), 2.55 (2H, br t, J = 7.5 Hz, C3-H2), 1.64 (2H, tt, J = 7.5, 7.0 Hz, 
C2-H2), 1.57 (3H, dt, J = 7.0, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 140.0 (ArC), 139.6 (C4), 128.5 
(ArCH), 128.1 (ArCH), 126.5 (ArCH), 123.0 (C5), 51.7 (C1), 35.6 (C3), 34.3 (Ms CH3), 25.0 (C2), 
14.7 (C6). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due  
to their weak intensity. δF (377 MHz, CDCl3) -135.7 – -135.8 (2F, m), -145.3 (1F, tt, J = 20.5, 
5.5 Hz), -158.8 – -159.0 (2F, m). HRMS: (ESI+) Calculated for C20H18F5NNaO4S: 486.0769. Found 
[M+Na]+: 486.0761. Characteristic signals for the minor (E)-isomer: δH (400 MHz, CDCl3) 5.81 (1H, 
q, J = 6.5 Hz), 2.75 (2H, t, J = 7.5 Hz), 1.84 (3H, d, J = 7.0 Hz). 
  





General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 18.8 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 15 hours. Substrate 160a (64.9 mg, 0.140 mmol) was 
employed. FCC (gradient elution: 14:1 – 9:1 – 7:1 – 4:1 – 3:1 – 2:1 hexane:EtOAc) afforded 161a 
(4.1 mg, 12 %) as a pale-orange oil. νmax / cm-1: (film) 2926 (m), 1447 (m), 1334 (s), 1149 (s). 
δH (500 MHz, CDCl3) 7.50 – 7.45 (2H, m, 2 × ArCH), 7.38 – 7.34 (2H, m, 2 × ArCH), 7.30 – 7.26 (1H, 
m, ArCH), 6.50 (1H, dd, J = 17.5, 10.5 Hz, C5-H), 5.49 (1H, dd, J = 17.5, 0.5 Hz, C6-H’), 5.47 (1H, 
dd, J = 10.5, 0.5 Hz, C6-H), 3.77 (1H, ddd, J = 8.5, 8.0, 4.5 Hz, C1-H), 3.57 (1H, ddd, J = 9.5, 8.0, 
7.5 Hz, C1-H’), 2.81 (3H, s, Ms CH3), 2.44 (1H, ddd, J = 12.5, 9.5, 6.5 Hz, C3-H), 2.27 – 2.18 (1H, m, 
C3-H’), 1.99 – 1.89 (1H, m, C2-H), 1.89 – 1.79 (1H, m, C2-H’). δC (126 MHz, CDCl3) 143.6 (ArC), 
139.4 (C5), 128.1 (ArCH), 127.2 (ArCH), 126.8 (ArCH), 116.5 (C6), 73.0 (C4), 49.9 (C1), 41.0 (C3), 




This compound was prepared according to a literature procedure.227 A solution of 3-methylbutanal 
(16.1 mL, 150 mmol), aqueous formaldehyde (12.3 M, 12.2 mL, 150 mmol), pyrrolidine (1.25 mL, 
15.0 mmol) and propionic acid (1.12 mL, 15.0 mmol) in i-PrOH (15 mL) was heated to 45 °C for 
5 hours. The reaction mixture was cooled to room temperature before addition of saturated aqueous 
NaHCO3 (100 mL) and extraction with CH2Cl2 (3 × 40 mL). The combined organic phases were dried 
over Na2SO4 and concentrated in vacuo. Distillation failed to separate completely the desired enal from 
i-PrOH. FCC (eluent: 14:1 pentane:Et2O) afforded the title compound (4.00 g, 27 %) as a colourless 
oil. δH (400 MHz, CDCl3) 9.52 (1H, s), 6.23 (1H, d, J = 1.0 Hz), 5.94 (1H, s), 2.79 (1H, hept d, J = 7.0, 
1.0 Hz), 1.07 (6H, d, J = 7.0 Hz). δC (101 MHz, CDCl3) 194.6, 156.4, 132.1, 26.1, 21.3. The 
spectroscopic properties were consistent with the data available in the literature.227 
  





To a solution of MeLi (1.6 M in Et2O, 16.0 mL, 25.6 mmol) in anhydrous Et2O (40 mL) at 0 °C was 
added a solution of the preceding aldehyde (3.00 g, 30.6 mmol) in anhydrous Et2O (10 mL). The 
reaction mixture was stirred at 0 °C for 1 hour before addition of water (5 mL) and saturated aqueous 
NH4Cl (40 mL). The resulting phases were separated, and the aqueous phase was extracted with Et2O 
(2 × 50 mL). The combined organic phases were washed with brine (50 mL), dried over Na2SO4 and 
concentrated in vacuo to afford 158b (2.86 g, 82 %) as a colourless oil. νmax / cm-1: (film) 3345 (br s), 
2962 (s), 1647 (m), 1460 (m), 1098 (s). δH (400 MHz, CDCl3) 5.05 (1H, dd, J = 1.0, 1.0 Hz, C4-H), 
4.86 (1H, d, J = 1.0 Hz, C4-H’), 4.28 (1H, q, J = 6.5 Hz, C2-H), 2.30 (1H, qqd, J = 7.0, 7.0, 1.0 Hz, 
CH(CH3)2), 1.58 (1H, br s, OH), 1.29 (3H, d, J = 6.5 Hz, C1-H3), 1.08 (3H, d, J = 7.0 Hz, 
CHCH3(CH3)’), 1.05 (3H, d, J = 7.0 Hz, CHCH3(CH3)’). δC (101 MHz, CDCl3) 160.4 (C3), 105.8 (C4), 
70.0 (C2), 30.2 (CH(CH3)2), 23.1 (CHCH3(CH3)’), 22.8 (C1), 22.6 (CHCH3(CH3)’). HRMS: (ESI+) 
Calculated for C7H14NaO: 137.0937. Found [M+Na]+: 137.0934. 
Ethyl (Z)-4-isopropylhex-4-enoate 
 
General procedure L: Allylic alcohol 158b (2.28 g, 20.0 mmol) was employed. The reaction time was 
13 hours. FCC (eluent: 19:1 hexane:Et2O) afforded the title compound (2.60 g, 71 %, 11:1 mixture of 
(Z)- and (E)-isomers) as a colourless oil. The major product was assigned as the (Z)-isomer based on 
the observed NOE correlation between the C3 and the C5 protons. Spectroscopic data for the major 
(Z)-isomer: νmax / cm-1: (film) 2962 (s), 2872 (s), 1736 (s), 1155 (s). δH (400 MHz, CDCl3) 5.09 (1H, q, 
J = 7.0 Hz, C5-H), 4.12 (2H, q, J = 7.0 Hz, OCH2CH3), 2.85 (1H, hept, J = 7.0 Hz, CH(CH3)2), 2.44 – 
2.37 (2H, m, C2-H2), 2.28 – 2.22 (2H, m, C3-H2), 1.59 (3H, dt, J = 7.0, 1.5 Hz, C6-H3), 1.25 (3H, t, J = 
7.0 Hz, OCH2CH3), 0.98 (6H, d, J = 7.0 Hz, CH(CH3)2). δC (101 MHz, CDCl3) 173.7 (C1), 143.4 (C4), 
116.9 (C5), 60.2 (OCH2CH3), 33.8 (C2), 28.4 (CH(CH3)2), 26.0 (C3), 20.8 (CH(CH3)2), 14.2 
(OCH2CH3), 12.7 (C6). HRMS: (ESI+) Calculated for C11H20NaO2: 207.1356. Found [M+Na]+: 
207.1353. Characteristic signals for the minor (E)-isomer: δH (400 MHz, CDCl3) 5.27 (1H, q, J = 
7.0 Hz), 2.35 – 2.32 (4H, m). 
 





General procedure I: The preceding ester (1.20 g, 6.51 mmol) was employed, using anhydrous Et2O 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in Et2O). Alcohol 159b (922 mg, 100 %, 11:1 mixture of (Z)- 
and (E)-isomers) was isolated as a colourless oil. Spectroscopic data for the major (Z)-isomer:  
νmax / cm-1: (film) 3327 (br s), 2959 (s), 1465 (m), 1056 (s). δH (400 MHz, CDCl3) 5.14 (1H, q, J = 
7.0 Hz, C5-H), 3.64 (2H, t, J = 6.5 Hz, C1-H2), 2.84 (1H, hept, J = 7.0 Hz, CH(CH3)2), 2.01 – 1.94 (2H, 
m, C3-H2), 1.66 (2H, tt, J = 7.5, 6.5 Hz, C2-H2), 1.59 (3H, dt, J = 7.0, 1.5 Hz, C6-H3), 0.97 (6H, d, J = 
7.0 Hz, CH(CH3)2). δC (101 MHz, CDCl3) 144.4 (C4), 117.0 (C5), 63.1 (C1), 32.1 (C2), 28.5 
(CH(CH3)2), 27.5 (C3), 20.9 (CH(CH3)2), 12.7 (C6). HRMS: (EI+) Calculated for C9H18O: 142.1358. 
Found [M]+: 142.1358. Characteristic signals for the minor (E)-isomer: δH (400 MHz, CDCl3) 5.24 
(1H, q, J = 7.0 Hz), 2.12 – 2.05 (2H, m). 
(Z)-N-(4-Isopropylhex-4-en-1-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 676 mg, 3.00 mmol) was employed with alcohol 159b 
(1.1 eq.). The reaction time was 14 hours. FCC (eluent: 1:4 hexane:PhMe) afforded the title compound 
(942 mg, 90 %, 12:1 mixture of (Z)- and (E)-isomers) as a colourless oil. Spectroscopic data for the 
major (Z)-isomer: νmax / cm-1: (film) 2958 (s), 2877 (s), 1460 (m), 1350 (s), 1164 (s). δH (400 MHz, 
CDCl3) 5.12 (1H, qt, J = 7.0, 1.5 Hz, C5-H), 3.22 – 3.16 (2H, m, C1-H2), 2.91 – 2.78 (1H, m, CH(CH3)2), 
2.85 (3H, s, Ms CH3), 2.00 – 1.92 (2H, m, C3-H2), 1.78 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.60 (3H, dt, 
J = 7.0, 1.5 Hz, C6-H3), 1.01 – 0.95 (15H, m, CH(CH3)2 and Si(CH2CH3)3), 0.77 (6H, q, J = 8.0 Hz, 
Si(CH2CH3)3). δC (101 MHz, CDCl3) 143.5 (C4), 117.2 (C5), 55.6 (C1), 30.3 (Ms CH3), 2 × 28.4 (C3 
and CH(CH3)2), 26.2 (C2), 20.8 (CH(CH3)2), 12.8 (C6), 6.7 (Si(CH2CH3)3), 4.8 (Si(CH2CH3)3). 
HRMS: (ESI+) Calculated for C16H36NO3SSi: 350.2180. Found [M+H]+: 350.2171. Characteristic 
signals for the minor (E)-isomer: δH (400 MHz, CDCl3) 5.27 (1H, q, J = 6.5 Hz), 2.08 – 2.02 (2H, m). 
  





General procedure F: The preceding compound (932 mg, 2.67 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (621 mg, 99 %, 13:1 mixture of (Z)- and (E)-isomers) 
as a colourless oil. Spectroscopic data for the major (Z)-isomer: νmax / cm-1: (film) 3380 (br s), 2960 (s), 
2870 (m), 1464 (m), 1334 (s), 1160 (s). δH (400 MHz, CDCl3) 6.66 (1H, br s, OH), 5.15 (1H, qt, J = 
7.0, 1.5 Hz, C5-H), 3.22 – 3.16 (2H, m, C1-H2), 2.92 (3H, s, Ms CH3), 2.84 (1H, hept, J = 7.0 Hz, 
CH(CH3)2), 2.05 – 1.97 (2H, m, C3-H2), 1.86 – 1.77 (2H, m, C2-H2), 1.60 (3H, dt, J = 7.0, 1.5 Hz, 
C6-H3), 0.98 (6H, d, J = 7.0 Hz, CH(CH3)2). δC (101 MHz, CDCl3) 143.7 (C4), 117.4 (C5), 52.3 (C1), 
30.8 (Ms CH3), 28.5 (CH(CH3)2), 28.1 (C3), 26.2 (C2), 20.9 (CH(CH3)2), 12.8 (C6). HRMS: (ESI+) 
Calculated for C10H21NNaO3S: 258.1134. Found [M+Na]+: 258.1134. Characteristic signals for the 
minor (E)-isomer: δH (400 MHz, CDCl3) 5.26 (1H, q, J = 7.0 Hz), 2.15 – 2.08 (2H, m). 
(Z)-N-(4-Isopropylhex-4-en-1-yl)-N-(pentafluorobenzoyloxy)methanesulfonamide (160b) 
 
General procedure C: The preceding compound (564 mg, 2.40 mmol) was employed. FCC (gradient 
elution: 9:1 – 5:1 hexane:EtOAc) afforded 160b (975 mg, 95 %, 11:1 mixture of (Z)- and (E)-isomers) 
as a colourless crystalline solid. The major product was assigned as the (Z)-isomer based on the 
observed NOE correlation between the C3 and the C5 protons. Spectroscopic data for the major 
(Z)-isomer: νmax / cm-1: (solid) 3032 (m), 2962 (m), 2873 (m), 1790 (s), 1657 (m), 1505 (s), 1358 (s), 
1167 (s). δH (400 MHz, CDCl3) 5.14 (1H, q, J = 7.0 Hz, C5-H), 3.53 – 3.42 (2H, m, C1-H2), 3.04 (3H, 
s, Ms CH3), 2.84 (1H, hept, J = 7.0 Hz, CH(CH3)2), 2.09 (2H, br t, J = 7.5 Hz, C3-H2), 1.79 (2H, tt, J = 
7.5, 7.0 Hz, C2-H2), 1.60 (3H, dt, J = 7.0, 1.5 Hz, C6-H3), 0.97 (6H, d, J = 7.0 Hz, CH(CH3)2).  
δC (101 MHz, CDCl3) 143.2 (C4), 117.9 (C5), 52.4 (C1), 34.3 (Ms CH3), 28.4 (CH(CH3)2), 28.0 (C3), 
26.2 (C2), 20.8 (CH(CH3)2), 12.7 (C6). The 
13C signals corresponding to the pentafluorobenzoyl group 
could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.1 (2F, m), -145.4 
(1F, tt, J = 21.0, 5.5 Hz), -158.8 – -159.0 (2F, m). HRMS: (ESI+) Calculated for C17H20F5NNaO4S: 
452.0925. Found [M+Na]+: 452.0947. Characteristic signals for the minor (E)-isomer: δH (400 MHz, 
CDCl3) 5.29 (1H, q, J = 7.0 Hz), 2.23 – 2.16 (2H, m). 
 





General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 18.8 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; n-BuCN (0.1 M); 110 °C; 14 hours. Substrate 160b (60.1 mg, 0.140 mmol) was employed. FCC 
(gradient elution: 5:1 – 4:1 – 3:1 hexane:EtOAc) afforded 161b (9.5 mg, 31 %) as a pale-yellow oil. 
νmax / cm-1: (film) 2963 (m), 1468 (m), 1331 (s), 1141 (s). δH (400 MHz, CDCl3) 6.12 (1H, dd, J = 17.5, 
11.0 Hz, C5-H), 5.28 – 5.22 (2H, m, C6-H2), 3.45 – 3.33 (2H, m, C1-H2), 2.82 (3H, s, Ms CH3), 2.55 
(1H, qq, J = 7.0, 6.5 Hz, CH(CH3)2), 1.97 – 1.90 (2H, m, C3-H2), 1.89 – 1.79 (2H, m, C2-H2), 1.02 (3H, 
d, J = 6.5 Hz, CH(CH3)(CH3)’), 0.80 (3H, d, J = 7.0 Hz, CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 139.6 
(C5), 114.9 (C6), 73.8 (C4), 50.1 (C1), 38.7 (Ms CH3), 34.2 (CH(CH3)2), 29.3 (C3), 23.3 (C2), 18.3 
(CH(CH3)(CH3)’), 16.7 (CH(CH3)(CH3)’). HRMS: (ESI+) Calculated for C10H19NNaO2S: 240.1029. 
Found [M+Na]+: 240.1022. 
2-Benzylacrylaldehyde 
 
This compound was prepared according to a literature procedure.228 A solution of 3-phenylpropanal 
(3.93 mL, 29.8 mL), aqueous formaldehyde (12.3 M, 2.42 mL, 29.8 mmol), pyrrolidine (0.25 mL, 
2.98 mmol) and 4-(dimethylamino)benzoic acid (492 mg, 2.98 mmol) in anhydrous CH2Cl2 (30 mL) 
was heated at reflux for 1.5 hours. The reaction mixture was cooled to room temperature before addition 
of saturated aqueous NaHCO3 (20 mL). The resulting phases were separated, and the aqueous phase 
was extracted with CH2Cl2 (2 × 25 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 12:1 hexane:EtOAc) afforded the title compound (3.16 g, 73 %) 
as a colourless oil. νmax / cm-1: (film) 3063 (m), 3029 (m), 2918 (br m), 2827 (br m), 1688 (s), 1496 (s), 
1454 (s). δH (400 MHz, CDCl3) 9.61 (1H, s), 7.34 – 7.28 (2H, m), 7.25 – 7.22 (1H, m), 7.22 – 7.16 (2H, 
m), 6.11 (1H, td, J = 1.5, 1.0 Hz), 6.07 (1H, dt, J = 1.0, 1.0 Hz), 3.58 – 3.57 (2H, m). δC (101 MHz, 
CDCl3) 194.1, 149.8, 138.2, 135.3, 129.3, 128.7, 126.6, 34.3. The spectroscopic properties were 
consistent with the data available in the literature.228 
  





To a solution of MeLi (1.6 M in Et2O, 16.0 mL, 25.6 mmol) in anhydrous THF (20 mL) at 0 °C was 
added a solution of the preceding aldehyde (2.50 g, 17.1 mmol) in anhydrous THF (15 mL) dropwise. 
The reaction mixture was stirred at room temperature for 1 hour before addition of saturated aqueous 
NH4Cl (50 mL). The resulting phases were separated, and the aqueous phase was extracted with Et2O 
(2 × 50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo to afford 
158c (2.67 g, 96 %) as a pale-yellow oil. νmax / cm-1: (film) 3349 (br s), 3027 (m), 2975 (m), 1647 (m), 
1453 (m), 1070 (s). δH (400 MHz, CDCl3) 7.33 – 7.27 (2H, m, 2 × ArCH), 7.24 – 7.19 (3H, m, 3 × 
ArCH), 5.16 – 5.14 (1H, m, C4-H), 4.75 (1H, d, J = 1.5 Hz, C4-H’), 4.26 (1H, q, J = 6.5 Hz, C2-H), 
3.48 (1H, d, J = 15.5 Hz, C5-H), 3.36 (1H, d, J = 15.5 Hz, C5-H’), 1.52 (1H, br s, OH), 1.31 (3H, d, J = 
6.5 Hz, C1-H3). δC (101 MHz, CDCl3) 152.7 (C3), 139.5 (ArC), 129.3 (ArCH), 128.5 (ArCH), 126.3 
(ArCH), 111.0 (C4), 70.3 (C2), 39.1 (C5), 22.4 (C1). HRMS: (ESI+) Calculated for C11H14NaO: 
185.0939. Found [M+Na]+: 185.0941.  
Ethyl (Z)-4-benzylhex-4-enoate 
 
General procedure L: Allylic alcohol 158c (2.43 g, 15.0 mmol) was employed. The reaction time was 
15 hours. FCC (eluent: 29:1 hexane:EtOAc) afforded the title compound (2.98 g, 86 %) as a colourless 
oil. νmax / cm-1: (film) 3027 (m), 2980 (m), 1732 (s), 1602 (m), 1494 (m), 1452 (s), 1164 (s).  
δH (400 MHz, CDCl3) 7.30 – 7.24 (2H, m, 2 × ArCH), 7.21 – 7.13 (3H, m, 3 × ArCH), 5.45 (1H, q, J = 
6.5 Hz, C5-H), 4.09 (2H, q, J = 7.0 Hz, OCH2CH3), 3.42 (2H, s, C7-H2), 2.39 – 2.31 (2H, m, C2-H2), 
2.29 – 2.23 (2H, m, C3-H2), 1.72 (3H, d, J = 6.5 Hz, C6-H3), 1.22 (3H, t, J = 7.0 Hz, OCH2CH3).  
δC (101 MHz, CDCl3) 173.5 (C1), 140.0 (ArC), 137.0 (C4), 128.6 (ArCH), 128.5 (ArCH), 126.1 
(ArCH), 121.1 (C5), 60.3 (OCH2CH3), 35.8 (C7), 33.2 (C2), 31.9 (C3), 14.4 (OCH2CH3), 13.8 (C6). 
HRMS: (ESI+) Calculated for C15H20NaO2: 255.1356. Found [M+Na]+: 255.1354. 
  





General procedure I: The preceding ester (8.03 g, 34.6 mmol) was employed, using anhydrous THF 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in THF). FCC (eluent: 4:1 hexane:EtOAc) afforded 159c 
(6.12 g, 93 %) as a colourless oil. νmax / cm-1: (film) 3330 (br s), 3026 (m), 2929 (m), 1601 (m), 1452 (m), 
1055 (s). δH (400 MHz, CDCl3) 7.33 – 7.24 (2H, m, 2 × ArCH), 7.22 – 7.12 (3H, m, 3 × ArCH), 5.46 
(1H, q, J = 7.0 Hz, C5-H), 3.58 (2H, t, J = 6.5 Hz, C1-H2), 3.42 (2H, s, C7-H2), 2.02 – 1.97 (2H, m, 
C3-H2), 1.73 (3H, d, J = 7.0 Hz, C6-H3), 1.68 – 1.60 (2H, m, C2-H2), 1.35 (1H, br s, OH). δC (101 MHz, 
CDCl3) 140.3 (ArC), 138.2 (C4), 128.6 (ArCH), 128.5 (ArCH), 126.0 (ArCH), 120.7 (C5), 62.9 (C1), 




General procedure E: MsNHOTES (vide supra, 676 mg, 3.00 mmol) was employed with alcohol 159c 
(1.1 eq.). The reaction time was 16 hours. FCC (eluent: PhMe) afforded the title compound (1.10 g, 
92 %) as a colourless oil. νmax / cm-1: (film) 2955 (m), 2877 (m), 1494 (m), 1454 (m), 1350 (s), 1164 (s). 
δH (400 MHz, CDCl3) 7.30 – 7.24 (2H, m, 2 × ArCH), 7.21 – 7.13 (3H, m, 3 × ArCH), 5.45 (1H, q, J = 
7.0 Hz, C5-H), 3.40 (2H, s, C7-H2), 3.12 – 3.06 (2H, m, C1-H2), 2.81 (3H, s, Ms CH3), 2.00 – 1.94 (2H, 
m, C3-H2), 1.77 – 1.67 (5H, m, C2-H2 and C6-H3), 0.97 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.73 (6H, q, 
J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 139.9 (ArC), 137.1 (C4), 2 × 128.4 (2 × ArCH), 125.9 
(ArCH), 121.2 (C5), 55.3 (C1), 35.6 (C7), 33.9 (C3), 30.4 (Ms CH3), 25.3 (C2), 13.7 (C6), 6.7 




General procedure F: The preceding compound (1.07 g, 2.69 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (732 mg, 96 %) as a colourless crystalline solid.  
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νmax / cm-1: (solid) 3304 (br s), 2931 (m), 1493 (m), 1447 (m), 1324 (s), 1152 (s). δH (400 MHz, CDCl3) 
7.30 – 7.25 (2H, m, 2 × ArCH), 7.21 – 7.14 (3H, m, 3 × ArCH), 6.41 (1H, br s, OH), 5.46 (1H, qt, J = 
7.0, 1.5 Hz, C5-H), 3.41 (2H, s, C7-H2), 3.12 – 3.06 (2H, m, C1-H2), 2.87 (3H, s, Ms CH3), 2.05 – 1.98 
(2H, m, C3-H2), 1.79 – 1.70 (5H, m, C2-H2 and C6-H3). δC (101 MHz, CDCl3) 140.0 (ArC), 137.2 (C4), 
128.5 (ArCH), 128.4 (ArCH), 125.9 (ArCH), 121.2 (C5), 51.9 (C1), 35.6 (C7), 33.3 (C3), 30.9 




General procedure C: The preceding compound (704 mg, 2.50 mmol) was employed. FCC (gradient 
elution: 7:1 – 6:1 hexane:EtOAc) afforded 160c (1.11 g, 93 %) as a colourless crystalline solid. 
m.p. 82-83 °C (Et2O:hexane, needles). νmax / cm-1: (solid) 3028 (m), 2934 (m), 1780 (s), 1655 (m), 
1597 (m), 1499 (s), 1169 (s). δH (400 MHz, CDCl3) 7.27 – 7.22 (2H, m, 2 × ArCH), 7.18 – 7.13 (3H, 
m, 3 × ArCH), 5.48 (1H, q, J = 7.0 Hz, C5-H), 3.43 – 3.33 (4H, m, C1-H2 and C7-H2), 3.00 (3H, s, 
Ms CH3), 2.10 (2H, t, J = 7.0 Hz, C3-H2), 1.77 – 1.68 (5H, m, C2-H2 and C6-H3). δC (101 MHz,  
CDCl3) 140.0 (ArC), 136.8 (C4), 128.6 (ArCH), 128.5 (ArCH), 126.0 (ArCH), 122.0 (C5), 52.2 (C1), 
35.7 (C7), 34.5 (Ms CH3), 33.5 (C3), 25.2 (C2), 13.9 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.7 – -135.9 (2F, m), -145.3 (1F, tt, J = 20.5, 5.5 Hz), -158.7 – -158.9 (2F, m). HRMS: (ESI+) 
Calculated for C21H20F5NNaO4S: 500.0925. Found [M+Na]+: 500.0919. 
2-Benzyl-1-mesyl-2-vinylpyrrolidine (161c) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
n-BuCN (0.1 M); 95 °C; 16 hours. Substrate 160c (66.8 mg, 0.140 mmol) was employed. FCC (gradient 
elution: 5:1 – 3:1 hexane:EtOAc) afforded 161c (19.9 mg, 54 %) as a pale-yellow oil. νmax / cm-1: (film) 
3027 (m), 2978 (m), 1602 (m), 1496 (m), 1318 (s), 1144 (s). δH (500 MHz, CDCl3) 7.32 – 7.27 (4H, m, 
4 × ArCH), 7.25 – 7.21 (1H, m, ArCH), 6.24 (1H, dd, J = 17.5, 11.0 Hz, C5-H), 5.27 (1H, dd, J = 11.0, 
0.5 Hz, C6-H), 5.26 (1H, dd, J = 17.5, 0.5 Hz, C6-H’), 3.40 (1H, d, J = 13.5 Hz, C7-H), 3.35 – 3.26 
(2H, m, C1-H2), 3.06 (1H, d, J = 13.5 Hz, C7-H’), 2.90 (3H, s, Ms CH3), 2.05 (1H, ddd, J = 13.0, 7.0, 
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6.5 Hz, C3-H), 1.93 (1H, ddd, J = 13.0, 7.0, 7.0 Hz, C3-H’), 1.71 – 1.62 (1H, m, C2-H), 1.34 (1H, dddd, 
J = 14.0, 12.5, 7.0, 7.0 Hz, C2-H’). δC (126 MHz, CDCl3) 140.3 (C5), 137.3 (ArC), 131.1 (ArCH), 
128.2 (ArCH), 126.7 (ArCH), 115.5 (C6), 70.1 (C4), 49.9 (C1), 44.7 (C7), 39.4 (Ms CH3), 36.4 (C3), 
22.4 (C2). HRMS: (ESI+) Calculated for C14H19NNaO2S: 288.1029. Found [M+Na]+: 288.1017. 
Methyl 3-cyclopropyl-3-oxopropanoate 
 
This compound was prepared according to a literature procedure.101 To a suspension of NaH (60 % in 
mineral oil, 2.88 g, 72.0 mmol) and dimethyl carbonate (5.05 mL, 60.0 mmol) in anhydrous THF 
(50 mL) was added cyclopropyl methyl ketone (5.94 mL, 60.0 mmol) over around 20 minutes. The 
reaction mixture was heated at reflux for 2 hours before being cooled to room temperature, concentrated 
in vacuo, dissolved in 0.5 M aqueous HCl (100 mL) and extracted with Et2O (3 × 100 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (4.88 g, 57 %) as an orange oil. νmax / cm-1: (film) 
3013 (m), 2956 (s), 1743 (s), 1699 (s), 1385 (s), 1074 (s). δH (400 MHz, CDCl3) 3.74 (3H, s), 3.58 (2H, 
s), 2.03 (1H, tt, J = 8.0, 4.5 Hz), 1.13 – 1.09 (2H, m), 0.99 – 0.93 (2H, m). δC (101 MHz, CDCl3) 202.7, 




To a suspension of NaH (60 % in mineral oil, 720 mg, 18.0 mmol) in anhydrous DMF (35 mL) was 
added the preceding compound (2.31 mL, 18.0 mmol) dropwise. The reaction mixture was stirred at 
room temperature for 1 hour before addition of (E)-1-bromo-2-methylbut-2-ene (vide supra, 1.42 mL, 
12.0 mmol) and then heated at 80 °C for 13 hours. The reaction mixture was cooled to room temperature 
before addition of saturated aqueous NH4Cl (50 mL) and extraction with Et2O (3 × 50 mL). The organic 
phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 19:1 – 
14:1 hexane:EtOAc) afforded the title compound (2.01 g, 80 %) as a colourless oil. νmax / cm-1: (film) 
2954 (m), 1740 (s), 1701 (s), 1436 (s), 1382 (s), 1160 (s). δH (400 MHz, CDCl3) 5.26 (1H, qq, J = 7.0, 
1.5 Hz, C7-H), 3.77 (1H, t, J = 7.5 Hz, C4-H), 3.72 (3H, s, OCH3), 2.61 – 2.54 (2H, m, C5-H2), 2.05 
(1H, tt, J = 8.0, 4.5 Hz, C2-H), 1.61 (3H, br s, C9-H3), 1.55 (3H, dq, J = 7.0, 1.0 Hz, C8-H3), 1.08 – 
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1.03 (2H, m, 2 × C1-H), 0.95 – 0.88 (2H, m, 2 × C1-H’). δC (101 MHz, CDCl3) 205.1 (C3), 170.2 (C10), 
131.6 (C6), 121.4 (C7), 58.6 (C4), 52.3 (OCH3), 38.0 (C5), 19.7 (C2), 15.5 (C9), 13.5 (C8), 11.8 (C1), 
11.6 (C1’). HRMS: (ESI+) Calculated for C12H18NaO3: 233.1148. Found [M+Na]+: 233.1151.  
(E)-1-Cyclopropyl-4-methylhex-4-en-1-ol (162) 
 
To a solution of the preceding compound (1.94 g, 9.23 mmol) in MeOH (25 mL) and water (15 mL) 
was added KOH (2.07 g, 36.9 mmol). The reaction mixture was stirred at room temperature for 
40 minutes before addition of 2.0 M aqueous HCl (25 mL) and extraction with Et2O (3 × 70 mL). The 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude mixture was dissolved in 
EtOAc (30 mL) and heated at reflux for 3 hours before being concentrated in vacuo. The resulting oil 
was dissolved in MeOH (20 mL) and cooled to 0 °C before addition of NaBH4 (349 mg, 9.23 mmol). 
The reaction mixture was stirred at 0 °C for 2 hours before addition of 1.0 M aqueous HCl (20 mL) and 
extraction with Et2O (3 × 40 mL). The organic phases were dried over Na2SO4 and concentrated in 
vacuo. FCC (eluent: 5:2 pentane:Et2O) afforded 162 (688 mg, 48 %) as a colourless oil.  
νmax / cm-1: (film) 3360 (br s), 3080 (m), 2918 (m), 1432 (m), 1019 (s). δH (400 MHz, CDCl3) 5.24 (1H, 
qq, J = 6.5, 1.0 Hz, C7-H), 2.84 (1H, ddd, J = 8.5, 7.5, 5.0 Hz, C3-H), 2.20 – 2.00 (2H, m, C5-H2), 1.73 
– 1.65 (2H, m, C4-H2), 1.63 (1H, br s, OH), 1.60 (3H, br s, C9-H3), 1.56 (3H, dq, J = 6.5, 1.0 Hz, 
C8-H3), 0.89 (1H, dtt, J = 8.5, 8.5, 5.0 Hz, C2-H), 0.55 – 0.44 (2H, m, 2 × C1-H), 0.29 – 0.16 (2H, m, 
2 × C1-H’). δC (101 MHz, CDCl3) 135.7 (C6), 118.5 (C7), 76.6 (C3), 35.8 (C4), 35.3 (C5), 17.9 (C9), 
15.6 (C8), 13.3 (C2), 2.7 (C1), 2.5 (C1’). HRMS: (ESI+) Calculated for C10H18NaO: 177.1250. Found 




General procedure K: Alcohol 162 (540 mg, 3.50 mmol) was employed with TsNHOFBz (vide supra). 
The reaction time was 15 hours. FCC (gradient elution: 49:1 – 24:1 hexane:EtOAc) afforded 163 
(1.09 g, 60 %) as a pale-yellow oil. νmax / cm-1: (film) 2926 (m), 1786 (s), 1653 (m), 1598 (m), 1497 (s), 
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1164 (s). δH (500 MHz, CDCl3) 7.86 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.35 (2H, d, J = 8.0 Hz, 2 × ArCH), 
5.25 (1H, br s, C7-H), 3.50 – 3.28 (1H, m, C3-H), 2.47 (3H, s, Ts CH3), 2.39 – 2.13 (2H, m, C5-H2), 
1.85 – 1.69 (2H, m, C4-H2), 1.63 – 1.54 (6H, m, C8-H3 and C9-H3), 1.18 – 0.95 (1H, m, C2-H), 0.72 – 
0.55 (3H, m, C1-H and C1’-H2), 0.33 (1H, br s, C1-H’). δC (126 MHz, CDCl3) 156.2 (C=O), 145.4 
(ArC), 134.7 (C6), 133.4 (ArC), 129.6 (ArCH), 129.3 (ArCH), 119.3 (C7), 67.4 (C3), 36.3 (C5), 31.2 
(C4), 21.7 (Ts CH3), 15.5 (C9), 13.4 (C8), 12.8 (C2), 5.7 (C1’), 4.8 (C1). The aromatic 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.3 – -136.5 (2F, m), -146.4 (1F, tt, J = 21.0, 5.0 Hz), -158.9 – -159.1 (2F, m). 
HRMS: (ESI+) Calculated for C24H24F5NNaO4S: 540.1238. Found [M+Na]+: 540.1232.  
(2R*,5S*)-5-Cyclopropyl-2-methyl-1-tosyl-2-vinylpyrrolidine (164) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
PhMe (0.1 M); 140 °C; 14 hours. Substrate 163 (79.6 mg, 0.154 mmol, added as a solution in PhMe) 
was employed. FCC (two times, first eluent: 19:1 hexane:EtOAc; second eluent: 99:1 PhMe:EtOAc) 
afforded 164 (30.1 mg, 64 %, 20:1 mixture of diastereomers) as a pale-yellow oil. m.p. 94-97 °C 
(CH2Cl2:petrol, tabular). The relative stereochemistry of the major diastereomer was assigned based 
on the observed NOE correlation between the C2 and the C7 protons, as well as the correlation between 
the C3 and the C9 protons. Spectroscopic data for the major diastereomer: νmax / cm-1: (film) 3084 (m), 
2972 (m), 1599 (m), 1496 (m), 1327 (s), 1151 (s). δH (400 MHz, CDCl3) 7.77 (2H, d, J = 8.0 Hz, 2 × 
ArCH), 7.22 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.10 (1H, dd, J = 17.5, 10.5 Hz, C7-H), 5.23 (1H, dd, J = 
17.5, 1.0 Hz, C8-H’), 5.08 (1H, dd, J = 10.5, 1.0 Hz, C8-H), 3.33 (1H, ddd, J = 8.5, 7.0, 1.5 Hz, C3-H), 
2.39 (3H, s, Ts CH3), 2.15 (1H, ddd, J = 12.5, 12.0, 6.5 Hz, C5-H), 2.01 (1H, dddd, J = 12.5, 12.5, 8.5, 
7.0 Hz, C4-H), 1.77 – 1.66 (2H, m, C4-H’ and C5-H’), 1.55 (3H, s, C9-H3), 0.90 (1H, ddddd, J = 8.5, 
8.5, 8.5, 5.0, 5.0 Hz, C2-H), 0.53 – 0.46 (1H, m, C1-H), 0.44 – 0.32 (2H, m, C1-H’ and C1’-H), 0.09 – 
0.00 (1H, m, C1’-H’). δC (101 MHz, CDCl3) 145.1 (C7), 142.4 (ArC), 140.7 (ArC), 129.1 (ArCH), 
127.7 (ArCH), 112.9 (C8), 69.0 (C6), 66.7 (C3), 40.1 (C5), 29.6 (C4), 24.4 (C9), 21.6 (Ts CH3), 17.1 
(C2), 7.2 (C1), 2.8 (C1’). HRMS: (ESI+) Calculated for C17H23NNaO2S: 328.1342. Found [M+Na]+: 
328.1353. Characteristic signals for the minor diastereomer: δH (500 MHz, CDCl3) 5.91 (1H, dd, J = 
17.5, 11.0 Hz), 5.17 (1H, dd, J = 17.5, 1.0 Hz), 5.02 (1H, dd, J = 11.0, 1.0 Hz). 
 





General procedure I: 2-Cyclopentene-1-acetic acid (165) (806 mg, 6.81 mmol) was employed, using 
anhydrous Et2O as the solvent and 2.0 eq. LiAlH4 (1.0 M in Et2O). The title compound (713 mg, 93 %) 
was isolated as a pale-yellow oil. νmax / cm-1: (film) 3327 (br s), 3051 (m), 2928 (s), 2851 (s), 1614 (m), 
1057 (s). δH (400 MHz, CDCl3) 5.74 (1H, ddt, J = 6.0, 2.0, 2.0 Hz), 5.69 (1H, ddt, J = 6.0, 2.0, 2.0 Hz), 
3.76 – 3.64 (2H, m), 2.82 – 2.72 (1H, m), 2.41 – 2.22 (2H, m), 2.12 – 2.02 (1H, m), 1.70 (1H, ddt, 
J = 13.5, 6.5, 6.5 Hz), 1.62 – 1.52 (1H, m), 1.49 – 1.36 (2H, m). δC (101 MHz, CDCl3) 134.6, 130.7, 




General procedure K: The preceding alcohol (135 mg, 1.20 mmol) was employed with TsNHOFBz 
(vide supra). The reaction time was 20 hours. FCC (gradient elution: 4:1 – 1:0 hexane:PhMe) afforded 
166 (506 mg, 89 %) as a colourless crystalline solid. m.p. 95-96 °C (Et2O:hexane, needles).  
νmax / cm-1: (solid) 3056 (m), 2936 (m), 1792 (s), 1655 (m), 1595 (m), 1504 (s), 1167 (s). δH (400 MHz, 
CDCl3) 7.80 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.38 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.74 (1H, ddt, J = 5.5, 
2.0, 2.0 Hz, C5-H), 5.61 (1H, ddt, J = 5.5, 2.0, 2.0 Hz, C4-H), 3.26 (2H, br s, C1-H2), 2.88 – 2.76 (1H, 
m, C3-H), 2.47 (3H, s, Ts CH3), 2.39 – 2.21 (2H, m, C6-H2), 2.06 (1H, dtd, J = 13.0, 8.5, 5.0 Hz, C7-H), 
1.70 (1H, ddt, J = 13.5, 7.0, 7.0 Hz, C2-H), 1.63 – 1.55 (1H, m, C2-H’), 1.37 (1H, ddt, J = 13.0, 9.0, 
6.5 Hz, C7-H’). δC (101 MHz, CDCl3) 146.0 (ArC), 133.7 (C4), 131.6 (C5), 130.2 (ArC), 130.0 (ArCH), 
129.8 (ArCH), 51.5 (C1), 42.7 (C3), 32.8 (C2), 32.0 (C6), 29.7 (C7), 21.9 (Ts CH3). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.0 – -136.1 (2F, m), -146.1 (1F, tt, J = 21.0, 5.0 Hz), -159.0 – -159.2 (2F, m). 
HRMS: (ESI+) Calculated for C21H18F5NNaO4S: 498.0769. Found [M+Na]+: 498.0786. 
  





General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; n-BuCN (0.1 M); 110 °C; 17 hours. Substrate 166 (66.5 mg, 0.140 mmol) was employed. FCC 
(gradient elution: 9:1 – 4:1 hexane:EtOAc) afforded 20 (33.7 mg, 91 %) as a colourless crystalline solid. 
m.p. 66-67 °C (Et2O:hexane). νmax / cm-1: (solid) 2865 (m), 1596 (m), 1339 (s), 1155 (s). δH (400 MHz, 
CDCl3) 7.73 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.83 – 5.79 (1H, m, 
C5-H), 5.76 – 5.71 (1H, m, C6-H), 4.55 (1H, dd, J = 8.0, 2.0 Hz, C4-H), 3.36 (1H, ddd, J = 9.5, 7.0, 
4.5 Hz, C1-H), 3.10 – 3.02 (1H, m, C1-H’), 2.61 (1H, ddddd, J = 8.0, 8.0, 8.0, 7.5, 2.0 Hz, C3-H), 2.53 
– 2.44 (1H, m, C7-H), 2.42 (3H, s, Ts CH3), 2.10 (1H, ddd, J = 17.0, 2.0, 2.0 Hz, C7-H’), 1.88 – 1.79 
(1H, m, C2-H), 1.51 (1H, dddd, J = 12.5, 7.5, 7.5, 7.0 Hz, C2-H’). δC (101 MHz, CDCl3) 143.4 (ArC), 
134.9 (ArC), 132.0 (C6), 131.4 (C5), 129.7 (ArCH), 127.7 (ArCH), 70.2 (C4), 48.4 (C1), 40.0 (C3), 




To a solution of 3-cyclohexene-1-carboxaldehyde (113) (11.0 g, 100 mmol) in MeOH (150 mL) at 0 °C 
was added NaBH4 (1.51 g, 40.0 mmol). The reaction mixture was stirred at 0 °C for 1 hour before 
addition of water (100 mL) and extraction with Et2O (3 × 150 mL). The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 3:1 – 1:1 pentane:Et2O) afforded 
the title compound (8.00 g, 71 %) as a pale-yellow oil. δH (400 MHz, CDCl3) 5.70 – 5.62 (2H, m), 3.56 
– 3.46 (2H, m), 2.14 – 2.02 (3H, m), 1.86 – 1.67 (4H, m), 1.32 – 1.20 (1H, m). δC (101 MHz, CDCl3) 
127.2, 126.0, 67.9, 36.4, 28.2, 25.3, 24.7. The spectroscopic properties were consistent with the data 
available in the literature.230 
  





General procedure E: MsNHOTES (vide supra, 1.35 g, 6.00 mmol) was employed with the preceding 
alcohol (1.3 eq.). The reaction time was 16 hours. FCC (eluent: 10:1 hexane:EtOAc) afforded the title 
compound (1.88 g, 98 %) as a pale-yellow oil. νmax / cm-1: (film) 2956 (m), 2913 (m), 2878 (m), 1351 (s), 
1165 (s). δH (400 MHz, CDCl3) 5.74 – 5.62 (2H, m, C4-H and C5-H), 3.11 (1H, dd, J = 13.0, 7.5 Hz, 
C1-H), 3.04 (1H, dd, J = 13.0, 6.5 Hz, C1-H’), 2.85 (3H, s, Ms CH3), 2.22 – 2.14 (1H, m, C3-H), 2.11 
– 2.03 (2H, m, C6-H2), 2.03 – 1.95 (1H, m, C2-H), 1.94 – 1.85 (1H, m, C7-H), 1.80 – 1.68 (1H, m, 
C3-H’), 1.37 – 1.26 (1H, m, C7-H’), 0.99 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.78 (6H, q, J = 8.0 Hz, 
Si(CH2CH3)3). δC (101 MHz, CDCl3) 127.2 (C5), 125.4 (C4), 61.3 (C1), 31.4 (C2), 29.9 (Ms CH3), 29.6 
(C3), 26.4 (C7), 24.2 (C6), 6.7 (Si(CH2CH3)3), 4.9 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for 
C14H29NNaO3SSi: 342.1530. Found [M+Na]+: 342.1533. 
N-(Cyclohex-3-en-1-ylmethyl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (1.78 g, 5.57 mmol) was employed. FCC (gradient 
elution: 4:1 – 3:1 hexane:EtOAc) afforded the title compound (1.03 g, 90 %) as a colourless crystalline 
solid. νmax / cm-1: (solid) 3332 (br s), 3027 (m), 2919 (m), 2840 (m), 1438 (s), 1328 (s), 1147 (s).  
δH (400 MHz, CDCl3) 6.86 (1H, br s, OH), 5.73 – 5.62 (2H, m, C4-H and C5-H), 3.13 (1H, dd, J = 12.5, 
7.0 Hz, C1-H), 3.07 (1H, dd, J = 12.5, 7.0 Hz, C1-H’), 2.93 (3H, s, Ms CH3), 2.25 – 2.16 (1H, m, C3-H), 
2.15 – 2.01 (3H, m, C2-H and C6-H2), 1.91 – 1.73 (2H, m, C3-H’ and C7-H), 1.36 (1H, dddd, J = 13.0, 
10.5, 8.5, 7.0 Hz, C7-H’). δC (101 MHz, CDCl3) 127.1 (C5), 125.4 (C4), 57.5 (C1), 31.5 (C2), 30.7 
(Ms CH3), 29.2 (C3), 26.0 (C7), 24.2 (C6). HRMS: (ESI+) Calculated for C8H15NNaO3S: 228.0665. 
Found [M+Na]+: 228.0660. 
  





General procedure C:  The preceding compound (1.00 g, 4.87 mmol) was employed. FCC (gradient 
elution: 4:1 – 3:1 hexane:EtOAc) afforded 114b (1.85 g, 95 %) as a colourless crystalline solid. 
m.p. 109-110 °C (CH2Cl2:hexane, needles). νmax / cm-1: (solid) 3029 (m), 2917 (m), 1782 (s), 1653 (s), 
1505 (s), 1353 (s), 1162 (s). δH (400 MHz, CDCl3) 5.73 – 5.62 (2H, m, C4-H and C5-H), 3.45 – 3.28 
(2H, m, C1-H2), 3.04 (3H, s, Ms CH3), 2.36 – 2.24 (1H, m, C3-H), 2.16 – 2.02 (2H, m, C6-H2), 2.02 – 
1.79 (3H, m, C2-H, C3-H’ and C7-H), 1.50 – 1.38 (1H, m, C7-H’). δC (101 MHz, CDCl3) 156.4 (C=O), 
127.3 (C5), 125.2 (C4), 57.7 (C1), 34.2 (Ms CH3), 31.6 (C2), 29.2 (C3), 25.9 (C7), 24.1 (C6). The 
aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their 
weak intensity. δF (377 MHz, CDCl3) -135.7 – -135.9 (2F, m), -145.3 (1F, tt, J = 21.0, 5.5 Hz), -158.8 




General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
1:1 n-BuCN:THF (0.1 M); 110 °C, 17 hours. Substrate 114b (55.9 mg, 0.140 mmol) was employed. 
FCC (eluent: 9:1 PhMe:EtOAc) afforded 115b (19.9 mg, 76 %) as a colourless crystalline solid.  
m.p. 61-62 °C (Et2O:hexane, cubes). νmax / cm-1: (solid) 3034 (m), 2967 (m), 1312 (s), 1133 (s). 
δH (400 MHz, CDCl3) 6.06 (1H, dddd, J = 10.5, 5.5, 2.0, 1.0 Hz, C5-H), 5.73 – 5.68 (1H, m, C6-H), 
4.17 (1H, ddd, J = 5.5, 5.0, 1.0 Hz, C4-H), 3.64 – 3.59 (1H, m, C1-H), 3.09 (1H, d, J = 10.0 Hz, C1-H’), 
2.81 (3H, s, Ms CH3), 2.72 – 2.67 (1H, m, C2-H), 2.55 – 2.47 (1H, m, C7-H), 2.16 – 2.09 (1H, m, 
C7-H’), 1.95 (1H, ddd, J = 11.0, 5.0, 5.0 Hz, C3-H), 1.83 (1H, ddd, J = 11.0, 1.0, 1.0 Hz, C3-H’).  
δC (101 MHz, CDCl3) 129.8 (C5), 128.5 (C6), 54.1 (C1), 54.0 (C4), 37.7 (Ms CH3), 35.6 (C7), 34.7 
(C3), 33.4 (C2). HRMS: (ESI+) Calculated for C8H13NNaO2S: 210.0559. Found [M+Na]+: 210.0561. 




ORTEP view of 115b. 
Non-1,8-dien-5-ol (167) 
 
This compound was prepared according to a literature procedure.231 To a suspension of magnesium 
turnings (1.22 g, 50.0 mmol), activated with a few crystals of iodine, in anhydrous THF (50 mL) was 
added 4-bromobut-1-ene (5.10 mL, 50.0 mmol) dropwise at such a rate as to maintain a gentle reflux. 
The reaction mixture was stirred for 1 hour before dropwise addition of methyl formate (1.54 mL, 
25.0 mmol) and then stirred for a further 4 hours at room temperature before addition of saturated 
aqueous NH4Cl (30 mL) and extraction with EtOAc (3 × 70 mL). The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 20:1 – 2:1 hexane:EtOAc) 
afforded alcohol 167 (2.47 g, 70 %) as a pale-yellow oil. νmax / cm-1: (film) 3344 (br s), 3078 (m), 
2931 (m), 1641 (m), 1449 (m). δH (400 MHz, CDCl3) 5.83 (2H, ddt, J = 17.0, 10.0, 6.5 Hz), 5.04 (2H, 
ddt, J = 17.0, 1.5, 1.5 Hz), 4.96 (2H, ddt, J = 10.0, 1.5, 1.5 Hz), 3.65 (1H, tt, J = 7.5, 4.5 Hz), 2.25 – 
2.06 (4H, m), 1.91 (1H, s), 1.62 – 1.46 (4H, m). δC (101 MHz, CDCl3) 138.6, 114.8, 71.0, 36.5, 30.1. 
The spectroscopic properties were consistent with the data available in the literature.231 
N-((tert-Butyldimethylsilyl)oxy)-N-(nona-1,8-dien-5-yl)-4-toluenesulfonamide 
 
General procedure E: TsNHOTBS (vide supra, 1.00 g, 3.33 mmol) was employed with alcohol 167 
(1.5 eq.). The reaction time was 19 hours. FCC (eluent: 1:1 hexane:PhMe) afforded the title compound 
(1.40 g, 100 %) as a colourless oil. νmax / cm-1: (film) 2930 (m), 2859 (m), 1641 (m), 1598 (m), 1355 (s), 
1170 (s). δH (400 MHz, CDCl3) 7.74 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.5 Hz, 2 × ArCH), 
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5.61 (2H, ddt, J = 18.5, 9.5, 7.0 Hz, 2 × C4-H), 4.94 – 4.91 (2H, m, 2 × C5-H), 4.92 – 4.86 (2H, m, 2 × 
C5-H’), 3.50 (1H, tt, J = 6.5, 6.5 Hz, C1-H), 2.43 (3H, s, Ts CH3), 1.98 (4H, ddddd, J = 7.0, 4.0, 4.0, 
1.0, 1.0 Hz, 2 × C3-H2), 1.33 – 1.23 (2H, m, 2 × C2-H), 1.19 – 1.08 (2H, 2 × C2-H’), 0.94 (9H, s, 
SiC(CH3)3), 0.31 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 144.5 (ArC), 137.9 (C4), 133.5 (ArC), 129.5 
(ArCH), 129.2 (ArCH), 115.0 (C5), 62.7 (C1), 31.2 (C3), 30.4 (C2), 26.3 (SiC(CH3)3), 21.7 (Ts CH3), 




To a reaction vessel charged with Grubbs-Hoveyda 2nd generation catalyst (18.2 mg, 29.0 µmol) was 
added a solution of the preceding compound (1.23 g, 2.90 mmol) in anhydrous CH2Cl2 (200 mL, argon 
sparged). The reaction mixture was heated at reflux for 4 hours before being cooled to room 
temperature, partially concentrated in vacuo and filtered through a plug of silica, eluting with  
CH2Cl2. The filtrate was concentrated in vacuo to afford 91 (1.07 g, 93 %) as a pale-green oil (the 
colouration was due to the presence of trace amounts of Ru-impurities). m.p. 92-93 °C (Et2O:hexane).  
νmax / cm-1: (film) 3023 (m), 2932 (m), 2856 (m), 1596 (m), 1470 (m), 1446 (m), 1349 (s), 1163 (s).  
δH (400 MHz, CDCl3) 7.76 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.71 – 
5.67 (2H, m, 2 × C4-H), 3.67 (1H, tt, J = 11.0, 3.0 Hz, C1-H), 2.44 (3H, s, Ts CH3), 2.12 – 2.02 (2H, 
m, 2 × C3-H), 1.86 – 1.76 (2H, m, 2 × C3-H’), 1.54 – 1.45 (2H, m, 2 × C2-H), 1.31 (2H, ddd, J = 13.5, 
11.0, 2.0 Hz, 2 × C2-H’), 0.94 (9H, s, SiC(CH3)3), 0.30 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 144.4 
(ArC), 133.7 (ArC), 131.6 (C4), 129.5 (ArCH), 129.2 (ArCH), 67.7 (C1), 31.4 (C2), 26.3 (SiC(CH3)3), 
25.7 (C3), 21.8 (Ts CH3), 18.8 (SiC(CH3)3), -4.0 (Si(CH3)3). HRMS: (ESI+) Calculated for 
C20H34NO3SSi: 396.2023. Found [M+H]+: 396.2026. 
N-(Cyclohept-4-en-1-yl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure B: Compound 91 (1.07 g, 2.71 mmol) was employed. FCC (gradient elution: 19:1 
– 7:1 hexane:EtOAc) was required to separate deprotected product from unconsumed 91 (242 mg 
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recovered, 23 %) and afforded the title compound (185 mg, 25 %) as a pale-yellow crystalline solid. 
This compound was used in the following step with minimal delay due to concerns about its stability. 
δH (400 MHz, CDCl3) 7.82 (2H, d, J = 8.5 Hz), 7.33 (2H, d, J = 8.5 Hz), 5.97 (1H, s), 5.70 (2H, dt, J = 
4.5, 2.0 Hz), 3.90 (1H, tt, J = 10.0, 4.0 Hz), 2.45 (3H, s), 2.22 – 2.13 (2H, m), 2.01 – 1.90 (2H, m), 1.73 
– 1.64 (2H, m), 1.63 – 1.55 (2H, m). 
N-(Cyclohept-4-en-1-yl)-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (168a) 
 
General procedure C: The preceding compound (169 mg, 0.601 mmol) was employed. FCC (eluent: 
14:1 hexane:EtOAc) afforded 168a (224 mg, 78 %) as a colourless crystalline solid. m.p. 110-111 °C 
(Et2O:hexane). νmax / cm-1: (film) 2942 (m), 1785 (s), 1652 (m), 1597 (m), 1496 (s), 1164 (s).  
δH (400 MHz, CDCl3) 7.83 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.33 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.75 
(2H, ddd, J = 4.5, 2.0, 2.0 Hz, 2 × C4-H), 4.19 (1H, tt, J = 10.5, 3.5 Hz, C1-H), 2.44 (3H, s, Ts CH3), 
2.19 (2H, br s, 2 × C3-H), 2.02 (4H, br s, 2 × C2-H and 2 × C3-H’), 1.56 – 1.46 (2H, m, 2 × C2-H’).  
δC (101 MHz, CDCl3) 156.6 (C=O), 145.6 (ArC), 133.1 (ArC), 131.5 (C4), 129.8 (ArCH), 129.2 
(ArCH), 65.6 (C1), 2 × 24.9 (C2 and C3), 21.7 (Ts CH3). The aromatic 
13C signals corresponding to 
the pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) 
-135.8 – -136.0 (2F, m), -146.1 (1F, tt, J = 21.0, 5.0 Hz), -158.9 – -159.1 (2F, m). HRMS: (ESI+) 
Calculated for C21H19F5NO4S: 476.0949. Found [M+H]+: 476.0928. 
8-Tosyl-8-azabicyclo[3.2.1]oct-2-ene (169a) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 37 hours. Substrate 168a (66.6 mg, 0.140 mmol) was employed. 
FCC (eluent: 9:1 hexane:EtOAc) afforded 169a (19.9 mg, 54 %) as a pale-yellow crystalline solid.  
m.p. 105-107 °C (CH2Cl2:petrol). νmax / cm-1: (solid) 2953 (m), 2883 (m), 1597 (m), 1450 (m), 1330 (s), 
1149 (s). δH (400 MHz, CDCl3) 7.75 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.25 (2H, d, J = 8.0 Hz, 2 × ArCH), 
5.89 (1H, dddd, J = 9.5, 4.0, 4.0, 2.0 Hz, C4-H), 5.44 – 5.38 (1H, m, C3-H), 4.32 – 4.27 (2H, m, C1-H 
and C5-H), 2.65 – 2.57 (1H, m, C2-H), 2.41 (3H, s, Ts CH3), 1.94 (1H, dddd, J = 9.5, 8.0, 6.0, 5.5 Hz, 
C7-H), 1.88 – 1.80 (2H, m, C2-H’ and C6-H), 1.69 (1H, dddd, J = 12.0, 11.5, 6.0, 6.0 Hz, C6-H’), 1.58 
Chapter 7 - Experimental 
198 
 
(1H, dddd, J = 12.0, 9.5, 3.5, 3.5 Hz, C7-H’). δC (101 MHz, CDCl3) 143.3 (ArC), 137.6 (ArC), 131.4 
(C4), 129.6 (ArCH), 127.6 (ArCH), 123.8 (C3), 55.9 (C5), 55.6 (C1), 36.1 (C2), 35.6 (C6), 30.2 (C7), 
21.7 (Ts CH3). HRMS: (ESI+) Calculated for C14H17NNaO2S: 286.0872. Found [M+Na]+: 286.0863. 
 
ORTEP view of compound 169a. 
N-(Nona-1,8-dien-5-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 676 mg, 3.00 mmol) was employed with alcohol 167 
(1.1 eq.). The reaction time was 16 hours. FCC (gradient elution: 1:4 – 0:1 hexane:PhMe) afforded the 
title compound (858 mg, 82 %) as a colourless oil. νmax / cm-1: (film) 3078 (m), 2956 (s), 2878 (s), 
1641 (m), 1458 (m), 1415 (m), 1348 (s), 1164 (s). δH (400 MHz, CDCl3) 5.80 (2H, ddt, J = 17.0, 10.0, 
6.5 Hz, 2 × C4-H), 5.05 (2H, ddt, J = 17.0, 2.0, 1.5 Hz, 2 × C5-H’), 5.00 (2H, ddt, J = 10.0, 2.0, 1.0 Hz, 
2 × C5-H), 3.55 (1H, tt, J = 6.5, 6.5 Hz, C1-H), 2.89 (3H, s, Ms CH3), 2.20 – 2.12 (4H, m, 2 × C3-H2), 
1.73 (2H, dddd, J = 13.5, 8.5, 7.0, 6.5 Hz, 2 × C2-H), 1.64 – 1.54 (2H, m, 2 × C2-H’), 0.99 (9H, t, J = 
8.0 Hz, Si(CH2CH3)3), 0.78 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 137.5 (C4), 115.5 
(C5), 62.4 (C1), 34.7 (Ms CH3), 30.9 (C3), 30.7 (C2), 6.8 (Si(CH2CH3)3), 5.0 (Si(CH2CH3)3).  
HRMS: (ESI+) Calculated for C16H33NNaO3SSi: 370.1843. Found [M+Na]+: 370.1840. 
  





To a solution of the preceding compound (728 mg, 2.09 mmol) in anhydrous CH2Cl2 (80 mL, argon 
sparged) was added Grubbs-Hoveyda 2nd generation catalyst (13.1 mg, 20.9 μmol). The reaction 
mixture was stirred at room temperature for 3 days before addition of MeOH (40 mL) and 12 M aqueous 
HCl (8 mL). The reaction mixture was stirred for 1 hour before addition of saturated aqueous Na2CO3 
(50 mL). The resulting phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 × 
70 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (156 mg, 36 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3317 (br s), 3037 (m), 2948 (m), 2848 (m), 1446 (m), 1317 (s), 1152 (s). 
δH (400 MHz, CDCl3) 6.10 (1H, s, OH), 5.83 – 5.74 (2H, m, 2 × C4-H), 3.92 (1H, tt, J = 10.0, 4.0 Hz 
C1-H), 3.02 (3H, s, Ms CH3), 2.35 – 2.25 (2H, m, 2 × C3-H), 2.12 – 2.02 (2H, m, 2 × C3-H’), 2.02 – 
1.93 (2H, m, 2 × C2-H), 1.84 – 1.73 (2H, m, 2 × C2-H’). δC (101 MHz, CDCl3) 131.6 (C4), 63.4 (C1), 




General procedure C: The preceding compound (147 mg, 0.716 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 168b (261 mg, 91 %) as a colourless crystalline solid. m.p. 78-79 °C 
(CH2Cl2:hexane, plates). νmax / cm-1: (solid) 2939 (m), 2845 (m), 1768 (s), 1651 (s), 1591 (s), 1157 (s). 
δH (500 MHz, CDCl3) 5.83 – 5.79 (2H, m, 2 × C4-H), 4.20 (1H, tt, J = 10.5, 3.5 Hz, C1-H), 3.09 (3H, 
s, Ms CH3), 2.32 – 2.24 (2H, m, 2 × C3-H), 2.21 – 2.14 (2H, m, 2 × C2-H), 2.12 – 2.04 (2H, m, 2 × 
C3-H’), 1.69 – 1.59 (2H, m, 2 × C2-H’). δC (126 MHz, CDCl3) 157.3 (C=O), 131.6 (C4), 65.6 (C1), 
39.7 (Ms CH3), 31.0 (C3), 24.8 (C2). The aromatic 
13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.8 – -136.0 (2F, m), 
-145.2 (1F, tt, J = 21.0, 5.5 Hz), -158.5 – -158.7 (2F, m). HRMS: (ESI+) Calculated for 
C15H14F5NNaO4S: 422.0456. Found [M+Na]+: 422.0459. 





General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 16 hours. Substrate 168b (55.9 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 5:1 – 4:1 – 3:1 hexane:EtOAc) afforded 169b (15.6 mg, 60 %) as a colourless 
crystalline solid. νmax / cm-1: (solid) 3046 (m), 2958 (m), 2926 (m), 1458 (m), 1321 (s), 1137 (s).  
δH (400 MHz, CDCl3) 5.99 (1H, dddd, J = 9.5, 5.5, 2.0, 2.0 Hz, C4-H), 5.62 – 5.56 (1H, m, C3-H), 4.33 
– 4.25 (2H, m, C1-H and C5-H), 2.93 (3H, s, Ms CH3), 2.77 – 2.67 (1H, m, C2-H), 2.31 – 2.20 (1H, m, 
C7-H), 2.13 – 1.90 (3H, m, C2-H’ and C6-H2), 1.77 – 1.67 (1H, m, C7-H’). δC (101 MHz, CDCl3) 131.5 
(C4), 124.1 (C3), 55.6 (C1 or C5), 55.5 (C1 or C5), 40.9 (Ms CH3), 36.1 (C6), 35.6 (C2), 30.8 (C7). 
HRMS: (ESI+) Calculated for C8H14NO2S: 188.0740. Found [M+H]+: 188.0744. 
 
ORTEP view of 169b. 
Cyclohex-1-en-1-ylmethanol 
 
To a solution of methyl 1-cyclohexene-1-carboxylate (5.00 g, 35.6 mmol) in anhydrous CH2Cl2 
(100 mL) at -78 °C was added DiBAl-H (1.0 M in CH2Cl2, 78.0 mL, 78.0 mmol). The reaction mixture 
was stirred at -78 °C for 2 hours before addition of MeOH (70 mL) and saturated aqueous Rochelle salt 
(70 mL). The mixture was warmed to room temperature and stirred for 15 hours before the resulting 
phases were separated, and the aqueous phase was extracted with EtOAc (2 × 100 mL). The  
combined organic phases were washed with brine (100 mL) followed by saturated aqueous Rochelle  
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salt (100 mL), dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 8:1 – 
4:1 hexane:EtOAc) afforded the title compound (3.98 g, 100 %) as a colourless oil. νmax / cm-1: (film) 
3307 (br s), 2924 (s), 2857 (s), 2835 (s), 1437 (s), 1004 (s). δH (400 MHz, CDCl3) 5.68 – 5.65 (1H, m), 
3.96 (2H, s), 2.05 – 1.97 (4H, m), 1.68 – 1.54 (4H, m), 1.52 (1H, s). δC (101 MHz, CDCl3) 137.7, 123.1, 




General procedure J:  The preceding alcohol (3.50 g, 31.1 mmol) was employed to afford the title 
compound (4.26 g, 78 %) as a colourless oil. δH (400 MHz, CDCl3) 5.88 – 5.85 (1H, m), 3.93 (2H, s), 
2.14 – 2.09 (2H, m), 2.06 – 1.99 (2H, m), 1.70 – 1.62 (2H, m), 1.60 – 1.52 (2H, m). δC (101 MHz, 
CDCl3) 134.6, 128.1, 39.8, 26.3, 25.4, 22.4, 21.8. m/z (EI+) 176 and 174 ([M]+, 52 and 53 %), 
95 ([M-Br]+, 100 %), 84 (80 %). The spectroscopic properties were consistent with the data available 
in the literature.101 
3-(Cyclohex-1-en-yl)propanoic acid 
 
General procedure H: The preceding allylic bromide (1.36 mL, 10.0 mmol) was employed. The crude 
product was used in the next step without further purification. δH (400 MHz, CDCl3) 5.51 – 5.39 (1H, 
m), 2.48 – 2.43 (2H, m), 2.25 (2H, t, J = 8.0 Hz), 2.00 – 1.88 (4H, m), 1.65 – 1.58 (2H, m), 1.57 – 1.50 
(2H, m). δC (101 MHz, CDCl3) 178.5, 135.7, 121.7, 32.6, 32.3, 28.2, 25.1, 22.8, 22.3. The spectroscopic 
properties were consistent with the data available in the literature.232 
3-(Cyclohex-1-en-yl)propan-1-ol 
 
General procedure I: The preceding crude carboxylic acid was employed, using anhydrous THF as 
the solvent and 1.5 eq. LiAlH4 (1.0 M in Et2O). FCC (eluent: 4:1 hexane:EtOAc) afforded the title 
compound (1.26 g, 90 % over two steps) as a pale-yellow oil. νmax / cm-1: (film) 3326 (br s), 2923 (s), 
2834 (s), 1438 (m), 1058 (s). δH (400 MHz, CDCl3) 5.44 – 5.40 (1H, m), 3.61 (2H, t, J = 6.5 Hz), 2.02 
– 1.88 (6H, m), 1.74 (1H, s), 1.69 – 1.48 (6H, m). δC (101 MHz, CDCl3) 137.5, 121.4, 63.0, 34.5, 30.6, 
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General procedure E: TsNHOTBS (vide supra, 1.00 g, 3.32 mmol) was employed with 
3-(cyclohex-1-en-yl)propan-1-ol (vide supra, 1.3 eq.). The reaction time was 14 hours. FCC (eluent: 
1:1 hexane:PhMe) afforded the title compound (1.40 g, 100 %) as a colourless oil. νmax / cm-1: (film) 
2928 (m), 2857 (m), 1598 (m), 1462 (m), 1357 (s), 1169 (s). δH (400 MHz, CDCl3) 7.72 (2H, d, J = 
8.0 Hz, 2 × ArCH), 7.32 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.36 – 5.32 (1H, m, C5-H), 2.89 – 2.83 (2H, 
m, C1-H2), 2.44 (3H, s, Ts CH3), 1.99 – 1.81 (6H, m, C3-H2, C6-H2 and C9-H2), 1.69 – 1.45 (6H, m, 
C2-H2, C7-H2 and C8-H2), 0.91 (9H, s, SiC(CH3)3), 0.28 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 144.4 
(ArC), 136.4 (C4), 130.0 (ArC), 129.9 (ArCH), 129.2 (ArCH), 121.6 (C5), 55.8 (C1), 35.2 (C3), 28.2 
(C9), 26.0 (SiC(CH3)3), 25.2 (C6), 25.0 (C2), 22.9 (C8), 22.5 (C7), 21.6 (Ts CH3), 18.2 (SiC(CH3)3), -
4.2 (Si(CH3)2). HRMS: (ESI+) Calculated for C22H37NNaO3SSi: 446.2156. Found [M+Na]+: 446.2149. 
N-(3-(Cyclohex-1-en-1-yl)propyl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure B: The preceding compound (1.34 g, 3.16 mmol) was employed. The title 
compound (796 mg, 81 %) was isolated as a colourless crystalline solid. νmax / cm-1: (solid) 3352 (br s), 
2919 (s), 1598 (m), 1334 (s), 1169 (s). δH (400 MHz, CDCl3) 7.77 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.35 
(2H, d, J = 8.0 Hz, 2 × ArCH), 6.22 (1H, br s, OH), 5.41 – 5.36 (1H, m, C5-H), 2.88 (2H, t, J = 7.0 Hz, 
C1-H2), 2.45 (3H, s, Ts CH3), 2.00 – 1.92 (4H, m, C3-H2 and C6-H2), 1.90 – 1.83 (2H, m, C9-H2), 1.70 
(2H, tt, J = 7.0, 7.0 Hz, C2-H2), 1.62 – 1.48 (4H, m, C7-H2 and C8-H2). δC (101 MHz, CDCl3) 144.8 
(ArC), 136.6 (C4), 129.7 (ArCH), 2 × 129.5 (ArC and ArCH), 121.6 (C5), 52.3 (C1), 34.8 (C3), 28.2 
(C9), 25.2 (C6), 24.7 (C2), 22.9 (C8), 22.5 (C7), 21.6 (Ts CH3). HRMS: (ESI+) Calculated for 
C16H23NNaO3S: 332.1291. Found [M+Na]+: 332.1291. 
  





General procedure C: The preceding compound (785 mg, 2.54 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 170a (1.18 g, 92 %) as a colourless crystalline solid. m.p. 71-72 °C 
(Et2O:hexane, needles). νmax / cm-1: (solid) 2930 (m), 2833 (m), 1788 (s), 1651 (m), 1595 (m), 1502 (s), 
1169 (s). δH (400 MHz, CDCl3) 7.79 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.37 (2H, d, J = 8.0 Hz, 2 × ArCH), 
5.39 – 5.35 (1H, m, C5-H), 3.18 (2H, br s, C1-H2), 2.46 (3H, s, Ts CH3), 2.03 (2H, t, J = 7.5 Hz, C3-H2), 
1.98 – 1.91 (2H, m, C6-H2), 1.88 – 1.81 (2H, m, C9-H2), 1.66 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.61 – 
1.45 (4H, m, C7-H2 and C8-H2). δC (101 MHz, CDCl3) 145.8 (ArC), 136.0 (C4), 130.1 (ArC), 129.8 
(ArCH), 129.6 (ArCH), 122.1 (C5), 52.3 (C1), 34.6 (C3), 28.0 (C9), 25.2 (C6), 24.6 (C2), 22.9 (C8), 
22.4 (C7), 21.7 (Ts CH3). The 
13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.0 (2F, m), -146.1 (1F, tt, J = 
21.0, 5.0 Hz), -158.9 – -159.1 (2F, m). HRMS: (ESI+) Calculated for C23H22F5NNaO4S: 526.1082. 
Found [M+Na]+: 526.1071.  
1-Tosyl-1-azaspiro[4.5]dec-6-ene (171a) and iso-171a 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 50 mol% 
Et3N; n-BuCN (0.1 M); 110 °C; 15 hours. Substrate 170a (70.5 mg, 0.140 mmol) was employed. FCC 
(gradient elution: 14:1 – 9:1 – 4:1 hexane:EtOAc) afforded 171a and iso-171a (13.2 mg, 32 %, 
5:1 mixture of 171a and iso-171a) as a pale-yellow crystalline solid. Spectroscopic data for 171a:  
νmax / cm-1: (film) 2926 (m), 1599 (m), 1447 (m), 1334 (s), 1154 (s). δH (400 MHz, CDCl3) 7.72 (2H, d, 
J = 8.0 Hz, 2 × ArCH), 7.25 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.77 – 5.69 (1H, m, C6-H), 5.41 – 5.36 
(1H, m, C5-H), 3.55 (1H, ddd, J = 9.5, 6.0, 2.5 Hz, C1-H), 3.27 (1H, ddd, J = 9.5, 9.0, 7.0 Hz, C1-H’), 
2.47 – 2.37 (4H, m, C9-H and Ts CH3), 2.18 – 2.07 (1H, m, C7-H), 1.99 – 1.64 (7H, m, C2-H2, C3-H2, 
C7-H’, C8-H and C9-H’), 1.56 – 1.44 (1H, m, C8-H’). δC (101 MHz, CDCl3) 142.5 (ArC), 138.7 (ArC), 
131.8 (C5), 129.2 (ArCH), 128.3 (C6), 127.4 (ArCH), 67.3 (C4), 49.1 (C1), 40.8 (C3), 34.7 (C9), 24.3 
(C7), 22.8 (C2), 21.7 (C8), 21.5 (Ts CH3). HRMS: (ESI+) Calculated for C16H21NNaO2S: 314.1185. 
Found [M+Na]+: 314.1188. Characteristic signals for iso-171a: δH (400 MHz, CDCl3) 5.61 – 5.51 (2H, 
m), 3.02 – 2.94 (1H, m), 2.54 (1H, td, J = 12.0, 6.0 Hz). 





General procedure E: MsNHOTES (vide supra, 564 mg, 2.50 mmol) was employed with 
3-(cyclohex-1-en-yl)propan-1-ol (vide supra, 1.1 eq.). The reaction time was 19 hours. FCC (gradient 
elution: 1:4 – 0:1 hexane:PhMe) afforded the title compound (776 mg, 89 %) as a colourless oil.  
νmax / cm-1: (film) 2935 (s), 2878 (s), 1351 (s), 1165 (s). δH (400 MHz, CDCl3) 5.43 – 5.40 (1H, m, 
C5-H), 3.18 – 3.13 (2H, m, C1-H2), 2.86 (3H, s, Ms CH3), 2.02 – 1.95 (4H, m, C3-H2 and C6-H2), 1.94 
– 1.87 (2H, m, C9-H2), 1.77 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.66 – 1.59 (2H, m, C8-H2), 1.59 – 1.51 
(2H, m, C7-H2), 1.00 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.78 (6H, q, J = 8.0 Hz, Si(CH2CH3)3).  
δC (101 MHz, CDCl3) 136.2 (C4), 121.8 (C5), 55.4 (C1), 35.1 (C3), 30.4 (Ms CH3), 28.2 (C9), 25.2 
(C6), 25.0 (C2), 22.9 (C8), 22.5 (C7), 6.7 (Si(CH2CH3)3), 4.8 (Si(CH2CH3)3). HRMS: (ESI+) Calculated 
for C16H33NNaO3SSi: 370.1843. Found [M+Na]+: 370.1859. 
N-(3-(Cyclohex-1-en-1-yl)propyl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (712 mg, 2.05 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (475 mg, 99 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3352 (br s), 2926 (s), 2834 (m), 1436 (m), 1326 (s), 1146 (s). δH (400 MHz, CDCl3) 
6.58 (1H, br s, OH), 5.46 – 5.42 (1H, m, C5-H), 3.17 (2H, t, J = 7.0 Hz, C1-H2), 2.93 (3H, s, Ms CH3), 
2.06 – 1.96 (4H, m, C3-H2 and C6-H2), 1.95 – 1.89 (2H, m, C9-H2), 1.81 (2H, tt, J = 7.0, 7.0 Hz, C2-H2), 
1.66 – 1.59 (2H, m, C8-H2), 1.59 – 1.51 (2H, m, C7-H2). δC (101 MHz, CDCl3) 136.4 (C4), 121.8 (C5), 
52.1 (C1), 34.7 (C3), 30.9 (Ms CH3), 28.2 (C9), 25.2 (C6), 24.8 (C2), 22.9 (C8), 22.5 (C7). 
HRMS: (ESI+) Calculated for C10H19NNaO3S: 256.0978. Found [M+Na]+: 256.0977. 
N-3-(Cyclohex-1-en-yl)propyl-N-(pentafluorobenzoyloxy)methanesulfonamide (170b) 
 
General procedure C: The preceding compound (442 mg, 1.89 mmol) was employed. FCC (eluent: 
6:1 hexane:EtOAc) afforded 170b (685 mg, 85 %) as a colourless crystalline solid. m.p. 98-99 °C 
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(Et2O:hexane, needles). νmax / cm-1: (solid) 3023 (m), 2932 (m), 1779 (s), 1653 (m), 1501 (s), 1323 (s), 
1162 (s). δH (400 MHz, CDCl3) 5.46 – 5.41 (1H, m, C5-H), 3.45 (2H, br t, J = 7.0 Hz, C1-H2), 3.04 
(3H, s, Ms CH3), 2.10 (2H, t, J = 7.5 Hz, C3-H2), 2.01 – 1.94 (2H, m, C6-H2), 1.92 – 1.87 (2H, m, 
C9-H2), 1.78 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.65 – 1.58 (2H, m, C7-H2), 1.58 – 1.50 (2H, m, C8-H2). 
δC (101 MHz, CDCl3) 136.0 (C4), 122.5 (C5), 52.3 (C1), 34.7 (C3), 34.6 (Ms CH3), 28.2 (C9), 25.3 
(C6), 24.9 (C2), 23.0 (C8), 22.6 (C7). The 13C signals corresponding to the pentafluorobenzoyl group 
could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.8 – -136.0 (2F, m), -145.3 
(1F, tt, J = 21.0, 5.5 Hz), -158.7 – -158.9 (2F, m). HRMS: (ESI+) Calculated for C17H18F5NNaO4S: 
450.0769. Found [M+Na]+: 450.0769. 
1-Mesyl-1-azaspiro[4.5]dec-6-ene (171b) 
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 18.8 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 16 hours. Substrate 170b (59.8 mg, 0.140 mmol) was 
employed. FCC (eluent: 29:1 PhMe:acetone) afforded 171b (12.8 mg, 42 %) as a yellow crystalline 
solid. νmax / cm-1: (solid) 3023 (m), 2929 (m), 1447 (m), 1317 (s), 1143 (s). δH (400 MHz, CDCl3) 5.82 
(1H, ddd, J = 10.0, 5.5, 2.5 Hz, C6-H), 5.62 – 5.57 (1H, m, C5-H), 3.57 (1H, ddd, J = 10.5, 6.0, 3.5 Hz, 
C1-H), 3.42 – 3.34 (1H, m, C1-H’), 2.89 (3H, s, Ms CH3), 2.35 (1H, ddd, J = 13.0, 13.0, 3.5 Hz, C9-H), 
2.09 (1H, dddd, J = 16.5, 11.0, 5.5, 2.5 Hz, C7-H), 2.02 – 1.78 (6H, m, C2-H2, C3-H2, C7-H’ and C8-H), 
1.77 – 1.68 (1H, m, C9-H’), 1.58 – 1.47 (1H, m, C8-H’). δC (101 MHz, CDCl3) 131.5 (C5), 129.2 (C6), 
66.6 (C4), 49.2 (C1), 41.1 (C3), 40.0 (Ms CH3), 34.4 (C9), 24.3 (C7), 22.6 (C2), 21.6 (C8). 
HRMS: (ESI+) Calculated for C10H17NNaO2S: 238.0872. Found [M+Na]+: 238.0878. 
(E)-2-(But-2-en-1-yl)cyclohexan-1-one (173) 
 
To a suspension of NaH (60 % in mineral oil, 1.05 g, 26.3 mmol) in anhydrous DMF (60 mL) was 
added ethyl 2-oxocyclohexanecarboxylate (172) (4.00 mL, 25.0 mmol). The reaction mixture was 
stirred at room temperature for 1 hour before addition of crotyl bromide (vide supra, 3.10 mL, 
30.1 mmol.). The reaction mixture was stirred for 26 hours before addition of water (100 mL) and 
extraction with Et2O (3 × 100 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude mixture was dissolved in MeOH (60 mL) and water (60 mL); KOH 
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(20.0 g, 356 mmol) was added to this solution, which was then heated at reflux for 2 hours. The reaction 
mixture was cooled to room temperature before addition of brine (100 mL) and extraction with Et2O 
(3 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC 
(eluent: 9:1 hexane:Et2O) afforded 173 (2.71 g, 71 %) as a colourless oil. νmax / cm-1: (film) 2933 (s), 
2859 (m), 1708 (s), 1448 (m), 1126 (m). δH (400 MHz, CDCl3) 5.53 – 5.31 (2H, m), 2.49 – 2.35 (2H, 
m), 2.33 – 2.23 (2H, m), 2.15 – 1.99 (2H, m), 1.95 – 1.80 (2H, m), 1.73 – 1.57 (5H, m), 1.41 – 1.28 
(1H, m). δC (101 MHz, CDCl3) 213.1, 128.9, 126.9, 50.9, 42.2, 33.5, 32.7, 28.1, 25.0, 18.1. The data 
available in the literature is for a mixture of the (E) and (Z)-isomers.233 The spectroscopic properties 
of 173 were consistent with those provided for the (E)-isomer, with the exception of one signal in the 
13C spectrum which appears to have been misassigned to the (Z)-isomer. 
(1R*,2R*)-2-((E)-But-2-en-1-yl)cyclohexan-1-ol (174a) and (1R*,2S*)-2-((E)-But-2-en-1-yl)-
cyclohexan-1-ol (174b) 
 
To a solution of ketone 173 (1.52 g, 10.0 mmol) in MeOH (50 mL) at 0 °C was added NaBH4 (378 mg, 
10.0 mmol). The reaction mixture was stirred at 0 °C for 2 hours before addition of 1.0 M aqueous HCl 
(50 mL) and extraction with Et2O (3 × 50 mL). The Et2O extracts were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 11:1 hexane:EtOAc) afforded 174a (534 mg, 35 %) as a colourless 
oil and 174b (509 mg, 33 %) as a colourless oil. Spectroscopic data for 174a: νmax / cm-1: (film) 
3401 (br s), 2956 (s), 1448 (m). δH (400 MHz, CDCl3) 5.52 – 5.37 (2H, m, C8-H and C9-H), 3.90 – 
3.85 (1H, m, C1-H), 2.12 – 2.02 (1H, m, C7-H), 1.99 – 1.90 (1H, m, C7-H’), 1.82 – 1.72 (1H, m, C2-H), 
1.68 – 1.61 (4H, m, C4-H and C10-H3), 1.62 – 1.55 (1H, m, C3-H), 1.53 – 1.42 (5H, m, C2-H’, C3-H’, 
C5-H, C6-H and OH), 1.42 – 1.35 (1H, m, C5-H’), 1.32 – 1.23 (1H, m, C4-H’).  
δC (101 MHz, CDCl3) 129.7 (C8), 126.2 (C9), 69.1 (C1), 41.6 (C6), 35.4 (C7), 33.0 (C2), 26.4 (C5), 
25.2 (C4), 20.5 (C3), 17.9 (C10). HRMS: (ESI+) Calculated for C10H18NaO: 177.1250. Found [M+Na]+: 
177.1251. 
Spectroscopic data for 174b: νmax / cm-1: (film) 3338 (br s), 2923 (s), 2855 (s), 1448 (s), 1063 (s).  
δH (500 MHz, CDCl3) 5.51 – 5.48 (2H, m, C8-H and C9-H), 3.27 (1H, ddd, J = 9.5, 9.5, 4.5 Hz, C1-H), 
2.38 – 2.31 (1H, m, C7-H), 2.00 – 1.90 (2H, m, C2-H and C7-H’), 1.80 (1H, br s, OH), 1.79 – 1.71 (2H, 
m, C3-H and C5-H), 1.69 – 1.61 (4H, m, C4-H and C10-H3), 1.34 – 1.12 (4H, m, C2-H’, C3-H’, C4-H’ 
and C6-H), 0.99 – 0.89 (1H, m, C5-H’). δC (101 MHz, CDCl3) 129.8 (C8), 126.5 (C9), 74.8 (C1), 45.2 
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(C6), 36.3 (C7), 35.4 (C2), 30.5 (C5), 25.6 (C4), 24.9 (C3), 17.9 (C10). HRMS: (ESI+) Calculated for 
C10H18NaO: 177.1250. Found [M+Na]+: 177.1242. 
N-((1R*,2S*)-2-((E)-But-2-en-1-yl)cyclohexyl)-N-(triethylsilyl)oxy)-4-toluenesulfonamide 
 
General procedure E: TsNHOTES (vide supra, 603 mg, 2.00 mmol) was employed with alcohol 174a 
(1.3 eq.). The reaction time was 25 hours. FCC (gradient elution: 1:4 – 0:1 hexane:PhMe) afforded the 
title compound (338 mg, 39 %) as a colourless crystalline solid. m.p. 91-93 °C (Et2O:hexane, plates). 
νmax / cm-1: (solid) 2936 (m), 2876 (m), 1597 (m), 1450 (m), 1345 (s), 1166 (s). δH (400 MHz, CDCl3) 
7.74 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.30 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.50 – 5.33 (2H, m, C8-H and 
C9-H), 3.24 (1H, ddd, J = 11.5, 11.5, 3.5 Hz, C1-H), 2.72 – 2.63 (1H, m, C7-H), 2.44 (3H, s, Ts CH3), 
1.96 – 1.87 (1H, m, C5-H), 1.80 – 1.70 (1H, m, C7-H’), 1.69 – 1.64 (3H, m, C10-H3), 1.58 – 1.52 (1H, 
m, C4-H), 1.50 – 1.43 (1H, m, C3-H), 1.41 – 1.31 (1H, m, C6-H), 1.26 – 1.13 (1H, m, C2-H), 1.08 – 
1.00 (9H, m, Si(CH2CH3)3), 0.99 – 0.74 (9H, m, C3-H’, C4-H’, C5-H’ and Si(CH2CH3)3), 0.72 – 0.61 
(1H, m, C2-H’). δC (101 MHz, CDCl3) 144.1 (ArC), 133.8 (ArC), 129.3 (ArCH), 129.1 (C9), 129.0 
(ArCH), 126.6 (C8), 66.3 (C1), 40.7 (C6), 36.3 (C7), 31.9 (C5), 26.2 (C2), 25.6 (C3), 25.5 (C4),  
21.6 (Ts CH3), 18.1 (C10), 6.9 (Si(CH2CH3)3), 5.1 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for 
C23H39NNaO3SSi: 460.2314. Found [M+Na]+: 460.2314. 
N-((1R*,2S*)-2-((E)-But-2-en-1-yl)cyclohexyl)-N-hydroxy-4-toluenesulfonamide  
 
General procedure F: The preceding compound (321 mg, 0.733 mmol) was employed. FCC (eluent: 
6:1 hexane:EtOAc) afforded the title compound (209 mg, 88 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3316 (br s), 2919 (m), 2856 (m), 1599 (m), 1332 (s), 1161 (s). δH (400 MHz, CDCl3) 
7.82 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.91 (1H, br s, OH), 5.49 – 
5.36 (2H, m, C8-H and C9-H), 3.49 (1H, ddd, J = 11.0, 11.0, 4.0 Hz, C1-H), 2.44 (3H, s, Ts CH3), 2.42 
– 2.35 (1H, m, C7-H), 1.95 – 1.80 (2H, m, C5-H and C7-H’), (3H, d, J = 4.0 Hz, C10-H3), 1.62 – 1.55 
(2H, m, C3-H and C4-H), 1.55 – 1.47 (1H, m, C6-H), 1.45 – 1.33 (1H, m, C2-H), 1.28 – 1.20 (1H, m, 
C2-H’), 1.18 – 0.97 (3H, m, C3-H’, C4-H’ and C5-H’). δC (101 MHz, CDCl3) 144.2 (ArC), 134.7 (ArC), 
129.5 (ArCH), 129.0 (C9), 128.7 (ArCH), 126.8 (C8), 63.7 (C1), 39.9 (C6), 35.9 (C7), 31.7 (C5), 26.2 
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(C2), 25.5 (C3), 25.3 (C4), 21.6 (Ts CH3), 18.0 (C10). HRMS: (ESI+) Calculated for C17H25NNaO3S: 




General procedure C: The preceding compound (208 mg, 0.643 mmol) was employed. FCC (eluent: 
19:1 hexane:EtOAc) afforded 175a (227 mg, 68 %) as a colourless crystalline solid. m.p. 108-109 °C 
(CH2Cl2:petrol, cubes). νmax / cm-1: (solid) 2930 (m), 1773 (s), 1651 (m), 1595 (m), 1493 (s), 1170 (s). 
δH (400 MHz, CDCl3) 7.82 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.33 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.45 
(1H, dq, J = 15.0, 6.5 Hz, C9-H), 5.38 – 5.28 (1H, m, C8-H), 3.76 (1H, ddd, J = 11.0, 11.0, 6.5 Hz, 
C1-H), 2.82 – 2.70 (1H, m, C7-H), 2.45 (3H, s, Ts CH3), 1.99 – 1.87 (2H, m, C5-H and C7-H’), 1.80 – 
1.46 (7H, m, C2-H2, C3-H, C4-H and C10-H3), 1.34 – 1.15 (2H, m, C3-H’ and C6-H), 1.13 – 0.94 (2H, 
m, C4-H’ and C5-H’). δC (101 MHz, CDCl3) 156.3 (C=O), 145.5 (ArC), 133.2 (ArC), 129.7  
(ArCH), 129.2 (ArCH), 128.5 (C9), 127.1 (C8), 64.7 (C1), 40.5 (C6), 35.6 (C7), 31.5 (C5), 27.7 (C2), 
25.5 (C3), 25.2 (C4), 21.7 (Ts CH3), 18.0 (C10). The aromatic 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.9 – -136.1 (2F, m), -146.2 (1F, tt, J = 21.5, 5.0 Hz), -159.0 – -159.1 (2F, m). HRMS: (ESI+) 
Calculated for C24H24F5NNaO4S: 540.1238. Found [M+Na]+: 540.1223. 
 
ORTEP view of 175a. 
  





General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
PhMe (0.1 M); 140 °C; 17 hours. Substrate 175a (72.5 mg, 0.140 mmol) was employed. FCC (gradient 
elution: 29:1 – 19:1 – 14:1 – 9:1 – 3:1 hexane:EtOAc) afforded 176a (19.4 mg, 45 %, 4:3 mixture of 
diastereomers) as a pale-yellow oil. Spectroscopic data for both diastereomers: δH (400 MHz, CDCl3) 
7.71 – 7.66 (2H, m), 7.31 (1.2H, d, J = 8.5 Hz), 7.26 – 7.23 (0.8H, m), 5.85 (0.6H, ddd, J = 17.0, 10.5, 
5.0 Hz), 5.64 (0.4H, ddd, J = 17.0, 10.0, 8.0 Hz), 5.34 (0.6H, ddd, J = 17.0, 1.5, 1.5 Hz), 5.20 (0.4H, 
ddd, J = 17.0, 1.0, 1.0 Hz), 5.13 (0.6H, ddd, J = 10.5, 1.5, 1.5 Hz), 5.04 (0.4H, ddd, J = 10.0, 1.0, 
1.0 Hz), 4.39 (0.4H, br dt, J = 8.0, 8.0 Hz), 4.27 – 4.20 (0.6H, m), 2.76 (0.4H, ddd, J = 11.5, 10.5, 
3.5 Hz), 2.56 – 2.45 (1.6H, m), 2.43 (1.8H, s), 2.41 (1.2H, s), 2.22 – 2.14 (0.4H, m), 1.88 – 1.53 (4.2H, 
m), 1.50 – 0.9 (5.4H, m). δC (101 MHz, CDCl3) 143.2, 142.5, 2 × 139.6, 139.3, 134.6, 129.5, 129.3, 
127.7, 127.2, 115.4, 115.1, 66.8, 65.4, 63.3, 61.8, 45.5, 42.8, 38.0, 35.8, 32.6, 30.9, 29.9, 29.6, 25.3, 




General procedure K: Alcohol 174a (vide supra, 242 mg, 1.57 mmol) was employed with TsNHOFBz 
(vide supra). The reaction time was 14 hours. FCC (gradient elution: 3:1 – 1:1 hexane:PhMe) afforded 
177 (345 mg, 47 %) as a colourless crystalline solid. Desired product 175a was not observed.  
An alternative procedure was devised to prepare 177: To a suspension of NaH (60 % in mineral oil, 
105 mg, 2.62 mmol) in anhydrous DMF (30 mL) was added a solution of TsNHOFBz (vide supra, 
1.00 g, 2.62 mmol) in anhydrous THF (30 mL) dropwise. The reaction mixture was stirred at room 
temperature for 16 hours before addition of brine (60 mL) and extraction with Et2O (3 × 60 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
9:1 hexane:EtOAc) afforded 177 (419 mg, 44 %) as a colourless crystalline solid. m.p. 144-145 °C 
(CH2Cl2:hexane, cubes). νmax / cm-1: (solid) 1816 (s), 1594 (m), 1533 (s), 1499 (s), 1184 (s). 
δH (400 MHz, CDCl3) 7.75 – 7.69 (2H, m, 2 × ArCH), 7.38 – 7.33 (2H, m, 2 × ArCH), 2.46 (3H, s, 
Chapter 7 - Experimental 
210 
 
Ts CH3). δC (101 MHz, CDCl3) 148.3 (ArC), 130.5 (ArCH), 130.0 (ArCH), 127.6 (ArC), 22.0 (Ts CH3). 
The 13C signals corresponding to the carbonyl and fluorinated arene groups could not be resolved due 
to their weak intensity. δF (377 MHz, CDCl3) -136.7 – -136.9 (1F, m), -137.8 (1F, ddd, J = 19.0, 19.0, 
9.5 Hz), -140.6 (1F, ddd, J = 20.0, 19.0, 3.5 Hz), -151.4 – -151.6 (1F, m). HRMS: (ESI+) Calculated for 
C14H7F4NNaO4S: 383.9924. Found [M+Na]+: 383.9916. 
 
ORTEP view of 177. 
(E)-Pent-3-en-1-ol (123) 
 
General procedure I: (E)-Pent-3-enoic acid (5.00 g, 49.9 mmol) was employed, using anhydrous Et2O 
as the solvent and 2.0 eq. LiAlH4 (1.0 M in Et2O). Alcohol 123 (3.98 g, 93 %) was isolated as a pale-
yellow oil. δH (400 MHz, CDCl3) 5.55 (1H, dqt, J = 15.5, 6.5, 1.5 Hz), 5.39 (1H, dtq, J = 15.5, 6.5, 
1.5 Hz), 3.60 (2H, t, J = 6.5 Hz), 2.23 (2H, dtdq, J = 6.5, 6.5, 1.5, 1.5 Hz), 1.74 (1H, br s), 1.67 (3H, 
ddt, J = 6.5, 1.5, 1.5 Hz). δC (101 MHz, CDCl3) 128.6, 127.2, 62.1, 36.1, 18.1. The spectroscopic 
properties were consistent with the data available in the literature.234  
(E)-N-(Pent-3-en-1-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 564 mg, 2.50 mmol) was employed with alcohol 123 
(1.3 eq.). The reaction time was 15 hours. FCC (eluent: 1:4 hexane:PhMe) afforded the title compound 
(1.73 g, 98 %) as a colourless oil. νmax / cm-1: (film) 2957 (m), 2878 (m), 1457 (m), 1351 (s), 1165 (s). 
δH (400 MHz, CDCl3) 5.55 (1H, dqt, J = 15.0, 6.5, 1.5 Hz, C4-H), 5.38 (1H, dtq, J = 15.0, 7.0, 1.5 Hz, 
C3-H), 3.23 – 3.16 (2H, m, C1-H2), 2.85 (3H, s, Ms CH3), 2.39 – 2.31 (2H, m, C2-H2), 1.66 (3H, dq, 
J = 6.5, 1.5 Hz, C5-H3), 0.99 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.77 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). 
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δC (101 MHz, CDCl3) 128.1 (C4), 126.9 (C3), 55.7 (C1), 30.6 (C2), 30.5 (Ms CH3), 18.1 (C5), 6.8 




General procedure F: The preceding compound (1.71 g, 5.83 mmol) was employed. FCC (eluent: 
3:1 hexane:EtOAc) afforded the title compound (735 mg, 70 %) as a colourless oil. νmax / cm-1: (film) 
3384 (br s), 2919 (m), 1438 (m), 1334 (s), 1162 (s). δH (400 MHz, CDCl3) 7.08 (1H, s, OH), 5.55 (1H, 
dqt, J = 15.0, 6.5, 1.5 Hz, C4-H), 5.41 (1H, dtq, J = 15.0, 7.5, 1.5 Hz, C3-H), 3.19 (2H, t, J = 7.0 Hz, 
C1-H2), 2.92 (3H, s, Ms CH3), 2.37 (2H, dtt, J = 7.5, 7.0, 1.5 Hz, C2-H2), 1.65 (3H, dq, J = 6.5, 1.5 Hz, 
C5-H3). δC (101 MHz, CDCl3) 128.0 (C4), 126.9 (C3), 52.5 (C1), 31.0 (Ms CH3), 30.3 (C2), 18.1 (C5). 
HRMS: (ESI+) Calculated for C6H13NNaO3S: 202.0508. Found [M+Na]+: 202.0515. 
(E)-N-(Pent-3-en-1-yl)-N-((pentafluorobenzoyl)oxy)methanesulfonamide (178) 
 
General procedure C: The preceding compound (705 mg, 3.93 mmol) was employed. FCC (gradient 
elution: 6:1 – 4:1 hexane:EtOAc) afforded 178 (1.35 g, 92 %) as a colourless crystalline solid.  
m.p. 80-81 °C (CH2Cl2:petrol, fibres). νmax / cm-1: (solid) 3024 (m), 2940 (m), 1787 (s), 1655 (m), 
1504 (s), 1348 (s) 1161 (s). δH (400 MHz, CDCl3) 5.62 – 5.52 (1H, m, C4-H), 5.47 – 5.38 (1H, m, 
C3-H), 3.54 – 3.43 (2H, m, C1-H2), 3.04 (3H, s, Ms CH3), 2.39 (2H, dt, J = 7.0, 7.0 Hz, C2-H2), 1.64 
(3H, ddt, J = 6.5, 1.5, 1.5 Hz, C5-H3). δC (101 MHz, CDCl3) 128.9 (C4), 125.9 (C3), 52.7 (C1), 34.5 
(Ms CH3), 30.4 (C2), 18.0 (C5). The 
13C signals corresponding to the pentafluorobenzoyl group could 
not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.8 – -135.9 (2F, m), -145.3 (1F, 
tt, J = 21.0, 5.5 Hz), -158.8 – -159.0 (2F, m). HRMS: (ESI+) Calculated for C13H12F5NNaO4S: 396.0299. 
Found [M+Na]+: 396.0308. 
Cyclohex-2-en-1-ylmethanol (179) 
 
This compound was prepared according to a literature procedure.235 To a suspension of KOt-Bu (9.43 g, 
84.0 mmol) in cyclohexene (50 mL, argon sparged) was added n-BuLi (1.55 M in hexane, 58.0 mL, 
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89.9 mmol). The reaction mixture was stirred at room temperature for 15 hours then heated to 60 °C 
before addition of paraformaldehyde (2.88 g, 96.0 mmol). The reaction mixture was stirred at 60 °C for 
2 hours before being cooled to room temperature, addition of saturated aqueous NH4Cl (200 mL) and 
extraction with CH2Cl2 (3 × 100 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 3:2 hexane:Et2O) afforded 179 (4.58 g, 49 %) as a pale-yellow oil. 
δH (400 MHz, CDCl3) 5.85 – 5.78 (1H, m), 5.62 – 5.55 (1H, m), 3.53 (2H, d, J = 6.0 Hz), 2.37 – 2.24 
(1H, m), 2.04 – 1.93 (2H, m), 1.83 – 1.68 (2H, m), 1.61 – 1.47 (2H, m), 1.45 – 1.33 (1H, m). 
δC (101 MHz, CDCl3) 129.8, 127.8, 67.2, 38.4, 25.6, 25.4, 21.1. The spectroscopic properties were 
consistent with the data available in the literature.235 
N-(Cyclohex-2-en-1-ylmethyl)-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (180) 
 
General procedure K: Alcohol 179 (28.0 mg, 0.250 mmol) was employed with TsNHOFBz (vide 
supra). The reaction time was 21 hours. FCC (eluent: 3:7 hexane:PhMe) afforded 180 (88.5 mg, 74 %) 
as a colourless crystalline solid. m.p. 123-125 °C (CH2Cl2:petrol, hexagonal). νmax / cm-1: (solid) 
2934 (m), 1780 (s), 1653 (m), 1597 (m), 1496 (s), 1169 (s). δH (400 MHz, CDCl3) 7.80 (2H, d, J = 
8.0 Hz, 2 × ArCH), 7.39 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.77 (1H, dtd, J = 10.0, 3.5, 3.0 Hz, C4-H), 
5.58 (1H, br s, C3-H), 3.08 (2H, br s, C1-H2), 2.47 (3H, s, Ts CH3), 2.29 (1H, br s, C2-H), 1.98 (2H, 
br s, C5-H2), 1.92 – 1.81 (1H, m, C7-H), 1.78 – 1.66 (1H, m, C6-H), 1.57 – 1.49 (2H, m, C6-H’ and 
C7-H’). δC (101 MHz, CDCl3) 146.0 (ArC), 130.3 (ArC), 2 × 130.0 (C4 and ArCH), 129.7 (ArCH), 
127.2 (C3), 57.6 (C1), 33.2 (C2), 26.5 (C7), 25.2 (C5), 21.9 (Ts CH3), 20.7 (C6). δF (377 MHz, CDCl3) 
-135.7 – -135.9 (2F, m), -146.1 (1F, tt, J = 21.0, 5.0 Hz), -159.1 – -159.3 (2F, m). HRMS: (ESI+) 
Calculated for C21H18F5NNaO4S: 498.0769. Found [M+Na]+: 498.0773. 
(E)-7-Phenylhept-5-en-1-ol (184) and (E)-6-Phenylhex-4-en-1-ol (121) 
 
The synthesis of this compound produced material containing a significant impurity of chain-shortened 
alcohol 121. It was not possible to separate 184 and 121; consequently, subsequent compounds in this 
sequence were all produced with the analogous impurity. To a solution of Grubbs-Hoveyda 2nd 
generation catalyst (62.5 mg, 99.8 μmol) in anhydrous CH2Cl2 (80 mL, argon sparged) was added 
hex-5-en-1-ol (1.20 mL, 9.98 mmol) and allyl benzene (8.00 mL, 60.4 mmol). The reaction mixture 
was stirred at room temperature for 4 days before being concentrated in vacuo. FCC (eluent: 
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7:1 PhMe:EtOAc) afforded 184 (430 mg, 23 %, 5:1 mixture of 184 and 121) as a light-brown oil (the 
colouration was due to the presence of trace amounts of Ru-impurities). Spectroscopic data for 184: 
νmax / cm-1: (film) 3335 (br s), 3026 (m), 2927 (s), 1603 (m), 1453 (s), 1055 (s). δH (400 MHz, CDCl3) 
7.34 – 7.26 (2H, m, 2 × ArCH), 7.22 – 7.15 (3H, m, 3 × ArCH), 5.66 – 5.45 (2H, m, C5-H and C6-H), 
3.64 (2H, t, J = 6.5 Hz, C1-H2), 3.33 (2H, d, J = 6.5 Hz, C7-H2), 2.06 (2H, tdd, J = 7.5, 6.0, 1.0 Hz, 
C4-H2), 1.63 – 1.53 (2H, m, C2-H2), 1.50 – 1.41 (2H, m, C3-H2), 1.40 (1H, br s, OH). δC (101 MHz, 
CDCl3) 141.0 (ArC), 131.5 (C5), 129.2 (C6), 128.5 (ArCH), 128.3 (ArCH), 125.9 (ArCH), 62.8 (C1), 
39.0 (C7), 2 × 32.2 (C2 and C4), 25.6 (C3). HRMS: (EI+) Calculated for C13H18O: 190.1358. Found 
[M]+: 190.1353. Characteristic signals for 121: δH (400 MHz, CDCl3) 2.14 (2H, dt, J = 7.0, 6.5 Hz).  
δC (101 MHz, CDCl3) 62.4, 28.8. 
(E)-N-(7-Phenylhept-5-en-1-yl)-N-((tert-butyldimethylsilyl)oxy)-4-toluenesulfonamide 
 
General procedure E: TsNHOTBS (vide supra, 645 mg, 2.14 mmol) was employed with alcohol 184 
(1.1 eq.). The reaction time was 16 hours. FCC (eluent: 3:5 hexane:PhMe) afforded the title compound 
(946 mg, 93 %, undetermined mixture of the title compound and chain-shortened impurity) as a 
colourless oil. Spectroscopic data for the title compound: νmax / cm-1: (film) 2929 (s), 2858 (s), 1598 (m), 
1356 (s), 1169 (s). δH (400 MHz, CDCl3) 7.73 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.37 – 7.25 (4H, m, 4 × 
ArCH), 7.21 – 7.13 (3H, m, 3 × ArCH), 5.62 – 5.50 (1H, m, C6-H), 5.49 – 5.38 (1H, m, C5-H), 3.31 
(2H, d, J = 6.5 Hz, C7-H2), 2.88 (2H, t, J = 7.5 Hz, C1-H2), 2.44 (3H, s, Ts CH3), 2.01 (2H, dt, J = 7.0, 
7.0 Hz, C4-H2), 1.61 – 1.51 (2H, m, C2-H2), 1.37 (2H, tt, J = 7.5, 7.0 Hz, C3-H2), 0.92 (9H, s, 
SiC(CH3)3), 0.29 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 144.4 (ArC), 140.8 (ArC), 131.1 (C5), 130.0 
(ArC), 129.9 (ArCH), 129.4 (C6), 129.2 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 125.9 (ArCH), 55.9 
(C1), 39.0 (C7), 32.0 (C4), 26.8 (C3), 26.6 (C2), 26.0 (SiC(CH3)3), 21.6 (Ts CH3), 18.3 
(SiC(CH3)3), -4.2 (Si(CH3)2). HRMS: (ESI+) Calculated for C26H39NNaO3SSi: 496.2312. Found 
[M+Na]+: 496.2303. Characteristic signals for the chain-shortened impurity: δC (101 MHz, CDCl3) 
130.3, 29.8, 26.7. 
(E)-N-(7-Phenylhept-5-en-1-yl)-N-hydroxy-4-toluenesulfonamide 
 
General procedure B: The preceding compound (897 mg, 1.89 mmol) was employed. The title 
compound (608 mg, 89 %, 8:1 mixture of the title compound and chain-shortened impurity) was 
Chapter 7 - Experimental 
214 
 
isolated as a colourless oil. Spectroscopic data for the title compound: νmax / cm-1: (film) 3382 (s), 
3027 (m), 2924 (s), 1598 (m), 1340 (s), 1165 (s). δH (400 MHz, CDCl3) 7.78 (2H, d, J = 8.0 Hz, 2 × 
ArCH), 7.35 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.29 – 7.24 (2H, m, 2 × ArCH), 7.20 – 7.14 (3H, m, 3 × 
ArCH), 6.80 (1H, br s, OH), 5.62 – 5.52 (1H, m, C6-H), 5.52 – 5.42 (1H, m, C5-H), 3.31 (2H, d, J = 
6.5 Hz, C7-H2), 2.90 (2H, t, J = 7.0 Hz, C1-H2), 2.45 (3H, s, Ts CH3), 2.04 (2H, dt, J = 7.0, 6.5 Hz, 
C4-H2), 1.63 (2H, tt, J = 7.0, 7.0 Hz, C2-H2), 1.45 (2H, tt, J = 7.0, 6.5 Hz, C3-H2). δC (101 MHz, CDCl3) 
144.8 (ArC), 140.9 (ArC), 131.3 (C5), 129.7 (ArCH), 129.5 (ArCH), 129.4 (ArC), 129.3 (C6), 128.5 
(ArCH), 128.3 (ArCH), 125.9 (ArCH), 52.4 (C1), 39.0 (C7), 32.0 (C4), 26.4 (C3), 26.1 (C2), 21.7 
(Ts CH3). HRMS: (ESI+) Calculated for C20H26NO3S: 360.1628. Found [M+H]+: 360.1636. 
Characteristic signals for the chain-shortened impurity: δH (400 MHz, CDCl3) 2.11 (2H, dt, J = 6.5, 
6.5 Hz). δC (101 MHz, CDCl3) 52.0, 29.4.  
(E)-N-(7-Phenylhept-5-en-1-yl)-N-(pentafluorobenzoyloxy)-4-toluenesulfonamide (185) and 126 
 
General procedure C: The preceding compound (562 mg, 1.56 mmol) was employed. FCC (eluent: 
19:1 hexane:EtOAc) afforded 185 (627 mg, 73 %, 4:1 mixture of 185 and 126) as a colourless crystalline 
solid. Spectroscopic data for 185: νmax / cm-1: (solid) 2919 (m), 1775 (s), 1651 (m), 1594 (m), 1493 (s), 
1169 (s). δH (400 MHz, CDCl3) 7.78 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.37 (2H, d, J = 8.0 Hz, 2 × ArCH), 
7.28 – 7.23 (2H, m, 2 × ArCH), 7.18 – 7.12 (3H, m, 3 × ArCH), 5.55 (1H, dt, J = 15.0, 6.5 Hz, C6-H), 
5.44 (1H, dt, J = 15.0, 7.0 Hz, C5-H), 3.30 (2H, d, J = 6.5 Hz, C7-H2), 3.20 (2H, br s, C1-H2), 2.46 (3H, 
s, Ts CH3), 2.03 (2H, dt, J = 7.0, 6.5 Hz, C4-H2), 1.66 – 1.46 (4H, m, C2-H2 and C3-H2). δC (101 MHz, 
CDCl3) 145.8 (ArC), 140.8 (ArC), 130.9 (C5), 130.0 (ArC), 129.9 (ArCH), 2 × 129.6 (C6 and ArCH), 
128.4 (ArCH), 128.3 (ArCH), 125.8 (ArCH), 52.5 (C1), 38.9 (C7), 31.8 (C4), 2 × 26.1 (C2 and C3), 
21.7 (Ts CH3). δF (377 MHz, CDCl3) -135.9 – -136.1 (2F, m), -146.1 (1F, tt, J = 21.0, 5.5 Hz), -158.9 
– -159.1 (2F, m). HRMS: (ESI+) Calculated for C27H24F5NNaO4S: 576.1238. Found [M+Na]+: 
576.1234. Characteristic signals for 126: δH (400 MHz, CDCl3) 2.17 (2H, dt, J = 7.0, 7.0 Hz).  
δC (101 MHz, CDCl3) 29.3, 26.5. 
Chapter 7 - Experimental 
215 
 
(E)-2-Styryl-1-tosylpiperidine (186) and 128 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 20 hours. Substrate 185 (77.5 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 9:1 – 4:1 hexane:EtOAc) afforded 186 (4.7 mg, 10 %) as a pale-yellow oil and 
128 (5.0 mg, 11 %) as a pale-yellow oil. Spectroscopic data for 186: δH (500 MHz, CDCl3) 7.70 (2H, 
d, J = 8.5 Hz), 7.30 – 7.28 (2H, m), 7.26 – 7.16 (5H, m), 6.42 (1H, dd, J = 16.0, 1.5 Hz), 6.00 (1H, dd, 
J = 16.0, 6.5 Hz), 4.80 – 4.73 (1H, m), 3.80 – 3.75 (1H, m), 3.09 – 2.99 (1H, m), 2.37 (3H, s), 1.84 – 
1.76 (2H, m), 1.69 – 1.49 (4H, m). δC (126 MHz, CDCl3) 142.9, 137.5, 136.6, 132.2, 129.4, 128.5, 
127.6, 127.5, 126.4, 126.3, 55.1, 42.0, 30.7, 25.2, 21.4, 19.3. The spectroscopic properties were 




This compound was prepared according to a literature procedure.237 To a solution of TBSCl (16.6 g, 
110 mmol), Et3N (16.7 mL, 120 mmol) and DMAP (611 mg, 5.00 mmol) in anhydrous CH2Cl2 
(120 mL) at 0 °C was added hex-5-yn-1-ol (11.0 mL, 100 mmol). The reaction mixture was stirred at 
room temperature for 23 hours before being poured into saturated aqueous NH4Cl (150 mL). The 
resulting phases were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 100 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. Distillation (b.p.: 58 °C, 
2 mbar) afforded 187 (19.8 g, 93 %) as a colourless oil. νmax / cm-1: (film) 3314 (m), 2930 (s), 2858 (s), 
2120 (m), 1472 (m), 1254 (s), 1104 (s). δH (400 MHz, CDCl3) 3.62 (2H, t, J = 6.0 Hz), 2.20 (2H, td, J = 
7.0, 2.5 Hz), 1.92 (1H, t, J = 2.5 Hz), 1.67 – 1.52 (4H, m), 0.88 (9H, s), 0.03 (6H, s). δC (101 MHz, 
CDCl3) 84.7, 68.4, 62.7, 32.0, 26.1, 25.1, 18.5, 18.4, -5.2. HRMS: (ESI+) Calculated for C12H24NaOSi: 
235.1489. Found [M+Na]+: 235.1479. The spectroscopic properties were consistent with the data 
available in the literature.238 





This compound was prepared according to a literature procedure.239 To a solution of alkyne 187 (4.00 g, 
18.8 mmol) in anhydrous THF (40 mL) at -78 °C was added n-BuLi (1.60 M in hexane, 12.4 mL, 
19.8 mmol). The reaction mixture was stirred at -78 °C for 2 hours before addition of MeI (1.53 mL, 
24.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for a further 20 hours before 
addition of saturated aqueous NH4Cl (50 mL) and extraction with Et2O (3 × 50 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Distillation (b.p.: 78-79 °C, 2 mbar) 
afforded 188 (4.06 g, 95 %) as a colourless oil. δH (400 MHz, CDCl3) 3.62 (2H, t, J = 6.5 Hz), 2.18 – 
2.11 (2H, m), 1.77 (3H, t, J = 2.5 Hz), 1.64 – 1.57 (2H, m), 1.57 – 1.47 (2H, m), 0.89 (9H, s), 0.05 (6H, 
s). δC (101 MHz, CDCl3) 79.1, 75.5, 62.7, 32.0, 26.0, 25.4, 18.5, 18.3, 3.4, -5.3. The spectroscopic 
properties were consistent with the data available in the literature.239 
(Z)-tert-Butyl(hept-5-en-1-yloxy)dimethylsilane 
 
A solution of alkyne 188 (2.00 g, 8.83 mmol), Lindlar catalyst (94.1 mg, 44.2 μmol) and a few drops 
of quinoline in anhydrous hexane (30 mL) was stirred under an atmosphere of H2 (balloon pressure) for 
1 hour. The reaction mixture was filtered through celite, and the filter cake was rinsed with CH2Cl2 
(25 mL). The filtrate was washed with 1.0 M aqueous HCl (30 mL) and concentrated in vacuo to afford 
the title compound (1.71 g, 85 %) as a colourless oil. νmax / cm-1: (film) 3014 (m), 2929 (s), 2858 (s), 
1472 (m), 1254 (s), 1099 (s). δH (400 MHz, CDCl3) 5.49 – 5.33 (2H, m, C5-H and C6-H), 3.61 (2H, t, 
J = 6.5 Hz, C1-H2), 2.05 (2H, dt, J = 7.5, 7.5 Hz, C4-H2), 1.60 (3H, dd, J = 6.0, 1.0 Hz, C7-H3), 1.57 – 
1.49 (2H, m, C2-H2), 1.44 – 1.35 (2H, m, C3-H2), 0.90 (9H, s, SiC(CH3)3), 0.05 (6H, s, Si(CH3)2).  
δC (101 MHz, CDCl3) 130.6 (C5), 123.8 (C6), 63.1 (C1), 32.5 (C2), 26.6 (C4), 26.0 (SiC(CH3)3), 25.8 
(C3), 18.4 (SiC(CH3)3), 12.7 (C7), -5.3 (Si(CH3)2). HRMS: (ESI+) Calculated for C13H28NaOSi: 
251.1802. Found [M+Na]+: 251.1799. 





General procedure M: The preceding silyl ether (1.63 g, 7.14 mmol) was employed with 1.5 eq. 
TBAF. The reaction time was 3 hours. FCC (eluent: 2:1 hexane:Et2O) afforded (Z)-189 (695 mg, 85 %) 
as a colourless oil. νmax / cm-1: (film) 3326 (br s), 3013 (m), 2933 (s), 1441 (m), 1056 (s). δH (400 MHz, 
CDCl3) 5.48 – 5.39 (1H, m), 5.40 – 5.31 (1H, m), 3.62 (2H, t, J = 6.5 Hz), 2.09 – 2.00 (2H, m), 1.63 – 
1.53 (5H, m), 1.51 (1H, s), 1.45 – 1.36 (2H, m). δC (101 MHz, CDCl3) 130.3, 124.1, 62.9, 32.3, 26.5, 
25.6, 12.7. The spectroscopic properties were consistent with the data available in the literature.240 
(Z)-N-(Hept-5-en-1-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 676 mg, 3.00 mmol) was employed with alcohol 
(Z)-189 (1.1 eq.). The reaction time was 15 hours. FCC (eluent: PhMe) afforded the title compound 
(915 mg, 95 %) as a colourless oil. νmax / cm-1: (film) 3014 (m), 2955 (s), 2877 (s), 1459 (m), 1350 (s), 
1164 (s). δH (400 MHz, CDCl3) 5.47 (1H, dqt, J = 10.5, 6.5, 1.5 Hz, C6-H), 5.36 (1H, dtq, J = 10.5, 7.0, 
1.5 Hz, C5-H), 3.21 – 3.14 (2H, m, C1-H2), 2.84 (3H, s, Ms CH3), 2.07 (2H, br td, J = 7.5, 7.0 Hz, 
C4-H2), 1.71 – 1.63 (2H, m, C2-H2), 1.60 (3H, ddt, J = 6.5, 1.5, 1.0 Hz, C7-H3), 1.41 (2H, tt, J = 7.5, 
7.5 Hz, C3-H2), 0.99 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.77 (6H, q, J = 8.0 Hz, Si(CH2CH3)3).  
δC (101 MHz, CDCl3) 129.8 (C5), 124.5 (C6), 55.5 (C1), 30.3 (Ms CH3), 2 × 26.7 (C2 and C3), 26.3 
(C4), 12.7 (C7), 6.7 (Si(CH2CH3)3), 4.8 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for C14H32NO3SSi: 
322.1867. Found [M+H]+: 322.1871. 
(Z)-N-(Hept-5-en-1-yl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (874 mg, 2.72 mmol) was employed. FCC (eluent: 
3:1 hexane:EtOAc) afforded the title compound (561 mg, 99 %) as a colourless oil. νmax / cm-1: (film) 
3379 (br s), 3014 (m), 2934 (m), 1440 (m), 1334 (s), 1160 (s). δH (400 MHz, CDCl3) 6.97 (1H, s, OH), 
5.46 (1H, dq, J = 10.5, 6.5 Hz, C6-H), 5.36 (1H, dt, J = 10.5, 7.0 Hz, C5-H), 3.18 (2H, t, J = 7.0 Hz, 
C1-H2), 2.91 (3H, s, Ms CH3), 2.07 (2H, td, J = 7.5, 7.0 Hz, C4-H2), 1.70 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 
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1.60 (3H, d, J = 6.5 Hz, C7-H3), 1.45 (2H, tt, J = 7.5, 7.5 Hz, C3-H2). δC (101 MHz, CDCl3) 130.1 (C5), 
124.5 (C6), 52.4 (C1), 31.0 (Ms CH3), 2 × 26.5 (C2 and C3), 26.4 (C4), 12.9 (C7). HRMS: (ESI+) 
Calculated for C8H17NNaO3S: 230.0821. Found [M+Na]+: 230.0811. 
(Z)-N-(Hept-5-en-1-yl)-N-(pentafluorobenzoyloxy)methanesulfonamide (190) 
 
General procedure C: The preceding compound (529 mg, 2.55 mmol) was employed. FCC (eluent: 
5:1 hexane:EtOAc) afforded 190 (915 mg, 89 %) as a colourless crystalline solid. m.p. 43-44 °C 
(Et2O:hexane, needles). δH (400 MHz, CDCl3) 5.53 – 5.40 (1H, m, C6-H), 5.35 (1H, dtq, J = 10.5, 7.0, 
1.5 Hz, C5-H), 3.53 – 3.41 (2H, m, C1-H2), 3.03 (3H, s, Ms CH3), 2.08 (2H, td, J = 7.5, 7.0 Hz, C4-H2), 
1.69 (2H, tt, J = 8.0, 7.0 Hz, C2-H2), 1.61 – 1.49 (5H, m, C3-H2 and C7-H3). δC (101 MHz, CDCl3) 
156.3 (C=O), 129.5 (C5), 124.7 (C6), 52.3 (C1), 34.3 (Ms CH3), 26.2 (C2), 2 × 26.1 (C3 and C4), 12.7 
(C7). The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.0 (2F, m), -145.3 (1F, tt, J = 21.0, 




General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 14 hours. Substrate 190 (56.2 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 4:1 – 3:1 – 2:1 hexane:EtOAc) afforded 191 (3.7 mg, 14 %) as a pale-yellow 
oil. νmax / cm-1: (film) 2933 (s), 2857 (m), 1446 (m), 1324 (s), 1146 (s). δH (500 MHz, CDCl3) 6.06 (1H, 
ddd, J = 17.0, 10.5, 7.0 Hz, C6-H), 5.36 – 5.29 (2H, m, C7-H2), 4.59 – 4.52 (1H, m, C5-H), 3.72 – 3.66 
(1H, m, C1-H), 3.04 (1H, ddd, J = 12.5, 12.5, 3.0 Hz, C1-H’), 1.91 – 1.51 (6H, m, C2-H2, C3-H2 and 
C4-H2). δC (126 MHz, CDCl3) 134.7 (C6), 118.1 (C7), 55.4 (C5), 41.4 (C1), 39.0 (Ms CH3), 30.4 (C4), 
25.5 (C2), 19.0 (C3). HRMS: (ESI+) Calculated for C8H15NNaO2S: 212.0716. Found [M+Na]+: 
212.0725. 





To a solution of ethylene glycol (7.76 g, 125 mmol) and KOH (2.81 g, 50.0 mmol) in water (20 mL) at 
0 °C was added crotyl bromide (vide supra, 2.57 mL, 25.0 mmol). The resulting suspension was stirred 
at room temperature for 18 hours before addition of 1.0 M aqueous HCl (50 mL) and extraction with 
Et2O (3 × 50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. 
FCC (eluent: 2:3 hexane:Et2O) afforded 192 (1.44 g, 50 %) as a colourless oil. νmax / cm-1: (film) (br s), 
2858 (m), 1450 (m), 1053 (s). δH (400 MHz, CDCl3) 5.77 – 5.66 (1H, m, C5-H), 5.62 – 5.51 (1H, m, 
C4-H), 3.94 (2H, d, J = 6.5 Hz, C3-H2), 3.73 – 3.68 (2H, m, C1-H2), 3.54 – 3.48 (2H, m, C2-H2), 2.26 
(1H, br s, OH), 1.70 (3H, d, J = 6.5 Hz, C6-H3). δC (101 MHz, CDCl3) 129.9 (C5), 127.3 (C4), 71.8 




General procedure E: MsNHOTES (vide supra, 1.13 g, 5.00 mmol) was employed with alcohol 192 
(1.1 eq.). The reaction time was 19 hours. FCC (eluent: 19:1 PhMe:Et2O) afforded the title compound 
(1.12 g, 69 %) as a colourless oil. νmax / cm-1: (film) 2955 (m), 2877 (m), 1458 (m), 1350 (s), 1165 (s). 
δH (400 MHz, CDCl3) 5.79 – 5.65 (1H, m, C5-H), 5.55 (1H, dtq, J = 15.0, 6.5, 1.5 Hz, C4-H), 3.92 (2H, 
dq, J = 6.5, 1.0 Hz, C3-H2), 3.64 (2H, t, J = 6.0 Hz, C2-H2), 3.43 (2H, t, J = 6.0 Hz, C1-H2), 2.90 (3H, s, 
Ms CH3), 1.71 (3H, br d, J = 6.5 Hz, C6-H3), 0.98 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.78 (6H, q, 
J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 130.0 (C5), 127.1 (C4), 71.6 (C3), 65.8 (C2), 54.8 
(C1), 30.8 (Ms CH3), 17.7 (C6), 6.7 (Si(CH2CH3)3), 4.6 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for 
C13H29NNaO4SSi: 346.1479. Found [M+Na]+: 346.1492. 
(E)-N-(2-(But-2-en-1-yloxy)ethyl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (1.09 g, 3.37 mmol) was employed. FCC (eluent: 
2:1 hexane:EtOAc) afforded the title compound (702 mg, 100 %) as a colourless oil. νmax / cm-1: (film) 
3368 (br s), 2918 (m), 1449 (m), 1335 (s), 1162 (s). δH (400 MHz, CDCl3) 7.81 (1H, br s, OH), 5.79 – 
5.65 (1H, m, C5-H), 5.61 – 5.48 (1H, m, C4-H), 3.96 (2H, dq, J = 6.5, 1.0 Hz, C3-H2), 3.70 (2H, t, J = 
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5.5 Hz, C2-H2), 3.40 (2H, t, J = 5.5 Hz, C1-H2), 2.95 (3H, s, Ms CH3), 1.70 (3H, br d, J = 6.5 Hz, 
C6-H3). δC (101 MHz, CDCl3) 130.5 (C5), 126.8 (C4), 71.6 (C3), 65.9 (C2), 51.5 (C1), 31.9 (Ms CH3), 
17.7 (C6). HRMS: (ESI+) Calculated for C7H15NNaO4S: 232.0614. Found [M+Na]+: 232.0619. 
(E)-N-(2-(But-2-en-1-yloxy)ethyl)-N-(pentafluorobenzoyloxy)methanesulfonamide (194) 
 
General procedure C: The preceding compound (650 mg, 3.11 mmol) was employed. FCC (eluent: 
3:1 hexane:EtOAc) afforded 194 (1.07 g, 85 %) as a colourless crystalline solid. m.p. 67-68 °C 
(Et2O:hexane). νmax / cm-1: (solid) 3021 (m), 2939 (m), 1789 (s), 1652 (m), 1503 (s), 1365 (s), 1165 (s). 
δH (400 MHz, CDCl3) 5.65 (1H, dqt, J = 15.5, 6.5, 1.0 Hz, C5-H), 5.49 – 5.40 (1H, m, C4-H), 3.86 (2H, 
ddq, J = 6.5, 1.0, 1.0 Hz, C3-H2), 3.76 – 3.71 (2H, m, C2-H2), 3.70 – 3.65 (2H, m, C1-H2), 3.06 (3H, s, 
Ms CH3), 1.64 (3H, ddt, J = 6.5, 1.5, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 130.3 (C5), 126.8 (C4), 
72.1 (C3), 67.2 (C2), 52.1 (C1), 34.6 (Ms CH3), 17.7 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.2 – -135.3 (2F, m), -145.4 (1F, tt, J = 21.0, 6.0 Hz), -159.1 – -159.3 (2F, m). HRMS: (ESI+) 
Calculated for C14H14F5NNaO5S: 426.0405. Found [M+Na]+: 426.0412. 
4-Mesyl-3-vinylmorpholine (196) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 15 hours. Substrate 194 (56.5 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 7:2 – 3:1 – 5:2 – 1:1 hexane:EtOAc) afforded 196 (1.2 mg, 4 %) as an orange 
oil. νmax / cm-1: (film) 2925 (m), 1455 (m), 1325 (s), 1151 (s). δH (500 MHz, CDCl3) 6.26 (1H, ddd, J = 
17.5, 10.5, 8.5 Hz, C5-H), 5.45 (1H, ddd, J = 17.5, 1.0, 1.0 Hz, C6-H’), 5.41 (1H, ddd, J = 10.5, 1.0, 
1.0 Hz, C6-H), 4.25 – 4.21 (1H, m, C4-H), 3.97 (1H, ddd, J = 11.5, 3.5, 2.0 Hz, C2-H), 3.88 (1H, dd, 
J = 11.5, 2.0 Hz, C3-H), 3.81 (1H, dd, J = 11.5, 3.0 Hz, C3-H’), 3.68 (1H, ddd, J = 11.5, 11.5, 3.0 Hz, 
C2-H’), 3.48 (1H, ddd, J = 12.5, 3.0, 2.0 Hz, C1-H), 3.30 (1H, ddd, J = 12.5, 11.5, 3.5 Hz, C1-H’), 2.84 
(3H, s, Ms CH3). δC (126 MHz, CDCl3) 132.5 (C5), 120.0 (C6), 71.2 (C3), 66.8 (C2), 56.4 (C4), 41.4 
(C1), 38.2 (Ms CH3). HRMS: (ESI+) Calculated for C7H13NNaO3S: 214.0508. Found [M+Na]+: 
214.0511. 





This compound was prepared according to a literature procedure.241 To a solution of ethanolamine 
(6.02 mL, 100 mmol) and TsCl (21.0 g, 110 mmol) in anhydrous CH2Cl2 (250 mL) at 0 °C was added 
Et3N (15.3 mL, 110 mmol) dropwise. The reaction mixture was stirred at room temperature for 19 hours 
before dilution with CH2Cl2 (100 mL) and addition of water (150 mL). The resulting phases were 
separated, and the aqueous phase was extracted with CH2Cl2 (2 × 100 mL). The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 2:1 – 1:1 – 
1:2 hexane:EtOAc) afforded the title compound (15.2 g, 71 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3559 (br s), 3262 (br s), 2935 (m), 2882 (m), 1597 (m), 1310 (s), 1151 (s), 1066 (s). 
δH (400 MHz, CDCl3) 7.74 (2H, d, J = 8.0 Hz), 7.30 (2H, d, J = 8.0 Hz), 5.42 (1H, t, J = 6.0 Hz),  
3.67 (2H, dt, J = 5.5, 5.0 Hz), 3.06 (2H, dt, J = 6.0, 5.0 Hz), 2.61 (1H, t, J = 5.5 Hz), 2.41 (3H, s).  
δC (101 MHz, CDCl3) 143.6, 136.5, 129.8, 127.1, 61.3, 45.2, 21.5. HRMS: (ESI+) Calculated for 
C9H13NNaO3S: 238.0508. Found [M+Na]+: 238.0499. The spectroscopic properties were consistent 
with the data available in the literature.242 
(E)-N-(But-2-en-1-yl)-N-(2-hydroxyethyl)-4-toluenesulfonamide (193) 
 
A solution of the preceding compound (2.15 g, 10.0 mmol), K2CO3 (2.07 g, 15.0 mmol) and crotyl 
bromide (vide supra, 1.54 mL, 15.0 mmol) in acetone (20 mL) was stirred at room temperature for 
30 hours before being concentrated in vacuo. FCC (gradient elution: 2:1 – 3:2 – 1:1 hexane:EtOAc) 
afforded 193 (2.19 g, 81 %) as a colourless oil. νmax / cm-1: (film) 3520 (br s), 2920 (m), 1598 (m), 
1330 (s), 1153 (s). δH (400 MHz, CDCl3) 7.70 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.30 (2H, d, J = 8.0 Hz, 
2 × ArCH), 5.60 (1H, dqt, J = 15.0, 6.5, 1.0 Hz, C5-H), 5.29 (1H, dtq, J = 15.0, 6.5, 1.5 Hz, C4-H), 
3.77 (2H, br d, J = 6.5 Hz, C3-H2), 3.71 (2H, t, J = 5.5 Hz, C1-H2), 3.21 (2H, t, J = 5.5 Hz, C2-H2), 2.42 
(3H, s, Ts CH3), 2.17 (1H, br s, OH), 1.64 (3H, br d, J = 6.5 Hz, C6-H3). δC (101 MHz, CDCl3) 143.5 
(ArC), 136.3 (ArC), 131.0 (C5), 129.7 (ArCH), 127.3 (ArCH), 125.6 (C4), 61.1 (C1), 51.5 (C3), 49.5 
(C2), 21.5 (Ts CH3), 17.6 (C6). HRMS: (ESI+) Calculated for C13H19NNaO3S: 292.0978. Found 
[M+Na]+: 292.0990. 






General procedure E: MsNHOTES (vide supra, 1.13 g, 5.00 mmol) was employed with alcohol 193 
(1.1 eq.). The reaction time was 18 hours. FCC (gradient elution: 1:0 – 19:1 – 9:1 PhMe:Et2O) afforded 
the title compound (2.15 g, 90 %) as a colourless oil. νmax / cm-1: (film) 2957 (m), 2878 (m), 1599 (m), 
1350 (s), 1159 (s). δH (400 MHz, CDCl3) 7.67 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.30 (2H, d, J = 8.0 Hz, 
2 × ArCH), 5.62 (1H, dq, J = 15.0, 7.0 Hz, C5-H), 5.28 (1H, dt, J = 15.0, 7.0 Hz, C4-H), 3.71 (2H, d, 
J = 7.0 Hz, C3-H2), 3.44 – 3.37 (2H, m, C1-H2), 3.35 – 3.27 (2H, m, C2-H2), 2.86 (3H, s, Ms CH3), 
2.42 (3H, s, Ts CH3), 1.65 (3H, d, J = 7.0 Hz, C6-H3), 0.99 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.75 (6H, 
q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 143.5 (ArC), 136.1 (ArC), 131.6 (C5), 129.7 
(ArCH), 127.2 (ArCH), 125.2 (C4), 55.1 (C1), 51.6 (C3), 45.0 (C2), 30.4 (Ms CH3), 21.5 (Ts CH3), 
17.7 (C6), 6.7 (Si(CH2CH3)3), 4.5 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for C20H37N2O5S2Si: 
477.1908. Found [M+H]+: 477.1901. 
(E)-N-(But-2-en-1-yl)-N-(2-(N-hydroxymethylsulfonamido)ethyl)-4-toluenesulfonamide 
 
General procedure F: The preceding compound (2.05 g, 4.30 mmol) was employed. FCC (eluent: 
2:1 hexane:EtOAc) afforded the title compound (1.51 g, 97 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3389 (br s), 3027 (m), 2939 (m), 1599 (m), 1341 (s), 1155 (s). δH (400 MHz, CDCl3) 
7.72 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.02 (1H, br s, OH), 5.62 (1H, 
dq, J = 15.0, 6.5 Hz, C5-H), 5.27 (1H, dt, J = 15.0, 7.0 Hz, C4-H), 3.76 (2H, d, J = 7.0 Hz, C3-H2), 3.45 
(2H, t, J = 5.5 Hz, C2-H2), 3.34 (2H, t, J = 5.5 Hz, C1-H2), 3.00 (3H, s, Ms CH3), 2.43 (3H, s, Ts CH3), 
1.64 (3H, d, J = 6.5 Hz, C6-H3). δC (101 MHz, CDCl3) 143.6 (ArC), 136.7 (ArC), 131.4 (C5), 129.8 
(ArCH), 127.2 (ArCH), 125.1 (C4), 50.1 (C3), 49.1 (C1), 43.2 (C2), 33.1 (Ms CH3), 21.5 (Ts CH3), 
17.6 (C6). HRMS: (ESI+) Calculated for C14H22N2NaO5S2: 385.0862. Found [M+Na]+: 385.0860. 






General procedure C: The preceding compound (1.47 g, 4.06 mmol) was employed. FCC (gradient 
elution: 3:1 – 2:1 hexane:EtOAc) afforded 195 (1.57 g, 69 %) as a colourless crystalline solid.  
m.p. 109-110 °C (CH2Cl2:hexane, needles). νmax / cm-1: (solid) 3018 (m), 2946 (m), 1785 (s), 1655 (m), 
1599 (m), 1503 (s), 1361 (s), 1158 (s). δH (400 MHz, CDCl3) 7.66 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.30 
(2H, d, J = 8.0 Hz, 2 × ArCH), 5.62 (1H, dq, J = 15.0, 6.5 Hz, C5-H), 5.26 (1H, dtq, J = 15.0, 7.0, 
1.5 Hz, C4-H), 3.78 – 3.68 (4H, m, C1-H2 and C3-H2), 3.40 – 3.33 (2H, m, C2-H2), 3.06 (3H, s, 
Ms CH3), 2.42 (3H, s, Ts CH3), 1.62 (3H, dd, J = 6.5, 1.5 Hz, C6-H3). δC (101 MHz, CDCl3) 143.8 
(ArC), 135.8 (ArC), 132.0 (C5), 129.8 (ArCH), 127.2 (ArCH), 124.9 (C4), 52.5 (C1), 51.7 (C3), 44.5 
(C2), 34.6 (Ms CH3), 21.5 (Ts CH3), 17.6 (C6). The 
13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.5 – -135.6 (2F, m), 
-144.6 (1F, tt, J = 21.0, 6.0 Hz), -158.5 – -158.7 (2F, m). HRMS: (ESI+) Calculated for 
C21H21F5N2NaO6S2: 579.0653. Found [M+Na]+: 579.0649. 
1-Mesyl-4-tosyl-2-vinylpiperazine 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 16 hours. Substrate 195 (77.9 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 4:1 – 3:1 – 2:1 – 1:1 hexane:EtOAc) afforded 197 (8.4 mg, 17 %) as a yellow 
oil. νmax / cm-1: (film) 2927 (m), 1598 (m), 1454 (m), 1338 (s), 1163 (s). δH (500 MHz, CDCl3) 7.63 (2H, 
d, J = 8.0 Hz, 2 × ArCH), 7.37 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.21 (1H, ddd, J = 17.5, 10.5, 8.0 Hz, 
C5-H), 5.49 (1H, ddd, J = 17.5, 1.0, 1.0 Hz, C6-H’), 5.45 (1H, ddd, J = 10.5, 1.0, 1.0 Hz, C6-H), 4.50 
– 4.46 (1H, m, C4-H), 3.80 – 3.73 (2H, m, C2-H and C3-H), 3.70 – 3.65 (1H, m, C1-H), 3.36 – 3.27 
(1H, m, C1-H’), 2.82 (3H, s, Ms CH3), 2.63 (1H, dd, J = 11.5, 3.5 Hz, C3-H’), 2.49 – 2.45 (4H, m, 
C2-H’ and Ts CH3). δC (126 MHz, CDCl3) 144.3 (ArC), 132.1 (ArC), 131.9 (C5), 129.9 (ArCH), 127.7 
(ArCH), 120.8 (C6), 55.3 (C4), 50.4 (C3), 46.1 (C2), 40.6 (C1), 39.0 (Ms CH3), 21.6 (Ts CH3). 
HRMS: (ESI+) Calculated for C14H20N2NaO4S2: 367.0757. Found [M+Na]+: 367.0761. 
  





This compound was prepared according to a literature procedure.243 To a solution of 2-bromobenzyl 
alcohol (9.00 g, 48.1 mmol) and 3,4-dihydropyran (5.26 g, 62.5 mmol) in CH2Cl2 (120 mL) at 0 °C was 
added TsOH·H2O (183 mg, 0.962 mmol). The reaction mixture was stirred at room temperature for 
8 hours before addition of 5 % aqueous K2CO3 (100 mL). The resulting phases were separated, and the 
aqueous phase was extracted with CH2Cl2 (2 × 50 mL). The combined organic phases were dried over 
Na2SO4 and concentrated in vacuo. FCC (eluent: 14:1 hexane:EtOAc) afforded 200 (8.98 g, 69 %) as a 
colourless oil. νmax / cm-1: (film) 2941 (m), 1569 (m), 1440 (m), 1200 (m), 1124 (s), 1022 (s). 
δH (400 MHz, CDCl3) 7.56 – 7.49 (2H, m), 7.34 – 7.28 (1H, m), 7.17 – 7.11 (1H, m), 4.83 (1H, d, 
J = 13.5 Hz), 4.78 (1H, dd, J = 3.5, 3.5 Hz), 4.58 (1H, d, J = 13.5 Hz), 3.93 (1H, ddd, J = 11.5, 8.5, 
3.0 Hz), 3.61 – 3.53 (1H, m), 1.97 – 1.83 (1H, m), 1.83 – 1.67 (2H, m), 1.67 – 1.49 (3H, m).  
δC (101 MHz, CDCl3) 137.8, 132.5, 129.0, 128.7, 127.3, 122.7, 98.4, 68.5, 62.2, 30.5, 25.4, 19.3. The 
spectroscopic properties were consistent with the data available in the literature.243 
(E)-(2-(But-2-en-1-yl)phenyl)methanol (201) 
 
This compound was prepared according to a literature procedure.244 To a suspension of magnesium 
turnings (493 mg, 20.3 mmol), activated with a crystal of iodine, in anhydrous THF (5 mL) was added 
a solution of bromide 200 (5.00 g, 18.4 mmol) in anhydrous THF (15 mL) at such a rate as to maintain 
a gentle reflux. The reaction mixture was stirred for 45 minutes before addition of crotyl bromide (vide 
supra, 2.45 mL, 23.9 mmol). The reaction mixture was stirred at room temperature for 19 hours before 
addition of saturated aqueous NH4Cl (35 mL) and Et2O (80 mL). The resulting phases were separated, 
and the organic phase was washed with water (40 mL), dried over Na2SO4 and concentrated in vacuo. 
The crude mixture was dissolved in MeOH (10 mL) and 1.0 M aqueous HCl (10 mL) and stirred at 
room temperature for 5 hours before being concentrated to an aqueous solution. The reaction mixture 
was dissolved in Et2O (150 mL) then washed with 5 % aqueous NaHCO3 (2 × 50 mL), water (50 mL) 
and brine (50 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
19:1 PhMe:EtOAc) afforded 201 (1.74 g, 58 %) as a colourless oil. νmax / cm-1: (film) 3317 (br s), 
3022 (m), 2916 (m), 2855 (m), 1489 (m), 1452 (s), 1004 (s). δH (400 MHz, CDCl3) 7.40 – 7.36 (1H, m, 
ArCH), 7.29 – 7.18 (3H, m, 3 × ArCH), 5.65 – 5.56 (1H, m, C3-H), 5.45 (1H, dqt, J = 15.5, 6.5, 1.5 Hz, 
C4-H), 4.70 (2H, s, C1-H2), 3.40 (2H, ddq, J = 6.5, 1.5, 1.5 Hz, C2-H2), 1.67 (3H, ddt, J = 6.5, 1.5, 
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1.5 Hz, C5-H3). δC (101 MHz, CDCl3) 138.8 (ArC), 138.5 (ArC), 130.0 (C3), 129.7 (ArCH), 128.2 
(ArCH), 128.0 (ArCH), 2 × 126.5 (C4 and ArCH), 63.2 (C1), 35.6 (C2), 17.9 (C5). HRMS: (ESI+) 
Calculated for C11H14NaO: 185.0937. Found [M+Na]+: 185.0939. The 
1H NMR and IR spectra were 
consistent with the data available in the literature; however, the 13C NMR spectrum differed in the 
aromatic region.244 The data presented here is supported by HSQC analysis. 
(E)-N-(2-(But-2-en-1-yl)benzyl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (vide supra, 1.13 g, 5.00 mmol) was employed with alcohol 201 
(1.1 eq.). The reaction time was 15 hours. FCC (eluent: 1:4 hexane:PhMe) afforded the title compound 
(1.62 g, 88 %) as a colourless oil. νmax / cm-1: (film) 3025 (m), 2955 (s), 2877 (s), 1492 (m), 1456 (s), 
1349 (s), 1165 (s). δH (400 MHz, CDCl3) 7.34 – 7.16 (4H, m, 4 × ArCH), 5.54 (1H, dtq, J = 15.0, 6.5, 
1.5 Hz, C3-H), 5.46 (1H, dqt, J = 15.0, 6.0, 1.0 Hz, C4-H), 4.32 (2H, s, C1-H2), 3.49 (2H, br d, J = 
6.5 Hz, C2-H2), 2.94 (3H, s, Ms CH3), 1.66 (3H, ddt, J = 6.0, 1.5, 1.5 Hz, C5-H3), 0.79 (9H, t, J = 
8.0 Hz, Si(CH2CH3)3), 0.35 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 141.0 (ArC), 2 × 
132.1 (ArC and ArCH), 129.8 (ArCH), 129.2 (C3), 128.9 (ArCH), 126.7 (C4), 126.0 (ArCH), 56.9 
(C1), 35.4 (C2), 30.1 (Ms CH3), 17.9 (C5), 6.6 (Si(CH2CH3)3), 4.3 (Si(CH2CH3)3). HRMS: (ESI+) 
Calculated for C18H31NNaO3SSi: 392.1686. Found [M+Na]+: 392.1689. 
(E)-N-(2-(But-2-en-1-yl)benzyl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (1.55 g, 4.19 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded the title compound (959 mg, 90 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3342 (br s), 3031 (m), 2963 (m), 1491 (m), 1448 (s), 1329 (s), 1152 (s).  
δH (400 MHz, CDCl3) 7.36 – 7.17 (4H, m, 4 × ArCH), 6.05 (1H, br s, OH), 5.56 (1H, dtq, J = 15.0, 6.5, 
1.5 Hz, C3-H), 5.45 (1H, dqt, J = 15.0, 6.0, 1.5 Hz, C4-H), 4.36 (2H, s, C1-H2), 3.44 (2H, br d, J = 
6.5 Hz, C2-H2), 3.00 (3H, s, Ms CH3), 1.66 (3H, ddt, J = 6.0, 1.5, 1.5 Hz, C5-H3). δC (101 MHz, CDCl3) 
140.4 (ArC), 132.0 (ArC), 131.1 (ArCH), 130.0 (ArCH), 129.3 (C3), 128.7 (ArCH), 126.7 (C4), 126.2 
(ArCH), 53.8 (C1), 35.4 (C2), 31.6 (Ms CH3), 17.9 (C5). HRMS: (ESI+) Calculated for C12H17NNaO3S: 
278.0821. Found [M+Na]+: 278.0823. 





General procedure C: The preceding compound (949 mg, 3.72 mmol) was employed. FCC (eluent: 
29:1 hexane:EtOAc) afforded 202 (1.09 g, 65 %) as a colourless crystalline solid. m.p. 122-123 °C 
(CH2Cl2:hexane, needles). νmax / cm-1: (solid) 3028 (m), 1790 (s), 1654 (m), 1509 (s), 1348 (s), 1159 (s). 
δH (400 MHz, CDCl3) 7.32 – 7.21 (3H, m, 3 × ArCH), 7.17 – 7.12 (1H, m, ArCH), 5.59 (1H, dtq, J = 
15.5, 6.0, 1.5 Hz, C3-H), 5.50 (1H, dqt, J = 15.5, 6.0, 1.0 Hz, C4-H), 4.63 (2H, br s, C1-H2), 3.57 (2H, 
br d, J = 6.0 Hz, C2-H2), 3.12 (3H, s, Ms CH3), 1.67 (3H, ddt, J = 6.0, 1.5, 1.5 Hz, C5-H3).  
δC (101 MHz, CDCl3) 141.2 (ArC), 130.9 (ArCH), 130.2 (ArCH), 129.7 (ArC), 129.3 (ArCH), 129.0 
(C3), 126.9 (C4), 126.2 (ArCH), 53.9 (C1), 35.4 (C2), 34.8 (Ms CH3), 17.9 (C5). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -135.7 – -135.8 (2F, m), -145.6 (1F, tt, J = 21.0, 5.5 Hz), -158.9 – -159.1 (2F, m). 
HRMS: (ESI+) Calculated for C19H16F5NNaO4S: 472.0162. Found [M+Na]+: 472.0604. 
2-Mesyl-3-vinyl-1,2,3,4-tetrahydroisoquinoline (203) and N-(2-((E)-But-2-en-1-yl)benzylidene)-
methanesulfonamide (204) 
  
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
PhMe (0.1 M); 160 °C; 15 hours. Substrate 202 (62.9 mg, 0.140 mmol) was employed. FCC (gradient 
elution: 6:1 – 4:1 – 3:1 hexane:EtOAc) afforded 203 (11.5 mg, 35 %) as a pale-yellow oil.  
The standard conditions afforded a reduced yield of 203, along with a considerable amount of side 
product 204: General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 
25 mol% Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 17 hours. Substrate 202 (62.9 mg, 0.140 mmol) 
was employed. FCC (gradient elution: 5:1 – 3:1 – 2:1 – 1:1 hexane:EtOAc) afforded 204 (16.0 mg, 
48 %) as a colourless oil and 203 (5.0 mg, 15 %) as a pale-yellow oil. Spectroscopic data for 203: 
νmax / cm-1: (film) 2929 (m), 1455 (m), 1325 (s), 1151 (s). δH (400 MHz, CDCl3) 7.24 – 7.19 (2H, m, 2 × 
ArCH), 7.18 – 7.14 (1H, m, ArCH), 7.12 – 7.08 (1H, m, ArCH), 5.83 (1H, ddd, J = 17.0, 10.5, 6.5 Hz, 
C4-H), 5.32 (1H, ddd, J = 17.0, 1.5, 1.5 Hz, C5-H’), 5.21 (1H, ddd, J = 10.5, 1.5, 1.5 Hz, C5-H), 4.79 
Chapter 7 - Experimental 
227 
 
– 4.73 (1H, m, C3-H), 4.67 (1H, d, J = 16.0 Hz, C1-H), 4.30 (1H, d, J = 16.0 Hz, C1-H’), 3.27 (1H, dd, 
J = 16.0, 6.0 Hz, C2-H), 2.88 – 2.79 (4H, m, C2-H’ and Ms CH3). δC (101 MHz, CDCl3) 135.1 (C4), 
132.0 (ArC), 131.5 (ArC), 129.2 (ArCH), 127.2 (ArCH), 126.6 (ArCH), 126.0 (ArCH), 118.4 (C5), 
54.0 (C3), 43.6 (C1), 38.4 (Ms CH3), 33.5 (C2). HRMS: (ESI+) Calculated for C12H15NNaO2S: 
260.0716. Found [M+Na]+: 260.0711.  
Spectroscopic data for 204: δH (400 MHz, CDCl3) 9.35 (1H, s, C1-H), 8.11 (1H, dd, J = 8.0, 1.5 Hz, 
ArCH), 7.59 – 7.53 (1H, m, ArCH), 7.38 – 7.28 (2H, m, 2 × ArCH), 5.58 (1H, dtq, J = 15.5, 6.0, 1.5 Hz, 
C3-H), 5.43 (1H, dqt, J = 15.5, 6.5, 1.5 Hz, C4-H), 3.64 (2H, br d, J = 6.0 Hz, C2-H2), 3.12 (3H, s, 
Ms CH3), 1.66 (3H, ddt, J = 6.5, 1.5, 1.5 Hz, C5-H3). δC (101 MHz, CDCl3) 170.1 (C1), 145.1 (ArC), 
135.0 (ArCH), 130.9 (ArCH), 130.0 (ArC), 129.9 (ArCH), 129.3 (C3), 127.8 (C4), 127.0 (ArCH), 40.3 




This compound was prepared according to a literature procedure.245 To a suspension of 
ethyltriphenylphosphonium iodide (25.1 g, 60.0 mmol) in anhydrous THF (400 mL) at -78 °C was 
added n-BuLi (1.55 M in hexane, 38.7 mL, 60.0 mmol). The reaction mixture was stirred at room 
temperature for 2 hours, then cooled to -78 °C before addition of 2-bromobenzaldehyde (5.84 mL, 
50.0 mmol). The reaction mixture was stirred at -78 °C for 4 hours and then at room temperature for a 
further 20 hours. The reaction mixture was cooled to -40 °C before addition of water (75 mL) and 
extraction with Et2O (3 × 200 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 40:1 pentane:Et2O) afforded 205 (5.82 g, 59 %, 3:1 mixture of (Z)- 
and (E)-isomers) as a colourless oil. νmax / cm-1: (film) 3022 (m), 2913 (m), 1467 (s), 1431 (s). 1023 (s). 
1H and 13C NMR data for the major (Z)-isomer: δH (400 MHz, CDCl3) 7.61 – 7.56 (1H, m, ArCH), 7.33 
– 7.21 (2H, m, 2 × ArCH), 7.14 – 7.07 (1H, m, ArCH), 6.49 (1H, dq, J = 11.5, 2.0 Hz, C1-H), 5.90 (1H, 
dq, J = 11.5, 7.0 Hz, C2-H), 1.79 (3H, dd, J = 7.0, 2.0 Hz, C3-H3). δC (101 MHz, CDCl3) 137.5 (ArC), 
132.7 (ArCH), 130.8 (ArCH), 129.5 (C1), 128.3 (ArCH), 128.2 (C2), 126.9 (ArCH), 124.2 (ArC), 14.5 
(C3). 1H and 13C NMR data for the minor (E)-isomer: δH (400 MHz, CDCl3) 7.54 – 7.50 (1H, m, ArCH), 
7.49 – 7.45 (1H, m, ArCH), 7.32 – 7.21 (1H, m, ArCH), 7.08 – 7.02 (1H, m, ArCH), 6.74 (1H, dq, J = 
15.5, 2.0 Hz, C1-H), 6.19 (1H, dq, J = 15.5, 6.5 Hz, C2-H), 1.93 (3H, dd, J = 6.5, 2.0 Hz, C3-H3).  
δC (101 MHz, CDCl3) 137.8 (ArC), 132.9 (ArCH), 130.0 (C1), 129.0 (C2), 128.2 (ArCH), 127.5 
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To a solution of the bromide 205 (2.96 g, 15.0 mmol) in anhydrous THF (40 mL) at -78 °C was added 
n-BuLi (1.55 M in hexane, 10.6 mL, 16.5 mmol). The reaction mixture was stirred at -78 °C for 2 hours 
before addition of ethylene oxide (approx. 3 M in THF, 7.5 mL, 22.5 mmol). The reaction mixture was 
stirred at room temperature for 18 hours before addition of saturated aqueous NH4Cl (30 mL). The 
resulting phases were separated, and the aqueous phase was extracted with Et2O (2 × 40 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
3:1 hexane:EtOAc) afforded 206 (1.50 g, 62 %, 3:1 mixture of (Z)- and (E)-isomers) as a pale-yellow 
oil. νmax / cm-1: (film) 3322 (br s), 3017 (m), 2937 (m), 2876 (m), 1484 (s), 1446 (s), 1041 (s). 
1H and 
13C NMR data for the major (Z)-isomer: δH (400 MHz, CDCl3) 7.25 – 7.15 (4H, m, 4 × ArCH), 6.55 
(1H, dq, J = 11.5, 2.0 Hz, C3-H), 5.86 (1H, dq, J = 11.5, 7.0 Hz, C4-H), 3.78 (2H, t, J = 7.0 Hz, C1-H2), 
2.88 (2H, t, J = 7.0 Hz, C2-H2), 1.73 (3H, dd, J = 7.0, 2.0 Hz, C5-H3), 1.46 (1H, br s, OH).  
δC (101 MHz, CDCl3) 136.9 (ArC), 136.6 (ArC), 2 × 130.0 (2 × ArCH), 128.7 (C3), 127.8 (C4), 127.1 
(ArCH), 126.3 (ArCH), 63.1 (C1), 36.9 (C2), 14.4 (C5). 1H and 13C NMR data for the minor (E)-isomer: 
δH (400 MHz, CDCl3) 7.46 – 7.41 (1H, m, ArCH), 7.25 – 7.15 (3H, m, 3 × ArCH), 6.66 (1H, dq, J = 
15.5, 2.0 Hz, C3-H), 6.12 (1H, dq, J = 15.5, 6.5 Hz, C4-H), 3.82 (2H, t, J = 7.0 Hz, C1-H2), 2.96 (2H, 
t, J = 7.0 Hz, C2-H2), 1.91 (3H, dd, J = 6.5, 2.0 Hz, C5-H3), 1.46 (1H, br s, OH). δC (101 MHz, CDCl3) 
137.5 (ArC), 135.0 (ArC), 130.3 (ArCH), 128.5 (C3), 128.0 (C4), 127.1 (ArCH), 127.0 (ArCH), 126.3 




General procedure E: MsNHOTES (vide supra, 902 mg, 4.00 mmol) was employed with alcohol 206 
(1.3 eq.). The reaction time was 16 hours. FCC (eluent: PhMe) afforded the title compound (1.11 g, 
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75 %, 3:1 mixture of (Z)- and (E)-isomers) as a colourless oil. νmax / cm-1: (film) 2956 (m), 2877 (m), 
1458 (m), 1351 (s), 1164 (s). 1H and 13C NMR data for the major (Z)-isomer: δH (400 MHz, CDCl3) 
7.24 – 7.13 (4H, m, 4 × ArCH), 6.52 (1H, dq, J = 11.5, 1.5 Hz, C3-H), 5.89 (1H, dq, J = 11.5, 7.0 Hz, 
C4-H), 3.37 – 3.30 (2H, m, C1-H2), 3.01 – 2.96 (2H, m, C2-H2), 2.86 (3H, s, Ms CH3), 1.73 (3H, dd, 
J = 7.0, 1.5 Hz, C5-H3), 1.06 – 0.99 (9H, m, Si(CH2CH3)3), 0.85 – 0.77 (6H, m, Si(CH2CH3)3).  
δC (101 MHz, CDCl3) 136.5 (ArC), 136.1 (ArC), 129.8 (ArCH), 129.5 (ArCH), 128.1 (C4), 128.0 (C3), 
127.2 (ArCH), 126.4 (ArCH), 56.0 (C1), 31.6 (C2), 30.6 (Ms CH3), 14.3 (C5), 6.7 (Si(CH2CH3)3), 4.8 
(Si(CH2CH3)3). 
1H and 13C NMR data for the minor (E)-isomer: δH (400 MHz, CDCl3) 7.44 – 7.39 (1H, 
m, ArCH), 7.24 – 7.13 (3H, m, 3 × ArCH), 6.64 (1H, dq, J = 15.5, 2.0 Hz, C3-H), 6.14 (1H, dq, J = 
15.5, 6.5 Hz, C4-H), 3.37 – 3.30 (2H, m, C1-H2), 3.09 – 3.04 (2H, m, C2-H2), 2.87 (3H, s, Ms CH3), 
1.92 (3H, dd, J = 6.5, 2.0 Hz, C5-H3), 1.06 – 0.99 (9H, m, Si(CH2CH3)3), 0.85 – 0.77 (6H, m, 
Si(CH2CH3)3). δC (101 MHz, CDCl3) 137.1 (ArC), 134.6 (ArC), 129.9 (ArCH), 128.4 (C3), 127.9 (C4), 
127.2 (ArCH), 127.1 (ArCH), 126.2 (ArCH), 56.0 (C1), 31.6 (C2), 30.5 (Ms CH3), 18.8 (C5), 6.7 




General procedure F: The preceding compound (1.08 g, 2.92 mmol) was employed. FCC (eluent: 
3:1 hexane:EtOAc) afforded the title compound (697 mg, 93 %, 3:1 mixture of (Z)- and (E)-isomers) 
as a colourless oil. νmax / cm-1: (film) 3381 (br s), 3019 (m), 2936 (m), 1333 (s), 1160 (s). 
1H and 13C NMR 
data for the major (Z)-isomer: δH (400 MHz, CDCl3) 7.25 – 7.15 (4H, m, 4 × ArCH), 6.72 (1H, br s, 
OH), 6.55 (1H, dq, J = 11.5, 2.0 Hz, C3-H), 5.89 (1H, dq, J = 11.5, 7.0 Hz, C4-H), 3.39 – 3.33 (2H, m, 
C1-H2), 3.04 – 2.98 (2H, m, C2-H2), 2.90 (3H, s, Ms CH3), 1.73 (3H, dd, J = 7.0, 2.0 Hz, C5-H3).  
δC (101 MHz, CDCl3) 136.6 (ArC), 136.1 (ArC), 129.8 (ArCH), 129.6 (ArCH), 128.3 (C3), 128.1 (C4), 
127.2 (ArCH), 126.4 (ArCH), 52.8 (C1), 31.2 (C2), 31.1 (Ms CH3), 14.3 (C5). 
1H and 13C NMR data 
for the minor (E)-isomer: δH (400 MHz, CDCl3) 7.44 – 7.40 (1H, m, ArCH), 7.25 – 7.15 (3H, m, 3 × 
ArCH), 6.80 (1H, s, OH), 6.65 (1H, dq, J = 15.5, 2.0 Hz, C3-H), 6.15 (1H, dq, J = 15.5, 6.5 Hz, C4-H), 
3.41 – 3.33 (2H, m, C1-H2), 3.12 – 3.06 (2H, m, C2-H2), 2.91 (3H, s, Ms CH3), 1.92 (3H, dd, J =  
6.5, 2.0 Hz, C5-H3). δC (101 MHz, CDCl3) 137.1 (ArC), 134.5 (ArC), 129.9 (ArCH), 128.4 (C4),  
128.0 (C3), 2 × 127.1 (2 × ArCH), 126.2 (ArCH), 53.1 (C1), 2 × 31.1 (C2 and Ms CH3), 18.8 (C5).  
HRMS: (ESI+) Calculated for C12H17NNaO3S: 278.0821. Found [M+Na]+: 278.0822. 





General procedure C: The preceding compound (659 mg, 2.45 mmol) was employed. FCC (gradient 
elution: 10:1 – 4:1 – 3:1 hexane:EtOAc) afforded 207 (1.00 g, 91 %, 3:1 mixture of (Z)- and 
(E)-isomers) as a colourless crystalline solid. νmax / cm-1: (solid) 3024 (m), 2943 (m), 1787 (s), 1653 (m), 
1498 (s), 1165 (s). 1H and 13C NMR data for the major (Z)-isomer: δH (400 MHz, CDCl3) 7.26 – 7.10 
(4H, m, 4 × ArCH), 6.49 (1H, dq, J = 11.5, 2.0 Hz, C3-H), 5.86 (1H, dq, J = 11.5, 7.0 Hz, C4-H), 3.66 
– 3.58 (2H, m, C1-H2), 3.05 – 3.02 (2H, m, C2-H2), 3.00 (3H, s, Ms CH3), 1.69 (3H, dd, J = 7.0, 2.0 Hz, 
C5-H3). δC (101 MHz, CDCl3) 136.6 (ArC), 135.1 (ArC), 129.9 (ArCH), 129.7 (ArCH), 128.4 (C4), 
127.8 (C3), 127.2 (ArCH), 126.7 (ArCH), 52.7 (C1), 34.7 (Ms CH3), 31.4 (C2), 14.3 (C5). The 
13C 
signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. 1H and 13C NMR data for the minor (E)-isomer: δH (400 MHz, CDCl3) 7.41 – 7.37 (1H, m, 
ArCH), 7.24 – 7.13 (3H, m, 3 × ArCH), 6.59 (1H, dq, J = 15.5, 2.0 Hz, C3-H), 6.13 (1H, dq, J = 15.5, 
6.5 Hz, C4-H), 3.67 – 3.57 (2H, m, C1-H2), 3.13 – 3.08 (2H, m, C2-H2), 3.02 (3H, s, Ms CH3), 1.89 
(3H, dd, J = 6.5, 2.0 Hz, C5-H3). δC (101 MHz, CDCl3) 137.2 (ArC), 133.5 (ArC), 129.9 (ArCH), 128.9 
(C4), 127.6 (C3), 127.4 (ArCH), 127.2 (ArCH), 126.4 (ArCH), 53.1 (C1), 34.7 (Ms CH3), 31.2 (C2), 
18.7 (C5). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to 
their weak intensity. 19F NMR signals for both isomers: δF (377 MHz, CDCl3) -135.6 – -135.8 (2F, m), 
-144.9 – -145.2 (1F, m), -158.6 – -158.8 (2F, m). HRMS: (ESI+) Calculated for C19H16F5NNaO4S: 
472.0612. Found [M+Na]+: 472.0614.  
2-Mesyl-1-vinyl-1,2,3,4-tetrahydroisoquinoline (208) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 19 hours. Substrate 207 (62.9 mg, 0.140 mmol) was employed. 
FCC (gradient elution: 9:1 – 7:1 – 4:1 – 2:1 hexane:EtOAc) afforded 208 (14.1 mg, 42 %) as a pale-
yellow oil. νmax / cm-1: (film) 3022 (m), 2931 (m), 1492 (m), 1452 (m), 1327 (s), 1151 (s). δH (500 MHz, 
CDCl3) 7.22 – 7.18 (2H, m, 2 × ArCH), 7.17 – 7.13 (1H, m, ArCH), 7.12 – 7.08 (1H, m, ArCH), 6.02 
(1H, ddd, J = 17.0, 10.0, 6.5 Hz, C4-H), 5.40 (1H, br d, J = 6.5 Hz, C3-H), 5.28 (1H, ddd, J = 10.0, 1.5, 
Chapter 7 - Experimental 
231 
 
1.5 Hz, C5-H), 5.21 (1H, ddd, J = 17.0, 1.5, 1.5 Hz, C5-H’), 3.91 (1H, ddd, J = 13.5, 6.5, 2.5 Hz, C1-H), 
3.37 (1H, ddd, J = 13.5, 11.5, 4.5 Hz, C1-H’), 3.07 (1H, ddd, J = 16.5, 11.5, 6.5 Hz, C2-H), 2.83 (3H, 
s, Ms CH3), 2.79 (1H, ddd, J = 16.5, 4.5, 2.5 Hz, C2-H’). δC (126 MHz, CDCl3) 136.8 (C4), 133.7 
(ArC), 133.3 (ArC), 129.2 (ArCH), 128.0 (ArCH), 127.3 (ArCH), 126.4 (ArCH), 118.1 (C5), 58.2 (C3), 
39.7 (Ms CH3), 39.2 (C1), 28.2 (C2). HRMS: (ESI+) Calculated for C12H15NNaO2S: 260.0716. Found 
[M+Na]+: 260.0716.  
 (E)-1-Bromo-4,5-dimethoxy-2-(prop-1-en-1-yl)benzene 
 
This compound was prepared according to a literature procedure.246 To a solution of methyl isoeugenol 
(4.46 g, 25.0 mmol) in CHCl3 (125 mL) was added a solution of Br2 (2.81 mL, 55.0 mmol) in CHCl3 
(12.5 mL) over around 15 minutes. The reaction mixture was stirred at room temperature for 2.5 hours 
before addition of water (100 mL) and separation of the resulting phases. The organic phase was washed 
with 10 % aqueous Na2SO3 (50 mL), 10 % aqueous Na2CO3 (50 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude mixture was dissolved in acetone (250 mL) before addition of NaI 
(15.0 g, 100 mL). The reaction mixture was heated at reflux for 2 hours before being cooled to room 
temperature and concentrated in vacuo. The crude material was dissolved in hexane (150 mL) and water 
(100 mL); the resulting phases were separated, and the aqueous phase was extracted with (2 × 60 mL). 
The combined organic phases were washed with 10 % aqueous Na2SO3 (2 × 100 mL), dried over 
Na2SO4 and concentrated in vacuo. FCC (eluent: 7:1 hexane:EtOAc) afforded a red oil which was 
dissolved in Et2O (70 mL) and washed with 10 % aqueous Na2SO3 (2 × 50 mL), 10 % aqueous Na2CO3 
(50 mL) and water (2 × 50 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo 
to afford the title compound (4.59 g, 71 %) as a cream-coloured gum. δH (400 MHz, CDCl3) 6.96 (1H, 
s), 6.95 (1H, s), 6.63 (1H, dq, J = 15.5, 1.5 Hz), 6.06 (1H, dq, J = 15.5, 6.5 Hz), 3.86 (3H, s), 3.83 (3H, 
s), 1.89 (3H, dd, J = 6.5, 1.5 Hz). δC (101 MHz, CDCl3) 148.7, 148.5, 129.9, 129.6, 126.9, 115.3, 113.3, 
109.0, 56.2, 56.0, 18.6. The spectroscopic properties were consistent with the data available in the 
literature.246 
  





To a solution of the preceding bromide (2.82 g, 11.0 mmol) in anhydrous THF (30 mL) at -78 °C was 
added n-BuLi (1.55 M in hexane, 14.2 mL, 22.0 mmol). The reaction mixture was stirred at room 
temperature for 2 hours, then cooled to -78 °C before addition of ethylene oxide (approx. 3 M in THF, 
5.5 mL, 16.5 mmol). The reaction mixture was stirred at room temperature for 14 hours before addition 
of saturated aqueous NH4Cl (20 mL). The resulting phases were separated, and the aqueous phase was 
extracted with Et2O (2 × 25 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 3:1 hexane:EtOAc) afforded the title compound (1.69 g, 69 %, 
11:1 mixture of (E)- and (Z)-isomers) as a colourless crystalline solid. Spectroscopic data for the major 
(E)-isomer: νmax / cm-1: (solid) 3263 (br s), 2947 (m), 2832 (m), 1606 (m), 1506 (s), 1212 (s), 1034 (s). 
δH (400 MHz, CDCl3) 6.94 (1H, s, ArCH), 6.66 (1H, s, ArCH), 6.58 (1H, dq, J = 15.5, 1.5 Hz, C3-H), 
6.02 (1H, dq, J = 15.5, 6.5 Hz, C4-H), 3.87 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.77 (2H, t, J = 7.0 Hz, 
C1-H2), 2.88 (2H, t, J = 7.0 Hz, C2-H2), 1.88 (3H, dd, J = 6.5, 1.5 Hz, C5-H3), 1.60 (1H, br s, OH).  
δC (101 MHz, CDCl3) 148.2 (ArC), 147.8 (ArC), 129.7 (ArC), 128.1 (C3), 127.5 (ArC), 126.0 (C4), 
113.3 (ArCH), 109.2 (ArCH), 63.5 (C1), 2 × 56.0 (2 × OCH3), 36.1 (C2), 18.8 (C5). HRMS: (ESI+) 
Calculated for C13H18NaO3: 245.1148. Found [M+Na]+: 245.1154. Characteristic signals for the minor 
(Z)-isomer: δH (400 MHz, CDCl3) 6.73 (2H, s, 2 × ArCH), 6.48 (1H, dq, J = 11.0, 2.0 Hz, C3-H), 5.78 
(1H, dq, J = 11.0, 7.0 Hz, C4-H), 2.80 (2H, t, J = 7.0 Hz, C2-H2), 1.73 (3H, dd, J = 7.0, 2.0 Hz, C5-H3). 
(E)-N-(4,5-Dimethoxy-2-(prop-1-en-1-yl)phenethyl)-N-((triethylsilyl)oxy)methanesulfonamide
 
General procedure E: MsNHOTES (vide supra, 564 mg, 2.50 mmol) was employed with the 
preceding alcohol (1.2 eq.). The reaction time was 22 hours. FCC (gradient elution: 49:1 – 39:1 – 
19:1 PhMe:EtOAc) afforded the title compound (1.04 g, 97 %, 11:1 mixture of (E)- and (Z)-isomers) 
as a colourless oil. Spectroscopic data for the major (E)-isomer: νmax / cm-1: (film) 2956 (m), 2878 (m), 
1607 (m), 1512 (s), 1349 (s), 1164 (s). δH (400 MHz, CDCl3) 6.93 (1H, s, ArCH), 6.66 (1H, s, ArCH), 
6.55 (1H, dq, J = 15.5, 1.5 Hz, C3-H), 6.05 (1H, dq, J = 15.5, 6.5 Hz, C4-H), 3.88 (3H, s, OCH3), 3.86 
(3H, s, OCH3), 3.36 – 3.28 (2H, m, C1-H2), 3.04 – 2.96 (2H, m, C2-H2), 2.87 (3H, s, Ms CH3), 1.90 
(3H, dd, J = 6.5, 1.5 Hz, C5-H3), 1.03 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.81 (6H, q, J = 8.0 Hz, 
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Si(CH2CH3)3). δC (101 MHz, CDCl3) 148.4 (ArC), 148.1 (ArC), 129.5 (ArCH), 127.7 (C3), 127.1 
(ArCH), 126.6 (C4), 113.0 (ArC), 109.1 (ArC), 56.7 (C1), 2 × 56.1 (2 × OCH3), 31.3 (C2), 30.7 
(Ms CH3), 18.8 (C5), 6.9 (Si(CH2CH3)3), 4.9 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for 
C20H35NNaO5SSi: 452.1897. Found [M+Na]+: 452.1891. Characteristic signals for the minor 
(Z)-isomer: δH (400 MHz, CDCl3) 6.73 (2H, s, 2 × ArCH), 6.46 (1H, dq, J = 11.5, 2.0 Hz, C3-H), 5.83 
(1H, dq, J = 11.5, 7.0 Hz, C4-H), 1.75 (3H, dd, J = 7.0, 2.0 Hz, C5-H3). 
(E)-N-(4,5-Dimethoxy-2-(prop-1-en-1-yl)phenethyl)-N-hydroxymethanesulfonamide 
 
General procedure F: The preceding compound (1.02 g, 2.37 mmol) was employed. FCC (gradient 
elution: 2:1 – 3:2 hexane:EtOAc) afforded the title compound (700 mg, 94 %, 11:1 mixture of (E)- and 
(Z)-isomers) as a colourless crystalline solid. Spectroscopic data for the major (E)-isomer: νmax / cm-1: 
(solid) 3378 (br s), 3031 (m), 2940 (m), 1607 (m), 1508 (s), 1345 (s), 1161 (s). δH (400 MHz, CDCl3) 
6.94 (1H, s, ArCH), 6.68 (1H, s, ArCH), 6.62 (1H, s, OH), 6.57 (1H, dq, J = 15.5, 2.0 Hz, C3-H), 6.05 
(1H, dq, J = 15.5, 6.5 Hz, C4-H), 3.88 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.39 – 3.32 (2H, m, C1-H2), 
3.06 – 3.00 (2H, m, C2-H2), 2.91 (3H, s, Ms CH3), 1.90 (3H, dd, J = 6.5, 2.0 Hz, C5-H3). δC (101 MHz, 
CDCl3) 148.3 (ArC), 148.1 (ArC), 129.6 (ArCH), 127.8 (C3), 127.1 (ArCH), 126.6 (C4), 113.0 (ArC), 
109.2 (ArC), 56.2 (OCH3), 56.0 (OCH3), 53.4 (C1), 31.3 (Ms CH3), 30.9 (C2), 18.9 (C5). HRMS: (ESI+) 
Calculated for C14H21NNaO5S: 338.1033. Found [M+Na]+: 338.1030. Characteristic signals for the 
minor (Z)-isomer: δH (400 MHz, CDCl3) 6.75 (1H, s, ArCH), 6.73 (1H, s, ArCH), 6.49 (1H, dq, J = 




General procedure C: The preceding compound (683 mg, 2.17 mmol) was employed. FCC (gradient 
elution: 2:1 – 1:4 hexane:EtOAc) afforded 209 (1.07 g, 97 %, 12:1 mixture of (E)- and (Z)-isomers) as 
a colourless crystalline solid. Spectroscopic data for the major (E)-isomer: νmax / cm-1: (solid) 3021 (m), 
2932 (m), 1778 (s), 1649 (m), 1495 (s), 1354 (s), 1161 (s). δH (400 MHz, CDCl3) 6.91 (1H, s, ArCH), 
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6.67 (1H, s, ArCH), 6.51 (1H, dq, J = 15.5, 1.5 Hz, C3-H), 6.04 (1H, dq, J = 15.5, 6.5 Hz, C4-H), 3.87 
(6H, s, 2 × OCH3), 3.62 (2H, t, J = 8.0 Hz, C1-H2), 3.07 – 3.00 (5H, m, C2-H2 and Ms CH3), 1.88 (3H, 
dd, J = 6.5, 1.5 Hz, C5-H3). δC (101 MHz, CDCl3) 2 × 148.3 (2 × ArC), 129.6 (ArCH), 127.5 (C3), 
127.0 (C4), 126.1 (ArCH), 113.1 (ArC), 109.3 (ArC), 56.1 (OCH3), 56.0 (OCH3), 53.4 (C1), 34.9 
(Ms CH3), 31.0 (C2), 18.7 (C5). The 
13C signals corresponding to the pentafluorobenzoyl group could 
not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.6 – -135.7 (2F, m), -144.9 (1F, 
tt, J = 21.0, 5.5 Hz), -158.6 – -158.8 (2F, m). HRMS: (ESI+) Calculated for C21H20F5NNaO6S: 532.0824. 
Found [M+Na]+: 532.0809. Characteristic signals for the minor (Z)-isomer: δH (400 MHz, CDCl3) 6.76 
(1H, s, ArCH), 6.70 (1H, s, ArCH), 6.43 (1H, dq, J = 11.0, 1.5 Hz, C3-H), 5.81 (1H, dq, J = 11.0, 
7.0 Hz, C4-H), 1.72 (3H, dd, J = 7.0, 2.0 Hz, C5-H3). 
(2-Vinylphenyl)methanol 
 
To a solution of 2-bromostyrene (1.25 mL, 10.0 mmol) in anhydrous THF (30 mL) at -78 °C was added 
n-BuLi (1.55 M in hexane, 7.10 mL, 11.0 mmol). The reaction mixture was stirred at -78 °C for 
1.5 hours before addition of paraformaldehyde (450 mg, 15.0 mmol). The reaction mixture was stirred 
at room temperature for 5 hours before addition of saturated aqueous NH4Cl (20 mL). The resulting 
phases were separated, and the aqueous phase was extracted with Et2O (2 × 40 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 4:1 hexane:EtOAc) 
afforded the title compound (279 mg, 21 %) as a colourless oil. νmax / cm-1: (film) 3317 (br s), 2885 (m), 
1627 (m), 1414 (m), 1003 (s). δH (500 MHz, CDCl3) 7.54 (1H, dd, J = 7.0, 1.5 Hz), 7.37 (1H, dd, J = 
7.0, 2.0 Hz), 7.33 – 7.26 (2H, m), 7.06 (1H, dd, J = 17.5, 11.0 Hz), 5.71 (1H, dd, J = 17.5, 1.5 Hz), 5.36 
(1H, dd, J = 11.0, 1.5 Hz), 4.77 (2H, s), 1.58 (1H, br s). δC (126 MHz, CDCl3) 137.7, 136.8, 133.9, 
128.5, 128.4, 128.1, 126.1, 116.7, 63.6. The spectroscopic properties were consistent with the data 
available in the literature.247 
N-((Pentafluorobenzoyl)oxy)-N-(2-vinylbenzyl)methanesulfonamide (211) 
 
General procedure N: The preceding alcohol (268 mg, 2.00 mmol) was employed with MsNHOFBz 
(vide supra, 507 mg, 1.66 mmol). The reaction time was 15 hours. FCC (eluent: PhMe) afforded  
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211 (347 mg, 50 %) as a colourless crystalline solid. m.p. 137-138 °C (CH2Cl2:petrol, fibres).  
νmax / cm-1: (solid) 3027 (m), 1788 (s), 1653 (m), 1497 (s), 1357 (s), 1164 (s). δH (400 MHz, CDCl3) 
7.55 (1H, ddd, J = 8.0, 1.0, 1.0 Hz, ArCH), 7.35 (1H, ddd, J = 8.0, 7.5, 1.5 Hz, ArCH), 7.31 – 7.15 (3H, 
m, 2 × ArCH and C2-H), 5.70 (1H, dd, J = 17.5, 1.5 Hz, C3-H’), 5.41 (1H, dd, J = 11.0, 1.5 Hz, C3-H), 
4.68 (2H, br s, C1-H2), 3.13 (3H, s, Ms CH3). δC (101 MHz, CDCl3) 138.9 (ArC), 133.6 (C2), 131.1 
(ArCH), 129.6 (ArCH), 128.9 (ArC), 127.9 (ArCH), 126.7 (ArCH), 117.6 (C3), 53.9 (C1), 35.3 
(Ms CH3). The 
13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to 
their weak intensity. δF (377 MHz, CDCl3) -135.6 – -135.8 (2F, m), -145.5 (1F, tt, J = 21.0, 




A suspension of MeNHOH·HCl (7.18 g, 86.0 mmol) and MgO (3.01 g, 74.8 mmol) in MeOH (27 mL) 
and water (18 mL) was stirred at room temperature for 10 minutes. To the suspension was added TsCl 
(7.13 g, 37.4 mmol) in THF (300 mL) followed by MgO (1.51 g, 37.4 mmol). The reaction mixture was 
stirred for 4 hours before being filtered through celite. The filtrate was dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 2:1 hexane:EtOAc) afforded the title compound (6.18 g, 82 %) as 
a colourless crystalline solid. νmax / cm-1: (solid) 3383 (br s), 2933 (m), 1594 (s), 1336 (s), 1161 (s).  
δH (400 MHz, CDCl3) 7.78 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.37 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.75 
(1H, s, OH), 2.82 (3H, s, NCH3), 2.45 (3H, s, Ts CH3). δC (101 MHz, CDCl3) 145.1 (ArC), 129.9 
(ArCH), 129.5 (ArCH), 128.2 (ArC), 40.4 (NCH3), 21.7 (Ts CH3). HRMS: (ESI+) Calculated for 
C8H12NO3S: 202.0532. Found [M+H]+: 202.0538. 
N-Methyl-N-((pentafluorobenzoyl)oxy)-4-toluenesulfonamide (218a) 
 
General procedure C: The preceding compound (1.01 g, 5.00 mmol) was employed. FCC (eluent: 
4:1 hexane:EtOAc) afforded 218a (1.76 g, 89 %) as a colourless crystalline solid. m.p. 128-129 °C 
(CH2Cl2:hexane, plates). νmax / cm-1: (film) 2988 (m), 2935 (m), 1781 (s), 1652 (s), 1597 (m), 1497 (s), 
1162 (s). δH (400 MHz, CDCl3) 7.81 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.39 (2H, d, J = 8.5 Hz, 2 × ArCH), 
3.08 (3H, s, NCH3), 2.47 (3H, s, Ts CH3). δC (101 MHz, CDCl3) 146.0 (ArC), 129.9 (ArCH), 129.8 
(ArCH), 128.9 (ArC), 40.1 (NCH3), 21.7 (Ts CH3). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
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CDCl3) -135.7 – -135.8 (2F, m), -145.8 (1F, tt, J = 21.0, 5.0 Hz), -159.0 – -159.2 (2F, m). HRMS: (ESI+) 
Calculated for C15H10F5NNaO4S: 418.0143. Found [M+Na]+: 418.0131. 
N-Methyl-N-hydroxymethanesulfonamide 
 
A suspension of MeNHOH·HCl (5.07 g, 60.7 mmol) and MgO (2.13 g, 52.8 mmol) in MeOH (18 mL) 
and water (12 mL) was stirred at room temperature for 10 minutes. To the suspension was added MsCl 
(2.04 mL, 26.4 mmol) in THF (200 mL) followed by MgO (1.06 g, 26.4 mmol). The reaction mixture 
was stirred at room temperature for 3 hours before being filtered through celite. The filtrate was dried 
over Na2SO4 and concentrated in vacuo. FCC (eluent: 3:2 hexane:EtOAc) afforded the title compound 
(2.86 g, 87 %) as a colourless crystalline solid. νmax / cm-1: (solid) 3376 (br s), 2937 (m), 2851 (m), 
1439 (s), 1318 (s), 1149 (s). δH (400 MHz, CDCl3) 7.03 (1H, br s, OH), 3.04 (3H, s, NCH3), 2.93 (3H, 
s, Ms CH3). δC (101 MHz, CDCl3) 40.3 (NCH3), 30.0 (Ms CH3). HRMS: (ESI+) Calculated for 
C2H7NNaO3S: 148.0039. Found [M+Na]+: 148.0035.  
N-Methyl-N-((pentafluorobenzoyl)oxy)methanesulfonamide (218b) 
 
General procedure C: The preceding compound (1.00 g, 7.99 mmol) was employed. FCC (eluent: 
2:1 hexane:EtOAc) afforded 218b (1.93 g, 76 %) as a colourless crystalline solid. m.p. 139-140 °C 
(CH2Cl2:hexane, plates). νmax / cm-1: (solid) 2945 (m), 1782 (s), 1655 (m), 1498 (s), 1361 (s), 1159 (s). 
δH (400 MHz, CDCl3) 3.30 (3H, s, NCH3), 3.07 (3H, s, Ms CH3). δC (101 MHz, CDCl3) 39.5 (NCH3), 
33.7 (Ms CH3). The 
13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. δF (377 MHz, CDCl3) -135.7 – -135.8 (2F, m), -144.9 (1F, tt, J = 21.0, 




To a solution of MeNH2 (33 % in EtOH, 20 mL, 212 mmol) in EtOH (5 mL) at 0 °C was added MsCl 
(3.30 mL, 42.4 mmol) dropwise. The reaction mixture was stirred at room temperature for 9 hours 
before being concentrated in vacuo. The crude mixture was dissolved in CH2Cl2 (20 mL), filtered and 
the filtrate was concentrated in vacuo. FCC (gradient elution: 1:1 – 2:3 hexane:EtOAc) afforded 222 
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(3.46 g, 75 %) as a colourless oil. δH (400 MHz, CDCl3) 4.65 (1H, br s), 2.93 (3H, s), 2.80 (3H, d, J = 
5.5 Hz). δC (101 MHz, CDCl3) 38.7, 29.4. The spectroscopic properties were consistent with the data 
available in the literature.248 
Palladium(II) bis(tris(3,5-bis(trifluoromethyl)phenyl)phosphine) dichloride (223) 
 
This compound was prepared according to a literature procedure.249 To a reaction vessel charged with 
(MeCN)2PdCl2 (259 mg, 1.00 mmol) and P(3,5-(CF3)2C6H3)3 (1.34 g, 2.00 mmol) was added anhydrous 
CH2Cl2 (75 mL, argon sparged). The reaction mixture was stirred at room temperature for 15 hours 
before being concentrated in vacuo. The crude material was suspended in PhMe and filtered to afford 
223 (1.09 g, 72 %) as a yellow crystalline solid. δH (400 MHz, CDCl3) 8.11 (6H, s), 8.08 – 8.03 (12H, 
m). δP (162 MHz, CDCl3) 25.5 (s). δF (377 MHz, CDCl3) -63.2 (s). The spectroscopic properties were 
consistent with the data available in the literature.249 
(E)-2-(Hex-4-en-1-yl)isoindoline-1,3-dione 
 
To a solution of phthalimide (2.21 g, 15.0 mmol) and PPh3 (5.25 g, 20.0 mmol) in anhydrous PhMe 
(70 mL) at 0 °C was added DIAD (3.94 mL, 20.0 mmol). The reaction mixture was stirred at 0 °C for 
1 hour before addition of a solution of (E)-hex-4-en-1-ol (87) (1.00 g, 10.0 mmol) in anhydrous THF 
(30 mL). The reaction mixture was stirred at room temperature for 16 hours before being concentrated 
in vacuo. FCC (eluent: 7:1 hexane:EtOAc) afforded the title compound (2.21 g, 96 %) as a colourless 
crystalline solid. m.p. 53-55 °C (CH2Cl2:petrol, hexagonal). νmax / cm-1: (solid) 3028 (m), 2937 (m), 
1696 (s), 1396 (s). δH (400 MHz, CDCl3) 7.81 (2H, dd, J = 5.5, 3.0 Hz, 2 × ArCH), 7.68 (2H, dd, J = 
5.5, 3.0 Hz, 2 × ArCH), 5.49 – 5.34 (2H, m, C4-H and C5-H), 3.69 – 3.63 (2H, m, C1-H2), 2.05 – 1.98 
(2H, m, C3-H2), 1.72 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.60 – 1.56 (3H, m, C6-H3). δC (101 MHz, CDCl3) 
168.5 (C=O), 133.9 (ArCH), 132.3 (ArC), 129.9 (C4), 125.9 (C5), 123.2 (ArCH), 37.8 (C1), 30.0 (C3), 
28.3 (C2), 18.0 (C6). HRMS: (ESI+) Calculated for C14H15NNaO2: 252.0995. Found [M+Na]+: 
252.1000.  





A solution of the preceding compound (1.61 g, 7.00 mmol) and 55 % aqueous hydrazine (0.79 mL, 
14.0 mmol) in EtOH (20 mL) was heated at reflux for 1 hour. The reaction mixture was cooled to room 
temperature, filtered and the filter cake was rinsed with CH2Cl2 (80 mL). To the filtrate was added TsCl 
(1.33 g, 7.00 mmol) and Et3N (3.00 mL, 21.5 mmol). The reaction mixture was stirred at room 
temperature for 5 hours before addition of 1.0 M aqueous HCl (50 mL) and separation of the resulting 
phases. The organic phase was washed with 1.0 M aqueous K2CO3 (50 mL), brine (50 mL), dried over 
Na2SO4 and concentrated in vacuo. FCC (eluent: 4:1 hexane:EtOAc) afforded (E)-8 (792 mg, 45 %) as 
a colourless oil. δH (500 MHz, CDCl3) 7.76 (2H, d, J = 8.0 Hz), 7.33 (2H, d, J = 8.0 Hz), 5.44 – 5.36 
(1H, m), 5.31 (1H, dtd, J = 15.0, 7.0, 1.5 Hz), 4.34 (1H, t, J = 6.5 Hz), 2.96 (2H, td, J = 7.0, 6.5 Hz), 
2.45 (3H, s), 1.98 (2H, dtt, J = 7.0, 7.0, 1.0 Hz), 1.63 (3H, dd, J = 6.0, 1.5 Hz), 1.53 (2H, tt, J = 7.0, 
7.0 Hz). δC (126 MHz, CDCl3) 143.5, 137.1, 2 × 129.8, 127.3, 126.4, 42.8, 29.6, 29.4, 21.7, 18.0. The 
1H NMR spectrum was consistent with the data available in the literature for both the (E)- and the 
(Z)-isomer.105 The 13C NMR spectrum was consistent with the data corresponding to the (Z)-isomer, 
although only one resonance is reported around 129.8 ppm.105 Based on the observed coupling constant 
between the alkene protons of 8, it appears that NMR data for the (E)-isomer has been reported for the 
(Z)-isomer, and vice versa. 
(E)-2-Styryl-1-tosylpyrrolidine 
 
In the following experiment, a mixture of aza-Heck (126) and aza-Wacker ((E)-8) substrates were 
submitted to the reaction conditions. The fact that only 126 afforded cyclised product is consistent with 
an aza-Heck mechanism (Section 2.5). General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 
12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; n-BuCN (0.1 M); 110 °C; 18 hours. Substrates 126 
(vide supra, 75.5 mg, 0.140 mmol) and (E)-8 (25.3 mg, 0.100 mmol) were employed. From analysis of 
the 1H NMR spectrum of the crude reaction mixture, the yield of 128 was determined to be 72 % and 
no aza-Wacker product (12) was observed. Characterisation data for 128 has been provided earlier. 





The following reaction was conducted in the presence of TEMPO. General procedure D: Conditions: 
2.5 mol% Pd2(dba)3; 12.5 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 150 mol% TEMPO; n-BuCN 
(0.1 M); 110 °C; 16 hours. Substrate 125 (65.0 mg, 0.140 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 12 (27.0 mg, 77 %) as a colourless crystalline solid. No products derived 
from TEMPO-trapping of radical intermediates were observed. Characterisation data for 12 has been 
provided earlier. 
2-((1E)-4-Methoxy-3-phenylbuta-1,3-dien-1-yl)-1-tosylpyrrolidine ((E)-233) and  
2-((1E)-3-methoxy-4-phenylbuta-1,3-dien-1-yl)-1-tosylpyrrolidine ((E)-232) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
6:1 n-BuCN:DMF (0.1 M); 110 °C; 25 hours. Substrate 228 (126 mg, 0.212 mmol, added as a solution 
in n-BuCN) was employed. FCC (gradient elution: 99:1 – 74:1 PhMe:EtOAc) afforded 233 and 232 
(25.3 mg, 31 %, 7:5:1 mixture of (E)-233, (E)-232 and (Z)-232) as a pale-yellow oil. The relative 
stereochemistry of (E)-233 and (E)-232 was assigned by analogy to the related dihydropyrrole 
products.120 νmax / cm-1: (film) 2932 (m), 1731 (m), 1598 (m), 1492 (m), 1343 (s), 1156 (s). 
1H and 13C 
NMR data for (E)-233 (A) and (E)-232 (B): δH (500 MHz, CDCl3) 7.72 (1.2H, d, J = 8.0 Hz, A: 2 × 
ArCH), 7.69 (0.8H, d, J = 8.0 Hz, B: 2 × ArCH), 7.37 – 7.18 (7H, m, A and B: 7 × ArCH), 6.75 (0.6H, 
dd, J = 16.0, 1.0 Hz, A: C6-H), 6.49 (0.4H, dd, J = 15.5, 1.0 Hz, B: C6-H), 6.13 (0.4H, dd, J = 15.5, 
6.5 Hz, B: C5-H), 6.04 (0.6H, s, A: C8-H), 5.80 (0.4H, s, B: C8-H), 5.42 (0.6H, dd, J = 16.0, 7.5 Hz, 
A: C5-H), 4.25 – 4.17 (1H, m, A and B: C4-H), 3.74 (1.8H, s, A: OCH3), 3.72 (1.2H, s, B: OCH3), 3.43 
– 3.22 (2H, m, A and B: C1-H2), 2.42 (1.8H, s, A: Ts CH3), 2.41 (1.2H, s, B: Ts CH3), 1.85 – 1.59 (4H, 
m, A and B: C2-H2 and C3-H2). δC (126 MHz, CDCl3) 153.4 (B: C7), 147.1 (A: C8), 143.1 (B: ArC), 
142.9 (A: ArC), 137.7 (A: ArC), 136.6 (B: ArC), 135.7 (A: ArC), 135.3 (B: ArC), 132.4 (B: C5), 130.2 
(A: C5), 2 × 129.5 (A and B: ArCH), 129.4 (B: ArCH), 129.3 (A: ArCH), 128.2 (B: ArCH), 128.1 (A: 
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ArCH), 2 × 127.5 (A and B: ArCH), 126.7 (A: ArCH), 125.8 (B: ArCH), 124.8 (A: C6), 123.6 (B: C6), 
119.2 (A: C7), 103.8 (B: C8), 62.4 (A: C4), 61.4 (B: C4), 60.3 (A: OCH3), 54.8 (B: OCH3), 2 × 48.7 (A 
and B: C1), 33.2 (A: C3), 32.8 (B: C3), 2 × 24.0 (A and B: C2), 2 × 21.50 (A and B: Ts CH3). 
HRMS: (ESI+) Calculated for C22H26NO3S: 384.1628. Found [M+H]+: 384.1622. Characteristic 
1H and 
13C NMR signals for (Z)-232: δH (500 MHz, CDCl3) 5.94 (1H, dd, J = 15.5, 6.5 Hz, C5-H), 5.84 (1H, 
s, C8-H), 3.64 (3H, s, OCH3). δC (126 MHz, CDCl3) 131.1 (C5), 117.0 (C8), 58.5 (OCH3). 
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7.4 Experimental procedures for the studies in Chapter 3 
Benzyl hydroxycarbamate 
 
This compound was prepared according to a literature procedure.250 A solution of NH2OH·HCl (10.0 g, 
144 mmol) and K2CO3 (19.9 g, 144 mmol) in water (100 mL) and Et2O (200 mL) was stirred at room 
temperature for 1 hour then cooled to 0 °C before addition of CbzCl (13.7 mL, 96.0 mmol). The reaction 
mixture was stirred at room temperature for 1 hour before the phases were separated, and the aqueous 
phase was extracted with Et2O (2 × 100 mL). The combined organic phases were dried over Na2SO4 
and concentrated in vacuo to afford the title compound (16.0 g, 100 %) as a colourless crystalline solid. 
m.p. 71-72 °C (Et2O:hexane) [Lit., 62-63 °C (no recrystallisation solvent quoted)]250. νmax / cm-1: (solid) 
3365 (br s), 3297 (s), 3061 (m), 2978 (m), 1699 (s), 1495 (s), 1272 (s), 1111 (s).  
δH (500 MHz, CD3CN) 7.97 (1H, br s), 7.40 – 7.32 (5H, m), 6.70 (1H, br s), 5.11 (2H, s). δC (126 MHz, 
CD3CN) 159.1, 137.7, 129.5, 129.1, 128.9, 67.4. HRMS: (ESI+) Calculated for C8H9NNaO3: 190.0475. 




This compound was prepared according to a literature procedure.251 To a solution of the preceding 
compound (15.7 g, 94.0 mmol) in anhydrous CH2Cl2 (200 mL) at 0 °C was added Et3N (13.1 mL, 
94.0 mmol) followed by TBSCl (14.2 g, 94.0 mmol) in three roughly equal portions. The reaction 
mixture was stirred at room temperature for 1.5 hours before addition of water (80 mL). The resulting 
phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 14:1 hexane:EtOAc) 
afforded CbzNHOTBS (25.8 g, 98 %) as a colourless low-melting solid. νmax / cm-1: (film) 3273 (br s), 
2930 (m), 2858 (m), 1731 (s), 1463 (s), 1251 (s), 1101 (s). δH (400 MHz, CDCl3) 7.38 – 7.30 (5H, m), 
6.93 (1H, s), 5.17 (2H, s), 0.94 (9H, s), 0.16 (6H, s). δC (101 MHz, CDCl3) 158.7, 135.8, 128.7, 2 × 
128.5, 67.8, 26.0, 18.2, -5.6. HRMS: (ESI+) Calculated for C14H24NO3Si: 282.1520. Found [M+H]+: 
282.1518. The spectroscopic properties were consistent with the data available in the literature.252 
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Benzyl ((tert-butyldimethylsilyl)oxy)(pent-4-en-1-yl)carbamate (237) 
 
General procedure A: CbzNHOTBS (vide supra, 2.81 g, 10.0 mmol) was employed with 
5-bromopent-1-ene. FCC (gradient elution: 24:1 – 9:1 hexane:EtOAc) afforded 237 (3.20 g, 92 %) as a 
colourless oil. νmax / cm-1: (film) 2930 (m), 2858 (m), 1704 (s), 1251 (s). δH (400 MHz, CDCl3) 7.40 – 
7.29 (5H, m, 5 × ArCH), 5.78 (1H, ddt, J = 17.0, 10.5, 6.5 Hz, C4-H), 5.15 (2H, s, OCH2Ph), 5.01 (1H, 
ddt, J = 17.0, 2.0, 1.5 Hz, C5-H’), 4.96 (1H, ddt, J = 10.5, 2.0, 1.5 Hz, C5-H), 3.49 (2H, t, J = 7.5 Hz, 
C1-H2), 2.04 (2H, tddd, J = 7.0, 6.5, 1.5, 1.5 Hz, C3-H2), 1.75 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 0.91 (9H, 
s, SiC(CH3)3), 0.10 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 158.5 (C=O), 137.9 (C4), 136.2 (ArC), 
128.6 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 115.1 (C5), 67.9 (OCH2Ph), 52.1 (C1), 30.9 (C3), 25.9 
(SiC(CH3)3), 25.3 (C2), 18.0 (SiC(CH3)3), -5.0 (Si(CH3)2). HRMS: (ESI+) Calculated for 
C19H31NNaO3Si: 372.1965. Found [M+Na]+: 372.1973. 
Benzyl hydroxy(pent-4-en-1-yl)carbamate 
 
General procedure M: Compound 237 (3.20 g, 9.15 mmol) was employed with 2.0 eq. TBAF. The 
reaction time was 4 hours. FCC (gradient elution: 3:1 – 2:1 hexane:EtOAc) afforded the title compound 
(1.78 g, 83 %) as a colourless oil. νmax / cm-1: (film) 3257 (br s), 3068 (m), 2936 (m), 1697 (s), 1455 (s), 
1210 (s). δH (400 MHz, CDCl3) 7.39 – 7.30 (5H, m, 5 × ArCH), 6.82 (1H, s, OH), 5.79 (1H, ddt, J = 
17.0, 10.0, 6.5 Hz, C4-H), 5.17 (2H, s, OCH2Ph), 5.04 – 4.94 (2H, m, C5-H2), 3.56 (2H, t, J = 7.0 Hz, 
C1-H2), 2.07 (2H, tddd, J = 7.0, 6.5, 1.5, 1.5 Hz, C3-H2), 1.74 (2H, tt, J = 7.0, 7.0 Hz, C2-H2).  
δC (126 MHz, CDCl3) 157.5 (C=O), 137.9 (C4), 136.1 (ArC), 128.7 (ArCH), 128.5 (ArCH), 128.2 
(ArCH), 115.3 (C5), 68.1 (OCH2Ph), 49.8 (C1), 30.7 (C3), 26.2 (C2). HRMS: (ESI+) Calculated for 
C13H17NNaO3: 258.1101. Found [M+Na]+: 258.1094. 
Benzyl pent-4-en-1-yl((pentafluorobenzoyl)oxy)carbamate (238a) 
 
General procedure C: The preceding compound (1.53 g, 6.51 mmol) was employed. FCC (eluent: 
9:1 hexane:EtOAc) afforded 238a (2.42 g, 87 %) as a colourless oil. νmax / cm-1: (film) 3070 (m), 
2943 (m), 1784 (s), 1727 (s), 1652 (m), 1498 (s), 1174 (s). δH (400 MHz, CDCl3) 7.41 – 7.29 (5H, m, 
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5 × ArCH), 5.78 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, C4-H), 5.22 (2H, s, OCH2Ph), 4.97 (2H, m, C5-H2), 
3.76 (2H, t, J = 7.0 Hz, C1-H2), 2.14 (2H, tddd, J = 7.0, 6.5, 1.5, 1.5 Hz, C3-H2), 1.75 (2H, tt, J = 7.0, 
7.0 Hz, C2-H2). δC (126 MHz, CDCl3) 157.4 (FBz C=O), 155.5 (Cbz C=O), 137.3 (C4), 135.3 (ArC), 
128.7 (ArCH), 128.6 (ArCH), 128.2 (ArCH), 115.7 (C5), 68.9 (OCH2Ph), 50.7 (C1), 30.5 (C3), 26.1 
(C2). The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.1 (2F, m), -146.0 (1F, tt, J = 21.0, 
5.5 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C20H16F5NNaO4: 452.0892. Found 
[M+Na]+: 452.0884. 
Benzyl (4-oxopentyl)carbamate (239) 
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 15 mol% P(3,5-(CF3)2C6H3)3; 200 mol% 
Et3N; DMF (0.12 M); 120 °C; 2 hours. Substrate 238a (51.0 mg, 0.119 mmol) was employed. FCC 
(gradient elution: 9:1 – 1:1 hexane:EtOAc) afforded 239 (14.0 mg, 50 %) as a colourless oil.  
νmax / cm-1: (film) 3340 (br, s), 3034 (m), 2938 (m), 1697 (s), 1528 (s), 1244 (s). δH (500 MHz, CDCl3) 
7.38 – 7.29 (5H, m, 5 × ArCH), 5.09 (2H, s, OCH2Ph), 4.86 (1H, br s, NH), 3.20 (2H, dt, J = 6.5, 6.5 Hz, 
C1-H2), 2.48 (2H, t, J = 7.0 Hz, C3-H2), 2.13 (3H, s, C5-H3), 1.78 (2H, tt, J = 7.0, 6.5 Hz, C2-H2).  
δC (126 MHz, CDCl3) 208.4 (C4), 156.6 (Cbz C=O), 136.7 (ArC), 128.7 (ArCH), 128.3 (ArCH), 128.2 
(ArCH), 66.8 (OCH2Ph), 40.8 (C3), 40.6 (C1), 30.1 (C5), 24.0 (C2). HRMS: (ESI+) Calculated for 
C13H17NNaO3: 258.1101. Found [M+Na]+: 258.1096. 
Benzyl ((tert-butyldimethylsilyl)oxy)(2-(cyclohex-2-en-1-yl)ethyl)carbamate 
 
General procedure A: CbzNHOTBS (vide supra, 2.25 g, 8.00 mmol) was employed with 
3-(2-bromoethyl)cyclohex-1-ene (Section 7.3). FCC (eluent: 39:1 hexane:EtOAc) afforded the title 
compound (2.50 g, 80 %) as a colourless oil. νmax / cm-1: (film) 2929 (s), 2858 (m), 1705 (s), 1250 (s). 
δH (400 MHz, CDCl3) 7.39 – 7.28 (5H, m, 5 × ArCH), 5.69 – 5.64 (1H, m, C5-H), 5.53 (1H, ddt, J = 
10.0, 2.5, 2.5 Hz, C4-H), 5.15 (2H, s, OCH2Ph), 3.53 (2H, t, J = 7.5 Hz, C1-H2), 2.11 – 2.03 (1H, m, 
C3-H), 1.99 – 1.92 (2H, m, C6-H2), 1.81 – 1.43 (5H, m, C2-H2 C7-H2 and C8-H), 1.28 – 1.16 (1H, m, 
C8-H’), 0.92 (9H, s, SiC(CH3)3), 0.11 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 158.3 (C=O), 136.0 
(ArC), 131.1 (C4), 128.4 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 127.4 (C5), 67.7 (OCH2Ph), 50.4 (C1), 
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32.8 (C3), 32.2 (C2), 28.8 (C8), 25.7 (SiC(CH3)3), 25.2 (C6), 21.3 (C7), 17.9 (SiC(CH3)3), -5.1 
(Si(CH3)2). HRMS: (ESI+) Calculated for C22H36NO3Si: 390.2459. Found [M+H]+: 390.2459. 
Benzyl (2-(cyclohex-2-en-1-yl)ethyl)(hydroxy)carbamate 
 
General procedure M: The preceding compound (2.50 g, 6.42 mmol) was employed with 2.0 eq. 
TBAF. The reaction time was 14 hours. The title compound (1.66 g, 94 %) was isolated as a pale-yellow 
oil, which was used without further purification. νmax / cm-1: (film) 3257 (br s), 3017 (m), 2926 (m), 
1697 (s), 1453 (s), 1112 (s). δH (500 MHz, CDCl3) 7.43 – 7.30 (5H, m, 5 × ArCH), 6.35 (1H, br s, OH), 
5.69 (1H, ddt, J = 10.0, 3.0, 3.0 Hz, C5-H), 5.57 (1H, ddt, J = 10.0, 2.5, 2.5 Hz, C4-H), 5.18 (2H, s, 
OCH2Ph), 3.63 (2H, dd, J = 7.0, 7.0 Hz, C1-H2), 2.18 – 2.09 (1H, m, C3-H), 2.01 – 1.95 (2H, m, C6-H2), 
1.80 (1H, dddd, J = 12.5, 6.0, 6.0, 3.0 Hz, C8-H), 1.76 – 1.67 (2H, m, C2-H and C7-H), 1.65 – 1.57 
(1H, m, C2-H’), 1.54 – 1.42 (1H, m, C7-H’), 1.28 – 1.20 (1H, m, C8-H’). δC (126 MHz, CDCl3) 157.5 
(C=O), 136.1 (ArC), 131.2 (C4), 128.6 (ArCH), 128.4 (ArCH), 128.1 (ArCH), 127.5 (C5), 68.0 
(OCH2Ph), 48.3 (C1), 33.2 (C2), 32.5 (C3), 28.8 (C8), 25.3 (C6), 21.4 (C7). HRMS: (ESI+) Calculated 
for C16H21NNaO3: 298.1414. Found [M+Na]+: 298.1409.  
Benzyl (2-(cyclohex-2-en-1-yl)ethyl)((pentafluorobenzoyl)oxy)carbamate (241) 
 
General procedure C: The preceding compound (130 mg, 0.472 mmol) was employed. FCC (eluent: 
14:1 hexane:EtOAc) afforded 241 (200 mg, 90 %) as a colourless oil. νmax / cm-1: (film) 3019 (m), 
2930 (m), 1785 (s), 1726 (s), 1652 (m), 1498 (s), 1171 (s). δH (400 MHz, CDCl3) 7.39 – 7.30 (5H, m, 
5 × ArCH), 5.71 (1H, dtd, J = 10.0, 3.5, 2.5 Hz, C5-H), 5.55 (1H, ddt, J = 10.0, 2.0, 2.0 Hz, C4-H), 
5.23 (2H, s, OCH2Ph), 3.83 (2H, dd, J = 7.5, 7.5 Hz, C1-H2), 2.21 (1H, dddddd, J = 11.0, 6.0, 5.5, 3.5, 
2.5, 2.0 Hz, C3-H), 2.02 – 1.94 (2H, m, C6-H2), 1.82 (1H, dddd, J = 12.5, 6.0, 6.0, 3.0 Hz, C8-H), 1.78 
– 1.60 (3H, m, C2-H2 and C7-H), 1.59 – 1.47 (1H, m, C7-H’), 1.25 (1H, dddd, J = 12.5, 11.0, 8.5, 
3.0 Hz, C8-H’). δC (101 MHz, CDCl3) 157.3 (FBz C=O), 155.4 (Cbz C=O), 135.3 (ArC), 130.6 (C4), 
128.6 (ArCH), 128.5 (ArCH), 128.2 (ArCH), 127.9 (C5), 68.8 (OCH2Ph), 49.2 (C1), 33.1 (C2), 32.4 
(C3), 28.7 (C8), 25.3 (C6), 21.3 (C7). The aromatic 13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.0 (2F, m), 
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-146.0 (1F, tt, J = 21.0, 5.0 Hz), -159.1 – -159.3 (2F, m). HRMS: (ESI+) Calculated for C23H20F5NNaO4: 
492.1210. Found [M+Na]+: 492.1200. 
tert-Butyl ((tert-butoxycarbonyl)oxy)carbamate 
 
This compound was prepared according to a literature procedure.253 To a solution of NH2OH·HCl 
(8.00 g, 115 mmol) and Na2CO3 (15.9 g, 150 mmol) in water (70 mL) at 35 °C was added Boc2O 
(55.6 mL, 242 mmol) in six roughly equal portions over around 2.5 hours. The reaction mixture was 
stirred for 30 minutes at 35 °C and then a further 16 hours at room temperature before being extracted 
with PhMe (4 × 100 mL). The combined organic phases were washed with brine (100 mL), dried over 
Na2SO4 and concentrated in vacuo to afford BocNHOBoc (24.9 g, 93 %) as a colourless crystalline 
solid. m.p. 66-67 °C (CH2Cl2:petrol, plates) [Lit., 66-69 °C (petrol)].254 δH (400 MHz, CDCl3) 7.51 (1H, 
s), 1.53 (9H, s), 1.50 (9H, s). δC (101 MHz, CDCl3) 155.8, 153.7, 85.6, 83.4, 28.2, 27.7. The 
spectroscopic properties were consistent with the data available in the literature.255 
(E)-Hex-4-en-1-yl 4-toluenesulfonate 
 
To a solution of (E)-4-hexen-1-ol (87) (2.50 g, 25.0 mmol) in anhydrous CH2Cl2 (40 mL) at 0 °C was 
added TsCl (6.20 g, 32.5 mmol) and pyridine (2.22 mL, 27.5 mmol). The reaction mixture was stirred 
at room temperature for 2 days before addition of 1.0 M aqueous HCl (30 mL). The resulting phases 
were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 30 mL). The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 9:1 hexane:EtOAc) afforded 
the title compound (4.86 g, 76 %) as a colourless oil. δH (400 MHz, CDCl3) 7.79 (2H, d, J = 8.0 Hz), 
7.34 (2H, d, J = 8.0 Hz), 5.40 – 5.20 (2H, m), 4.01 (2H, t, J = 6.5 Hz), 2.45 (3H, s), 1.99 (2H, br dt, J = 
7.5, 7.0 Hz), 1.68 (2H, tt, J = 7.0, 6.5 Hz), 1.58 (3H, ddt, J = 5.5, 1.5, 1.5 Hz). δC (101 MHz, CDCl3) 
144.8, 133.3, 129.9, 129.2, 128.1, 126.6, 70.0, 28.7, 28.3, 21.8, 18.0. The spectroscopic properties were 
consistent with the data available in the literature.256 
tert-Butyl (E)-((tert-butoxycarbonyl)oxy)(hex-4-en-1-yl)carbamate 
 
To a solution of BocNHOBoc (vide supra, 3.92 g, 16.8 mmol) and the preceding tosylate (3.56 g, 
14.0 mmol) in DMF (120 mL) was added Cs2CO3 (6.84 g, 21.0 mmol). The reaction mixture was stirred 
at room temperature for 17 hours before addition of brine (100 mL) and water (50 mL). The reaction 
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mixture was extracted with Et2O (4 × 100 mL). The combined organic phases were dried over Na2SO4 
and concentrated in vacuo. FCC (eluent: 24:1 hexane:EtOAc) afforded the title compound (3.72 g, 
84 %) as a colourless oil. νmax / cm-1: (film) 2981 (m), 1782 (s), 1716 (s), 1456 (m), 1369 (s), 1251 (s), 
1149 (s). δH (400 MHz, CDCl3) 5.50 – 5.32 (2H, m, C4-H and C5-H), 3.56 (2H, br s, C1-H2), 2.03 (2H, 
dt, J = 7.0, 6.5 Hz, C3-H2), 1.70 – 1.60 (5H, m, C2-H2 and C6-H3), 1.53 (9H, s, OC(CH3)3), 1.47 (9H, 
s, OC(CH3)3). δC (101 MHz, CDCl3) 155.0 (C=O), 152.5 (C=O), 130.3 (C5), 125.9 (C4), 84.8 
(OC(CH3)3), 82.3 (OC(CH3)3), 49.8 (C1), 29.7 (C3), 28.3 (OC(CH3)3), 27.8 (OC(CH3)3), 27.0 (C2), 
18.1 (C6). HRMS: (ESI+) Calculated for C16H29NNaO5: 338.1938. Found [M+Na]+: 338.1954. 
(E)-N-(Hex-4-en-1-yl)hydroxylammonium trifluoroacetate (245) 
 
The preceding compound (2.86 g, 9.01 mmol) was dissolved in TFA (10 mL) and left to stand for 
4 hours before being concentrated in vacuo to afford 245 (1.67 g, 81 %) as a colourless crystalline solid. 
νmax / cm-1: (solid) 2848 (m), 1678 (s), 1656 (s), 1600 (s), 1447 (s), 1184 (s), 1146 (s). δH (400 MHz, 
CDCl3) 11.27 – 9.98 (1H, br s, OH), 9.25 – 7.90 (2H, br s, NH2), 5.50 (1H, dqt, J = 15.0, 6.5, 1.5 Hz, 
C5-H), 5.41 – 5.28 (1H, m, C4-H), 3.24 – 3.19 (2H, m, C1-H2), 2.09 (2H, br dt, J = 7.0, 7.0 Hz, C3-H2), 
1.81 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.65 (3H, dq, J = 6.5, 1.5 Hz, C6-H3). δC (101 MHz, CDCl3) 128.5 
(C4), 127.8 (C5), 51.0 (C1), 29.3 (C3), 23.2 (C2), 18.0 (C6). The 13C signals corresponding to the 
trifluoroacetate counterion could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -75.6 (3F). HRMS: (ESI+) Calculated for C6H14NO: 116.1070. Found [M–F3CCO2]+: 116.1067. 
(E)-N-(Hex-4-en-1-yl)-N-hydroxybenzamide 
 
To a solution of 245 (200 mg, 0.873 mmol) and K2CO3 (156 mg, 1.13 mmol) in THF (2 mL) and H2O 
(2 mL) at 0 °C was added a solution of BzCl (0.12 mL, 1.05 mmol) in THF (1 mL). The reaction 
mixture was stirred at room temperature for 3.5 hours before addition of water (10 mL) and extraction 
with Et2O (3 × 15 mL). The combined organic phases were dried over Na2SO4 and concentrated in 
vacuo. FCC (gradient elution: 9:1 – 4:1 – 1:1 hexane:EtOAc) afforded the title compound (112 mg, 
59 %) as an orange oil. νmax / cm-1: (film) 3163 (br s), 2934 (m), 1691 (m), 1598 (s), 1450 (s).  
δH (400 MHz, CDCl3) 9.19 – 7.89 (1H, br s, OH), 7.52 – 7.39 (5H, m, 5 × ArCH), 5.38 – 5.22 (2H, m, 
C4-H and C5-H), 3.63 (2H, t, J = 7.0 Hz, C1-H2), 1.94 (2H, br td, J = 7.0, 6.5 Hz, C3-H2), 1.79 (2H, tt, 
J = 7.5, 7.0 Hz, C2-H2), 1.56 (3H, ddt, J = 6.0, 1.5, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 167.0 (C=O), 
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132.6 (ArC), 130.9 (ArCH), 129.7 (C4), 128.6 (ArCH), 127.9 (ArCH), 126.2 (C5), 50.3 (C1), 29.3 (C3), 
27.3 (C2), 18.0 (C6). HRMS: (ESI+) Calculated for C13H18NO2: 220.1332. Found [M+H]+: 220.1334. 
(E)-N-(Hex-4-en-1-yl)-N-((pentafluorobenzoyl)oxy)benzamide (243b) 
 
General procedure C: The preceding compound (111 mg, 0.506 mmol) was employed. FCC (two 
times, first eluent: 14:1 hexane:EtOAc; second eluent, gradient elution: 1:9 – 0:1 hexane:PhMe) 
afforded 243b (102 mg, 49 %) as a pale-yellow oil. νmax / cm-1: (film) 2936 (m), 1779 (s), 1680 (s), 
1498 (s), 1173 (s). δH (400 MHz, CDCl3) 7.62 – 7.58 (2H, m, 2 × ArCH), 7.51 – 7.45 (1H, m, ArCH), 
7.43 – 7.38 (2H, m, 2 × ArCH), 5.49 – 5.31 (2H, m, C4-H and C5-H), 3.83 (2H, t, J = 7.5 Hz, C1-H2), 
2.07 (2H, br dt, J = 7.0, 7.0 Hz, C3-H2), 1.80 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.61 (3H, ddt, J = 6.0, 
1.0, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 170.6 (Bz C=O), 157.3 (FBz C=O), 133.2 (ArC), 131.5 
(ArCH), 129.6 (C4), 128.5 (ArCH), 128.0 (ArCH), 126.5 (C5), 50.8 (C1), 29.5 (C3), 27.0 (C2), 18.0 
(C6). The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. δF (377 MHz, CDCl3) -135.7 – -136.0 (2F, m), -145.6 (1F, t, J = 22.0 Hz), 




To a solution of 245 (2.08 g, 9.08 mmol) and K2CO3 (627 mg, 4.54 mmol) in THF (10 mL) and H2O 
(10 mL) at 0 °C was added a solution of Boc2O (2.18 g, 10.0 mmol) in THF (20 mL). The reaction 
mixture was stirred at room temperature for 3 hours before being concentrated to an aqueous solution. 
The reaction mixture was suspended in CH2Cl2 (50 mL) and washed with water (2 × 30 mL) followed 
by brine (30 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. FCC (gradient 
elution: 8:1 – 6:1 – 4:1 hexane:EtOAc) afforded the title compound (951 mg, 49 %) as an orange oil. 
νmax / cm-1: (film) 3226 (br s), 2934 (m), 1690 (s), 1367 (s), 1164 (s). δH (400 MHz, CDCl3) 7.10 – 6.56 
(1H, m, OH), 5.51 – 5.36 (2H, m, C4-H and C5-H), 3.52 – 3.42 (2H, m, C1-H2), 2.00 (1H, dt, J = 6.5, 
6.0 Hz, C3-H2), 1.72 – 1.61 (5H, m, C2-H2 and C6-H3), 1.48 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 
157.1 (C=O), 130.5 (C4), 125.7 (C5), 81.8 (OC(CH3)3), 49.6 (C1), 29.6 (C3), 28.5 (OC(CH3)3), 26.9 
(C2), 18.1 (C6). HRMS: (ESI+) Calculated for C11H21NNaO3: 238.1414. Found [M+Na]+: 238.1411. 
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tert-Butyl (E)-hex-4-en-1-yl((pentafluorobenzoyl)oxy)carbamate (243c) 
 
General procedure C: The preceding compound (918 mg, 4.26 mmol) was employed. FCC (eluent: 
29:1 hexane:EtOAc) afforded 243c (1.82 g, 99 %) as a colourless oil. νmax / cm-1: (film) 2982 (m), 
2938 (m), 1783 (s), 1721 (s), 1653 (m), 1504 (s), 1155 (s). δH (400 MHz, CDCl3) 5.51 – 5.35 (2H, m, 
C4-H and C5-H), 3.69 – 3.63 (2H, m, C1-H2), 2.06 (2H, dt, J = 7.5, 6.5 Hz, C3-H2), 1.73 – 1.62 (5H, 
m, C2-H2 and C6-H3), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 157.5 (FBz C=O), 154.7 
(Boc C=O), 129.9 (C4), 126.2 (C5), 83.3 (OC(CH3)3), 50.6 (C1), 29.5 (C3), 28.2 (OC(CH3)3), 26.8 
(C2), 18.0 (C6). The aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.4 – -136.6 (2F, m), -146.7 (1F, tt, J = 




This compound was prepared according to a literature procedure.164 To a solution of BocNHOH (6.66 g, 
50.0 mmol) in CH2Cl2 (150 mL) at 0 °C was added FBzCl (6.90 mL, 50.0 mmol) followed by Et3N 
(7.00 mL, 50.0 mmol). The reaction mixture was stirred at room temperature for 3 hours before addition 
of water (100 mmol). The resulting phases were separated, and the aqueous phase was extracted with 
CH2Cl2 (70 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. 
FCC (eluent: 9:1 hexane:EtOAc) afforded BocNHOFBz (14.7 g, 90 %) as a colourless crystalline solid. 
m.p. 72-74 °C (CH2Cl2:petrol, cubes). νmax / cm-1: (solid) 3270 (br s), 2996 (m), 1779 (s), 1719 (s), 
1654 (s), 1505 (s), 1152 (s). δH (301 MHz, CDCl3) 8.10 (1H, s, NH), 1.52 (9H, s, OC(CH3)3).  
δC (101 MHz, CDCl3) 154.9 (Boc C=O), 84.4 (OC(CH3)3), 28.1 (OC(CH3)3). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (283 MHz, CDCl3) -135.3 – -135.5 (2F, m), -145.5 (1F, tt, J = 21.0, 5.5 Hz), -159.1 – -159.4 (2F, m). 
HRMS: (ESI+) Calculated for C12H10F5NNaO4: 350.0422. Found [M+Na]+: 350.0433. The 
spectroscopic properties were consistent with the data available in the literature.164 
  





General procedure L: Hept-1-en-3-ol (5.71 g, 50.0 mmol) was employed. The reaction time was 
14 hours. FCC (eluent: 49:1 hexane:EtOAc) afforded the title compound (7.10 g, 77 %) as a colourless 
oil. νmax / cm-1: (film) 2959 (m), 2927 (m), 1735 (s), 1446 (m), 1150 (s). δH (400 MHz, CDCl3) 5.51 – 
5.33 (2H, m, C4-H and C5-H), 4.12 (2H, q, J = 7.0 Hz, OCH2CH3), 2.38 – 2.26 (4H, m, C2-H2 and 
C3-H2), 1.97 (2H, dt, J = 6.5, 6.5 Hz, C6-H2), 1.35 – 1.26 (4H, m, C7-H2 and C8-H2), 1.25 (3H, t, J = 
7.0 Hz, OCH2CH3), 0.90 – 0.85 (3H, m, C9-H3). δC (101 MHz, CDCl3) 173.3 (C1), 131.9 (C5), 128.0 
(C4), 60.3 (OCH2CH3), 34.5 (C2), 32.3 (C6), 31.7 (C7), 28.1 (C3), 22.2 (C8), 14.4 (OCH2CH3), 14.0 
(C9). HRMS: (ESI+) Calculated for C11H20NaO2: 207.1356. Found [M+Na]+: 207.1354.  
(E)-Non-4-en-1-ol 
 
General procedure I: The preceding ester (7.10 g, 38.5 mmol) was employed, using anhydrous Et2O 
as solvent and 0.8 eq. LiAlH4 (1.0 M in Et2O). The title compound (5.42 g, 99 %) was isolated as a 
colourless oil. δH (400 MHz, CDCl3) 5.49 – 5.36 (2H, m), 3.65 (2H, t, J = 6.5 Hz), 2.07 (2H, dt, J = 7.0, 
7.0 Hz), 1.98 (2H, dt, J = 6.0, 6.0 Hz), 1.63 (2H, tt, J = 7.0, 6.5 Hz), 1.39 – 1.23 (5H, m), 0.88 (3H, t, 
J = 7.0 Hz). δC (101 MHz, CDCl3) 131.4, 129.5, 62.7, 32.6, 32.4, 31.9, 29.1, 22.3, 14.1. The 
spectroscopic properties were consistent with the data available in the literature.257 
tert-Butyl (E)-non-4-en-1-yl((pentafluorobenzoyl)oxy)carbamate (246a) 
 
General procedure O: (E)-Non-4-en-1-ol (vide supra, 213 mg, 1.50 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 23 hours. FCC (eluent: 1:1 petrol:PhMe) afforded 
246a (450 mg, 66 %) as a colourless oil. νmax / cm-1: (film) 2931 (m), 1784 (s), 1722 (s), 1652 (m), 
1505 (s), 1154 (s). δH (400 MHz, CDCl3) 5.51 – 5.34 (2H, m, C4-H and C5-H), 3.69 (2H, t, J = 7.0 Hz, 
C1-H2), 2.09 (2H, td, J = 7.5, 7.0 Hz, C3-H2), 2.00 (2H, dt, J = 8.0, 6.0 Hz, C6-H2), 1.72 (2H, tt, J = 
7.5, 7.0 Hz, C2-H2), 1.52 (9H, s, OC(CH3)3), 1.39 – 1.26 (4H, m, C7-H2 and C8-H2), 0.94 – 0.87 (3H, 
m, C9-H3). δC (101 MHz, CDCl3) 154.6 (Boc C=O), 131.7 (C5), 128.5 (C4), 83.2 (OC(CH3)3), 50.5 
(C1), 32.2 (C6), 31.7 (C7), 29.4 (C3), 28.0 (OC(CH3)3), 26.8 (C2), 22.2 (C8), 13.9 (C9). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
Chapter 7 - Experimental 
250 
 
δF (377 MHz, CDCl3) -136.4 – -136.7 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.4 – -159.6 (2F, m). 
HRMS: (ESI+) Calculated for C21H26F5NNaO4: 474.1674. Found [M+Na]+: 474.1658.  
tert-Butyl (E)-2-(pent-1-en-1-yl)pyrrolidine-1-carboxylate (247a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 246a 
(47.4 mg, 0.105 mmol) was employed. FCC (gradient elution: 39:1 – 19:1 PhMe:EtOAc) afforded 247a 
(21.4 mg, 85 %) as a pale-yellow oil. νmax / cm-1: (film) 2964 (m), 2928 (m), 1692 (s), 1389 (s), 1167 (s). 
δH (400 MHz, CDCl3) 5.52 – 5.37 (1H, m, C6-H), 5.37 – 5.22 (1H, m, C5-H), 4.38 – 4.10 (1H, m, 
C4-H), 3.46 – 3.23 (2H, m, C1-H2), 2.01 – 1.92 (3H, m, C3-H and C7-H2), 1.89 – 1.74 (2H, m, C2-H2), 
1.65 (1H, dddd, J = 12.5, 6.0, 3.0, 3.0 Hz, C3-H’), 1.46 – 1.31 (11H, m, C8-H2 and OC(CH3)3), 0.88 
(3H, t, J = 7.5 Hz, C9-H3). δC (101 MHz, CDCl3) 154.8 (C=O), 130.8 (C5), 130.2 (C6), 79.0 
(OC(CH3)3), 58.7 (C4), 46.2 (C1), 34.4 (C7), 32.6 (C3), 28.7 (OC(CH3)3), 23.0 (C2), 22.6 (C8), 13.8 
(C9). HRMS: (ESI+) Calculated for C14H25NNaO2: 262.1777. Found [M+Na]+: 262.1776.  
1,3,5,7-Tetramethyl-8-(4-(trifluoromethyl)phenyl)-2,4,6-trioxa-8-phosphaadamantane (L2) 
 
General procedure P: 1,3,5,7-Tetramethyl-2,4,6-trioxa-8-phosphaadamantane (248)XLIV (1.30 g, 
6.00 mmol) was employed with 1-bromo-4-(trifluoromethyl)benzene (0.70 mL, 5.00 mmol). The 
reaction time was 20 hours. FCC (gradient elution: 1:9 – 0:1 hexane:PhMe) afforded L2 (1.34 g, 74 %) 
as a colourless crystalline solid. m.p. 132-133 °C (CH2Cl2:petrol, plates). νmax / cm-1: (solid) 3005 (m), 
2920 (m), 1606 (m), 1322 (s), 1119 (s). δH (400 MHz, CDCl3) 7.96 (2H, ddq, J = 8.5, 7.5, 1.0 Hz, 
2 × ArCH), 7.61 (2H, dq, J = 7.5, 1.0 Hz, 2 × ArCH), 2.06 (1H, dd, J = 13.5, 7.5 Hz, C3-H), 1.94 (1H, 
dd, J = 24.5, 13.5 Hz, C3-H’), 1.66 (1H, d, J = 13.5 Hz, C3’-H), 1.52 (3H, d, J = 13.0 Hz, C1-H3), 1.50 
(1H, dd, J = 13.5, 4.0 Hz, C3’-H’), 2 × 1.42 (3H, s, C5-H3 and 3H, s, C5’-H3), 1.26 (3H, d, J = 13.0 Hz, 
C1’-H3). δC (101 MHz, CDCl3) 139.2 (d, J = 31.0 Hz, ArC), 135.2 (d, J = 19.5 Hz, ArCH), 131.3 (q, 
J = 32.5 Hz, ArC), 124.9 (dq, J = 7.5, 3.5 Hz, ArCH), 96.8 (C4), 96.1 (C4’), 73.3 (d, J = 22.5 Hz, C2), 
                                                     
XLIV Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 
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73.1 (d, J = 8.0 Hz, C2’), 45.1 (d, J = 17.5 Hz, C3), 36.3 (d, J = 2.0 Hz, C3’), 28.0 (C5’), 27.7 (C5), 
27.4 (d, J = 22.0 Hz, C1’), 26.8 (d, J = 11.0 Hz, C1). The 13C signal corresponding to the trifluoromethyl 
group could not be resolved due to its weak intensity. δF (377 MHz, CDCl3) -63.0 (3F). δP (162 MHz, 
CDCl3) -25.0. HRMS: (ESI+) Calculated for C17H21F3O3P: 361.1175. Found [M+H]+: 361.1174. 
Ethyl 4-(1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantan-8-yl)benzoate (L3) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed ethyl 
4-bromobenzoate. The reaction time was 16 hours. FCC (eluent: 39:1 pentane:acetone) afforded L3 
(636 mg, 87 %) as a colourless crystalline solid. m.p. 114-116 °C (CH2Cl2:petrol, cubes).  
νmax / cm-1: (solid) 2985 (m), 2917 (m), 1715 (s), 1596 (m), 1371 (s), 1262 (s). δH (400 MHz, CDCl3) 
8.02 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.91 (2H, dd, J = 8.0, 7.0 Hz, 2 × ArCH), 4.39 (2H, q, J = 7.0 Hz, 
OCH2CH3), 2.06 (1H, dd, J = 13.5, 7.5 Hz, C3-H), 1.94 (1H, dd, J = 24.5, 13.5 Hz, C3-H’), 1.67 (1H, 
d, J = 13.5 Hz, C3’-H), 1.53 (3H, d, J = 13.0 Hz, C1-H3), 1.47 (1H, dd, J = 13.5, 4.0 Hz, C3’-H’), 1.43 
– 1.37 (9H, m, C5-H3, C5’-H3 and OCH2CH3), 1.25 (3H, d, J = 13.0 Hz, C1’-H3). δC (101 MHz, CDCl3) 
166.5 (C=O), 140.3 (d, J = 30.5 Hz, ArC), 135.0 (d, J = 19.5 Hz, ArCH), 131.3 (ArC), 129.2 (d, J = 
7.0 Hz, ArCH), 97.0 (C4), 96.2 (C4’), 2 × 73.4 (d, J = 22.0 Hz, C2 and d, J = 8.0 Hz, C2’), 61.3 
(OCH2CH3), 45.3 (d, J = 17.5 Hz, C3), 36.5 (d, J = 2.0 Hz, C3’), 28.1 (C5’), 27.9 (C5), 27.6 (d, J = 
21.5 Hz, C1’), 27.0 (d, J = 11.0 Hz, C1), 14.5 (OCH2CH3). δP (162 MHz, CDCl3) -24.6. HRMS: (ESI+) 
Calculated for C19H25NaO5P: 387.1332. Found [M+Na]+: 387.1333.  
8-(3,5-Bis(trifluoromethyl)phenyl)-1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantane (L6) 
 
General procedure P: 1,3,5,7-Tetramethyl-2,4,6-trioxa-8-phosphaadamantane (248)XLV (1.30 g, 
6.00 mmol) was employed with 1-bromo-3,5-bis(trifluoromethyl)benzene (0.88 mL, 5.00 mmol). The 
reaction time was 20 hours. FCC (eluent: 1:9 hexane:PhMe) afforded L6 (891 mg, 42 %) as a colourless 
                                                     
XLV Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 
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crystalline solid. m.p. 133-134 °C (CH2Cl2:petrol, needles). νmax / cm-1: (solid) 2980 (m), 2940 (m), 
1615 (m), 1357 (s), 1276 (s), 1124 (s). δH (400 MHz, CDCl3) 8.33 (2H, br d, J = 6.0 Hz, 2 × ArCH), 
7.88 (1H, br s, ArCH), 2.05 (1H, dd, J = 13.5, 8.0 Hz, C3-H), 1.96 (1H, dd, J = 24.5, 13.5 Hz, C3-H’), 
1.55 – 1.53 (2H, m, C3’-H2), 1.51 (3H, d, J = 13.0 Hz, C1-H3), 1.43 (3H, s, C5-H3), 1.41 (3H, s, C5’-H3), 
1.26 (3H, d, J = 13.5 Hz, C1’-H3). δC (101 MHz, CDCl3) 138.4 (d, J = 35.5 Hz, ArC), 135.1 (d, J = 
19.5 Hz, ArCH), 131.6 (d, J = 33.5 Hz, ArC), 123.3 (ArCH), 97.1 (C4), 96.2 (C4’), 73.4 (d, J = 22.0 Hz, 
C2), 73.2 (d, J = 8.0 Hz, C2’), 45.1 (d, J = 17.5 Hz, C3), 36.3 (C3’), 28.0 (C5’), 27.8 (C5), 27.5 (d, J = 
22.0 Hz, C1), 26.9 (d, J = 11.0 Hz, C1’). The 13C signal corresponding to the trifluoromethyl groups 
could not be resolved due to its weak intensity. δF (377 MHz, CDCl3) -63.0 (6F). δP (162 MHz, CDCl3) 
-26.2. HRMS: (ESI+) Calculated for C18H20F6O3P: 429.1049. Found [M+H]+: 429.1031. 
8-(4-Fluorophenyl)-1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantane (L8) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 
1-bromo-4-fluorobenzene. The reaction time was 20 hours. FCC (two times: first, gradient elution: 12:1 
– 6:1 – 2:1 hexane:EtOAc; second, gradient elution: 1:4 – 0:1 hexane:PhMe) afforded L8 (178 mg, 
29 %) as a colourless crystalline solid. m.p. 103-104 °C (CH2Cl2:petrol, tabular). νmax / cm-1: (solid) 
2924 (m), 1587 (s), 1494 (s), 1379 (s), 1160 (s). δH (400 MHz, CDCl3) 7.85 – 7.78 (2H, m, 2 × ArCH), 
7.10 – 7.04 (2H, m, 2 × ArCH), 2.05 (1H, dd, J = 13.0, 7.0 Hz, C3-H), 1.93 (1H, dd, J = 25.0, 13.0 Hz, 
C3-H’), 1.73 (1H, d, J = 13.5 Hz, C3’-H), 1.57 – 1.47 (1H, m, C3’-H’), 1.49 (3H, d, J = 13.0 Hz, C1-H3), 
1.42 (3H, s, C5-H3), 1.41 (3H, s, C5’-H3), 1.23 (3H, d, J = 13.0 Hz, C1’-H3). δC (126 MHz, CDCl3) 
163.9 (d, J = 250.0 Hz, ArCF), 137.2 (dd, J = 21.0, 8.0 Hz, ArCH), 129.5 (dd, J = 27.5, 3.5 Hz, ArC), 
115.8 (dd, J = 20.5, 8.0 Hz, ArCH), 97.0 (C4), 96.2 (C4’), 73.5 (d, J = 21.5 Hz, C2), 73.1 (d, J = 7.5 Hz, 
C2’), 45.5 (d, J = 17.5 Hz, C3), 36.2 (d, J = 2.0 Hz, C3’), 28.2 (C5’), 27.9 (C5), 27.5 (d, J = 22.0 Hz, 
C1’), 26.9 (d, J = 11.5 Hz, C1). δF (377 MHz, CDCl3) -110.9 (1F, d, J = 3.0 Hz). δP (162 MHz, CDCl3) 
-25.7. HRMS: (ESI+) Calculated for C16H21FO3P: 311.1207. Found [M+H]+: 311.1216. 
  





General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 
4-bromobenzonitrile. The reaction time was 19 hours. FCC (gradient elution: 14:1 – 9:1 hexane:EtOAc) 
afforded L9 (133 mg, 21 %) as a colourless crystalline solid. m.p. 185-187 °C (CH2Cl2:petrol, equant). 
νmax / cm-1: (solid) 2973 (m), 2914 (m), 2227 (m), 1593 (m), 1381 (s), 1184 (s). δH (500 MHz, CDCl3) 
7.96 (2H, dd, J = 8.0, 6.5 Hz, 2 × ArCH), 7.64 (2H, d, J = 8.0 Hz, 2 × ArCH), 2.04 (1H, dd, J = 13.5, 
7.5 Hz, C3-H), 1.95 (1H, dd, J = 25.0, 13.5 Hz, C3-H’), 1.60 (1H, d, J = 13.5 Hz, C3’-H), 1.54 – 1.48 
(4H, m, C1-H3 and C3’-H’), 1.42 (3H, s, C5-H3), 1.41 (3H, s, C5’-H3), 1.26 (3H, d, J = 13.0 Hz, C1’-H3). 
δC (126 MHz, CDCl3) 141.2 (d, J = 33.5 Hz, ArC), 135.5 (d, J = 19.5 Hz, ArCH), 131.7 (d, J = 7.0 Hz, 
ArCH), 118.6 (ArC), 113.2 (C≡N), 97.0 (C4), 96.2 (C4’), 2 × 73.4 (d, J = 22.5 Hz, C2 and d, J = 8.0 Hz, 
C2’), 45.1 (d, J = 17.5 Hz, C3), 36.5 (d, J = 2.0 Hz, C3’), 28.1 (C5’), 27.8 (C5), 27.6 (d, J = 22.0 Hz, 
C1’), 26.9 (d, J = 11.5 Hz, C1). δP (162 MHz, CDCl3) -24.4. HRMS: (ESI+) Calculated for 
C17H20NNaO3P: 340.1073. Found [M+Na]+: 340.1082. 
1,3,5,7-Tetramethyl-8-(3,4,5-trifluorophenyl)-2,4,6-trioxa-8-phosphaadamantane (L11) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 1-bromo-3,4,5-
trifluorobenzene. The reaction time was 20 hours. FCC (two times: first, gradient elution: 39:1 – 19:1 
– 9:1 hexane:EtOAc; second, gradient elution: 1:9 – 0:1 hexane:PhMe) afforded L11 (223 mg, 32 %) 
as a colourless crystalline solid. νmax / cm-1: (solid) 3086 (m), 2934 (m), 1607 (s), 1518 (s), 1214 (s), 
1039 (s). δH (400 MHz, CDCl3) 7.50 (2H, dt, J = 8.0, 6.5 Hz, 2 × ArCH), 2.01 (1H, dd, J = 13.5, 8.0 Hz, 
C3-H), 1.93 (1H, dd, J = 24.5, 13.5 Hz, C3-H’), 1.68 (1H, d, J = 13.5 Hz, C3’-H), 1.55 – 1.50 (1H, m, 
C3’-H’), 1.47 (3H, d, J = 13.0 Hz, C1-H3), 1.42 (3H, s, C5-H3), 1.41 (3H, s, C5’-H3), 1.25 (3H, d, J = 
13.0 Hz, C1’-H3). δC (126 MHz, CDCl3) 151.1 (br d, J = 253.5 Hz, ArCF), 140.8 (br d, J = 255.5 Hz, 
ArCF), 130.7 (d, J = 39.0 Hz, ArC), 119.0 (d, J = 21.0 Hz, ArCH), 97.0 (C4), 96.2 (C4’), 73.4 (d, J = 
2.0 Hz, C2), 73.1 (d, J = 8.0 Hz, C2’), 45.2 (d, J = 17.5 Hz, C3), 36.3 (d, J = 2.0 Hz, C3’), 28.1 (C5’), 
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27.8 (C5), 27.6 (d, J = 22.0 Hz, C1’), 26.8 (d, J = 11.0 Hz, C1). δF (377 MHz, CDCl3) -133.3 (2F, d, 
J = 20.5 Hz), -157.8 (1F, t, J = 20.5 Hz). δP (162 MHz, CDCl3) -24.5. HRMS: (ESI+) Calculated for 
C16H19F3O3P: 347.1018. Found [M+H]+: 347.1024. 
1,3,5,7-Tetramethyl-8-(4-acetylphenyl)-2,4,6-trioxa-8-phosphaadamantane (L13) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 
4-bromoacetophenone. The reaction time was 14 hours. FCC (gradient elution: 29:1 – 
19:1 PhMe:EtOAc) afforded L13 (527 mg, 79 %) as a colourless crystalline solid. m.p. 108-111 °C 
(CH2Cl2:petrol, tabular) [Lit., 107.5-110.5 °C (No recrystallisation solvent quoted)].149 δH (400 MHz, 
CDCl3) 7.97 – 7.90 (4H, m), 2.61 (3H, s), 2.05 (1H, dd, J = 13.5, 7.0 Hz), 1.94 (1H, dd, J = 24.5, 
13.5 Hz), 1.66 (1H, d, J = 13.5 Hz), 1.53 (3H, d, J = 12.5 Hz), 1.48 (1H, dd, J = 13.5, 4.5 Hz), 1.42 
(3H, s), 1.41 (3H, s), 1.26 (3H, d, J = 13.0 Hz). δC (101 MHz, CDCl3) 198.0, 140.8 (d, J = 31.0 Hz), 
137.6, 135.2 (d, J = 19.5 Hz), 127.9 (d, J = 7.0 Hz), 97.0, 96.2, 2 × 73.4 (d, J = 22.0 Hz and d, J = 
8.0 Hz), 45.3 (d, J = 17.0 Hz), 36.6 (d, J = 2.0 Hz), 28.1, 27.9, 27.6 (d, J = 22.0 Hz), 27.0 (d, J = 
11.5 Hz), 26.8. δP (162 MHz, CDCl3) -24.6. The spectroscopic properties were consistent with the data 
available in the literature.149 
1,3,5,7-Tetramethyl-8-(thiophen-2-yl)-2,4,6-trioxa-8-phosphaadamantane (L14) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 
2-bromothiophene. The reaction time was 17 hours. FCC (eluent: PhMe) afforded L14 (323 mg, 54 %) 
as a colourless crystalline solid. m.p. 92-94 °C (CH2Cl2:petrol, plates). νmax / cm-1: (solid) 3100 (m), 
2962 (m), 2911 (m), 1450 (m), 1380 (s), 1343 (s), 1212 (s). δH (400 MHz, CDCl3) 7.64 (1H, dd, J = 5.0, 
1.0 Hz, ArCH), 7.53 (1H, ddd, J = 7.0, 3.5, 1.0 Hz, ArCH), 7.13 (1H, ddd, J = 5.0, 3.5, 1.5 Hz, ArCH), 
2.11 (1H, d, J = 13.5 Hz, C3’-H), 2.05 (1H, dd, J = 13.0, 7.5 Hz, C3-H), 1.96 (1H, dd, J = 25.0, 13.0 Hz, 
C3-H’), 1.54 (1H, dd, J = 13.5, 4.5 Hz, C3’-H’), 1.45 (3H, s, C5-H3), 1.42 (3H, s, C5’-H3), 1.40 (3H, d, 
J = 13.0 Hz, C1-H3), 1.26 (3H, d, J = 14.0 Hz, C1’-H3). δC (101 MHz, CDCl3) 139.2 (d, J = 29.5 Hz, 
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ArCH), 132.9 (ArCH), 132.0 (d, J = 45.5 Hz, ArC), 127.5 (d, J = 9.5 Hz, ArCH), 97.0 (C4), 96.4 (C4’), 
2 × 73.2 (d, J = 18.0 Hz, C2 and d, J = 7.0 Hz, C2’), 45.0 (d, J = 18.0 Hz, C3), 37.0 (d, J = 2.0 Hz, C3’), 
28.1 (C5’), 27.9 (C5), 27.7 (d, J = 23.5 Hz, C1’), 27.1 (d, J = 11.0 Hz, C1). δP (162 MHz, CDCl3) -34.3. 
HRMS: (ESI+) Calculated for C14H20O3PS: 299.0865. Found [M+H]+: 299.0874.  
1,3,5,7-Tetramethyl-8-(5-acetylthiophen-2-yl)-2,4,6-trioxa-8-phosphaadamantane (L15) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 2-acetyl-5-
bromothiophene. The reaction time was 22 hours. FCC (gradient elution: 99:1 – 49:1 PhMe:acetone) 
afforded L15 (377 mg, 55 %) as a colourless crystalline solid. m.p. 104-105 °C (CH2Cl2:petrol, 
tabular). νmax / cm-1: (solid) 2969 (m), 2915 (m), 1662 (s), 1514 (m), 1213 (s). δH (400 MHz, CDCl3) 
7.66 (1H, dd, J = 4.0, 1.0 Hz, ArCH), 7.50 (1H, dd, J = 6.5, 4.0 Hz, ArCH), 2.56 (3H, s, C(O)CH3), 
2.06 – 1.90 (3H, m, C3-H2 and C3’-H), 1.56 (1H, dd, J = 13.5, 4.5 Hz, C3’-H’), 1.45 (3H, s, C5-H3), 
1.43 (3H, d, J = 13.0 Hz, C1-H3), 1.41 (3H, s, C5’-H3), 1.29 (3H, d, J = 14.0 Hz, C1’-H3). δC (101 MHz, 
CDCl3) 190.4 (C(O)CH3), 150.0 (ArC), 142.3 (d, J = 51.0 Hz, ArC), 138.9 (d, J = 28.0 Hz, ArCH), 
132.0 (d, J = 8.5 Hz, ArCH), 96.9 (C4), 96.2 (C4’), 73.2 (d, J = 8.0 Hz, C2’), 72.9 (d, J = 19.0 Hz, C2), 
44.5 (d, J = 17.5 Hz, C3), 36.8 (d, J = 2.0 Hz, C3’), 27.9 (C5’), 27.7 (C5), 27.6 (d, J = 23.0 Hz, C1’), 
27.2 (C(O)CH3), 27.0 (d, J = 11.0 Hz, C1). δP (162 MHz, CDCl3) -32.4. HRMS: (ESI+) Calculated for 
C16H22O4PS: 341.071. Found [M+H]+: 341.0980. 
1,3,5,7-Tetramethyl-8-(4-nitrophenyl)-2,4,6-trioxa-8-phosphaadamantane (L16) 
 
General procedure P: The reaction was conducted on a 2.00 mmol scale and employed  
1-bromo-4-nitrobenzene. The reaction time was 40 hours. FCC (gradient elution: 29:1 – 
19:1 hexane:acetone) afforded L16 (257 mg, 38 %) as a pale-yellow crystalline solid. m.p. 168-170 °C 
(CH2Cl2:petrol, plates). νmax / cm-1: (solid) 3099 (m), 2969 (m), 1593 (s), 1517 (s), 1344 (s).  
δH (400 MHz, CDCl3) 8.22 – 8.17 (2H, m), 8.06 – 7.99 (2H, m), 2.05 (1H, dd, J = 13.5, 7.5 Hz), 1.96 
(1H, dd, J = 24.5, 13.5 Hz), 1.59 (1H, d, J = 13.5 Hz), 1.53 (3H, d, J = 13.0 Hz), 1.51 (1H, dd, J = 13.5, 
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4.0 Hz), 2 × 1.42 (2 × 3H, s), 1.28 (3H, d, J = 13.0 Hz). δC (101 MHz, CDCl3) 148.6, 143.7 (d, J = 
34.0 Hz), 135.9 (d, J = 19.5 Hz), 123.1 (d, J = 7.0 Hz), 97.0, 96.3, 73.5 (d, J = 8.5 Hz), 73.4 (d, J = 
22.0 Hz), 45.1 (d, J = 17.5 Hz), 36.6 (d, J = 2.0 Hz), 28.1, 27.8, 27.6 (d, J = 21.5 Hz), 27.0 (d, J = 
11.0 Hz). δP (162 MHz, CDCl3) -24.8. HRMS: (ESI+) Calculated for C16H21NO5P: 338.1152. Found 




General procedure P: The reaction was conducted on a 2.00 mmol scale and employed 
4-bromobenzenesulfonamide. The reaction time was 21 hours. FCC (two times: first, gradient elution: 
7:3 – 6:4 – 0:1 hexane:EtOAc; second eluent: 2:1 PhMe:EtOAc) afforded L17 (302 mg, 41 %) as a 
pale-yellow crystalline solid. m.p. 225-226 °C (acetone:petrol, cubes). νmax / cm-1: (solid) 3366 (br s), 
3251 (br s), 2966 (m), 1557 (m), 1349 (s), 1167 (s). δH (400 MHz, CD3CN) 8.02 – 7.97 (2H, m, 
2 × ArCH), 7.88 – 7.84 (2H, m, 2 × ArCH), 5.73 (2H, br s, NH2), 2.03 (1H, dd, J = 13.5, 7.0 Hz, C3-H), 
1.89 (1H, dd, J = 25.0, 13.5 Hz, C3-H’), 1.64 (1H, d, J = 13.5 Hz, C3’-H), 1.47 (3H, d, J = 13.0 Hz, 
C1-H3), 1.45 (1H, dd, J = 13.5, 4.0 Hz, C3’-H’), 1.35 (3H, s, C5’-H3), 1.33 (3H, s, C5-H3), 1.20 (3H, d, 
J = 13.0 Hz, C1’-H3) δC (126 MHz, CDCl3) 145.0 (ArC), 140.7 (d, J = 31.5 Hz, ArC), 136.4 (d, J = 
20.0 Hz, ArCH), 126.6 (d, J = 7.0 Hz, ArCH), 97.7 (C4), 97.0 (C4’), 74.0 (d, J = 22.0 Hz, C2), 73.9 (d, 
J = 8.0 Hz, C2’), 45.8 (d, J = 17.5 Hz, C3), 36.9 (d, J = 2.0 Hz, C3’), 28.1 (C5’), 28.0 (C5), 27.8 (d, J = 
22.0 Hz, C1’), 27.0 (d, J = 11.5 Hz, C1). δP (162 MHz, CDCl3) -25.0. HRMS: (ESI+) Calculated for 
C16H22NNaO5PS: 394.0849. Found [M+Na]+: 394.0856. 
Isopropyl N-hydroxycarbamate 
 
To a suspension of NH2OH·HCl (5.00 g, 72.0 mmol) and K2CO3 (8.29 g, 60.0 mmol) in THF (120 mL) 
at 0 °C was added a solution of isopropyl chloroformate (1.0 M in PhMe, 60.0 mL, 60.0 mmol) 
dropwise over around 30 minutes. The reaction mixture was stirred at room temperature for 48 hours 
before being filtered; the filtrate was then concentrated in vacuo. FCC (eluent: 1:1 hexane:EtOAc) 
afforded the title compound (2.18 g, 31 %) as a colourless crystalline solid. νmax / cm-1: (film) 
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3290 (br s), 2984 (m), 2934 (m), 1704 (s), 1267 (s), 1103 (s). δH (400 MHz, CDCl3) 7.28 – 7.11 (2H, 
m, NH and OH), 4.99 (1H, hept, J = 6.5 Hz, OCH(CH3)2), 1.26 (6H, d, J = 6.5 Hz, OCH(CH3)2).  
δC (101 MHz, CDCl3) 159.4 (C=O), 70.5 (OCH(CH3)2), 22.1 (OCH(CH3)2). HRMS: (ESI+) Calculated 
for C4H9NNaO3: 142.0475. Found [M+Na]+: 142.0478. 
Isopropyl ((pentafluorobenzoyl)oxy)carbamate 
 
General procedure G: The preceding compound (2.00 g, 16.8 mmol) was employed. The reaction time 
was 18 hours. FCC (eluent: 9:1 hexane:EtOAc) afforded i-PrO(CO)NHOFBz (3.86 g, 73 %) as a 
colourless crystalline solid. m.p. 54-55 °C (CH2Cl2:petrol, columnar). νmax / cm-1: (solid) 3230 (br s), 
2988 (m), 1776 (s), 1717 (s), 1654 (m), 1489 (s), 1191 (s). δH (400 MHz, CDCl3) 8.22 (1H, s, NH),  
5.05 (1H, hept, J = 6.5 Hz, OCH(CH3)2), 1.30 (6H, d, J = 6.5 Hz, OCH(CH3)2). δC (101 MHz, CDCl3) 
155.5 (i-PrO–C=O), 71.9 (OCH(CH3)2), 21.7 (OCH(CH3)2). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.3 – -135.5 (2F, m), -145.3 (1F, tt, J = 21.0, 6.0 Hz), -159.1 – -159.2 (2F, m). HRMS: (ESI+) 
Calculated for C11H8F5NNaO4: 336.0266. Found [M+Na]+: 336.0281.  
Isopropyl (E)-non-4-en-1-yl((pentafluorobenzoyl)oxy)carbamate (246b) 
 
General procedure O: (E)-Non-4-en-1-ol (vide supra, 284 mg, 2.00 mmol) was employed with 
i-PrO(CO)NHOFBz (vide supra). The reaction time was 15 hours. FCC (gradient elution: 2:3 – 
1:4 hexane:PhMe) afforded 246b (550 mg, 63 %) as a pale-yellow oil. νmax / cm-1: (film) 2931 (m), 
1786 (s), 1724 (s), 1652 (m), 1505 (s), 1326 (s), 1172 (s). δH (400 MHz, CDCl3) 5.49 – 5.32 (2H, m, 
C4-H and C5-H), 5.01 (1H, hept, J = 6.5 Hz, OCH(CH3)2), 3.73 – 3.67 (2H, m, C1-H2), 2.11 – 2.03 
(2H, m, C3-H2), 2.02 – 1.94 (2H, m, C6-H2), 1.70 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.34 – 1.28 (4H, m, 
C7-H2 and C8-H2), 1.28 (6H, d, J = 6.5 Hz, OCH(CH3)2), 0.90 – 0.86 (3H, m, C9-H3). δC (101 MHz, 
CDCl3) 157.4 (FBz C=O), 155.4 (i-PrO–C=O), 132.0 (C5), 128.5 (C4), 71.4 (OCH(CH3)2), 50.6 (C1), 
32.4 (C6), 31.8 (C7), 29.5 (C3), 26.9 (C2), 22.3 (C8), 22.0 (OCH(CH3)2), 14.1 (C9). The aromatic 
13C 
signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.3 – -136.7 (2F, m), -146.5 (1F, tt, J = 21.0, 5.0 Hz), -159.2 – -159.4 
(2F, m). HRMS: (ESI+) Calculated for C20H24F5NNaO4: 460.1518. Found [M+Na]+: 460.1512.  
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Isopropyl (E)-2-(pent-1-en-1-yl)pyrrolidine-1-carboxylate (247b) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 246b 
(45.9 mg, 0.105 mmol) was employed. FCC (gradient elution: 29:1 – 19:1 PhMe:EtOAc) afforded 247b 
(18.5 mg, 78 %) as a pale-yellow oil. νmax / cm-1: (film) 2959 (m), 2928 (m), 1697 (s), 1403 (s), 1113 (s). 
δH (500 MHz, CDCl3) 5.59 – 5.42 (1H, m, C6-H), 5.41 – 5.26 (1H, m, C5-H), 4.92 (1H, hept, J = 6.5 Hz, 
OCH(CH3)2), 4.42 – 4.20 (1H, m, C4-H), 3.53 – 3.29 (2H, m, C1-H2), 2.04 – 1.96 (3H, m, C3-H and 
C7-H2), 1.92 – 1.79 (2H, m, C2-H2), 1.73 – 1.67 (1H, m, C3-H’), 1.39 (2H, tq, J = 7.5, 7.5 Hz, C8-H2), 
1.27 – 1.18 (6H, m, OCH(CH3)2), 0.90 (3H, t, J = 7.5 Hz, C9-H3). δC (126 MHz, CDCl3) 155.0 (C=O), 
2 × 130.4 (C5 and C6), 67.8 (OCH(CH3)2), 58.5 (C4), 46.2 (C1), 34.2 (C7), 32.4 (C3), 22.9 (C2), 2 × 
22.4 (C8 and OCH(CH3)(CH3)’), 22.3 (OCH(CH3)(CH3)’), 13.6 (C9). HRMS: (ESI+) Calculated for 
C13H23NNaO2: 248.1621. Found [M+Na]+: 248.1626.  
Methyl ((pentafluorobenzoyl)oxy)carbamate 
 
To a solution of methyl N-hydroxycarbamateXLVI (4.55 g, 50.0 mmol) in CH2Cl2 (150 mL) at 0 °C was 
added FBzCl (6.90 mL, 50.0 mmol) followed by Et3N (7.00 mL, 50.0 mmol). The reaction mixture was 
stirred at room temperature for 5 hours before addition of water (100 mmol). The resulting phases were 
separated, and the aqueous phase was extracted with CH2Cl2 (70 mL). The organic phase was dried over 
Na2SO4 and concentrated in vacuo. FCC (eluent: 4:1 hexane:EtOAc) afforded MeO(CO)NHOFBz 
(12.2 g, 86 %) as a colourless crystalline solid. m.p. 46-47 °C (CH2Cl2:petrol, prisms).  
νmax / cm-1: (solid) 3220 (br s), 2971 (m), 1794 (s), 1737 (s), 1654 (m), 1503 (s), 1169 (s). δH (400 MHz, 
CDCl3) 8.34 (1H, s, NH), 3.87 (3H, s, OCH3). δC (101 MHz, CDCl3) 156.5 (MeO–C=O), 54.1 (OCH3). 
The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -135.2 – -135.4 (2F, m), -145.2 (1F, tt, J = 21.0, 6.0 Hz), -159.2 – -159.4 
(1F, m). HRMS: (ESI+) Calculated for C9H4F5NNaO4: 307.9953. Found [M+Na]+: 307.9964.  
                                                     
XLVI Methyl N-hydroxycarbamate was prepared by Rafaela Carmona (University of Bristol) according to a 
reported procedure.108 
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Methyl (E)-non-4-en-1-yl((pentafluorobenzoyl)oxy)carbamate (246c) 
 
General procedure O: (E)-Non-4-en-1-ol (vide supra, 284 mg, 2.00 mmol) was employed with 
MeO(CO)NHOFBz (vide supra). The reaction time was 15 hours. FCC (two times, first eluent: 
1:4 hexane:PhMe; second eluent: 24:1 hexane:EtOAc) afforded 246c (413 mg, 50 %) as a colourless 
oil. νmax / cm-1: (film) 2930 (m), 1786 (s), 1730 (s), 1652 (m), 1498 (s), 1326 (s), 1172 (s). δH (400 MHz, 
CDCl3) 5.48 – 5.31 (2H, m, C4-H and C5-H), 3.81 (3H, s, OCH3), 3.74 – 3.69 (2H, m, C1-H2), 2.07 
(2H, dt, J = 7.0, 7.0 Hz, C3-H2), 2.01 – 1.94 (2H, m, C6-H2), 1.71 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.35 
– 1.26 (4H, m, C7-H2 and C8-H2), 0.91 – 0.85 (3H, m, C9-H3). δC (101 MHz, CDCl3) 157.4 (FBz C=O), 
156.2 (MeO–C=O), 132.0 (C5), 128.5 (C4), 54.0 (OCH3), 50.9 (C1), 32.4 (C6), 31.8 (C7), 29.5 (C3), 
26.8 (C2), 22.3 (C8), 14.1 (C9). The aromatic 13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -135.9 – -136.1 (2F, m), 
-146.1 (1F, tt, J = 20.5, 5.0 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C18H20F5NNaO4: 
432.1205. Found [M+Na]+: 432.1209.  
Methyl (E)-2-(pent-1-en-1-yl)pyrrolidine-1-carboxylate (247c) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 246c 
(43.0 mg, 0.105 mmol) was employed. FCC (eluent: 19:1 PhMe:EtOAc) afforded 247c (14.6 mg, 70 %) 
as a colourless oil. νmax / cm-1: (film) 2956 (m), 2873 (m), 1699 (s), 1447 (s), 1381 (s). The 
1H and 
13C NMR spectra were acquired at high temperature: δH (500 MHz, CD3CN, 65 °C) 5.57 – 5.48 (1H, 
m, C6-H), 5.43 (1H, ddt, J = 15.0, 6.0, 1.0 Hz, C5-H), 4.33 – 4.26 (1H, m, C4-H), 3.64 (3H, s, OCH3), 
3.42 – 3.37 (2H, m, C1-H2), 2.08 – 1.99 (3H, m, C3-H and C7-H2), 1.95 – 1.80 (2H, m, C2-H2), 1.71 
(1H, dddd, J = 12.0, 6.5, 4.0, 3.0 Hz, C3-H’), 1.43 (2H, tq, J = 7.5, 7.5 Hz, C8-H2), 0.93 (3H, t, J = 
7.5 Hz, C9-H3). δC (126 MHz, CD3CN, 65 °C) 155.1 (C=O), 130.9 (C5), 129.9 (C6), 58.6 (C4), 51.2 
(OCH3), 46.2 (C1), 33.8 (C7), 31.8 (C3), 22.9 (C2), 22.2 (C8), 12.7 (C9). HRMS: (ESI+) Calculated for 
C11H19NNaO2: 220.1308. Found [M+Na]+: 220.1303.  
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Benzyl (E)-hex-4-en-1-yl((pentafluorobenzoyl)oxy)carbamate (243a) 
 
General procedure O: (E)-Hex-4-en-1-ol (87) (0.33 mL, 2.80 mmol) was employed with 
CbzNHOFBz.XLVII The reaction time was 16 hours. FCC (eluent: 2:3 hexane:PhMe) afforded 243a 
(734 mg, 59 %) as a colourless oil. νmax / cm-1: (film) 2940 (m), 1786 (s), 1730 (s), 1653 (m), 1500 (s), 
1175 (s). δH (400 MHz, CDCl3) 7.39 – 7.30 (5H, m, 5 × ArCH), 5.50 – 5.33 (2H, m, C4-H and C5-H), 
5.22 (2H, s, OCH2Ph), 3.75 (2H, t, J = 7.0 Hz, C1-H2), 2.06 (2H, td, J = 7.5, 6.5 Hz, C3-H2), 1.71 (2H, 
tt, J = 7.5, 7.0 Hz, C2-H2), 1.63 (3H, dq, J = 6.0, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 155.5 
(Cbz C=O), 135.4 (ArC), 129.7 (C4), 128.7 (ArCH), 128.6 (ArCH), 128.2 (ArCH), 126.3 (C5), 68.9 
(OCH2Ph), 50.8 (C1), 29.4 (C3), 26.8 (C2), 18.0 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.8 – -136.1 (2F, m), -145.9 – -146.1 (1F, m), -159.2 – -159.4 (2F, m). HRMS: (ESI+) 
Calculated for C21H18F5NNaO4: 466.1048. Found [M+Na]+: 466.1050.  
Benzyl 2-vinylpyrrolidine-1-carboxylate (244a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 243a (46.6 mg, 0.105 mmol) was employed. FCC 
(eluent: 29:1 PhMe:EtOAc) afforded 244a (18.9 mg, 78 %) as a colourless oil. δH (500 MHz, CDCl3) 
7.41 – 7.27 (5H, m), 5.83 – 5.70 (1H, m), 5.19 – 4.98 (4H, m), 4.46 – 4.35 (1H, m), 3.53 – 3.39 (2H, 
m), 2.08 – 1.96 (1H, m), 1.94 – 1.79 (2H, m), 1.78 – 1.67 (1H, m). This compound exists as an 
approximately 1:1 mixture of rotamers; this results in the doubling up of several signals in the 13C 
spectrum. δC (126 MHz, CDCl3) 155.1 and 154.8, 138.5 and 138.0, 137.1, 128.4 and 128.3, 127.8, 
127.7, 114.3 and 114.1, 66.6, 59.5 and 59.0, 46.7 and 46.4, 32.0 and 31.2, 23.5 and 22.6. The 
spectroscopic properties were consistent with the data available in the literature.163 
(9H-Fluoren-9-yl)methyl hydroxycarbamate 
 
This compound was prepared according to a literature procedure.259 To a solution of NH2OH·HCl 
(2.08 g, 30.0 mmol) and NaHCO3 (5.54 g, 66.0 mmol) in water (100 mL) at 0 °C was added a solution 
                                                     
XLVII CbzNHOFBz was prepared by Dr Xiaofeng Ma (University of Bristol) according to a reported procedure.117 
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of Fmoc N-hydroxysuccinimide ester (10.1 g, 30.0 mmol) in EtOAc (100 mL) dropwise. The reaction 
mixture was stirred at room temperature for 5 hours before the phases were separated. The organic 
phase was washed with saturated aqueous NaHSO4 (50 mL), brine (50 mL) and concentrated in vacuo. 
FCC (gradient elution: 3:2 – 1:1 – 2:3 – 0:1 hexane:EtOAc) afforded the title compound (5.92 g, 77 %) 
as a colourless crystalline solid. m.p. 167-168 °C (acetone:petrol, fibres) [Lit., 164.5-167.5 °C 
(hexane)].260 δH (400 MHz, DMSO-d6) 9.76 (1H, s), 8.78 (1H, s), 7.89 (1H, d, J = 7.5 Hz), 7.69 (2H, 
br d, J = 7.5 Hz), 7.42 (1H, dd, J = 7.5, 7.5 Hz), 7.33 (2H, ddd, J = 7.5, 7.5, 1.0 Hz), 4.33 (2H, d, J = 
7.5 Hz), 4.23 (1H, t, J = 7.5 Hz). δC (101 MHz, DMSO-d6) 157.6, 143.7, 140.7, 127.7, 127.1, 125.2, 




General procedure G: The preceding compound (5.87 g, 23.0 mmol) was employed. The reaction time 
was 20 hours. FCC (gradient elution: 4:1 – 3:1 – 0:1 hexane:EtOAc) afforded impure material which 
was recrystallised from EtOAc:hexane to afford the title compound (2.58 g, 25 %) as a colourless 
crystalline solid. m.p. 179-180 °C (fibres). νmax / cm-1: (solid) 3190 (br m), 2949 (m), 1783 (s), 1728 (s), 
1655 (m), 1500 (s), 1180 (s). δH (400 MHz, CDCl3) 8.27 (1H, br s, NH), 7.75 (2H, dd, J = 7.5, 1.0 Hz, 
2 × ArCH), 7.61 – 7.55 (2H, m, 2 × ArCH), 7.43 – 7.37 (2H, m, 2 × ArCH), 7.32 (2H, ddd, J = 7.5, 7.5, 
1.0 Hz, 2 × ArCH), 4.60 (2H, d, J = 6.5 Hz, OCH2CHR2), 4.28 (1H, t, J = 6.5 Hz, OCH2CHR2). 
δC (101 MHz, CDCl3) 155.8 (Fmoc C=O), 143.1 (ArC), 141.5 (ArC), 128.1 (ArCH), 127.4 (ArCH), 
125.1 (ArCH), 120.2 (ArCH), 68.9 (OCH2CHR2), 46.9 (OCH2CHR2). The 
13C signals corresponding 
to the pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) 
-134.6 – -134.8 (2F, m), -144.7 (1F, tt, J = 21.0, 6.0 Hz), -158.9 – -159.1 (2F, m). HRMS: (ESI+) 
Calculated for C22H12F5NNaO4: 472.0579. Found [M+Na]+: 472.0597. 
Benzaldehyde oxime 
 
A solution of benzaldehyde (20.0 g, 188 mmol), NaOAc (23.0 g, 280 mmol) and NH2OH·HCl (19.5 g, 
280 mmol) in MeOH (300 mL) was heated at reflux for 2 hours. The reaction mixture was cooled to 
room temperature, diluted with brine (400 mL) and extracted with EtOAc (2 × 500 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo to afford the title compound (22.6 g, 
99 %) as a colourless crystalline solid. δH (400 MHz, CDCl3) 8.65 – 8.22 (1H, br s), 8.17 (1H, s), 7.62 
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– 7.54 (2H, m), 7.42 – 7.36 (3H, m). δC (126 MHz, CDCl3) 150.5, 132.0, 130.20, 128.9, 127.2. The 
spectroscopic properties were consistent with the data available in the literature.262 
N-Benzylhydroxylamine 
 
To a suspension of the preceding oxime (5.00 g, 41.3 mmol), NaBH3CN (5.71 g, 90.9 mmol) and a 
small amount of methyl orange in MeOH (40 mL) was added a pre-mixed solution of MeOH:AcCl (3:1) 
dropwise at such a rate as to keep the solution pink. After 1 hour the reaction mixture was concentrated 
in vacuo. The crude product was dissolved in water (200 mL), made basic with NaOH and extracted 
with CH2Cl2 (6 × 100 mL). The combined organic phases were dried over Na2SO4 and concentrated in 
vacuo to afford BnNHOH (3.50 g, 69 %) as a colourless crystalline solid. δH (400 MHz, CDCl3) 7.41 – 
7.23 (5H, m), 6.63 – 5.04 (2H, br s), 4.00 (2H, s). δC (101 MHz, CD3CN) 139.7, 129.8, 129.2, 128.0, 
58.6. HRMS: (ESI+) Calculated for C7H10NO: 124.0757. Found [M+H]+: 124.0761. The spectroscopic 
properties were consistent with the data available in the literature.263 
(E)-But-2-en-1-yl 1H-imidazole-1-carboxylate 
 
This compound was prepared according to a literature procedure.264 To a solution of carbonyl 
diimidazole (4.86 g, 30.0 mmol) in anhydrous CH2Cl2 (50 mL) at 0 °C was added (E)-but-2-en-1-ol 
(1.71 mL, 20.0 mmol) dropwise. The reaction mixture was stirred at room temperature for 19 hours 
before being washed with water (2 × 40 mL), dried over Na2SO4 and concentrated in vacuo to afford 
the title compound (1.77 g, 53 %) as a pale-yellow oil. νmax / cm-1: (film) 2945 (m), 1755 (s), 1472 (m), 
1396 (s), 1236 (s). δH (400 MHz, CDCl3) 8.13 (1H, dd, J = 1.0, 1.0 Hz), 7.42 (1H, dd, J = 1.5, 1.0 Hz), 
7.06 (1H, dd, J = 1.5, 1.0 Hz), 5.95 (1H, dqt, J = 15.5, 6.5, 1.0 Hz), 5.73 – 5.64 (1H, m), 4.82 (2H, br d, 
J = 7.0 Hz), 1.77 (3H, ddt, J = 6.5, 2.0, 1.0 Hz). δC (101 MHz, CDCl3) 148.7, 137.3, 134.3, 130.7, 123.6, 
117.3, 69.0, 18.0. The spectroscopic properties were consistent with the data available in the 
literature.264 
  





To a solution of the preceding compound (332 mg, 2.00 mmol) and BnNHOH (vide supra, 369 mg, 
3.00 mmol) in anhydrous CH2Cl2 (10 mL) was added Et3N (0.42 mL, 3.00 mmol). The reaction mixture 
was stirred at room temperature for 8 hours before being diluted with CH2Cl2 (10 mL), then washed 
with 1.0 M aqueous HCl (15 mL) followed by brine (15 mL). The organic phase was concentrated in 
vacuo. FCC (gradient elution: 5:1 – 3:1 hexane:EtOAc) afforded the title compound (112 mg, 25 %) as 
a pale-yellow oil. νmax / cm-1: (film) 3287 (br s), 3032 (m), 2919 (m), 1699 (s), 1453 (s), 1237 (s), 
1101 (s). δH (400 MHz, CDCl3) 7.38 – 7.27 (5H, m, 5 × ArCH), 6.33 – 6.11 (1H, br s, OH), 5.87 – 5.76 
(1H, m, C3-H), 5.67 – 5.55 (1H, m, C2-H), 4.70 (2H, s, NCH2Ph), 4.60 (2H, d, J = 6.5 Hz, C1-H2), 1.73 
(3H, d, J = 6.5 Hz, C4-H3). δC (101 MHz, CDCl3) 157.4 (C=O), 136.1 (ArC), 132.0 (C3), 128.7 (ArCH), 
128.4 (ArCH), 128.0 (ArCH), 125.2 (C2), 67.4 (C1), 54.3 (NCH2Ph), 17.9 (C4). HRMS: (ESI+) 
Calculated for C12H15NNaO3: 244.0944. Found [M+Na]+: 244.0943. 
(E)-But-2-en-1-yl benzyl((pentafluorobenzoyl)oxy)carbamate (249) 
 
General procedure C: The preceding compound (107 mg, 0.484 mmol) was employed. FCC (eluent: 
14:1 hexane:EtOAc) afforded 249 (139 mg, 69 %) as a colourless oil. νmax / cm-1: (film) 2945 (m), 
1789 (s), 1725 (s), 1655 (m), 1504 (s), 1324 (s), 1172 (s). δH (400 MHz, CDCl3) 7.38 – 7.28 (5H, m, 
5 × ArCH), 5.82 (1H, dqt, J = 15.5, 6.5, 1.5 Hz, C3-H), 5.59 (1H, dtq, J = 15.5, 6.5, 1.5 Hz, C2-H), 4.89 
(2H, s, NCH2Ph), 4.66 (2H, br d, J = 6.5 Hz, C1-H2), 1.73 (3H, ddt, J = 6.5, 1.5, 1.5 Hz, C4-H3).  
δC (101 MHz, CDCl3) 155.6 (Carbamate C=O), 134.6 (ArC), 132.5 (C3), 2 × 128.7 (2 × ArCH), 128.3 
(ArCH), 124.5 (C2), 68.2 (C1), 55.1 (NCH2Ph), 17.9 (C4). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.9 – -136.1 (2F, m), -146.3 (1F, tt, J = 21.0, 5.0 Hz), -159.3 – -159.5 (2F, m). HRMS: (ESI+) 
Calculated for C19H14F5NNaO4: 438.0735. Found [M+Na]+: 438.0739. 
  





A solution of pent-4-enoic acid (0.35 mL, 3.40 mmol) and carbonyl diimidazole (827 mg, 5.10 mmol) 
in anhydrous MeCN (20 mL) was stirred at room temperature for 6 hours before addition of BnNHOH 
(vide supra, 628 mg, 5.10 mmol). The reaction mixture was stirred for a further 16 hours before being 
concentrated in vacuo, dissolved in Et2O (50 mL) and washed with 4.0 M aqueous NaOH (2 × 50 mL) 
and water (50 mL). The combined organic phases were dried and concentrated in vacuo to afford the 
title compound (650 mg, 93 %) as a colourless oil, which was used without further purification. 
δH (500 MHz, CDCl3) 8.98 – 8.27 (1H, br s), 7.38 – 7.21 (5H, m), 5.88 – 5.72 (1H, m), 5.04 (1H, d, J = 
17.5 Hz), 4.99 (1H, br d, J = 9.5 Hz), 4.85 – 4.73 (2H, m), 2.64 – 2.30 (4H, m). HRMS: (ESI+) 
Calculated for C12H15NNaO2: 228.0995. Found [M+Na]+: 228.0993. The spectroscopic properties were 
consistent with the data available in the literature.265 
N-Benzyl-N-((pentafluorobenzoyl)oxy)pent-4-enamide (251) 
 
General procedure C: The preceding compound (300 mg, 1.47 mmol) was employed. FCC (two times, 
first eluent: 29:1 PhMe:EtOAc; second eluent: 19:1 hexane:EtOAc) afforded 251 (360 mg, 61 %) as a 
colourless crystalline solid. This compound exists as an approximately 4:1 mixture of rotamers A and B. 
m.p. 31-32 °C (CH2Cl2:petrol, fibres). νmax / cm-1: (solid) 3070 (m), 2927 (m), 1797 (s), 1673 (s), 
1500 (s). δH (500 MHz, CDCl3) 7.41 – 7.18 (5H, m, A and B: 5 × ArCH), 5.83 – 5.65 (0.2H, m, B: 
C4-H), 5.57 – 5.42 (0.8H, m, A: C4-H), 5.13 – 4.84 (3.6H, m, A: C5-H2 and NCH2Ph; B: C5-H2), 4.74 
(0.4H, br s, B: NCH2Ph), 2.54 (0.4H, br s, B: C2-H2), 2.40 (0.4H, br s, B: C3-H2), 2.24 – 2.18 (1.6H, 
m, A: C2-H2), 2.17 – 2.10 (1.6H, m, A: C3-H2). δC (126 MHz, CDCl3) 170.1 (A and B: C1), 158.6 (A 
and B: FBz C=O), 143.6 (d, J = 254.0 Hz, A and B: ArCF), 142.5 (d, J = 262.5 Hz, A and B: ArCF), 
137.6 (d, J = 251.5 Hz, A and B: ArCF), 134.9 (A and B: C4), 133.7 (A and B: ArC), 128.9 (A and B: 
ArCH), 2 × 128.6 (A and B: 2 × ArCH), 116.4 (A and B: C5), 109.6 (A and B: ArC), 55.5 (B: NCH2Ph), 
51.9 (A: NCH2Ph), 30.7 (A and B: C2), 28.0 (A and B: C3). δF (377 MHz, CDCl3) -138.4 (0.4F, br s), 
-138.8 – -139.2 (1.6F, m), -149.4 (0.2F, br s), -150.6 (0.8F, t, J = 20.5 Hz), -158.9 (0.4F, br s), -160.0 
– -160.4 (1.6F, m). HRMS: (ESI+) Calculated for C19H15F5NO3: 400.0967. Found [M+H]+: 400.0972. 
  





To a suspension of NH2OH·HCl (3.47 g, 50.0 mmol), K2CO3 (6.91 g, 50.0 mmol) and PivCl (6.22 mL, 
50.5 mmol) in Et2O (30 mL) was added water (24 mL) dropwise. The reaction mixture was stirred at 
room temperature for 3 hours before the phases were separated, and the aqueous phase was extracted 
with EtOAc (30 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. 
FCC (gradient elution: 3:7 – 0:1 hexane:EtOAc) afforded the title compound (741 mg, 13 %) as a 
colourless crystalline solid. This compound decomposed at around 154 °C during melting point 
analysis. δH (400 MHz, CDCl3) 8.32 (1H, br s), 7.73 (1H, br s), 1.22 (9H, s). δC (126 MHz, CDCl3) 




General procedure G: The preceding compound (682 mg, 5.82 mmol) was employed. The reaction 
time was 13 hours. FCC (eluent: 4:1 hexane:EtOAc) afforded PivNHOFBz (1.30 g, 72 %) as a 
colourless crystalline solid. m.p. 141-142 °C (CH2Cl2:petrol, needles). νmax / cm-1: (solid) 3217 (br s), 
2977 (m), 1780 (s), 1669 (s), 1505 (s). δH (400 MHz, CDCl3) 9.14 (1H, s, NH), 1.33 (9H, s, C(CH3)3). 
δC (101 MHz, CDCl3) 177.0 (Piv C=O), 39.0 (C(CH3)3), 27.3 (C(CH3)3). The 
13C signals corresponding 
to the pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) 
-134.9 – -135.0 (2F, m), -145.1 (1F, tt, J = 21.0, 6.0 Hz), -159.1 – -159.3 (2F, m). HRMS: (ESI+) 
Calculated for C12H10F5NNaO3: 334.0473. Found [M+Na]+: 334.0491. 
(E)-N-(Non-4-en-1-yl)-N-((pentafluorobenzoyl)oxy)pivalamide (246d) 
 
General procedure O: (E)-Non-4-en-1-ol (vide supra, 284 mg, 2.00 mmol) was employed with 
PivNHOFBz (vide supra). The reaction time was 18 hours. FCC (gradient elution: 1:1 – 
3:7 hexane:PhMe) afforded 246d (255 mg, 29 %) as a colourless oil. νmax / cm-1: (film) 2961 (m), 
2931 (m), 1767 (s), 1616 (m), 1499 (s), 1199 (s). δH (400 MHz, CDCl3) 5.48 – 5.29 (2H, m, C4-H and 
C5-H), 4.36 (2H, t, J = 6.5 Hz, C1-H2), 2.08 (2H, tdd, J = 7.5, 6.0, 1.0 Hz, C3-H2), 1.96 (2H, td, J = 
6.5, 6.0 Hz, C6-H2), 1.72 (2H, tt, J = 7.5, 6.5 Hz, C2-H2), 1.33 – 1.26 (4H, m, C7-H2 and C8-H2), 1.23 
(9H, s, C(CH3)3), 0.90 – 0.85 (3H, m, C9-H3). δC (101 MHz, CDCl3) 169.2 (Piv C=O), 132.0 (C5), 
128.4 (C4), 73.7 (C1), 38.0 (C(CH3)3), 32.3 (C6), 31.8 (C7), 30.1 (C2), 28.6 (C3), 27.6 (C(CH3)3), 22.3 
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(C8), 14.0 (C9). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved 
due to their weak intensity. δF (377 MHz, CDCl3) -137.5 – -137.7 (2F, m), -148.1 (1F, t, J = 20.5 Hz), 
-159.7 – -159.9 (2F, m). HRMS: (ESI+) Calculated for C21H27F5NO3: 436.1906. Found [M+H]+: 
436.1935. 
tert-Butyl (E)-(6-phenylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (254) 
 
General procedure O: Alcohol 121 (Section 7.3, 824 mg, 4.67 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (eluent: 1:4 hexane:PhMe) afforded 
254 (1.18 g, 52 %, 6:1 mixture of (E)- and (Z)-isomers) as a colourless oil. Spectroscopic data for the 
major (E)-isomer: νmax / cm-1: (film) 2938 (m), 1784 (s), 1722 (s), 1653 (m), 1506 (s), 1327 (s), 1154 (s). 
δH (400 MHz, CDCl3) 7.30 – 7.25 (2H, m, 2 × ArCH), 7.21 – 7.15 (3H, m, 3 × ArCH), 5.66 – 5.57 (1H, 
m, C5-H), 5.54 – 5.45 (1H, m, C4-H), 3.68 (2H, t, J = 7.0 Hz, C1-H2), 3.33 (2H, d, J = 6.5 Hz, C6-H2), 
2.12 (2H, dt, J = 7.5, 7.5 Hz, C3-H2), 1.73 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.49 (9H, s, OC(CH3)3).  
δC (101 MHz, CDCl3) 154.7 (Boc C=O), 140.9 (ArC), 130.4 (C4), 130.2 (C5), 128.6 (ArCH), 128.5 
(ArCH), 126.1 (ArCH), 83.4 (OC(CH3)3), 50.6 (C1), 39.1 (C6), 29.5 (C3), 28.2 (OC(CH3)), 26.8 (C2). 
The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.4 – -136.7 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.3 
– -159.5 (2F, m). HRMS: (ESI+) Calculated for C24H24F5NNaO4: 508.1518. Found [M+Na]+: 508.1525. 
Characteristic signals for the minor (Z)-isomer: δH (400 MHz, CDCl3) 3.40 (2H, d, J = 7.5 Hz), 2.26 
(2H, dt, J = 7.0, 7.0 Hz). 
tert-Butyl (E)-2-styrylpyrrolidine-1-carboxylate (255) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 254 (51.0 mg, 0.105 mmol) was employed. FCC 
(gradient elution: 99:1 – 49:1 – 24:1 PhMe:EtOAc) afforded 255 (22.3 mg, 78 %) as a colourless 
crystalline solid. m.p. 81-88 °C (CH2Cl2:petrol, equant) [Lit., 96-98 °C (No recrystallisation solvent 
quoted)].268 δH (400 MHz, CDCl3) 7.38 – 7.27 (4H, m), 7.25 – 7.16 (1H, m), 6.40 (1H, br d, J = 15.5 Hz), 
6.18 – 6.01 (1H, m), 4.61 – 4.30 (1H, m), 3.46 (2H, br s), 2.16 – 2.01 (1H, m), 1.99 – 1.73 (3H, m), 
1.43 (9H, s). δC (126 MHz, CDCl3) 154.8, 137.2, 130.9, 129.5, 128.6, 127.4, 126.4, 79.3, 59.1, 46.4, 
32.7, 28.7, 23.2. The spectroscopic properties were consistent with the data available in the 
literature.268 
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Methyl (E)-6-((tert-butoxycarbonyl)((pentafluorobenzoyl)oxy)amino)hex-2-enoate (256) 
 
General procedure O: Alcohol 122 (Section 7.3, 214 mg, 1.48 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (eluent: 49:1 PhMe:EtOAc) afforded 
256 (381 mg, 57 %) as a pale-yellow oil. νmax / cm-1: (film) 2952 (m), 1782 (s), 1721 (s), 1654 (m), 
1504 (s), 1151 (s). δH (400 MHz, CDCl3) 6.95 (1H, dt, J = 15.5, 7.0 Hz, C4-H), 5.85 (1H, dt, J = 15.5, 
1.5 Hz, C5-H), 3.73 – 3.68 (5H, m, C1-H2 and OCH3), 2.32 (2H, tdd, J = 7.5, 7.0, 1.5 Hz, C3-H2), 1.80 
(2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 167.0 (C6), 154.6 (Boc 
C=O), 147.8 (C4), 121.9 (C5), 83.7 (OC(CH3)3), 51.6 (OCH3), 50.2 (C1), 29.1 (C3), 28.1 (OC(CH3)3), 
25.6 (C2). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due  
to their weak intensity. δF (377 MHz, CDCl3) -136.2 – -136.6 (2F, m), -146.2 (1F, tt, J = 20.0, 
4.5 Hz), -159.0 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C19H20F5NNaO6: 476.1103. Found 
[M+Na]+: 476.1114.  
tert-Butyl (E)-2-(2-methoxy-2-oxoethylidene)pyrrolidine-1-carboxylate (257) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 256 
(47.6 mg, 0.105 mmol) was employed. FCC (eluent: 9:1 hexane:EtOAc) afforded 257 (24.0 mg, 95 %) 
as a colourless crystalline solid. δH (400 MHz, CDCl3) 6.44 (1H, t, J = 2.0 Hz), 3.68 – 3.63 (5H, m), 
3.17 (2H, td, J = 7.5, 2.0 Hz), 1.87 (2H, tt, J = 7.5, 7.5 Hz), 1.51 (9H, s). δC (101 MHz, CDCl3) 169.5, 
157.8, 152.1, 95.7, 82.2, 50.8, 49.9, 32.1, 28.3, 21.1. m/z (ESI+) 264 ([M+Na]+, 100 %), 164  
([M-(t-BuO–C=O)+H+Na]+, 22 %). The spectroscopic properties were consistent with the data 
available in the literature.269 
tert-Butyl (E)-(1-phenylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (258a) 
 
General procedure O: Alcohol 133 (Section 7.3, 176 mg, 1.00 mmol) was employed with 
BocNHOFBz (vide supra), and the reaction was performed at -78 °C. The reaction time was 18 hours. 
FCC (eluent: 2:3 hexane:PhMe) afforded impure material which was dissolved in Et2O (15 mL) and 
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washed with 10 % aqueous AcOH (2 × 10 mL). The organic phase was dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 19:1 hexane:EtOAc) afforded 258a (248 mg, 51 %) as a colourless 
oil. νmax / cm-1: (film) 2981 (m), 1787 (s), 1720 (s), 1652 (m), 1506 (s), 1326 (s), 1158 (s). δH (500 MHz, 
CDCl3) 7.43 – 7.37 (2H, m, 2 × ArCH), 7.37 – 7.29 (3H, m, 3 × ArCH), 5.52 – 5.40 (2H, m, C4-H and 
C5-H), 5.38 – 5.21 (1H, m, C1-H), 2.23 – 2.04 (3H, m, C2-H and C3-H2), 1.99 (1H, br s, C2-H’), 1.68 
(2H, d, J = 4.5 Hz, C6-H3), 1.56 – 1.36 (9H, br s, OC(CH3)3). δC (126 MHz, CDCl3) 157.0 (FBz C=O), 
154.4 (Boc C=O), 145.4 (d, J = 261.0 Hz, ArCF), 143.7 (d, J = 261.0 Hz, ArCF), 138.8 (ArC), 137.8 
(d, J = 255.0 Hz, ArCF), 129.7 (C4), 128.4 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 126.3 (C5), 106.1 
(ArC), 83.5 (OC(CH3)3), 63.1 (C1), 31.5 (C2), 29.2 (C3), 28.0 (OC(CH3)3), 17.9 (C6). δF (377 MHz, 
CDCl3) -136.0 – -136.7 (2F, m), -147.0 (1F, tt, J = 21.0, 5.0 Hz), -159.2 – -159.9 (2F, m). HRMS: (ESI+) 
Calculated for C24H24F5NNaO4: 508.1518. Found [M+Na]+: 508.1516.  
tert-Butyl (2R*,5S*)-2-phenyl-5-vinylpyrrolidine-1-carboxylate (260a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate 258a (51.0 mg, 0.105 mmol) was employed. FCC 
(two times, first eluent: 59:1 petrol:acetone; second eluent: 99:1 PhMe:EtOAc) afforded 260a (16.6 mg, 
58 %, 10:1 mixture of cis and trans diastereomers) as a colourless oil. It was not possible to determine 
the relative stereochemistry of 260a by NOE analysis. The removal of the Boc group was necessary to 
obtain satisfactory data; details of this are given below. Spectroscopic data for the major cis 
diastereomer: νmax / cm-1: (film) 2974 (m), 1693 (s), 1380 (s), 1165 (s). δH (500 MHz, CDCl3) 7.34 – 
7.27 (2H, m, 2 × ArCH), 7.27 – 7.24 (2H, m, 2 × ArCH), 7.23 – 7.18 (1H, m, ArCH), 6.13 – 5.93 (1H, 
m, C5-H), 5.34 – 5.14 (2H, m, C6-H2), 4.93 – 4.70 (1H, m, C1-H), 4.55 – 4.34 (1H, m, C4-H), 2.26 
(1H, dddd, J = 12.5, 6.5, 6.0, 6.0 Hz, C2-H), 2.06 (1H, dddd, J = 12.0, 8.0, 7.5, 6.5 Hz, C3-H), 1.88 
(1H, dddd, J = 12.5, 7.5, 6.5, 6.5 Hz, C2-H’), 1.84 – 1.75 (1H, m, C3-H’), 1.47 – 1.10 (9H, m, 
OC(CH3)3). δC (126 MHz, CDCl3) 155.1 (C=O), 144.6 (ArC), 139.5 (C5), 128.3 (ArCH), 126.6 (ArCH), 
126.0 (ArCH), 115.3 (C6), 79.6 (OC(CH3)3), 63.1 (C1), 61.2 (C4), 34.9 (C2), 30.7 (C3), 28.4 
(OC(CH3)3). HRMS: (ESI+) Calculated for C17H23NNaO2: 296.1621. Found [M+Na]+: 296.1630. 
Characteristic signals for the minor trans diastereomer: δH (500 MHz, CDCl3) 5.91 – 5.78 (1H, m), 
2.37 (1H, dddd, J = 13.5, 11.5, 6.0, 5.5 Hz), 2.18 (1H, dddd, J = 13.0, 8.5, 6.0, 6.0 Hz). 
  





General procedure Q: Pyrrolidine 260a (15.7 mg, 57.4 μmol) was employed to afford the title 
compound (15.7 mg, 95 %, 14:1 mixture of cis and trans diastereomers) as a pale-yellow crystalline 
solid. The major product was assigned as the cis diastereomer based on the observed NOE correlation 
between the C1 and the C4 protons. Spectroscopic data for the major cis diastereomer:  
νmax / cm-1: (film) 2924 (m), 1666 (s), 1432 (s), 1130 (s). δH (500 MHz, CDCl3) 10.52 (1H, br s, NH), 
8.71 (1H, br s, NH’), 7.37 – 7.27 (5H, m, 5 × ArCH), 5.72 (1H, ddd, J = 17.0, 10.5, 8.0 Hz, C5-H), 5.19 
(1H, d, J = 17.0 Hz, C6-H’), 4.99 (1H, d, J = 10.5 Hz, C6-H), 4.57 – 4.48 (1H, m, C1-H), 4.10 – 3.99 
(1H, m, C4-H), 2.45 – 2.24 (3H, m, C2-H2 and C3-H), 2.16 – 2.09 (1H, m, C3-H’). δC (101 MHz, 
CDCl3) 133.9 (ArC), 131.7 (C5), 129.3 (ArCH), 128.9 (ArCH), 127.7 (ArCH), 121.4 (C6), 63.1 (C1), 
62.7 (C4), 29.9 (C2), 29.2 (C3). The 13C signals corresponding to the trifluoroacetate counterion could 
not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -75.8 (3F, s). HRMS: (ESI+) 
Calculated for C12H16N: 174.1277. Found [M–F3CCO2]+: 174.1280. Characteristic signals for the 
minor trans diastereomer: δH (500 MHz, CDCl3) 9.87 (1H, br s), 9.17 (1H, br s), 5.11 (1H, d, J = 
10.5 Hz), 4.22 – 4.13 (1H, m). 
Methyl (E)-(1-phenylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (258b) 
 
General procedure O: Alcohol 133 (Section 7.3, 438 mg, 2.50 mmol) was employed with 
MeOC(O)NHOFBz (vide supra). The reaction time was 23 hours. FCC (gradient elution: 2:3 – 
1:4 hexane:PhMe) afforded 258b (278 mg, 25 %) as a colourless oil. νmax / cm-1: (film) 3032 (m), 
2959 (m), 1787 (s), 1732 (s) 1652 (m), 1497 (s), 1172 (s). δH (500 MHz, CDCl3) 7.44 – 7.29 (5H, m, 
5 × ArCH), 5.56 – 5.38 (2H, m, C4-H and C5-H), 5.33 (1H, br s, C1-H), 3.80 (3H, s, OCH3), 2.25 – 
1.95 (4H, m, C2-H2 and C3-H2), 1.68 (3H, d, J = 4.5 Hz, C6-H3). δC (126 MHz, CDCl3) 156.0  
(MeO–C=O), 138.4 (ArC), 129.7 (C4), 128.7 (ArCH), 128.4 (ArCH), 128.1 (ArCH), 126.6 (C5), 63.4 
(C1), 54.1 (OCH3), 31.4 (C2), 29.3 (C3), 18.1 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.6 – -136.5 (2F, m), -146.5 (1F, tt, J = 21.0, 5.0 Hz), -159.0 – -159.8 (2F, m). HRMS: (ESI+) 
Calculated for C21H18F5NNaO4: 466.1048. Found [M+Na]+: 466.1049. 
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Methyl (2R*,5S*)-2-phenyl-5-vinylpyrrolidine-1-carboxylate (260b) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15.0 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 258b (46.6 mg, 0.105 mmol) was employed. FCC (two 
times, first eluent: 29:1 PhMe:EtOAc; second eluent: 19:1 petrol:acetone) afforded 260b (7.7 mg, 32 %) 
as a colourless oil. The relative stereochemistry of 260b was assigned by analogy to 260a, as it was not 
possible to determine by NOE analysis. νmax / cm-1: (film) 3029 (m), 2952 (m), 1699 (s), 1445 (s), 
1372 (s). δH (500 MHz, CDCl3) 7.38 – 7.21 (5H, m, 5 × ArCH), 6.02 (1H, ddd, J = 17.0, 10.5, 6.5 Hz, 
C5-H), 5.33 (1H, br d, J = 17.0 Hz, C6-H’), 5.22 (1H, br d, J = 10.5 Hz, C6-H), 4.96 (1H, dd, J = 7.5, 
6.0 Hz, C1-H), 4.51 (1H, br ddd, J = 7.5, 7.0, 6.5 Hz, C4-H), 3.62 (3H, br s, OCH3), 2.31 (1H, dddd, 
J = 12.5, 7.5, 7.0, 7.0 Hz, C2-H), 2.10 (1H, dddd, J = 12.5, 7.0, 7.0, 6.5 Hz, C3-H), 1.95 (1H, dddd, J = 
12.5, 7.0, 6.5, 6.0 Hz, C2-H’), 1.88 – 1.79 (1H, m, C3-H’). δC (126 MHz, CDCl3) 156.6 (C=O), 143.6 
(ArC), 139.1 (C5), 128.4 (ArCH), 126.9 (ArCH), 126.0 (ArCH), 115.8 (C6), 62.9 (C1), 61.6 (C4), 52.5 
(OCH3), 34.4 (C2), 30.5 (C3). HRMS: (ESI+) Calculated for C14H18NO2: 232.1332. Found [M+H]+: 
232.1334. 
tert-Butyl (E)-(2-phenylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (261) 
 
General procedure O: Alcohol 142 (Section 7.3, 441 mg, 2.50 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 15 hours. FCC (two times, first eluent: 
2:3 hexane:PhMe; second eluent: 29:1 hexane:EtOAc) afforded 261 (353 mg, 29 %) as a pale-yellow 
oil. νmax / cm-1: (film) 3026 (m), 2981 (m), 1783 (s), 1721 (s), 1652 (m), 1497 (s), 1153 (s).  
δH (400 MHz, CDCl3) 7.30 – 7.24 (2H, m, 2 × ArCH), 7.22 – 7.13 (3H, m, 3 × ArCH), 5.49 – 5.38 (1H, 
m, C5-H), 5.32 – 5.22 (1H, m, C4-H), 3.97 (1H, dd, J = 15.0, 7.0 Hz, C1-H), 3.84 (1H, dd, J = 15.0, 
8.0 Hz, C1-H’), 3.00 (1H, dtd, J = 8.0, 7.5, 7.0 Hz, C2-H), 2.50 – 2.31 (2H, m, C3-H2), 1.57 (3H, dd, 
J = 6.5, 1.5 Hz, C6-H3), 1.39 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 157.1 (FBz C=O), 154.0 
(Boc C=O), 141.9 (ArC), 128.3 (ArCH), 2 × 128.0 (C4 and ArCH), 127.4 (C5), 126.5 (ArCH), 83.1 
(OC(CH3)3), 55.6 (C1), 44.1 (C2), 36.5 (C3), 27.9 (OC(CH3)3), 17.9 (C6). The aromatic 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.0 – -136.4 (2F, m), -146.6 (1F, tt, J = 21.0, 5.0 Hz), -159.5 – -159.7 (2F, m). 
HRMS: (ESI+) Calculated for C24H24F5NNaO4: 508.1518. Found [M+Na]+: 508.1514.  
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tert-Butyl (2R*,4S*)-4-phenyl-2-vinylpyrrolidine-1-carboxylate (262) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 261 
(51.0 mg, 0.105 mmol) was employed. FCC (gradient elution: 12:1 – 9:1 hexane:EtOAc) afforded 262 
(25.3 mg, 88 %, 4:1 mixture of cis and trans diastereomers) as a pale-yellow oil. It was not possible to 
determine the relative stereochemistry of 262 by NOE analysis. The removal of the Boc group was 
necessary to obtain satisfactory data, details of this are given below. Spectroscopic data for the major 
cis diastereomer: νmax / cm-1: (film) 2975 (m), 2928 (m), 1689 (s), 1390 (s), 1164 (s). δH (500 MHz, 
CDCl3) 7.38 – 7.32 (2H, m, 2 × ArCH), 7.28 – 7.24 (3H, m, 3 × ArCH), 5.96 – 5.73 (1H, m, C5-H), 
5.29 – 5.04 (2H, m, C6-H2), 4.42 – 4.24 (1H, m, C4-H), 4.20 – 3.94 (1H, m, C1-H), 3.34 – 3.25 (2H, 
m, C1-H’ and C2-H), 2.59 – 2.48 (1H, m, C3-H), 1.88 (1H, ddd, J = 12.0, 11.0, 11.0 Hz, C3-H’), 1.48 
(9H, s, OC(CH3)3). Although not observable in the 
1H spectrum, from the 13C spectrum it is apparent 
that this compound exists as an approximately 3:2 mixture of rotamers A and B. δC (126 MHz, CDCl3) 
154.9 (A: C=O), 154.6 (B: C=O), 140.6 (A and B: ArC), 140.2 (A: C5), 139.7 (B: C5), 128.7 (A and 
B: ArCH), 127.3 (A and B: ArCH), 127.0 (A and B: ArCH), 114.4 (A and B: C6), 79.7 (A and B: 
OC(CH3)3), 60.5 (A and B: C4), 53.8 (B: C1), 52.9 (A: C1), 43.3 (B: C2), 42.8 (A: C2), 41.1 (A: C3), 
40.7 (B: C3), 28.6 (A and B: OC(CH3)3). HRMS: (ESI+) Calculated for C17H23NNaO2: 296.1621. Found 
[M+Na]+: 296.1632. Characteristic signals for the minor trans diastereomer: δH (500 MHz, CDCl3) 
3.93 – 3.80 (1H, m), 2.26 – 2.17 (1H, m), 2.13 – 2.04 (1H, m). 
(2R*,4S*)-4-Phenyl-2-vinylpyrrolidin-1-ium trifluoroacetate 
 
General procedure Q: Pyrrolidine 262 (25.3 mg, 92.5 μmol) was employed to afford the title 
compound (24.9 mg, 94 %, 4:1 mixture of cis and trans diastereomers) as an orange oil. The major 
product was assigned as the cis diastereomer based on the observed NOE correlation between the C2 
and the C4 protons. Spectroscopic data for the major cis diastereomer: νmax / cm-1: (film) 3404 (br s), 
2979 (m), 1668 (s), 1429 (m), 1129 (s). δH (400 MHz, CDCl3) 10.01 (1H, br s, NH), 9.45 (1H, br s, 
NH’), 7.38 – 7.31 (2H, m, 2 × ArCH), 7.31 – 7.22 (3H, m, 3 × ArCH), 6.00 (1H, ddd, J = 17.5, 10.5, 
8.0 Hz, C5-H), 5.46 (1H, d, J = 17.5 Hz, C6-H’), 5.36 (1H, d, J = 10.5 Hz, C6-H), 4.26 – 4.11 (1H, m, 
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C4-H), 3.80 – 3.65 (1H, m, C1-H), 3.64 – 3.50 (1H, m, C2-H), 3.40 – 3.22 (1H, m, C1-H’), 2.50 (1H, 
ddd, J = 12.5, 6.0, 6.0 Hz, C3-H), 2.10 (1H, ddd, J = 12.5, 12.0, 12.0 Hz, C3-H’). δC (101 MHz, CDCl3) 
138.1 (ArC), 131.7 (C5), 129.0 (ArCH), 127.7 (ArCH), 127.1 (ArCH), 122.1 (C6), 62.8 (C4), 50.6 (C1), 
43.7 (C2), 39.3 (C3). The 13C signals corresponding to the trifluoroacetate counterion could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -75.6 (3F, s). HRMS: (ESI+) Calculated for 
C12H16N: 174.1277. Found [M–F3CCO2]+: 174.1281. Characteristic signals for the minor trans 
diastereomer: δH (400 MHz, CDCl3) 10.13 (1H, br s), 9.34 (1H, br s), 5.44 (1H, d, J = 17.0 Hz), 4.41 – 
4.29 (1H, m), 2.41 – 2.26 (2H, m). δC (101 MHz, CDCl3) 61.6, 51.1, 42.2, 38.3. 
tert-Butyl (E)-(3-phenylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (263a) 
 
General procedure O: Alcohol 149 (Section 7.3, 353 mg, 2.00 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 15 hours. FCC (eluent: 2:3 hexane:PhMe) afforded 
263a (554 mg, 57 %) as a colourless oil. νmax / cm-1: (film) 3028 (m), 2981 (m), 1782 (s), 1722 (s), 
1652 (m), 1504 (s), 1326 (s), 1152 (s). δH (400 MHz, CDCl3) 7.32 – 7.27 (2H, m, 2 × ArCH), 7.21 – 
7.16 (3H, m, 3 × ArCH), 5.60 – 5.45 (2H, m, C4-H and C5-H), 3.72 – 3.55 (2H, m, C1-H2), 3.34 (1H, 
dt, J = 7.5, 7.5 Hz, C3-H), 2.01 (2H, dt, J = 7.5, 7.5 Hz, C2-H2), 1.67 (3H, d, J = 5.5 Hz, C6-H3), 1.47 
(9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.5 (Boc C=O), 144.0 (ArC), 133.8 (C4), 128.6 (ArCH), 
127.4 (ArCH), 126.3 (ArCH), 125.7 (C5), 83.3 (OC(CH3)3), 49.5 (C1), 45.9 (C3), 32.8 (C2), 28.0 
(OC(CH3)3), 17.9 (C6). The 
13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.2 – -136.6 (2F, m), -146.5 (1F, tt, J = 
21.0, 5.5 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C24H24F5NNaO4: 508.1518. Found 
[M+Na]+: 508.1512.  
tert-Butyl (2R*,3R*)-3-phenyl-2-vinylpyrrolidine-1-carboxylate (264a) 
 
General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 22.5 mol% P(4-(CF3)C6H4)3; 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 263a (51.0 mg, 0.105 mmol) was employed. FCC 
(eluent: 74:1 PhMe:EtOAc) afforded 264a (19.5 mg, 68 %, 15:1 mixture of trans and cis diastereomers) 
as a pale-yellow oil. The major product was assigned as the trans diastereomer based on the observed 
NOE correlation between the C3 and the C5 protons. This compound exists as an approximately 3:2 
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mixture of rotamers A and B. Spectroscopic data for the major trans diastereomer: νmax / cm-1: (film) 
3029 (m), 2975 (m), 1691 (s), 1454 (m), 1390 (s), 1165 (s). δH (500 MHz, CDCl3) 7.35 – 7.27 (2H, m, 
A and B: 2 × ArCH), 7.25 – 7.18 (3H, m, A and B: 3 × ArCH), 5.79 (1H, s, A and B: C5-H), 5.13 – 
4.88 (2H, m, A and B: C6-H2), 4.35 (0.4H, br s, B: C4-H), 4.20 (0.6H, br s, A: C4-H), 3.79 – 3.58 (1H, 
m, A and B: C1-H), 3.48 – 3.39 (1H, m, A and B: C1-H’), 3.13 – 3.01 (1H, m, A and B: C3-H), 2.29 – 
2.18 (1H, m, A and B: C2-H), 2.00 – 1.87 (1H, m, A and B: C2-H’), 1.45 (9H, s, A and B: OC(CH3)3). 
δC (126 MHz, CDCl3) 154.7 (A and B: C=O), 142.1 (A and B: ArC), 138.7 (A: C5), 138.2 (B: C5), 
128.7 (A and B: ArCH), 127.4 (A and B: ArCH), 126.9 (A and B: ArCH), 114.7 (A and B: C6), 79.6 
(A and B: OC(CH3)3), 66.6 (A: C4), 66.0 (B: C4), 51.5 (A: C3), 50.7 (B: C3), 45.9 (A and B: C1), 32.3 
(B: C2), 31.6 (A: C2), 28.6 (A and B: OC(CH3)3). HRMS: (ESI+) Calculated for C17H23NNaO2: 
296.1621. Found [M+Na]+: 296.1629. Characteristic signals for the minor cis diastereomer:  
δH (500 MHz, CDCl3) 5.37 – 5.25 (1H, m, A and B: C5-H), 4.72 – 4.66 (0.4H, m, B: C4-H), 4.54 (0.6H, 
dd, J = 6.5, 6.5 Hz, A: C4-H), 2.14 – 2.06 (1H, m, A and B: C2-H’). 
Methyl (E)-(3-phenylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (263b) 
 
General procedure O: Alcohol 149 (Section 7.3, 353 mg, 2.00 mmol) was employed with 
MeO(CO)NHOFBz (vide supra). The reaction time was 16 hours. FCC (two times, first eluent: 
1:4 petrol:PhMe; second eluent: 19:1 petrol:acetone) afforded 263b (514 mg, 58 %) as a colourless oil. 
νmax / cm-1: (film) 3030 (m), 2959 (m), 1784 (s), 1731 (s), 1652 (m), 1497 (s), 1173 (s). δH (400 MHz, 
CDCl3) 7.32 – 7.27 (2H, m, 2 × ArCH), 7.22 – 7.16 (3H, m, 3 × ArCH), 5.60 – 5.44 (2H, m, C4-H and 
C5-H), 3.79 (3H, s, OCH3), 3.75 – 3.61 (2H, m, C1-H2), 3.35 (1H, dt, J = 7.5, 7.5 Hz, C3-H), 2.02 (2H, 
dt, J = 7.5, 7.5 Hz, C2-H2), 1.67 (3H, dd, J = 5.5, 1.0 Hz, C6-H3). δC (101 MHz, CDCl3) 156.2  
(MeO–C=O), 144.1 (ArC), 133.8 (C4), 128.7 (ArCH), 127.5 (ArCH), 126.5 (ArCH), 126.0 (C5), 54.1 
(OCH3), 49.9 (C1), 46.1 (C3), 32.9 (C2), 18.1 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.9 – -136.1 (2F, m), -146.1 (1F, tt, J = 21.0, 5.5 Hz), -159.2 – -159.5 (2F, m). HRMS: (ESI+) 
Calculated for C21H18F5NNaO4: 466.1048. Found [M+Na]+: 466.1049.  
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Methyl (2R*,3R*)-3-phenyl-2-vinylpyrrolidine-1-carboxylate (264b) 
   
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate 263b (46.6 mg, 0.105 mmol) was employed. FCC 
(eluent: 7:1 petrol:EtOAc) afforded 264b (18.8 mg, 77 %) as a colourless oil. The product was assigned 
as the trans diastereomer based on the observed NOE correlation between the C3 and the C5 protons. 
νmax / cm-1: (film) 3030 (m), 2953 (m), 1701 (s), 1448 (s), 1383 (s). δH (500 MHz, CDCl3) 7.34 – 7.30 
(2H, m, 2 × ArCH), 7.26 – 7.22 (1H, m, ArCH), 7.22 – 7.18 (2H, m, 2 × ArCH), 5.83 (1H, ddd, J = 
17.0, 10.5, 6.0 Hz, C5-H), 5.17 – 4.94 (2H, m, C6-H2), 4.45 – 4.25 (1H, m, C4-H), 3.84 – 3.64 (4H, m, 
C1-H and OCH3), 3.56 – 3.44 (1H, m, C1-H’), 3.13 (1H, ddd, J = 6.5, 6.5, 6.5 Hz, C3-H), 2.27 (1H, 
dddd, J = 13.5, 6.5, 6.5, 6.5 Hz, C2-H), 1.98 (1H, dddd, J = 13.5, 7.0, 7.0, 6.5 Hz, C2-H’). This 
compound exists as an approximately 1:1 mixture of rotamers; this results in in the doubling up of 
several signals in the carbon spectrum. δC (126 MHz, CDCl3) 155.9 and 155.6 (C=O), 142.1 and 141.9 
(ArC), 138.2 and 137.7 (C5), 128.8 (ArCH), 127.3 (ArCH), 127.0 (ArCH), 115.4 and 114.7 (C6), 66.3 
(C4), 52.5 (OCH3), 51.2 and 50.4 (C3), 46.3 and 46.0 (C1), 32.3 and 31.4 (C2). HRMS: (ESI+) 
Calculated for C14H18NO2: 232.1332. Found [M+H]+: 232.1332.  
8-Fluoro-1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantane (L4) 
 
To a solution of 1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantane (248)XLVIII (1.08 g, 5.00 mmol) 
in anhydrous CH2Cl2 (30 mL) at 0 °C was added Br2 (0.28 mL, 5.50 mmol). The reaction mixture was 
stirred at room temperature for 7 hours before addition of TBAF (1.0 M in THF, 12.5 mL, 12.5 mmol). 
The reaction mixture was stirred at room temperature for 2 hours before being diluted with Et2O 
(150 mL) and washed with brine (2 × 70 mL), followed by saturated aqueous Na2SO3 (70 mL). The 
organic phase was dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 19:1 petrol:EtOAc) 
afforded L4 (330 mg, 28 %) as a colourless crystalline solid. δH (400 MHz, CDCl3) 1.93 (1H, dd, J = 
13.5, 5.0 Hz), 1.88 – 1.84 (1H, m), 1.82 (1H, d, J = 3.5 Hz), 1.61 (1H, ddd, J = 13.5, 5.5, 4.0 Hz), 1.45 
(3H, d, J = 9.0 Hz), 1.42 (3H, d, J = 9.5 Hz), 1.40 (3H, s), 1.36 (3H, s). δF (377 MHz, CDCl3) -210.4 
                                                     
XLVIII Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 
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(1F, d, J = 903.0 Hz). δP (162 MHz, CDCl3) 124.1 (d, J = 903.0 Hz). The spectroscopic properties were 
consistent with the data available in the literature.270 
1,3,5,7-Tetramethyl-8-(trifluoromethyl)-2,4,6-trioxa-8-phosphaadamantane (L5) 
 
To a suspension of L4 (100 mg, 0.427 mmol) and CsF (13.0 mg, 85.4 µmol) in anhydrous THF (4 mL, 
argon sparged) at 0 °C was added TMSCF3 (0.19 mL, 1.28 mmol). The reaction mixture was stirred at 
room temperature for 5 hours before being filtered through celite and concentrated in vacuo. FCC 
(eluent: 24:1 pentane:Et2O) afforded L5 (92.2 mg, 76 %) as a colourless crystalline solid. m.p. 77-78 °C 
(CH2Cl2:petrol, tabular). νmax / cm-1: (solid) 2998 (m), 1449 (m), 1380 (s), 1213 (s), 1077 (s).  
δH (400 MHz, CDCl3) 1.97 – 1.82 (3H, m, C3-H2 and C3’-H), 1.76 (1H, dd, J = 13.5, 5.0 Hz, C3’-H’), 
1.53 (3H, d, J = 12.5 Hz, C1-H3), 1.51 (3H, d, J = 13.5 Hz, C1’-H3), 1.39 (3H, s, C5-H3), 1.38 (3H, s, 
C5’-H3). δC (101 MHz, CDCl3) 96.8 (C4), 95.9 (C4’), 72.5 (C2), 72.1 (C2’), 44.7 (d, J = 17.5 Hz, C3), 
38.3 (C3’), 28.7 (d, J = 21.0 Hz, C1’), 27.7 (C5’), 27.5 (C5), 26.9 (d, J = 10.5 Hz, C1). The 13C signal 
corresponding to the trifluoromethyl group could not be resolved due to its weak intensity.  
δF (377 MHz, CDCl3) -48.6 (3F, d, J = 62.0 Hz). δP (162 MHz, CDCl3) -20.0 (q, J = 62.0 Hz).  
HRMS: (ESI+) Calculated for C11H16F3NaO4P: 323.0631. Found [M+O+Na]+: 323.0645. The apparent 
ease with which L5 undergoes oxidation in solution meant it was not possible to obtain HRMS data for 
the unoxidised ligand. 
Methyl (E)-(3-phenylhex-4-en-1-yl)carbamate (265) 
 
This compound was prepared from 263b by modification of General procedure D. Formic acid was 
included to effect reduction of the N–O bond of 263b. General procedure D: Conditions: 5 mol% 
Pd2(dba)3; 25 mol% PPh3; 200 mol% Et3N; 100 mol% HCO2H; THF (0.1 M); 110 °C; 24 hours. 
Substrate 263b (295 mg, 0.665 mmol) was employed. FCC (eluent: 5:1 petrol:EtOAc) afforded 265 
(88.0 mg, 57 %) as a pale-yellow oil. νmax / cm-1: (film) 3333 (br s), 3026 (m), 2938 (m), 1697 (s), 
1528 (s), 1251 (s). δH (400 MHz, CDCl3) 7.34 – 7.25 (2H, m, 2 × ArCH), 7.24 – 7.14 (3H, m, 3 × 
ArCH), 5.59 – 5.43 (2H, m, C4-H and C5-H), 4.59 (1H, br s, NH), 3.65 (3H, s, OCH3), 3.25 (1H, dt, 
J = 7.5, 7.5 Hz, C3-H), 3.21 – 3.03 (2H, m, C1-H2), 1.93 – 1.83 (2H, m, C2-H2), 1.66 (3H, d, J = 6.0 Hz, 
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C6-H3). δC (101 MHz, CDCl3) 157.1 (MeO–C=O), 144.4 (ArC), 134.3 (C4), 128.7 (ArCH),  
127.5 (ArCH), 126.4 (ArCH), 125.5 (C5), 52.1 (OCH3), 46.7 (C3), 39.7 (C1), 36.1 (C2), 18.1 (C6).  
HRMS: (ESI+) Calculated for C14H19NNaO2: 256.1320. Found [M+Na]+: 256.1313.  
Methyl (2R*,3R*)-3-phenyl-2-vinylpyrrolidine-1-carboxylate (264b) 
   
This compound was prepared using an adaptation of a literature procedure.26 A solution of 265 
(23.3 mg, 0.100 mmol) and Pd(OAc)2 (2.2 mg, 10.0 μmol) in DMSO (0.4 mL) was stirred under an 
atmosphere of O2 (balloon pressure) at 55 °C for 24 hours. The reaction mixture was diluted with Et2O 
(5 mL) and washed with water (3 × 5 mL). The organic phase was dried over Na2SO4 and concentrated 
in vacuo. FCC (eluent: 9:1 petrol:EtOAc) afforded 264b (16.5 mg, 71 %, 4:1 mixture of trans and  
cis diastereomers) as a colourless oil. Conditions reported by Stahl (Pd(OAc)2 (5 mol%); pyridine 
(10 mol%); O2 (balloon pressure); xylene (0.1 M); heated at 80 °C for 24 hours)
55 for the aza-Wacker 
cyclisation of carbamates provided 264b in 37 % yield and approximately 4:3 d.r. (trans:cis) based on 
1H NMR analysis of the crude reaction mixture. Characterisation data for the major diastereomer of 
264b has been provided earlier. 1H NMR signals for the minor cis diastereomer were obtained from 1D 
TOCSY analysis of the mixture of trans and cis diastereomers. The minor diastereomer exists as an 
approximately 1:1 mixture of rotamers; this results in the doubling of several signals in the 1H and 13C 
NMR spectra. Characteristic signals for the minor cis diastereomer: δH (400 MHz, CDCl3) 5.35 – 5.30 
(1H, m, C5-H), 5.04 (1H, d, J = 12.5 Hz, C6-H), 4.97 (1H, d, J = 16.0 Hz, C6-H’), 4.77 – 4.70 and 4.67 
– 4.60 (2 × 0.5H, m, C4-H), 3.72 – 3.61 (2H, m, C1-H2), 3.59 – 3.45 (1H, m, C3-H), 2.36 – 2.22 (1H, 
m, C2-H), 2.17 – 2.08 (1H, m, C2-H’). δC (126 MHz, CDCl3) 134.7 and 134.2 (C5), 116.1 and 115.8 
(C6), 62.9 and 62.5 (C4), 48.0 and 47.2 (C3), 45.7 and 45.5 (C1), 27.0 and 25.9 (C2). 
tert-Butyl (Z)-(4-benzylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (266a) 
 
General procedure O: Alcohol 159c (Section 7.3, 860 mg, 4.52 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (eluent: 3:7 hexane:PhMe) afforded 
266a (1.35 g, 60 %) as a colourless oil. The product was assigned as the (Z)-isomer based on the 
observed NOE correlation between the C6 and the C7 protons. νmax / cm-1: (film) 3030 (m), 2935 (m), 
1783 (s), 1721 (s), 1653 (m), 1505 (s), 1326 (s), 1150 (s). δH (400 MHz, CDCl3) 7.26 – 7.21 (2H, m, 
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2 × ArCH), 7.17 – 7.12 (3H, m, 3 × ArCH), 5.44 (1H, q, J = 7.0 Hz, C5-H), 3.59 (2H, t, J = 7.0 Hz, 
C1-H2), 3.39 (2H, s, C7-H2), 1.98 (2H, t, J = 7.5 Hz, C3-H2), 1.74 – 1.65 (5H, m, C2-H2 and C6-H3), 
1.46 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.5 (Boc C=O), 140.0 (ArC), 137.2 (C4), 128.4 
(ArCH), 128.3 (ArCH), 125.8 (ArCH), 121.1 (C5), 83.2 (OC(CH3)3), 50.6 (C1), 35.5 (C7), 33.4 (C3), 
28.0 (OC(CH3)3), 25.1 (C2), 13.7 (C6). The 
13C signals corresponding to the pentafluorobenzoyl group 
could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.3 – -136.5 (2F, m), -146.6 
(1F, tt, J = 21.0, 5.5 Hz), -159.3 – -159.5 (2F, m). HRMS: (ESI+) Calculated for C25H26F5NNaO4: 
522.1674. Found [M+Na]+: 522.1666.  
tert-Butyl 2-benzyl-2-vinylpyrrolidine-1-carboxylate (267a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 266a (52.4 mg, 0.105 mmol) was employed. FCC 
(eluent: 39:1 hexane:EtOAc) afforded 267a (26.3 mg, 87 %) as a pale-yellow oil. νmax / cm-1: (film) 
2974 (m), 1686 (s), 1381 (s), 1168 (s). This compound exists as an approximately 1:1 mixture of 
rotamers A and B. δH (400 MHz, CDCl3) 7.31 – 7.13 (5H, m, A and B: 5 × ArCH), 6.10 (0.5H, dd, J = 
17.5, 10.5 Hz, A: C5-H), 5.99 (0.5H, dd, J = 17.5, 10.5 Hz, B: C5-H), 5.12 – 4.96 (2H, m, A and B: 
C6-H2), 3.67 (0.5H, d, J = 13.5 Hz, B: C7-H), 3.55 – 3.46 (1H, m, A: C1-H and C7-H), 3.40 (0.5H, ddd, 
J = 11.5, 8.0, 4.0 Hz, B: C1-H), 3.06 (0.5H, ddd, J = 11.0, 7.5, 7.5 Hz, A: C1-H’), 3.01 – 2.82 (1.5H, 
m, A: C7-H’; B: C1-H’ and C7-H’), 2.04 – 1.92 (1H, m, A and B: C3-H), 1.80 – 1.70 (1H, m, A and B: 
C3-H’), 1.60 – 1.48 (10H, m, A and B: C2-H and OC(CH3)3), 1.26 – 1.08 (1H, m, A and B: C2-H’).  
δC (101 MHz, CDCl3) 154.5 (B: C=O), 153.8 (A: C=O), 143.5 (B: C5), 142.5 (A: C5), 138.2 (A: ArC), 
138.1 (B: ArC), 131.0 (B: ArCH), 130.7 (A: ArCH), 128.3 (A: ArCH), 128.0 (B: ArCH), 126.5 (B: 
ArCH), 126.3 (A: ArCH), 112.0 (B: C6), 111.7 (A: C6), 79.9 (B: OC(CH3)3), 79.0 (A: OC(CH3)3), 67.3 
(B: C4), 66.8 (A: C4), 2 × 48.8 (A and B: C1), 42.3 (A: C7), 41.5 (B: C7), 37.9 (A: C3), 36.3 (B: C3), 
28.8 (A and B: OC(CH3)3), 21.4 (B: C2), 21.0 (A: C2). HRMS: (ESI+) Calculated for C18H25NNaO2: 
310.1778. Found [M+Na]+: 310.1788.  
  





General procedure I: 1-Acetyl-1-cyclohexene (5.14 mL, 40.0 mmol) was employed, using anhydrous 
Et2O as solvent and 0.5 eq. LiAlH4 (1.0 M in Et2O). The title compound (3.98 g, 79 %) was isolated as 
a colourless oil. δH (400 MHz, CDCl3) 5.68 – 5.60 (1H, m), 4.20 – 4.10 (1H, m), 2.09 – 1.90 (4H, m), 
1.69 – 1.47 (5H, m), 1.24 (3H, d, J = 6.5 Hz). δC (101 MHz, CDCl3) 141.4, 121.6, 72.3, 25.0, 23.8, 22.8, 
22.7, 21.6. The spectroscopic properties were consistent with the data available in the literature.271 
Ethyl (E)-2-(2-ethylidenecyclohexyl)acetate 
 
General procedure L: The preceding allylic alcohol (2.52 g, 20.0 mmol) was employed. The reaction 
time was 19 hours. FCC (eluent: 49:1 hexane:EtOAc) afforded the title compound (1.99 g, 51 %) as a 
colourless oil. δH (400 MHz, CDCl3) 5.10 (1H, q, J = 6.5 Hz, C9-H), 4.16 – 4.06 (2H, m, OCH2CH3), 
2.59 – 2.48 (2H, m, C2-H and C3-H), 2.36 – 2.24 (2H, m, C2-H’ and C7-H), 2.04 – 1.93 (1H, m, C7-H’), 
1.75 – 1.39 (8H, m, C4-H, C5-H2, C6-H2 and C10-H3), 1.32 – 1.19 (4H, m, C4-H’ and OCH2CH3).  
δC (101 MHz, CDCl3) 173.2 (C1), 141.2 (C8), 114.2 (C9), 60.1 (OCH2CH3), 41.0 (C3), 38.0 (C2), 33.8 
(C4), 27.6 (C6), 26.8 (C7), 24.4 (C5), 14.3 (OCH2CH3), 12.6 (C10). The spectroscopic properties were 
consistent with the data available in the literature,272 although the 1H NMR spectrum is incorrectly 
assigned. The assignment provided here is supported by 2D NMR data. 
(E)-2-(2-Ethylidenecyclohexyl)ethan-1-ol (268) 
 
General procedure I: The preceding ester (1.98 g, 10.1 mmol) was employed, using anhydrous THF 
as solvent and 0.8 eq. LiAlH4 (1.0 M in THF). FCC (eluent: 4:1 hexane:EtOAc) afforded 268 (627 mg, 
40 %) as a colourless oil. νmax / cm-1: (film) 3323 (br s), 2922 (s), 2854 (m), 1446 (m), 1053 (s).  
δH (400 MHz, CDCl3) 5.18 (1H, q, J = 6.5 Hz, C9-H), 3.62 (2H, dd, J = 6.5, 6.5 Hz, C1-H2), 2.24 – 2.04 
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(3H, m, C3-H and C7-H2), 1.90 (1H, ddt, J = 13.5, 9.0, 6.5 Hz, C2-H), 1.70 – 1.32 (10H, m, C2-H’, 
C4-H2, C5-H2, C6-H2 and C10-H3). δC (101 MHz, CDCl3) 142.4 (C8), 115.0 (C9), 61.9 (C1), 41.4 (C3), 
34.8 (C2), 33.9 (C4), 27.8 (C6), 25.7 (C7), 23.3 (C5), 12.6 (C10). HRMS: (ESI+) Calculated for 
C10H18NaO: 177.1250. Found [M+Na]+: 177.1248.  
tert-Butyl (E)-(2-(2-ethylidenecyclohexyl)ethyl)((pentafluorobenzoyl)oxy)carbamate (269) 
 
General procedure O: Alcohol 268 (309 mg, 2.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 14 hours. FCC (eluent: 1:1 hexane:PhMe) afforded 269 (555 mg, 60 %) 
as a colourless oil. The product was assigned as the (E)-isomer based on the observed NOE correlation 
between the C2 and the C9 protons. νmax / cm-1: (film) 2929 (m), 1785 (s), 1723 (s), 1653 (m), 1507 (s), 
1156 (s). δH (400 MHz, CDCl3) 5.15 (1H, q, J = 6.5 Hz, C9-H), 3.62 (2H, dd, J = 7.5, 7.5 Hz, C1-H2), 
2.18 – 2.05 (3H, m, C3-H and C7-H2), 1.93 (1H, ddt, J = 13.5, 8.0, 7.5 Hz, C2-H), 1.72 – 1.34 (19H, 
m, C2-H’, C4-H2, C5-H2, C6-H2, C10-H3 and OC(CH3)3). δC (101 MHz, CDCl3) 154.7 (Boc C=O), 
141.2 (C8), 115.5 (C9), 83.3 (OC(CH3)3), 50.0 (C1), 41.9 (C3), 33.9 (C4), 29.0 (C2), 28.2 (OC(CH3)3), 
27.9 (C6), 26.0 (C7), 23.7 (C5), 12.8 (C10). The 13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.4 – -136.6 (2F, m), 
-146.7 (1F, tt, J = 21.0, 5.5 Hz), -159.2 – -159.5 (2F, m). HRMS: (ESI+) Calculated for C22H26F5NNaO4: 
486.1674. Found [M+Na]+: 486.1681.  
tert-Butyl (3aR*,7aS*)-7a-vinyloctahydro-1H-indole-1-carboxylate (270) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 269 (48.7 mg, 0.105 mmol) was employed. FCC 
(eluent: 79:1 pentane:acetone) afforded 270 (24.2 mg, 92 %) as a colourless oil. It was not possible to 
determine the relative stereochemistry of 270 by NOE analysis. The removal of the Boc group was 
necessary to obtain satisfactory data, details of this are given below. This compound exists as an 
approximately 3:2 mixture of rotamers A and B. νmax / cm-1: (film) 2928 (m), 1682 (s), 1364 (s).  
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δH (500 MHz, CDCl3) 5.83 – 5.69 (1H, m, A and B: C9-H), 5.10 – 5.03 (1H, m, A and B: C10-H), 4.99 
(1H, d, J = 17.5 Hz, A and B: C10-H’), 3.63 – 3.47 (1H, m, A and B: C1-H), 3.46 – 3.34 (1H, m, A and 
B: C1-H’), 2.53 – 2.43 (0.4H, m, B: C7-H), 2.13 – 2.04 (0.6H, m, A: C7-H), 1.99 – 1.85 (1H, m, A and 
B: C3-H), 1.84 – 1.67 (2H, m, A and B: C2-H and C7-H’), 1.62 – 1.26 (16H, m, A and B: C2-H’, C4-H2, 
C5-H2, C6-H2 and OC(CH3)3). δC (126 MHz, CDCl3) 155.3 (A: C=O), 154.2 (B: C=O), 143.0 (A: C9), 
142.6 (B: C9), 112.7 (A: C10), 112.5 (B: C10), 79.4 (A: OC(CH3)3), 78.7 (B: OC(CH3)3), 66.2 (B: C8), 
65.4 (A: C8), 46.6 (B: C1), 46.5 (A: C1), 44.8 (A: C3), 43.4 (B: C3), 32.0 (A: C7), 31.3 (B: C7), 28.8 
(B: OC(CH3)3), 28.7 (A: OC(CH3)3), 27.1 (B: C4), 26.7 (B: C2), 26.6 (A: C4), 26.2 (A: C2), 23.8 (B: 
C5), 23.2 (A: C5), 22.1 (A: C6), 22.0 (B: C6). HRMS: (ESI+) Calculated for C15H25NNaO2: 275.1778. 
Found [M+Na]+: 274.1776.  
(3aR*,7aS*)-7a-Vinyloctahydro-1H-indol-1-ium trifluoroacetate 
 
General procedure Q: Pyrrolidine 270 (13.0 mg, 51.7 μmol) was employed to afford the title 
compound (13.5 mg, 98 %) as a colourless oil. The relative stereochemistry of the product was assigned 
based on the observed NOE correlation between the C3 and the C9 protons. νmax / cm-1: (film) 
3418 (br s), 2941 (m), 1670 (s), 1425 (m), 1201 (s). δH (400 MHz, CDCl3) 9.45 (1H, br s, NH), 9.19 
(1H, br s, NH’), 5.94 (1H, dd, J = 17.5, 11.0 Hz, C9-H), 5.50 (1H, d, J = 17.5 Hz, C10-H’), 5.44 (1H, 
d, J = 11.0 Hz, C10-H), 3.45 – 3.31 (2H, m, C1-H2), 2.44 (1H, dddd, J = 8.5, 8.5, 4.0, 4.0 Hz, C3-H), 
2.13 – 2.02 (2H, m, C2-H2), 1.93 (1H, ddd, J = 13.0, 3.5, 3.5 Hz, C7-H), 1.74 – 1.55 (4H, m, C4-H2, 
C6-H and C7-H’), 1.52 – 1.42 (2H, m, C5-H2), 1.41 – 1.27 (1H, m, C6-H’). δC (101 MHz, CDCl3) 136.1 
(C9), 120.0 (C10), 67.5 (C8), 41.9 (C1), 41.0 (C3), 28.9 (C7), 26.5 (C2), 24.2 (C4), 21.7 (C6), 20.0 
(C5). The 13C signals corresponding to the trifluoroacetate counterion could not be resolved due to 
their weak intensity. δF (377 MHz, CDCl3) -75.6 (3F, s). HRMS: (ESI+) Calculated for C8H12N: 
152.1434. Found [M–F3CCO2]+: 152.1435.  
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tert-Butyl (2-(cyclohex-2-en-1-yl)ethyl)((pentafluorobenzoyl)oxy)carbamate (241b) 
 
General procedure O: Alcohol 83 (Section 7.3, 240 mg, 1.90 mmol) was employed with BocNHOFBz 
(vide supra). The reaction time was 16 hours. FCC (eluent: 2:3 hexane:PhMe) afforded 241b (334 mg, 
40 %) as a pale-yellow oil. νmax / cm-1: (film) 2932 (m), 1783 (s), 1721 (s), 1652 (m), 1504 (s), 1154 (s). 
δH (400 MHz, CDCl3) 5.69 (1H, dtd, J = 10.0, 3.5, 2.5 Hz, C5-H), 5.54 (1H, ddt, J = 10.0, 2.5, 2.5 Hz, 
C4-H), 3.73 (2H, t, J = 7.5 Hz, C1-H2), 2.22 – 2.13 (1H, m, C3-H), 1.99 – 1.93 (2H, m, C6-H2), 1.81 
(1H, dddd, J = 12.5, 6.0, 6.0, 3.0 Hz, C8-H), 1.75 – 1.50 (4H, m, C2-H2 and C7-H2), 1.48 (9H, s, 
OC(CH3)3), 1.24 (1H, dddd, J = 12.5, 11.0, 8.5, 3.0 Hz, C8-H’). δC (101 MHz, CDCl3) 154.7 (Boc C=O), 
130.8 (C4), 127.9 (C5), 83.4 (OC(CH3)3), 49.0 (C1), 33.2 (C2), 32.6 (C3), 28.8 (C8), 28.2 (OC(CH3)3), 
25.4 (C6), 21.4 (C7). The 13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.4 – -136.6 (2F, m), -146.6 (1F, tt, J = 
21.0, 4.5 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C20H22F5NNaO4: 458.1361. Found 
[M+Na]+: 458.1350.  
tert-Butyl (3aR*,7aS*)-2,3,3a,4,5,7a-hexahydro-1H-indole-1-carboxylate (242b) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 243b (45.7 mg, 0.105 mmol) was employed. FCC 
(eluent: 59:1 pentane:acetone) afforded 242b (18.2 mg, 78 %) as a colourless oil. The Boc group of 
242b was removed to confirm that the presence of two sets of signals are due to the presence of two 
rotamers rather than two alkene isomers, details of this are given below. This compound exists as an 
approximately 3:2 mixture of rotamers A and B. νmax / cm-1: (film) 2925 (m), 1690 (s), 1388 (s), 1114 (s). 
δH (500 MHz, CDCl3) 5.92 (0.4H, br d, J = 10.5 Hz, B: C5-H), 5.77 (0.6H, br d, J = 10.5 Hz, A: C5-H), 
5.75 – 5.69 (1H, m, A and B: C6-H), 4.23 (0.4H, br s, B: C4-H), 4.13 (0.6H, br s, A: C4-H), 3.49 – 3.27 
(2H, m, A and B: C1-H2), 2.39 (1H, br s, A and B: C3-H), 2.10 – 1.92 (2H, m, A and B: C7-H2), 1.85 
– 1.72 (3H, m, A and B: C2-H2 and C8-H), 1.71 – 1.63 (1H, m, A and B: C8-H’), 1.49 (5.4H, s, A: 
OC(CH3)3), 1.48 (3.6H, s, B: OC(CH3)3). δC (126 MHz, CDCl3) 154.8 (A and B: C=O), 127.6 (A: C6), 
127.3 (B: C6), 127.0 (A: C5), 126.7 (B: C5), 79.2 (A: OC(CH3)3), 79.0 (B: OC(CH3)3), 55.1 (A: C4), 
54.9 (B: C4), 45.4 (B: C1), 45.0 (A: C1), 36.6 (A: C3), 35.8 (B: C3), 28.7 (A and B: OC(CH3)3), 27.3 
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(B: C2), 26.5 (A: C2), 22.8 (A and B: C8), 2 × 20.9 (A and B: C7). HRMS: (ESI+) Calculated for 
C13H21NNaO2: 246.1465. Found [M+Na]+: 246.1470.  
(3aR*,7aS*)-2,3,3a,4,5,7a-Hexahydro-1H-indol-1-ium trifluoroacetate 
 
General procedure Q: Pyrrolidine 242b (12.3 mg, 55.1 μmol) was employed to afford the title 
compound (12.4 mg, 95 %) as a pale-yellow oil. The product was assigned as the cis diastereomer 
based on the observed NOE correlation between the C3 and the C4 protons. νmax / cm-1: (film) 
3425 (br s), 2936 (m), 1673 (s), 1429 (m), 1201 (s). δH (400 MHz, CDCl3) 10.07 (1H, br s, NH), 8.98 
(1H, br s, NH’), 6.16 – 6.10 (1H, m, C6-H), 5.75 (1H, dddd, J = 10.5, 4.0, 2.0, 2.0 Hz, C5-H), 3.96 (1H, 
br s, C4-H), 3.38 (1H, br s, C1-H), 3.28 (1H, br s, C1-H’), 2.55 – 2.41 (1H, m, C3-H), 2.24 – 2.11 (2H, 
m, C2-H and C7-H), 2.08 – 1.93 (1H, m, C7-H’), 1.86 (1H, dddd, J = 13.5, 8.5, 5.5, 5.5 Hz, C2-H’), 
1.76 (1H, dddd, J = 13.5, 5.0, 5.0, 5.0 Hz, C8-H), 1.58 (1H, dddd, J = 13.5, 10.0, 8.0, 5.5 Hz, C8-H’). 
δC (101 MHz, CDCl3) 135.3 (C6), 120.3 (C5), 56.3 (C4), 43.0 (C1), 35.1 (C3), 28.5 (C2), 22.8 (C8), 
22.6 (C7). The 13C signals corresponding to the trifluoroacetate counterion could not be resolved due 
to their weak intensity. δF (377 MHz, CDCl3) -75.7 (3F, s). HRMS: (ESI+) Calculated for C8H14N: 
124.1121. Found [M–F3CCO2]+: 124.1120.  
tert-Butyl (3-(cyclohex-1-en-1-yl)propyl)((pentafluorobenzoyl)oxy)carbamate (271) 
 
General procedure O: 3-(Cyclohex-1-en-1-yl)propan-1-ol (Section 7.3, 280 mg, 2.00 mmol) was 
employed with BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (gradient elution: 3:7 
– 0:1 hexane:PhMe) afforded 271 (561 mg, 62 %) as a colourless oil. νmax / cm-1: (film) 2932 (m), 
1783 (s), 1721 (s), 1652 (m), 1505 (s), 1326 (s), 1150 (s). δH (400 MHz, CDCl3) 5.44 – 5.39 (1H, m, 
C5-H), 3.64 (2H, t, J = 7.5 Hz, C1-H2), 2.03 – 1.94 (4H, m, C3-H2 and C6-H2), 1.93 – 1.87 (2H, m, 
C9-H2), 1.74 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.65 – 1.58 (2H, m, C8-H2), 1.57 – 1.51 (2H, m, C7-H2), 
1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.7 (Boc C=O), 136.5 (C4), 121.9 (C5), 83.3 
(OC(CH3)3), 50.9 (C1), 34.9 (C3), 28.3 (C9), 28.2 (OC(CH3)3), 25.4 (C6), 24.9 (C2), 23.1 (C8), 22.6 
(C7). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their 
weak intensity. δF (377 MHz, CDCl3) -136.4 – -136.8 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.4 
– -159.6 (2F, m). HRMS: (ESI+) Calculated for C21H24F5NNaO4: 472.1518. Found [M+Na]+: 472.1514.  
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tert-Butyl 1-azaspiro[4.5]dec-6-ene-1-carboxylate (272) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 271 (47.2 mg, 0.105 mmol) was employed. FCC 
(eluent: 39:1 PhMe:EtOAc) afforded 272 (20.3 mg, 81 %) as a colourless oil. The Boc group of 272 
was removed to confirm that the presence of two sets of signals is due to the presence of two rotamers, 
rather than two alkene isomers. Details of this are given below. This compound exists as an 
approximately 13:7 mixture of rotamers A and B. νmax / cm-1: (film) 2969 (m), 2927 (m), 1683 (s), 
1380 (s), 1159 (s). δH (500 MHz, CDCl3) 5.79 – 5.70 (0.35H, m, B: C5-H), 5.68 – 5.60 (0.65H, m, A: 
C5-H), 5.51 (0.35H, br d, J = 10.0 Hz, B: C6-H), 5.41 (0.65H, br d, J = 10.0 Hz, A: C6-H), 3.61 – 3.45 
(1H, m, A and B: C1-H), 3.43 – 3.31 (1H, m, A and B: C1-H’), 2.39 – 2.27 (0.35H, m, B: C9-H), 2.22 
– 2.09 (1H, m, A: C9-H and B: C7-H), 2.00 – 1.88 (2.65H, m, A: C3-H and C7-H2, B: C3-H and C7-H’), 
1.84 – 1.71 (4H, m, A and B: C2-H2, C3-H’ and C8-H), 1.65 – 1.50 (2H, m, A and B: C8-H’ and C9-H’), 
1.45 (9H, s, A and B: OC(CH3)3). δC (126 MHz, CDCl3) 154.6 (A: C=O), 153.3 (B: C=O), 134.7 (A: 
C6), 134.1 (B: C6), 126.6 (B: C5), 126.0 (A: C5), 79.2 (A: OC(CH3)3), 78.8 (B: OC(CH3)3), 62.3 (A 
and B: C4), 47.9 (B: C1), 47.6 (A: C1), 40.1 (A: C3), 39.3 (B: C3), 32.1 (A: C9), 30.9 (B: C9), 28.8 (B: 
OC(CH3)3), 28.5 (A: OC(CH3)3), 24.5 (A: C7), 24.2 (B: C7), 22.5 (B: C2), 22.0 (A: C2), 21.9 (A: C8), 
21.6 (B: C8). HRMS: (ESI+) Calculated for C14H23NNaO2: 260.1621. Found [M+Na]+: 260.1626.  
1-Azaspiro[4.5]dec-6-en-1-ium trifluoroacetate 
 
General procedure Q: Pyrrolidine 272 (17.3 mg, 72.9 μmol) was employed to afford the title 
compound (17.7 mg, 97 %) as a pale-yellow oil. νmax / cm-1: (film) 3422 (br s), 2946 (m), 1671 (s), 
1431 (m), 1201 (s). δH (400 MHz, CDCl3) 9.25 (2H, br s, NH2), 6.00 (1H, dt, J = 10.0, 4.0 Hz, C6-H), 
5.70 (1H, d, J = 10.0 Hz, C5-H), 3.44 – 3.24 (2H, m, C1-H2), 2.17 – 1.89 (7H, m, C2-H2, C3-H2,  
C7-H2 and C9-H), 1.85 – 1.61 (3H, m, C8-H2 and C9-H’). δC (101 MHz, CDCl3) 134.0 (C6), 126.0 
(C5), 65.6 (C4), 44.0 (C1), 37.6 (C3), 31.8 (C9), 24.6 (C7), 22.8 (C2), 19.5 (C8). The 13C signals 
corresponding to the trifluoroacetate counterion could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -75.6 (3F, s). HRMS: (ESI+) Calculated for C9H16N: 138.1277. Found  
[M–F3CCO2]+: 138.1283.  
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tert-Butyl (cyclohex-3-en-1-ylmethyl)((pentafluorobenzoyl)oxy)carbamate (273) 
 
General procedure O: Cyclohex-3-en-1-ylmethanol (Section 7.3, 224 mg, 2.00 mmol) was employed 
with BocNHOFBz (vide supra). The reaction time was 21 hours. FCC (eluent: 2:3 hexane:PhMe) 
afforded 273 (451 mg, 54 %) as a low-melting solid. νmax / cm-1: (film) 3026 (m), 2920 (m), 1784 (s), 
1720 (s), 1652 (m), 1504 (s), 1326 (s), 1152 (s). δH (400 MHz, CDCl3) 5.72 – 5.61 (2H, m, C4-H and 
C5-H), 3.68 – 3.55 (2H, m, C1-H2), 2.21 – 2.11 (1H, m, C3-H), 2.11 – 2.02 (2H, m, C6-H2), 2.02 – 1.92 
(1H, m, C2-H), 1.88 – 1.73 (2H, m, C3-H’ and C7-H), 1.49 (9H, s, OC(CH3)3), 1.39 – 1.27 (1H, m, 
C7-H’). δC (101 MHz, CDCl3) 154.7 (Boc C=O), 127.2 (C5), 125.6 (C4), 83.3 (OC(CH3)3), 56.3 (C1), 
32.1 (C2), 29.2 (C3), 28.2 (OC(CH3)3), 26.1 (C7), 24.5 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.2 – -136.6 (2F, m), -146.5 (1F, tt, J = 21.0, 5.0 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) 
Calculated for C19H20F5NNaO4: 444.1205. Found [M+Na]+: 444.1207.  
tert-Butyl (1R*,5R*)-6-azabicyclo[3.2.1]oct-3-ene-6-carboxylate (274) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 273 
(44.2 mg, 0.105 mmol) was employed. FCC (eluent: 49:1 PhMe:EtOAc) afforded 274 (14.0 mg, 64 %) 
as a pale-yellow oil. The Boc group of 274 was removed to confirm that the presence of two sets of 
signals are due to the presence of two rotamers rather than two alkene isomers, details of this are given 
below. This compound exists as an approximately 3:2 mixture of rotamers A and B. νmax / cm-1: (film) 
2928 (m), 1690 (s), 1397 (s), 1099 (s). δH (400 MHz, CDCl3) 6.18 (0.4H, dd, J = 8.0, 7.0 Hz, B: C5-H), 
6.07 (0.6H, dd, J = 7.5, 7.5 Hz, A: C5-H), 5.60 – 5.51 (1H, m, A and B: C6-H), 4.26 – 4.20 (0.4H, m, 
B: C4-H), 4.13 – 4.06 (0.6H, m, A: C4-H), 3.56 – 3.46 (1H, m, A and B: C1-H), 3.22 (0.6H, br d, J = 
11.0 Hz, A: C1-H’), 3.14 (0.4H, br d, J = 11.0 Hz, B: C1-H’), 2.57 – 2.42 (2H, m, A and B: C2-H and 
C7-H), 2.09 (1H, br d, J = 18.0 Hz, A and B: C7-H’), 1.90 – 1.77 (1H, m, A and B: C3-H), 1.73 (1H, 
br d, J = 10.5 Hz, A and B: C3-H’), 1.45 (9H, s, A and B: OC(CH3)3). δC (126 MHz, CDCl3) 154.2 (A: 
C=O), 153.8 (B: C=O), 131.7 (B: C5), 131.4 (A: C5), 127.4 (A: C6), 127.1 (B: C6), 79.0 (A and B: 
OC(CH3)3), 53.1 (B: C1), 52.9 (A: C1), 51.6 (A: C4), 50.8 (B: C4), 2 × 35.4 (A and B: C7), 34.5 (A: 
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C3), 34.0 (B: C3), 33.2 (B: C2), 32.4 (A: C2), 28.7 (A and B: OC(CH3)3). HRMS: (ESI+) Calculated 
for C12H19NNaO2: 232.1308. Found [M+Na]+: 232.1315. 
(1R*,5R*)-6-Azabicyclo[3.2.1]oct-3-en-6-ium trifluoroacetate 
 
General procedure Q: Pyrrolidine 274 (4.8 mg, 22.9 μmol) was employed to afford the title compound 
(4.5 mg, 88 %) as a pale-yellow oil. νmax / cm-1: (film) 3415 (br s), 2981 (m), 1674 (s), 1430 (m), 
1201 (s). δH (500 MHz, CDCl3) 9.64 (1H, br s, NH), 9.34 (1H, br s, NH’), 5.99 – 5.92 (1H, m, C5-H), 
5.92 – 5.86 (1H, m, C6-H), 4.12 – 4.02 (1H, m, C4-H), 3.57 – 3.46 (1H, m, C1-H), 3.27 – 3.18 (1H, m, 
C1-H’), 2.78 – 2.69 (1H, m, C2-H), 2.56 (1H, br d, J = 19.0 Hz, C7-H), 2.19 (1H, br d, J = 19.0 Hz, 
C7-H’), 2.11 – 2.05 (1H, m, C3-H), 1.96 (1H, d, J = 12.0 Hz, C3-H’). δC (126 MHz, CDCl3) 132.2 (C6), 
125.7 (C5), 52.6 (C4), 50.4 (C1), 35.3 (C7), 32.8 (C3), 32.5 (C2). The 13C signals corresponding to the 
trifluoroacetate counterion could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -75.6 (3F, s). HRMS: (ESI+) Calculated for C7H12N: 110.0964. Found [M–F3CCO2]+: 110.0969.  
tert-Butyl (Z)-hept-5-en-1-yl((pentafluorobenzoyl)oxy)carbamate (275a) 
 
General procedure O: Alcohol (Z)-189 (Section 7.3, 228 mg, 2.00 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 18 hours. FCC (eluent: 1:4 hexane:PhMe) afforded 
275a (520 mg, 61 %) as a colourless oil. νmax / cm-1: (film) 2936 (m), 1783 (s), 1721 (s), 1652 (m), 
1505 (s), 1153 (s). δH (400 MHz, CDCl3) 5.50 – 5.41 (1H, m, C6-H), 5.42 – 5.29 (1H, m, C5-H), 3.68 
(2H, t, J = 7.0 Hz, C1-H2), 2.07 (2H, dt, J = 7.5, 7.5 Hz, C4-H2), 1.65 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 
1.60 (3H, d, J = 6.5 Hz, C7-H3), 1.49 (9H, s, OC(CH3)3), 1.44 (2H, tt, J = 7.5, 7.5 Hz, C3-H2).  
δC (101 MHz, CDCl3) 154.8 (Boc C=O), 130.1 (C5), 124.5 (C6), 83.4 (OC(CH3)3), 51.0 (C1), 28.2 
(OC(CH3)3), 26.6 (C2), 2 × 26.5 (C3 and C4), 12.9 (C7). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.4 – -136.6 (2F, m), -146.6 (1F, tt, J = 20.5, 5.5 Hz), -159.3 – -159.5 (2F, m). HRMS: (ESI+) 
Calculated for C19H22F5NNaO4: 446.1361. Found [M+Na]+: 446.1367. 
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tert-Butyl 2-vinylpiperidine-1-carboxylate (276a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; dioxane (0.4 M); 130 °C; 24 hours. Substrate 275a (102 mg, 0.240 mmol) was employed. FCC 
(two times, first eluent: 79:1 pentane:acetone; second, gradient elution: 1:0:0 – 0:1:0 – 0:0:1 
PhMe:pentane:Et2O) afforded 276a (15.0 mg, 30 %) as a colourless oil. δH (400 MHz, CDCl3) 5.75 (1H, 
ddd, J = 17.5, 10.5, 4.0 Hz), 5.17 (1H, ddd, J = 10.5, 1.5, 1.5 Hz), 5.03 (1H, ddd, J = 17.5, 1.5, 1.0 Hz), 
4.78 (1H, br s), 3.94 (1H, br d, J = 13.0 Hz), 2.82 (1H, ddd, J = 13.0, 13.0, 3.0 Hz), 1.78 – 1.32 (6H, 
m), 1.45 (9H, s). δC (101 MHz, CDCl3) 155.6, 137.0, 115.6, 79.4, 52.6, 39.8, 29.1, 28.6, 25.7, 19.6.  
The spectroscopic properties were consistent with the data available in the literature.273 
Ethyl 5-methylhept-5-enoate 
 
To a suspension of ethyltriphenylphosphonium bromide (6.68 g, 18.0 mmol) in anhydrous THF 
(140 mL) at 0 °C was added KHMDS (1.0 M in THF, 18.0 mL, 18.0 mmol). The reaction mixture was 
stirred at 0 °C for 1 hour before addition of ethyl 4-acetylbutyrate (1.92 mL, 50.0 mmol). The reaction 
mixture was stirred at room temperature for 23 hours before addition of acetone (10 mL). The reaction 
mixture was filtered through silica, eluted with Et2O, and the filtrate was concentrated in vacuo. FCC 
(gradient elution: 29:1 – 19:1 hexane:Et2O) afforded the title compound (1.00 g, 49 %, 1.2:1 mixture of 
alkene isomers A and B) as a colourless oil. νmax / cm-1: (film) 2933 (m), 1734 (s), 1447 (m), 1147 (s). 
δH (400 MHz, CDCl3) 5.27 – 5.17 (1H, m, A and B: C6-H), 4.12 (1.1H, q, J = 7.0 Hz, A: OCH2CH3), 
4.11 (0.9H, q, J = 7.0 Hz, B: OCH2CH3), 2.27 (1.1H, t, J = 7.5 Hz, A: C2-H2), 2.24 (0.9H, t, J = 7.5 Hz, 
B: C2-H2), 2.06 (1.1H, t, J = 7.5 Hz, A: C4-H2), 1.99 (0.9H, t, J = 7.5 Hz, B: C4-H2), 1.71 (2H, tt, J = 
7.5, 7.5 Hz, A and B: C3-H2), 1.67 – 1.65 (1.65H, m, A: C8-H3), 1.59 – 1.52 (4.35H, m, A: C7-H3; B: 
C7-H3 and C8-H3), 2 × 1.25 (1.65H, t, J = 7.0 Hz, A: OCH2CH3 and 1.35H, t, J = 7.0 Hz, B: OCH2CH3). 
δC (101 MHz, CDCl3) 174.0 (B: C1), 173.9 (A: C1), 135.1 (A: C5), 134.9 (B: C5), 120.1 (A: C6), 119.4 
(B: C6), 2 × 60.3 (A and B: OCH2CH3), 39.1 (B: C4), 34.0 (A: C2), 33.9 (B: C2), 30.7 (A: C4), 23.3 
(A: C8), 23.2 (B: C3), 23.1 (A: C3), 15.5 (B: C8), 2 × 14.4 (A and B: OCH2CH3), 13.5 (B: C7), 13.4 
(A: C7). HRMS: (ESI+) Calculated for C10H18NaO2: 193.1199. Found [M+Na]+: 193.1189.  
 





General procedure I: The preceding ester (935 mg, 5.49 mmol) was employed, using anhydrous Et2O 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in Et2O). Alcohol 277 (607 mg, 86 %, 1.2:1 mixture of alkene 
isomers A and B) was isolated as a colourless oil. νmax / cm-1: (film) 3326 (br s), 2932 (m), 2861 (m), 
1452 (m), 1056 (s). δH (400 MHz, CDCl3) 5.25 – 5.17 (1H, m, A and B: C6-H), 3.65 (2H, dt, J = 6.0, 
6.0 Hz, A and B: C1-H2), 2.05 (1.1H, t, J = 7.5 Hz, A: C4-H), 2.00 (0.9H, t, J = 7.5 Hz, B: C4-H), 1.68 
– 1.65 (1.65H, m, A: C8-H3), 1.61 – 1.40 (8.35H, m, A: C2-H2, C3-H2 and C7-H3, B: C2-H2, C3-H2, 
C7-H3 and C8-H3), 1.32 (1H, br s, A and B: OH). δC (101 MHz, CDCl3) 135.9 (A: C5), 135.7 (B: C5), 
119.3 (A: C6), 118.7 (B: C6), 2 × 63.1 (A and B: C1), 39.5 (B: C4), 32.7 (A: C2), 32.5 (B: C2),  
31.2 (A: C4), 24.1 (B: C3), 24.0 (A: C3), 23.4 (A: C8), 15.6 (B: C8), 13.5 (B: C7), 13.4 (A: C7). 
HRMS: (MALDI-) Calculated for C8H16ClO: 163.0895. Found [M+Cl]-: 163.0891. 
tert-Butyl (5-methylhept-5-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (278) 
 
General procedure O: Alcohol 277 (573 mg, 4.47 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 7 hours. FCC (eluent: 3:7 hexane:PhMe) afforded 278 (1.22 g, 62 %, 
1.2:1 mixture of alkene isomers A and B) as a colourless oil. νmax / cm-1: (film) 2935 (m), 1783 (s), 
1721 (s), 1652 (m), 1505 (s), 1151 (s). δH (400 MHz, CDCl3) 5.25 – 5.16 (1H, m, A and B: C6-H), 3.71 
– 3.64 (2H, m, A and B: C1-H2), 2.05 (1.1H, t, J = 7.5 Hz, A: C4-H2), 2.00 (0.9H, t, J = 7.5 Hz, B: 
C4-H2), 1.68 – 1.52 (8H, m, A and B: C2-H2, C7-H3 and C8-H3), 1.52 – 1.41 (11H, m, A and B: C3-H2 
and OC(CH3)3). δC (101 MHz, CDCl3) 2 × 154.8 (A and B: C=O), 135.6 (A: C5), 135.3 (B: C5), 119.5 
(A: C6), 118.9 (B: C6), 83.4 (A: OC(CH3)3), 83.3 (B: OC(CH3)3), 2 × 51.0 (A and B: C1), 39.2 (B: C4), 
30.9 (A: C4), 2 × 28.2 (A and B: OC(CH3)3), 26.8 (A: C2), 26.5 (B: C2), 24.8 (B: C3), 24.7 (A: C3), 
23.4 (A: C8), 15.5 (B: C8), 2 × 13.4 (A and B: C7). The 13C signals corresponding to the 
pentafluorobenzoate group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.4 – -136.8 (2F, m), -146.7 – -146.8 (1F, m), -159.4 – -159.6 (2F, m). HRMS: (ESI+) 
Calculated for C20H24F5NNaO4: 460.1518. Found [M+Na]+: 460.1513.  
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tert-Butyl 2-methyl-2-vinylpiperidine-1-carboxylate (279) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% ligand L6 (vide supra); 100 mol% 
Et3N; dioxane (0.4 M); 130 °C; 24 hours. Substrate 278 (45.9 mg, 0.105 mmol) was employed. FCC 
(eluent: 69:1 pentane:acetone) afforded a 5:1 mixture of 279 and 1,3,5-trimethoxybenzene (4.0 mg, 
15 % yield of 279) as a colourless oil. Spectroscopic data for 279: νmax / cm-1: (film) 2931 (m), 1684 (s), 
1604 (m), 1456 (m), 1365 (s), 1152 (s). δH (500 MHz, CDCl3) 5.99 (1H, dd, J = 17.5, 11.0 Hz, C6-H), 
4.90 (1H, dd, J = 11.0, 1.0 Hz, C7-H), 4.89 (1H, dd, J = 17.5, 1.0 Hz, C7-H’), 3.65 – 3.59 (1H, m, 
C1-H), 3.28 – 3.22 (1H, m, C1-H’), 1.67 – 1.45 (6H, m, C2-H2, C3-H2 and C4-H2), 1.44 (3H, s, C8-H3), 
1.42 (9H, s, OC(CH3)3). δC (126 MHz, CDCl3) 156.4 (C=O), 147.0 (C6), 108.7 (C7), 79.8 (OC(CH3)3), 
58.4 (C5), 41.6 (C1), 39.2 (C4), 28.6 (OC(CH3)3), 24.3 (C2), 22.4 (C8), 19.1 (C3). HRMS: (ESI+) 
Calculated for C13H23NNaO2: 248.1621. Found [M+Na]+: 248.1631.  
1H and 13C NMR data for 1,3,5-trimethoxybenzene: δH (500 MHz, CDCl3) 6.09 (3H, s), 3.77 (9H, s).  
δC (126 MHz, CDCl3) 161.7, 93.1, 55.5. 
8-Bromo-1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantane 
 
This compound was prepared according to a literature procedure.153 To a solution of  
1,3,5,7-tetramethyl-2,4,6-trioxa-8-phosphaadamantane (248)XLIX (649 mg, 3.00 mmol) in anhydrous 
CH2Cl2 (18 mL, argon sparged) at 0 °C was added a solution of Br2 (0.17 mL, 3.30 mmol) in anhydrous 
CH2Cl2 (12 mL, argon sparged) dropwise. The reaction mixture was stirred at 0 °C for 30 minutes, then 
at room temperature for a further 15 hours before being concentrated in vacuo to afford the title 
compound (860 mg, 97 %) as an orange crystalline solid. δH (400 MHz, CDCl3) 2.43 (1H, d, J = 
13.5 Hz), 2.07 (1H, s), 2.02 (1H, d, J = 9.5 Hz), 1.63 (1H, dd, J = 13.5, 4.5 Hz), 1.43 (3H, d, J = 1.5 Hz), 
1.42 (3H, s), 1.40 (3H, d, J = 1.0 Hz), 1.38 (3H, s). δC (101 MHz, CDCl3) 96.8 (d, J = 2.0 Hz), 96.0, 
74.1 (d, J = 27.0 Hz), 73.0 (d, J = 42.0 Hz), 44.0 (d, J = 19.5 Hz), 35.1, 27.8, 27.3 (d, J = 2.0 Hz), 27.2 
(d, J = 8.0 Hz), 27.0 (d, J = 3.5 Hz). δP (162 MHz, CDCl3) 52.2. The spectroscopic properties were 
consistent with the data available in the literature.153  
                                                     
XLIX Phosphine 248 was prepared by Charly Faradji (University of Bristol) according to a literature procedure.147 





This compound was prepared according to a literature procedure.153 To a solution of the preceding 
compound (590 mg, 2.00 mmol) in anhydrous THF (15 mL) at 0 °C was added a solution, prepared at 
0 °C, of PhOH (188 mg, 2.00 mmol) and n-BuLi (1.6 M in hexane, 1.25 mL, 2.00 mmol) in anhydrous 
THF (5 mL) dropwise over around 15 minutes. The reaction mixture was stirred at room temperature 
for 15 hours before being filtered through silica and eluted with CH2Cl2. The filtrate was concentrated 
in vacuo. FCC (gradient elution: 1:4 – 0:1 hexane:PhMe) afforded L10 (230 mg, 37 %) as a colourless 
crystalline solid. m.p. 85-87 °C (CH2Cl2:petrol, globular). δH (400 MHz, CDCl3) 7.32 – 7.26 (2H, m), 
7.12 – 7.07 (2H, m), 7.04 (1H, tt, J = 7.5, 1.0 Hz), 2.26 (1H, d, J = 13.0 Hz), 1.94 (1H, s), 1.90 (1H, d, 
J = 8.5 Hz), 1.62 (1H, dd, J = 13.0, 5.5 Hz), 1.46 (3H, s), 1.44 (3H, d, J = 13.0 Hz), 2 × 1.39 (3H, s and 
3H, d, J = 13.5 Hz). δC (101 MHz, CDCl3) 157.8, 129.7, 123.0, 119.1 (d, J = 9.5 Hz), 96.3, 96.0, 74.8 
(d, J = 26.5 Hz), 73.4 (d, J = 12.0 Hz), 43.3 (d, J = 18.0 Hz), 35.4, 28.0, 27.5, 27.4 (d, J = 23.0 Hz), 
25.9 (d, J = 13.0 Hz). δP (162 MHz, CDCl3) 78.7. The spectroscopic properties were consistent with the 
data available in the literature.153 
tert-Butyl(dec-5-yn-1-yloxy)dimethylsilane 
 
To a solution of dec-5-yn-1-ol (280) (771 mg, 5.00 mmol), Et3N (0.84 mL, 6.00 mmol) and DMAP 
(30.5 mg, 0.250 mmol) in CH2Cl2 at 0 °C was added TBSCl (829 mg, 5.50 mmol). The reaction mixture 
was stirred at room temperature for 16 hours before addition of saturated aqueous NH4Cl (15 mL). The 
resulting phases were separated, and the aqueous phase was extracted with CH2Cl2 (25 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
79:1 petrol:EtOAc) afforded the title compound (1.13 g, 84 %) as a colourless oil. νmax / cm-1: (film) 
2954 (m), 2930 (m), 2858 (m), 1463 (m), 1254 (m), 1103 (s). δH (400 MHz, CDCl3) 3.62 (2H, t, J = 
6.5 Hz, C1-H2), 2.19 – 2.10 (4H, m, C4-H2 and C7-H2), 1.65 – 1.34 (8H, m, C2-H2, C3-H2, C8-H2 and 
C9-H2), 0.93 – 0.86 (12H, m, C10-H3 and SiC(CH3)3), 0.05 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 
80.5 (C6), 80.1 (C5), 63.0 (C1), 32.2 (C2), 31.4 (C8), 26.1 (SiC(CH3)3), 25.7 (C3), 22.1 (C9), 18.7 (C4), 
18.6 (C7), 18.5 (SiC(CH3)3), 13.8 (C10), -5.1 (Si(CH3)2). HRMS: (ESI+) Calculated for C16H32NaOSi: 
291.2115. Found [M+Na]+: 291.2111. 





A solution of the preceding alkyne (1.00 g, 3.72 mmol), Lindlar catalyst (39.6 mg, 18.6 μmol) and 
quinoline (4.5 μL, 37.2 μmol) in petrol (25 mL) was stirred under an atmosphere of H2 (balloon 
pressure) for 2 hours. The reaction mixture was filtered through celite, and the filter cake was washed 
with petrol (25 mL). The filtrate was washed with 1.0 M aqueous HCl, dried over Na2SO4 and 
concentrated in vacuo to afford the title compound (983 mg, 98 %) as a colourless oil. νmax / cm-1: (film) 
2955 (m), 2928 (m), 2857 (m), 1463 (m), 1254 (m), 1100 (s). δH (400 MHz, CDCl3) 5.41 – 5.30 (2H, 
m, C5-H and C6-H), 3.61 (2H, t, J = 6.5 Hz, C1-H2), 2.09 – 1.98 (4H, m, C4-H2 and C7-H2), 1.59 – 
1.48 (2H, m, C2-H2), 1.42 – 1.27 (6H, m, C3-H2, C8-H2 and C9-H2), 0.94 – 0.86 (12H, m, C10-H3 and 
SiC(CH3)3), 0.05 (6H, s, Si(CH3)2). δC (101 MHz, CDCl3) 130.2 (C6), 129.8 (C5), 63.3 (C1), 32.7 (C2), 
32.1 (C8), 2 × 27.1 (C4 and C7), 2 × 26.1 (C3 and SiC(CH3)3), 22.5 (C9), 18.5 (SiC(CH3)3), 14.2 (C10), 
-5.1 (Si(CH3)2). HRMS: (ESI+) Calculated for C16H34NaOSi: 293.2271. Found [M+Na]+: 293.2276. 
(Z)-Dec-5-en-1-ol ((Z)-281) 
 
General procedure M: The preceding silyl ether (991 mg, 3.66 mmol) was employed with 1.5 eq. 
TBAF. The reaction time was 2.5 hours. FCC (eluent: 4:1 hexane:EtOAc) afforded (Z)-281 (460 mg, 
80 %) as a colourless oil. δH (400 MHz, CDCl3) 5.42 – 5.28 (2H, m), 3.63 (2H, t, J = 6.5 Hz), 2.09 – 
1.98 (4H, m), 1.62 – 1.52 (3H, m), 1.41 (2H, tt, J = 7.5, 6.5 Hz), 1.34 – 1.26 (4H, m), 0.92 – 0.86 (3H, 
m). δC (101 MHz, CDCl3) 130.5, 129.4, 63.0, 32.5, 32.0, 27.1, 27.0, 26.0, 22.5, 14.1. The spectroscopic 
properties were consistent with the data available in the literature.274,275 
tert-Butyl (Z)-dec-5-en-1-yl((pentafluorobenzoyl)oxy)carbamate ((Z)-282a) 
 
General procedure O: Alcohol (Z)-281 (932 mg, 5.96 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 16 hours. FCC (eluent: 2:3 hexane:PhMe) afforded (Z)-282a (1.89 g, 
68 %) as a colourless oil. νmax / cm-1: (film) 2932 (m), 1784 (s), 1721 (s), 1652 (m), 1505 (s), 1153 (s). 
δH (400 MHz, CDCl3) 5.42 – 5.28 (2H, m, C5-H and C6-H), 3.68 (2H, t, J = 7.0 Hz, C1-H2), 2.11 – 
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1.97 (4H, m, C4-H2 and C7-H2), 1.65 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.49 (9H, s, OC(CH3)3), 1.47 – 
1.38 (2H, m, C3-H2), 1.34 – 1.26 (4H, m, C8-H2 and C9-H2), 0.92 – 0.85 (3H, m, C10-H3).  
δC (101 MHz, CDCl3) 154.7 (Boc C=O), 130.7 (C6), 129.1 (C5), 83.3 (OC(CH3)3), 51.0 (C1), 32.0 (C8), 
28.2 (OC(CH3)3), 27.1 (C7), 26.8 (C4), 26.7 (C3), 26.6 (C2), 22.5 (C9), 14.1 (C10). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.5 – -136.8 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.4 – -159.7 (2F, m). 
HRMS: (ESI+) Calculated for C22H28F5NNaO4: 488.1831. Found [M+Na]+: 488.1831.  
tert-Butyl (E)-2-(pent-1-en-1-yl)piperidine-1-carboxylate (283a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate (Z)-282a (116 mg, 0.250 mmol) was employed. 
FCC (eluent: 39:1 petrol:EtOAc) afforded 283a (39.4 mg, 62 %) as a colourless oil. νmax / cm-1: (film) 
2932 (m), 2861 (m), 1693 (s), 1408 (s), 1164 (s). δH (400 MHz, CDCl3) 5.49 – 5.34 (2H, m, C6-H and 
C7-H), 4.72 (1H, br s, C5-H), 3.91 (1H, dd, J = 13.5, 4.0 Hz, C1-H), 2.81 (1H, ddd, J = 13.5, 13.0, 
3.0 Hz, C1-H’), 2.00 (2H, td, J = 7.0, 6.0 Hz, C8-H2), 1.69 – 1.29 (17H, m, C2-H2, C3-H2, C4-H2, C9-H2 
and OC(CH3)3), 0.88 (3H, t, J = 7.5 Hz, C10-H3). δC (101 MHz, CDCl3) 155.5 (Boc C=O), 131.7 (C7), 
128.4 (C6), 79.2 (OC(CH3)3), 52.0 (C5), 39.7 (C1), 34.6 (C8), 29.6 (C4), 28.6 (OC(CH3)3), 25.7 (C2), 
22.6 (C9), 19.6 (C3), 13.7 (C10). HRMS: (ESI+) Calculated for C15H27NNaO2: 276.1934. Found 
[M+Na]+: 276.1948.  
Methyl (Z)-dec-5-en-1-yl((pentafluorobenzoyl)oxy)carbamate ((Z)-282b) 
 
General procedure O: Alcohol (Z)-281 (195 mg, 1.25 mmol) was employed with MeOC(O)NHOFBz 
(vide supra). The reaction time was 15 hours. FCC (eluent: 1:9 hexane:PhMe) afforded (Z)-282b 
(352 mg, 67 %) as a pale-yellow oil. νmax / cm-1: (film) 2931 (m), 1786 (s), 1729 (s), 1652 (m), 1505 (s), 
1170 (s). δH (400 MHz, CDCl3) 5.42 – 5.28 (2H, m, C5-H and C6-H), 3.81 (3H, s, OCH3), 3.73 (2H, t, 
J = 7.0 Hz, C1-H2), 2.11 – 1.93 (4H, m, C4-H2 and C7-H2), 1.66 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.43 
(2H, tt, J = 7.5, 7.5 Hz, C3-H2), 1.37 – 1.24 (4H, m, C8-H2 and C9-H2), 0.93 – 0.83 (3H, m, C10-H3). 
δC (101 MHz, CDCl3) 156.2 (Boc C=O), 130.8 (C6), 129.0 (C5), 54.1 (OCH3), 51.3 (C1), 32.0 (C8), 
27.1 (C7), 26.8 (C4), 2 × 26.6 (C2 and C3), 22.5 (C9), 14.1 (C10). The 13C signals corresponding to 
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the pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) 
-136.0 – -136.2 (2F, m), -146.2 (1F, tt, J = 21.0, 5.5 Hz), -159.3 – -159.5 (2F, m). HRMS: (ESI+) 
Calculated for C19H22F5NNaO4: 446.1361. Found [M+Na]+: 446.1362. 
Methyl (E)-2-(pent-1-en-1-yl)piperidine-1-carboxylate (283b) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate (Z)-282b (106 mg, 0.250 mmol) was employed. 
FCC (two times, first eluent: 29:1 petrol:acetone; second eluent: 149:1 PhMe:acetone) afforded 283b 
(17.4 mg, 33 %) as a colourless oil. νmax / cm-1: (film) 2933 (m), 2861 (m), 1699 (s), 1444 (s), 1261 (s). 
δH (400 MHz, CDCl3) 5.48 (1H, dtd, J = 15.5, 7.0, 1.5 Hz, C7-H), 5.39 (1H, dd, J = 15.5, 4.5 Hz, C6-H), 
4.78 (1H, br s, C5-H), 3.96 (1H, br d, J = 13.5 Hz, C1-H), 3.68 (3H, s, OCH3), 2.88 (1H, ddd, J = 13.5, 
13.0, 3.0 Hz, C1-H’), 2.00 (2H, td, J = 7.5, 7.0 Hz, C8-H2), 1.74 – 1.48 (5H, m, C2-H, C3-H2 and 
C4-H2), 1.46 – 1.31 (3H, m, C2-H’ and C9-H2), 0.88 (3H, t, J = 7.5 Hz, C10-H3). δC (101 MHz, CDCl3) 
156.5 (C=O), 132.2 (C7), 128.2 (C6), 52.6 (OCH3), 52.1 (C5), 40.1 (C1), 34.6 (C8), 29.6 (C4), 25.8 
(C2), 22.5 (C9), 19.6 (C3), 13.8 (C10). HRMS: (ESI+) Calculated for C12H22NO2: 212.1645. Found 
[M+H]+: 212.1645.  
(E)-Dec-5-en-1-ol ((E)-281) 
 
A suspension of dec-5-yn-1-ol (280) (1.79 mL, 10.0 mmol) and LiAlH4 (2.28 g, 60.0 mmol) in 
anhydrous diglyme (70 mL) was heated at reflux for 14 hours before being cooled to 0 °C and diluted 
with Et2O (40 mL). The reaction mixture was quenched slowly with water (2.3 mL), 4.0 M aqueous 
NaOH (2.3 mL) and a further portion of water (6.9 mL). The reaction mixture was stirred at room 
temperature for 20 minutes before being dried over Na2SO4, filtered and concentrated in vacuo to 
remove Et2O. The crude mixture was dissolved in petrol (200 mL) and washed with water (3 × 200 mL). 
The organic phase was dried over Na2SO4 and concentrated in vacuo to afford (E)-281 (1.47 g, 94 %) 
as a colourless oil. δH (400 MHz, CDCl3) 5.46 – 5.33 (2H, m), 3.64 (2H, t, J = 6.5 Hz), 2.06 – 1.91 (4H, 
m), 1.57 (2H, tt, J = 7.0, 6.5 Hz), 1.41 (2H, tt, J = 7.0, 7.0 Hz), 1.36 – 1.24 (4H, m), 0.91 – 0.85 (3H, 
m). δC (101 MHz, CDCl3) 131.0, 129.9, 63.1, 3 × 32.4, 32.4, 31.9, 25.9, 22.3, 14.1. The spectroscopic 
properties were consistent with the data available in the literature.276,277 
Chapter 7 - Experimental 
293 
 
tert-Butyl (E)-dec-5-en-1-yl((pentafluorobenzoyl)oxy)carbamate ((E)-282a) 
 
General procedure O: Alcohol (E)-281 (185 mg, 1.18 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 13 hours. FCC (gradient elution: 2:3 – 1:4 hexane:PhMe) afforded 
(E)-282a (300 mg, 55 %) as a colourless oil. νmax / cm-1: (film) 2931 (m), 1784 (s), 1721 (s), 1652 (m), 
1505 (s), 1153 (s). δH (400 MHz, CDCl3) 5.46 – 5.30 (2H, m, C5-H and C6-H), 3.67 (2H, t, J = 7.0 Hz, 
C1-H2), 2.05 – 1.92 (4H, m, C4-H2 and C7-H2), 1.63 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.49 (9H, s, 
OC(CH3)3), 1.42 (2H, tt, J = 7.5, 7.5 Hz, C3-H2), 1.36 – 1.23 (4H, m, C8-H2 and C9-H2), 0.90 – 0.83 
(3H, m, C10-H3). δC (101 MHz, CDCl3) 154.8 (Boc C=O), 131.3 (C6), 129.5 (C5), 83.3 (OC(CH3)3), 
51.0 (C1), 32.4 (C7), 32.2 (C4), 31.9 (C8), 28.2 (OC(CH3)3), 26.5 (C3), 26.4 (C2), 22.3 (C9), 14.1 
(C10). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to 
their weak intensity. δF (377 MHz, CDCl3) -136.5 – -136.7 (2F, m), -146.7 – -146.8 (1F, m), -159.4 
– -159.6 (2F, m). HRMS: (ESI+) Calculated for C22H28F5NNaO4: 488.1831. Found [M+Na]+: 488.1850. 
3,5-Dimethyl-8-phenyl-1,7-bis(trifluoromethyl)-2,4,6-trioxa-8-phosphaadamantane (L18) 
 
To a solution of 1,1,1-trifluoro-2,4-pentanedione (1.82 mL, 15.0 mmol) in 5.0 M aqueous HCl (10 mL, 
argon sparged) was added PhPH2 (0.55 mL, 5.00 mmol) dropwise over around 10 minutes. The reaction 
mixture was stirred at room temperature for 2 days before being diluted with Et2O (60 mL) and washed 
with water (2 × 20 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. FCC 
(eluent: 14:1 petrol:Et2O) afforded L18 (156 mg, 8 %) as a colourless crystalline solid. m.p. 94-95 °C 
(Et2O:petrol, needles). νmax / cm-1: (solid) 2994 (m), 2944 (m), 1438 (m), 1384 (m), 1277 (s), 1166 (s). 
δH (400 MHz, CDCl3) 7.91 – 7.82 (2H, m, 2 × ArCH), 7.49 – 7.43 (1H, m, ArCH), 7.42 – 7.35 (2H, m, 
2 × ArCH), 2.34 (1H, dd, J = 21.0, 13.0 Hz, C3-H), 2.32 (1H, d, J = 13.5 Hz, C3’-H), 2.21 (1H, dd, J = 
13.0, 7.5 Hz, C3-H’), 1.97 (1H, dd, J = 13.5, 2.0 Hz, C3’-H’), 1.60 (3H, s, C5’-H3), 1.54 (3H, s, C5-H3). 
δC (101 MHz, CDCl3) 135.9 (ArCH), 131.2 (ArCH), 130.6 (d, J = 29.0 Hz, ArC), 128.4 (d, J = 9.0 Hz, 
ArCH), 97.3 (C4), 96.8 (C4’), 36.7 (dq, J = 13.5, 2.0 Hz, C3), 28.5 (C3’), 27.8 (C5’), 27.3 (C5).  
The 13C signals corresponding to C1 and C2 could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -77.5 (3F, d, J = 15.0 Hz), -79.3 (3F, d, J = 16.5 Hz). δP (162 MHz, CDCl3) -38.9 
(qq, J = 16.5, 15.0 Hz). HRMS: (ESI+) Calculated for C16H16F6O3P: 401.0736. Found [M+H]+: 
401.0734. 





To a solution of alkyne 187 (Section 7.3, 4.25 g, 20.0 mmol) in anhydrous THF (30 mL) and anhydrous 
DMPU (30 mL) at -78 °C was added n-BuLi (2.5 M in hexane, 8.4 mL, 21.0 mmol). The reaction 
mixture was stirred at -78 °C for 1.5 hours, then warmed to 0 °C before addition of cyclopropylmethyl 
bromide (2.52 mL, 26.0 mmol). The reaction mixture was stirred at room temperature for 14 hours 
before addition of saturated aqueous NH4Cl (50 mL), brine (50 mL) and Et2O (100 mL). The resulting 
phases were separated, and the aqueous phase was extracted with Et2O (2 × 100 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 19:1 – 9:1 – 
4:1 petrol:PhMe) provided impure material, which was distilled (b.p. 110 °C, 2 mbar) to afford the title 
compound (1.56 g, 29 %) as a colourless oil. νmax / cm-1: (film) 2929 (m), 2857 (m), 1472 (m), 1254 (s), 
1104 (s). δH (400 MHz, CDCl3) 3.62 (2H, t, J = 6.0 Hz, C1-H2), 2.23 – 2.13 (4H, m, C4-H2 and C7-H2), 
1.66 – 1.47 (4H, m, C2-H2 and C3-H2), 0.92 – 0.85 (1H, m, C8-H), 0.89 (9H, s, SiC(CH3)3), 0.48 – 0.40 
(2H, m, 2 × C9-H), 0.21 (2H, ddd, J = 6.0, 4.5, 4.5 Hz, 2 × C9-H’), 0.05 (6H, s, Si(CH3)2).  
δC (101 MHz, CDCl3) 80.5 (C5), 78.6 (C6), 62.9 (C1), 32.1 (C2), 26.1 (SiC(CH3)3), 25.7 (C3), 23.1 
(C7), 18.7 (C4), 18.5 (SiC(CH3)3), 9.8 (C8), 3.9 (C9), -5.1 (Si(CH3)2). HRMS: (MALDI-) Calculated 
for C16H29OSi: 265.1993. Found [M-H]-: 266.1999. 
(Z)-tert-Butyl((7-cyclopropylhept-5-en-1-yl)oxy)dimethylsilane 
 
A solution of the preceding alkyne (1.33 g, 5.00 mmol), Lindlar catalyst (53.2 mg, 25.0 μmol) and 
quinoline (6.0 μL, 50.0 μmol) in hexane (25 mL) was stirred under an atmosphere of H2 (balloon 
pressure) for 3 hours. The reaction mixture was filtered through celite, and the filter cake was rinsed 
with CH2Cl2 (30 mL). The filtrate was concentrated in vacuo. FCC (eluent: 24:1 petrol:PhMe) afforded 
the title compound (1.04 g, 77 %) as a colourless oil. νmax / cm-1: (film) 3077 (m), 3006 (m), 2929 (m), 
2857 (m), 1472 (m), 1254 (s), 1100 (s). δH (400 MHz, CDCl3) 5.51 – 5.33 (2H, m, C5-H and C6-H), 
3.61 (2H, t, J = 6.5 Hz, C1-H2), 2.03 (2H, dt, J = 7.5, 7.5 Hz, C4-H2), 1.96 (2H, dd, J = 7.0, 7.0 Hz, 
C7-H2), 1.59 – 1.47 (2H, m, C2-H2), 1.38 (2H, tt, J = 7.5, 7.5 Hz, C3-H2), 0.89 (9H, s, SiC(CH3)3), 0.76 
– 0.65 (1H, m, C8-H), 0.44 – 0.38 (2H, m, 2 × C9-H), 0.09 – 0.02 (8H, m, 2 × C9-H’ and Si(CH3)2).  
δC (101 MHz, CDCl3) 130.0 (C5), 129.0 (C6), 63.3 (C1), 32.6 (C2), 32.0 (C7), 27.2 (C4), 26.2 (C3), 
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26.1 (SiC(CH3)3), 18.5 (SiC(CH3)3), 11.1 (C8), 4.2 (C9), -5.1 (Si(CH3)2). HRMS: (ESI+) Calculated for 
C16H33OSi: 269.2295. Found [M+H]+: 269.2292.  
(Z)-7-Cyclopropylhept-5-en-1-ol ((Z)-284) 
 
General procedure M: The preceding silyl ether (943 mg, 3.51 mmol) was employed with 1.7 eq. 
TBAF. The reaction time was 2.5 hours. FCC (eluent: 3:2 petrol:Et2O) afforded (Z)-284 (510 mg, 94 %) 
as a colourless oil. νmax / cm-1: (film) 3328 (br s), 3076 (m), 3005 (m), 2932 (s), 1458 (m), 1427 (m), 
1043 (s). δH (400 MHz, CDCl3) 5.47 (1H, dtt, J = 11.0, 7.0, 1.5 Hz, C6-H), 5.42 – 5.33 (1H, m, C5-H), 
3.64 (2H, t, J = 6.5 Hz, C1-H2), 2.05 (2H, br dt, J = 7.5, 7.5 Hz, C4-H2), 1.96 (2H, dd, J = 7.0, 7.0 Hz, 
C7-H2), 1.63 – 1.52 (2H, m, C2-H2), 1.46 – 1.36 (2H, m, C3-H2), 0.77 – 0.64 (1H, m, C8-H), 0.45 – 
0.37 (2H, m, 2 × C9-H), 0.09 – 0.03 (2H, m, 2 × C9-H’). δC (101 MHz, CDCl3) 129.7 (C5), 129.3 (C6), 
63.1 (C1), 32.5 (C2), 32.0 (C7), 27.1 (C4), 26.0 (C3), 11.1 (C8), 4.2 (C9). HRMS: (ESI+) Calculated 
for C10H18NaO: 177.1250. Found [M+Na]+: 177.1238.  
tert-Butyl (Z)-(7-Cyclopropylhept-5-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (285a) 
 
General procedure O: Alcohol (Z)-284 (309 mg, 2.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 15 hours. FCC (eluent: 1:1 petrol:PhMe) afforded 285a (586 mg, 63 %) 
as a colourless oil. νmax / cm-1: (film) 3078 (m), 3006 (m), 2936 (m), 1783 (s), 1721 (s), 1652 (m), 
1505 (s), 1153 (s). δH (400 MHz, CDCl3) 5.52 – 5.43 (1H, m, C6-H), 5.40 – 5.32 (1H, m, C5-H), 3.67 
(2H, t, J = 7.0 Hz, C1-H2), 2.06 (2H, dt, J = 7.0, 7.0 Hz, C4-H2), 1.95 (2H, dd, J = 7.0, 7.0 Hz, C7-H2), 
1.64 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.49 (9H, s, OC(CH3)3), 1.43 (2H, tt, J = 7.5, 7.0 Hz, C3-H2), 0.75 
– 0.64 (1H, m, C8-H), 0.44 – 0.37 (2H, m, 2 × C9-H), 0.08 – 0.02 (2H, m, 2 × C9-H’). δC (101 MHz, 
CDCl3) 154.7 (Boc C=O), 129.5 (C6), 129.3 (C5), 83.4 (OC(CH3)3), 50.9 (C1), 31.9 (C7), 28.2 
(OC(CH3)3), 26.9 (C4), 26.7 (C3), 26.6 (C2), 11.0 (C8), 4.2 (C9). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.4 – -136.8 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.4 – -159.6 (2F, m). HRMS: (ESI+) 
Calculated for C22H26F5NNaO4: 486.1674. Found [M+Na]+: 486.1669.  
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tert-Butyl (E)-2-(2-cyclopropylvinyl)piperidine-1-carboxylate (286a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate 285a (116 mg, 0.250 mmol) was employed. FCC 
(gradient elution: 119:1 – 99:1 petrol:acetone) afforded 286a (39.4 mg, 63 %) as a colourless oil.  
νmax / cm-1: (film) 2933 (m), 1689 (s), 1408 (s), 1159 (s). δH (400 MHz, CDCl3) 5.50 (1H, dd, J = 15.5, 
5.0 Hz, C6-H), 4.98 (1H, ddd, J = 15.5, 8.5, 1.5 Hz, C7-H), 4.76 – 4.66 (1H, m, C5-H), 3.94 – 3.85 (1H, 
m, C1-H), 2.81 (1H, ddd, J = 13.0, 13.0, 3.0 Hz, C1-H’), 1.70 – 1.30 (16H, m, C2-H2, C3-H2, C4-H2, 
C8-H and OC(CH3)3), 0.72 – 0.64 (2H, m, 2 × C9-H), 0.37 – 0.27 (2H, m, 2 × C9-H’). δC (101 MHz, 
CDCl3) 155.5 (C=O), 135.7 (C7), 125.8 (C6), 79.2 (OC(CH3)3), 52.0 (C5), 39.7 (C1), 29.6 (C4), 28.6 
(OC(CH3)3), 25.7 (C2), 19.6 (C3), 13.7 (C8), 6.7 (C9). HRMS: (ESI+) Calculated for C15H25NNaO2: 
274.1778. Found [M+Na]+: 274.1785.  
Methyl (E)-7-hydroxyhept-2-enoate (287) 
 
To a solution of Hoveyda-Grubbs 2nd generation catalyst (31.3 mg, 50.0 μmol) in anhydrous CH2Cl2 
(60 mL, argon sparged) was added methyl acrylate (4.50 mL, 50.0 mmol) and hex-5-en-1-ol (0.60 mL, 
5.00 mmol). The reaction mixture was heated at reflux for 16 hours before being concentrated in vacuo. 
FCC (eluent: 3:2 hexane:EtOAc) afforded 287 (790 mg, 100 %) as a light-brown oil (the colouration 
was due to the presence of trace amounts of Ru-impurities). δH (400 MHz, CDCl3) 6.95 (1H, dt, J = 
15.5, 7.0 Hz), 5.82 (1H, dt, J = 15.5, 1.5 Hz), 3.71 (3H, s), 3.65 – 3.60 (2H, m), 2.25 – 2.19 (2H, m), 
1.84 (1H, br s), 1.73 – 1.48 (4H, m). δC (101 MHz, CDCl3) 167.3, 149.3, 121.3, 62.6, 51.6, 32.2, 32.0, 
24.4. The spectroscopic properties were consistent with the data available in the literature.278 
Methyl (E)-7-((tert-butoxycarbonyl)((pentafluorobenzoyl)oxy)amino)hept-2-enoate (288) 
 
General procedure O: Alcohol 287 (316 mg, 2.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 14 hours. FCC (eluent: 49:1 PhMe:EtOAc) afforded 288 (506 mg, 54 %) 
as a colourless oil. νmax / cm-1: (film) 2942 (m), 1782 (s), 1721 (s), 1654 (m), 1504 (s), 1150 (s).  
δH (400 MHz, CDCl3) 6.94 (1H, dt, J = 15.5, 7.0 Hz, C5-H), 5.83 (1H, dt, J = 15.5, 1.5 Hz, C6-H), 3.72 
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(3H, s, OCH3), 3.69 (2H, t, J = 7.0 Hz, C1-H2), 2.25 (2H, tdd, J = 7.5, 7.0, 1.5 Hz, C4-H2), 1.71 – 1.61 
(2H, m, C2-H2), 1.61 – 1.51 (2H, m, C3-H2), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 167.1 (C7), 
154.7 (Boc C=O), 148.8 (C5), 121.6 (C6), 83.5 (OC(CH3)3), 51.6 (OCH3), 50.6 (C1), 31.7 (C4), 28.2 
(OC(CH3)3), 26.5 (C2), 25.0 (C3). The 
13C signals corresponding to the pentafluorobenzoyl group could 
not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.4 – -136.7 (2F, m), -146.4 (1F, 
tt, J = 21.0, 5.0 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C20H22F5NNaO6: 490.1259. 
Found [M+Na]+: 490.1265. 
tert-Butyl (E)-2-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (289) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 288 (49.1 mg, 0.105 mmol) was employed. FCC 
(eluent: 79:1 PhMe:EtOAc) afforded 289 (10.3 mg, 38 %) as a colourless oil. The product was assigned 
as the (E)-isomer based on the observed NOE correlation between the C6 and the t-Bu protons.  
νmax / cm-1: (film) 2947 (m), 1698 (s), 1633 (m), 1367 (s), 1132 (s). δH (400 MHz, CDCl3) 5.95 (1H, s, 
C6-H), 3.68 (3H, s, OCH3), 3.62 – 3.57 (2H, m, C1-H2), 3.01 – 2.92 (2H, m, C4-H2), 1.74 – 1.66 (4H, 
m, C2-H2 and C3-H2), 1.47 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 168.1 (C7), 156.3 (C5), 153.5 
(Boc C=O), 110.0 (C6), 81.4 (OC(CH3)3), 51.1 (OCH3), 46.1 (C1), 28.4 (OC(CH3)3), 27.3 (C4), 24.1 
(C2), 22.9 (C3). HRMS: (ESI+) Calculated for C13H21NNaO4: 278.1363. Found [M+Na]+: 278.1369. 
(E)-1-Iodohex-3-ene 
 
To a solution of PPh3 (31.5 g, 120 mmol) and imidazole (8.17 g, 120 mmol) in CH2Cl2 (125 mL) at 
0 °C was added I2 (30.5 g, 120 mmol) in 9 roughly equal portions over around 30 minutes before 
addition of (E)-hex-3-en-1-ol (12.3 mL, 100 mmol) dropwise. The reaction mixture was stirred at room 
temperature for 3 hours before being concentrated in vacuo, filtered through silica and eluted with 
pentane. The filtrate was concentrated in vacuo to afford the title compound (18.6 g, 89 %) as a 
colourless oil. δH (400 MHz, CDCl3) 5.57 (1H, dt, J = 15.0, 7.0 Hz), 5.35 (1H, dt, J = 15.0, 6.5 Hz), 
3.14 (2H, t, J = 7.5 Hz), 2.54 (2H, td, J = 7.5, 6.5 Hz), 2.01 (2H, qd, J = 7.5, 7.0 Hz), 0.98 (3H, t, J = 
7.5 Hz). δC (101 MHz, CDCl3) 135.2, 127.4, 36.9, 25.7, 13.8, 6.3. The spectroscopic properties were 
consistent with the data available in the literature.279 





To a suspension of NaH (60 % in mineral oil, 596 mg, 14.9 mmol) in anhydrous DMF (25 mL) at 0 °C 
was added ethyl acetoacetate (2.00 mL, 14.9 mmol). The reaction mixture was stirred at room 
temperature for 1 hour before addition of a solution of the preceding iodide (2.09 g, 9.93 mmol) in 
anhydrous DMF (5 mL). The reaction mixture was stirred at room temperature for 16 hours before 
addition of saturated aqueous NH4Cl (30 mL) and extraction with Et2O (3 × 60 mL). The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 29:1 – 19:1 
– 14:1 hexane:EtOAc) afforded the title compound (1.42 g, 67 %) as a colourless oil. νmax / cm-1: (film) 
2963 (m), 1738 (s), 1714 (s), 1447 (m), 1149 (s). δH (400 MHz, CDCl3) 5.52 – 5.42 (1H, m, C7-H), 
5.32 (1H, dtt, J = 15.0, 6.5, 1.5 Hz, C6-H), 4.18 (2H, q, J = 7.0 Hz, OCH2CH3), 3.42 (1H, t, J = 7.0 Hz, 
C3-H), 2.21 (3H, s, C1-H3), 2.08 – 1.83 (6H, m, C4-H2, C5-H2 and C8-H2), 1.26 (3H, t, J = 7.0 Hz, 
OCH2CH3), 0.95 (3H, t, J = 7.5 Hz, C9-H3). δC (101 MHz, CDCl3) 203.4 (C2), 170.0 (C10), 133.9 (C6), 
127.3 (C7), 61.4 (OCH2CH3), 59.1 (C3), 30.3 (C5), 29.1 (C1), 28.0 (C4), 25.7 (C8), 14.2 (OCH2CH3), 
13.9 (C9). HRMS: (ESI+) Calculated for C12H21O3: 213.1485. Found [M+H]+: 213.1490. 
(E)-Non-6-en-2-one 
 
A solution of the preceding compound (1.31 g, 6.17 mmol) and KOH (1.39 g, 24.2 mmol) in MeOH 
(20 mL) and water (15 mL) was heated at 50 °C for 2 hours before addition of 12.0 M aqueous HCl 
(2.58 mL, 30.9 mmol). The reaction mixture was cooled to room temperature before being concentrated 
in vacuo to remove MeOH and extracted with Et2O (3 × 40 mL). The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo. The crude mixture was dissolved in CHCl3 (20 mL) and 
heated at reflux for 3 hours before being concentrated in vacuo to afford the title compound (333 mg, 
38 %) as a pale-yellow oil. δH (400 MHz, CDCl3) 5.51 – 5.41 (1H, m), 5.38 – 5.29 (1H, m), 2.41 (2H, 
t, J = 7.5 Hz), 2.13 (3H, s), 2.03 – 1.93 (4H, m), 1.63 (2H, tt, J = 7.5 Hz), 0.96 (3H, t, J = 7.5 Hz).  
δC (101 MHz, CDCl3) 209.4, 133.2, 128.3, 43.1, 32.0, 30.1, 25.7, 23.7, 14.1. The spectroscopic 
properties were consistent with the data available in the literature.280 
  





A solution of the preceding ketone (223 mg, 1.59 mmol) and NaBH4 (90.4 mg, 2.39 mmol) in MeOH 
(15 mL) was stirred at 0 °C for 4 hours before being concentrated in vacuo. The reaction mixture was 
dissolved in 1.0 M aqueous HCl (25 mL) and extracted with Et2O (3 × 25 mL). The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 3:1 – 
2:1 pentane:Et2O) afforded the title compound (192 mg, 85 %) as a colourless oil. δH (400 MHz, CDCl3) 
5.51 – 5.32 (2H, m), 3.80 (1H, tq, J = 6.0, 6.0 Hz), 2.05 – 1.94 (4H, m), 1.51 – 1.29 (5H, m), 1.21 – 
1.14 (3H, m), 0.96 (3H, t, J = 7.5 Hz). δC (101 MHz, CDCl3) 132.5, 129.0, 68.2, 39.0, 32.6, 25.9, 25.7, 
23.6, 14.1. The spectroscopic properties were consistent with the data available in the literature.280 
tert-Butyl (E)-non-6-en-2-yl((pentafluorobenzoyl)oxy)carbamate (290) 
 
General procedure O: The preceding alcohol (183 mg, 1.29 mmol) was employed with BocNHOFBz 
(vide supra), and the reaction was performed at -78 °C. The reaction time was 23 hours. FCC (eluent: 
1:9 hexane:PhMe) afforded impure material which was dissolved in Et2O (30 mL) and washed with 
10 % aqueous AcOH (3 × 15 mL). The Et2O phase was dried over Na2SO4 and concentrated in vacuo. 
FCC (eluent: 19:1 hexane:EtOAc) afforded 290 (137 mg, 24 %) as a colourless oil. νmax / cm-1: (film) 
2978 (m), 2935 (m), 1785 (s), 1717 (s), 1652 (m), 1504 (s), 1181 (s). δH (500 MHz, CDCl3) 5.44 (1H, 
dt, J = 15.0, 6.0 Hz, C7-H), 5.40 – 5.29 (1H, m, C6-H), 4.43 – 4.18 (1H, m, C2-H), 2.03 – 1.93 (4H, m, 
C5-H2 and C8-H2), 1.66 – 1.32 (4H, m, C3-H2 and C4-H2), 1.49 (9H, s, OC(CH3)3), 1.20 (3H, d, J = 
6.5 Hz, C1-H3), 0.94 (3H, t, J = 7.5 Hz, C9-H3). δC (126 MHz, CDCl3) 157.2 (FBz C=O), 154.7 
(Boc C=O), 145.5 (d, J = 256.0 Hz, ArCF), 143.8 (d, J = 261.0 Hz, ArCF), 137.9 (d, J = 253.0 Hz, 
ArCF), 132.7 (C7), 128.7 (C6), 106.4 (ArC), 83.3 (OC(CH3)3), 56.3 (C2), 33.1 (C3), 32.3 (C5), 28.2 
(OC(CH3)3), 26.3 (C4), 25.7 (C8), 17.6 (C1), 14.0 (C9). δF (377 MHz, CDCl3) -136.3 – -137.1 (2F, m), 
-146.9 – -147.4 (1F, m), -159.5 – -159.8 (2F, m). HRMS: (ESI+) Calculated for C21H26F5NNaO4: 
474.1674. Found [M+Na]+: 474.1677. 
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Ethyl (E)-2-phenyloct-5-enoate ((E)-292a) 
 
To a solution of LHMDS (1.0 M in THF, 20.0 mL, 20.0 mmol) in anhydrous DMF (40 mL) was added 
ethyl phenylacetate (3.18 mL, 20.0 mmol). The reaction mixture was stirred at room temperature for 
1 hour before addition of a solution of (E)-1-iodohex-3-ene (vide supra, 5.04 g, 24.0 mmol) in 
anhydrous DMF (10 mL). The reaction mixture was stirred at room temperature for 17 hours before 
being concentrated in vacuo to remove THF, poured into water (150 mL) and extracted with Et2O (3 × 
80 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
49:1 hexane:EtOAc) afforded (E)-292a (3.09 g, 63 %) as a colourless oil. νmax / cm-1: (film) 3030 (m), 
2961 (m), 1731 (s), 1602 (m), 1454 (m), 1153 (s). δH (400 MHz, CDCl3) 7.35 – 7.21 (5H, m, 5 × ArCH), 
5.48 – 5.30 (2H, m, C5-H and C6-H), 4.19 – 4.02 (2H, m, OCH2CH3), 3.54 (1H, dd, J = 7.5, 7.0 Hz, 
C2-H), 2.13 (1H, ddt, J = 13.0, 7.5, 7.5 Hz, C3-H), 2.04 – 1.91 (4H, m, C4-H2 and C7-H2), 1.89 – 1.75 
(1H, m, C3-H’), 1.20 (3H, t, J = 7.0 Hz, OCH2CH3), 0.96 (3H, t, J = 7.5 Hz, C8-H3). δC (101 MHz, 
CDCl3) 174.2 (C1), 139.4 (ArC), 133.3 (C6), 128.7 (ArCH), 128.1 (ArCH), 127.9 (C5), 127.2 (ArCH), 
60.8 (OCH2CH3), 51.1 (C2), 33.4 (C3), 30.5 (C4), 25.7 (C7), 14.3 (OCH2CH3), 14.0 (C8). 
HRMS: (ESI+) Calculated for C16H23O2: 247.1693. Found [M+H]+: 247.1698. 
(E)-2-Phenyloct-5-en-1-ol ((E)-293) 
 
General procedure I: Ester (E)-292a (2.97 g, 12.1 mmol) was employed, using anhydrous THF as 
solvent and 0.8 eq. LiAlH4 (1.0 M in THF). Alcohol (E)-293 (2.04 g, 83 %) was isolated as a colourless 
oil. νmax / cm-1: (film) 3343 (br s), 3027 (m), 2924 (m), 1602 (m), 1453 (m), 1029 (s). δH (400 MHz, 
CDCl3) 7.36 – 7.29 (2H, m, 2 × ArCH), 7.26 – 7.18 (3H, m, 3 × ArCH), 5.43 – 5.29 (2H, m, C5-H and 
C6-H), 3.78 – 3.68 (2H, m, C1-H2), 2.80 (1H, dddd, J = 9.5, 7.5, 5.5, 5.5 Hz, C2-H), 2.01 – 1.82 (4H, 
m, C4-H2 and C7-H2), 1.75 (1H, dddd, J = 13.5, 9.0, 6.5, 5.5 Hz, C3-H), 1.64 (1H, dddd, J = 13.5, 9.5, 
8.5, 6.0 Hz, C3-H’), 1.30 (1H, br s, OH), 0.95 (3H, t, J = 7.5 Hz, C8-H3). δC (101 MHz, CDCl3) 142.3 
(ArC), 132.7 (C6), 128.8 (ArCH), 128.6 (C5), 128.3 (ArCH), 126.9 (ArCH), 67.7 (C1), 48.1 (C2), 32.0 
(C3), 30.3 (C4), 25.7 (C7), 14.1 (C8). HRMS: (ESI+) Calculated for C14H20NaO: 227.1406. Found 
[M+Na]+: 227.1415. 
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tert-Butyl (E)-(2-phenyloct-5-en-1-yl)((pentafluorobenzoyl)oxy)carbamate ((E)-294) 
 
General procedure O: Alcohol (E)-293 (613 mg, 3.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 15 hours. FCC (eluent: 1:1 hexane:PhMe) afforded (E)-294 (606 mg, 
39 %) as a colourless crystalline solid. m.p. 60-63 °C (CH2Cl2:petrol, needles). νmax / cm-1: (solid) 
2932 (m), 1779 (s) 1719 (s), 1649 (m), 1495 (s), 1156 (s). δH (400 MHz, CDCl3) 7.30 – 7.24 (2H, m, 
2 × ArCH), 7.20 – 7.15 (3H, m, 3 × ArCH), 5.41 – 5.25 (2H, m, C5-H and C6-H), 3.92 (1H, dd, J = 
14.5, 7.0 Hz, C1-H), 3.83 (1H, dd, J = 14.5, 7.5 Hz, C1-H’), 3.03 – 2.94 (1H, m, C2-H), 2.00 – 1.76 
(5H, m, C3-H, C4-H2 and C7-H2), 1.75 – 1.64 (1H, m, C3-H’), 1.39 (9H, s, OC(CH3)3), 0.92 (3H, t, J = 
7.5 Hz, C8-H3). δC (101 MHz, CDCl3) 154.3 (Boc C=O), 141.9 (ArC), 132.9 (C6), 128.6 (ArCH), 128.4 
(C5), 128.2 (ArCH), 126.8 (ArCH), 83.3 (OC(CH3)3), 56.6 (C1), 43.4 (C2), 33.0 (C3), 30.1 (C4), 28.1 
(OC(CH3)3), 25.7 (C7), 14.0 (C8). The 
13C signals corresponding to the pentafluorobenzoyl group could 
not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.1 – -136.5 (2F, m), -146.5 
– -146.7 (1F, m), -159.4 – -159.7 (2F, m). HRMS: (ESI+) Calculated for C26H28F5NNaO4: 536.1831. 
Found [M+Na]+: 536.1825.  
(Z)-1-Iodohex-3-ene 
 
To a solution of PPh3 (13.3 g, 50.8 mmol) and imidazole (3.46 g, 50.8 mmol) in CH2Cl2 (50 mL) was 
added I2 (12.9 g, 50.8 mmol) in 5 roughly equal portions over around 10 minutes before addition of 
(Z)-hex-3-en-1-ol (5.00 mL, 42.3 mmol) dropwise. The reaction mixture was stirred at room 
temperature for 3 hours before being concentrated in vacuo, filtered through silica and eluted with 
pentane. The filtrate was concentrated in vacuo to afford the title compound (7.72 g, 87 %) as a pale-red 
oil. δH (500 MHz, CDCl3) 5.53 (1H, dtt, J = 10.5, 7.5, 1.5 Hz), 5.34 – 5.24 (1H, m), 3.14 (2H, t, J = 
7.5 Hz), 2.63 (2H, dtdt, J = 7.5, 7.5, 1.5, 0.5 Hz), 2.09 – 1.99 (2H, m), 0.98 (3H, t, J = 7.5 Hz).  
δC (126 MHz, CDCl3) 134.4, 127.3, 31.6, 20.9, 14.3, 5.8. The spectroscopic properties were consistent 
with the data available in the literature.279 
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Methyl (Z)-2-phenyloct-5-enoate ((Z)-292b) 
 
To a solution of methyl phenylacetate (2.82 mL, 20.0 mmol) in anhydrous DMF (40 mL) was added 
LHMDS (1.0 M in THF, 20.0 mL, 20.0 mmol). The reaction mixture was stirred at room temperature 
for 45 minutes before addition of a solution of the preceding iodide (5.04 g, 24.0 mmol) in anhydrous 
DMF (10 mL). The reaction mixture was stirred at room temperature for 18 hours before being 
concentrated in vacuo to remove THF, poured into water (150 mL) and extracted with MTBE (3 × 
50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
49:1 hexane:EtOAc) afforded (Z)-292b (3.43 g, 74 %) as a colourless oil. νmax / cm-1: (film) 3006 (m), 
2969 (m), 1734 (s), 1602 (m), 1454 (m), 1156 (s). δH (400 MHz, CDCl3) 7.35 – 7.22 (5H, m, 5 × ArCH), 
5.44 – 5.36 (1H, m, C6-H), 5.34 – 5.25 (1H, m, C5-H), 3.65 (3H, s, OCH3), 3.58 (1H, dd, J = 8.0, 
7.5 Hz, C2-H), 2.22 – 2.06 (1H, m, C3-H), 2.04 – 1.91 (4H, m, C4-H2 and C7-H2), 1.83 (1H, ddt, J = 
14.5, 7.5, 7.5 Hz, C3-H’), 0.93 (3H, t, J = 7.5 Hz, C8-H3). δC (101 MHz, CDCl3) 174.6 (C1), 139.2 
(ArC), 133.0 (C6), 128.7 (ArCH), 128.1 (ArCH), 127.8 (C5), 127.3 (ArCH), 52.0 (OCH3), 51.0 (C2), 




General procedure I: Ester (Z)-292b (3.25 g, 14.0 mmol) was employed, using anhydrous THF as 
solvent and 0.8 eq. LiAlH4 (1.0 M in THF). Alcohol (Z)-293 (2.61 g, 91 %) was isolated as a colourless 
oil. νmax / cm-1: (film) 3339 (br s), 3004 (m), 2931 (s), 1602 (m), 1453 (m), 1026 (s). δH (400 MHz, 
CDCl3) 7.36 – 7.31 (2H, m, 2 × ArCH), 7.27 – 7.19 (3H, m, 3 × ArCH), 5.39 – 5.25 (2H, m, C5-H and 
C6-H), 3.79 – 3.68 (2H, m, C1-H2), 2.81 (1H, dddd, J = 9.5, 7.5, 5.5, 5.5 Hz, C2-H), 1.98 – 1.85 (4H, 
m, C4-H2 and C7-H2), 1.80 – 1.60 (2H, m, C3-H2), 1.32 (1H, br s, OH), 0.90 (3H, t, J = 7.5 Hz, C8-H3). 
δC (101 MHz, CDCl3) 142.2 (ArC), 132.3 (C6), 128.8 (ArCH), 128.6 (C5), 128.3 (ArCH), 126.9 
(ArCH), 67.7 (C1), 48.3 (C2), 32.1 (C3), 24.9 (C4), 20.6 (C7), 14.4 (C8). HRMS: (ESI+) Calculated for 
C14H20NaO: 227.1406. Found [M+Na]+: 227.1402.  
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tert-Butyl (Z)-(2-phenyloct-5-en-1-yl)((pentafluorobenzoyl)oxy)carbamate ((Z)-294) 
 
General procedure O: Alcohol (Z)-293 (1.02 g, 5.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 20 hours. FCC (gradient elution: 1:1 – 2:3 hexane:PhMe) afforded 
(Z)-294 (1.12 g, 44 %) as a colourless crystalline solid. m.p. 44-46 °C (Et2O:petrol, fibres).  
νmax / cm-1: (solid) 2935 (m), 1795 (s), 1723 (s), 1652 (m), 1501 (s), 1151 (s). δH (400 MHz, CDCl3) 
7.31 – 7.25 (2H, m, 2 × ArCH), 7.21 – 7.15 (3H, m, 3 × ArCH), 5.37 – 5.19 (2H, m, C5-H and C6-H), 
3.93 (1H, dd, J = 15.0, 7.5 Hz, C1-H), 3.83 (1H, dd, J = 15.0, 7.5 Hz, C1-H’), 3.05 – 2.92 (1H, m, 
C2-H), 1.94 – 1.79 (5H, m, C3-H, C4-H2 and C7-H2), 1.75 – 1.65 (1H, m, C3-H’), 1.40 (9H, s, 
OC(CH3)3), 0.88 (3H, t, J = 7.5 Hz, C8-H3). δC (101 MHz, CDCl3) 154.2 (Boc C=O), 141.8 (ArC), 
132.4 (C6), 128.6 (ArCH), 128.3 (C5), 128.2 (ArCH), 126.8 (ArCH), 83.3 (OC(CH3)3), 56.6 (C1), 43.6 
(C2), 33.2 (C3), 28.1 (OC(CH3)3), 24.8 (C4), 20.6 (C7), 14.4 (C8). The 
13C signals corresponding to 
the pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) 
-136.1 – -136.5 (2F, m), -146.6 (1F, tt, J = 21.0, 5.0 Hz), -159.5 – -159.6 (2F, m). HRMS: (ESI+) 
Calculated for C26H28F5NNaO4: 536.1831. Found [M+Na]+: 536.1827.  
tert-Butyl (E)-5-phenyl-2-(prop-1-en-1-yl)piperidine-1-carboxylate (295) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; dioxane (0.4 M); 130 °C; 24 hours. Substrate (Z)-294 (53.9 mg, 0.105 mmol) was employed. FCC 
(two times, first eluent: PhMe; second eluent: 49:1 petrol:acetone) afforded 295 (14.2 mg, 45 %, 4:1 
mixture of cis and trans diastereomers) as a colourless oil.  
Alternative procedure starting from (E)-294: General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 
15 mol% ligand L2 (vide supra); 100 mol% Et3N; dioxane (0.4 M); 130 °C; 24 hours. Substrate (E)-294 
(53.9 mg, 0.105 mmol) was employed. FCC (two times, first eluent: 49:1 petrol:acetone; second, 
gradient elution: 1:9 – 0:1 petrol:PhMe) afforded 295 (9.8 mg, 31 %, 1:1 mixture cis and trans 
diastereomers) as a colourless oil. The trans diastereomer was assigned as such based on the following 
NOE correlations: one C1 proton to the aryl protons, the other C1 proton to the C6 proton. Neither C1 
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proton had an NOE correlation to both the C6 and the aryl protons. νmax / cm-1: (film) 2975 (m), 
2932 (m), 1689 (s), 1411 (m), 1161 (s). The cis diastereomer exists as an approximately 1:1 mixture of 
rotamers which results in the doubling of several signals in the 1H and 13C NMR spectra. Data for the 
cis diastereomer: δH (500 MHz, CDCl3) 7.35 – 7.16 (5H, m, 5 × ArCH), 5.59 – 5.46 (2H, m, C6-H and 
C7-H), 4.92 and 4.75 (2 × 0.5H, br s, C5-H), 4.14 and 3.98 (2 × 0.5H, br s, C1-H), 2.94 and 2.82 (2 × 
0.5H, br s, C1-H’), 2.65 (1H, br s, C2-H), 1.88 – 1.69 (7H, m, C3-H2, C4-H2 and C8-H3), 1.51 – 1.42 
(9H, m, OC(CH3)3). δC (126 MHz, CDCl3) 155.5 (C=O), 143.9 (ArC), 129.3 (C6), 128.6 (ArCH), 127.2 
(ArCH), 126.9 (C7), 126.3 (ArCH), 79.6 (OC(CH3)3), 52.0 and 50.6 (C5), 46.5 and 45.4 (C1), 43.2 and 
42.6 (C2), 29.7 and 29.5 (C3), 28.6 (OC(CH3)3), 27.2 and 26.7 (C4), 18.1 (C8). 
1H and 13C NMR data 
for the trans diastereomer: δH (500 MHz, CDCl3) 7.35 – 7.16 (5H, m, 5 × ArCH), 5.59 – 5.46 (2H, m, 
C6-H and C7-H), 4.69 – 4.64 (1H, m, C5-H), 4.28 (1H, br d, J = 14.0 Hz, C1-H), 3.34 (1H, dd, J = 14.0, 
4.5 Hz, C1-H’), 3.00 – 2.96 (1H, m, C2-H), 2.06 (1H, dddd, J = 13.0, 13.0, 5.0, 3.5 Hz, C3-H), 1.88 – 
1.69 (5H, m, C3-H’, C4-H and C8-H3), 1.51 – 1.42 (10H, m, C4-H’ and OC(CH3)3). δC (126 MHz, 
CDCl3) 155.5 (C=O), 143.9 (ArC), 129.7 (C6), 128.3 (ArCH), 127.8 (ArCH), 126.7 (C7), 126.0 
(ArCH), 79.6 (OC(CH3)3), 52.3 (C5), 42.8 (C1), 37.7 (C2), 28.6 (OC(CH3)3), 26.0 (C3), 24.9 (C4), 18.0 
(C8). HRMS: (ESI+) Calculated for C19H28NO2: 302.2115. Found [M+H]+: 302.2108. 
(E)-1-Bromohex-2-ene 
 
General procedure J:  (E)-Hex-2-en-1-ol (5.01 g, 50.0 mmol) was employed. The title compound 
(6.51 g, 80 %) was isolated as a colourless oil. δH (400 MHz, CDCl3) 5.82 – 5.63 (2H, m), 3.95 (2H, d, 
J = 7.5 Hz), 2.04 (2H, dt, J = 7.0, 7.0 Hz), 1.41 (2H, qt, J = 7.5, 7.0 Hz), 0.90 (3H, t, J = 7.5 Hz).  
δC (101 MHz, CDCl3) 136.6, 126.6, 34.2, 33.7, 22.1, 13.7. The spectroscopic properties were consistent 
with the data available in the literature.102 
(E)-2-Methylenenon-5-en-1-ol (296) 
 
A solution of TMEDA (9.4 mL, 62.5 mmol) and n-BuLi (1.55 M in hexane, 40.0 mL, 62.0 mmol) in 
anhydrous Et2O (90 mL) was stirred at 0 °C for 20 minutes. The reaction mixture was cooled to -78 °C 
before addition of 2-methylprop-2-en-1-ol (2.63 mL, 31.3 mmol) dropwise. The reaction mixture was 
stirred at room temperature for 22 hours, then cooled to -78 °C before addition of a solution of the 
preceding bromide (4.08 g, 25.0 mmol) in anhydrous Et2O (10 mL) dropwise. The reaction mixture was 
stirred at -78 °C for 4 hours, then at room temperature for a further 6 hours before addition of saturated 
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aqueous NH4Cl (100 mL). The resulting phases were separated, and the organic phase was washed with 
1.0 M aqueous HCl (100 mL) followed by brine (100 mL). The organic phase was dried over Na2SO4 
and concentrated in vacuo. FCC (eluent: 4:1 petrol:Et2O) afforded 296 (1.77 g, 46 %) as a colourless 
oil. νmax / cm-1: (film) 3326 (br s), 2926 (m), 1713 (m), 1653 (m), 1454 (m). δH (400 MHz, CDCl3) 5.48 
– 5.34 (2H, m, C5-H and C6-H), 5.02 (1H, s, C10-H), 4.87 (1H, s, C10-H’), 4.07 (2H, s, C1-H2), 2.20 
– 2.07 (4H, m, C3-H2 and C4-H2), 1.95 (2H, td, J = 7.0, 6.0 Hz, C7-H2), 1.61 (1H, br s, OH), 1.35 (2H, 
qt, J = 7.5, 7.0 Hz, C8-H2), 0.88 (3H, t, J = 7.5 Hz, C9-H3). δC (101 MHz, CDCl3) 148.8 (C2), 131.0 
(C6), 129.6 (C5), 109.6 (C10), 66.1 (C1), 34.8 (C7), 33.2 (C3), 31.0 (C4), 22.8 (C8), 13.8 (C9). 
HRMS: (MALDI+) Calculated for C10H19O: 155.1430. Found [M+H]+: 155.1435. 
tert-Butyl (E)-(2-methylenenon-5-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (297a) 
 
General procedure O: Alcohol 296 (309 mg, 2.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 15 hours. FCC (eluent: 2:3 petrol:PhMe) afforded 297a (512 mg, 55 %) 
as a colourless oil. νmax / cm-1: (film) 2932 (m), 1785 (s), 1722 (s), 1652 (m), 1505 (s), 1153 (s).  
δH (400 MHz, CDCl3) 5.48 – 5.34 (2H, m, C5-H and C6-H), 4.99 (1H, s, C10-H), 4.94 (1H, s, C10-H’), 
4.24 (2H, s, C1-H2), 2.19 – 2.14 (4H, m, C3-H2 and C4-H2), 1.94 (2H, td, J = 7.0, 6.0 Hz, C7-H2), 1.50 
(9H, s, OC(CH3)3), 1.35 (2H, qt, J = 7.5, 7.0 Hz, C8-H2), 0.87 (3H, t, J = 7.5 Hz, C9-H3). δC (101 MHz, 
CDCl3) 154.6 (Boc C=O), 142.9 (C2), 131.0 (C6), 129.4 (C5), 114.2 (C10), 83.6 (OC(CH3)3), 55.8 
(C1), 34.8 (C7), 33.4 (C3), 30.6 (C4), 28.2 (OC(CH3)3), 22.8 (C8), 13.8 (C9). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.2 – -136.4 (2F, m), -146.8 (1F, tt, J = 21.0, 5.0 Hz), -159.5 – -159.7 (2F, m). 
HRMS: (ESI+) Calculated for C22H26F5NNaO4: 486.1674. Found [M+Na]+: 486.1672. 
tert-Butyl (E)-2-(but-1-en-1-yl)-5-methylenepiperidine-1-carboxylate (298) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate 297a (48.7 mg, 0.105 mmol) was employed. FCC 
(two times, first eluent: 49:1 petrol:acetone; second eluent: PhMe) afforded 298 (3.0 mg, 11 %) as a 
colourless oil. νmax / cm-1: (film) 2963 (m), 2928 (m), 1694 (s), 1365 (s), 1172 (s). δH (500 MHz, CDCl3) 
5.63 – 5.54 (1H, m, C7-H), 5.47 – 5.40 (1H, m, C6-H), 4.82 (1H, s, C10-H), 4.77 (1H, br s, C5-H), 4.74 
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(1H, s, C10-H’), 4.33 (1H, d, J = 14.5 Hz, C1-H), 3.53 (1H, d, J = 14.5 Hz, C1-H’), 2.32 (1H, ddd, J = 
13.0, 9.5, 4.5 Hz, C3-H), 2.23 – 2.15 (1H, m, C3-H’), 2.09 (2H, qd, J = 7.5, 7.0 Hz, C8-H2), 1.82 – 1.75 
(2H, m, C4-H2), 1.48 (9H, s, OC(CH3)3), 1.01 (3H, t, J = 7.5 Hz, C9-H3). δC (126 MHz, CDCl3) 155.3 
(C=O), 143.5 (C2), 133.9 (C7), 126.8 (C6), 109.2 (C10), 79.6 (OC(CH3)3), 51.9 (C5), 46.0 (C1), 30.2 
(C4), 28.6 (OC(CH3)3), 28.3 (C3), 25.6 (C8), 13.9 (C9). HRMS: (ESI+) Calculated for C15H25NNaO2: 
274.1778. Found [M+Na]+: 274.1784. 
tert-Butyl (E)-(2-(but-2-en-1-yloxy)ethyl)((pentafluorobenzoyl)oxy)carbamate (299) 
 
General procedure O: Alcohol 192 (Section 7.3, 339 mg, 2.92 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (gradient elution: 1:0 – 49:1 
PhMe:EtOAc) afforded 299 (881 mg, 71 %) as a pale-yellow oil. νmax / cm-1: (film) 2981 (m), 2864 (m), 
1783 (s) 1722 (s), 1652 (m), 1499 (s). δH (400 MHz, CDCl3) 5.73 – 5.63 (1H, m, C5-H), 5.58 – 5.44 
(1H, m, C4-H), 3.93 – 3.85 (4H, m, C1-H2 and C3-H2), 3.63 (2H, t, J = 5.5 Hz, C2-H2), 1.67 (3H, ddt, 
J = 6.5, 1.5, 1.0 Hz, C6-H3), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.7 (Boc C=O), 129.9 
(C5), 127.4 (C4), 83.5 (OC(CH3)3), 71.9 (C3), 66.4 (C2), 50.6 (C1), 28.2 (OC(CH3)3), 17.8 (C6). The 
13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.0 – -136.3 (2F, m), -146.5 (1F, tt, J = 21.0, 5.0 Hz), -159.4 – -159.6 
(2F, m). HRMS: (ESI+) Calculated for C18H20F5NNaO5: 448.1154. Found [M+Na]+: 448.1160. 
tert-Butyl 3-vinylmorpholine-4-carboxylate (300) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate 299 (44.7 mg, 0.105 mmol) was employed. FCC 
(two times, first, gradient elution: 29:1 – 19:1 PhMe:EtOAc; second eluent: 19:1 petrol:acetone) 
afforded 300 (0.3 mg, 1 %) as a colourless oil. The yield determined by 1H analysis of the crude reaction 
mixture was 19 %. νmax / cm-1: (film) 2967 (m), 2925 (m), 1697 (s), 1393 (s), 1171 (s). δH (500 MHz, 
CDCl3) 5.94 (1H, ddd, J = 17.5, 10.5, 5.5 Hz, C5-H), 5.26 (1H, ddd, J = 10.5, 1.5, 1.5 Hz, C6-H), 5.19 
(1H, ddd, J = 17.5, 1.5, 1.5 Hz, C6-H’), 4.43 (1H, br s, C4-H), 3.90 (1H, d, J = 11.5 Hz, C3-H), 3.85 
(1H, dd, J = 11.5, 4.0 Hz, C2-H), 3.75 – 3.68 (1H, m, C1-H), 3.65 (1H, dd, J = 11.5, 3.5 Hz, C3-H’), 
3.48 (1H, ddd, J = 12.5, 11.5, 3.0 Hz, C2-H’), 3.17 (1H, ddd, J = 13.0, 12.5, 4.0 Hz, C1-H’), 1.46 (9H, 
s, OC(CH3)3). δC (126 MHz, CDCl3) 155.1 (C=O), 134.7 (C5), 117.2 (C6), 80.2 (OC(CH3)3), 69.8 (C3), 
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67.1 (C2), 53.4 (C4), 39.9 (C1), 28.5 (OC(CH3)3). HRMS: (ESI+) Calculated for C11H19NNaO3: 




General procedure O: Alcohol 193 (Section 7.3, 288 mg, 1.07 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (two times, first eluent: 
19:1 PhMe:EtOAc; second eluent: 9:1 hexane:EtOAc) afforded 301 (256 mg, 41 %) as a colourless oil.  
νmax / cm-1: (film) 2980 (m), 1782 (s), 1727 (s), 1653 (m), 1598 (m), 1499 (s), 1326 (s), 1152 (s).  
δH (400 MHz, CDCl3) 7.68 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.29 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.60 
(1H, dqt, J = 15.5, 6.5, 1.5 Hz, C5-H), 5.33 – 5.20 (1H, m, C4-H), 3.91 – 3.83 (2H, m, C1-H2), 3.76 
(2H, br d, J = 7.0 Hz, C3-H2), 3.36 – 3.31 (2H, m, C2-H2), 2.42 (3H, s, Ts CH3), 1.62 (3H, ddt, J = 6.5, 
1.5, 1.5 Hz, C6-H3), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.1 (Boc C=O), 143.5 (ArC), 
136.8 (ArC), 131.4 (C5), 129.8 (ArCH), 127.4 (ArCH), 125.4 (C4), 83.9 (OC(CH3)3), 51.2 (C3), 50.4 
(C1), 44.0 (C2), 28.1 (OC(CH3)3), 21.6 (Ts CH3), 17.8 (C6). The 
13C signals corresponding to the 
pentafluorobenzoate group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.1 – -136.3 (2F, m), -146.1 (1F, tt, J = 21.0, 5.0 Hz), -159.2 – -159.5 (2F, m).  
HRMS: (ESI+) Calculated for C25H27F5N2NaO6S: 601.1402. Found [M+Na]+: 601.1383. 
tert-Butyl 4-tosyl-2-vinylpiperazine-1-carboxylate (302) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 301 
(60.7 mg, 0.105 mmol) was employed. FCC (gradient elution: 39:1 – 19:1 PhMe:EtOAc) afforded 302 
(13.8 mg, 36 %) as a colourless oil. νmax / cm-1: (film) 2979 (m), 2926 (m), 1693 (s), 1597 (m), 1455 (m), 
1164 (s). δH (500 MHz, CDCl3) 7.62 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.33 (2H, d, J = 8.0 Hz, 2 × ArCH), 
5.88 (1H, ddd, J = 17.5, 10.5, 5.0 Hz, C5-H), 5.31 – 5.24 (2H, m, C6-H2), 4.69 (1H, br s, C4-H), 3.91 
(1H, d, J = 13.0 Hz, C1-H), 3.77 (1H, ddd, J = 11.5, 2.5, 2.0 Hz, C3-H), 3.65 (1H, dddd, J = 11.5, 3.5, 
2.0, 2.0 Hz, C2-H), 3.15 (1H, ddd, J = 13.0, 12.5, 3.5 Hz, C1-H’), 2.46 – 2.41 (4H, m, C3-H’ and 
Ts CH3), 2.25 (1H, ddd, J = 12.5, 11.5, 2.5 Hz, C2-H’), 1.41 (9H, s, OC(CH3)3). δC (126 MHz, CDCl3) 
154.5 (C=O), 144.0 (ArC), 134.0 (C5), 132.5 (ArC), 129.9 (ArCH), 127.9 (ArCH), 118.2 (C6), 80.6 
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(OC(CH3)3), 52.1 (C4), 48.8 (C3), 46.1 (C2), 38.9 (C1), 28.4 (OC(CH3)3), 21.7 (Ts CH3). HRMS: (ESI+) 
Calculated for C18H26N2NaO4S: 389.1505. Found [M+Na]+: 389.1509. 
(E)-But-2-en-1-yl 2-hydroxyacetate (303) 
 
A mixture of methyl glycolate (3.60 g, 40.0 mmol), K2CO3 (276 mg, 2.00 mmol) and (E)-but-2-en-1-ol 
(34 mL, 400 mmol) was heated at reflux under a Dean-Stark apparatus for 1.5 hours before being cooled 
to room temperature. FCC (eluent: 5:2 petrol:EtOAc) afforded 303 (3.11 g, 60 %) as a colourless oil. 
νmax / cm-1: (film) 3449 (br s), 2948 (m), 1737 (s), 1197 (s), 1090 (s). δH (400 MHz, CDCl3) 5.90 – 5.75 
(1H, m, C5-H), 5.58 (1H, dtq, J = 15.0, 6.5, 2.0 Hz, C4-H), 4.61 (2H, ddq, J = 6.5, 1.5, 1.0 Hz, C3-H2), 
4.15 (2H, s, C1-H2), 2.47 (1H, br s, OH), 1.72 (3H, ddt, J = 6.5, 2.0, 1.0 Hz, C6-H3). δC (101 MHz, 
CDCl3) 173.3 (C2), 132.7 (C5), 124.4 (C4), 66.3 (C3), 60.8 (C1), 17.9 (C6). HRMS: (ESI+) Calculated 
for C6H10NaO3: 153.0522. Found [M+Na]+: 153.0530. 
(E)-But-2-en-1-yl N-(tert-butoxycarbonyl)-N-((pentafluorobenzoyl)oxy)glycinate (305) 
 
General procedure O: Alcohol 303 (260 mg, 2.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 22 hours. FCC (two times, first, gradient elution: 2:8 – 1:9 petrol:PhMe; 
second eluent: 14:1 petrol:EtOAc) afforded 305 (404 mg, 46 %) as a colourless oil. νmax / cm-1: (film) 
2982 (m), 1786 (s), 1756 (s), 1730 (s), 1652 (m), 1499 (s), 1151 (s). δH (400 MHz, CDCl3) 5.82 (1H, 
dqt, J = 15.0, 6.5, 1.0 Hz, C5-H), 5.58 (1H, dtq, J = 15.0, 6.5, 1.5 Hz, C4-H), 4.61 (2H, ddq, J = 6.5, 
1.0, 1.0 Hz, C3-H2), 4.39 (2H, s, C1-H2), 1.72 (3H, ddt, J = 6.5, 1.5, 1.0 Hz, C6-H3), 1.51 (9H, s, 
OC(CH3)3). δC (101 MHz, CDCl3) 167.3 (C2), 154.7 (Boc C=O), 132.6 (C5), 124.4 (C4), 84.5 
(OC(CH3)3), 66.5 (C3), 52.7 (C1), 28.0 (OC(CH3)3), 17.9 (C6). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.1 – -136.6 (2F, m), -146.4 (1F, tt, J = 21.0, 5.0 Hz), -159.4 – -159.6 (2F, m). HRMS: (ESI+) 
Calculated for C18H18F5NNaO6: 462.0946. Found [M+Na]+: 462.0963. 
  





This compound was prepared according to a literature procedure.281 A suspension of crotyl bromide 
(Section 7.3, 2.06 mL, 20.0 mmol) and K2CO3 (3.46 g, 15.0 mmol) in BnNH2 (10.9 mL, 100 mmol) 
was heated at 70 °C for 16 hours. The reaction mixture was cooled to room temperature, diluted with 
EtOAc (50 mL) and washed with water (2 × 40 mL) followed by brine (40 mL). The organic phase was 
dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 30:20:1 petrol:EtOAc:Et3N) afforded the 
title compound (2.43 g, 75 %) as a colourless oil. δH (400 MHz, CDCl3) 7.34 – 7.30 (4H, m), 7.27 – 
7.21 (1H, m), 5.67 – 5.51 (2H, m), 3.78 (2H, s), 3.21 (2H, d, J = 5.5 Hz), 1.69 (3H, d, J = 5.5 Hz),  
1.32 (1H, br s). δC (101 MHz, CDCl3) 140.6, 129.6, 128.5, 128.3, 127.5, 127.0, 53.5, 51.3, 18.0.  
The spectroscopic properties were consistent with the data available in the literature.282 
(E)-2-(Benzyl(but-2-en-1-yl)amino)-2-oxoethyl acetate 
 
To a suspension of the preceding amine (1.64 g, 10.0 mmol) and K2CO3 (1.38 g, 10.0 mol) in anhydrous 
CH2Cl2 (30 mL) at 0 °C was added acetoxyacetyl chloride (1.29 mL, 12.0 mmol) dropwise. The 
reaction mixture was stirred at room temperature for 5 hours before addition of water (30 mL). The 
resulting phases were separated, and the aqueous phase was extracted with CH2Cl2 (30 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
2:1 petrol:EtOAc) afforded the title compound (2.49 g, 95 %) as a colourless oil. This compound exists 
as an approximately 8:5 mixture of rotamers A and B. νmax / cm-1: (film) 3031 (m), 2940 (m), 1747 (s), 
1662 (s), 1449 (s), 1211 (s). δH (400 MHz, CDCl3) 7.39 – 7.17 (5H, m, A and B: 5 × ArCH), 5.69 – 
5.49 (1H, m, A and B: C5-H), 5.47 – 5.28 (1H, m, A and B: C4-H), 4.77 (1.2H, s, A: C1-H2), 4.71 
(0.8H, s, B: C1-H2), 4.58 (1.2H, s, A: NCH2Ph), 4.43 (0.8H, s, B: NCH2Ph), 3.94 (0.8H, d, J = 6.5 Hz, 
B: C3-H2), 3.68 (1.2H, d, J = 5.5 Hz, A: C3-H2), 2.20 (1.8H, s, A: Ac CH3), 2.14 (1.2H, s, B: Ac CH3), 
1.71 (1.8H, d, J = 6.5 Hz, A: C6-H3), 1.67 (1.2H, d, J = 6.5 Hz, C6-H3). δC (101 MHz, CDCl3) 2 × 170.8 
(A and B: Ac C=O), 166.9 (A: C2), 166.8 (B: C2), 137.1 (A: ArC), 136.0 (B: ArC), 130.1 (B: C5), 
129.4 (A: C5), 129.1 (B: ArCH), 128.7 (A: ArCH), 128.5 (A: ArCH), 127.9 (B: ArCH), 127.6 (A: 
ArCH), 126.5 (B: ArCH), 125.2 (B: C4), 124.7 (A: C4), 61.7 (B: C1), 61.5 (A: C1), 49.0 (B: NCH2Ph), 
48.6 (A: NCH2Ph), 47.8 (B: C3), 47.6 (A: C3), 20.8 (A: Ac CH3), 20.7 (B: Ac CH3), 2 × 17.8 (A and B: 
C6). HRMS: (ESI+) Calculated for C15H20NO3: 262.1438. Found [M+H]+: 262.1447. 
 





A solution of the preceding compound (2.36 g, 9.03 mmol) and NaOMe (488 mg, 9.03 mmol) in MeOH 
(20 mL) was heated at reflux for 6 hours before being cooled to room temperature and concentrated in 
vacuo. The crude mixture was dissolved in saturated aqueous NH4Cl (20 mL) and brine (20 mL) before 
being extracted with EtOAc (3 × 40 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo to afford 304 (1.89 g, 95 %) as a colourless oil. This compound exists as an 
approximately 5:3 mixture of rotamers A and B. νmax / cm-1: (film) 3415 (br s), 3030 (m), 2918 (m), 
1642 (s), 1397 (s), 1078 (s). δH (400 MHz, CDCl3) 7.38 – 7.20 (4.4H, m, A: 4 × ArCH; B: 5 × ArCH), 
7.16 – 7.10 (0.6H, m, A: ArCH), 5.63 – 5.51 (1H, m, A and B: C5-H), 5.46 – 5.36 (0.4H, m, B: C4-H), 
5.35 – 5.25 (0.6H, m, A: C4-H), 4.62 (1.2H, s, A: NCH2Ph), 4.32 (0.8H, s, B: NCH2Ph), 4.22 (1.2H, d, 
J = 4.5 Hz, A: C1-H2), 4.20 (0.8H, d, J = 4.0 Hz, B: C1-H2), 3.98 (0.8H, d, J = 6.5 Hz, B: C3-H2), 3.70 
– 3.61 (1H, m, A and B: OH), 3.59 (1.2H, d, J = 6.0 Hz, A: C3-H2), 1.74 – 1.66 (3H, m, A and B: 
C6-H3). δC (101 MHz, CDCl3) 172.0 (A: C2), 171.9 (B: C2), 136.8 (A: ArC), 135.6 (B: ArC), 130.4 (B: 
C5), 129.9 (A: C5), 129.2 (B: ArCH), 128.8 (A: ArCH), 128.4 (A: ArCH), 128.0 (B: ArCH), 127.8 (B: 
ArCH), 126.6 (A: ArCH), 124.9 (B: C4), 124.4 (A: C4), 60.1 (B: C1), 60.0 (A: C1), 48.7 (A: NCH2Ph), 
48.1 (B: NCH2Ph), 47.7 (B: C3), 46.8 (A: C3), 2 × 17.8 (A and B: C6). HRMS: (ESI+) Calculated for 




General procedure O: Alcohol 304 (439 mg, 2.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 19 hours. FCC (gradient elution: 1:0 – 99:1 – 49:1 PhMe:EtOAc) afforded 
306 (802 mg, 76 %) as a colourless crystalline solid. This compound exists as an approximately 5:3 
mixture of rotamers A and B. m.p. 118-119 °C (acetone:petrol, fibres). νmax / cm-1: (solid) 2987 (m), 
1794 (s), 1738 (s), 1654 (s), 1500 (s), 1152 (s). δH (400 MHz, CDCl3) 7.39 – 7.13 (5H, m, A and B: 5 × 
ArCH), 5.65 – 5.48 (1H, m, A and B: C5-H), 5.46 – 5.27 (1H, m, A and B: C4-H), 4.59 (1.2H, s, A: 
NCH2Ph), 4.50 (1.2H, s, A: C1-H2), 4.44 (1.6H, s, B: C1-H2 and NCH2Ph), 3.98 (0.8H, d, J = 6.5 Hz, 
B: C3-H2), 3.70 (1.2H, d, J = 5.5 Hz, A: C3-H2), 1.70 (1.8H, d, J = 6.5 Hz, A: C6-H3), 1.67 (1.2H, d, 
J = 6.5 Hz, B: C6-H3), 1.53 (5.4H, s, A: OC(CH3)3), 1.51 (3.6H, s, B: OC(CH3)3). δC (101 MHz, CDCl3) 
166.2 (A: C2), 166.1 (B: C2), 155.6 (A and B: Boc C=O), 137.1 (A: ArC), 136.0 (B: ArC), 130.2 (B: 
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C5), 2 × 129.2 (A: C5; B: ArCH), 128.7 (A: ArCH), 128.5 (A: ArCH), 128.0 (B: ArCH), 127.7 (B: 
ArCH), 126.3 (A: ArCH), 125.3 (B: C4), 124.7 (A: C4), 84.0 (A and B: OC(CH3)3), 53.1 (A and B: 
C1), 49.0 (B: NCH2Ph), 48.9 (A: NCH2Ph), 48.0 (B: C3), 47.9 (A: C3), 28.1 (A and B: OC(CH3)3), 17.8 
(B: C6), 17.7 (A: C6). The 13C signals corresponding to the pentafluorobenzoyl group could not be 
resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.4 – -137.2 (2F, m), -146.8 – -147.1  




To a suspension of ethylene glycol (4.18 mL, 75.0 mmol) and K2CO3 (2.07 g, 15.0 mol) in CH2Cl2 
(40 mL) at 0 °C was added crotonoyl chloride (1.44 mL, 15.0 mmol) dropwise. The reaction mixture 
was stirred at 0 °C for 1 hour before being diluted with EtOAc (80 mL) and washed with brine (40 mL). 
The organic phase was dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 2:3 – 
2:5 petrol:Et2O) afforded the title compound (980 mg, 50 %) as a colourless oil. νmax / cm-1: (film) 
3416 (br s), 2950 (m), 1703 (s), 1656 (s), 1444 (m), 1181 (s). δH (400 MHz, CDCl3) 7.00 (1H, dq, J = 
15.5, 7.0 Hz, C5-H), 5.86 (1H, dq, J = 15.5, 1.5 Hz, C4-H), 4.26 – 4.22 (2H, m, C2-H2), 3.85 – 3.80 
(2H, m, C1-H2), 2.31 (1H, br s, OH), 1.87 (3H, dd, J = 7.0, 1.5 Hz, C6-H3). δC (101 MHz, CDCl3) 167.0 
(C3), 145.7 (C5), 122.3 (C4), 66.0 (C2), 61.4 (C1), 18.1 (C6). HRMS: (ESI+) Calculated for C6H10NO3: 
153.0522. Found [M+Na]+: 153.0529. 
2-((tert-Butoxycarbonyl)((pentafluorobenzoyl)oxy)amino)ethyl (E)-but-2-enoate (309) 
 
General procedure O: The preceding alcohol (260 mg, 2.00 mmol) was employed with BocNHOFBz 
(vide supra). The reaction time was 20 hours. FCC (gradient elution: 1:0 – 49:1 – 19:1 PhMe:EtOAc) 
afforded 309 (622 mg, 71 %) as a colourless oil. νmax / cm-1: (film) 2982 (m), 1784 (s), 1721 (s), 1653 (s), 
1499 (s), 1172 (s). δH (400 MHz, CDCl3) 6.98 (1H, dq, J = 15.5, 7.0 Hz, C5-H), 5.81 (1H, dq, J = 15.5, 
1.5 Hz, C4-H), 4.35 (2H, t, J = 5.5 Hz, C2-H2), 3.98 (2H, t, J = 5.5 Hz, C1-H2), 1.85 (3H, dd, J = 7.0, 
1.5 Hz, C6-H3), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 166.2 (C3), 154.3 (Boc C=O), 145.7 
(C5), 122.2 (C4), 83.9 (OC(CH3)3), 60.5 (C2), 49.7 (C1), 28.1 (OC(CH3)3), 18.1 (C6). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.1 – -136.3 (2F, m), -146.2 (1F, tt, J = 21.0, 5.5 Hz), -159.3 – -159.5 (2F, m). 
HRMS: (ESI+) Calculated for C18H18F5NNaO6: 462.0946. Found [M+Na]+: 462.0969. 
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tert-Butyl (2-(prop-1-en-1-yl)phenethyl)((pentafluorobenzoyl)oxy)carbamate (313a) 
 
General procedure O: 2-(2-(Prop-1-en-1-yl)phenyl)ethan-1-ol (Section 7.3, 324 g, 2.00 mmol) was 
employed with BocNHOFBz (vide supra). The reaction time was 16 hours. FCC (eluent: 
2:3 hexane:PhMe) afforded 313a (493 mg, 52 %, 3:1 mixture of (Z)- and (E)-isomers) as a colourless 
oil. νmax / cm-1: (film) 3020 (m), 2981 (m), 1783 (s), 1722 (s), 1652 (m), 1499 (s), 1326 (s), 1151 (s). 
1H 
and 13C NMR data for the major (Z)-isomer: δH (400 MHz, CDCl3) 7.24 – 7.12 (4H, m, 4 × ArCH), 
6.53 (1H, dq, J = 11.5, 2.0 Hz, C3-H), 5.86 (1H, dq, J = 11.5, 7.0 Hz, C4-H), 3.88 – 3.77 (2H, m, 
C1-H2), 3.00 – 2.92 (2H, m, C2-H2), 1.71 (3H, dd, J = 7.0, 2.0 Hz, C5-H3), 1.46 (9H, s, OC(CH3)3).  
δC (101 MHz, CDCl3) 154.2 (Boc C=O), 136.6 (ArC), 136.0 (ArC), 2 × 129.7 (2 × ArCH), 2 × 128.0 
(C3 and C4), 127.1 (ArCH), 126.3 (ArCH), 83.3 (OC(CH3)3), 51.4 (C1), 31.1 (C2), 28.0 (OC(CH3)3), 
14.3 (C5). The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to 
their weak intensity. 1H and 13C NMR data for the minor (E)-isomer: δH (400 MHz, CDCl3) 7.41 (1H, 
d, J = 7.0 Hz, ArCH), 7.24 – 7.12 (3H, m, 3 × ArCH), 6.64 (1H, dq, J = 15.5, 1.5 Hz, C3-H), 6.13 (1H, 
dq, J = 15.5, 6.5 Hz, C4-H), 3.88 – 3.77 (2H, m, C1-H2), 3.07 – 3.00 (2H, m, C2-H2), 1.89 (3H, dd, J = 
6.5, 1.5 Hz, C5-H3), 1.46 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.2 (Boc C=O), 137.2 (ArC), 
134.4 (ArC), 130.1 (ArCH), 128.2 (C4), 127.9 (C3), 127.1 (ArCH), 127.0 (ArCH), 126.1 (ArCH), 83.3 
(OC(CH3)3), 51.7 (C1), 30.8 (C2), 28.0 (OC(CH3)3), 18.7 (C5). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. 19F NMR signals for both 
isomers: δF (377 MHz, CDCl3) -136.2 – -136.4 (2F, m), -146.2 – -146.5 (1F, m), -159.2 – -159.4 (2F, m). 
HRMS: (ESI+) Calculated for C23H22F5NNaO4: 494.1361. Found [M+Na]+: 494.1362.  
tert-Butyl 1-vinyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (314a) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; dioxane (0.4 M); 130 °C; 24 hours. Substrate 313a (49.5 mg, 0.105 mmol) was employed. FCC 
(two times, first eluent: 79:1 pentane:acetone; second eluent: PhMe) afforded 314a (16.8 mg, 62 %) as 
a colourless oil. δH (400 MHz, CDCl3) 7.20 – 7.11 (4H, m), 5.96 (1H, ddd, J = 17.0, 10.0, 5.5 Hz), 5.55 
(1H, br s), 5.15 (1H, ddd, J = 10.0, 1.5, 1.5 Hz), 5.05 (1H, ddd, J = 17.0, 1.5, 1.5 Hz), 4.11 (1H, br s), 
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3.21 (1H, br s), 2.98 – 2.83 (1H, m), 2.73 (1H, ddd, J = 16.0, 4.0, 4.0 Hz), 1.49 (9H, s). δC (126 MHz, 
CDCl3) 154.9, 137.9, 135.1, 135.0, 129.0, 128.0, 126.8, 126.2, 115.8, 80.0, 57.3, 37.8, 28.9, 28.6.  
The spectroscopic properties were consistent with the data available in the literature.283 
Benzyl (2-(prop-1-en-1-yl)phenethyl)((pentafluorobenzoyl)oxy)carbamate (313b) 
 
General procedure O: 2-(2-(Prop-1-en-1-yl)phenyl)ethan-1-ol (Section 7.3, 324 mg, 2.00 mmol) was 
employed with CbzNHOFBz.L The reaction time was 18 hours. FCC (gradient elution: 1:1 – 
2:3 hexane:PhMe) afforded 313b (299 mg, 30 %, 3:1 mixture of (Z)- and (E)-isomers) as a colourless 
oil. Spectroscopic data for the major Z diastereomer: νmax / cm-1: (film) 3022 (m), 2948 (m), 1788 (s), 
1734 (s), 1654 (m), 1497 (s), 1171 (s). δH (400 MHz, CDCl3) 7.40 – 7.29 (5H, m, 5 × ArCH), 7.22 – 
7.12 (4H, m, 4 × ArCH), 6.48 (1H, dq, J = 11.5, 2.0 Hz, C3-H), 5.79 (1H, dq, J = 11.5, 7.0 Hz, C4-H), 
5.17 (2H, s, OCH2Ph), 3.91 – 3.86 (2H, m, C1-H2), 3.00 – 2.93 (2H, m, C2-H2), 1.67 (3H, dd, J = 7.0, 
2.0 Hz, C5-H3). δC (101 MHz, CDCl3) 157.3 (FBz C=O), 155.2 (Cbz C=O), 136.8 (ArC), 135.8 (ArC), 
135.3 (ArC), 130.0 (ArCH), 129.9 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.3 (ArCH), 128.2 (C4), 
128.1 (C3), 127.2 (ArCH), 126.6 (ArCH), 68.9 (OCH2Ph), 51.7 (C1), 31.3 (C2), 14.4 (C5). The 
aromatic 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their 
weak intensity. δF (377 MHz, CDCl3) -135.8 – -135.9 (2F, m), -145.9 (1F, tt, J = 21.0, 5.0 Hz), -159.1 
– -159.3 (2F, m). HRMS: (ESI+) Calculated for C26H20F5NNaO4: 528.1205. Found [M+Na]+: 528.1181. 
Characteristic signals for the minor E diastereomer: δH (400 MHz, CDCl3) 6.60 (1H, dq, J = 15.5, 
2.0 Hz), 6.08 (1H, dq, J = 15.5, 6.5 Hz), 5.16 (2H, s), 3.07 – 3.02 (2H, m), 1.85 (3H, dd, J = 6.5, 2.0 Hz). 
δC (101 MHz, CDCl3) 52.0, 31.0, 18.8. 
Benzyl 1-vinyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (314b) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.4 M); 130 °C; 24 hours. Substrate 313b (53.1 mg, 0.105 mmol) was employed. FCC 
(three times, first eluent: 24:1 petrol:acetone; second, gradient elution: 1:0 – 99:1 PhMe:EtOAc; third 
                                                     
L CbzNHOFBz was prepared by Dr Xiaofeng Ma (University of Bristol) according to a reported procedure.117 
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eluent: 14:1 petrol:EtOAc) afforded 314b (17.2 mg, 56 %) as a colourless oil. This compound exists as 
an approximately 1:1 mixture of rotamers; this results in the doubling of several signals in the 1H and 
13C NMR spectra. νmax / cm-1: (film) 3030 (m), 2933 (m), 1697 (s), 1425 (s). δH (500 MHz, CDCl3) 7.40 
– 7.29 (5H, m, 5 × ArCH), 7.21 – 7.09 (4H, m, 4 × ArCH), 5.98 (1H, ddd, J = 16.0, 10.0, 5.5 Hz, C4-H), 
5.73 and 5.64 (2 × 0.5H, br s, C3-H), 5.25 – 5.12 (3H, m, C5-H and OCH2Ph), 5.06 (1H, br s, C5-H’), 
4.21 and 4.08 (2 × 0.5H, br s, C1-H), 3.37 and 3.29 (2 × 0.5H, br s, C1-H’), 2.94 (1H, br s, C2-H), 2.78 
and 2.74 (2 × 0.5H, dd, J = 4.0, 4.0 Hz, C2-H’). δC (126 MHz, CDCl3) 155.5 (C=O), 137.6 (C4), 136.9 
(ArC), 134.7 (ArC), 129.1 (ArC), 128.6 (ArCH), 2 × 128.1 (2 × ArCH), 2 × 128.0 (2 × ArCH), 127.0 
(ArCH), 126.3 (ArCH), 116.3 (C5), 67.4 (OCH2Ph), 57.0 (C3), 39.1 and 38.6 (C1), 28.7 (C2). 
HRMS: (ESI+) Calculated for C19H20NO2: 294.1489. Found [M+H]+: 294.1487. 
tert-Butyl (E)-(2-(but-2-en-1-yl)benzyl)((pentafluorobenzoyl)oxy)carbamate (315) 
 
General procedure O: Alcohol 201 (Section 7.3, 324 mg, 2.00 mmol) was employed with 
BocNHOFBz (vide supra). The reaction time was 15 hours. FCC (gradient elution: 2:3 – 
3:7 hexane:PhMe) afforded 315 (589 mg, 62 %) as a colourless oil. νmax / cm-1: (film) 2981 (m), 
1785 (s), 1721 (s), 1652 (m), 1498 (s), 1152 (s). δH (400 MHz, CDCl3) 7.32 – 7.21 (2H, m, 2 × ArCH), 
7.21 – 7.14 (2H, m, 2 × ArCH), 5.61 – 5.53 (1H, m, C3-H), 5.49 – 5.39 (1H, m, C4-H), 4.89 (2H, s, 
C1-H2), 3.42 (2H, br d, J = 6.0 Hz, C2-H2), 1.66 (3H, ddt, J = 6.0, 1.5, 1.5 Hz, C5-H3), 1.52 (9H, s, 
OC(CH3)3). δC (101 MHz, CDCl3) 154.5 (Boc C=O), 139.8 (ArC), 132.7 (ArC), 130.0 (ArCH), 129.6 
(ArCH), 129.3 (C3), 128.4 (ArCH), 126.7 (C4), 126.4 (ArCH), 83.7 (OC(CH3)3), 52.3 (C1), 35.7 (C2), 
28.2 (OC(CH3)3), 18.0 (C5). The 
13C signals corresponding to the pentafluorobenzoyl group could not 
be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.0 – -136.3 (2F, m), -146.6 (1F, tt, 
J = 21.0, 5.0 Hz), -159.3 – -159.6 (2F, m). HRMS: (ESI+) Calculated for C23H22F5NNaO4: 494.1361. 
Found [M+Na]+: 494.1376.  
tert-Butyl 3-vinyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (316) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 315 
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(49.5 mg, 0.105 mmol) was employed. FCC (eluent: 69:1 petrol:acetone) afforded 316 (7.0 mg, 26 %) 
as a colourless oil. δH (500 MHz, CDCl3) 7.20 – 7.07 (4H, m), 5.66 (1H, ddd, J = 17.5, 10.5, 5.0 Hz), 
5.05 (1H, d, J = 17.5 Hz), 5.02 (1H, d, J = 10.5 Hz), 5.06 – 4.91 (1H, br s), 4.73 (1H, d, J = 16.5 Hz), 
4.33 (1H, d, J = 16.5 Hz), 3.14 (1H, dd, J = 15.5, 5.5 Hz), 2.81 (1H, d, J = 15.5 Hz), 1.50 (9H, s).  
δC (126 MHz, CDCl3) 155.2, 137.0, 133.5, 133.1, 128.8, 126.7, 126.4, 126.2, 116.0, 80.1, 52.0, 43.5, 
33.4, 28.6. The spectroscopic properties were consistent with the data available in the literature.273 
(S)-5-(((tert-Butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one (317) 
 
A solution of (S)-pyroglutaminol (3.45 g, 30.0 mmol), TBSCl (5.43 g, 36.0 mmol) and imidazole 
(3.06 g, 45.0 mmol) in CH2Cl2 (60 mL) was stirred at room temperature for 5 hours. The reaction 
mixture was washed with water (3 × 50 mL) followed by brine (50 mL), dried over Na2SO4 and 
concentrated in vacuo to afford 317 (6.84 g, 99 %) as a colourless oil. [α]D26 +44.9 (c = 0.44, CHCl3) 
[Lit., [α]D20 +44.7 (c = 1.8, CHCl3)].284 δH (400 MHz, CDCl3) 5.99 (1H, br s), 3.79 – 3.68 (1H, m), 3.61 
(1H, dd, J = 10.0, 4.0 Hz), 3.44 (1H, dd, J = 10.0, 7.5 Hz), 2.41 – 2.24 (2H, m), 2.16 (1H, dddd, J = 
13.0, 9.0, 8.0, 7.0 Hz), 1.73 (1H, dddd, J = 13.0, 9.5, 7.5, 5.5 Hz), 0.88 (9H, s), 0.05 (6H, s).  
δC (101 MHz, CDCl3) 178.1, 67.0, 55.9, 29.9, 25.9, 22.9, 18.3, -5.3. The spectroscopic properties were 
consistent with the data available in the literature.284 
(S,E)-1-(But-2-en-1-yl)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 
 
To a solution of pyrrolidone 317 (3.03 g, 13.2 mmol) in anhydrous THF (30 mL) and anhydrous DMF 
(15 mL) at 0 °C was added NaH (60 % in mineral oil, 528 mg, 13.2 mmol). The reaction mixture was 
stirred at room temperature for 2.5 hours, then cooled to 0 °C before addition of crotyl bromide 
(Section 7.3, 1.48 mL, 14.4 mmol). The reaction mixture was stirred at room temperature for 17 hours 
before addition of saturated aqueous NH4Cl (25 mL), brine (25 mL) and extraction with Et2O (3 × 
50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
3:2 petrol:EtOAc) afforded the title compound (3.05 g, 82 %) as a colourless oil. [α]D26 +28.0  
(c = 0.40, CH2Cl2). νmax / cm-1: (film) 2929 (m), 2857 (m), 1686 (s), 1110 (s). δH (400 MHz, CDCl3) 
5.69 – 5.53 (1H, m, C8-H), 5.42 – 5.29 (1H, m, C7-H), 4.22 (1H, dddq, J = 15.0, 5.5, 1.5, 1.5 Hz, C6-H), 
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3.69 – 3.54 (3H, m, C1-H2 and C2-H), 3.49 (1H, br dd, J = 15.0, 7.5 Hz, C6-H’), 2.45 (1H, ddd, J = 
16.5, 9.5, 8.0 Hz, C4-H), 2.28 (1H, ddd, J = 16.5, 10.0, 4.5 Hz, C4-H’), 2.05 (1H, dddd, J = 13.0, 10.0, 
8.0, 8.0 Hz, C3-H), 1.91 – 1.82 (1H, m, C3-H’), 1.67 (3H, dddd, J = 6.5, 1.5, 1.5, 1.0 Hz, C9-H3), 0.87 
(9H, s, SiC(CH3)3), 0.04 (3H, s, SiCH3), 0.03 (3H, s, Si(CH3)’). δC (101 MHz, CDCl3) 175.3 (C5), 128.9 
(C8), 125.9 (C7), 63.6 (C1), 58.8 (C2), 42.9 (C6), 30.6 (C4), 25.9 (SiC(CH3)3), 21.7 (C3), 18.3 
(SiC(CH3)3), 17.8 (C9), 2 × -5.4 (SiCH3 and Si(CH3)’). HRMS: (ESI+) Calculated for C15H29NNaO2Si: 
306.1860. Found [M+Na]+: 306.1873. 
(S,E)-1-(But-2-en-1-yl)-5-(hydroxymethyl)pyrrolidin-2-one (318) 
 
A solution of the preceding silyl ether (2.80 g, 9.88 mmol) and TBAF (1.0 M in THF, 15.0 mL, 
15.0 mmol) in THF (30 mL) was stirred at room temperature for 1 hour. The reaction mixture was 
concentrated in vacuo, dissolved in water (20 mL) and extracted with EtOAc (2 × 30 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient  
elution: 1:0 - 9:1 EtOAc:MeOH) afforded 318 (731 mg, 44 %) as a colourless oil. [α]D26 +60.6  
(c = 0.47, CH2Cl2) [Lit., [α]D20 +55.4 (c = 0.52, CH2Cl2)].285 δH (400 MHz, CDCl3) 5.71 – 5.58 (1H, m), 
5.42 – 5.31 (1H, m), 4.17 (1H, dddq, J = 15.0, 5.5, 1.5, 1.5 Hz), 3.81 – 3.75 (1H, m), 3.68 – 3.62 (1H, 
m), 3.60 – 3.50 (2H, m), 3.05 (1H, br s), 2.46 (1H, ddd, J = 16.5, 8.5, 8.5 Hz), 2.35 – 2.21 (1H, m), 2.12 
– 1.91 (2H, m), 1.67 (3H, br d, J = 6.5 Hz). δC (101 MHz, CDCl3) 175.8, 129.6, 125.6, 62.5, 59.0, 42.8, 





General procedure O: Alcohol 318 (508 mg, 3.00 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 22 hours. FCC (three times, first eluent: 2:1 PhMe:EtOAc; second, 
gradient elution: 9:1 – 6:1 – 4:1 PhMe:acetone; third eluent: 9:1 PhMe:MeOH) afforded 319 (472 mg, 
33 %) as a pale-yellow oil. [α]D26 +10.6 (c = 0.40, CH2Cl2). νmax / cm-1: (film) 2980 (m), 2934 (m), 
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1782 (s), 1690 (s), 1498 (s), 1148 (s). δH (400 MHz, CDCl3) 5.70 – 5.58 (1H, m, C8-H), 5.40 – 5.30 
(1H, m, C7-H), 4.32 – 4.23 (1H, m, C6-H), 3.91 – 3.80 (2H, m, C1-H and C2-H), 3.77 – 3.68 (1H, m, 
C1-H’), 3.47 (1H, dd, J = 15.0, 8.0 Hz, C6-H’), 2.51 (1H, ddd, J = 17.5, 9.0, 9.0 Hz, C4-H), 2.39 – 2.29 
(1H, m, C4-H’), 2.23 – 2.11 (1H, m, C3-H), 2.05 – 1.95 (1H, m, C3-H’), 1.67 (3H, d, J = 6.0 Hz, C9-H3), 
1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 175.0 (C5), 154.3 (Boc C=O), 130.0 (C8), 125.3 (C7), 
84.2 (OC(CH3)3), 55.5 (C2), 52.7 (C1), 43.0 (C6), 29.8 (C4), 28.1 (OC(CH3)3), 22.5 (C3), 17.8 (C9). 
The 13C signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.2 – -136.6 (2F, m), -145.6 (1F, tt, J = 21.0, 5.5 Hz), -158.8 – -159.1 
(2F, m). HRMS: (ESI+) Calculated for C21H24F5N2O5: 479.1600. Found [M+H]+: 479.1596. 
Methyl 2-oxotetrahydrofuran-3-carboxylate (321) 
 
To a suspension of NaH (60 % in mineral oil, 1.44 g, 36.0 mmol) in dimethyl carbonate (2.53 mL, 
30.0 mmol) and anhydrous THF (25 mL) was added γ-butyrolactone (2.31 mL, 30.0 mmol) dropwise. 
The reaction mixture was heated at reflux for 16 hours before being cooled to room temperature, 
addition of 0.5 M aqueous HCl (40 mL) and extraction with MTBE (3 × 50 mL). The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo to afford 321 (1.97 g, 68 %) as a pale-yellow 
oil. δH (400 MHz, CDCl3) 4.46 (1H, ddd, J = 9.0, 8.0, 5.5 Hz), 4.31 (1H, ddd, J = 9.0, 7.5, 7.5 Hz), 3.79 
(3H, s), 3.56 (1H, dd, J = 9.5, 8.0 Hz), 2.66 (1H, dddd, J = 13.0, 8.0, 8.0, 7.5 Hz), 2.50 (1H, dddd, J = 
13.0, 9.5, 7.5, 5.5 Hz). δC (101 MHz, CDCl3) 172.4, 168.3, 67.5, 53.2, 45.9, 26.5. The spectroscopic 
properties were consistent with the data available in the literature.286 
Methyl (E)-3-(but-2-en-1-yl)-2-oxotetrahydrofuran-3-carboxylate 
 
To a suspension of NaH (60 % in mineral oil, 1.03 g, 25.7 mmol) in anhydrous THF (50 mL) at 0 °C 
was added a solution of the preceding compound (3.71 g, 25.7 mmol) in anhydrous THF (15 mL). The 
reaction mixture was stirred at 0 °C for an hour before addition of crotyl bromide (Section 7.3, 2.91 mL, 
28.3 mmol). The reaction mixture was stirred at room temperature for 4 hours before addition of 0.5 M 
aqueous HCl (100 mL). The resulting phases were separated, and the aqueous phase was extracted with 
CH2Cl2 (2 × 50 mL). The combined organic phases were dried over Na2SO4 and concentrated in vacuo. 
Chapter 7 - Experimental 
318 
 
FCC (gradient elution: 6:1 – 2:1) afforded the title compound (3.33 g, 65 %) as a colourless oil.  
νmax / cm-1: (film) 2956 (m), 1771 (s), 1731 (s), 1164 (s), 1025 (s). δH (500 MHz, CDCl3) 5.61 (1H, dqdd, 
J = 15.0, 6.5, 1.0 Hz, C6-H), 5.31 (1H, dddq, J = 15.0, 7.5, 7.0, 1.5 Hz, C5-H), 4.36 – 4.26 (2H, m, 
C1-H2), 3.77 (3H, s, OCH3), 2.73 – 2.62 (2H, m, C2-H and C4-H), 2.54 (1H, ddqd, J = 14.0, 7.0, 1.5, 
1.0 Hz, C4-H’), 2.30 (1H, dt, J = 13.0, 8.5 Hz, C2-H’), 1.67 (3H, dddd, J = 6.5, 1.5, 1.5, 1.5 Hz, C7-H3). 
δC (101 MHz, CDCl3) 174.7 (C8), 170.2 (C9), 131.4 (C6), 124.2 (C5), 66.3 (C1), 54.2 (C3), 53.3 
(OCH3), 37.2 (C4), 31.0 (C2), 18.2 (C7). HRMS: (ESI+) Calculated for C10H14NaO4: 221.0784. Found 
[M+Na]+: 221.0786.  
(E)-2-(But-2-en-1-yl)-2-(hydroxymethyl)butane-1,4-diol (322) 
 
General procedure I: The preceding compound (3.27 g, 16.5 mmol) was employed, using anhydrous 
THF as solvent and 2.0 eq. LiAlH4 (1.0 M in THF). Alcohol 322 (2.04 g, 71 %) was isolated as a 
colourless oil. νmax / cm-1: (film) 3317 (br s), 2919 (s), 1439 (m), 1034 (s). δH (400 MHz, CDCl3) 5.54 – 
5.43 (1H, m, C6-H), 5.43 – 5.33 (1H, m, C5-H), 3.78 (2H, t, J = 5.5 Hz, C1-H2), 3.56 (4H, s, 2 × C8-H2), 
2.91 (3H, br s, 3 × OH), 1.95 (2H, d, J = 7.0 Hz, C4-H2), 1.72 – 1.64 (5H, m, C2-H2 and C7-H3).  
δC (101 MHz, CDCl3) 129.0 (C6), 126.0 (C5), 68.1 (C8), 58.7 (C1), 42.0 (C3), 36.4 (C4), 35.3 (C2), 
18.2 (C7). HRMS: (ESI+) Calculated for C9H18NaO3: 197.1148. Found [M+Na]+: 197.1154.  
(E)-2-(5-(But-2-en-1-yl)-1,3-dioxan-5-yl)ethan-1-ol (323) 
 
This compound was prepared using an adaptation of a literature procedure.287 A solution of alcohol 322 
(375 mg, 2.15 mmol), lithium bromide (37.3 mg, 430 μmol), TsOH·H2O (40.9 mg, 215 μmol) and 
dimethoxymethane (0.65 mL, 7.35 mmol) in CH2Cl2 (1.1 mL) was stirred at room temperature for 
18 hours. The reaction mixture was heated at 110 °C for 10 minutes before being cooled to room 
temperature; the resulting (solvent-free) material was purified by FCC (gradient elution: 9:1 – 
2:1 hexane:EtOAc) to afford 323 (148 mg, 37 %) as a colourless oil. νmax / cm-1: (film) 3401 (br s), 
2853 (m), 2768 (m), 1452 (m), 1165 (s), 1027 (s). δH (500 MHz, CDCl3) 5.50 (1H, dqt, J = 15.0, 6.5, 
1.0 Hz, C6-H), 5.34 (1H, dtq, J = 15.0, 7.5, 1.5 Hz, C5-H), 4.90 (1H, d, J = 6.0 Hz, C9-H), 4.73 (1H, 
d, J = 6.0 Hz, C9-H’), 3.84 – 3.79 (2H, m, C1-H2), 3.72 (2H, d, J = 11.5 Hz, 2 × C8-H), 3.59 (2H, d, 
J = 11.5 Hz, 2 × C8-H’), 2.38 (1H, br s, OH), 2.01 (2H, br d, J = 7.5 Hz, C4-H2), 1.69 – 1.65 (5H, m, 
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C2-H2 and C7-H3). δC (126 MHz, CDCl3) 129.5 (C6), 124.8 (C5), 94.1 (C9), 75.0 (C8), 59.1 (C1), 2 × 
37.5 (C2 and C4), 35.7 (C3), 18.2 (C7). HRMS: (ESI+) Calculated for C10H18NaO3: 209.1148. Found 




General procedure O: Alcohol 323 (587 mg, 3.15 mmol) was employed with BocNHOFBz (vide 
supra). The reaction time was 16 hours. FCC (gradient elution: 1:0 – 19:1 PhMe:EtOAc) afforded 324 
(671 mg, 43 %) as a pale-yellow oil. νmax / cm-1: (film) 2980 (m), 2851 (m), 2727 (m), 1783 (s), 1721 (s), 
1653 (m), 1504 (s), 1149 (s). δH (500 MHz, CDCl3) 5.58 – 5.49 (1H, m, C6-H), 5.36 (1H, dtq, J = 15.0, 
7.5, 1.5 Hz, C5-H), 4.82 (1H, d, J = 6.0 Hz, C9-H), 4.77 (1H, d, J = 6.0 Hz, C9-H’), 3.79 – 3.73 (2H, 
m, C1-H2), 3.64 – 3.56 (4H, m, 2 × C8-H2), 2.10 (2H, d, J = 7.5 Hz, C4-H2), 1.78 – 1.71 (2H, m, C2-H2), 
1.68 – 1.64 (3H, m, C7-H3), 1.50 (9H, s, OC(CH3)3). δC (126 MHz, CDCl3) 154.6 (Boc C=O), 129.8 
(C6), 124.5 (C5), 94.4 (C9), 83.7 (OC(CH3)3), 74.4 (C8), 46.7 (C1), 2 × 35.5 (C3 and C4), 29.5 (C2), 
28.2 (OC(CH3)3), 18.1 (C7). The 
13C signals corresponding to the pentafluorobenzoyl group could not 
be resolved due to their weak intensity. δF (470 MHz, CDCl3) -136.4 – -136.6 (2F, m), -146.4 (1F, tt, 
J = 21.0, 5.0 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C22H26F5NNaO6: 518.1572. 
Found [M+Na]+: 518.1574.  
tert-Butyl 8-vinyl-2,4-dioxa-9-azaspiro[5.5]undecane-9-carboxylate (325) 
 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 324 (52.0 mg, 0.105 mmol) was employed. FCC 
(eluent: 19:1 petrol:acetone) afforded 325 (20.4 mg, 69 %) as a colourless oil. νmax / cm-1: (film) 
2977 (m), 2845 (m), 2765 (m), 1688 (s), 1407 (s), 1157 (s). δH (400 MHz, CDCl3) 5.72 (1H, ddd, J = 
17.5, 10.5, 3.5 Hz, C6-H), 5.11 (1H, ddd, J = 10.5, 2.5, 1.0 Hz, C7-H), 4.99 (1H, ddd, J = 17.5, 2.5, 
1.0 Hz, C7-H’), 4.81 (1H, d, J = 6.0 Hz, C9-H), 4.77 (1H, d, J = 6.0 Hz, C9-H’), 4.76 – 4.71 (1H, m, 
C5-H), 4.00 – 3.88 (1H, m, C1-H), 3.79 (1H, d, J = 11.5 Hz, C8-H), 3.70 (1H, d, J = 11.5 Hz, C8-H’), 
3.48 (1H, d, J = 11.0 Hz, C8’-H), 3.41 (1H, d, J = 11.0 Hz, C8’-H’), 2.95 (1H, ddd, J = 13.5, 13.0, 
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3.0 Hz, C1-H’), 1.84 – 1.74 (2H, m, C2-H and C4-H), 1.53 (1H, dd, J = 14.0, 7.0 Hz, C4-H’), 1.44 (9H, 
s, OC(CH3)3), 1.29 (1H, ddd, J = 13.0, 13.0, 5.5 Hz, C2-H’). δC (101 MHz, CDCl3) 155.4 (C=O), 138.2 
(C6), 114.0 (C7), 94.5 (C9), 79.9 (OC(CH3)3), 77.7 (C8’), 73.3 (C8), 51.1 (C5), 35.5 (C1), 33.8 (C4), 




This compound was prepared according to a literature procedure.288 A solution of 2-bromophenethyl 
alcohol (326a) (2.01 g, 10.0 mmol), Pd(OAc)2 (112 mg, 500 μmol), tri(o-tolyl)phosphine (304 mg, 
1.00 mmol) and methyl acrylate (1.35 mL, 15.0 mmol) in anhydrous Et3N (7.0 mL) was sparged with 
argon for five minutes. The reaction mixture was heated at 95 °C in a sealed tube for 19 hours before 
being filtered through celite. The filter cake was rinsed with EtOAc, and the filtrate was concentrated 
in vacuo. FCC (gradient elution: 2:1 – 3:2 petrol:EtOAc) afforded the title compound (1.57 g, 76 %) as 
a pale-yellow oil. νmax / cm-1: (film) 3406 (br s), 2950 (m), 1698 (s), 1630 (s), 1318 (s), 1170 (s).  
δH (400 MHz, CDCl3) 8.02 (1H, d, J = 16.0 Hz, C3-H), 7.60 – 7.57 (1H, m, ArCH), 7.37 – 7.31 (1H, 
m, ArCH), 7.29 – 7.24 (2H, m, 2 × ArCH), 6.38 (1H, d, J = 16.0 Hz, C4-H), 3.87 – 3.78 (5H, m, C1-H2 
and OCH3), 3.04 (2H, t, J = 7.0 Hz, C2-H2), 1.71 – 1.64 (1H, br s, OH). δC (101 MHz, CDCl3) 167.5 
(C5), 142.2 (C3), 138.2 (ArC), 133.7 (ArC), 131.0 (ArCH), 130.3 (ArCH), 127.3 (ArCH), 127.0 
(ArCH), 119.7 (C4), 63.5 (C1), 51.9 (OCH3), 36.6 (C2). HRMS: (ESI+) Calculated for C12H14NaO3: 




General procedure O: The preceding alcohol (619 mg, 3.00 mmol) was employed with BocNHOFBz 
(vide supra). The reaction time was 16 hours. FCC (gradient elution: 99:1 – 19:1 PhMe:EtOAc) afforded 
327a (1.07 g, 69 %) as a pale-yellow oil. νmax / cm-1: (film) 2982 (m), 1783 (s), 1716 (s), 1652 (m), 
1634 (m), 1500 (s), 1150 (s). δH (400 MHz, CDCl3) 7.97 (1H, d, J = 16.0 Hz, C3-H), 7.58 – 7.54 (1H, 
m, ArCH), 7.35 – 7.29 (1H, m, ArCH), 7.29 – 7.23 (2H, m, 2 × ArCH), 6.37 (1H, d, J = 16.0 Hz, C4-H), 
3.87 (2H, t, J = 7.5 Hz, C1-H2), 3.77 (3H, s, OCH3), 3.12 (2H, t, J = 7.5 Hz, C2-H2), 1.42 (9H, s, 
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OC(CH3)3). δC (101 MHz, CDCl3) 167.0 (C5), 154.0 (Boc C=O), 141.4 (C3), 137.3 (ArC), 133.5 (ArC), 
130.7 (ArCH), 130.2 (ArCH), 127.4 (ArCH), 126.8 (ArCH), 120.0 (C4), 83.4 (OC(CH3)3), 51.8 (C1), 
51.6 (OCH3), 30.6 (C2), 27.9 (OC(CH3)3). The 
13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.1 – -136.4 (2F, m), 
-146.6 (1F, tt, J = 21.0, 5.5 Hz), -159.5 – -159.7 (2F, m). HRMS: (ESI+) Calculated for C24H22F5NNaO6: 
538.1259. Found [M+Na]+: 538.1272.  
tert-Butyl (Z)-1-(2-methoxy-2-oxoethylidene)-3,4-dihydroisoquinoline-2(1H)-carboxylate  
((Z)-328a) 
  
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.4 M); 130 °C; 24 hours. Substrate 327a (54.1 mg, 0.105 mmol) was employed. FCC 
(gradient elution: 49:1 - 19:1 PhMe:EtOAc) afforded (Z)-328a (23.9 mg, 75 %) as a pale-yellow oil. 
When the cyclisation is run to partial completion: General procedure D: Conditions: 2.5 mol% 
Pd2(dba)3; 15 mol% ligand L2 (vide supra); 500 mol% Et3N; THF (0.4 M); 130 °C, 3 hours. Substrate 
327a (54.1 mg, 0.105 mmol) was employed. By 1H NMR analysis of the crude product, 328a was found 
to be produced as a 14:1 mixture of (E)- and (Z)-isomers. FCC (eluent: 29:1 PhMe:EtOAc) exclusively 
afforded (Z)-328a (22.4 mg, 70 %) as a colourless oil. The product was assigned as the (Z)-isomer 
based on the observed NOE correlation between the OMe and the t-Bu protons. νmax / cm-1: (film) 
2976 (m), 2929 (m), 1698 (s), 1629 (s), 1149 (s). δH (400 MHz, CDCl3) 7.69 – 7.65 (1H, m, ArCH), 
7.33 – 7.20 (2H, m, 2 × ArCH), 7.18 – 7.14 (1H, m, ArCH), 6.30 (1H, s, C4-H), 4.24 – 3.54 (2H, br s, 
C1-H2), 3.74 (3H, s, OCH3), 2.90 (2H, br s, C2-H2), 1.43 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 
166.4 (C5), 152.9 (Boc C=O), 145.8 (C3), 136.7 (ArC), 131.6 (ArC), 129.9 (ArCH), 129.3 (ArCH), 
126.9 (ArCH), 124.5 (ArCH), 106.9 (C4), 81.3 (OC(CH3)3), 51.4 (OCH3), 43.5 (C1), 29.0 (C2), 28.3 
(OC(CH3)3). HRMS: (ESI+) Calculated for C17H21NNaO4: 326.1363. Found [M+Na]+: 326.1365.  
  





To a solution of LHDMS (0.5 M in THF, 150 mL, 75.0 mmol) was added 3-bromo-2-methylpyridine 
(2.88 mL, 25.0 mmol) dropwise. The reaction mixture was stirred for 2.5 hours before dropwise 
addition of dimethyl carbonate (3.37 mL, 40.0 mmol), and then stirred for a further 14 hours before 
being partially concentrated in vacuo. The reaction mixture was partitioned between EtOAc (100 mL) 
and water (50 mL). The phases were separated, and the aqueous phase was extracted with EtOAc (2 × 
30 mL). The combined organic phases were washed with brine (50 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the title compound (5.63 g, 98 %) as a red oil, which was used without 
further purification. νmax / cm-1: (film) 2953 (m), 1736 (s), 1574 (m), 1429 (s), 1023 (s). δH (400 MHz, 
CDCl3) 8.49 (1H, dd, J = 4.5, 1.5 Hz, ArCH), 7.86 (1H, dd, J = 8.0, 1.5 Hz, ArCH), 7.10 (1H, dd, J = 
8.0, 4.5 Hz, ArCH), 4.06 (2H, s, C2-H2), 3.73 (3H, s, OCH3). δC (101 MHz, CDCl3) 170.0 (C1), 153.6 
(ArC), 147.9 (ArCH), 140.3 (ArCH), 123.6 (ArCH), 122.0 (ArC), 52.3 (OCH3), 43.6 (C2). 
HRMS: (ESI+) Calculated for C8H9BrNO2: 229.9811. Found [M+H]+: 229.9811.  
2-(3-Bromopyridin-2-yl)ethan-1-ol (326b) 
 
This compound was prepared according to a literature procedure.289 To a solution of the preceding 
compound (4.60 g, 20.0 mmol) in anhydrous THF (80 mL) at -78 °C was added DiBAl-H (1.0 M in 
hexane, 40.0 mL, 40.0 mmol). The reaction mixture was stirred at room temperature for 3 hours before 
being diluted with Et2O and cooled to 0 °C. The reaction mixture was quenched slowly with water 
(1.6 mL), 4.0 M aqueous NaOH (1.6 mL) and a further portion of water (4.0 mL). The reaction mixture 
was stirred at room temperature for 20 minutes before being dried over Na2SO4, filtered and 
concentrated in vacuo. FCC (eluent: 2:3 petrol:EtOAc) afforded 326b (3.16 g, 78 %) as a red oil.  
δH (500 MHz, CDCl3) 8.45 (1H, dd, J = 5.0, 1.5 Hz), 7.86 (1H, dd, J = 8.0, 1.5 Hz), 7.07 (1H, ddt, J = 
8.0, 5.0, 0.5 Hz), 4.08 (2H, t, J = 5.5 Hz), 3.16 (2H, td, J = 5.5, 0.5 Hz). δC (126 MHz, CDCl3) 159.0, 
147.2, 140.3, 122.7, 121.8, 60.5, 38.1. The spectroscopic properties were consistent with the data 
available in the literature.289 
  





A solution of 326b (1.21 g, 6.00 mmol), Pd(OAc)2 (67.4 mg, 300 μmol), tri(o-tolyl)phosphine (183 mg, 
600 μmol), methyl acrylate (0.81 mL, 9.00 mmol) and Et3N (1.26 mL, 9.00 mmol) in anhydrous DMF 
(12 mL) was sparged with argon for five minutes. The reaction mixture was heated at 90 °C in a sealed 
tube for 21 hours before being diluted with brine (25 mL) and extracted with EtOAc (3 × 40 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 
1:0 – 9:1 EtOAc:MeOH) afforded the title compound (1.22 g, 98 %) as a red crystalline solid.  
m.p. 70-74 °C (acetone:petrol, needles). νmax / cm-1: (solid) 3163 (br s), 2855 (m), 1712 (s), 1637 (s), 
1169 (s), 1053 (s). δH (400 MHz, CDCl3) 8.53 (1H, dd, J = 5.0, 2.0 Hz, ArCH), 7.92 (1H, d, J = 16.0 Hz, 
C3-H), 7.85 (1H, dd, J = 8.0, 2.0 Hz, ArCH), 7.25 (1H, dd, J = 8.0, 5.0 Hz, ArCH), 6.40 (1H, d, J = 
16.0 Hz, C4-H), 4.11 (2H, t, J = 5.5 Hz, C1-H2), 3.85 (3H, s, OCH3), 3.17 (2H, t, J = 5.5 Hz, C2-H2). 
δC (101 MHz, CDCl3) 166.6 (C5), 159.2 (ArC), 149.6 (ArCH), 140.0 (C3), 134.3 (ArCH), 129.2 (ArC), 
121.9 (ArCH), 121.7 (C4), 60.8 (C1), 51.9 (OCH3), 35.7 (C2). HRMS: (ESI+) Calculated for 




General procedure O: The preceding alcohol (518 mg, 2.50 mmol) was employed with BocNHOFBz 
(vide supra). The reaction time was 16 hours. FCC (gradient elution: 19:1 – 14:1 – 9:1 PhMe:EtOAc) 
afforded 327b (837 mg, 65 %) as a pale-yellow oil. νmax / cm-1: (film) 2982 (m), 1782 (s), 1720 (s), 
1651 (m), 1501 (s), 1154 (s). δH (400 MHz, CDCl3) 8.53 (1H, dd, J = 5.0, 2.0 Hz, ArCH), 7.94 (1H, d, 
J = 16.0 Hz, C3-H), 7.79 (1H, dd, J = 8.0, 2.0 Hz, ArCH), 7.19 (1H, dd, J = 8.0, 5.0 Hz, ArCH), 6.36 
(1H, d, J = 16.0 Hz, C4-H), 4.14 (2H, t, J = 7.5 Hz, C1-H2), 3.79 (3H, s, OCH3), 3.30 (2H, t, J = 7.5 Hz, 
C2-H2), 1.45 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 166.6 (C5), 157.1 (ArC), 154.2 (Boc C=O), 
150.5 (ArCH), 140.2 (C3), 134.3 (ArCH), 129.5 (ArC), 122.2 (ArCH), 122.0 (C4), 83.6 (OC(CH3)3), 
51.9 (OCH3), 50.5 (C1), 32.7 (C2), 28.1 (OC(CH3)3). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.9 – -136.4 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.5 – -159.7 (2F, m). HRMS: (ESI+) 
Calculated for C23H22F5N2O6: 517.1393. Found [M+H]+: 517.1410.  






General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 17.5 mol% ligand L3 (vide supra); 100 mol% 
Et3N; dioxane (0.3 M); 130 °C; 24 hours. Substrate 327b (54.2 mg, 0.105 mmol) was employed. FCC 
(two times, first eluent: 3:2 PhMe:EtOAc; second eluent: 14:1 PhMe:acetone) afforded (Z)-328b 
(17.2 mg, 54 %) as a colourless crystalline solid. νmax / cm-1: (film) 2976 (m), 1720 (s), 1633 (s), 
1150 (s). δH (400 MHz, CDCl3) 8.52 (1H, dd, J = 5.0, 1.5 Hz, ArCH), 7.96 (1H, dd, J = 8.0, 1.5 Hz, 
ArCH), 7.21 (1H, dd, J = 8.0, 5.0 Hz, ArCH), 6.30 (1H, s, C4-H), 4.19 – 3.80 (2H, br s, C1-H2), 3.76 
(3H, s, OCH3), 3.09 (2H, t, J = 6.5 Hz, C2-H2), 1.45 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 165.8 
(C5), 156.0 (ArC), 152.4 (Boc C=O), 150.4 (ArCH), 143.4 (ArC), 131.8 (ArCH), 126.8 (C3), 121.9 
(ArCH), 107.7 (C4), 81.7 (OC(CH3)3), 51.4 (OCH3), 42.7 (C1), 32.2 (C2), 28.1 (OC(CH3)3).  
HRMS: (ESI+) Calculated for C16H20N2NaO4: 327.1315. Found [M+Na]+: 327.1311.  
 
ORTEP view of (Z)-328b. 
  





To a solution of LHDMS (0.5 M in THF, 150 mL, 75.0 mmol) was added 3-bromo-4-methylpyridine 
(2.88 mL, 25.0 mmol) dropwise. The reaction mixture was stirred at room temperature for 1.5 hours 
before addition of dimethyl carbonate (3.37 mL, 40.0 mmol) dropwise, and then stirred for a further 
15 hours before being partially concentrated in vacuo. The reaction mixture was partitioned between 
EtOAc (100 mL) and water (50 mL). The resulting phases were separated, and the aqueous phase was 
extracted with EtOAc (2 × 40 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo to afford the title compound (5.51 g, 96 %) as a red oil, which was used without 
further purification. δH (400 MHz, CDCl3) 8.71 (1H, s), 8.47 (1H, d, J = 5.0 Hz), 7.25 (1H, d, J = 
5.0 Hz), 3.79 (2H, s), 3.73 (3H, s). δC (101 MHz, CDCl3) 169.6, 152.2, 148.5, 142.8, 126.2, 123.6, 52.6, 
40.8. The spectroscopic properties were consistent with the data available in the literature.290  
2-(3-Bromopyridin-4-yl)ethan-1-ol (326c) 
 
This compound was prepared according to a literature procedure.289 To a solution of the preceding 
compound (4.60 g, 20.0 mmol) in anhydrous THF (80 mL) at -78 °C was added DiBAl-H (1.0 M in 
hexane, 40.0 mL, 40.0 mmol). The reaction mixture was stirred at room temperature for 4 hours before 
being diluted with Et2O and cooled to 0 °C. The reaction mixture was quenched slowly with water 
(1.6 mL), 4.0 M aqueous NaOH (1.6 mL) and a further portion of water (4.0 mL). The reaction mixture 
was stirred at room temperature for 20 minutes before being dried over Na2SO4, filtered and 
concentrated in vacuo. FCC (eluent: 1:4 petrol:EtOAc) afforded 326c (1.76 g, 44 %) as a yellow oil.  
δH (400 MHz, CDCl3) 8.65 (1H, s), 8.39 (1H, d, J = 5.0 Hz), 7.24 (1H, d, J = 5.0 Hz), 3.93 (2H, t, J = 
6.5 Hz), 3.01 (2H, t, J = 6.5 Hz), 1.87 (1H, br s). δC (101 MHz, CDCl3) 152.0, 148.2, 147.3, 126.2, 
123.5, 61.1, 38.6. The spectroscopic properties were consistent with the data available in the 
literature.289 
  





A solution of 326c (1.21 g, 6.00 mmol), Pd(OAc)2 (67.4 mg, 300 μmol), tri(o-tolyl)phosphine (183 mg, 
600 μmol), methyl acrylate (0.81 mL, 9.00 mmol) and Et3N (1.26 mL, 9.00 mmol) in anhydrous DMF 
(12 mL) was sparged with argon for five minutes. The reaction mixture was heated at 90 °C in a sealed 
tube for 17 hours before being diluted with brine (25 mL) and extracted with EtOAc (3 × 40 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 
1:0 – 19:1 EtOAc:MeOH) afforded the title compound (1.16 g, 93 %) as a yellow oil. νmax / cm-1: (film) 
3356 (br s), 2952 (m), 1717 (s), 1594 (m), 1436 (m), 1318 (s). δH (400 MHz, CDCl3) 8.72 (1H, s, ArCH), 
8.48 (1H, d, J = 5.0 Hz, ArCH), 7.94 (1H, d, J = 16.0 Hz, C3-H), 7.21 (1H, d, J = 5.0 Hz, ArCH), 6.44 
(1H, d, J = 16.0 Hz, C4-H), 3.89 (2H, t, J = 6.5 Hz, C1-H2), 3.83 (3H, s, OCH3), 3.01 (2H, t, J = 6.5 Hz, 
C2-H2), 1.82 (1H, br s, OH). δC (101 MHz, CDCl3) 166.9 (C5), 150.2 (ArCH), 147.8 (ArCH), 147.2 
(ArC), 139.3 (C3), 130.2 (ArC), 125.2 (ArCH), 121.3 (C4), 62.1 (C1), 52.1 (OCH3), 35.9 (C2).  




General procedure O: The preceding alcohol (518 mg, 2.50 mmol) was employed with BocNHOFBz 
(vide supra). The reaction time was 16 hours. FCC (two times, first eluent: 39:1 PhMe:Et3N;  
second, gradient elution: 5:1 – 5:2 PhMe:EtOAc) afforded 327c (400 mg, 31 %) as a pale-yellow oil.  
νmax / cm-1: (film) 2983 (m), 1784 (s), 1720 (s), 1653 (m), 1505 (s), 1155 (s). δH (400 MHz, CDCl3) 8.74 
(1H, s, ArCH), 8.51 (1H, d, J = 5.0 Hz, ArCH), 7.90 (1H, d, J = 16.0 Hz, C3-H), 7.21 (1H, d, J = 5.0 Hz, 
ArCH), 6.45 (1H, d, J = 16.0 Hz, C4-H), 3.92 (2H, t, J = 7.0 Hz, C1-H2), 3.79 (3H, s, OCH3), 3.10 (2H, 
t, J = 7.0 Hz, C2-H2), 1.41 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 166.6 (C5), 154.0 (Boc C=O), 
150.7 (ArCH), 148.3 (ArCH), 145.7 (ArC), 138.6 (C3), 130.1 (ArC), 125.0 (ArCH), 122.0 (C4), 84.0 
(OC(CH3)3), 52.0 (OCH3), 50.8 (C1), 30.2 (C2), 28.0 (OC(CH3)3). The 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -136.2 – -136.5 (2F, m), -146.1 (1F, tt, J = 21.0, 5.5 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) 
Calculated for C23H22F5N2O6: 517.1393. Found [M+H]+: 517.1391.  






General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 300 mol% 
Et3N; THF (0.4 M); 130 °C, 10 hours. Substrate 327c (54.2 mg, 0.105 mmol) was employed. FCC (two 
times, first, gradient elution: 10:1 – 8:1 PhMe:acetone; second eluent: 19:1 PhMe:MeOH) afforded 
(E)-328c (25.0 mg, 78 %, 6:1 mixture of (E)- and (Z)-isomers) as a colourless crystalline solid. 
Spectroscopic data for the major (E)-isomer: νmax / cm-1: (film) 2977 (m), 1707 (s), 1627 (s), 1321 (s), 
1139 (s). δH (400 MHz, CDCl3) 8.81 (1H, s, ArCH), 8.52 (1H, d, J = 5.0 Hz, ArCH), 7.13 (1H, d, J = 
5.0 Hz, ArCH), 6.61 (1H, s, C4-H), 3.67 (3H, s, OCH3), 3.62 (2H, t, J = 6.5 Hz, C1-H2), 2.83 (2H, t, 
J = 6.5 Hz, C2-H2), 1.52 (9H, s, OC(CH3)3). δC (126 MHz, CDCl3) 167.2 (C5), 153.1 (Boc C=O), 2 × 
150.2 (2 × ArCH), 145.4 (ArC), 145.1 (C3), 128.7 (ArC), 120.8 (ArCH), 110.4 (C4), 82.4 (OC(CH3)3), 
51.5 (OCH3), 43.4 (C1), 28.5 (C2), 28.4 (OC(CH3)3). HRMS: (ESI+) Calculated for C16H21N2O4: 
305.1496. Found [M+H]+: 305.1504. Characteristic signals for the minor (Z)-isomer: δH (400 MHz, 
CDCl3) 7.10 (1H, d, J = 5.0 Hz), 6.40 (1H, s), 3.75 (3H, s), 1.43 (9H, s). 
 
ORTEP view of (E)-328c. 
  





This compound was prepared according to a literature procedure.291 A solution of 
8-oxaspiro[4.5]decane-7,9-dione (330) (5.00 g, 29.7 mmol) and NaBH4 (3.37 g, 89.1 mmol) in 
anhydrous THF (50 mL) was stirred at room temperature for 4 hours, then cooled to 0 °C before 
addition of 1.0 M aqueous HCl (80 mL). The reaction mixture was extracted with EtOAc (3 × 60 mL). 
The combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 
2:1 hexane:EtOAc) afforded the title compound (3.37 g, 74 %) as a colourless oil. δH (400 MHz, CDCl3) 
4.36 (2H, t, J = 6.0 Hz), 2.41 (2H, s), 1.76 (2H, t, J = 6.0 Hz), 1.72 – 1.64 (4H, m), 1.59 – 1.45 (4H, m). 
δC (101 MHz, CDCl3) 171.4, 67.4, 42.5, 40.8, 38.7, 34.4, 23.8. The spectroscopic properties were 
consistent with the data available in the literature.292 
8-Oxaspiro[4.5]decan-7-ol (331) 
 
To a solution of the preceding lactone (2.31 g, 15.0 mmol) in anhydrous CH2Cl2 (35 mL) at -78 °C was 
added DiBAl-H (1.0 M in CH2Cl2, 16.5 mL, 16.5 mmol). The reaction mixture was stirred at -78 °C for 
2.5 hours before being diluted with Et2O and warmed to 0 °C. The reaction mixture was quenched 
slowly with water (0.65 mL), 4.0 M aqueous NaOH (0.65 mL) and a further portion of water (1.7 mL). 
The reaction mixture was stirred at room temperature for 20 minutes before being dried over Na2SO4, 
filtered and concentrated in vacuo. FCC (gradient elution: 9:1 – 6:1 PhMe:acetone) afforded 331 
(2.02 g, 86 %) as a colourless oil. δH (400 MHz, CDCl3) 4.87 – 4.81 (1H, m), 3.94 (1H, ddd, J = 11.5, 
4.0, 4.0 Hz), 3.59 (1H, ddd, J = 11.5, 10.5, 2.5 Hz), 3.34 – 3.13 (1H, m), 1.74 – 1.28 (12H, m).  
δC (101 MHz, CDCl3) 94.1, 62.4, 44.2, 41.2, 40.9, 36.5, 36.3, 24.3, 23.7. The spectroscopic properties 
were consistent with the data available in the literature.292 
  





A solution of hemiacetal 331 (1.56 g, 10.0 mmol) and methyl (triphenylphosphoranylidene)acetate 
(5.02 g, 15.0 mmol) in anhydrous PhMe (50 mL) was heated at reflux for 5 hours. The reaction mixture 
was cooled to room temperature and concentrated in vacuo. FCC (eluent: 4:1 petrol:acetone) afforded 
the title compound (1.82 g, 86 %, 9:1 mixture of (E)- and (Z)-isomers) as a colourless oil. Spectroscopic 
data for the major (E)-isomer: νmax / cm-1: (film) 3417 (br s), 2948 (m), 1721 (s), 1436 (s), 1166 (s).  
δH (400 MHz, CDCl3) 6.97 (1H, dt, J = 15.5, 7.5 Hz, C5-H), 5.84 (1H, dt, J = 15.5, 1.5 Hz, C6-H), 3.72 
(3H, s, OCH3), 3.71 – 3.66 (2H, m, C1-H2), 2.19 (2H, dd, J = 7.5, 1.5 Hz, C4-H2), 1.66 – 1.56 (6H, m, 
C2-H2 and 2 × C9-H2), 1.50 – 1.41 (4H, m, 2 × C8-H2), 1.38 (1H, br s, OH). δC (101 MHz, CDCl3) 
167.0 (C7), 147.2 (C5), 123.1 (C6), 60.1 (C1), 51.6 (OCH3), 44.5 (C3), 41.9 (C2), 41.6 (C4), 37.8  
(C8), 24.5 (C9). HRMS: (ESI+) Calculated for C12H20NaO3: 235.1305. Found [M+Na]+: 235.1305. 
Characteristic signals for the minor (Z)-isomer: δH (400 MHz, CDCl3) 6.29 (1H, dt, J = 11.5, 7.5 Hz), 




General procedure O: The preceding alcohol (531 mg, 2.50 mmol) was employed with BocNHOFBz 
(vide supra). The reaction time was 16 hours. FCC (gradient elution: 1:0 – 49:1 PhMe:EtOAc) afforded 
332 (859 mg, 66 %) as a colourless oil. The (E) and (Z)-isomers of 332 were separable by FCC; hence, 
this compound was isolated as a single alkene isomer. νmax / cm-1: (film) 2952 (m), 1783 (s), 1722 (s), 
1654 (m), 1506 (s), 1158 (s). δH (400 MHz, CDCl3) 6.93 (1H, dt, J = 15.5, 8.0 Hz, C5-H), 5.85 (1H, dt, 
J = 15.5, 1.5 Hz, C6-H), 3.71 (3H, s, OCH3), 3.70 – 3.65 (2H, m, C1-H2), 2.20 (2H, dd, J = 8.0, 1.5 Hz, 
C4-H2), 1.70 – 1.60 (6H, m, C2-H2 and 2 × C9-H2), 1.52 – 1.43 (13H, m, 2 × C8-H2 and OC(CH3)3).  
δC (101 MHz, CDCl3) 166.8 (C7), 154.6 (Boc C=O), 146.3 (C5), 123.4 (C6), 83.6 (OC(CH3)3), 51.5 
(OCH3), 47.9 (C1), 44.3 (C3), 41.1 (C4), 37.5 (C8), 35.4 (C2), 28.2 (OC(CH3)3), 24.6 (C9). The 
13C 
signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.5 – -136.7 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.4 – -159.5 
(2F, m). HRMS: (ESI+) Calculated for C24H28F5NNaO6: 544.1729. Found [M+Na]+: 544.1722. 
Chapter 7 - Experimental 
330 
 
tert-Butyl (E)-7-(2-methoxy-2-oxoethylidene)-8-azaspiro[4.5]decane-8-caarboxylate ((E)-333) 
  
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 300 mol% 
Et3N; THF (0.4 M); 130 °C, 8 hours. Substrate 322 (54.8 mg, 0.105 mmol) was employed. FCC (two 
times, first, gradient elution: 1:0 – 149:1 PhMe:acetone; second eluent: 24:1 petrol:acetone) afforded 
(E)-333 (21.7 mg, 67 %) as a colourless oil. The product was assigned as the (E)-isomer based on the 
observed NOE correlation between the C6 and the t-Bu protons. νmax / cm-1: (film) 2949 (m), 1698 (s), 
1365 (s), 1163 (s). δH (400 MHz, CDCl3) 5.96 (1H, s, C6-H), 3.67 (3H, s, OCH3), 3.61 – 3.57 (2H, m, 
C1-H2), 2.87 (2H, s, C4-H2), 1.74 – 1.56 (6H, m, C2-H2 and 2 × C9-H2), 1.55 – 1.44 (11H, m, 2 × C8-H 
and OC(CH3)3), 1.42 – 1.33 (2H, m, 2 × C8-H’). δC (101 MHz, CDCl3) 168.0 (C7), 155.2 (C5), 153.4 
(Boc C=O), 111.0 (C6), 81.3 (OC(CH3)3), 51.1 (OCH3), 44.2 (C1), 43.2 (C3), 38.5 (C4), 38.2 (C8), 
36.5 (C2), 28.4 (OC(CH3)3), 24.3 (C9). HRMS: (ESI+) Calculated for C17H27NNaO4: 332.1823. Found 
[M+Na]+: 332.1838.  
(E)-1-Iodonon-4-ene 
 
To a solution of PPh3 (3.15 g, 12.0 mmol) and imidazole (817 mg, 12.0 mmol) in CH2Cl2 (15 mL) was 
added iodine (3.05 g, 12.0 mmol) gradually over around 5 minutes. The reaction mixture was stirred 
for 30 minutes before addition of (E)-non-4-en-1-ol (vide supra, 1.42 g, 10.0 mmol). The reaction 
mixture was stirred at room temperature for 13 hours before being diluted with hexane (25 mL), filtered 
through silica and eluted with pentane. The filtrate was concentrated in vacuo. FCC (eluent: pentane) 
afforded the title compound (2.40 g, 95 %) as a colourless oil. νmax / cm-1: (film) 2955 (m), 2924 (m), 
1438 (m), 1219 (m). δH (400 MHz, CDCl3) 5.51 (1H, dtt, J = 15.0, 7.0, 1.5 Hz), 5.35 (1H, dtt, J = 15.0, 
7.0, 1.5 Hz), 3.21 (2H, t, J = 7.0 Hz), 2.12 (2H, dtd, J = 7.0, 7.0, 1.5 Hz), 2.01 (2H, dtd, J = 7.0, 7.0, 
1.5 Hz), 1.90 (2H, tt, J = 7.0, 7.0 Hz), 1.40 – 1.28 (4H, m), 0.94 – 0.88 (3H, m). δC (101 MHz, CDCl3) 
132.4, 127.8, 2 × 33.3, 32.4, 31.8, 22.3, 14.1, 6.8. The spectroscopic properties were consistent with 
the data available in the literature.293,294 
 





A solution of the preceding iodide (504 mg, 2.00 mmol) and potassium phthalimide (370 mg, 
2.00 mmol) in anhydrous DMF (8 mL) was heated at 60 °C for 16 hours. The reaction mixture was 
cooled to room temperature, diluted with Et2O (70 mL) and washed with brine (4 × 40 mL). The organic 
phase was dried over Na2SO4 and concentrated in vacuo to afford the title compound (523 mg, 96 %) 
as a pale-yellow oil. νmax / cm-1: (film) 2927 (m), 1707 (s), 1394 (s). δH (400 MHz, CDCl3) 7.83 (2H, dd, 
J = 5.5, 3.0 Hz, 2 × ArCH), 7.70 (2H, dd, J = 5.5, 3.0 Hz, 2 × ArCH), 5.48 – 5.33 (2H, m, C4-H and 
C5-H), 3.68 (2H, t, J = 7.5 Hz, C1-H2), 2.05 (2H, dt, J = 7.0, 7.0 Hz, C3-H2), 1.97 – 1.90 (2H, m, 
C6-H2), 1.74 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.33 – 1.24 (4H, m, C7-H2 and C8-H2), 0.90 – 0.83 (3H, 
m, C9-H3). δC (101 MHz, CDCl3) 168.4 (C=O), 133.8 (ArCH), 132.2 (ArC), 131.5 (C5), 128.5  
(C4), 123.1 (ArCH), 37.7 (C1), 32.2 (C6), 31.6 (C7), 29.9 (C3), 28.3 (C2), 22.2 (C8), 13.9 (C9). 
HRMS: (ESI+) Calculated for C17H21NNaO2: 294.1464. Found [M+Na]+: 294.1469.  
tert-Butyl (E)-non-4-en-1-ylcarbamate (334) 
 
A solution of the preceding compound (505 mg, 1.86 mmol) and hydrazine (55 % aqueous solution, 
0.31 mL, 5.58 mmol) in EtOH (10 mL) was heated at reflux for 2.5 hours. The reaction mixture was 
cooled to room temperature and filtered. The filtrate was concentrated in vacuo and dissolved in CH2Cl2 
(15 mL) before addition of Boc2O (0.52 mL, 2.23 mmol) and Et3N (0.39 mL, 2.79 mmol). The reaction 
mixture was stirred at room temperature for 16 hours before being concentrated in vacuo. FCC (eluent: 
9:1 petrol:EtOAc) afforded 334 (332 mg, 74 %) as a colourless oil. νmax / cm-1: (film) 3348 (br s), 
2927 (m), 1689 (s), 1514 (s), 1169 (s). δH (400 MHz, CDCl3) 5.46 – 5.29 (2H, m, C4-H and C5-H), 4.54 
(1H, br s, NH), 3.09 (2H, td, J = 7.0, 6.5 Hz, C1-H2), 2.04 – 1.91 (4H, m, C3-H2 and C6-H2), 1.52 (2H, 
tt, J = 7.5, 7.0 Hz, C2-H2), 1.42 (9H, s, OC(CH3)3), 1.34 – 1.25 (4H, m, C7-H2 and C8-H2), 0.89 – 0.83 
(3H, m, C9-H3). δC (101 MHz, CDCl3) 156.1 (C=O), 131.5 (C5), 129.1 (C4), 79.1 (OC(CH3)3), 40.3 
(C1), 32.4 (C6), 31.8 (C7), 2 × 30.0 (C2 and C3), 28.6 (OC(CH3)3), 22.3 (C8), 14.1 (C9). HRMS: (ESI+) 
Calculated for C14H27NNaO2: 264.1934. Found [M+Na]+: 264.1942.  
  
Chapter 7 - Experimental 
332 
 
tert-Butyl (3aR*,7aS*)-7a-vinyloctahydro-1H-indole-1-carboxylate (270) 
 
In the following experiment, a mixture of aza-Heck (269) and aza-Wacker (334) substrates were 
submitted to the reaction conditions. The fact that only 269 afforded cyclised product is consistent with 
an aza-Heck mechanism (Section 3.5). General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 
15 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-trioxa-8-phosphaadamantane (L1); 100 mol% Et3N; THF 
(0.4 M); 130 °C; 24 hours. Substrates 269 (vide supra, 48.7 mg, 0.105 mmol) and 334 (16.9 mg, 
70.0 μmol) were employed. From the 1H NMR spectrum the yield of 270 was determined to be 79 % 




A solution of 1,1,1-trifluoro-2-methylpropan-2-ol (4.92 g, 38.4 mmol) and carbonyl diimidazole 
(12.5 g, 76.8 mmol) in CHCl3 (80 mL) was stirred at room temperature for 22 hours before addition of 
water (80 mL). The resulting phases were separated, and the aqueous phase was extracted with CHCl3 
(40 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the title compound (5.51 g, 65 %) as a colourless crystalline solid.  
νmax / cm-1: (solid) 3151 (m), 3127 (m), 1759 (s), 1154 (s). δH (400 MHz, CDCl3) 8.08 (1H, dd, J = 1.0, 
1.0 Hz, ArCH), 7.37 (1H, dd, J = 1.5, 1.0 Hz, ArCH), 7.07 (1H, dd, J = 1.5, 1.0 Hz, ArCH), 1.83 (6H, 
q, J = 1.0 Hz, OC(CF3)(CH3)2). δC (101 MHz, CDCl3) 146.0 (C=O), 137.2 (ArCH), 131.0 (ArCH), 
124.4 (q, J = 282.5 Hz, OC(CF3)(CH3)2), 117.2 (ArCH), 83.7 (q, J = 30.5 Hz, OC(CF3)(CH3)2), 19.4 (q, 
J = 1.5 Hz, OC(CF3)(CH3)2). δF (377 MHz, CDCl3) -83.7 (3F, s). HRMS: (ESI+) Calculated for 
C8H9F3N2NaO2: 245.0508. Found [M+Na]+: 245.0511.  
  





A solution of NH2OH·HCl (3.00 g, 43.2 mmol) and NaHCO3 (5.44 g, 64.8 mmol) in THF (60 mL) and 
water (60 mL) was stirred at room temperature for 30 minutes before addition of the preceding 
compound (4.80 g, 21.6 mmol). The reaction mixture was stirred for 20 hours before addition of EtOAc 
(100 mL) and brine (100 mL). The resulting phases were separated, and the organic phase was 
concentrated in vacuo. The crude material was dissolved in EtOAc (100 mL), washed with water (3 × 
40 mL), dried over Na2SO4 and concentrated in vacuo to afford the title compound (1.77 g, 44 %) as a 
colourless crystalline solid. νmax / cm-1: (film) 3284 (br s), 2956 (m), 1703 (s), 1132 (s). δH (400 MHz, 
CDCl3) 7.43 – 7.16 (2H, br s, NH and OH), 1.71 (6H, q, J = 1.0 Hz, OC(CF3)(CH3)2). δC (101 MHz, 
CDCl3) 156.7 (C=O), 124.8 (q, J = 282.5 Hz, OC(CF3)(CH3)2), 81.3 (q, J = 30.0 Hz, OC(CF3)(CH3)2), 
19.7 (q, J = 1.5 Hz, OC(CF3)(CH3)2). δF (377 MHz, CDCl3) -83.8 (3F, s). HRMS: (ESI+) Calculated for 
C5H8F3NNaO3: 210.0348. Found [M+Na]+: 210.0347. 
1,1,1-Trifluoro-2-methylpropan-2-yl ((pentafluorobenzoyl)oxy)carbamate (335) 
 
General procedure G: The preceding compound (1.76 g, 9.41 mmol) was employed. The reaction time 
was 21 hours. FCC (gradient elution: 15:1 – 7:1 hexane:EtOAc) afforded 335 (2.67 g, 74 %) as a 
colourless crystalline solid. m.p. 87-88 °C (CH2Cl2:petrol, needles). νmax / cm-1: (solid) 3366 (s), 
2940 (m), 1782 (s), 1763 (s), 1655 (s), 1498 (s), 1133 (s). δH (400 MHz, CDCl3) 8.34 (1H, br s, NH), 
1.75 (6H, q, J = 1.0 Hz, OC(CF3)(CH3)2). δC (101 MHz, CDCl3) 158.5 (FBz C=O), 153.1 
(Carbamate C=O), 124.3 (q, J = 282.5 Hz, OC(CF3)(CH3)2), 82.5 (q, J = 30.5 Hz, OC(CF3)(CH3)2), 19.3 
(q, J = 1.5 Hz, OC(CF3)(CH3)2). The aromatic 
13C signals corresponding to the pentafluorobenzoyl 
group could not be resolved due to their weak intensity. δF (376 MHz, CDCl3) -83.8 (3F, s), -135.0 
– -135.2 (2F, m), -144.8 (1F, tt, J = 21.0, 6.0 Hz), -159.0 – -159.2 (2F, m). HRMS: (ESI+) Calculated 
for C12H7F8NNaO4: 404.0140. Found [M+Na]+: 404.0157.  
  






General procedure O: Alcohol 159c (Section 7.3, 381 mg, 2.00 mmol) was employed with 335. The 
reaction time was 15 hours. FCC (gradient elution: 3:2 – 3:7 hexane:PhMe) afforded 266b (587 mg, 
53 %) as a colourless oil. νmax / cm-1: (film) 2947 (m), 1786 (s), 1731 (s), 1652 (m), 1497 (s), 1166 (s). 
δH (500 MHz, CDCl3) 7.27 – 7.22 (2H, m, 2 × ArCH), 7.19 – 7.12 (3H, m, 3 × ArCH), 5.45 (1H, q, J = 
7.0 Hz, C5-H), 3.62 (2H, t, J = 7.0 Hz, C1-H2), 3.39 (2H, s, C7-H2), 1.99 (2H, t, J = 7.5 Hz,  
C3-H2), 1.75 – 1.68 (11H, m, C2-H2, C6-H3 and OC(CF3)(CH3)2). δC (126 MHz, CDCl3) 152.1 
(Carbamate C=O), 139.7 (ArC), 136.7 (C4), 2 × 128.1 (2 × ArCH), 125.6 (ArCH), 121.0 (C5), 81.6 (q, 
J = 30.0 Hz, OC(CF3)(CH3)2), 50.3 (C1), 35.2 (C7), 33.0 (C3), 24.8 (C2), 19.0 (OC(CF3)(CH3)2), 13.4 
(C6). The 13C signals corresponding to the pentafluorobenzoyl and trifluoromethyl groups could not be 
resolved due to their weak intensity. δF (470 MHz, CDCl3) -84.0 (3F, s), -135.6 – -135.8 (2F, m), -145.6 
(1F, tt, J = 21.0, 5.5 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) Calculated for C25H23F8NNaO4: 
576.1392. Found [M+Na]+: 576.1373.  
1,1,1-Trifluoro-2-methylpropan-2-yl 2-benzyl-2-vinylpyrrolidine-1-carboxylate (267b) 
 
The following reaction was conducted in an NMR spectrometer (without a magnetic stirrer) and  
the reaction progress was monitored by collecting 19F and solvent-supressed 1H spectra.  
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (vide supra); 100 mol% 
Et3N; THF (0.2 M); 130 °C; 24 hours. Substrate 266b (58.1 mg, 0.105 mmol) was employed. FCC  
(two times, first eluent: PhMe; second eluent: 59:1 petrol:acetone) afforded 267b (21.6 mg, 60 %)  
as a colourless oil. This compound exists as an approximately 3:2 mixture of rotamers A and B.  
νmax / cm-1: (film) 2978 (m), 1701 (s), 1382 (s), 1132 (s). δH (400 MHz, CDCl3) 7.31 – 7.19 (3H, m, A 
and B: 3 × ArCH), 7.19 – 7.11 (2H, m, A and B: 2 × ArCH), 6.07 (0.6H, dd, J = 17.5, 10.5 Hz, A: 
C5-H), 5.99 (0.4H, dd, J = 17.5, 10.5 Hz, B: C5-H), 5.12 (0.6H, d, J = 10.5 Hz, A: C6-H), 5.08 (0.4H, 
d, J = 10.5 Hz, B: C6-H), 5.01 (0.6H, d, J = 17.5 Hz, A: C6-H’), 4.98 (0.4H, d, J = 17.5 Hz, B: C6-H’), 
3.59 (0.6H, d, J = 13.5 Hz, A: C7-H), 3.53 (0.4H, ddd, J = 12.0, 7.5, 5.0 Hz, B: C1-H), 3.44 (0.6H, ddd, 
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J = 11.5, 8.0, 4.0 Hz, A: C1-H), 3.38 (0.4H, d, J = 13.5 Hz, B: C7-H), 3.10 (0.4H, ddd, J = 11.0, 7.5, 
7.5 Hz, B: C1-H’), 3.01 (0.6H, ddd, J = 11.0, 8.0, 7.0 Hz, A: C1-H’), 2.98 – 2.90 (1H, m, A and B: 
C7-H’), 2.09 – 1.95 (1H, m, A and B: C3-H), 1.84 – 1.70 (7H, m, A and B: C3-H’ and OC(CF3)(CH3)2), 
1.64 – 1.51 (1H, m, A and B: C2-H), 1.34 – 1.16 (1H, m, A and B: C2-H’). δC (101 MHz, CDCl3) 152.5 
(B: C=O), 151.6 (A: C=O), 142.1 (B: C5), 141.5 (A: C5), 137.6 (B: ArC), 137.5 (A: ArC), 130.7 (A: 
ArCH), 130.5 (B: ArCH), 128.2 (B: ArCH), 128.0 (A: ArCH), 126.5 (B: ArCH), 126.4 (A: ArCH), 
112.3 (A: C6), 112.2 (B: C6), 79.8 (q, J = 30.0 Hz, B: OC(CF3)(CH3)2), 79.3 (q, J = 29.0 Hz, A: 
OC(CF3)(CH3)2), 67.7 (A: C4), 67.3 (B: C4), 49.1 (B: C1), 48.8 (A: C1), 42.1 (B: C7), 41.2 (A: C7), 
37.7 (B: C3), 36.1 (A: C3), 21.3 (A: C2), 20.9 (B: C2), 20.0 (q, J = 1.5 Hz, B: OC(CF3)(CH3)(CH3)’), 
2 × 19.8 (q, J = 1.5 Hz, A: OC(CF3)(CH3)(CH3)’ and q, J = 1.5 Hz, A: OC(CF3)(CH3)(CH3)’), 19.7 (q, 
J = 1.5 Hz, B: OC(CF3)(CH3)(CH3)’). The 
13C signal corresponding to the trifluoromethyl group could 
not be resolved due to its weak intensity. δF (377 MHz, CDCl3) -82.8 (1.2F, s, B: CF3), -84.0 (1.8F, s, 
A: CF3). HRMS: (ESI+) Calculated for C18H23F3NO2: 342.1675. Found [M+H]+: 342.1691.  
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7.5 Experimental procedures for the studies in Chapter 4 
Methyl (Z)-(4-Benzylhex-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (266c) 
 
General procedure O: Alcohol 159c (Section 7.3, 285 mg, 1.50 mmol) was employed with 
MeOC(O)NHOFBz (Section 7.4). The reaction time was 16 hours. FCC (eluent: 1:9 hexane:PhMe) 
afforded 266c (387 mg, 56 %) as a colourless oil. νmax / cm-1: (film) 2919 (m), 1785 (s), 1729 (s), 
1652 (m), 1602 (m), 1496 (s), 1173 (s). δH (400 MHz, CDCl3) 7.28 – 7.22 (2H, m, 2 × ArCH), 7.18 – 
7.12 (3H, m, 3 × ArCH), 5.45 (1H, q, J = 7.0 Hz, C5-H), 3.79 (3H, s, OCH3), 3.67 – 3.62 (2H, m, 
C1-H2), 3.40 (2H, s, C7-H2), 2.00 (2H, t, J = 7.5 Hz, C3-H2), 1.76 – 1.67 (5H, m, C2-H2 and C6-H3).  
δC (101 MHz, CDCl3) 156.2 (MeO–C=O), 140.1 (ArC), 137.2 (C4), 128.6 (ArCH), 128.5 (ArCH),  
126.0 (ArCH), 121.3 (C5), 54.0 (OCH3), 51.1 (C1), 35.6 (C7), 33.5 (C3), 25.2 (C2), 13.8 (C6). The 
13C 
signals corresponding to the pentafluorobenzoyl group could not be resolved due to their weak 
intensity. δF (377 MHz, CDCl3) -136.0 – -136.1 (2F, m), -146.2 (1F, tt, J = 21.0, 5.5 Hz), -159.3 – -159.5 
(2F, m). HRMS: (ESI+) Calculated for C22H21F5NO4: 458.1385. Found [M+H]+: 458.1387. 
Methyl 2-benzyl-2-vinylpyrrolidine-1-carboxylate (267c) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% (S)-SIPHOS-PE; 100 mol% Et3N; 
THF (0.4 M); 130 °C; 24 hours. Substrate 266c (52.4 mg, 0.105 mmol) was employed. FCC (eluent: 
19:1 hexane:EtOAc) afforded 267c (15.0 mg, 58 %, 34 % e.e.) as a colourless oil. The following 
procedure was used to prepare a racemic sample of 267c for SFC analysis: General procedure D: 
Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (Section 7.4); 100 mol% Et3N; THF  
(0.4 M); 130 °C; 24 hours. Substrate 266c (52.4 mg, 0.105 mmol) was employed. FCC (eluent: 
19:1 hexane:EtOAc) afforded 267c (21.7 mg, 84 %) as a colourless oil. This compound exists as an 
approximately 2:1 mixture of rotamers A and B. SFC conditions: column: CHIRALPACK IC, elute: 
4.0 % MeOH/CO2, detector: 250 nm, flow rate: 1.5 mL/min, temperature: 40 °C, retention times: 
(major enantiomer) t1 = 10.6 min, (minor enantiomer) t2 = 11.3 min. νmax / cm-1: (film) 3027 (m), 
2953 (m), 2875 (m), 1693 (s), 1443 (s), 1380 (s). δH (400 MHz, CDCl3) 7.33 – 7.06 (5H, m, A and B: 
5 × ArCH), 6.13 (0.65H, dd, J = 17.5, 10.5 Hz, A: C5-H), 6.01 (0.35H, dd, J = 17.5, 10.5 Hz, B: C5-H), 
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5.11 (0.65H, d, J = 10.5 Hz, A: C6-H), 5.08 – 4.94 (1.35H, m, A: C6-H’; B: C6-H2), 3.78 (1H, s, B: 
OCH3), 3.74 (2H, s, A: OCH3), 3.61 (0.65H, d, J = 13.5 Hz, A: C7-H), 3.59 – 3.52 (0.35H, m, B: C1-H), 
3.49 – 3.39 (1H, m, A: C1-H; B: C7-H), 3.15 – 2.97 (1.65H, m, A: C1-H’ and C7-H’; B: C1-H’), 2.89 
(0.35H, d, J = 13.5 Hz, B: C7-H’), 2.06 – 1.91 (1H, m, A and B: C3-H), 1.80 – 1.71 (1H, m, A and B: 
C3-H’), 1.64 – 1.52 (1H, m, A and B: C2-H), 1.32 – 1.19 (1H, m, A and B: C2-H’). δC (101 MHz, 
CDCl3) 155.8 (B: C=O), 154.8 (A: C=O), 142.9 (B: C5), 142.0 (A: C5), 138.0 (A: ArC), 137.7 (B: 
ArC), 130.9 (A: ArCH), 130.7 (B: ArCH), 128.3 (B: ArCH), 128.1 (A: ArCH), 126.6 (B: ArCH), 126.4 
(A: ArCH), 112.4 (A: C6), 112.0 (B: C6), 67.7 (A: C4), 67.2 (B: C4), 52.2 (A and B: OCH3), 49.4 (B: 
C1), 48.5 (A: C1), 42.6 (B: C7), 41.5 (A: C7), 37.5 (B: C3), 36.0 (A: C3), 21.7 (A: C2), 21.1 (B: C2). 
HRMS: (ESI+) Calculated for C15H20NO2: 246.1489. Found [M+H]+: 246.1500. 
tert-Butyl (E)-2-styrylpyrrolidine-1-carboxylate (255) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% (S)-SIPHOS-PE; 100 mol% Et3N; 
THF (0.4 M); 130 °C; 24 hours. Substrate 254 (Section 7.4, 51.0 mg, 0.105 mmol) was employed. FCC 
(eluent: 49:1 PhMe:EtOAc) afforded 255 (18.0 mg, 63 %, 34 % e.e.) as a colourless crystalline solid. 
The procedure described in Section 7.4 was used to prepare a racemic sample of 255 for SFC analysis. 
SFC conditions: column: CHIRALPACK IC, elute: 4.0 % MeOH/CO2, detector: 250 nm, flow rate: 
1.5 mL/min, temperature: 40 °C, retention times: (minor enantiomer) t1 = 11.0 min, (major enantiomer) 
t2 = 11.6 min. Characterisation data for 255 has been provided earlier (Section 7.4). 
Benzyl 2-vinylpyrrolidine-1-carboxylate (244a) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% (S)-SIPHOS-PE; 100 mol% Et3N; 
THF (0.4 M); 130 °C; 24 hours. Substrate 243a (Section 7.4, 46.6 mg, 0.105 mmol) was employed. 
FCC (eluent: 29:1 PhMe:EtOAc) afforded 244a (13.2 mg, 54 %, 60 % e.e.) as a pale-yellow oil. The 
procedure described in Section 7.4 was used to prepare a racemic sample of 244a for SFC analysis. 
SFC conditions: column: CHIRALPACK IC, elute: 1.5 % MeOH/CO2, detector: 250 nm, flow rate: 
4.0 mL/min, temperature: 40 °C, retention times: (S) t1 = 11.6 min, (R) t2 = 12.6 min. Characterisation 
data for 244a has been provided earlier (Section 7.4). 
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tert-Butyl (Z)-(4-benzylhex-4-en-1-yl)(tosyloxy)carbamate (266d) 
 
General procedure R: Alcohol 159c (Section 7.3, 571 mg, 3.00 mmol) was employed with 
BocNHOTs.LI The reaction time was 17 hours. FCC (eluent: 1:4 petrol:PhMe) afforded 266d (812 mg, 
59 %) as a colourless oil. νmax / cm-1: (film) 2980 (m), 2932 (m), 1721 (s), 1599 (m), 1369 (s), 1179 (s). 
δH (400 MHz, CDCl3) 7.84 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.33 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.29 – 
7.23 (2H, m, 2 × ArCH), 7.21 – 7.11 (3H, m, 3 × ArCH), 5.41 (1H, q, J = 6.5 Hz, C5-H), 3.52 (2H, br s, 
C1-H2), 3.38 (2H, s, C7-H2), 2.45 (3H, s, Ts CH3), 1.87 (2H, t, J = 7.5 Hz, C3-H2), 1.76 – 1.63 (5H, m, 
C2-H2 and C6-H3), 1.20 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 155.6 (C=O), 145.7 (ArC), 140.1 
(ArC), 137.3 (C4), 131.4 (ArC), 129.8 (ArCH), 129.6 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 126.0 
(ArCH), 120.9 (C5), 83.2 (OC(CH3)3), 52.9 (C1), 35.6 (C7), 33.4 (C3), 27.7 (OC(CH3)3), 24.0 (C2), 
21.8 (Ts CH3), 13.8 (C6). HRMS: (ESI+) Calculated for C25H33NNaO5S: 482.1972. Found [M+Na]+: 
482.1950.  
tert-Butyl (R)-2-benzyl-2-vinylpyrrolidine-1-carboxylate ((R)-267a) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-PE; 300 mol% Et3N; 
THF (0.07 M); 110 °C; 72 hours. Substrate 266d (48.3 mg, 0.105 mmol) was employed. FCC (eluent: 
39:1 petrol:EtOAc) afforded (R)-267a (30.0 mg, 99 %, 95 % e.e.) as a colourless oil.  
Alternative procedure starting from OFBz substrate 267a: General procedure D: Conditions: 
5.0 mol% Pd2(dba)3; 20 mol% (S)-SIPHOS-PE; 100 mol% Et3N; THF (0.4 M); 130 °C; 24 hours. 
Substrate 266a (Section 7.4, 52.4 mg, 0.105 mmol) was employed. FCC (gradient elution: 39:1 – 
29:1 petrol:EtOAc) afforded (R)-267a (22.3 mg, 74 %, 61 % e.e.) as a colourless oil. The procedure 
described in Section 7.4 was used to prepare a racemic sample of 267a for SFC analysis. SFC 
conditions: column: CHIRALPACK IC, elute: 1.2 % MeOH/CO2, detector: 250 nm, flow rate: 
2.0 mL/min, temperature: 40 °C, retention times: (R) t1 = 10.0 min, (S) t2 = 11.1 min. For 95 % e.e. 
material: [α]D26 +82.2 (c = 0.40, CH2Cl2). Characterisation data for 267a has been provided earlier 
(Section 7.4). 
                                                     
LI BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 





To a suspension of magnesium turnings (875 mg, 36.0 mmol), activated with a few crystals of iodine, 
in anhydrous Et2O (30 mL) was added benzyl bromide (3.57 mL, 30.0 mmol). The reaction mixture 
was heated at reflux for 3 hours, then cooled to 0 °C before addition of methacrolein (3.71 mL, 
45.0 mmol). The reaction mixture was stirred at room temperature for 1.5 hours before addition of 
saturated aqueous NH4Cl (30 mL). The resulting phases were separated, and the aqueous phase was 
extracted with Et2O (2 × 60 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 7:1 petrol:EtOAc) afforded the title compound (2.80 g, 58 %) as a 
colourless oil. δH (400 MHz, CDCl3) 7.34 – 7.29 (2H, m), 7.27 – 7.21 (3H, m), 4.96 (1H, br s), 4.87 
(1H, br s), 4.29 (1H, dd, J = 8.5, 4.5 Hz), 2.92 (1H, dd, J = 13.5, 4.5 Hz), 2.77 (1H, dd, J = 13.5, 8.5 Hz), 
1.82 (3H, dd, J = 1.0, 1.0 Hz), 1.60 (1H, br s). δC (101 MHz, CDCl3) 146.9, 138.4, 129.5, 128.6, 126.7, 




General procedure L: The preceding allylic alcohol (3.24 g, 20.0 mmol) was employed. The reaction 
time was 14 hours. FCC (eluent: 39:1 petrol:EtOAc) afforded the title compound (2.56 g, 55 %) as a 
colourless oil. δH (400 MHz, CDCl3) 7.31 – 7.24 (2H, m), 7.21 – 7.13 (3H, m), 5.38 (1H, t, J = 7.5 Hz), 
4.10 (2H, q, J = 7.0 Hz), 3.35 (2H, d, J = 7.5 Hz), 2.47 – 2.41 (2H, m), 2.40 – 2.33 (2H, m), 1.74 (3H, 
s), 1.22 (3H, t, J = 7.0 Hz). δC (101 MHz, CDCl3) 173.5, 141.5, 134.7, 128.5, 128.4, 125.9, 124.0, 60.4, 




General procedure I: The preceding ester (2.48 g, 10.7 mmol) was employed, using anhydrous Et2O 
as solvent and 0.8 eq. LiAlH4 (1.0 M in THF). FCC (eluent: 3:1 petrol:EtOAc) afforded the title 
compound (1.68 g, 83 %) as a colourless oil. δH (400 MHz, CDCl3) 7.31 – 7.25 (2H, m), 7.21 – 7.15 
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(3H, m), 5.39 (1H, t, J = 7.5 Hz), 3.64 (2H, t, J = 6.5 Hz), 3.37 (2H, d, J = 7.5 Hz), 2.12 (2H, t, J = 
7.5 Hz), 1.76 – 1.67 (5H, m), 1.52 (1H, br s). δC (101 MHz, CDCl3) 141.7, 135.9, 128.5, 128.4, 125.9, 
123.6, 62.9, 36.1, 34.4, 30.9, 16.2. The spectroscopic properties were consistent with the data available 
in the literature.297 
tert-Butyl (E)-(4-methyl-6-phenylhex-4-en-1-yl)(tosyloxy)carbamate (342) 
 
General procedure R: The preceding alcohol (571 mg, 3.00 mmol) was employed with BocNHOTs.LII 
The reaction time was 18 hours. FCC (eluent: 1:4 petrol:PhMe) afforded 342 (1.19 g, 86 %) as a 
colourless crystalline solid. m.p. 69-70 °C (CH2Cl2:petrol, needles). νmax / cm-1: (solid) 2982 (m), 
2933 (m), 1751 (s), 1597 (m), 1452 (m), 1364 (s), 1149 (s). δH (400 MHz, CDCl3) 7.86 (2H, d, J = 
8.5 Hz, 2 × ArCH), 7.34 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.31 – 7.27 (2H, m, 2 × ArCH), 7.21 – 7.15 
(3H, m, 3 × ArCH), 5.34 (1H, tq, J = 7.5, 1.5 Hz, C5-H), 3.58 (2H, br s, C1-H2), 3.35 (2H, d, J = 7.5 Hz, 
C6-H2), 2.44 (3H, s, Ts CH3), 2.01 (2H, t, J = 7.5 Hz, C3-H2), 1.83 – 1.71 (2H, m, C2-H2), 1.70 (3H, 
br s, C7-H3), 1.22 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 155.6 (C=O), 145.8 (ArC), 141.7 (ArC), 
135.0 (C4), 131.5 (ArC), 129.9 (ArCH), 129.6 (ArCH), 2 × 128.5 (2 × ArCH), 125.9 (ArCH), 123.9 
(C5), 83.3 (OC(CH3)3), 53.0 (C1), 36.7 (C3), 34.4 (C6), 27.8 (OC(CH3)3), 24.1 (C2), 21.8 (Ts CH3), 
16.1 (C7). HRMS: (ESI+) Calculated for C25H33NNaO5S: 482.1972. Found [M+Na]+: 482.1955. 
tert-Butyl (S,E)-2-methyl-2-styrylpyrrolidine-1-carboxylate ((S)-344) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-PE; 300 mol% Et3N; 
THF (0.07 M); 110 °C; 72 hours. Substrate 342 (48.3 mg, 0.105 mmol) was employed. FCC (eluent: 
39:1 PhMe:EtOAc) afforded (S)-344 (23.7 mg, 79 %, 89 % e.e.) as a colourless oil. 
The following procedure was used to prepare a racemic sample of 344 for SFC analysis:  
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (Section 7.4); 100 mol% 
Et3N; THF (0.1 M); 130 °C; 24 hours. Substrate 342 (48.3 mg, 0.105 mmol) was employed. FCC 
(eluent: 49:1 PhMe:EtOAc) afforded 344 (25.5 mg, 85 %) as a pale-yellow oil. This compound exists 
as an approximately 11:4 mixture of rotamers A and B. SFC conditions: column: CHIRALPACK IA, 
                                                     
LII BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
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elute: 1.0 % MeOH/CO2, detector: 250 nm, flow rate: 1.2 mL/min, temperature: 40 °C, retention times: 
(R) t1 = 12.2 min, (S) t2 = 13.0 min. [α]D26 -89.3 (c = 0.40, CH2Cl2). νmax / cm-1: (film) 2970 (m), 
2875 (m), 1682 (s), 1386 (s), 1158 (s). δH (400 MHz, CDCl3) 7.39 – 7.27 (4H, m, A and B: 4 × ArCH), 
7.25 – 7.16 (1H, m, A and B: ArCH), 6.39 – 6.18 (2H, m, A and B: C5-H and C6-H), 3.65 – 3.39 (2H, 
m, A and B: C1-H2), 2.04 – 1.96 (1H, m, A and B: C3-H), 1.93 – 1.75 (3H, m, A and B: C2-H2 and 
C3-H’), 1.63 (0.8H, br s, B: C7-H3), 1.55 (2.2H, br s, A: C7-H3), 1.47 (2.4H, br s, B: OC(CH3)3), 1.39 
(6.6H, br s, A: OC(CH3)3). 
13C NMR data for rotamer A only: δC (101 MHz, CDCl3) 154.7 (C=O), 137.5 
(ArC), 136.2 (C5), 128.7 (ArCH), 127.2 (ArCH), 126.7 (C6), 126.3 (ArCH), 79.4 (OC(CH3)3), 63.1 
(C4), 48.2 (C1), 42.4 (C3), 28.6 (OC(CH3)3), 25.0 (C7), 21.8 (C2). HRMS: (ESI+) Calculated for 
C18H25NNaO2: 310.1777. Found [M+Na]+: 310.1767. 
3-Benzyl-1-phenylbut-3-en-2-ol 
 
This compound appears to be unstable, potentially to heat. Consequently, it is recommended to use a 
water bath at room temperature during concentration. To a suspension of magnesium turnings (255 mg, 
10.5 mmol), activated with a few crystals of iodine, in anhydrous Et2O (40 mL) was added benzyl 
bromide (1.19 mL, 10.0 mmol). The reaction mixture was heated at reflux for 2 hours, then cooled to 
room temperature before addition of a solution of 2-benzylacrylaldehyde (Section 7.3, 1.46 g, 
10.0 mmol) in anhydrous Et2O (20 mL) dropwise. The reaction mixture was stirred at room temperature 
for 1 hour before addition of saturated aqueous NH4Cl (40 mL). The resulting phases were separated, 
and the aqueous phase extracted with Et2O (50 mL). The combined organic phases were dried over 
Na2SO4 and concentrated in vacuo. FCC (two times, first, gradient elution: 7:1 – 5:1 petrol:EtOAc; 
second eluent: 7:1 petrol:acetone) afforded the title compound (603 mg, 25 %) as a colourless oil.  
δH (400 MHz, CDCl3) 7.36 – 7.28 (4H, m), 7.27 – 7.18 (6H, m), 5.18 (1H, ddt, J = 1.0, 1.0, 1.0 Hz), 
4.83 (1H, td, J = 1.5, 1.0 Hz), 4.29 (1H, br dd, J = 9.0, 4.0 Hz), 3.52 (1H, br d, J = 15.5 Hz), 3.39 (1H, 
br d, J = 15.5 Hz), 2.95 (1H, dd, J = 13.5, 4.0 Hz), 2.77 (1H, dd, J = 13.5, 9.0 Hz), 1.60 (1H, br s).  
δC (101 MHz, CDCl3) 150.8, 139.4, 138.4, 129.5, 129.4, 2 × 128.6, 126.7, 126.4, 112.4, 75.1, 42.9, 
39.5. The spectroscopic properties were consistent with the data available in the literature.298 
  





General procedure L: The preceding allylic alcohol (586 mg, 2.46 mmol) was employed. The reaction 
time was 14 hours. FCC (eluent: 19:1 petrol:EtOAc) afforded the title compound (420 mg, 55 %) as 
a colourless oil. νmax / cm-1: (film) 3027 (m), 2980 (m), 1731 (s), 1602 (m), 1453 (m), 1180 (s).  
δH (400 MHz, CDCl3) 7.33 – 7.24 (4H, m, 4 × ArCH), 7.23 – 7.15 (6H, m, 6 × ArCH), 5.57 (1H, t, J = 
7.5 Hz, C5-H), 4.06 (2H, q, J = 7.0 Hz, OCH2CH3), 3.53 (2H, s, C7-H2), 3.51 (2H, d, J = 7.5 Hz, 
C6-H2), 2.44 – 2.37 (2H, m, C2-H2), 2.35 – 2.28 (2H, m, C3-H2), 1.19 (3H, t, J = 7.0 Hz, OCH2CH3). 
δC (101 MHz, CDCl3) 173.3 (C1), 141.2 (ArC), 139.6 (ArC), 137.2 (C4), 128.7 (ArCH), 2 × 128.6 (2 × 
ArCH), 128.5 (ArCH), 126.2 (ArCH), 126.1 (ArCH), 125.8 (C5), 60.4 (OCH2CH3), 36.3 (C7), 34.4 
(C6), 33.2 (C2), 31.9 (C3), 14.3 (OCH2CH3). HRMS: (ESI+) Calculated for C21H24NaO2: 331.1669. 
Found [M+Na]+: 331.1683. 
(Z)-4-Benzyl-6-phenylhex-4-en-1-ol 
 
General procedure I: The preceding ester (399 mg, 1.29 mmol) was employed, using anhydrous Et2O 
as solvent and 0.8 eq. LiAlH4 (1.0 M in Et2O). The title compound (330 mg, 96 %) was isolated as a 
colourless oil. νmax / cm-1: (film) 3336 (br s), 3026 (m), 2937 (m), 1601 (m), 1494 (m), 1452 (m).  
δH (400 MHz, CDCl3) 7.33 – 7.25 (4H, m, 4 × ArCH), 7.23 – 7.17 (6H, m, 6 × ArCH), 5.58 (1H, t, J = 
7.5 Hz, C5-H), 3.59 (2H, td, J = 6.5, 6.0 Hz, C1-H2), 3.54 – 3.50 (4H, m, C6-H2 and C7-H2), 2.06 (2H, 
t, J = 7.5 Hz, C3-H2), 1.68 (2H, tt, J = 7.5, 6.5 Hz, C2-H2), 1.19 (1H, br s, OH). δC (101 MHz, CDCl3) 
141.4 (ArC), 139.9 (ArC), 138.3 (C4), 128.7 (ArCH), 2 × 128.6 (2 × ArCH), 128.5 (ArCH), 126.2 
(ArCH), 126.1 (ArCH), 125.4 (C5), 62.9 (C1), 36.2 (C7), 34.5 (C6), 32.9 (C3), 31.1 (C2). 
HRMS: (ESI+) Calculated for C19H22NaO: 289.1563. Found [M+Na]+: 289.1557. 
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tert-Butyl (Z)-(4-benzyl-6-phenylhex-4-en-1-yl)(tosyloxy)carbamate (343) 
 
General procedure R: The preceding alcohol (323 mg, 1.21 mmol) was employed with BocNHOTs.LIII 
The reaction time was 15 hours. FCC (gradient elution: 2:8 – 1:9 – 0:1 petrol:PhMe) afforded 343 
(457 mg, 71 %) as a colourless oil. νmax / cm-1: (film) 3027 (m), 2978 (m), 2935 (m), 1720 (s), 1599 (m), 
1369 (s), 1178 (s). δH (400 MHz, CDCl3) 7.84 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.36 – 7.26 (6H, m, 6 × 
ArCH), 7.24 – 7.15 (6H, m, 6 × ArCH), 5.55 (1H, t, J = 7.5 Hz, C5-H), 3.63 – 3.48 (6H, m, C1-H2, 
C6-H2 and C7-H2), 2.44 (3H, s, Ts CH3), 1.94 (2H, t, J = 7.5 Hz, C3-H2), 1.83 – 1.67 (2H, m, C2-H2), 
1.20 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 155.6 (C=O), 145.7 (ArC), 141.3 (ArC), 139.7 (ArC), 
137.6 (C4), 131.4 (ArC), 129.8 (ArCH), 129.6 (ArCH), 128.7 (ArCH), 2 × 128.6 (2 × ArCH), 128.5 
(ArCH), 126.2 (ArCH), 126.0 (ArCH), 125.6 (C5), 83.3 (OC(CH3)3), 52.9 (C1), 36.0 (C7), 34.4 (C6), 
33.5 (C3), 27.7 (OC(CH3)3), 24.1 (C2), 21.8 (Ts CH3). HRMS: (ESI+) Calculated for C31H37NNaO5S: 
558.2285. Found [M+Na]+: 558.2280. 
tert-Butyl (R,E)-2-benzyl-2-styrylpyrrolidine-1-carboxylate ((R)-345) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-PE; 300 mol% Et3N; 
THF (0.07 M); 110 °C; 72 hours. Substrate 343 (56.2 mg, 0.105 mmol) was employed. FCC (gradient 
elution: 149:1 – 99:1 PhMe:EtOAc) afforded (R)-345 (26.0 mg, 68 %, 95 % e.e.) as a colourless oil. 
The following procedure was used to prepare a racemic sample of 345 for SFC analysis:  
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (Section 7.4); 100 mol% 
Et3N; THF (0.1 M); 130 °C; 24 hours. Substrate 343 (56.2 mg, 0.105 mmol) was employed. FCC (two 
times, first eluent: 29:1 petrol:EtOAc; second eluent: 99:1 PhMe:EtOAc) afforded 345 (28.4 mg, 74 %) 
as a colourless oil. This compound exists as an approximately 3:2 mixture of rotamers A and B. SFC 
conditions: column: CHIRALPACK IA, elute: 2.0 % MeOH/CO2, detector: 250 nm, flow rate: 
2.5 mL/min, temperature: 40 °C, retention times: (S) t1 = 11.6 min, (R) t2 = 12.6 min. [α]D26 -26.5  
(c = 0.40, CH2Cl2). νmax / cm-1: (film) 3032 (m), 2973 (m), 2868 (m), 1676 (s), 1600 (m), 1385 (s).  
δH (400 MHz, CDCl3) 7.41 – 7.16 (10H, m, A and B: 10 × ArCH), 6.58 (0.4H, d, J = 16.0 Hz, B: C5-H), 
6.42 – 6.27 (1.6H, m, A: C5-H and C6-H; B: C6-H), 3.73 (0.4H, d, J = 13.5 Hz, B: C7-H), 3.64 – 3.56 
                                                     
LIII BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
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(1.2H, m, A: C1-H and C7-H), 3.47 (0.4H, ddd, J = 9.5, 7.5, 4.0 Hz, B: C1-H), 3.15 – 2.94 (2H, m, A 
and B: C1-H’ and C7-H’), 2.14 – 2.02 (1H, m, A and B: C3-H), 1.92 – 1.83 (1H, m, A and B: C3-H’), 
1.66 – 1.57 (1H, m, A and B: C2-H), 1.54 (3.6H, s, B: OC(CH3)3), 1.50 (5.4H, s, A: OC(CH3)3), 1.35 – 
1.29 (0.4H, m, B: C2-H’), 1.24 – 1.15 (0.6H, m, A: C2-H’). δC (101 MHz, CDCl3) 154.5 (A: C=O), 
153.8 (B: C=O), 138.1 (B: ArC), 137.9 (A: ArC), 137.5 (B: ArC), 137.3 (A: ArC), 135.6 (A: C5), 134.3 
(B: C5), 131.0 (B: ArCH), 130.7 (A: ArCH), 128.8 (A: ArCH), 2 × 128.5 (B: 2 × ArCH), 128.4 (A: 
ArCH), 128.1 (B: ArCH), 127.4 (A: ArCH), 127.3 (B: C6), 127.1 (A: C6), 2 × 126.6 (A and B: ArCH), 
2 × 126.3 (A and B: ArCH), 80.0 (A: OC(CH3)3), 79.0 (B: OC(CH3)3), 67.3 (B: C4), 66.6 (A: C4), 2 × 
48.8 (A and B: C1), 42.8 (A: C7), 42.3 (B: C7), 38.3 (A: C3), 36.4 (B: C3), 28.8 (A and B: OC(CH3)3), 
21.6 (B: C2), 21.2 (A: C2). HRMS: (ESI+) Calculated for C24H30NO2: 364.2271. Found [M+H]+: 
364.2284. 
tert-Butyl (Z)-(4-isopropylhex-4-en-1-yl)(tosyloxy)carbamate (346) 
 
General procedure R: Alcohol 159b (Section 7.3, 284 mg, 2.00 mmol) was employed with 
BocNHOTs.LIV The reaction time was 16 hours. FCC (eluent: 1:4 petrol:PhMe) afforded 346 (615 mg, 
75 %, 13:1 mixture of (Z)- and (E)-isomers) as a colourless oil. Spectroscopic data for the major 
(Z)-isomer: νmax / cm-1: (film) 2962 (m), 1715 (s), 1597 (m), 1355 (s). δH (400 MHz, CDCl3) 7.86 (2H, 
d, J = 8.5 Hz, 2 × ArCH), 7.34 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.10 (1H, q, J = 7.0 Hz, C5-H), 3.60 (2H, 
br s, C1-H2), 2.82 (1H, hept, J = 7.0 Hz, CH(CH3)2), 2.45 (3H, s, Ts CH3), 1.87 (2H, br t, J = 8.0 Hz, 
C3-H2), 1.78 – 1.65 (2H, m, C2-H2), 1.59 (3H, dt, J = 7.0, 1.5 Hz, C6-H3), 1.23 (9H, s, OC(CH3)3), 0.95 
(6H, d, J = 7.0 Hz, CH(CH3)2). δC (101 MHz, CDCl3) 155.6 (C=O), 145.7 (ArC), 143.6 (C4), 131.5 
(ArC), 129.8 (ArCH), 129.6 (ArCH), 117.3 (C5), 83.2 (OC(CH3)3), 53.2 (C1), 28.6 (CH(CH3)2), 28.2 
(C3), 27.8 (OC(CH3)3), 25.1 (C2), 21.8 (Ts CH3), 21.0 (CH(CH3)2), 12.9 (C6). HRMS: (ESI+) 
Calculated for C21H33NNaO5S: 434.1972. Found [M+Na]+: 434.1984. Characteristic signals for the 
minor (E)-isomer: δH (400 MHz, CDCl3) 5.23 (1H, q, J = 7.0 Hz, C5-H), 2.23 – 2.13 (1H, m, CH(CH3)2), 
1.97 (2H, t, J = 8.0 Hz, C3-H2). 
  
                                                     
LIV BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
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tert-Butyl (R)-2-isopropyl-2-vinylpyrrolidine-1-carboxylate ((R)-347) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-PE; 300 mol% Et3N; 
THF (0.07 M); 110 °C; 72 hours. Substrate 346 (43.2 mg, 0.105 mmol) was employed. FCC (eluent: 
59:1 PhMe:EtOAc) afforded (R)-347 (19.6 mg, 78 %, 95 % e.e.) as a colourless oil. It was necessary to 
convert the protecting group from Boc to Bz in order to determine the e.e. of this compound. Details of 
this are provided below. [α]D26 -22.9 (c = 0.40, CH2Cl2). This compound exists as an approximately  
1:1 mixture of rotamers A and B. νmax / cm-1: (film) 2970 (m), 2875 (m), 1686 (s), 1466 (m), 1380 (s). 
δH (400 MHz, CDCl3) 6.16 (0.5H, dd, J = 17.5, 10.5 Hz, B: C5-H), 6.02 (0.5H, dd, J = 17.5, 10.5 Hz, 
A: C5-H), 5.07 – 4.90 (2H, m, A and B: C6-H2), 3.75 – 3.66 (0.5H, m, A: C1-H), 3.63 – 3.54 (0.5H, m, 
B: C1-H), 3.26 – 3.12 (1H, m, A and B: C1-H’), 2.79 (0.5H, qq, J = 7.5, 7.0 Hz, B: CH(CH3)2), 2.52 
(0.5H, qq, J = 7.0, 7.0 Hz, A: CH(CH3)2), 1.89 – 1.61 (4H, m, A and B: C2-H2 and C3-H2), 1.44 (9H, 
s, A and B: OC(CH3)3), 0.91 – 0.83 (3H, m, A and B: CH(CH3)(CH3)’), 0.83 – 0.74 (3H, m, A and B: 
CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 154.5 (A: C=O), 153.5 (B: C=O), 140.4 (A: C5), 140.1 (B: 
C5), 112.0 (A: C6), 111.9 (B: C6), 79.4 (A: OC(CH3)3), 78.7 (B: OC(CH3)3), 70.6 (B: C4), 70.1 (A: 
C4), 49.3 (B: C1), 49.2 (A: C1), 32.3 (A: CH(CH3)2), 31.2 (B: CH(CH3)2), 30.9 (A: C3), 29.5 (B: C3), 
28.7 (A and B: OC(CH3)3), 21.7 (B: C2), 21.1 (A: C2), 18.4 (A: CH(CH3)(CH3)’), 18.1 (B: 
CH(CH3)(CH3)’), 16.4 (B: CH(CH3)(CH3)’), 16.2 (A: CH(CH3)(CH3)’). HRMS: (ESI+) Calculated for 
C14H25NNaO2: 262.1777. Found [M+Na]+: 262.1785. 
(R)-1-Benzoyl-2-isopropyl-2-vinylpyrrolidine 
 
A solution of pyrrolidine (R)-347 (18.4 mg, 76.9 µmol) in TFA (2 mL) and CH2Cl2 (2 mL) was stirred 
at room temperature for 1 hour before being concentrated in vacuo. The crude mixture was dissolved 
in CH2Cl2 (3 mL) before addition of Et3N (54 µL, 0.385 mmol) and BzCl (27 µL, 0.231 mmol). The 
reaction mixture was stirred at room temperature for 2.5 hours before being concentrated in vacuo. FCC 
(eluent: 5:1 petrol:EtOAc) afforded the title compound (14.2 mg, 76 %, 95 %) as a colourless oil. 
The following procedure was used to prepare a racemic sample of the title compound for SFC analysis: 
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L2 (Section 7.4); 100 mol% 
Et3N; THF (0.1 M); 130 °C; 24 hours. Substrate 346 (43.2 mg, 0.105 mmol) was employed. The crude 
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reaction mixture was dissolved in CH2Cl2 (2 mL) and TFA (2 mL) and stirred at room temperature for 
two hours before being concentrated in vacuo. The crude reaction mixture was dissolved in CH2Cl2 
(3 mL) before addition of Et3N (73 µL, 0.525 mmol) and BzCl (37 µL, 0.315 mmol). The reaction 
mixture was stirred at room temperature for 3 hours before being concentrated in vacuo. FCC (gradient 
elution: 7:1 – 4:1 petrol:EtOAc) afforded the title compound (12.8 mg, 50 %) as a colourless oil.  
SFC conditions: column: CHIRALPACK IC, elute: 4.5 % MeOH/CO2, detector: 250 nm, flow rate: 
2.5 mL/min, temperature: 40 °C, retention times: (R) t1 = 15.3 min, (S) t2 = 16.3 min. [α]D26 +4.7  
(c = 0.40, CH2Cl2). νmax / cm-1: (film) 3079 (m), 2957 (m), 2874 (m), 1626 (s), 1400 (s). δH (400 MHz, 
CDCl3) 7.43 – 7.33 (5H, m, 5 × ArCH), 6.45 (1H, dd, J = 17.5, 11.0 Hz, C5-H), 5.15 (1H, dd, J = 11.0, 
1.0 Hz, C6-H), 5.07 (1H, dd, J = 17.5, 1.0 Hz, C6-H’), 3.44 – 3.30 (2H, m, C1-H2), 3.11 (1H, qq, J = 
7.0, 7.0 Hz, CH(CH3)2), 2.00 – 1.84 (2H, m, C3-H2), 1.83 – 1.65 (2H, m, C2-H2), 0.99 (3H, d, J = 
7.0 Hz, CH(CH3)(CH3)’), 0.93 (3H, d, J = 7.0 Hz, CH(CH3)(CH3)’). δC (101 MHz, CDCl3) 169.1 (C=O), 
139.5 (C5), 139.2 (ArC), 129.3 (ArCH), 128.4 (ArCH), 126.3 (ArCH), 112.5 (C6), 72.8 (C4), 52.9 (C1), 
30.8 (CH(CH3)2), 29.6 (C3), 22.9 (C2), 18.1 (CH(CH3)(CH3)’), 16.5 (CH(CH3)(CH3)’). HRMS: (ESI+) 
Calculated for C16H21NNaO: 266.1515. Found [M+Na]+: 266.1509. 
tert-Butyl (E)-dec-5-en-1-yl(tosyloxy)carbamate (282c) 
 
General procedure R: Alcohol (E)-281 (Section 7.4, 469 mg, 3.00 mmol) was employed with 
BocNHOTs.LV The reaction time was 16 hours. FCC (two times, first, gradient elution: 14:1 – 
9:1 petrol:EtOAc; second, gradient elution: 1:3 – 1:4 – 0:1 petrol:PhMe) afforded 282c (856 mg, 67 %) 
as a colourless oil. νmax / cm-1: (film) 2929 (m), 2860 (m), 1722 (s), 1599 (m), 1369 (s), 1179 (s).  
δH (400 MHz, CDCl3) 7.86 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.34 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.44 – 
5.27 (2H, m, C5-H and C6-H), 3.60 (2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 2.00 – 1.92 (4H, m, C4-H2 
and C7-H2), 1.61 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.35 – 1.25 (6H, m, C3-H2, C8-H2 and C9-H2), 1.22 
(9H, s, OC(CH3)3), 0.88 (3H, t, J = 7.0 Hz, C10-H3). δC (101 MHz, CDCl3) 155.7 (C=O), 145.7 (ArC), 
131.5 (ArC), 131.2 (C5), 129.9 (ArCH), 2 × 129.6 (ArCH and C6), 83.2 (OC(CH3)3), 52.9 (C1), 32.4 
(C7), 32.3 (C4), 31.9 (C8), 27.8 (OC(CH3)3), 26.7 (C3), 25.4 (C2), 22.3 (C9), 21.9 (Ts CH3), 14.1 (C10). 
HRMS: (ESI+) Calculated for C22H35NNaO5S: 448.2128. Found [M+Na]+: 448.2126. 
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tert-Butyl (S,E)-2-(pent-1-en-1-yl)piperidine-1-carboxylate ((S)-283a) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-PE; 300 mol% Et3N; 
THF (0.07 M); 110 °C; 72 hours. Substrate 282c (44.7 mg, 0.105 mmol) was employed. FCC (eluent: 
9:1 petrol:EtOAc) afforded (S)-283a (14.9 mg, 56 %, 95 % e.e.) as a colourless oil. It was necessary to 
convert the protecting group from Boc to Cbz in order to determine the e.e. of this compound  
(vide infra). [α]D23 -30.5 (c = 1.13, CHCl3). Characterisation data for 283a has been provided earlier 
(Section 7.4). 
Benzyl (E)-dec-5-en-1-yl(tosyloxy)carbamate (282d) 
 
General procedure R: Alcohol (E)-281 (Section 7.4, 250 mg, 1.60 mmol) was employed with 
CbzNHOTs.LVI The reaction time was 19 hours. FCC (eluent: 1:4 petrol:PhMe) afforded 282d (550 mg, 
75 %) as a colourless crystalline solid. m.p. 48-49 °C (CH2Cl2:petrol, needles). νmax / cm-1: (solid) 
2935 (m), 1715 (s), 1596 (m), 1496 (m), 1370 (s), 1180 (s). δH (400 MHz, CDCl3) 7.76 (2H, d, J = 
8.5 Hz, 2 × ArCH), 7.35 – 7.30 (3H, m, 3 × ArCH), 7.20 – 7.12 (4H, m, 4 × ArCH), 5.43 – 5.27 (2H, 
m, C5-H and C6-H), 4.90 (2H, s, OCH2Ph), 3.65 (2H, br s, C1-H2), 2.39 (3H, s, Ts CH3), 2.01 – 1.91 
(4H, m, C4-H2 and C7-H2), 1.67 – 1.58 (2H, m, C2-H2), 1.36 – 1.24 (6H, m, C3-H2, C8-H2 and C9-H2), 
0.92 – 0.85 (3H, m, C10-H3). δC (101 MHz, CDCl3) 156.7 (C=O), 145.8 (ArC), 135.0 (ArC), 131.2 
(C5), 131.0 (ArC), 2 × 129.6 (2 × ArCH), 129.4 (C6), 2 × 128.5 (2 × ArCH), 128.2 (ArCH), 68.7 
(OCH2Ph), 53.1 (C1), 32.4 (C7), 32.2 (C4), 31.9 (C8), 26.6 (C3), 25.5 (C2), 22.3 (C9), 21.9 (Ts CH3), 
14.1 (C10). HRMS: (ESI+) Calculated for C25H33NNaO5S: 482.1972. Found [M+Na]+: 492.1951. 
Benzyl (S,E)-2-(pent-1-en-1-yl)piperidine-1-carboxylate ((S)-283d) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-PE; 300 mol% Et3N; 
THF (0.07 M); 110 °C; 72 hours. Substrate 282d (48.3 mg, 0.105 mmol) was employed. FCC (two 
                                                     
LVI CbzNHOTs was prepared by Dr Xiaofeng Ma (University of Bristol) according to a literature procedure.164 
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times, first eluent: 99:1 PhMe:acetone; second eluent: 39:1 petrol:acetone) afforded (S)-283d (16.7 mg, 
55 %, 89 % e.e.) as a colourless oil.  
The following procedure was used to prepare a racemic sample of 283d for SFC analysis: A solution 
of N-Boc-protected piperidine 283a (Section 7.4, 40.9 mg, 0.161 mmol) in TFA (3 mL) and CH2Cl2 
(3 mL) was stirred at room temperature for 30 minutes before being concentrated in vacuo. The crude 
mixture was dissolved in CH2Cl2 (5 mL) before addition of Et3N (67 µL, 0.483 mmol) and CbzCl 
(35 µL, 0.242 mmol). The reaction mixture was stirred at room temperature for 16 hours before being 
concentrated in vacuo. FCC (eluent: 14:1 petrol:EtOAc) afforded 283d (24.7 mg, 53 %) as a colourless 
oil. An analogous procedure was used to convert (S)-283a to (S)-283d. SFC conditions: column: 
CHIRALPACK IC, elute: 1.5 % MeOH/CO2, detector: 250 nm, flow rate: 4.0 mL/min, temperature: 
40 °C, retention times: (S) t1 = 6.75 min, (R) t2 = 7.31 min. For 95 % e.e. material: [α]D26 -40.5 (c = 
0.40, CH2Cl2). νmax / cm-1: (film) 2933 (m), 2860 (m), 1694 (s), 1418 (s), 1255 (s). δH (400 MHz, CDCl3) 
7.40 – 7.27 (5H, m, 5 × ArCH), 5.52 – 5.37 (2H, m, C6-H and C7-H), 5.17 (1H, d, J = 12.5 Hz, 
OCHH’Ph), 5.11 (1H, d, J = 12.5 Hz, OCHH’Ph), 4.85 (1H, br s, C5-H), 4.02 (1H, br d, J = 13.0 Hz, 
C1-H), 2.91 (1H, ddd, J = 13.0, 13.0, 3.0 Hz, C1-H’), 2.00 (2H, dt, J = 7.0, 7.0 Hz, C8-H2), 1.74 – 1.40 
(6H, m, C2-H2, C3-H2 and C4-H2), 1.38 (2H, qt, J = 7.5, 7.0 Hz, C9-H2), 0.88 (2H, t, J = 7.5 Hz, 
C10-H3). δC (101 MHz, CDCl3) 155.9 (C=O), 137.2 (ArC), 132.3 (C7), 128.5 (ArCH), 128.1 (C6), 
127.9 (ArCH), 127.8 (ArCH), 67.0 (OCH2Ph), 52.3 (C5), 40.1 (C1), 34.6 (C8), 29.6 (C4), 25.8 (C2), 




A solution of silyl ether 188 (Section 7.3, 3.92 g, 17.3 mmol) and TBAF (1.0 M in THF, 26.0 mL, 
26.0 mmol) in THF (70 mL) was stirred at room temperature for 2 hours before being concentrated in 
vacuo. FCC (gradient elution: 1:0 – 1:1 pentane:Et2O) afforded the title compound (1.92 g, 99 %) as a 
colourless oil. δH (400 MHz, CDCl3) 3.67 (2H, t, J = 6.5 Hz), 2.17 (2H, tq, J = 7.0, 2.5 Hz), 1.78 (3H, 
t, J = 2.5 Hz), 1.71 – 1.63 (2H, m), 1.60 – 1.51 (2H, m), 1.32 (1H, br s). δC (101 MHz, CDCl3) 79.1, 
76.0, 62.7, 32.0, 25.4, 18.6, 3.6. The spectroscopic properties were consistent with the data available 
in the literature.299 
  





A suspension of the preceding compound (1.92 g, 17.1 mmol) and LiAlH4 (3.26 g, 86.0 mmol) in 
anhydrous diglyme (80 mL) was heated at reflux for 16 hours before being cooled to 0 °C and diluted 
with Et2O (40 mL). The reaction mixture was quenched slowly with water (3.3 mL), 4.0 M aqueous 
NaOH (3.3 mL) and a further portion of water (10 mL). The reaction mixture was stirred at room 
temperature for 20 minutes before being dried over Na2SO4, filtered and concentrated in vacuo to 
remove Et2O. The crude mixture was dissolved in petrol (500 mL) and washed with water (500 mL), 
the aqueous phase was extracted with Et2O (150 mL). The combined organic phases were dried over 
Na2SO4 and concentrated in vacuo. The crude mixture was dissolved in Et2O (300 mL) and washed 
with water (5 × 200 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo to afford 
(E)-189 (1.15 g, 59 %) as a pale-yellow oil. νmax / cm-1: (film) 3322 (br s), 2932 (m), 1438 (m), 1057 (s). 
δH (400 MHz, CDCl3) 5.48 – 5.36 (2H, m, C5-H and C6-H), 3.64 (2H, t, J = 6.5 Hz, C1-H2), 2.04 – 
1.97 (2H, m, C4-H2), 1.66 – 1.63 (3H, m, C7-H3), 1.61 – 1.52 (2H, m, C2-H2), 1.46 – 1.36 (2H, m, 
C3-H2), 1.25 (1H, br s, OH). δC (101 MHz, CDCl3) 131.2 (C5), 125.3 (C6), 63.1 (C1), 2 × 32.4 (C2 and 
C4), 25.8 (C3), 18.1 (C7). HRMS: (MALDI-) Calculated for C7H13O: 113.0972. Found [M-H]-: 
113.0977. 
tert-Butyl (E)-hept-5-en-1-yl(tosyloxy)carbamate (275b) 
 
General procedure R: Alcohol (E)-189 (228 mg, 2.00 mmol) was employed with BocNHOTs.LVII  
The reaction time was 22 hours. FCC (gradient elution: 7:3 – 1:4 petrol:PhMe) afforded 275b  
(579 mg, 75 %) as a colourless oil. νmax / cm-1: (film) 2933 (m), 1720 (s), 1598 (m), 1368 (s), 1178 (s).  
δH (400 MHz, CDCl3) 7.86 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.34 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.46 – 
5.31 (2H, m, C5-H and C6-H), 3.60 (2H, br s, C1-H2), 2.45 (3H, s, Ts CH3), 1.97 (2H, dt, J = 7.0, 
7.0 Hz, C4-H2), 1.66 – 1.56 (5H, m, C2-H2 and C7-H3), 1.30 (2H, tt, J = 7.5, 7.0 Hz, C3-H2), 1.22 (9H, 
s, OC(CH3)3). δC (101 MHz, CDCl3) 155.7 (C=O), 145.8 (ArC), 131.5 (ArC), 130.9 (C5), 129.9 (ArCH), 
129.6 (ArCH), 125.5 (C6), 83.2 (OC(CH3)3), 53.0 (C1), 32.2 (C4), 27.8 (OC(CH3)3), 26.6 (C3), 25.4 
(C2), 21.8 (Ts CH3), 18.0 (C7). HRMS: (ESI+) Calculated for C19H29NNaO5S: 406.1659. Found 
[M+Na]+: 406.1667. 
                                                     
LVII BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
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Benzyl (E)-hept-5-en-1-yl(tosyloxy)carbamate (275c) 
 
General procedure R: Alcohol (E)-189 (275 mg, 2.41 mmol) was employed with CbzNHOTs.LVIII The 
reaction time was 20 hours. FCC (gradient elution: 1:4 – 9:1 – 0:1 petrol:PhMe) afforded 275c (722 mg, 
72 %) as a colourless crystalline solid. m.p. 50-52 °C (Et2O:petrol, tabular). νmax / cm-1: (film) 2934 (m), 
1725 (s), 1597 (m), 1455 (m), 1384 (s), 1178 (s). δH (400 MHz, CDCl3) 7.76 (2H, d, J = 8.5 Hz, 2 × 
ArCH), 7.35 – 7.30 (3H, m, 3 × ArCH), 7.20 – 7.13 (4H, m, 4 × ArCH), 5.45 – 5.30 (2H, m, C5-H and 
C6-H), 4.90 (2H, s, OCH2Ph), 3.64 (2H, br s, C1-H2), 2.40 (3H, s, Ts CH3), 1.94 (2H, td, J = 7.0, 6.5 Hz, 
C4-H2), 1.67 – 1.57 (5H, m, C2-H2 and C7-H3), 1.28 (2H, tt, J = 7.5, 7.0 Hz, C3-H2). δC (101 MHz, 
CDCl3) 156.8 (C=O), 145.8 (ArC), 135.1 (ArC), 131.1 (ArC), 130.8 (C5), 2 × 129.6 (2 × ArCH), 2 × 
128.6 (2 × ArCH), 128.3 (ArCH), 125.5 (C6), 68.7 (OCH2Ph), 53.2 (C1), 32.2 (C4), 26.5 (C3), 25.5 
(C2), 22.0 (Ts CH3), 18.1 (C7). HRMS: (ESI+) Calculated for C22H27NNaO5S: 440.1502. Found 
[M+Na]+: 440.1510. 
Benzyl (S)-2-vinylpiperidine-1-carboxylate ((S)-276c) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-IP;LIX 300 mol% Et3N; 
THF (0.07 M); 110 °C; 24 hours. Substrate 275c (43.8 mg, 0.105 mmol) was employed. FCC (eluent: 
29:1 petrol:acetone) afforded (S)-276c (18.3 mg, 71 %, 84 % e.e.) as a colourless oil.  
The following procedure was used to prepare a racemic sample of 276c for SFC analysis:  
General procedure D: Conditions: 2.5 mol% Pd2(dba)3; 15 mol% ligand L3 (Section 7.4); 200 mol% 
Et3N; THF (0.1 M); 130 °C; 24 hours. Substrate 275c (43.8 mg, 0.105 mmol) was employed. FCC 
(eluent: 29:1 petrol:acetone) afforded 276c (8.7 mg, 34 %) as a colourless oil. 
The following procedure started from Boc-protected substrate 275b. N-Boc piperidine (S)-276a was 
converted to N-Cbz analogue (S)-276c without isolation. General procedure D: Conditions: 5.0 mol% 
Pd2(dba)3; 12 mol% (S)-SIPHOS-IP;LIX 300 mol% Et3N; THF (0.07 M); 110 °C; 24 hours. Substrate 
275b (40.3 mg, 0.105 mmol) was employed. The crude mixture was dissolved in TFA (1 mL) and 
CH2Cl2 (3 mL) and stirred at room temperature for 4 hours before being concentrated in vacuo. The 
                                                     
LVIII CbzNHOTs was prepared by Dr Xiaofeng Ma (University of Bristol) according to a literature procedure.164 
LIX (S)-SIPHOS-IP was prepared by Dr Xiaofeng Ma (University of Bristol) using an adaptation of a literature 
procedure.165 
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crude mixture was dissolved in CH2Cl2 (3 mL) before addition of Et3N (0.15 mL, 1.08 mmol) and 
CbzCl (3.0 M in PhMe, 0.18 mL, 0.540 mmol). The reaction mixture was stirred at room temperature 
for 20 hours before being concentrated in vacuo. FCC (two times, first eluent: 39:1 petrol:acetone; 
second eluent: 64:1 PhMe:Et2O) afforded (S)-276c (5.2 mg, 20 %, 92 % e.e.) as a colourless oil. SFC 
conditions: column: CHIRALPACK IC, elute: 1.5 % MeOH/CO2, detector: 210 nm, flow rate: 
4.0 mL/min, temperature: 40 °C, retention times: (S) t1 = 6.25 min, (R) t2 = 6.70 min. For 92 % e.e. 
material: [α]D26 -22.0 (c = 0.17, CHCl3) [Lit., [α]D28 -17.5 (c = 0.20, CHCl3)].166 δH (500 MHz, CDCl3) 
7.37 – 7.28 (5H, m), 5.78 (1H, ddd, J = 17.5, 10.5, 4.0 Hz), 5.20 (1H, ddd, J = 10.5, 2.0, 1.5 Hz), 5.17 
– 5.11 (2H, m), 5.07 (1H, ddd, J = 17.5, 2.0, 1.5 Hz), 4.89 (1H, br s), 4.04 (1H, br d, J = 13.0 Hz), 2.92 
(1H, ddd, J = 13.0, 13.0, 3.0 Hz), 1.80 – 1.37 (6H, m). δC (126 MHz, CDCl3) 156.0, 137.1, 136.7, 128.6, 
128.0, 127.9, 116.1, 67.1, 52.9, 40.2, 29.1, 25.7, 19.5. The spectroscopic properties were consistent 
with the data available in the literature.166  
7-Cyclopropylhept-5-yn-1-ol 
 
To a solution of alkyne 187 (Section 7.3, 4.25 g, 20.0 mmol) in anhydrous THF (100 mL) and 
anhydrous DMPU (20 mL) at -78 °C was added n-BuLi (1.6 M in hexane, 12.5 mL, 20.0 mmol). The 
reaction mixture was stirred at -20 °C for 1 hour, then cooled to -78 °C before addition of 
cyclopropylmethyl bromide (2.52 mL, 26.0 mmol). The reaction mixture was stirred at -78 °C for 
1 hour and then at room temperature for 18 hours before addition of saturated aqueous NH4Cl (50 mL). 
The reaction mixture was extracted with Et2O (3 × 50 mL), and the combined organic phases were 
concentrated in vacuo. The crude mixture was dissolved in Et2O (80 mL) and petrol (80 mL) and then 
washed with water (4 × 80 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. 
Distillation afforded impure material which was dissolved in THF (30 mL) before addition of TBAF 
(1.0 M in THF, 27.0 mL, 27.0 mmol). The reaction mixture was stirred at room temperature for 4 hours 
before being concentrated in vacuo, dissolved in Et2O (100 mL) and washed with water (100 mL). The 
organic phase was dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 9:1 PhMe:EtOAc) 
afforded the title compound (552 mg, 18 %) as a colourless oil. νmax / cm-1: (film) 3331 (br s), 3079 (m), 
2937 (m), 2174 (m), 1433 (m), 1057 (m). δH (400 MHz, CDCl3) 3.67 (2H, t, J = 6.5 Hz, C1-H2), 2.23 – 
2.16 (4H, m, C4-H2 and C7-H2), 1.72 – 1.63 (2H, m, C2-H2), 1.61 – 1.52 (2H, m, C3-H2), 1.42 (1H, 
br s, OH), 0.94 – 0.84 (1H, m, C8-H), 0.48 – 0.37 (2H, m, 2 × C9-H), 0.24 – 0.15 (2H, m, 2 × C9-H’). 
δC (101 MHz, CDCl3) 80.3 (C5), 78.9 (C6), 62.7 (C1), 32.0 (C2), 25.5 (C3), 23.0 (C7), 18.7 (C4), 9.8 
(C8), 3.9 (C9). HRMS: (ESI+) Calculated for C10H16NaO: 175.1093. Found [M+Na]+: 175.1095. 
 





A suspension of the preceding compound (512 mg, 3.36 mmol) and LiAlH4 (638 mg, 16.8 mmol) in 
anhydrous diglyme (16 mL) was heated at reflux for 15 hours before being cooled to 0 °C and diluted 
with Et2O (10 mL). The reaction mixture was quenched slowly with water (0.65 mL), 4.0 M aqueous 
NaOH (0.65 mL) and a further portion of water (2.0 mL). The reaction mixture was stirred at room 
temperature for 20 minutes before being dried over Na2SO4 and filtered. The filtrate was dissolved in 
Et2O (70 mL) and washed with water (5 × 100 mL). The organic phase was dried over Na2SO4 and 
concentrated in vacuo to afford (E)-284 (418 mg, 81 %) as a pale-yellow oil. νmax / cm-1: (film) 
3326 (br s), 3076 (m), 2931 (m), 1427 (m), 1056 (m). δH (400 MHz, CDCl3) 5.53 – 5.40 (2H, m, C5-H 
and C6-H), 3.65 (2H, t, J = 6.5 Hz, C1-H2), 2.07 – 2.00 (2H, m, C4-H2), 1.93 – 1.85 (2H, m, C7-H2), 
1.62 – 1.54 (2H, m, C2-H2), 1.48 – 1.39 (2H, m, C3-H2), 1.27 (1H, br s, OH), 0.71 (1H, ttt, J = 8.0, 6.5, 
5.0 Hz, C8-H), 0.44 – 0.38 (2H, m, 2 × C9-H), 0.07 – 0.01 (2H, m, 2 × C9-H’). δC (101 MHz, CDCl3) 
130.3 (C5), 129.8 (C6), 63.1 (C1), 37.4 (C7), 2 × 32.4 (C2 and C4), 25.8 (C3), 10.7 (C8), 4.2 (C9). 
HRMS: (MALDI-) Calculated for C10H17O: 153.1285. Found [M-H]-: 153.1291. 
Benzyl (E)-(7-cyclopropylhept-5-en-1-yl)(tosyloxy)carbamate (285b) 
 
General procedure R: Alcohol (E)-284 (170 mg, 1.10 mmol) was employed with CbzNHOTs.LX The 
reaction time was 19 hours. FCC (gradient elution: 1:9 – 0:1 petrol:PhMe) afforded 285b (388 mg, 
77 %) as a colourless crystalline solid. m.p. 45-46 °C (CH2Cl2:petrol, needles). νmax / cm-1: (film) 
3073 (m), 2927 (m), 1724 (s), 1597 (m), 1456 (m), 1383 (s), 1178 (s). δH (400 MHz, CDCl3) 7.76 (2H, 
d, J = 8.5 Hz, 2 × ArCH), 7.35 – 7.30 (3H, m, 3 × ArCH), 7.19 – 7.13 (4H, m, 4 × ArCH), 5.50 – 5.32 
(2H, m, C5-H and C6-H), 4.90 (2H, s, OCH2Ph), 3.65 (2H, br s, C1-H2), 2.40 (3H, s, Ts CH3), 1.97 
(2H, dt, J = 7.0, 7.0 Hz, C4-H2), 1.88 (2H, dd, J = 6.5, 6.5 Hz, C7-H2), 1.63 (2H, tt, J = 7.5, 7.0 Hz, 
C2-H2), 1.31 (2H, tt, J = 7.5, 7.0 Hz, C3-H2), 0.78 – 0.63 (1H, m, C8-H), 0.43 – 0.39 (2H, m, 2 × C9-H), 
0.06 – 0.01 (2H, m, 2 × C9-H’). δC (101 MHz, CDCl3) 156.8 (C=O), 145.8 (ArC), 135.1 (ArC), 131.1 
(ArC), 130.1 (C6), 129.8 (C5), 2 × 129.6 (2 × ArCH), 2 × 128.6 (2 × ArCH), 128.3 (ArCH), 68.7 
(OCH2Ph), 53.2 (C1), 37.4 (C7), 32.3 (C4), 26.5 (C3), 25.5 (C2), 21.9 (Ts CH3), 10.7 (C8), 4.2 (C9). 
HRMS: (ESI+) Calculated for C25H32NO5S: 458.1996. Found [M+H]+: 458.2009. 
                                                     
LX CbzNHOTs was prepared by Dr Xiaofeng Ma (University of Bristol) according to a literature procedure.164 
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Benzyl (S,E)-2-(2-cyclopropylvinyl)piperidine-1-carboxylate ((S)-286b) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-IP;LXI 300 mol% Et3N; 
THF (0.07 M); 110 °C; 48 hours. Substrate 285b (48.0 mg, 0.105 mmol) was employed. FCC (two 
times, first eluent: 199:1 PhMe:acetone; second eluent: 39:1 petrol:acetone) afforded (S)-286b 
(15.3 mg, 51 %, 90 % e.e.) as a colourless oil.  
The following procedure was used to prepare a racemic sample of 286b for SFC analysis: A solution 
of N-Boc-protected piperidine 286a (Section 7.4, 17.6 mg, 70.0 µmol) in TFA (1 mL) and CH2Cl2 
(3 mL) was stirred at room temperature for 18 hours before being concentrated in vacuo. The crude 
mixture was dissolved in CH2Cl2 (3 mL) before addition of Et3N (98 µL, 0.700 mmol) and CbzCl 
(3.0 M in PhMe, 0.12 mL, 0.350 mmol). The reaction mixture was stirred at room temperature for 
4 hours before being concentrated in vacuo. FCC (eluent: 65:1 PhMe:Et2O) afforded 286b (9.7 mg, 
49 %) as a colourless oil. SFC conditions: column: CHIRALPACK IC, elute: 1.5 % MeOH/CO2, 
detector: 210 nm, flow rate: 4.0 mL/min, temperature: 40 °C, retention times: (S) t1 = 9.89 min,  
(R) t2 = 10.9 min. [α]D26 -37.4 (c = 0.40, CH2Cl2). νmax / cm-1: (film) 3004 (m), 2935 (m), 1694 (s), 
1419 (s), 1261 (s). δH (500 MHz, CDCl3) 7.38 – 7.27 (5H, m, 5 × ArCH), 5.54 (1H, dd, J = 15.5, 5.5 Hz, 
C6-H), 5.17 (1H, d, J = 12.5 Hz, OCHH’Ph), 5.10 (1H, d, J = 12.5 Hz, OCHH’Ph), 5.00 (1H, dd, J = 
15.5, 9.0 Hz, C7-H), 4.86 – 4.80 (1H, m, C5-H), 4.01 (1H, br d, J = 13.0 Hz, C1-H), 2.91 (1H, ddd, J = 
13.0, 13.0, 3.0 Hz, C1-H’), 1.74 – 1.50 (5H, m, C2-H, C3-H2 and C4-H2), 1.47 – 1.32 (2H, m,  
C2-H’ and C8-H), 0.72 – 0.64 (2H, m, C9-H and C9’-H), 0.36 – 0.26 (2H, m, C9-H’ and C9’-H’).  
δC (126 MHz, CDCl3) 155.8 (C=O), 137.3 (ArC), 136.2 (C7), 128.6 (ArCH), 128.0 (ArCH), 127.9 
(ArCH), 125.5 (C6), 67.0 (OCH2Ph), 52.3 (C5), 40.1 (C1), 29.7 (C4), 25.7 (C2), 19.5 (C3), 13.8 (C8), 
2 × 6.8 (C9 and C9’). HRMS: (ESI+) Calculated for C18H24NO2: 286.1802. Found [M+H]+: 286.1812. 
  
                                                     
LXI (S)-SIPHOS-IP was prepared by Dr Xiaofeng Ma (University of Bristol) using an adaptation of a literature 
procedure.165 
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tert-Butyl (E)-(2-methylenenon-5-en-1-yl)(tosyloxy)carbamate (297b) 
 
General procedure R: Alcohol 296 (Section 7.4, 309 mg, 2.00 mmol) was employed with 
BocNHOTs.LXII The reaction time was 14 hours. FCC (eluent: 1:4 petrol:PhMe) afforded 297b (625 mg, 
74 %) as a colourless oil. νmax / cm-1: (film) 2958 (m), 2930 (m), 1721 (s), 1598 (m), 1369 (s), 1179 (s). 
δH (400 MHz, CDCl3) 7.86 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.35 (2H, d, J = 8.5 Hz, 2 × ArCH), 5.45 – 
5.31 (2H, m, C5-H and C6-H), 4.92 (1H, s, C10-H), 4.86 (1H, s, C10-H’), 4.19 (2H, br s, C1-H2), 2.45 
(3H, s, Ts CH3), 2.16 – 2.08 (2H, m, C4-H2), 2.04 – 1.97 (2H, m, C3-H2), 1.93 (2H, td, J = 7.0, 6.5 Hz, 
C7-H2), 1.34 (2H, qt, J = 7.5, 7.0 Hz, C8-H2), 1.23 (9H, s, OC(CH3)3), 0.87 (3H, t, J = 7.5 Hz, C9-H3). 
δC (101 MHz, CDCl3) 155.3 (C=O), 145.8 (ArC), 142.3 (C2), 131.5 (ArC), 131.1 (C6), 129.8 (ArCH), 
129.7 (ArCH), 129.4 (C5), 113.4 (C10), 83.4 (OC(CH3)3), 56.8 (C1), 34.8 (C7), 33.9 (C3), 30.6 (C4), 
27.7 (OC(CH3)3), 22.8 (C8), 21.9 (Ts CH3), 13.8 (C9). HRMS: (ESI+) Calculated for C22H33NNaO5S: 
446.1972. Found [M+Na]+: 446.1978. 
(E)-2-(Hex-2-en-1-ylthio)ethan-1-ol 
 
A suspension of (E)-1-bromohex-2-ene (Section 7.4, 1.48 mL, 11.0 mmol), 2-mercaptoethanol 
(0.70 mL, 10.0 mmol) and K2CO3 (1.66 g, 12.0 mmol) in anhydrous THF (10 mL) was stirred at room 
temperature for 6 hours before being filtered and concentrated in vacuo. FCC (eluent: 1:1 petrol:Et2O) 
afforded the title compound (1.05 g, 66 %) as a colourless oil. νmax / cm-1: (film) 3367 (br s), 2957 (m), 
2925 (m), 1419 (m), 1045 (s). δH (400 MHz, CDCl3) 5.52 (1H, dtt, J = 15.5, 6.5, 1.0 Hz, C5-H), 5.40 
(1H, dtt, J = 15.5, 7.0, 1.0 Hz, C4-H), 3.69 (2H, t, J = 6.0 Hz, C1-H2), 3.10 (2H, ddt, J = 7.0, 1.0, 1.0 Hz, 
C3-H2), 2.68 (2H, t, J = 6.0 Hz, C2-H2), 2.14 (1H, br s, OH), 2.01 (2H, br td, J = 7.5, 6.5 Hz, C6-H2), 
1.39 (2H, tq, J = 7.5, 7.5 Hz, C7-H2), 0.89 (3H, t, J = 7.5 Hz, C8-H3). δC (101 MHz, CDCl3) 134.3 (C5), 
125.9 (C4), 60.3 (C1), 34.4 (C6), 33.8 (C2), 33.5 (C3), 22.6 (C7), 13.8 (C8). HRMS: (ESI+) Calculated 
for C8H16NaOS: 183.0814. Found [M+Na]+: 183.0818. 
  
                                                     
LXII BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
Chapter 7 - Experimental 
355 
 
tert-Butyl (E)-(2-(hex-2-en-1-ylthio)ethyl)(tosyloxy)carbamate (348) 
 
General procedure R: The preceding alcohol (321 mg, 2.00 mmol) was employed with 
BocNHOTs.LXIII The reaction time was 24 hours. FCC (gradient elution: 1:4 – 1:9 petrol:PhMe) 
afforded 348 (522 mg, 61 %) as a colourless crystalline solid. m.p. 69-71 °C (CH2Cl2:petrol, tabular). 
νmax / cm-1: (solid) 2955 (m), 2927 (m), 1713 (s), 1598 (m), 1443 (m), 1376 (s), 1190 (s). δH (400 MHz, 
CDCl3) 7.86 (2H, d, J = 8.0 Hz, 2 × ArCH), 7.35 (2H, d, J = 8.0 Hz, 2 × ArCH), 5.56 (1H, dtt, J = 14.5, 
7.0, 1.0 Hz, C5-H), 5.41 – 5.32 (1H, m, C4-H), 3.79 (2H, br s, C1-H2), 3.06 (2H, dd, J = 7.0, 1.0 Hz, 
C3-H2), 2.70 (2H, t, J = 7.5 Hz, C2-H2), 2.46 (3H, s, Ts CH3), 2.02 (2H, td, J = 7.5, 7.0 Hz, C6-H2), 
1.40 (2H, tq, J = 7.5, 7.5 Hz, C7-H2), 1.21 (9H, s, OC(CH3)3), 0.90 (3H, t, J = 7.5 Hz, C8-H3).  
δC (101 MHz, CDCl3) 155.3 (C=O), 145.9 (ArC), 134.6 (C4), 131.3 (ArC), 129.9 (ArCH), 129.7 
(ArCH), 125.5 (C5), 83.5 (OC(CH3)3), 51.6 (C1), 34.5 (C6), 33.7 (C3), 27.7 (OC(CH3)3), 25.9 (C2), 




General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 12 mol% (S)-SIPHOS-IP;LXIV 300 mol% 
Et3N; THF (0.07 M); 110 °C; 24 hours. Substrate 348 (45.1 mg, 0.105 mmol) was employed. FCC 
(eluent: 2:1 pentane:EtOAc) afforded 349 (4.0 mg, 19 %) as a colourless oil. Desired product 350 was 
not observed. νmax / cm-1: (film) 2960 (m), 2926 (m), 1759 (s), 1384 (s), 1208 (s). δH (500 MHz, CDCl3) 
5.62 (1H, dt, J = 15.0, 7.0 Hz, C6-H), 5.53 (1H, dt, J = 15.0, 7.0 Hz, C5-H), 4.29 (2H, dd, J = 9.0, 
7.0 Hz, C2-H2), 3.76 (2H, dd, J = 9.0, 7.0 Hz, C3-H2), 3.45 (2H, d, J = 7.0 Hz, C4-H2), 2.02 (2H, td, 
J = 7.5, 7.0 Hz, C7-H2), 1.39 (2H, tq, J = 7.5, 7.5 Hz, C8-H2), 0.90 (3H, t, J = 7.5 Hz, C9-H3). 
δC (126 MHz, CDCl3) 159.1 (C1), 136.4 (C6), 123.4 (C5), 62.1 (C2), 49.7 (C3), 40.1 (C4), 34.5 (C7), 
22.3 (C8), 13.7 (C9). HRMS: (ESI+) Calculated for C9H16NO2S: 202.0896. Found [M+H]+: 202.0898. 
  
                                                     
LXIII BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
LXIV (S)-SIPHOS-IP was prepared by Dr Xiaofeng Ma (University of Bristol) using an adaptation of a literature 
procedure.165 
Chapter 7 - Experimental 
356 
 
7.6 Experimental procedures for the studies in Chapter 5 
2-Methylenehex-5-en-1-ol 
 
This compound was prepared according to a literature procedure.300 A solution of TMEDA (24.0 mL, 
160 mmol) and n-BuLi (1.6 M in hexane, 100 mL, 160 mmol) in anhydrous Et2O (200 mL) was stirred 
at 0 °C for 20 minutes. The reaction mixture was cooled to -78 °C before addition of 
2-methylprop-2-en-1-ol (6.73 mL, 80.0 mmol) dropwise. The reaction mixture was stirred at room 
temperature for 19 hours and then cooled to -78 °C before addition of a solution of allyl bromide 
(5.19 mL, 60.0 mmol) in anhydrous Et2O (10 mL) dropwise. The reaction mixture was stirred at -78 °C 
for 2 hours and then at room temperature for a further 6 hours before addition of saturated aqueous 
NH4Cl (150 mL). The resulting phases were separated, and the aqueous phase was extracted with Et2O 
(2 × 50 mL). The combined organic phases were washed with water (100 mL), saturated aqueous 
CuSO4 (2 × 100 mL) and brine (2 × 100 mL) before being dried over Na2SO4 and concentrated in vacuo. 
FCC (eluent: 2:1 hexane:Et2O) afforded the title compound (2.99 g, 44 %) as a pale-yellow oil.  
νmax / cm-1: (film) 3319 (br s), 3078 (m), 2921 (s), 1641 (s), 1449 (s), 1022 (s). δH (400 MHz, CDCl3) 
5.81 (1H, ddt, J = 17.0, 10.0, 6.5 Hz), 5.03 (1H, br s), 5.02 (1H, ddt, J = 17.0, 2.0, 1.5 Hz), 4.96 (1H, 
ddt, J = 10.0, 2.0, 1.0 Hz), 4.87 (1H, br s), 4.05 (2H, s), 2.25 – 2.18 (2H, m), 2.17 – 2.11 (2H, m), 1.94 
(1H, br s). δC (101 MHz, CDCl3) 148.3, 138.1, 114.8, 109.6, 65.8, 32.2, 31.9. The spectroscopic 
properties were consistent with the data available in the literature.300,301 
Ethyl 4-methyleneoct-7-enoate 
 
General procedure L: The preceding allylic alcohol (2.24 g, 20.0 mmol) was employed. The reaction 
time was 16 hours. FCC (eluent: 29:1 hexane:EtOAc) afforded the title compound (2.26 g, 62 %) as a 
colourless oil. νmax / cm-1: (film) 3079 (m), 2981 (s), 2934 (s), 1785 (s), 1643 (s), 1445 (s), 1371 (s), 
1154 (s). δH (400 MHz, CDCl3) 5.80 (1H, ddt, J = 17.0, 10.5, 6.5 Hz, C7-H), 5.02 (1H, ddt, J = 17.0, 
2.0, 1.5 Hz, C8-H’), 4.95 (1H, ddt, J = 10.5, 2.0, 1.0 Hz, C8-H), 4.76 (1H, br s, C9-H), 4.74 (1H, br s, 
C9-H’), 4.12 (2H, q, J = 7.0 Hz, OCH2CH3), 2.47 – 2.42 (2H, m, C2-H2), 2.36 – 2.30 (2H, m,  
C3-H2), 2.23 – 2.16 (2H, m, C6-H2), 2.14 – 2.08 (2H, m, C5-H2), 1.25 (3H, t, J = 7.0 Hz, OCH2CH3).  
δC (101 MHz, CDCl3) 173.4 (C1), 147.5 (C4), 138.3 (C7), 114.8 (C8), 109.7 (C9), 60.5 (OCH2CH3), 
35.7 (C5), 32.9 (C2), 32.1 (C6), 31.1 (C3), 14.4 (OCH2CH3). HRMS: (ESI+) Calculated for C11H18NaO2: 
205.1199. Found [M+Na]+: 205.1190. 





General procedure I: The preceding ester (1.00 g, 5.49 mmol) was employed, using anhydrous Et2O 
as the solvent and 0.8 eq. LiAlH4 (1.0 M in Et2O). The title compound (765 mg, 99 %) was isolated as 
a colourless oil. νmax / cm-1: (film) 3323 (br s), 3078 (m), 2932 (s), 1642 (s), 1442 (s), 1057 (s).  
δH (400 MHz, CDCl3) 5.81 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, C7-H), 5.01 (1H, ddt, J = 17.0, 1.5, 1.5 Hz, 
C8-H’), 4.97 – 4.92 (1H, m, C8-H), 4.76 (1H, br s, C9-H), 4.75 (1H, br s, C9-H’), 3.64 (2H, t, J = 6.5 Hz, 
C1-H2), 2.23 – 2.15 (2H, m, C6-H2), 2.14 – 2.05 (4H, m, C3-H2 and C5-H2), 1.77 (1H, br s, OH), 1.70 
(2H, tt, J = 7.5, 6.5 Hz, C2-H2). δC (101 MHz, CDCl3) 148.7 (C4), 138.5 (C7), 114.7 (C8), 109.5 (C9), 
62.7 (C1), 35.4 (C5), 32.5 (C3), 32.1 (C6), 30.7 (C2). HRMS: (EI+) Calculated for C9H14: 122.1096. 
Found [M-H2O]+: 122.1091. 
N-(4-Methyleneoct-7-en-1-yl)-N-((triethylsilyl)oxy)methanesulfonamide 
 
General procedure E: MsNHOTES (Section 7.3, 676 mg, 3.00 mmol) was employed with the 
preceding alcohol (1.1 eq.). The reaction time was 16 hours. FCC (eluent: PhMe) afforded the title 
compound (1.01 g, 97 %) as a colourless oil. νmax / cm-1: (film) 3078 (m), 2956 (s), 2878 (s), 1642 (m), 
1458 (m), 1350 (s), 1164 (s). δH (400 MHz, CDCl3) 5.81 (1H, ddt, J = 17.0, 10.5, 6.5 Hz, C7-H), 5.02 
(1H, ddt, J = 17.0, 2.0, 1.5 Hz, C8-H’), 4.96 (1H, ddt, J = 10.5, 2.0, 1.0 Hz, C8-H), 4.78 (1H, s, C9-H), 
4.76 (1H, s, C9-H’), 3.18 (2H, t, J = 7.5 Hz, C1-H2), 2.85 (3H, s, Ms CH3), 2.24 – 2.15 (2H, m, C6-H2), 
2.14 – 2.04 (4H, m, C3-H2 and C5-H2), 1.81 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 1.00 (9H, t, J = 8.0 Hz, 
Si(CH2CH3)3), 0.77 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). δC (101 MHz, CDCl3) 147.5 (C4), 138.2 (C7), 
114.6 (C8), 110.0 (C9), 55.3 (C1), 35.3 (C5), 33.2 (C3), 31.9 (C6), 30.3 (Ms CH3), 25.1 (C2), 6.7 
(Si(CH2CH3)3), 4.8 (Si(CH2CH3)3). HRMS: (ESI+) Calculated for C16H33NNaO3SSi: 370.1843. Found 
[M+Na]+: 370.1860. 
  





General procedure F: The preceding compound (955 mg, 2.75 mmol) was employed. FCC 
(eluent: 3:1 hexane:EtOAc) afforded the title compound (639 mg, 100 %) as a colourless oil.  
νmax / cm-1: (film) 3347 (br s), 3078 (m), 2934 (m), 1642 (m), 1445 (m), 1340 (s), 1158 (s). δH (400 MHz, 
CDCl3) 7.32 (1H, br s, OH), 5.81 (1H, ddt, J = 17.0, 10.0, 6.5 Hz, C7-H), 5.05 – 4.99 (1H, m, C8-H’), 
4.97 – 4.93 (1H, m, C8-H), 4.77 (2H, s, C9-H2), 3.17 (2H, t, J = 7.0 Hz, C1-H2), 2.91 (3H, s, Ms CH3), 
2.23 – 2.15 (2H, m, C6-H2), 2.14 – 2.07 (4H, m, C3-H2 and C5-H2), 1.84 (2H, tt, J = 7.5, 7.0 Hz, C2-H2). 
δC (101 MHz, CDCl3) 147.9 (C4), 138.4 (C7), 114.7 (C8), 110.1 (C9), 52.2 (C1), 35.4 (C5), 32.9 (C3), 




General procedure C: The preceding compound (595 mg, 2.55 mmol) was employed. FCC (eluent: 
5:1 hexane:EtOAc) afforded 372 (831 mg, 76 %) as a colourless crystalline solid. νmax / cm-1: (solid) 
3078 (m), 2940 (s), 1782 (s), 1656 (m), 1500 (s), 1355 (s), 1162 (s). δH (400 MHz, CDCl3) 5.81 (1H, 
ddt, J = 17.0, 10.0, 7.0 Hz, C7-H), 5.02 (1H, ddt, J = 17.0, 2,0, 1.0 Hz, C8-H’), 4.96 (1H, ddt, J = 10.0, 
2.0, 1.0 Hz, C8-H), 4.80 (1H, s, C9-H), 4.78 (1H, s, C9-H’), 3.48 (2H, t, J = 7.0 Hz, C1-H2), 3.04 (3H, 
s, Ms CH3), 2.20 (4H, m, C3-H2 and C6-H2), 2.10 (2H, t, J = 7.5 Hz, C5-H2), 1.82 (2H, tt, J = 7.5, 
7.0 Hz, C2-H2). δC (101 MHz, CDCl3) 156.4 (C=O), 147.3 (C4), 138.3 (C7), 114.8 (C8), 110.5 (C9), 
52.2 (C1), 35.3 (C5), 34.4 (Ms CH3), 32.7 (C3), 32.0 (C6), 24.9 (C2). The aromatic 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -135.8 – -136.0 (2F, m), -145.2 (1F, tt, J = 21.0, 5.5 Hz), -158.7 – -158.9 (2F, m). 
HRMS: (ESI+) Calculated for C17H18F5NNaO4S: 450.0769. Found [M+Na]+: 450.0764. 
  





General procedure D: Conditions: 3.75 mol% Pd2(dba)3; 18.8 mol% P(3,5-(CF3)2C6H3)3; 25 mol% 
Et3N; 6:1 n-BuCN:DMF (0.1 M); 110 °C; 16 hours. Substrate 372 (59.8 mg, 0.140 mmol) was 
employed. FCC (gradient elution: 4:1 – 2:1 hexane:EtOAc) afforded 374 (25.9 mg, 86 %) as a colourless 
crystalline solid. m.p. 64-66 °C (Et2O:hexane, cubes). νmax / cm-1: (solid) 3069 (m), 2930 (m), 1655 (m), 
1311 (s), 1143 (s). δH (400 MHz, CDCl3) 4.89 – 4.86 (1H, m, C8-H), 4.83 – 4.80 (1H, m, C8-H’), 3.51 
– 3.37 (2H, m, C1-H2), 3.09 (1H, dddd, J = 15.5, 3.0, 3.0, 3.0 Hz, C9-H), 2.86 (3H, s, Ms CH3), 2.59 – 
2.42 (2H, m, C5-H and C6-H), 2.27 – 2.16 (2H, m, C6-H’ and C9-H’), 1.90 – 1.74 (4H, m, C2-H2 and 
C3-H2), 1.65 (1H, ddd, J = 10.0, 6.0, 2.0 Hz, C5-H’). δC (101 MHz, CDCl3) 147.8 (C7), 107.4  
(C8), 72.0 (C4), 50.0 (C1), 44.4 (C9), 40.1 (C3), 39.3 (Ms CH3), 36.3 (C5), 29.8 (C6), 22.6 (C2).  
HRMS: (ESI+) Calculated for C10H17NNaO2S: 238.0872. Found [M+Na]+: 238.0878. 
Octa-1,7-dien-4-ol 
 
This compound was prepared according to a literature procedure.302 To a solution of allylmagnesium 
chloride (2.0 M in THF, 8.33 mL, 16.7 mmol) in anhydrous Et2O (25 mL) at 0 °C was added 
pent-4-enal (1.10 mL, 11.1 mmol) dropwise. The reaction mixture was stirred at room temperature for 
3 hours before addition of saturated aqueous NH4Cl (20 mL). The resulting phases were separated, and 
the aqueous phase was extracted with Et2O (2 × 50 mL). The combined organic phases were dried over 
Na2SO4 and concentrated in vacuo. FCC (eluent: 4:1 pentane:Et2O) afforded the title compound (1.16 g, 
83 %) as a colourless oil. νmax / cm-1: (film) 3357 (br s), 3078 (m), 2933 (m), 1641 (m). δH (500 MHz, 
CDCl3) 5.88 – 5.78 (2H, m), 5.16 – 5.11 (2H, m), 5.05 (1H, ddt, J = 17.0, 1.5, 1.5 Hz), 4.97 (1H, ddt, 
J = 10.0, 2.5, 1.5 Hz), 3.67 (1H, dddd, J = 7.5, 7.5, 4.5, 4.5 Hz), 2.30 (1H, ddddd, J = 13.5, 7.0, 4.5, 
1.5, 1.5 Hz), 2.26 – 2.10 (3H, m), 1.66 (1H, br s), 1.60 – 1.52 (2H, m). δC (126 MHz, CDCl3) 138.6, 
134.8, 118.3, 114.9, 70.3, 42.1, 36.0, 30.2. The spectroscopic properties were consistent with the data 
available in the literature.303 
  





General procedure K: The preceding alcohol (379 mg, 3.00 mmol) was employed with MsNHOFBz 
(Section 7.3). The reaction time was 16 hours. FCC (eluent: 24:1 hexane:EtOAc) afforded 375 (651 mg, 
52 %) as a pale-yellow oil. νmax / cm-1: (film) 3079 (m), 2942 (m), 1784 (s), 1653 (m), 1499 (s), 1420 (m), 
1163 (s). δH (400 MHz, CDCl3) 5.88 – 5.72 (2H, m, C2-H and C7-H), 5.16 – 5.09 (2H, m, C1-H2), 5.07 
(1H, dddd, J = 17.0, 1.5, 1.5, 1.0 Hz, C8-H’), 5.01 (1H, dddd, J = 10.0, 1.5, 1.5, 1.0 Hz, C8-H), 4.14 – 
4.04 (1H, m, C4-H), 3.12 (3H, s, Ms CH3), 2.56 (1H, br s, C3-H), 2.43 – 2.29 (2H, m, C3-H’ and C6-H), 
2.23 (1H, ddddd, J = 15.0, 7.5, 7.5, 1.0, 1.0 Hz, C6-H’), 1.82 – 1.71 (1H, m, C5-H), 1.63 (1H, br s, 
C5-H’). δC (126 MHz, CDCl3) 157.2 (C=O), 137.2 (C7), 133.9 (C2), 118.3 (C1), 115.7 (C8), 61.5 (C4), 
40.0 (Ms CH3), 36.3 (C3), 30.5 (C5), 30.3 (C6). The aromatic 
13C signals corresponding to the 
pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
CDCl3) -135.8 – -135.9 (2F, m), -145.1 (1F, tt, J = 21.0, 5.5 Hz), -158.5 – -158.7 (2F, m). HRMS: (ESI+) 
Calculated for C16H16F5NNaO4S: 436.0612. Found [M+Na]+: 436.0595.  
2-Allyl-5-methyl-1-mesyl-2,3-dihydro-1H-pyrrole (378) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
n-BuCN (0.1 M); 110 °C; 15 hours. Substrate 375 (60.6 mg, 0.147 mmol, added as a solution in 
n-BuCN) was employed. FCC (gradient elution: 49:1 – 19:1 – 14:1 PhMe:EtOAc) afforded 378 
(16.9 mg, 57 %) as a pale-yellow oil. νmax / cm-1: (film) 3078 (m), 2929 (m), 1434 (m), 1337 (s), 1156 (s). 
δH (400 MHz, CDCl3) 5.76 (1H, ddt, J = 17.5, 10.5, 7.0 Hz, C2-H), 5.14 – 5.06 (2H, m, C1-H2), 4.96 
(1H, br s, C6-H), 4.22 – 4.14 (1H, m, C4-H), 2.85 (3H, s, Ms CH3), 2.76 – 2.64 (1H, m, C5-H), 2.48 – 
2.30 (2H, m, C3-H2), 2.21 – 2.11 (1H, m, C5-H’), 1.98 (3H, br s, C8-H3). δC (101 MHz, CDCl3) 138.8 
(C7), 133.2 (C2), 118.1 (C1), 110.7 (C6), 61.8 (C4), 41.3 (C3), 36.6 (Ms CH3), 32.7 (C5), 15.5 (C8). 
HRMS: (ESI+) Calculated for C9H15NNaO2S: 224.0716. Found [M+Na]+: 224.0714. 
  





To a solution of Grubbs-Hoveyda 2nd generation catalyst (18.8 mg, 30.0 μmol) in anhydrous CH2Cl2 
(60 mL, argon sparged) was added methyl acrylate (6.75 mL, 75.0 mmol) and octa-1,7-dien-4-ol (vide 
supra, 0.42 mL, 3.00 mmol). The reaction mixture was heated at reflux for 2 days before being 
concentrated in vacuo. FCC (gradient elution: 1:1 – 0:1 hexane:Et2O) afforded the title compound 
(303 mg, 42 %) as a light-brown oil (the colouration was due to the presence of trace amounts of 
Ru-impurities). νmax / cm-1: (film) 3441 (br s), 2951 (m), 1717 (s), 1655 (s), 1436 (s), 1271 (s).  
δH (400 MHz, CDCl3) 6.98 – 6.86 (2H, m, C3-H and C8-H), 5.86 (1H, d, J = 15.5 Hz, C2-H), 5.80 (1H, 
d, J = 15.5 Hz, C9-H), 3.76 – 3.70 (1H, m, C5-H), 3.68 (3H, s, OCH3), 3.67 (3H, s, OCH3), 2.55 (1H, 
br s, OH), 2.41 – 2.19 (4H, m, C4-H2 and C7-H2), 1.62 – 1.54 (2H, m, C6-H2). δC (101 MHz, CDCl3) 
167.1 (C10), 166.9 (C1), 148.8 (C8), 145.3 (C3), 123.6 (C2), 121.4 (C9), 69.6 (C5), 51.6 (OCH3), 51.5 





General procedure K: The preceding alcohol (378 mg, 1.56 mmol) was employed with TsNHOFBz 
(Section 7.3). The reaction time was 16 hours. FCC (eluent: 24:1 PhMe:acetone) afforded 379 (265 mg, 
28 %) as a colourless crystalline solid. m.p. 94-95 °C (Et2O, fibres). νmax / cm-1: (film) 2950 (m), 
1786 (s), 1721 (s), 1655 (s), 1497 (s), 1167 (s). δH (500 MHz, CDCl3) 7.82 (2H, d, J = 8.0 Hz, 2 × 
ArCH), 7.37 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.92 – 6.68 (2H, m, C3-H and C8-H), 5.86 – 5.70 (2H, m, 
C2-H and C9-H), 4.06 (1H, dddd, J = 8.5, 8.5, 4.5, 4.5 Hz, C5-H), 3.72 (2 × 3H, s, OCH3), 2.65 (1H, 
br s, C7-H), 2.50 – 2.24 (6H, m, C4-H2, C7-H’ and Ts CH3), 1.72 – 1.43 (2H, m, C6-H2). δC (126 MHz, 
CDCl3) 167.0 (C10), 166.4 (C1), 156.6 (C=O), 147.5 (C8), 146.4 (ArC), 146.1 (d, J = 260.0 Hz, ArCF), 
144.2 (d, J = 262.5 Hz, ArCF), 143.6 (C3), 138.0 (d, J = 258.5 Hz, ArCF), 132.6 (ArC), 130.2 (ArCH), 
129.4 (ArCH), 124.3 (C2), 122.1 (C9), 105.1 (ArC), 60.4 (C5), 51.8 (OCH3), 51.6 (OCH3), 34.1 (C4), 
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30.4 (C6), 28.9 (C7), 21.9 (Ts CH3). δF (377 MHz, CDCl3) -135.7 – -135.9 (2F, m), -145.2 (1F, tt, J = 
21.0, 5.0 Hz), -158.5 – -158.7 (2F, m). HRMS: (ESI+) Calculated for C26H24F5NNaO8S: 628.1035. 
Found [M+Na]+: 628.1035. 
Methyl (E)-4-((E)-5-(2-methoxy-2-oxoethylidene)-1-tosylpyrrolidin-2-yl)but-2-enoate (382) 
 
General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 25 mol% P(3,5-(CF3)2C6H3)3; 25 mol% Et3N; 
n-BuCN (0.1 M); 110 °C; 17 hours. Substrate 379 (74.8 mg, 0.140 mmol) was employed. FCC (gradient 
elution: 3:1 – 2:1 hexane:EtOAc) afforded 382 (43.4 mg, 79 %) as a pale-yellow oil. νmax / cm-1: (film) 
2950 (m), 1710 (s), 1622 (s), 1437 (m), 1346 (s), 1130 (s). δH (400 MHz, CDCl3) 7.72 (2H, d, J = 
8.0 Hz, 2 × ArCH), 7.31 (2H, d, J = 8.0 Hz, 2 × ArCH), 6.88 (1H, ddd, J = 15.5, 8.0, 7.0 Hz, C3-H), 
6.00 (1H, dd, J = 2.0, 2.0 Hz, C9-H), 5.92 (1H, ddd, J = 15.5, 1.5, 1.5 Hz, C2-H), 4.37 (1H, dddd, J = 
9.5, 7.0, 3.5, 3.5 Hz, C5-H), 3.73 (3H, s, OCH3), 3.64 (3H, s, OCH3), 3.18 (1H, dddd, J = 18.5, 8.5, 4.0, 
2.0 Hz, C7-H), 2.95 – 2.81 (2H, m, C4-H and C7-H’), 2.53 (1H, dddd, J = 14.5, 9.5, 8.0, 1.5 Hz, C4-H’), 
2.42 (3H, s, Ts CH3), 1.79 – 1.68 (2H, m, C6-H2). δC (101 MHz, CDCl3) 168.0 (C10), 166.5 (C1), 156.3 
(C8), 145.0 (ArC), 143.4 (C3), 135.3 (ArC), 130.0 (ArCH), 127.3 (ArCH), 124.5 (C2), 96.5 (C9), 62.9 
(C5), 51.7 (OCH3), 51.1 (OCH3), 38.4 (C4), 30.1 (C7), 26.2 (C6), 21.7 (Ts CH3). HRMS: (ESI+) 
Calculated for C19H24NO6S: 394.1319. Found [M+H]+: 394.1305. 
1-(Benzyloxy)-4-(cyclohex-1-en-1-yl)butan-2-ol (392) 
 
To a suspension of magnesium turnings (207 mg, 8.51 mmol), benzyl glycidyl ether (393) (0.65 mL, 
4.26 mmol) and CuI (81.1 mg, 0.426 mmol) in anhydrous THF (30 mL) was added a solution of 
1-(bromomethyl)cyclohex-1-ene (Section 7.3, 1.49 g, 8.51 mmol) in anhydrous THF (15 mL). The 
reaction mixture was heated at reflux for 3 hours, then cooled to room temperature before addition of 
saturated aqueous NH4Cl (50 mL). The reaction mixture was extracted with Et2O (2 × 100 mL). The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. FCC (gradient elution: 
9:1 – 7:1 petrol:EtOAc) afforded 392 (329 mg, 30 %) as a colourless oil. νmax / cm-1: (film) 3436 (br s), 
3030 (m), 2922 (m), 1453 (m), 1089 (s). δH (400 MHz, CDCl3) 7.38 – 7.27 (5H, m, 5 × ArCH), 5.41 
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(1H, br s, C6-H), 4.56 (2H, s, OCH2Ph), 3.81 (1H, dddd, J = 8.0, 7.5, 5.5, 3.0 Hz, C2-H), 3.51 (1H, dd, 
J = 9.5, 3.0 Hz, C1-H), 3.34 (1H, dd, J = 9.5, 7.5 Hz, C1-H’), 2.13 – 1.88 (6H, m, C4-H2, C7-H2 and 
C10-H2), 1.64 – 1.49 (6H, m, C3-H2, C8-H2 and C9-H2). δC (101 MHz, CDCl3) 138.1 (ArC), 137.4 
(C5), 128.6 (ArCH), 2 × 127.9 (2 × ArCH), 121.4 (C6), 74.7 (C1), 73.5 (OCH2Ph), 70.4 (C2), 34.0 
(C4), 31.2 (C3), 28.4 (C10), 25.3 (C7), 23.1 (C9), 22.6 (C8). HRMS: (ESI+) Calculated for C17H24NaO2: 
283.1669. Found [M+Na]+: 283.1674. 
tert-Butyl (1-(benzyloxy)-4-(cyclohex-1-en-1-yl)butan-2-yl)(tosyloxy)carbamate (391) 
 
General procedure R: Alcohol 392 (325 mg, 1.25 mmol) was employed with BocNHOTs.LXV The 
reaction time was 15 hours. FCC (gradient elution: 1:4 – 1:9 – 0:1 petrol:PhMe) afforded 391 (193 mg, 
29 %) as a colourless oil. νmax / cm-1: (film) 2927 (m), 1723 (s), 1598 (m), 1454 (m), 1369 (s), 1179 (s). 
δH (500 MHz, CDCl3) 7.88 (2H, d, J = 8.5 Hz, 2 × ArCH), 7.35 – 7.22 (7H, m, 7 × ArCH), 5.39 (1H, 
br s, C6-H), 4.48 (2H, s, OCH2Ph), 4.21 (1H, dddd, J = 9.0, 8.5, 5.0, 5.0 Hz, C2-H), 3.67 (1H, dd, J = 
9.5, 9.0 Hz, C1-H), 3.43 (1H, dd, J = 9.5, 5.0 Hz, C1-H’), 2.44 (3H, s, Ts CH3), 2.12 – 1.93 (4H, m, 
C4-H2 and C7-H2), 1.92 – 1.87 (2H, m, C10-H2), 1.86 – 1.76 (1H, m, C3-H), 1.63 – 1.57 (2H, m, C9-H2), 
1.57 – 1.40 (3H, m, C3-H’ and C8-H2), 1.21 (9H, s, OC(CH3)3). δC (126 MHz, CDCl3) 156.8 (C=O), 
145.5 (ArC), 138.3 (ArC), 136.8 (C5), 132.0 (ArC), 129.9 (ArCH), 129.6 (ArCH), 128.4 (ArCH), 127.8 
(ArCH), 127.6 (ArCH), 121.7 (C6), 83.2 (OC(CH3)3), 73.1 (OCH2Ph), 69.5 (C1), 63.6 (C2), 34.8 (C4), 
28.4 (C10), 27.7 (OC(CH3)3), 27.2 (C3), 25.4 (C7), 23.1 (C9), 22.7 (C8), 21.8 (Ts CH3). HRMS: (ESI+) 
Calculated for C29H39NNaO6S: 552.2390. Found [M+Na]+: 552.2370. 
Methyl (4-methylpent-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (386d) 
 
General procedure O: 4-Methylpent-4-en-1-ol (170 mg, 1.70 mmol) was employed with 
MeOC(O)NHOFBz (Section 7.4). The reaction time was 20 hours. FCC (two times, first, gradient 
elution: 3:7 – 3:17 petrol:PhMe; second eluent: 14:1 petrol:acetone) afforded 386d (491 mg, 79 %) as 
a colourless oil. δH (400 MHz, CDCl3) 4.75 (1H, s), 4.70 (1H, s), 3.81 (3H, s), 3.72 (2H, t, J = 7.5 Hz), 
2.10 (2H, t, J = 7.5 Hz), 1.80 (2H, tt, J = 7.5, 7.5 Hz), 1.72 (3H, s). δC (101 MHz, CDCl3) 156.2, 144.5, 
                                                     
LXV BocNHOTs was prepared by Joshua Farndon (University of Bristol) according to a literature procedure.164 
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110.9, 54.1, 51.1, 34.5, 24.8, 22.4. The 13C signals corresponding to the pentafluorobenzoyl group could 
not be resolved due to their weak intensity. δF (377 MHz, CDCl3) -136.0 – -136.3 (2F, m), -146.1 (1F, 
tt, J = 21.0, 5.5 Hz), -159.3 – -159.5 (2F, m). The spectroscopic properties were consistent with the 
data available in the literature.108 
((1-(Methoxycarbonyl)-2-methylpyrrolidin-2-yl)methyl)boronic acid pinacol ester (405a) 
 
General procedure S: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 25 mol% Et3N; 200 mol% B2Pin2; n-Bu2O (0.4 M); 130 °C; 
48 hours. Substrate 386d (36.7 mg, 0.100 mmol) was employed. FCC (eluent: 5:1 petrol:EtOAc) 
afforded 405a (11.1 mg, 39 %) as a pale-yellow oil. This compound exists as an approximately  
5:4 mixture of rotamers A and B. νmax / cm-1: (film) 2976 (m), 1692 (s), 1445 (s), 1369 (s), 1143 (s).  
δH (500 MHz, CDCl3) 3.68 (1.35H, s, B: OCH3), 3.62 (1.65H, s, A: OCH3), 3.56 – 3.50 (0.45H, m, B: 
C1-H), 3.47 – 3.38 (1H, m, A: C1-H; B: C1-H’), 3.37 – 3.30 (0.55H, m, A: C1-H’), 2.11 – 2.03 (0.45H, 
m, B: C3-H), 1.97 – 1.90 (0.55H, m, A: C3-H), 1.82 – 1.71 (3H, m, A and B: C2-H2 and C3-H’), 1.69 
– 1.48 (2H, m, A and B: C5-H2), 1.41 (1.65H, s, A: C6-H3), 1.33 (1.35H, s, B: C6-H3), 1.22 (6.6H, s, 
A: OC(CH3)2C(CH3)2O), 1.21 (5.4H, s, B: OC(CH3)2C(CH3)2O). δC (126 MHz, CDCl3) 155.8 (B: C=O), 
154.5 (A: C=O), 83.1 (B: OC(CH3)2C(CH3)2O), 82.9 (A: OC(CH3)2C(CH3)2O), 62.1 (A: C4), 61.5 (B: 
C4), 51.9 (B: OCH3), 51.6 (A: OCH3), 48.8 (B: C1), 47.8 (A: C1), 41.7 (B: C3), 41.0 (A: C3), 27.6 (B: 
C6), 26.6 (A: C6), 25.0 (A: OC(CH3)2C(CH3)2O), 24.9 (B: OC(CH3)2C(CH3)2O), 22.5 (A: C2), 22.1 (B: 
C2). The 13C signal corresponding to C5 could not be resolved due to their weak intensity.  
δB (128 MHz, CDCl3) 32.8. HRMS: (ESI+) Calculated for C14H27BNO4: 284.2030. Found [M+H]+: 
284.2041. 
tert-Butyl (4-methylpent-4-en-1-yl)((pentafluorobenzoyl)oxy)carbamate (386e) 
 
General procedure O: 4-Methylpent-4-en-1-ol (200 mg, 2.00 mmol) was employed with BocNHOFBz 
(Section 7.4). The reaction time was 21 hours. FCC (gradient elution: 1:1 – 2:3 petrol:PhMe) afforded 
386e (663 mg, 81 %) as a colourless oil. νmax / cm-1: (film) 2982 (m), 2938 (m), 1783 (s), 1721 (s), 
1652 (m), 1504 (s), 1151 (s). δH (400 MHz, CDCl3) 4.74 (1H, s, C5-H), 4.70 (1H, s, C5-H’), 3.68 (2H, 
t, J = 7.0 Hz, C1-H2), 2.10 (2H, t, J = 7.5 Hz, C3-H2), 1.79 (2H, tt, J = 7.5, 7.0 Hz, C2-H2), 1.73 (3H, s, 
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C6-H3), 1.49 (9H, s, OC(CH3)3). δC (101 MHz, CDCl3) 154.7 (Boc C=O), 144.6 (C4), 110.8 (C5),  
83.4 (OC(CH3)3), 50.8 (C1), 34.6 (C3), 28.2 (OC(CH3)3), 24.9 (C2), 22.4 (C6). The 
13C signals 
corresponding to the pentafluorobenzoyl group could not be resolved due to their weak intensity.  
δF (377 MHz, CDCl3) -136.5 – -136.8 (2F, m), -146.7 (1F, tt, J = 21.0, 5.0 Hz), -159.3 – -159.6 (2F, m). 
HRMS: (ESI+) Calculated for C18H20F5NNaO4: 432.1205. Found [M+Na]+: 432.1194. 
2-(2-Methylenecyclohexyl)ethan-1-ol 
 
General procedure L: Cyclohex-1-en-1-ylmethanol (Section 7.3, 2.24 g, 20.0 mmol) was employed. 
The reaction time was 14 hours. The crude mixture was used in the next step without further 
purification. General procedure I: The preceding crude mixture was employed, using anhydrous THF 
as solvent and 1.0 eq. LiAlH4 (2.0 M in THF). FCC (gradient elution: 7:3 – 1:1 pentane:Et2O) afforded 
the title compound (1.40 g, 50 % over two steps) as a colourless oil. δH (400 MHz, CDCl3) 4.67 (1H, 
s), 4.61 (1H, s), 3.68 (2H, t, J = 6.5 Hz), 2.29 – 2.18 (2H, m), 2.09 – 1.99 (1H, m), 1.97 – 1.86 (1H, m), 
1.79 – 1.70 (1H, m), 1.70 – 1.60 (1H, m), 1.59 – 1.40 (4H, m), 1.36 – 1.26 (1H, m). δC (101 MHz, 
CDCl3) 152.8, 106.1, 61.7, 40.0, 35.2, 34.6, 34.1, 28.9, 24.0. The spectroscopic properties were 
consistent with the data available in the literature.304 
Methyl (2-(2-methylenecyclohexyl)ethyl)((pentafluorobenzoyl)oxy)carbamate (408) 
 
General procedure O: The preceding alcohol (421 mg, 3.00 mmol) was employed with 
MeOC(O)NHOFBz (Section 7.4). The reaction time was 22 hours. FCC (two times, first, gradient 
elution: 3:7 – 1:4 petrol:PhMe; second eluent: 24:1 petrol:acetone) afforded 408 (726 mg, 59 %) as a 
colourless oil. νmax / cm-1: (film) 2931 (m), 2857 (m), 1787 (s), 1730 (s), 1651 (m), 1505 (s), 1177 (s). 
δH (400 MHz, CDCl3) 4.70 (1H, s, C9-H), 4.59 (1H, s, C9-H’), 3.81 (3H, s, OCH3), 3.74 (2H, dd, J = 
7.5, 7.5 Hz, C1-H2), 2.28 – 2.11 (2H, m, C3-H and C7-H), 2.08 – 1.93 (2H, m, C2-H and C7-H’), 1.80 
– 1.71 (1H, m, C4-H), 1.70 – 1.41 (5H, m, C2-H’, C5-H2 and C6-H2), 1.36 – 1.25 (1H, m, C4-H’).  
δC (101 MHz, CDCl3) 156.2 (MeO–C=O), 151.5 (C8), 106.5 (C9), 54.1 (OCH3), 50.0 (C1), 40.4  
(C3), 34.6 (C7), 34.0 (C4), 29.2 (C2), 28.8 (C6), 24.2 (C5). The 13C signals corresponding  
to the pentafluorobenzoyl group could not be resolved due to their weak intensity. δF (377 MHz, 
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CDCl3) -136.1 – -136.3 (2F, m), -146.2 (1F, tt, J = 21.0, 5.5 Hz), -159.2 – -159.4 (2F, m). HRMS: (ESI+) 
Calculated for C18H18F5NNaO4: 430.1048. Found [M+Na]+: 430.1042. 
(((3aR*,7aR*)-1-(Methoxycarbonyl)octahydro-7aH-indol-7a-yl)methyl)boronic acid pinacol 
ester (409) 
 
General procedure S: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 25 mol% Et3N; 200 mol% B2Pin2; n-Bu2O (0.4 M); 130 °C; 
48 hours. Substrate 408 (40.7 mg, 0.100 mmol) was employed. FCC (eluent: 7:1 petrol:EtOAc) 
afforded 409 (12.4 mg, 38 %) as a pale-yellow oil. This compound exists as an approximately  
1:1 mixture of rotamers A and B. νmax / cm-1: (film) 2926 (m), 1694 (s), 1447 (s), 1370 (s), 1144 (s).  
δH (400 MHz, CDCl3) 3.60 (1.5H, s, B: OCH3), 3.55 (1.5H, s, A: OCH3), 3.55 – 3.48 (0.5H, m, B: 
C1-H), 3.45 – 3.37 (0.5H, m, A: C1-H), 3.31 – 3.18 (1H, m, A and B: C1-H’), 2.31 – 2.22 (0.5H, m, B: 
C3-H), 2.10 – 1.95 (1H, m, A: C3-H and C7-H), 1.89 – 1.81 (0.5H, m, B: C7-H), 1.78 – 1.04 (23H, m, 
A and B: C2-H2, C4-H2, C5-H2, C6-H2, C7-H’, C9-H2 and OC(CH3)2C(CH3)2O). δC (101 MHz, CDCl3) 
156.0 (B: C=O), 154.8 (A: C=O), 82.9 (B: OC(CH3)2C(CH3)2O), 82.7 (A: OC(CH3)2C(CH3)2O),  
62.9 (A: C8), 62.3 (B: C8), 51.8 (B: OCH3), 51.6 (A: OCH3), 46.7 (B: C1), 45.9 (A: C1), 43.2 (A: C3), 
43.1 (B: C3), 35.7 (B: C7), 34.4 (A: C7), 26.8 (A: C2), 26.2 (B: C2), 25.7 (A: C4), 25.4 (B:  
C4), 25.2 (B: OC(CH3)(CH3)’C(CH3)(CH3)’O), 25.0 (A: OC(CH3)(CH3)’C(CH3)(CH3)’O), 24.9 (A: 
OC(CH3)(CH3)’C(CH3)(CH3)’O), 24.8 (B: OC(CH3)(CH3)’C(CH3)(CH3)’O), 22.8 (B: C6), 22.7 (A: 
C6), 21.9 (A: C5), 21.4 (B: C5). The 13C signals corresponding to C9 could not be resolved due to their 
weak intensity. δB (128 MHz, CDCl3) 32.8. HRMS: (ESI+) Calculated for C17H31BNO4: 324.2343. 
Found [M+H]+: 324.2353. 
(6aR*,10aR*)-Hexahydro-1H,3H,5H-oxazolo[4,3-i]indol-3-one (410) 
 
To a solution of boronic ester 409 (38.4 mg, 0.119 mmol) in THF (3 mL) at 0 °C was added mixture of 
2.0 M aqueous NaOH (2.0 mL) and 30 % aqueous H2O2 (1.0 mL) dropwise over around 10 minutes. 
The reaction mixture was stirred at room temperature for 24 hours before addition of water (15 mL) 
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and extraction with Et2O (3 × 15 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. FCC (eluent: 1:4 petrol:Et2O) afforded 410 (16.7 mg, 77 %) as a colourless 
crystalline solid. The relative stereochemistry of the product was assigned based on the observed NOE 
correlation between the C3 and the C9 protons. m.p. 58-59 °C (Et2O:petrol, globular). νmax / cm-1: (film) 
2930 (m), 2862 (m), 1752 (s), 1054 (m). δH (400 MHz, CDCl3) 4.27 (1H, d, J = 8.5 Hz, C9-H), 4.09 
(1H, d, J = 8.5 Hz, C9-H’), 3.62 (1H, ddd, J = 12.0, 8.5, 8.5 Hz, C1-H), 3.26 (1H, ddd, J = 12.0, 7.5, 
5.0 Hz, C1-H’), 2.07 – 1.91 (3H, m, C2-H2 and C3-H), 1.86 – 1.47 (6H, m, C4-H2, C5-H, C6-H and 
C7-H2), 1.39 – 1.26 (1H, m, C5-H’), 1.04 (1H, ddddd, J = 13.5, 13.5, 13.5, 3.5, 3.5 Hz, C6-H’).  
δC (101 MHz, CDCl3) 161.5 (C=O), 73.6 (C9), 66.4 (C8), 44.0 (C1), 41.4 (C3), 32.1 (C7), 28.5 (C2), 
23.9 (C4), 22.9 (C6), 19.7 (C5). HRMS: (ESI+) Calculated for C10H16NO2: 182.1176. Found [M+H]+: 
182.1177. 
Methyl 2-methyl-2-(thiophen-2-ylmethyl)pyrrolidine-1-carboxylate (399a) 
 
This compound was prepared using an adaptation of a literature procedure.193 To a solution of thiophene 
(15 µL, 0.187 mmol) in anhydrous THF (1 mL) at -78 °C was added a solution of n-BuLi (1.46 M in 
hexane, 0.13 mL, 0.187 mmol). The reaction mixture was stirred at room temperature for 1 hour and 
then cooled to -78 °C before addition of a solution of 405a (44.2 mg, 0.156 mmol) in anhydrous THF 
(2 mL). The reaction mixture was stirred at -78 °C for 1 hour before addition of a solution of NBS 
(33.3 mg, 0.187 mmol) in anhydrous THF (2 mL), then stirred at -78 °C for a further 1 hour before 
addition of saturated aqueous Na2SO3 (2 mL). The reaction mixture was warmed to room temperature 
before addition of water (10 mL) and extraction with EtOAc (3 × 15 mL). The combined organic phases 
were dried over Na2SO4 and concentrated in vacuo. FCC (eluent: 24:1 PhMe:EtOAc) afforded 399a 
(9.7 mg, 26 %) as a colourless oil. Impure 405a was also isolated; FCC (5:1 petrol:EtOAc) of this 
material afforded 405a (20.0 mg, 45 %). This compound exists as an approximately 7:3 mixture of 
rotamers A and B. δH (400 MHz, CDCl3) 7.15 (1H, d, J = 5.0 Hz, A and B: ArCH), 6.92 (1H, dd, J = 
5.0, 3.5 Hz, A and B: ArCH), 6.79 – 6.74 (1H, m, A and B: ArCH), 3.79 (0.9H, s, B: OCH3), 3.73 – 
3.66 (2.8H, m, A: C5-H and OCH3), 3.58 – 3.38 (1.3H, m, A: C1-H; B: C1-H and C5-H), 3.26 – 3.08 
(1H, m, A and B: C1-H’), 3.07 (0.7H, d, J = 14.5 Hz, A: C5-H’), 2.99 (0.3H, d, J = 14.5 Hz, B: C5-H’), 
2.11 – 1.98 (1H, m, A and B: C3-H), 1.71 – 1.61 (2H, m, A and B: C2-H and C3-H’), 1.47 (2.1H, s, A: 
C6-H3), 1.45 – 1.36 (1.9H, m, A: C2-H’; B: C2-H’ and C6-H3). δC (126 MHz, CDCl3) 155.6 (B: C=O), 
154.7 (A: C=O), 140.5 (A: ArC), 140.0 (B: ArC), 126.9 (A and B: ArCH), 126.6 (B: ArCH), 126.5 (A: 
ArCH), 124.7 (B: ArCH), 124.4 (A: ArCH), 63.8 (A: C4), 63.1 (B: C4), 52.2 (B: OCH3), 52.0 (A: 
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OCH3), 49.3 (B: C1), 48.4 (A: C1), 2 × 39.0 (B: C3 and C5), 2 × 37.8 (A: C3 and C5), 26.6 (B: C6), 
25.5 (A: C6), 22.1 (A: C2), 21.6 (B: C2). The spectroscopic properties were consistent with the data 




General procedure D: Conditions: 5.0 mol% Pd2(dba)3; 20 mol% 1,3,5,7-tetramethyl-8-phenyl-2,4,6-
trioxa-8-phosphaadamantane (L1); 25 mol% Et3N; n-Bu2O (0.4 M); 130 °C; 48 hours. Substrate 402LXVI 
(44.3 mg, 0.100 mmol) was employed. FCC (eluent: 24:1 petrol:acetone) afforded 411 (12.6 mg, 54 %) 
as a pale-yellow oil. The product was assigned as the cis diastereomer based on the observed NOE 
correlation between the C3 and the C6 protons. This compound exists as an approximately 2:1 mixture 
of rotamers A and B. νmax / cm-1: (film) 2955 (m), 1696 (s), 1444 (s), 1371 (s). δH (500 MHz, CDCl3) 
7.21 – 7.11 (4H, m, A and B: 4 × ArCH), 3.80 (0.65H, d, J = 17.0 Hz, A: C5-H), 3.75 (1.05H, s, B: 
OCH3), 3.69 – 3.59 (0.35H, m, B: C1-H), 3.62 (1.95H, s, A: OCH3), 3.59 – 3.43 (2H, m, A: C1-H and 
C3-H; B: C5-H and C3-H), 3.18 (0.35H, ddd, J = 10.5, 10.0, 6.5 Hz, B: C1-H’), 3.06 – 2.96 (1.65H, m, 
A: C1-H’ and C5-H’; B: C5-H’), 2.29 – 2.13 (1H, m, A and B: C2-H), 2.13 – 1.96 (1H, m, A and B: 
C2-H’), 1.63 (1.95H, s, A: C6-H3), 1.56 (1.05H, s, B: C6-H3). δC (126 MHz, CDCl3) 155.5 (B: C=O), 
154.5 (A: C=O), 143.5 (A: ArC), 143.4 (B: ArC), 143.0 (A: ArC), 142.3 (B: ArC), 2 × 127.4 (A and B: 
ArCH), 126.9 (B: ArCH), 126.7 (A: ArCH), 125.1 (A: ArCH), 125.0 (B: ArCH), 123.7 (B: ArCH), 
123.6 (A: ArCH), 71.6 (A: C4), 70.8 (B: C4), 58.5 (B: C3), 57.1 (A: C3), 52.3 (B: OCH3), 51.8 (A: 
OCH3), 48.2 (B: C1), 48.0 (A: C1), 44.9 (B: C5), 43.4 (A: C5), 28.3 (A: C2), 28.1 (B: C2), 25.0 (B: 
C6), 23.7 (A: C6). HRMS: (ESI+) Calculated for C14H18NO2: 232.1332. Found [M+H]+: 232.1343. 
 
                                                     






Table 21 – Monodentate ligand screen for the palladium(0)-catalysed cyclisation of substrate 103a. Yields were determined 






Table 22 – Bidentate ligand screen for the palladium(0)-catalysed cyclisation of substrate 103a. Yields were determined by 





Table 23 – Ligand screen for the palladium(0)-catalysed 1,2-aminoborylation of 386d. 
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